,doc_id,sent_id,triple_list,Unnamed: 0,abstract_sents
0,0.0,0.0,"['submacular hemorrhage relate sars-cov-2', 'submacular hemorrhage relate vaccine', 'age-related relate sars-cov-2', 'age-related relate vaccine', 'macular relate sars-cov-2', 'macular relate vaccine', '-related relate sars-cov-2', '-related relate vaccine']",0,report retinal vein occlusion rvo age-related macular degeneration amd -related submacular hemorrhage developing administration sars-cov-2 vaccines single-center retrospective observational case series conducted 
1,0.0,4.0,"['twelve vaccinate chadox1', 'twelve vaccinate vaccine', 'patient vaccinate chadox1', 'patient vaccinate vaccine', '609 vaccinate chadox1', '609 vaccinate vaccine', 'vaccine vaccinate chadox1']",4,twelve patients 609 vaccinated pfizer vaccine bnt162b2 8 astrazeneca chadox1 vaccine 
2,1.0,0.0,"['sars-cov-2 follow covid-19', 'sars-cov-2 follow mrna', 'sars-cov-2 follow vaccine', '200 follow covid-19', '200 follow mrna', '200 follow vaccine', 'worker follow covid-19', 'worker follow mrna', 'worker follow vaccine', 'pfizer-biontech follow covid-19', 'pfizer-biontech follow mrna', 'pfizer-biontech follow vaccine', 'sars-cov-2 die pfizer-biontech', 'sars-cov-2 die bnt162b2', 'sars-cov-2 die covid-19', 'sars-cov-2 die mrna', 'sars-cov-2 die vaccine', '200 die pfizer-biontech', '200 die bnt162b2', '200 die covid-19', '200 die mrna', '200 die vaccine']",10,background prospective assessment sars-cov-2 seroconversion pass study following 200 healthcare workers received pfizer-biontech bnt162b2 covid-19 mrna vaccine 
3,1.0,2.0,"['serum test receptor', 'serum test sars-cov-2', 'serum test oc43', 'serum test hku1', 'serum test nl63', 'antibody test receptor', 'antibody test sars-cov-2', 'antibody test oc43', 'antibody test hku1', 'antibody test nl63', 'serum induce antibody', 'serum induce receptor', 'serum induce sars-cov-2', 'serum induce oc43', 'serum induce hku1', 'serum induce nl63']",12,methods serial serum samples obtained pre-vaccination 1 month second dose tested igg antibodies full pre-fusion spike protein receptor binding domain rbd sars-cov-2 well full pre-fusion spike proteins oc43 hku1 229e nl63 
4,1.0,8.0,"['vaccine associate vaccine-induced', 'coronavirus associate vaccine-induced']",18,longitudinal sampling enable assessment vaccine durability determination whether baseline seasonal coronavirus antibody levels associated altered duration detectable covid-19 vaccine-induced antibody responses 
5,1.0,9.0,"['astra fund usg', 'astra fund david', 'astra fund md', 'astra fund zeneca', 'astra fund usu', 'astra fund covid-19', 'astra fund vaccine', 'astra fund usg', 'zeneca fund usg', 'zeneca fund david', 'zeneca fund md', 'zeneca fund usu', 'zeneca fund covid-19', 'zeneca fund vaccine', 'zeneca fund usg', 'usu fund usg', 'usu fund david', 'usu fund md', 'usu fund zeneca', 'usu fund covid-19', 'usu fund vaccine', 'usu fund usg', 'covid-19 fund usg', 'covid-19 fund david', 'covid-19 fund md', 'covid-19 fund zeneca', 'covid-19 fund usu', 'covid-19 fund vaccine', 'covid-19 fund usg', 'vaccine fund usg', 'vaccine fund david', 'vaccine fund md', 'vaccine fund zeneca', 'vaccine fund usu', 'vaccine fund covid-19', 'vaccine fund usg', 'astra sponsor usu', 'astra sponsor covid-19', 'astra sponsor vaccine', 'astra sponsor usg', 'zeneca sponsor usu', 'zeneca sponsor covid-19', 'zeneca sponsor vaccine', 'zeneca sponsor usg', 'usu sponsor covid-19', 'usu sponsor vaccine', 'usu sponsor usg', 'covid-19 sponsor usu', 'covid-19 sponsor vaccine', 'covid-19 sponsor usg', 'vaccine sponsor usu', 'vaccine sponsor covid-19', 'vaccine sponsor usg', 'usg sponsor usu', 'usg sponsor covid-19', 'usg sponsor vaccine', 'david sponsor usu', 'david sponsor covid-19', 'david sponsor vaccine', 'david sponsor usg', 'md sponsor usu', 'md sponsor covid-19', 'md sponsor vaccine', 'md sponsor usg', 'zeneca sponsor usu', 'zeneca sponsor covid-19', 'zeneca sponsor vaccine', 'zeneca sponsor usg']",19,disclosures simon pollett mbbs astra zeneca financial material support hjf support usu idcrp funded crada augment conduct unrelated phase iii covid-19 vaccine trial sponsored astrazeneca part usg response unrelated work david tribble md drph astra zeneca financial material support hjf support usu idcrp funded crada augment conduct unrelated phase iii covid-19 vaccine trial sponsored astrazeneca part usg response unrelated work 
6,2.0,0.0,"['cancer include immune-stimulants', 'cancer include cytokine', 'cancer include vaccine', 'cancer include inhibitor', 'cancer include icis', 'immunotherapy include immune-stimulants', 'immunotherapy include cytokine', 'immunotherapy include cancer', 'immunotherapy include vaccine', 'immunotherapy include inhibitor', 'immunotherapy include icis']",20,wide range cancer immunotherapy approaches developed including non-specific immune-stimulants cytokines cancer vaccines immune checkpoint inhibitors icis adoptive cell therapy 
7,2.0,3.0,['icis induce anticancer therapies'],23,novel mechanism action icis immune cell activation leads unusual patterns response imaging advent so-called pseudoprogression pronounced frequently observed compared anticancer therapies 
8,2.0,4.0,"['patient treat lesion', 'icis treat lesion', 'tumour treat lesion']",24,pseudoprogression described 2ÃÂÂ10 patients treated icis corresponds increase tumour burden andor appearance new lesions due infiltration activated cells disease responds therapy 
9,2.0,8.0,['immunotherapeutic evaluate immunotherapy'],28,paper reviews current immunotherapeutic approaches summarises radiologic criteria evaluate new patterns response immunotherapy 
10,3.0,0.0,"['budd-chiari syndrome cause hepatic venules', 'budd-chiari syndrome cause inferior', 'budd-chiari syndrome cause vena', 'budd-chiari syndrome cause cava', 'venous outflow cause hepatic venules', 'venous outflow cause inferior', 'venous outflow cause vena', 'venous outflow cause cava', 'hepatic cause hepatic venules', 'hepatic cause inferior', 'hepatic cause vena', 'hepatic cause cava']",30,background budd-chiari syndrome bcs complex thrombotic disorder caused due obstruction hepatic venous outflow involving anywhere small hepatic venules entrance inferior vena cava right atrium 
11,3.0,2.0,"['patient improve liver', 'bcs improve liver']",32,prognosis patients bcs improved significantly long-term anticoagulation measures like trans-jugular-intrahepatic-porto-systemic shunt tips liver transplantation 
12,3.0,4.0,['patient receive thrombosis'],34,methods appropriate investigational review board permission identified patients history bcs following thrombosis clinical practice year 2010 onwards 
13,3.0,7.0,['two compare transplant'],37, compared two categories patients needed tipsliver transplants versus 
14,3.0,11.0,"['patient include 294000l 14000-767000l', 'patient include white', 'patient include obese', 'patient include woman', 'patient include oral', 'patient include pill', 'patient include thrombosis', 'patient include stroke', 'patient include hemoglobin', 'patient include 134', 'patient include blood', 'patient include cell', 'patient include 9400l', 'patient include platelet', 'patient include serum', 'patient include creatinine', 'patient include 087', 'patient include gmdl', 'patient include bilirubin']",41,results study included 23 patients baseline characteristics including median age 36 years 11-59 years 91 whites 61 females 44 smokers 61 obese median bmi 299 kgm 2 6 14 women oral contraceptive pills 22 thrombosis history 17 stroke history median hemoglobin 134 gmdl 89-20 gmdl white blood cell count 9400l 3050-31500l platelet count 294000l 14000-767000l serum creatinine 087 mgl 055-252 mgdl total protein 63 gmdl 52-88 gmdl bilirubin 21 mgdl 01-202 mgdl aspartate aminotransferase ast 61 ul 16-1037 ul alanine aminotransferase alt 43ul 18-1694 ul meld score 15 range 7-38 cp score 9 5-14 74 cirrhosis 82 ascites one point 57 myeloproliferative neoplasm mpn 43 paroxysmal nocturnal hemoglobinuria pnh 17 antiphospholipid antibodies positive aps 13 positive antinuclear antibodies 35 needed tips 44 required liver transplantation 
15,3.0,16.0,"['bilirubin compare cirrhosis', 'bilirubin compare ascites', 'bilirubin compare jak2', 'bilirubin compare p-value']",46,group needing tipsliver transplantdied compared higher bilirubin meld pc score deficiency cirrhosis ascites jak2 mutation p-value significant table 1 
16,3.0,18.0,"['two die patient', 'two die neoplasm', 'two die mpn', 'patient die neoplasm', 'patient die mpn']",48,two patients 87 died total 23 conclusions data indicate patients bcs neoplasms 61 particularly mpn 57 commonly diagnosed 
17,4.0,4.0,"['cancer select vaccine', 'patient select vaccine']",57,online survey within hours 1106 cancer patients selected either yes plan get vaccine no get vaccine 
18,4.0,7.0,"['706 indicate 294', '706 indicate nwtv', 'patient indicate 294', 'patient indicate nwtv', 'vaccine indicate 294', 'vaccine indicate nwtv', '706 induce nwtv', 'patient induce nwtv', 'vaccine induce nwtv', '294 induce nwtv']",60,results overall 706 patients indicated willingness get vaccine wtv 294 reported opposite nwtv 
19,4.0,9.0,"['patient elapse 451', 'patient elapse uk', 'patient elapse breast', 'patient elapse lung', 'patient elapse prostate', 'patient elapse 33', 'patient elapse 19', 'patient elapse 15']",62,next strongest determinant time elapsed since patient s diagnosis largest population available diagnosis date 451 uk patients average time since diagnosis patients wtv vs nwtv breast 35 vs 25 years lung 16 vs 14 years prostate 24 vs 33 years colorectal 19 vs 15 years 
20,4.0,10.0,"['patient increase spanish', 'patient increase french', 'patient increase german', '148 increase spanish', '148 increase patient', '148 increase french', '148 increase patient', '148 increase german', '148 increase patient', 'italian increase spanish', 'italian increase patient', 'italian increase french', 'italian increase patient', 'italian increase german', 'italian increase patient', 'patient increase spanish', 'patient increase french', 'patient increase german']",63,among patients countries available diagnosis date time since diagnosis increased among 148 italian patients wtv gradually increased among 94 spanish patients wtv substantially decreased among 85 french patients wtv gradually decreased among 50 german patients wtv substantially increased 
21,4.0,14.0,['patient collect vaccine'],67,patient input collected shortly first vaccine s approval 
22,5.0,1.0,['hcws include igg'],71,methods consenting hcws invited circulating igg levels measured vaccination 6 subsequent timepoints 
23,5.0,3.0,"['igg circulate infection', 'igg circulate kruskall-wallis', 'igg boost kruskall-wallis', 'infection boost kruskall-wallis']",73,described trends circulating igg geometric mean concentration age ethnicity timing boosting previous infection status compared strata using kruskall-wallis tests 
24,5.0,8.0,"['igg boost 8-9', 'igg boost p002', '6-7 boost 8-9', '6-7 boost p002', 'igg dose p002', '6-7 dose p002']",78,igg gmc boosted 6-7 months dose 2 lower compared boosted 8-9 months 1999-vs 2736 p002 
25,5.0,10.0,"['igg infect infection', 'igg infect immunity']",80,igg titres decrease among previously infected individuals proportion reinfected individuals group comparable proportion breakthrough infection previously uninfected individuals suggests individuals hybrid immunity infectionvaccination may also require doses 
26,7.0,2.0,['hamster induce sars-cov-2'],96,immunizing hamsters wild-type mutant sars-cov-2 bearing variant spikes alpha beta gamma epsilon animals developed faster greater neutralization activities homologous sars-cov-2 variants heterologous variants including delta 
27,7.0,5.0,['hamster vaccinate sars-cov-2'],99,nevertheless immunized hamsters protected challenges sars-cov-2 variants including exhibiting lowest neutralizing antibody titers 
28,8.0,0.0,"['age-dependent include dengue', 'age-dependent include brazil', 'age-dependent include dengvaxia', 'mosquito include dengue', 'mosquito include brazil', 'mosquito include dengvaxia', 'biting include dengue', 'biting include brazil', 'biting include dengvaxia']",101,paper introduce single serotype transmission model including age-dependent mosquito biting rate find optimal vaccination age dengue brazil dengvaxia 
29,8.0,5.0,"['ade include primary infections', 'ade include tertiary quaternary', 'ade include cross-immunity']",106,ade assumed imply risk-free primary infections permanent cross-immunity implies risk-free tertiary quaternary infections 
30,8.0,10.0,['ade induce optimal'],111,assumption ade generally leads higher optimal vaccination age case 
31,9.0,0.0,['influenza recommend adult'],117,introduction annual influenza vaccination recommended older adults evidence regarding impact repeated vaccination inconclusive 
32,9.0,1.0,"['vaccine investigate influenza', 'vaccine investigate adult', 'vaccine confirm adult', 'influenza confirm adult']",118,aim investigated vaccine effectiveness laboratory-confirmed influenza impact repeated vaccination 10 previous seasons current season among older adults 
33,9.0,7.0,"['patient vaccinate ci Ã\x83\x83Ã\x83\x82Ã\x83\x824', 'patient receive ci Ã\x83\x83Ã\x83\x82Ã\x83\x824', 'patient receive ci Ã\x83\x83Ã\x83\x82Ã\x83\x824', 'patient receive ci Ã\x83\x83Ã\x83\x82Ã\x83\x824']",124,patients vaccinated current season received vaccinations previous 10 seasons higher current season 34 95 ci 9 52 patients received 1ÃÂÂ3 26 95 ci 13 37 4ÃÂÂ6 24 95 ci 15 33 7ÃÂÂ8 13 95 ci 2 22 9ÃÂÂ10 7 95 ci ÃÂÂ4 16 vaccinations trend test p 0001 
34,10.0,5.0,['covid-19 confirm transcriptase'],133,meta-analysis included studies confirmed cases covid-19 using reverse transcriptase polymerase chain reaction 
35,10.0,6.0,['8926 emerge vaccine'],134,study detected 8926 eligible research articles published covid-19 vaccines 
36,10.0,12.0,"['antibody neutralize respiratory', 'antibody neutralize syndrome', 'antibody neutralize coronavirus', 'antibody neutralize sars-cov-2', 'antibody neutralize vaccine', 'antibody bind syndrome', 'antibody bind coronavirus', 'antibody bind sars-cov-2', 'antibody bind vaccine']",140,production neutralizing antibodies receptor-binding domains rbds severe acute respiratory syndrome coronavirus 2 sars-cov-2 90 vaccinated samples reported within 0ÃÂÂ30 days first second dose vaccine 
37,10.0,14.0,"['fever receive people', 'fever receive mrna', 'fever receive vaccine', 'people receive mrna', 'people receive vaccine', 'adenovirus receive people', 'adenovirus receive mrna', 'adenovirus receive vaccine', 'vaccine receive people', 'vaccine receive mrna', 'fatigue receive people', 'fatigue receive mrna', 'fatigue receive vaccine']",142,fever 02 ÃÂÂ95 prevalent people receiving adenovirus vector vaccines fatigue 84 ÃÂÂ55 common side effect people receiving mrna vaccines 
38,10.0,15.0,"['mrna provide covid-19', 'mrna provide infection', 'mrna provide people', 'mrna provide 18', 'vaccine provide covid-19', 'vaccine provide infection', 'vaccine provide people', 'vaccine provide 18', 'adenovirus provide covid-19', 'adenovirus provide infection', 'adenovirus provide people', 'adenovirus provide 18', 'vaccine provide covid-19', 'vaccine provide infection', 'vaccine provide people', 'vaccine provide 18']",143,studies suggest mrna vaccines adenovirus vector vaccines provide moderate high protection covid-19 infection people 18 years 
39,11.0,1.0,"['cohort show chadox1-ncov-19', 'cohort show bnt162b2', 'cohort show n66', 'cohort show mrna-1273', 'cohort show mrna-regimens', 'cohort show n43', 'cohort show bnt162b2', 'cohort show n59', 'cohort show mrna-1273', 'cohort show chadox1-ncov-19', 'cohort show n62', '331 show chadox1-ncov-19', '331 show bnt162b2', '331 show n66', '331 show mrna-1273', '331 show mrna-regimens', '331 show n43', '331 show bnt162b2', '331 show n59', '331 show mrna-1273', '331 show chadox1-ncov-19', '331 show n62', 'cellular show chadox1-ncov-19', 'cellular show bnt162b2', 'cellular show n66', 'cellular show mrna-1273', 'cellular show mrna-regimens', 'cellular show n43', 'cellular show bnt162b2', 'cellular show n59', 'cellular show mrna-1273', 'cellular show chadox1-ncov-19', 'cellular show n62', 'immunity show chadox1-ncov-19', 'immunity show bnt162b2', 'immunity show n66', 'immunity show mrna-1273', 'immunity show mrna-regimens', 'immunity show n43', 'immunity show bnt162b2', 'immunity show n59', 'immunity show mrna-1273', 'immunity show chadox1-ncov-19', 'immunity show n62', 'cohort follow bnt162b2', 'cohort follow n59', 'cohort follow mrna-1273', 'cohort follow chadox1-ncov-19', 'cohort follow n62', '331 follow bnt162b2', '331 follow n59', '331 follow mrna-1273', '331 follow chadox1-ncov-19', '331 follow n62', 'cellular follow bnt162b2', 'cellular follow n59', 'cellular follow mrna-1273', 'cellular follow chadox1-ncov-19', 'cellular follow n62', 'immunity follow bnt162b2', 'immunity follow n59', 'immunity follow mrna-1273', 'immunity follow chadox1-ncov-19', 'immunity follow n62', 'chadox1-ncov-19 follow bnt162b2', 'chadox1-ncov-19 follow n59', 'chadox1-ncov-19 follow mrna-1273', 'chadox1-ncov-19 follow n62', 'bnt162b2 follow n59', 'bnt162b2 follow mrna-1273', 'bnt162b2 follow chadox1-ncov-19', 'bnt162b2 follow n62', 'n66 follow bnt162b2', 'n66 follow n59', 'n66 follow mrna-1273', 'n66 follow chadox1-ncov-19', 'n66 follow n62', 'mrna-1273 follow bnt162b2', 'mrna-1273 follow n59', 'mrna-1273 follow chadox1-ncov-19', 'mrna-1273 follow n62', 'mrna-regimens follow bnt162b2', 'mrna-regimens follow n59', 'mrna-regimens follow mrna-1273', 'mrna-regimens follow chadox1-ncov-19', 'mrna-regimens follow n62']",147,using convenience cohort 331 healthy individuals show humoral cellular immunity vaccination chadox1-ncov-19 followed either bnt162b2 n66 mrna-1273 n101 equivalent superior homologous mrna-regimens n43 bnt162b2 n59 mrna-1273 pronounced homologous chadox1-ncov-19 vaccination n62 
40,11.0,3.0,"['combination observe cd4 t-cell', 'combination observe mrna-1273', 'combination observe bnt162b2']",149,among mrna-containing combinations spike-specific cd4 t-cell levels regimens including mrna-1273 higher respective combinations bnt162b2 
41,11.0,5.0,['five induce chadox1-ncov-19-priming'],151,five regimens well tolerated pronounced reactogenicity upon chadox1-ncov-19-priming mrna-1273-boosting 
42,11.0,6.0,"['vectormrna-boosting boost mrna', 'vectormrna-boosting boost vaccine', 'mrna-regimens boost mrna', 'mrna-regimens boost vaccine', 'vector-regimens boost mrna', 'vector-regimens boost vaccine']",152,conclusion immunogenicity heterologous vectormrna-boosting homologous mrna-regimens superior homologous vector-regimens notable differences mrna vaccines 
43,12.0,0.0,"['woman characterize placenta', 'plasmodium characterize placenta', 'falciparum characterize placenta', 'malaria characterize placenta', 'blood characterize placenta']",153,background endemic areas pregnant women highly susceptible plasmodium falciparum malaria characterized accumulation parasitized red blood cells prbc placenta 
44,12.0,1.0,"['woman develop malaria', 'woman develop antibody', 'woman develop antigen', 'woman associate antigen', 'immunity associate antigen', 'malaria associate antigen']",154,subsequent pregnancies women develop protective immunity pregnancy-associated malaria hypothesized due acquisition antibodies parasite variant surface antigen var2csa 
45,12.0,3.0,"['woman base falciparum', 'woman base falciparum', 'woman base antigen', 'woman base malaria', 'woman base peripheral', 'woman base anaemia', 'woman base malaria', 'woman emerge falciparum', 'woman emerge antigen', 'woman emerge malaria', 'woman emerge peripheral', 'woman emerge anaemia', 'woman emerge malaria', 'falciparum emerge antigen', 'falciparum emerge malaria', 'falciparum emerge peripheral', 'falciparum emerge anaemia', 'falciparum emerge malaria', 'woman induce malaria', 'woman induce peripheral', 'woman induce anaemia', 'woman induce malaria', 'falciparum induce malaria', 'falciparum induce peripheral', 'falciparum induce anaemia', 'falciparum induce malaria', 'falciparum induce malaria', 'falciparum induce peripheral', 'falciparum induce anaemia', 'falciparum induce malaria', 'antigen induce malaria', 'antigen induce peripheral', 'antigen induce anaemia', 'antigen induce malaria', 'woman test anaemia', 'woman test malaria', 'falciparum test anaemia', 'falciparum test malaria', 'falciparum test anaemia', 'falciparum test malaria', 'antigen test anaemia', 'antigen test malaria', 'malaria test anaemia', 'peripheral test anaemia', 'peripheral test malaria']",156,methods conducted systematic review meta-analysis population-based studies published 07 june 2019 pregnant women living p falciparum endemic areas examined antibody responses pregnancy-specific p falciparum antigens outcomes including placental malaria low birthweight preterm birth peripheral parasitaemia maternal anaemia severe malaria 
46,12.0,6.0,['antigen test antibody'],159,included studies varied terms antigens tested methodology used measure antibody responses epidemiological setting 
47,12.0,7.0,"['pregnancy-specific associate infection', 'antigen associate infection', 'malaria associate infection', 'pregnancy-specific evaluate infection', 'antigen evaluate infection', 'malaria evaluate infection']",160,antibody responses pregnancy-specific prbc var2csa antigens measured delivery associated placental malaria 9 studies may therefore represent markers infection rather correlates protection 
48,12.0,9.0,"['antigen associate peripheral', 'antigen associate malaria']",162,conclusions whilst antibody responses several antigens positively associated presence placental peripheral infections review identify evidence specific antibody response associated protection pregnancy-associated malaria across multiple populations 
49,12.0,10.0,"['cohort standardize antigen', 'cohort standardize pregnancy-specific', 'cohort standardize falciparum', 'cohort standardize antigen', 'cohort standardize vaccine', 'cohort standardize woman', 'cohort test antigen', 'cohort test pregnancy-specific', 'cohort test falciparum', 'cohort test antigen', 'cohort test vaccine', 'cohort test woman', 'cohort receive woman', 'antigen receive woman', 'pregnancy-specific receive woman', 'falciparum receive woman', 'antigen receive woman', 'vaccine receive woman']",163,prospective cohort studies using standardized laboratory methods examine responses broad range antigens different epidemiological settings throughout gestational period necessary identify prioritize pregnancy-specific p falciparum antigens advance development vaccines serosurveillance tools targeting pregnant women 
50,13.0,3.0,['meta-analyze observe 15310'],167, meta-analyze randomized controlled trials efficacy data 3 trials n 15310 immunogenicity data 17 trials n 9062 
51,13.0,4.0,"['influenza vaccines provide influenza 026', 'influenza vaccines provide child', 'influenza vaccines confirm child', 'influenza 026 confirm child']",168,compared non-adjuvanted counterparts adjuvanted influenza vaccines provide significantly better protection weighted estimate risk ratio rt-pcr-confirmed influenza 026 significantly immunogenic weighted estimates seroprotection rate ratio 46 79 healthy immunologically naive young children 
52,13.0,6.0,"['influenza vaccines improve child', 'influenza vaccines improve influenza', 'oil-in-water improve child', 'oil-in-water improve influenza', 'emulsion improve child', 'emulsion improve influenza']",170,results indicate oil-in-water emulsion adjuvant improves efficacy inactivated influenza vaccines healthy young children first-time seasonal influenza vaccination 
53,14.0,0.0,"['hcc show tlr-78rig-i', 'hcc show agonist', 'hcc show curevac']",171,background previously shown hcc patients healthy subjects equally responsive rnadjuvant ÃÂ novel tlr-78rig-i agonist based noncoding rna developed curevac ex vivo evaluation 
54,14.0,2.0,"['cancer evaluate immune', 'cancer evaluate patient', 'vaccine evaluate immune', 'vaccine evaluate cancer', 'vaccine evaluate patient']",173,different adjuvants currently used cancer vaccine clinical trials evaluated present study immune cells cancer patients chemotherapy ex vivo setting 
55,14.0,3.0,"['pbmcs induce volunteer', 'pbmcs induce patient', 'pbmcs induce colon', 'pbmcs induce oma', 'pbmcs induce lung', 'pbmcs induce cancer', 'pbmcs affect cancer', 'volunteer affect cancer', 'patient affect cancer', 'colon affect cancer', 'oma affect cancer']",174,methods pbmcs obtained 4 healthy volunteers 23 patients affected either colon oma lung cancer ot 
56,14.0,7.0,['hla-dr receive cd4 cell'],178,indeed cd80 cd86 hla-dr expression found upregulated circulating dendritic cells promoted cd4 cell differentiation towards effector phenotype 
57,14.0,11.0,"['cancer induce vaccine', 'patient induce cancer', 'patient induce vaccine']",182,conclusions present study first analysis immunological effects induced adjuvants cancer patients undergo chemotherapy enrolled currently ongoing cancer vaccine clinical trials 
58,14.0,13.0,"['chemotherapy show cancer', 'chemotherapy show patient', 'chemotherapy show cancer', 'chemotherapy show vaccine']",184,importantly demonstrated chemotherapy significantly impair immune system implying cancer patients likely respond cancer vaccine even chemotherapy treatment 
59,16.0,3.0,"['cohort vary igg', '473 vary igg', 'survivor vary igg']",196,cohort 473 survivors varying disease severity asymptomatic mild moderate severe observed positive correlation virusÃÂÂspecific igg antibody titers covidÃÂÂ19 severity 
60,17.0,0.0,"['covid-19 make cancer', 'covid-19 make patient']",200,recently vaccination covid-19 gained wide diffusion especially among vulnerable individuals cancer patients 
61,17.0,1.0,"['patient undergo axillary', 'patient undergo nodal', 'petct undergo axillary', 'petct undergo nodal']",201,time patients undergoing petct examinations vaccination increasing number cases false-positive axillary nodal uptake described mostly 18 f-fdg pet 
62,18.0,0.0,"['immunization become respiratory syndrome', 'covid19 become respiratory syndrome']",203,introduction generalized immunization covid19 become cornerstone prevention associated severe acute respiratory syndrome 
63,18.0,2.0,"['bnt162b2 document peritoneal', 'bnt162b2 document patient', 'vaccine document peritoneal', 'vaccine document patient']",205,efficacy security bnt162b2 vaccine well documented general population mdp particularly peritoneal dialysis pd patients 
64,18.0,5.0,"['igg evaluate auml', 'igg evaluate two']",208,specific anti-spike igg measured arbitrary units per milliliter auml two separate occasions 3 weeks first dose 3 weeks second 
65,18.0,6.0,['two compare non-responders'],209,two modality groups compared absolute value number non-responders nr inoculations 
66,18.0,10.0,"['phi0383 respond one', 'phi0383 respond p008']",213,hd status associated non-responding first dose phi0383 p 001 second one p008 
67,19.0,3.0,"['2021 receive vaccine', '2021 receive moderna', '414 receive vaccine', '414 receive moderna', 'mrna receive vaccine', 'mrna receive moderna']",221,results december 2020 february 2021 recorded 414 cutaneous reactions mrna covid-19 vaccines moderna 83 pfizer 17 
68,19.0,4.0,"['injection follow morbilliform eruptions', 'injection follow urticarial', 'injection follow eruption']",222,delayed large local reactions common followed local injection site reactions urticarial eruptions morbilliform eruptions 
69,20.0,1.0,"['paratuberculosis cause ruminant', 'paratuberculosis cause gastroenteritis', 'paratuberculosis cause ruminant', 'paratuberculosis cause gastroenteritis']",232,paratuberculosis m paratuberculosis causes johneÃÂÂs disease ruminants characterized chronic gastroenteritis leading heavy economic losses dairy industry worldwide 
70,20.0,2.0,"['vaccine prevent herd', 'bacterin prevent herd', 'oil prevent herd']",233,currently available vaccine inactivated bacterin oil base effective preventing pathogen shedding rarely used control johneÃÂÂs disease dairy herds 
71,20.0,3.0,"['vaccine prevent polyanhydride', 'vaccine prevent antigen', 'vaccine prevent cell', 'vaccine prevent paratuberculosis', 'vaccine use cell', 'vaccine use paratuberculosis', 'polyanhydride use cell', 'polyanhydride use paratuberculosis', 'antigen use cell', 'antigen use paratuberculosis', 'vaccine encapsulate paratuberculosis', 'polyanhydride encapsulate paratuberculosis', 'antigen encapsulate paratuberculosis', 'cell encapsulate paratuberculosis']",234,develop better vaccine prevent spread johneÃÂÂs disease utilized polyanhydride nanoparticles pan encapsulate mycobacterial antigens composed whole cell lysate pan-lysate culture filtrate pan-cf m paratuberculosis 
72,20.0,4.0,"['nanoparticle-based base mouse', 'nanoparticle-based base injection', 'vaccine base mouse', 'vaccine base injection']",235,nanoparticle-based vaccines ie nanovaccines well tolerated mice causing inflammatory lesions site injection 
73,20.0,6.0,"['animal vaccinate cd8 cells', 'animal vaccinate ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'animal vaccinate tnf-Ã\x83\x83Ã\x83\x82', 'animal vaccinate cytokine', 'animal vaccinate ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'animal vaccinate vaccine', 'animal continue cd8 cells', 'animal continue ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'animal continue tnf-Ã\x83\x83Ã\x83\x82', 'animal continue cytokine', 'animal continue ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'animal continue vaccine', 'animal induce cd8 cells', 'animal induce cytokine', 'animal induce ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'animal induce vaccine', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ induce cd8 cells', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ induce cytokine', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ induce animal', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ induce vaccine']",237,following challenge animals vaccinated pan-cf continued produce significant levels double ifn-ÃÂ³ tnf-ÃÂ single cytokine ifn-ÃÂ³ secreting cd8 cells compared animals vaccinated inactivated vaccine 
74,20.0,8.0,"['polyanhydride induce immunity', 'polyanhydride induce intracellular', 'polyanhydride induce intracellular', 'immunity induce intracellular']",239,overall use polyanhydride nanovaccines resulted development protective sustained immunity johneÃÂÂs disease approach could applied counter intracellular pathogens 
75,21.0,0.0,"['two-dose provide sars-cov-2', 'two-dose provide vaccine', 'mrna provide sars-cov-2', 'mrna provide vaccine']",240,although two-dose mrna vaccination provides excellent protection sars-cov-2 little information vaccine efficacy variants concern voc individuals eighty years age 1 
76,21.0,2.0,"['serum bind eighty years', 'serum bind vaccine', 'serum bind participant', 'igg bind eighty years', 'igg bind vaccine', 'igg bind participant', 'serum dose eighty years', 'serum dose participant', 'igg dose eighty years', 'igg dose participant', 'iga dose eighty years', 'iga dose participant', 'vaccine dose eighty years', 'vaccine dose participant']",242,serum neutralization levels binding igg iga first vaccine dose lower older individuals marked drop participants eighty years old 
77,21.0,3.0,"['participant show alpha', 'participant show b1351', 'participant show beta', 'eighty show alpha', 'eighty show b1351', 'eighty show beta']",243,sera participants eighty showed lower neutralization potency b117 alpha b1351 beta p1 
78,21.0,7.0,['participant show cell'],247,elderly participants showed clear reduction somatic hypermutation class-switched cells 
79,22.0,0.0,"['sars-cov-2 induce health professionals', 'sars-cov-2 induce spain', 'sars-cov-2 induce 12-15']",250,background sars-cov-2 infection presents high transmission group health professionals spain 12-15 infected 
80,22.0,4.0,"['participant make covid', 'participant make anesthesia', 'participant make aerosol-generating', 'health-care make covid', 'health-care make anesthesia', 'health-care make aerosol-generating']",254,participants adult health-care professionals 18-65 years working areas high exposure high risk transmission sars-cov-2 covid areas intensive care unit -icus- emergency anesthesia performing aerosol-generating procedures included 
81,22.0,6.0,"['patient randomize oral', 'patient randomize hydroxychloroquine', 'patient randomize 200mg', 'patient randomize two']",256,interventions patients randomized 11 receive once-daily oral hydroxychloroquine 200mg two months hc group placebo p group addition protective measures appropriate level exposure established hospital 
82,22.0,8.0,['infection induce sars-cov-2'],258,primary outcome percentage subjects presenting infection seroconversion andor pcr ve sars-cov-2 virus observation period 
83,22.0,10.0,"['vaccine await prophylaxis', 'vaccine await sars-cov-2', 'vaccine await professional']",260,discussion awaiting vaccine hygiene measures social distancing personal protective equipment primary prophylaxis measures sars-cov-2 sufficient protect healthcare professionals 
84,22.0,13.0,"['hydroxychloroquine confirm professional', 'hydroxychloroquine confirm infection']",263,hypothesis confirmed hydroxychloroquine help professionals fight infection guarantees 
85,22.0,15.0,"['health professionals make valdecilla', 'health professionals make sars', 'health professionals make cov2', 'health professionals make covid', 'health professionals make anesthesia', 'health professionals make aerosol-generating', '450 make valdecilla', '450 make sars', '450 make cov2', '450 make covid', '450 make anesthesia', '450 make aerosol-generating']",265,450 health professionals working hospital universitario marquÃÂs de valdecilla areas high exposure high risk transmission sars cov2 covid hospital areas intensive care unit emergency anesthesia performing aerosol-generating procedures included 
86,22.0,16.0,"['health professionals collect two', '65 collect two', 'comply collect two', 'health professionals age comply', 'health professionals age two']",266,inclusion criteria 1 health professionals aged 18 65 years inclusive time first screening visit 2 must provide signed written informed consent agree comply study protocol 3 active work high exposure areas last two weeks following weeks 
87,22.0,17.0,"['heart failure induce new york', 'heart failure induce heart', 'heart failure induce qtc', 'heart failure induce cancer', 'heart failure induce cell', 'sars induce new york', 'sars induce heart', 'sars induce qtc', 'sars induce cancer', 'sars induce cell', 'cov2 induce new york', 'cov2 induce heart', 'cov2 induce qtc', 'cov2 induce cancer', 'cov2 induce cell', 'coronavirus induce new york', 'coronavirus induce heart', 'coronavirus induce qtc', 'coronavirus induce cancer', 'coronavirus induce cell', 'sars induce new york', 'sars induce heart', 'sars induce qtc', 'sars induce cancer', 'sars induce cell', 'cov2 induce new york', 'cov2 induce heart', 'cov2 induce qtc', 'cov2 induce cancer', 'cov2 induce cell', 'symptom induce new york', 'symptom induce heart', 'symptom induce qtc', 'symptom induce cancer', 'symptom induce cell', 'hydroxychloroquine induce new york', 'hydroxychloroquine induce heart', 'hydroxychloroquine induce qtc', 'hydroxychloroquine induce cancer', 'hydroxychloroquine induce cell', 'chloroquine induce new york', 'chloroquine induce heart', 'chloroquine induce qtc', 'chloroquine induce cancer', 'chloroquine induce cell', 'hypersensitivity induce new york', 'hypersensitivity induce heart', 'hypersensitivity induce qtc', 'hypersensitivity induce cancer', 'hypersensitivity induce cell', 'allergy induce new york', 'allergy induce heart', 'allergy induce qtc', 'allergy induce cancer', 'allergy induce cell', 'hydroxychloroquine induce new york', 'hydroxychloroquine induce heart', 'hydroxychloroquine induce qtc', 'hydroxychloroquine induce cancer', 'hydroxychloroquine induce cell', 'tamoxifen induce new york', 'tamoxifen induce heart', 'tamoxifen induce qtc', 'tamoxifen induce cancer', 'tamoxifen induce cell', 'raloxifene induce new york', 'raloxifene induce heart', 'raloxifene induce qtc', 'raloxifene induce cancer', 'raloxifene induce cell', 'eye induce new york', 'eye induce heart', 'eye induce qtc', 'eye induce cancer', 'eye induce cell']",267,exclusion criteria 1 previous infection sars cov2 positive coronavirus pcr positive serology sars cov2 negative pcr absence symptoms 2 current treatment hydroxychloroquine chloroquine 3 hypersensitivity allergy contraindication taking hydroxychloroquine technical sheet 4 previous current treatment tamoxifen raloxifene 5 previous eye disease especially maculopathy 6 known heart failure grade iii iv new york heart association classification prolonged qtc 7 type cancer except basal cell last 5 years 6 refusal give informed consent 8 evidence unstable clinically significant untreated immune endocrine hematological gastrointestinal neurological neoplastic psychiatric illness 9 antibodies positive human immunodeficiency virus 10 significant kidney liver disease 11 pregnancy lactation 
88,22.0,19.0,"['hydroxychloroquine sulfate coat 225', 'hydroxychloroquine sulfate coat one', 'hydroxychloroquine sulfate coat hydroxychloroquine', 'hydroxychloroquine sulfate coat tablet', 'hydroxychloroquine sulfate coat two', 'hydroxychloroquine sulfate coat sars', 'hydroxychloroquine sulfate coat cov2', 'hydroxychloroquine sulfate coat sars-cov2', 'hydroxychloroquine sulfate coat healthcare', 'hydroxychloroquine sulfate coat pneumonia', 'hydroxychloroquine sulfate coat curb', 'hydroxychloroquine sulfate coat 8805', '225 coat one', '225 coat hydroxychloroquine', '225 coat tablet', '225 coat two', '225 coat sars', '225 coat cov2', '225 coat sars-cov2', '225 coat healthcare', '225 coat pneumonia', '225 coat curb', '225 coat 8805', 'one coat 225', 'one coat hydroxychloroquine', 'one coat tablet', 'one coat two', 'one coat sars', 'one coat cov2', 'one coat sars-cov2', 'one coat healthcare', 'one coat pneumonia', 'one coat curb', 'one coat 8805', '200 coat 225', '200 coat one', '200 coat hydroxychloroquine', '200 coat tablet', '200 coat two', '200 coat sars', '200 coat cov2', '200 coat sars-cov2', '200 coat healthcare', '200 coat pneumonia', '200 coat curb', '200 coat 8805', 'tablet coat 225', 'tablet coat one', 'tablet coat hydroxychloroquine', 'tablet coat two', 'tablet coat sars', 'tablet coat cov2', 'tablet coat sars-cov2', 'tablet coat healthcare', 'tablet coat pneumonia', 'tablet coat curb', 'tablet coat 8805', 'hydroxychloroquine sulfate evaluate healthcare', 'hydroxychloroquine sulfate evaluate pneumonia', 'hydroxychloroquine sulfate evaluate curb', 'hydroxychloroquine sulfate evaluate 8805', '225 evaluate healthcare', '225 evaluate pneumonia', '225 evaluate curb', '225 evaluate 8805', 'one evaluate healthcare', 'one evaluate pneumonia', 'one evaluate curb', 'one evaluate 8805', '200 evaluate healthcare', '200 evaluate pneumonia', '200 evaluate curb', '200 evaluate 8805', 'tablet evaluate healthcare', 'tablet evaluate pneumonia', 'tablet evaluate curb', 'tablet evaluate 8805', 'two evaluate healthcare', 'two evaluate pneumonia', 'two evaluate curb', 'two evaluate 8805', '225 evaluate healthcare', '225 evaluate pneumonia', '225 evaluate curb', '225 evaluate 8805', 'one evaluate healthcare', 'one evaluate pneumonia', 'one evaluate curb', 'one evaluate 8805', 'hydroxychloroquine evaluate healthcare', 'hydroxychloroquine evaluate pneumonia', 'hydroxychloroquine evaluate curb', 'hydroxychloroquine evaluate 8805', 'tablet evaluate healthcare', 'tablet evaluate pneumonia', 'tablet evaluate curb', 'tablet evaluate 8805', 'two evaluate healthcare', 'two evaluate pneumonia', 'two evaluate curb', 'two evaluate 8805', 'sars evaluate healthcare', 'sars evaluate pneumonia', 'sars evaluate curb', 'sars evaluate 8805', 'cov2 evaluate healthcare', 'cov2 evaluate pneumonia', 'cov2 evaluate curb', 'cov2 evaluate 8805', 'sars-cov2 evaluate healthcare', 'sars-cov2 evaluate pneumonia', 'sars-cov2 evaluate curb', 'sars-cov2 evaluate 8805', 'hydroxychloroquine sulfate induce 8805', '225 induce 8805', 'one induce 8805', '200 induce 8805', 'tablet induce 8805', 'two induce 8805', '225 induce 8805', 'one induce 8805', 'hydroxychloroquine induce 8805', 'tablet induce 8805', 'two induce 8805', 'sars induce 8805', 'cov2 induce 8805', 'sars-cov2 induce 8805', 'healthcare induce 8805', 'pneumonia induce 8805']",269,1 intervention n 225 one 200 mg hydroxychloroquine sulfate coated tablet daily two months2 comparator control group n 225 one hydroxychloroquine placebo tablet identical drug daily two months main outcomes primary outcome study evaluate number percentage healthcare personnel presenting symptomatic asymptomatic infection see diagnosis sars cov2 infection sars-cov2 virus study observation period 8 weeks treatment arms number percentage healthcare personnel group presenting pneumonia severity criteria curb 65 8805 2 number percentage healthcare personnel requiring admission intensive care unit icu treatment arms 
89,22.0,21.0,"['sars-cov-2 perform takara', 'sars-cov-2 perform cdc', 'sars-cov-2 perform covid-19', 'sars-cov-2 perform participant', 'sars-cov-2 perform 1', 'sars-cov-2 confirm cdc', 'sars-cov-2 confirm covid-19', 'sars-cov-2 confirm participant', 'sars-cov-2 confirm 1', 'one confirm cdc', 'one confirm covid-19', 'one confirm sars-cov-2', 'one confirm participant', 'one confirm 1', 'takara confirm cdc', 'takara confirm covid-19', 'takara confirm sars-cov-2', 'takara confirm participant', 'takara confirm 1', 'sars-cov-2 perform 1', 'one perform 1', 'takara perform 1', 'cdc perform 1', 'covid-19 perform 1', 'sars-cov-2 perform 1', 'participant perform 1']",271,cases seroconversion sars-cov-2 pcr performed rule confirm active infection rt-pcr one step rt performed mastermix takara idt probes following protocol published validated cdc evaluation covid-19 case sars-cov-2 infection randomisation participants allocated intervention comparator groups according balanced randomization scheme 1 1 
90,22.0,23.0,"['infection detect 450', 'infection detect participant', 'spain detect 450', 'spain detect participant', 'two-tailed detect 450', 'two-tailed detect participant', 'dropout detect 450', 'dropout detect participant']",273,numbers randomised sample size taking account current high prevalence infection healthcare personnel spain 15 detect difference equal greater 8 percentage estimates two-tailed 95 ci statistical power 80 dropout rate 5 total 450 participants need included 250 arm 
91,23.0,0.0,"['israeli start bnt162b2', 'israeli start vaccine']",277,december 2020 israeli health ministry began mass vaccination campaign bnt162b2 vaccine 
92,23.0,3.0,"['patient acquire autoimmune disease', 'patient acquire bnt162b2', 'patient acquire vaccine', 'thrombotic acquire autoimmune disease', 'thrombotic acquire bnt162b2', 'thrombotic acquire vaccine', 'thrombocytopenic acquire autoimmune disease', 'thrombocytopenic acquire bnt162b2', 'thrombocytopenic acquire vaccine', 'purpura acquire autoimmune disease', 'purpura acquire bnt162b2', 'purpura acquire vaccine']",280,describe case series patients developed acquired thrombotic thrombocytopenic purpura rare autoimmune disease within several days receiving bnt162b2 vaccine 
93,23.0,4.0,"['thrombospondin type evaluate adamts13', 'metalloproteinase evaluate adamts13', 'patient evaluate adamts13']",281,disintegrin metalloproteinase thrombospondin type 1 motif member 13 adamts13 activity evaluated patients history attp vaccination especially sarsÃÂÂcovÃÂÂ2 vaccination immunosuppression treatment considered vaccination cases low adamts13 activity 
94,23.0,6.0,"['thrombocytopenia include thrombocytopenic', 'thrombocytopenia include purpura', 'thrombocytopenia include thrombotic', 'thrombocytopenia include thrombocytopenic', 'thrombocytopenia include purpura']",283,post vaccination thrombocytopenia assessment include immune thrombocytopenic purpura vaccineÃÂÂinduced immune thrombotic thrombocytopenia acquired thrombotic thrombocytopenic purpura 
95,24.0,0.0,"['malaria-endemic receive blood', 'human receive blood', 'immunomodulatory receive blood', 'salivary receive blood']",284,background malaria-endemic areas human populations frequently exposed immunomodulatory salivary components injected mosquito blood feeding 
96,24.0,3.0,"['cross-sectional induce blood', 'cross-sectional induce child', 'cross-sectional induce two', 'cross-sectional induce malaria']",287,methods cross-sectional study carried bouakÃÂ cÃÂte dÃÂÂivoire entomological data blood samples children 0ÃÂÂ14 years collected two sites similar malaria prevalence 
97,24.0,6.0,"['anopheles evaluate gsg6-p1', 'anopheles evaluate salivary', 'anopheles evaluate peptide', 'bite evaluate anopheles', 'bite evaluate gsg6-p1', 'bite evaluate salivary', 'bite evaluate peptide', 'bite evaluate anopheles']",290,individual level exposure anopheles bites evaluated quantifying specific igg response anopheles gsg6-p1 salivary peptide represents proxy anopheles exposure 
98,24.0,7.0,"['child receive petessou', 'child receive igg1', 'child receive igg3', 'anopheles receive petessou', 'anopheles receive igg1', 'anopheles receive igg3', 'pfmsp1 receive petessou', 'pfmsp1 receive igg1', 'pfmsp1 receive igg3', 'child match anopheles', 'child match pfmsp1', 'child match petessou', 'child match igg1', 'child match igg3', 'child induce igg3', 'anopheles induce igg3', 'pfmsp1 induce igg3', 'petessou induce igg3']",291,results anti-plasmodium humoral responses different according level exposure children highly exposed anopheles presenting significantly lower antibody responses pfmsp1 total population igg igg3 petessou village igg igg1 igg3 
99,24.0,9.0,"['culex report anopheles', 'culex report bite', 'child report anopheles', 'child report bite', 'antigen report anopheles', 'antigen report bite']",293,dar-es-salam neighbourhood high culex density reported children presented low antibody levels specific antigens difference according exposure anopheles bites found 
100,25.0,1.0,"['0-11 years select phd', 'patient select phd', 'discharge select phd', 'covid-19 select phd', 'icd-10 select phd']",297,methods hospitalized pediatric patients 0-11 years age primary secondary discharge diagnosis code covid-19 icd-10 code u071 selected 1 april 2020 30 september 2021 us premier healthcare database special release phd sr 
101,25.0,2.0,"['patient evaluate three', 'covid-19-associated evaluate three', 'four evaluate three', 'covid-19 evaluate three', 'patient associate three', 'covid-19-associated associate three', 'four associate three', 'covid-19 associate three', 'patient stratify three', 'covid-19-associated stratify three', 'four stratify three', 'covid-19 stratify three']",298,patient characteristics hospital length stay los in-hospital mortality hospital costs hospital charges covid-19-associated readmission outcomes evaluated stratified age groups 0-4 5-11 four covid-19 disease progression states based intensive care unit icu invasive mechanical ventilation imv usage three sequential calendar periods 
102,25.0,4.0,"['4573 hospitalize patient', '4573 hospitalize 680', '4573 hospitalize 0-4', '4573 hospitalize 320', '4573 hospitalize 560', '4573 hospitalize 672', '4573 hospitalize medicaid', '4573 age 680', '4573 age 0-4', '4573 age 320', '4573 age 560', '4573 age 672', '4573 age medicaid', 'patient age 680', 'patient age 0-4', 'patient age 320', 'patient age 560', 'patient age 672', 'patient age medicaid']",300,results among 4573 hospitalized pediatric patients aged 0-11 years 680 0-4 years 320 5-11 years mean median age 32 1 years 560 male 672 covered medicaid 
103,25.0,11.0,"['0-11 years experience covid-19', 'child experience covid-19', 'child emphasize 0-11 years', 'child emphasize covid-19', 'child emphasize covid-19', '0-11 years need covid-19', 'child need covid-19']",307,conclusions findings underscore children aged 0-11 years experience severe covid-19 illness requiring hospitalization substantial hospital resource use supporting recommendations covid-19 vaccination 
104,26.0,2.0,"['vaccine need infection', 'vaccine block infection']",310,new improved vaccines enteric pathogens needed development hindered lack immunological correlates protection especially site infection 
105,26.0,3.0,['tissue provide infection'],311,tissue resident memory rm cells provide immediate adaptive effector immune responsiveness infection site 
106,26.0,6.0,['ileum biopsies induce volunteer'],314,methods terminal ileum biopsies obtained consenting volunteers undergoing routine colonoscopy either immunized orally 4 doses ty21a 
107,26.0,7.0,"['lamina use ebv-b', 'propria use ebv-b', 'mononuclear use ebv-b', 'lpmc use ebv-b', 'iel use ebv-b', 'cd4t use ebv-b']",315,isolated lamina propria mononuclear cells lpmc intraepithelial lymphocytes iel cd4t rm immune responses determined using either s typhi-infected non-infected autologous ebv-b cell lines stimulator cells 
108,26.0,9.0,"['cd4t rm decrease cytokine', 'cd4t rm decrease il-17a', 'cd4t rm decrease cytokine', 'cd4t rm decrease il-17a', 'cd103 decrease cytokine', 'cd103 decrease il-17a', 'cd103 decrease cytokine', 'cd103 decrease il-17a']",317,results although frequencies lpmc cd103 cd4t rm significant decreased cd103 cd103ÃÂÂ cd4t rm subsets spontaneously produced significantly higher levels cytokines ifnÃÂ³ il-17a following ty21a-immunization 
109,26.0,12.0,"['cd4t rm observe immunization', 'iel observe immunization', 'iel observe immunization', 'cd103 observe immunization']",320,addition determined effect ty21a-immunization iel observed significant changes frequencies iel cd103 decrease cd103ÃÂÂ cd4t rm increase following immunization 
110,26.0,13.0,"['iel cd103Ã\x83\x83Ã\x83\x82Ã\x83\x82 observe cd4t rm', 'iel cd103Ã\x83\x83Ã\x83\x82Ã\x83\x82 observe cd4t rm', 'iel cd103Ã\x83\x83Ã\x83\x82Ã\x83\x82 observe cd103', 'iel cd103Ã\x83\x83Ã\x83\x82Ã\x83\x82 observe cytokine', 'iel cd103Ã\x83\x83Ã\x83\x82Ã\x83\x82 observe il-17a']",321,finally observed iel cd103ÃÂÂ cd4t rm cd103 cd4t rm produced increased cytokines ifnÃÂ³ tnfÃÂ il-17a s typhi-specific stimulation following ty21a-immunization 
111,27.0,1.0,"['aluminum hydroxide purify zika', 'aluminum hydroxide purify zikv', 'zika purify zikv', 'vaccine purify zika', 'vaccine purify zikv']",326,study evaluated antibody responses efficacy aluminum hydroxide adjuvanted purified inactivated zika vaccine pizv challenge zika virus zikv strain prvabc59 
112,27.0,2.0,"['indian challenge immunization', 'rhesus challenge immunization', 'macaque challenge immunization', 'two challenge immunization', 'pizv challenge immunization', 'zikv challenge immunization', 'six challenge immunization', 'indian receive two', 'indian receive pizv', 'indian receive zikv', 'indian receive six', 'indian receive one', 'indian receive immunization', 'rhesus receive two', 'rhesus receive pizv', 'rhesus receive zikv', 'rhesus receive six', 'rhesus receive one', 'rhesus receive immunization', 'macaque receive two', 'macaque receive pizv', 'macaque receive zikv', 'macaque receive six', 'macaque receive one', 'macaque receive immunization', 'indian vary zikv', 'indian vary six', 'indian vary one', 'indian vary immunization', 'rhesus vary zikv', 'rhesus vary six', 'rhesus vary one', 'rhesus vary immunization', 'macaque vary zikv', 'macaque vary six', 'macaque vary one', 'macaque vary immunization', 'two vary zikv', 'two vary six', 'two vary one', 'two vary immunization', 'pizv vary zikv', 'pizv vary six', 'pizv vary one', 'pizv vary immunization', 'indian range zikv', 'indian range six', 'indian range one', 'indian range immunization', 'rhesus range zikv', 'rhesus range six', 'rhesus range one', 'rhesus range immunization', 'macaque range zikv', 'macaque range six', 'macaque range one', 'macaque range immunization', 'two range zikv', 'two range six', 'two range one', 'two range immunization', 'pizv range zikv', 'pizv range six', 'pizv range one', 'pizv range immunization']",327,indian rhesus macaques received two doses pizv varying concentrations ranging 0016 ÃÂµg ÃÂÂ 10 ÃÂµg subsequently challenged zikv six weeks one year following second immunization 
113,27.0,3.0,"['pizv induce immunization', 'pizv dose immunization']",328,pizv induced dose-dependent immune response boosted second immunization 
114,27.0,4.0,"['zikv perform 2', 'zikv perform 10', 'zikv perform pizv']",329,complete protection zikv infection achieved higher pizv doses 04 ÃÂµg 2 ÃÂµg 10 ÃÂµg 6 weeks 10 ug pizv 1 year following vaccination 
115,28.0,0.0,"['patient treat covid-19', 'patient treat covid-19', 'patient treat vaccine', 'patient develop covid-19', 'patient develop vaccine', 'covid-19 develop vaccine']",333,patients treated anti-cd20 therapy particularly risk developing severe covid-19 however little known regarding covid-19 vaccine effectiveness population 
116,28.0,1.0,"['rheumatic diseases base ocrelizumab', 'rheumatic diseases base n37', 'rheumatic diseases base n22', 't-cell base ocrelizumab', 't-cell base n37', 't-cell base n22', 'mrna-based base ocrelizumab', 'mrna-based base n37', 'mrna-based base n22', 'covid-19 base ocrelizumab', 'covid-19 base n37', 'covid-19 base n22', 'vaccine base ocrelizumab', 'vaccine base n37', 'vaccine base n22', 'patient base ocrelizumab', 'patient base n37', 'patient base n22', 'rituximab base ocrelizumab', 'rituximab base n37', 'rituximab base n22', 'rheumatic diseases treat n22', 't-cell treat n22', 'mrna-based treat n22', 'covid-19 treat n22', 'vaccine treat n22', 'patient treat n22', 'rituximab treat n22', 'ocrelizumab treat n22', 'n37 treat n22']",334,study assesses humoral t-cell responses mrna-based covid-19 vaccines patients treated rituximab rheumatic diseases ocrelizumab multiple sclerosis n37 compared immunocompetent individuals n22 
117,28.0,3.0,"['cd4 cells detect th1', 'antibody detect th1', 'spike detect th1', '-specific detect th1', 'patient detect th1', '85-90 detect th1']",336,contrast antibodies spike -specific cd4 cells equally detected immunocompetent anti-cd20 treated patients 85-90 mostly th1 phenotype 
118,28.0,6.0,"['patient induce t-cell', 'patient induce mrna', 'patient induce covid-19', 'patient induce vaccine']",339,summary study suggests patients anti-cd20 treatment able mount potent t-cell responses mrna covid-19 vaccines despite impaired humoral responses 
119,29.0,0.0,"['vaccine die ama1', 'plasmodium die ama1', 'falciparum die ama1', 'antigen die ama1', 'vaccine base plasmodium', 'vaccine base falciparum', 'vaccine base antigen', 'vaccine base ama1', 'vaccine base polymorphism', 'vaccine base ama1']",341,vaccines based plasmodium falciparum apical membrane antigen 1 ama1 failed due extensive polymorphism ama1 
120,29.0,2.0,"['malaria induce peptide', 'malaria induce epitope', 'child induce peptide', 'child induce epitope']",343,following clinical malaria episodes children short-lived sequence-independent increases average whole-protein seroreactivity well strain-specific responses peptides representing diverse epitopes 
121,29.0,4.0,"['peptide receive four', 'peptide receive epitope', 'peptide receive infection', 'peptide vaccinate four', 'peptide vaccinate epitope', 'peptide vaccinate infection', 'child vaccinate four', 'child vaccinate epitope', 'child vaccinate infection']",345,high-density peptide analysis revealed vaccinated children increases seroreactivity four distinct epitopes exceeded responses natural infection 
122,29.0,6.0,"['antigen bias epitope', 'antigen conserve epitope']",347,antibody measurements using whole antigens may biased towards conserved immunodominant epitopes 
123,29.0,7.0,"['peptide serve epitope', 'peptide serve vaccine', 'peptide serve strain-specific', 'peptide serve vaccine-induced', 'peptide serve antibody', 'peptide receive epitope', 'peptide receive vaccine', 'peptide receive strain-specific', 'peptide receive vaccine-induced', 'peptide receive antibody', 'peptide describe strain-specific', 'peptide describe vaccine-induced', 'peptide describe antibody', 'epitope describe strain-specific', 'epitope describe vaccine-induced', 'epitope describe antibody']",348,peptide microarrays may help identify immunogenic epitopes define correlates vaccine protection measure strain-specific vaccine-induced antibodies 
124,30.0,2.0,"['patient randomize two', 'ic43 randomize two', '100 randomize two', 'saline randomize two', 'patient age ic43', 'patient age 100', 'patient age saline', 'patient age two', 'patient include ic43', 'patient include 100', 'patient include saline', 'patient include two', 'patient induce ic43', 'patient induce 100', 'patient induce saline', 'patient induce two']",351,methods eight hundred patients aged 18 80 years admitted icu expected need mechanical ventilation ÃÂÂ 48 h randomized 11 either ic43 100 ÃÂg saline placebo given two vaccinations 7 days apart 
125,30.0,10.0,"['ic43 induce patient', '100 induce patient', 'vaccine induce patient']",359,interpretation ic43 100 ÃÂg vaccine well tolerated large population medically ill mechanically ventilated patients 
126,31.0,0.0,"['death collect covid-19', 'death collect patient', 'death collect symptom', 'death collect covid-19', 'death collect patient', 'death collect pneumonia', 'death collect one', 'covid-19 collect death', 'covid-19 collect death', 'covid-19 collect patient', 'covid-19 collect symptom', 'covid-19 collect patient', 'covid-19 collect pneumonia', 'covid-19 collect one', 'death generalize symptom', 'death generalize covid-19', 'death generalize patient', 'death generalize pneumonia', 'death generalize one', 'covid-19 generalize symptom', 'covid-19 generalize patient', 'covid-19 generalize pneumonia', 'covid-19 generalize one', 'ehrs generalize symptom', 'ehrs generalize covid-19', 'ehrs generalize patient', 'ehrs generalize pneumonia', 'ehrs generalize one', 'death generalize symptom', 'death generalize covid-19', 'death generalize patient', 'death generalize pneumonia', 'death generalize one', 'covid-19 generalize symptom', 'covid-19 generalize patient', 'covid-19 generalize pneumonia', 'covid-19 generalize one', 'death generalize symptom', 'death generalize covid-19', 'death generalize patient', 'death generalize pneumonia', 'death generalize one', 'patient generalize symptom', 'patient generalize covid-19', 'patient generalize pneumonia', 'patient generalize one', 'death predict ehrs', 'death predict covid-19', 'death predict patient', 'death predict symptom', 'death predict covid-19', 'death predict patient', 'death predict pneumonia', 'death predict one', 'death use ehrs', 'death use covid-19', 'death use patient', 'death use symptom', 'death use covid-19', 'death use patient', 'death use pneumonia', 'death use one', 'covid-19 use ehrs', 'covid-19 use death', 'covid-19 use death', 'covid-19 use patient', 'covid-19 use symptom', 'covid-19 use patient', 'covid-19 use pneumonia', 'covid-19 use one', 'death receive covid-19', 'death receive patient', 'death receive symptom', 'death receive covid-19', 'death receive patient', 'death receive pneumonia', 'death receive one', 'covid-19 receive death', 'covid-19 receive death', 'covid-19 receive patient', 'covid-19 receive symptom', 'covid-19 receive patient', 'covid-19 receive pneumonia', 'covid-19 receive one', 'ehrs receive death', 'ehrs receive covid-19', 'ehrs receive death', 'ehrs receive patient', 'ehrs receive symptom', 'ehrs receive covid-19', 'ehrs receive patient', 'ehrs receive pneumonia', 'ehrs receive one', 'death combine covid-19', 'death combine patient', 'death combine symptom', 'death combine covid-19', 'death combine patient', 'death combine pneumonia', 'death combine one', 'covid-19 combine death', 'covid-19 combine death', 'covid-19 combine patient', 'covid-19 combine symptom', 'covid-19 combine patient', 'covid-19 combine pneumonia', 'covid-19 combine one', 'ehrs combine death', 'ehrs combine covid-19', 'ehrs combine death', 'ehrs combine patient', 'ehrs combine symptom', 'ehrs combine covid-19', 'ehrs combine patient', 'ehrs combine pneumonia', 'ehrs combine one', 'death induce patient', 'death induce symptom', 'death induce covid-19', 'death induce patient', 'death induce pneumonia', 'death induce one', 'covid-19 induce death', 'covid-19 induce patient', 'covid-19 induce symptom', 'covid-19 induce patient', 'covid-19 induce pneumonia', 'covid-19 induce one', 'ehrs induce death', 'ehrs induce patient', 'ehrs induce symptom', 'ehrs induce covid-19', 'ehrs induce patient', 'ehrs induce pneumonia', 'ehrs induce one', 'death induce patient', 'death induce symptom', 'death induce covid-19', 'death induce patient', 'death induce pneumonia', 'death induce one', 'covid-19 induce death', 'covid-19 induce patient', 'covid-19 induce symptom', 'covid-19 induce patient', 'covid-19 induce pneumonia', 'covid-19 induce one', 'death develop symptom', 'death develop covid-19', 'death develop patient', 'death develop pneumonia', 'death develop one', 'covid-19 develop symptom', 'covid-19 develop patient', 'covid-19 develop pneumonia', 'covid-19 develop one', 'ehrs develop symptom', 'ehrs develop covid-19', 'ehrs develop patient', 'ehrs develop pneumonia', 'ehrs develop one', 'death develop symptom', 'death develop covid-19', 'death develop patient', 'death develop pneumonia', 'death develop one', 'covid-19 develop symptom', 'covid-19 develop patient', 'covid-19 develop pneumonia', 'covid-19 develop one', 'death develop symptom', 'death develop covid-19', 'death develop patient', 'death develop pneumonia', 'death develop one', 'patient develop symptom', 'patient develop covid-19', 'patient develop pneumonia', 'patient develop one', 'death boost covid-19', 'death boost patient', 'death boost pneumonia', 'death boost one', 'covid-19 boost patient', 'covid-19 boost pneumonia', 'covid-19 boost one', 'ehrs boost covid-19', 'ehrs boost patient', 'ehrs boost pneumonia', 'ehrs boost one', 'death boost covid-19', 'death boost patient', 'death boost pneumonia', 'death boost one', 'covid-19 boost patient', 'covid-19 boost pneumonia', 'covid-19 boost one', 'death boost covid-19', 'death boost patient', 'death boost pneumonia', 'death boost one', 'patient boost covid-19', 'patient boost pneumonia', 'patient boost one', 'symptom boost covid-19', 'symptom boost patient', 'symptom boost pneumonia', 'symptom boost one', 'death predict covid-19', 'death predict patient', 'death predict pneumonia', 'death predict one', 'covid-19 predict patient', 'covid-19 predict pneumonia', 'covid-19 predict one', 'ehrs predict covid-19', 'ehrs predict patient', 'ehrs predict pneumonia', 'ehrs predict one', 'death predict covid-19', 'death predict patient', 'death predict pneumonia', 'death predict one', 'covid-19 predict patient', 'covid-19 predict pneumonia', 'covid-19 predict one', 'death predict covid-19', 'death predict patient', 'death predict pneumonia', 'death predict one', 'patient predict covid-19', 'patient predict pneumonia', 'patient predict one', 'symptom predict covid-19', 'symptom predict patient', 'symptom predict pneumonia', 'symptom predict one', 'death base covid-19', 'death base patient', 'death base pneumonia', 'death base one', 'covid-19 base patient', 'covid-19 base pneumonia', 'covid-19 base one', 'ehrs base covid-19', 'ehrs base patient', 'ehrs base pneumonia', 'ehrs base one', 'death base covid-19', 'death base patient', 'death base pneumonia', 'death base one', 'covid-19 base patient', 'covid-19 base pneumonia', 'covid-19 base one', 'death base covid-19', 'death base patient', 'death base pneumonia', 'death base one', 'patient base covid-19', 'patient base pneumonia', 'patient base one', 'symptom base covid-19', 'symptom base patient', 'symptom base pneumonia', 'symptom base one', 'death know pneumonia', 'death know one', 'covid-19 know pneumonia', 'covid-19 know one', 'ehrs know pneumonia', 'ehrs know one', 'death know pneumonia', 'death know one', 'covid-19 know pneumonia', 'covid-19 know one', 'death know pneumonia', 'death know one', 'patient know pneumonia', 'patient know one', 'symptom know pneumonia', 'symptom know one', 'covid-19 know pneumonia', 'covid-19 know one', 'patient know pneumonia', 'patient know one', 'death contract one', 'covid-19 contract one', 'ehrs contract one', 'death contract one', 'covid-19 contract one', 'death contract one', 'patient contract one', 'symptom contract one', 'covid-19 contract one', 'patient contract one', 'pneumonia contract one']",363,study aims predict death covid-19 using past medical information routinely collected electronic health records ehrs understand differences risk factors across age groups combining computational methods clinical expertise curated clusters represent 46 clinical conditions potential risk factors death covid-19 infection trained age-stratified generalized linear models glms component-wise gradient boosting predict probability death based know patients contracted virus despite relying previously documented demographics comorbidities models demonstrated similar performance prognostic models require assortment symptoms laboratory values images time diagnosis course illness general found age important predictor mortality covid-19 patients history pneumonia rarely asked typical epidemiology studies one important risk factors predicting covid-19 mortality history diabetes complications cancer breast prostate notable risk factors patients ages 45 65 years patients aged 65-85 years diseases affect pulmonary system including interstitial lung disease chronic obstructive pulmonary disease lung cancer smoking history important predicting mortality ability compute precise individual-level risk scores exclusively based ehr crucial effectively allocating distributing resources prioritizing vaccination among general population
127,32.0,1.0,"['muscle edema observe covid-19', 'injection observe covid-19']",365,muscle edema injection site observed mri secondary immune response ipsilateral breast imaging observations edema reported seen covid-19 vaccinations date 
128,32.0,2.0,"['skin see breast', 'skin see edema', 'skin see covid-19', 'skin see vaccine', 'edema see breast', 'edema see covid-19', 'edema see vaccine', 'capillary see breast', 'capillary see edema', 'capillary see covid-19', 'capillary see vaccine', 'lymphatic see breast', 'lymphatic see edema', 'lymphatic see covid-19', 'lymphatic see vaccine', 'skin increase capillary', 'skin increase lymphatic', 'skin increase drainage', 'skin increase breast', 'skin increase edema', 'skin increase covid-19', 'skin increase vaccine', 'edema increase capillary', 'edema increase lymphatic', 'edema increase drainage', 'edema increase breast', 'edema increase covid-19', 'edema increase vaccine']",366,mammographic findings trabecular skin thickening along increased echogenicity ultrasound seen edema secondary capillary leak poor lymphatic drainage considered possible etiology observed breast edema following recent covid-19 vaccine 
129,32.0,3.0,"['breast describe patient', 'breast describe swelling', 'breast describe injection', 'axillary describe patient', 'axillary describe swelling', 'axillary describe injection']",367,inflammatory changes observed breast axillary tail post vaccination described case series transient clinically relevant patients experience swelling following injection 
130,32.0,4.0,"['mastitis suspect patient', 'mastitis suspect ipsilateral', 'mastitis follow patient', 'mastitis follow ipsilateral']",368,similar evaluations suspected mastitis short interval imaging follow confirm resolution may appropriate patients ipsilateral vaccination histories could potentially reduce number false positive examinations clinical scenario 
131,32.0,5.0,"['inflammatory breast mimic cancer', 'mimic mimic cancer']",369,however inflammatory breast cancer mimic inflammation infection therefore close follow resolution critical miss cancer 
132,33.0,0.0,"['covid-19 induce sars-cov-2', 'covid-19 induce respiratory', 'covid-19 induce syndrome', 'covid-19 induce coronavirus', 'coronavirus induce sars-cov-2', 'coronavirus induce respiratory', 'coronavirus induce syndrome', 'vaccine induce sars-cov-2', 'vaccine induce respiratory', 'vaccine induce syndrome', 'vaccine induce coronavirus', 'covid-19 induce vaccine', 'covid-19 induce sars-cov-2', 'covid-19 induce respiratory', 'covid-19 induce syndrome', 'covid-19 induce coronavirus', 'coronavirus induce vaccine', 'coronavirus induce sars-cov-2', 'coronavirus induce respiratory', 'coronavirus induce syndrome', 'covid-19 prevent respiratory', 'covid-19 prevent syndrome', 'covid-19 prevent coronavirus', 'coronavirus prevent respiratory', 'coronavirus prevent syndrome', 'vaccine prevent respiratory', 'vaccine prevent syndrome', 'vaccine prevent coronavirus', 'sars-cov-2 prevent respiratory', 'sars-cov-2 prevent syndrome', 'sars-cov-2 prevent coronavirus']",370,covid-19 coronavirus disease 2019 represents pandemic several vaccines produced prevent infection andor severe sequelae associated sars-cov-2 severe acute respiratory syndrome coronavirus 2 infection 
133,33.0,1.0,['thrombotic associate vaccine'],371,several reports infrequent post vaccine associated thrombotic events particular adenovirus-based vaccines 
134,33.0,2.0,"['vaccine-induced induce thrombocytopenia syndrome', 'vaccine-induced induce thrombocytopenia', 'vaccine-induced induce vaccine-associated', 'vaccine-induced induce thrombotic', 'vaccine-induced induce thrombocytopenia', 'vaccine-induced induce tt', 'vaccine-induced induce thrombosis', 'thrombocytopenia induce thrombocytopenia syndrome', 'thrombocytopenia induce vaccine-associated', 'thrombocytopenia induce thrombotic', 'thrombocytopenia induce tt', 'thrombocytopenia induce thrombosis', 'vaccine-induced induce thrombocytopenia syndrome', 'vaccine-induced induce thrombocytopenia', 'vaccine-induced induce vaccine-associated', 'vaccine-induced induce thrombotic', 'vaccine-induced induce thrombocytopenia', 'vaccine-induced induce tt', 'vaccine-induced induce thrombosis']",372,variously termed vipit vaccine-induced prothrombotic immune thrombocytopenia vitt vaccine-induced immune thrombotic thrombocytopenia vatt vaccine-associated immune thrombotic thrombocytopenia tts thrombosis thrombocytopenia syndrome 
135,33.0,6.0,"['summary establish platelet factor', 'summary establish fibrinogen', 'summary establish pf4', 'summary establish antibody']",376,summary testing typically comprises platelet counts d-dimer fibrinogen various immunological functional assays platelet factor 4 pf4 antibodies 
136,33.0,8.0,"['platelet receive hitt', 'heparin receive hitt', 'vitt receive hitt']",378,addition functional platelet activation assays standard doses heparin identified inhibit activation suspected vitt tend augment activation hitt 
137,33.0,9.0,"['thrombosis receive patient', 'pf4-elisa receive patient']",379,conversely also important over-diagnose vitt given cases thrombosis post vaccination immune basis pf4-elisa positive patients vitt 
138,34.0,0.0,"['covid-19 induce child', 'covid-19 induce adolescent', 'covid-19 induce adult', 'covid-19 induce child', 'covid-19 induce adolescent']",380,although covid-19 generally results milder disease children adolescents adults severe illness covid-19 occur children adolescents might require hospitalization intensive care unit icu support 1-3 
139,34.0,1.0,"['b16172 know sars-cov-2', 'b16172 know covid-19', 'b16172 know 2021', 'b16172 know child', 'b16172 know adolescent']",381,known whether b16172 delta variant predominant variant sars-cov-2 virus causes covid-19 united states since late june 2021 ÃÂ causes different clinical outcomes children adolescents compared variants circulated earlier 
140,34.0,2.0,"['child become person', 'adolescent become person', 'covid-19 become person', 'covid-19 become person', 'patient become person', 'covid-19 become person', 'covid-19 become person', 'covid-19-related become person', '0-4 become person', '5-11 become person', 'patient become person', 'child test covid-19', 'child test patient', 'child test covid-19', 'child test person', 'child test covid-19', 'child test covid-19-related', 'child test person', 'child test 0-4', 'child test 5-11', 'child test patient', 'child test covid-19', 'child test person', 'adolescent test covid-19', 'adolescent test patient', 'adolescent test covid-19', 'adolescent test person', 'adolescent test covid-19', 'adolescent test covid-19-related', 'adolescent test person', 'adolescent test 0-4', 'adolescent test 5-11', 'adolescent test patient', 'adolescent test covid-19', 'adolescent test person', 'covid-19 test patient', 'covid-19 test person', 'covid-19 test covid-19-related', 'covid-19 test person', 'covid-19 test 0-4', 'covid-19 test 5-11', 'covid-19 test patient', 'covid-19 test person', 'child confirm covid-19', 'child confirm covid-19-related', 'child confirm person', 'child confirm 0-4', 'child confirm 5-11', 'child confirm patient', 'child confirm covid-19', 'child confirm person', 'adolescent confirm covid-19', 'adolescent confirm covid-19-related', 'adolescent confirm person', 'adolescent confirm 0-4', 'adolescent confirm 5-11', 'adolescent confirm patient', 'adolescent confirm covid-19', 'adolescent confirm person', 'covid-19 confirm covid-19-related', 'covid-19 confirm person', 'covid-19 confirm 0-4', 'covid-19 confirm 5-11', 'covid-19 confirm patient', 'covid-19 confirm person', 'covid-19 confirm covid-19-related', 'covid-19 confirm person', 'covid-19 confirm 0-4', 'covid-19 confirm 5-11', 'covid-19 confirm patient', 'covid-19 confirm person', 'patient confirm covid-19', 'patient confirm covid-19-related', 'patient confirm person', 'patient confirm 0-4', 'patient confirm 5-11', 'patient confirm covid-19', 'patient confirm person', 'covid-19 confirm covid-19-related', 'covid-19 confirm person', 'covid-19 confirm 0-4', 'covid-19 confirm 5-11', 'covid-19 confirm patient', 'covid-19 confirm person', 'person confirm covid-19', 'person confirm covid-19-related', 'person confirm 0-4', 'person confirm 5-11', 'person confirm patient', 'person confirm covid-19', 'child age covid-19', 'child age covid-19-related', 'child age person', 'child age 0-4', 'child age 5-11', 'child age patient', 'child age covid-19', 'child age person', 'adolescent age covid-19', 'adolescent age covid-19-related', 'adolescent age person', 'adolescent age 0-4', 'adolescent age 5-11', 'adolescent age patient', 'adolescent age covid-19', 'adolescent age person', 'covid-19 age covid-19-related', 'covid-19 age person', 'covid-19 age 0-4', 'covid-19 age 5-11', 'covid-19 age patient', 'covid-19 age person', 'covid-19 age covid-19-related', 'covid-19 age person', 'covid-19 age 0-4', 'covid-19 age 5-11', 'covid-19 age patient', 'covid-19 age person', 'patient age covid-19', 'patient age covid-19-related', 'patient age person', 'patient age 0-4', 'patient age 5-11', 'patient age covid-19', 'patient age person', 'covid-19 age covid-19-related', 'covid-19 age person', 'covid-19 age 0-4', 'covid-19 age 5-11', 'covid-19 age patient', 'covid-19 age person', 'person age covid-19', 'person age covid-19-related', 'person age 0-4', 'person age 5-11', 'person age patient', 'person age covid-19']",382,assess trends among children adolescents cdc analyzed new covid-19 cases emergency department ed visits covid-19 diagnosis code hospital admissions patients confirmed covid-19 among persons aged 0-17 years august 1 2020-august 27 2021 since july 2021 delta become predominant circulating variant rate new covid-19 cases covid-19-related ed visits increased persons aged 0-4 5-11 12-17 years hospital admissions patients confirmed covid-19 increased persons aged 0-17 years 
141,34.0,3.0,"['person age 2-week', 'person age 2021', 'person age covid-19-related', 'person age ed']",383,among persons aged 0-17 years recent 2-week period august 14-27 2021 covid-19-related ed visits hospital admissions states lowest vaccination coverage 34 37 times states highest vaccination coverage respectively 
142,35.0,1.0,"['mucosal age enteropathy', 'mucosal age peripheral', 'mucosal age blood', 'mucosal age gut-homing', 'mucosal age cd4', 'oral age enteropathy', 'oral age peripheral', 'oral age blood', 'oral age gut-homing', 'oral age cd4', 'poliovirus age enteropathy', 'poliovirus age peripheral', 'poliovirus age blood', 'poliovirus age gut-homing', 'poliovirus age cd4', 'vaccine age enteropathy', 'vaccine age peripheral', 'vaccine age blood', 'vaccine age gut-homing', 'vaccine age cd4', 'opv age enteropathy', 'opv age peripheral', 'opv age blood', 'opv age gut-homing', 'opv age cd4', '292 age enteropathy', '292 age peripheral', '292 age blood', '292 age gut-homing', '292 age cd4', 'indian age enteropathy', 'indian age peripheral', 'indian age blood', 'indian age gut-homing', 'indian age cd4', 'infant age enteropathy', 'infant age peripheral', 'infant age blood', 'infant age gut-homing', 'infant age cd4', 'plasma age enteropathy', 'plasma age peripheral', 'plasma age blood', 'plasma age gut-homing', 'plasma age cd4', 'cytokine age enteropathy', 'cytokine age peripheral', 'cytokine age blood', 'cytokine age gut-homing', 'cytokine age cd4', 'fecal age enteropathy', 'fecal age peripheral', 'fecal age blood', 'fecal age gut-homing', 'fecal age cd4', 'mucosal include gut-homing', 'mucosal include cd4', 'oral include gut-homing', 'oral include cd4', 'poliovirus include gut-homing', 'poliovirus include cd4', 'vaccine include gut-homing', 'vaccine include cd4', 'opv include gut-homing', 'opv include cd4', '292 include gut-homing', '292 include cd4', 'indian include gut-homing', 'indian include cd4', 'infant include gut-homing', 'infant include cd4', 'plasma include gut-homing', 'plasma include cd4', 'cytokine include gut-homing', 'cytokine include cd4', 'fecal include gut-homing', 'fecal include cd4', 'enteropathy include gut-homing', 'enteropathy include cd4', 'peripheral include gut-homing', 'peripheral include cd4']",387,measured mucosal systemic immune parameters time vaccination oral poliovirus vaccine opv 292 indian infants aged 6ÃÂÂ11 months including plasma cytokines leukocyte counts fecal biomarkers environmental enteropathy peripheral blood t-cell phenotype focused gut-homing regulatory cd4 populations 
143,35.0,2.0,"['opv associate stool', 'opv associate immunization', 'opv associate infant', 'opv associate 639', 'opv associate 456']",388,find distinct immune phenotype associated opv immunogenicity although viral pathogens prevalent stool time immunization among infants failed seroconvert 639 vs 456 p 0002 
144,35.0,3.0,"['machine-learning predict infection', 'machine-learning receive infection']",389,using machine-learning approach could predict seroconversion priori using immune parameters infection status median 58 accuracy cross-validation iqr 50ÃÂÂ69 compared 50 expected chance 
145,35.0,4.0,"['mucosal tissue need oral', 'mucosal tissue need poliovirus']",390,better identification immune predictors opv immunogenicity likely require sampling mucosal tissue improved oral poliovirus infection models 
146,36.0,3.0,"['cohort document death', 'vaxzevria document death', 'vaccine document death', 'covid-19-related document death', 'brazilian document death', 'vaccinee document death', 'coronavirus document death', 'sars-cov-2 document death', 'covid-19-related document death', 'cohort evaluate vaxzevria', 'cohort evaluate vaccine', 'cohort evaluate covid-19-related', 'cohort evaluate brazilian', 'cohort evaluate vaccinee', 'cohort evaluate coronavirus', 'cohort evaluate sars-cov-2', 'cohort evaluate covid-19-related', 'cohort evaluate death', 'cohort relate coronavirus', 'cohort relate sars-cov-2', 'cohort relate covid-19-related', 'cohort relate death', 'vaxzevria relate coronavirus', 'vaxzevria relate sars-cov-2', 'vaxzevria relate covid-19-related', 'vaxzevria relate death', 'vaccine relate coronavirus', 'vaccine relate sars-cov-2', 'vaccine relate covid-19-related', 'vaccine relate death', 'covid-19-related relate coronavirus', 'covid-19-related relate sars-cov-2', 'covid-19-related relate death', 'brazilian relate coronavirus', 'brazilian relate sars-cov-2', 'brazilian relate covid-19-related', 'brazilian relate death', 'vaccinee relate coronavirus', 'vaccinee relate sars-cov-2', 'vaccinee relate covid-19-related', 'vaccinee relate death']",394,methodsthe present retrospective cohort study evaluated effectiveness vaxzevria coronavac vaccines covid-19-related infection 75919840 brazilian vaccinees january 18 july 24 2021 study outcomes included documented infection severe acute respiratory syndrome coronavirus 2 sars-cov-2 covid-19-related hospitalization icu admission death 
147,37.0,0.0,"['influenza cause tract', 'influenza cause infection', 'million cause tract', 'million cause infection', 'people cause tract', 'people cause infection', 'globe cause tract', 'globe cause infection', 'influenza infect million', 'influenza infect people', 'influenza infect globe', 'influenza infect tract', 'influenza infect infection']",404,influenza viruses infect millions people around globe annually usually causing self-limited upper respiratory tract infections 
148,37.0,7.0,"['four provide patient', 'influenza provide patient', 'gata2 provide patient', 'irf7 provide patient', 'irf9 provide patient', 'influenza provide patient', 'pneumonitis provide patient']",411,four monogenic causes severe influenza pneumonitisÃÂÂdeficiencies gata2 irf7 irf9 tlr3ÃÂÂhave provided evidence severe influenza pneumonitis genetic often patients severe infections 
149,38.0,6.0,"['703 receive 296', '703 receive 114', 'vaccine receive 296', 'vaccine receive 114']",421,total 1820 hcw 703 total received first dose vaccine january 10-16 2021 296 114 following week 
150,38.0,8.0,"['sars-cov-2 decline mrna', 'sars-cov-2 decline vaccine', 'hcw decline mrna', 'hcw decline sars-cov-2', 'hcw decline vaccine', '2-4 decline mrna', '2-4 decline sars-cov-2', '2-4 decline vaccine']",423,new sars-cov-2 infections hcw declined 62 2-4 weeks first dose mrna sars-cov-2 vaccination virtually disappeared second dose vaccine 
151,38.0,12.0,"['mrna associate sars-cov-2', 'mrna associate hcw', 'mrna associate vaccine', 'sars-cov-2 associate hcw', 'sars-cov-2 associate vaccine']",427,mrna sars-cov-2 vaccination associated dramatic decline new sars-cov-2 infection among hcw even administration second dose vaccine 
152,39.0,1.0,"['fluorescence-based develop bauml', 'fluorescence-based develop sars-cov-2', 'lifa develop bauml', 'lifa develop sars-cov-2', 'fluorescence-based base bauml', 'fluorescence-based base sars-cov-2', 'lifa base bauml', 'lifa base sars-cov-2']",429,recently novel fluorescence-based lifa test developed quantitative measurement total binding antibody units bauml receptor-binding domain sars-cov-2 spike protein s-rbd 
153,39.0,5.0,"['two compare france', 'surrogate compare france']",433,qualitative quantitative validation fincartm measurements bauml results fincaretm compared results two reference assays surrogate virus-neutralizing test svnt genscript usa vidas3 automated assay biomerieux france 
154,39.0,6.0,['finecaretm show 100'],434,results finecaretm showed 92 sensitivity 100 specificity compared pcr 
155,39.0,7.0,"['cohen declare svnt', 'cohen declare vidas3', 'cohen declare 051-095', 'kappa declare svnt', 'kappa declare vidas3', 'kappa declare 051-095', 'cohen range 051-095', 'kappa range 051-095', 'svnt range 051-095', 'vidas3 range 051-095']",435,cohen s kappa statistic denoted moderate excellent agreement svnt vidas3 ranging 0557 95 ci 032-078 0731 95 ci 051-095 respectively 
156,40.0,0.0,"['two show covid-19', 'two show adult', 'two show second', 'two show sars-cov-2', 'mrna show covid-19', 'mrna show adult', 'mrna show second', 'mrna show sars-cov-2', 'two prevent sars-cov-2', 'mrna prevent sars-cov-2', 'covid-19 prevent sars-cov-2', 'adult prevent sars-cov-2']",438,background two doses mrna vaccination shown 94 efficacy preventing covid-19 mostly naÃÂve adults clear second dose needed maximize effectiveness previously exposed sars-cov-2 factors affect responsiveness 
157,40.0,9.0,"['pre-exposed receive igg', 'pre-exposed receive 300']",447,among pre-exposed non-vaccinated 90 igg seropositive 300 days post-infection 
158,40.0,17.0,"['sars-cov-2 induce infectious diseases', 'sars-cov-2 induce influenza', 'reagent induce infectious diseases', 'reagent induce influenza']",455,development sars-cov-2 reagents partially supported national institute allergy infectious diseases centers excellence influenza research surveillance contract number hhsn272201400008c 
159,41.0,0.0,['peritoneal metastases predict chemotherapy'],457,background peritoneal metastases portend poor prognosis setting standard chemotherapy 
160,41.0,3.0,"['patient undergo appendiceal', 'patient undergo colorectal', 'patient undergo peritoneal', 'patient undergo mesothelioma']",460,methods patients undergoing crshipec appendiceal cancer colorectal cancer peritoneal mesothelioma enrolled 
161,41.0,4.0,"['chemotherapy receive tumor-loaded', 'chemotherapy receive vaccine', 'patient receive tumor-loaded', 'patient receive vaccine']",461,addition standard adjuvant chemotherapy patients received intranodal intradermal injections autologous tumor-loaded ÃÂdc1 vaccine 
162,41.0,5.0,"['vaccine booster receive celecoxib', 'vaccine booster receive interferon', 'vaccine booster receive ifn', 'vaccine booster receive rintatolimod', 'patient receive celecoxib', 'patient receive interferon', 'patient receive ifn', 'patient receive rintatolimod']",462,vaccine booster patients received ckm 4 days consisting celecoxib interferon ifn -ÃÂ rintatolimod 
163,41.0,6.0,"['forty-six follow mesothelioma', 'patient follow mesothelioma', 'crshipec follow mesothelioma']",463,results forty-six patients underwent crshipec followed ÃÂdc1 treatment including 24 appendiceal primaries 20 colorectal 2 mesotheliomas 
164,41.0,8.0,"['tumor challenge patient', 'peritoneal challenge patient', 'tumor challenge patient']",465,tumor cell recovery peritoneal tumors challenging resulting 17 patients receiving target dose ÃÂdc1 
165,42.0,0.0,"['adenovirus report hadv-d8 -d54', 'adenovirus report china', 'adenovirus report japan', 'adenovirus report hadv-b14p1', 'adenovirus report usa', 'adenovirus report europe', 'adenovirus report china', 'adenovirus report hadv-b55', 'adenovirus report china', 'adenovirus report singapore', 'adenovirus report france', 'hadv report hadv-d8 -d54', 'hadv report china', 'hadv report japan', 'hadv report hadv-b14p1', 'hadv report usa', 'hadv report europe', 'hadv report china', 'hadv report hadv-b55', 'hadv report china', 'hadv report singapore', 'hadv report france', 'hadv-b7 report hadv-d8 -d54', 'hadv-b7 report china', 'hadv-b7 report japan', 'hadv-b7 report hadv-b14p1', 'hadv-b7 report usa', 'hadv-b7 report europe', 'hadv-b7 report china', 'hadv-b7 report hadv-b55', 'hadv-b7 report china', 'hadv-b7 report singapore', 'hadv-b7 report france', 'israel report hadv-d8 -d54', 'israel report china', 'israel report japan', 'israel report hadv-b14p1', 'israel report usa', 'israel report europe', 'israel report china', 'israel report hadv-b55', 'israel report china', 'israel report singapore', 'israel report france', 'singapore report hadv-d8 -d54', 'singapore report china', 'singapore report japan', 'singapore report hadv-b14p1', 'singapore report usa', 'singapore report europe', 'singapore report china', 'singapore report hadv-b55', 'singapore report china', 'singapore report france', 'usa report hadv-d8 -d54', 'usa report china', 'usa report japan', 'usa report hadv-b14p1', 'usa report europe', 'usa report china', 'usa report hadv-b55', 'usa report china', 'usa report singapore', 'usa report france', 'hadv-b7d report hadv-d8 -d54', 'hadv-b7d report china', 'hadv-b7d report japan', 'hadv-b7d report hadv-b14p1', 'hadv-b7d report usa', 'hadv-b7d report europe', 'hadv-b7d report china', 'hadv-b7d report hadv-b55', 'hadv-b7d report china', 'hadv-b7d report singapore', 'hadv-b7d report france']",472,background number serious human adenovirus hadv outbreaks recently reported hadv-b7 israel singapore usa hadv-b7d usa china hadv-d8 -d54 -c2 japan hadv-b14p1 usa europe china hadv-b55 china singapore france 
166,42.0,1.0,"['hadv infections test 137', 'hadv infections test patient', 'hadv infections test singapore', 'hadv infections test hadv', 'hadv infections test hadvs', 'singapore test 137', 'singapore test patient', 'singapore test hadv', 'singapore test hadvs', '533 test 137', '533 test patient', '533 test singapore', '533 test hadv', '533 test hadvs', '396 test 137', '396 test patient', '396 test singapore', '396 test hadv', '396 test hadvs', 'hadv infections collect hadv', 'hadv infections collect hadvs', 'singapore collect hadv', 'singapore collect hadvs', '533 collect hadv', '533 collect hadvs', '396 collect hadv', '396 collect hadvs', '137 collect hadv', '137 collect hadvs', 'patient collect hadv', 'patient collect hadvs', 'singapore collect hadv', 'singapore collect hadvs']",473,methods understand epidemiology hadv infections singapore studied 533 hadv-positive clinical samples collected 396 pediatric 137 adult patients singapore 2012 2018 genome sequencing phylogenetic analyses performed identify hadv genotypes clonal clusters recombinant novel hadvs 
167,42.0,2.0,"['hadv-b3 receive 154', 'hadv-b3 receive hadv-e4', 'hadv-b3 receive 152', '356 receive 154', '356 receive hadv-e4', '356 receive 152']",474,results prevalent genotypes identified hadv-b3 356 hadv-b7 154 hadv-e4 152 
168,42.0,3.0,"['hadv-c detect ci 39Ã\x83\x83Ã\x83\x82Ã\x83\x82467', 'hadv-c detect 146', 'hadv-c detect hadv-e4', 'hadv-c detect 136', 'hadv-c detect patient', 'hadv-b7 detect ci 39Ã\x83\x83Ã\x83\x82Ã\x83\x82467', 'hadv-b7 detect 146', 'hadv-b7 detect hadv-e4', 'hadv-b7 detect 136', 'hadv-b7 detect patient']",475,detected 4 new hadv-c strains detected incursions hadv-b7 odds ratio 146 95 confidence interval ci 41ÃÂÂ520 hadv-e4 136 95 ci 39ÃÂÂ467 among pediatric patients time 
169,42.0,4.0,"['aor 114 adjust ci 12Ã\x83\x83Ã\x83\x82Ã\x83\x82109', 'aor 114 adjust ci 11Ã\x83\x83Ã\x83\x82Ã\x83\x8289', 'aor 114 adjust patient', 'aor 114 adjust hadv-c2', 'aor 114 adjust aor', 'aor 114 adjust hadv-b7', 'aor 114 adjust hadv-e4', 'immunocompromised adjust ci 12Ã\x83\x83Ã\x83\x82Ã\x83\x82109', 'immunocompromised adjust ci 11Ã\x83\x83Ã\x83\x82Ã\x83\x8289', 'immunocompromised adjust patient', 'immunocompromised adjust hadv-c2', 'immunocompromised adjust aor', 'immunocompromised adjust hadv-b7', 'immunocompromised adjust hadv-e4', 'patient adjust ci 12Ã\x83\x83Ã\x83\x82Ã\x83\x82109', 'patient adjust ci 11Ã\x83\x83Ã\x83\x82Ã\x83\x8289', 'patient adjust hadv-c2', 'patient adjust aor', 'patient adjust hadv-b7', 'patient adjust hadv-e4', 'aor 114 infect ci 11Ã\x83\x83Ã\x83\x82Ã\x83\x8289', 'aor 114 infect hadv-e4', 'ci 12Ã\x83\x83Ã\x83\x82Ã\x83\x82109 infect ci 11Ã\x83\x83Ã\x83\x82Ã\x83\x8289', 'ci 12Ã\x83\x83Ã\x83\x82Ã\x83\x82109 infect hadv-e4', 'immunocompromised infect ci 11Ã\x83\x83Ã\x83\x82Ã\x83\x8289', 'immunocompromised infect hadv-e4', 'patient infect ci 11Ã\x83\x83Ã\x83\x82Ã\x83\x8289', 'patient infect hadv-e4', 'patient infect ci 11Ã\x83\x83Ã\x83\x82Ã\x83\x8289', 'patient infect hadv-e4', 'hadv-c2 infect ci 11Ã\x83\x83Ã\x83\x82Ã\x83\x8289', 'hadv-c2 infect hadv-e4', 'aor infect ci 11Ã\x83\x83Ã\x83\x82Ã\x83\x8289', 'aor infect hadv-e4', 'hadv-b7 infect ci 11Ã\x83\x83Ã\x83\x82Ã\x83\x8289', 'hadv-b7 infect hadv-e4']",476,addition immunocompromised patients adjusted aor 114 95 ci 38ÃÂÂ348 patients infected hadv-c2 aor 85 95 ci 15ÃÂÂ480 hadv-b7 aor 37 95 ci 12ÃÂÂ109 hadv-e4 aor 32 95 ci 11ÃÂÂ89 increased risk severe disease 
170,42.0,5.0,"['singapore benefit hadv', 'singapore benefit patient', 'singapore benefit brincidofovir', 'singapore benefit hadv', 'singapore benefit vaccine', 'singapore aim hadv', 'singapore aim vaccine', 'hadv aim vaccine', 'patient aim hadv', 'patient aim vaccine', 'brincidofovir aim hadv', 'brincidofovir aim vaccine', 'singapore receive brincidofovir', 'singapore receive hadv', 'singapore receive vaccine', 'hadv receive brincidofovir', 'hadv receive vaccine', 'patient receive brincidofovir', 'patient receive hadv', 'patient receive vaccine']",477,conclusions singapore would benefit frequent studies clinical hadv genotypes identify patients risk severe disease help guide use new antiviral therapies brincidofovir potential administration hadv 4 7 vaccine 
171,43.0,2.0,"['patient undergo gemcitabine', 'patient undergo tg01gm-csf', 'patient undergo two']",480,methods patients stage ii pancreatic adenocarcinoma undergone surgical resection r0 r1 received adjuvant gemcitabine tg01gm-csf using two schedules vaccination 
172,43.0,4.0,"['thirty-two enrol nineteen', 'thirty-two enrol antigen', 'thirty-two enrol tg01', 'thirty-two enrol allergic', 'patient enrol nineteen', 'patient enrol antigen', 'patient enrol tg01', 'patient enrol allergic', 'thirty-two treat tg01', 'thirty-two treat allergic', 'patient treat tg01', 'patient treat allergic', 'nineteen treat tg01', 'nineteen treat allergic', 'antigen treat tg01', 'antigen treat allergic']",482,results thirty-two patients enrolled february 2013 may 2016 nineteen treated high antigen burden four serious adverse reactions considered possibly related tg01 treatment including three allergic reactions 
173,43.0,5.0,"['patient receive tg01', 'patient modify tg01', 'antigen modify tg01']",483,basis 13 patients received modified vaccination schedule reduced antigen burden serious adverse events related tg01 
174,44.0,1.0,"['antibody bind ace2', 'antibody bind covid-19', 'antibody bind vaccine', 'antibody bind 100', 'antibody bind 152', 'sars-cov-2 bind ace2', 'sars-cov-2 bind covid-19', 'sars-cov-2 bind vaccine', 'sars-cov-2 bind 100', 'sars-cov-2 bind 152', 'antibody induce 152', 'sars-cov-2 induce 152', 'ace2 induce 152', 'covid-19 induce 152', 'vaccine induce 152', '100 induce 152']",491,measured circulating antibodies receptor-binding domain rbd sars-cov-2 spike protein ace2 displacement live viral neutralization activities one month following first second covid-19 vaccine doses 100 adult plwh 152 controls 
175,44.0,3.0,['cd4 t-cell range 280'],493,nadir cd4 t-cell counts ranged low 10 median 280 iqr 120ÃÂÂ490 cellsmm 3 
176,44.0,4.0,"['vaccine-related associate ace2', 'vaccine-related associate p002', 'vaccine-related associate p01', 'vaccine-related associate one', 'vaccine-related associate vaccine', 'vaccine-related relate ace2', 'vaccine-related relate p002', 'vaccine-related relate p01', 'vaccine-related relate one', 'vaccine-related relate vaccine']",494,adjustment sociodemographic health vaccine-related variables hiv infection significantly associated 02 log 10 lower anti-rbd antibody concentrations p003 11 lower ace2 displacement activity p002 lower viral neutralization p01 one vaccine dose 
177,44.0,6.0,"['two receive mrna', 'two receive vaccine', 'chadox1 receive mrna', 'chadox1 receive vaccine']",496,rather older age higher burden chronic health conditions received two chadox1 doses versus heterologous dual mrna vaccine regimen independently associated lower responses 
178,44.0,7.0,"['two observe vaccine', 'two observe plwh', 'vaccine observe plwh']",497,two vaccine doses significant correlation observed recent nadir cd4 t-cell counts vaccine responses plwh 
179,44.0,8.0,"['plwh observe covid-19', 'plwh observe vaccine', 'plwh observe immunization', 'plwh observe co-morbidities', 'plwh observe vaccine', 'plwh observe vaccine', 'cd4 t-cell need vaccine', 'plwh need vaccine', 'covid-19 need vaccine', 'immunization need vaccine', 'co-morbidities need vaccine']",498,results suggest plwh well-controlled viral loads antiretroviral therapy cd4 t-cell counts healthy range generally require third covid-19 vaccine dose part initial immunization series though factors older age co-morbidities vaccine regimen type durability vaccine responses influence group may benefit additional doses 
180,45.0,0.0,"['sars-cov-2 increase 2021', 'sars-cov-2 increase one', 'sars-cov-2 compare one', '2021 compare one', '2021 compare sars-cov-2']",500,sars-cov-2 delta variant concern voc shown increased transmission compared previous variants emerged rapidly globally first half 2021 became one widespread sars-cov-2 variants worldwide 
181,46.0,3.0,['second induce vaccine'],509,project aimed study common side effects resulting first second doses four vaccines 
182,46.0,4.0,"['311 respond one', '311 respond four', '311 respond vaccine']",510,data collected online questionnaire answered 311 individuals received doses one four vaccines 
183,46.0,5.0,"['vaccine receive participant', 'vaccine receive second']",511,results study revealed regardless vaccine identity participants experienced side effects second dose 
184,46.0,6.0,"['pain observe vaccine', 'injection observe vaccine', 'pain pain vaccine', 'pain pain vaccine']",512,among different side effects pain site injection primarily observed first dose pfizer vaccine 43 followed astrazeneca vaccine 31 
185,46.0,7.0,"['fever observe sputnik', 'fever observe vaccine', 'fever observe headache', 'fever observe vaccine']",513,moreover fever observed participants first dose sputnik vaccine 37 headache mainly observed first dose pfizer vaccine 32 
186,46.0,8.0,"['fatigue observe respondent', 'four observe respondent', 'fatigue observe four', 'fatigue observe vaccine', 'fatigue observe respondent']",514,important note fatigue observed first dose four vaccines reported highest proportion respondents pfizer group 28 
187,46.0,10.0,"['headache correlate pain', 'headache correlate injection']",516,similarly headache correlated fever r 0801 pain site injection r 0868 
188,46.0,11.0,"['recipient observe vaccine', 'recipient observe four', 'recipient observe vaccine']",517,overall observed recipients sinopharm vaccine reported mildest side effects among four vaccines 
189,47.0,3.0,"['cell perform worker', 'cell perform bnt162b2', 'cell perform vaccine', 'cohort perform worker', 'cohort perform bnt162b2', 'cohort perform vaccine', '20 perform worker', '20 perform bnt162b2', '20 perform vaccine']",522,methods serological cell analysis performed cohort 20 healthcare workers receiving first dose pfizerbiontech bnt162b2 vaccine 
190,47.0,5.0,"['cell bind vaccine', 'cell bind sars-cov-2', 'cell bind antibody', 'antibody bind vaccine', 'antibody bind sars-cov-2']",524,results spike-specific cells binding antibodies detectable 10 days first dose vaccine contrast receptor-blocking sars-cov-2 neutralising antibodies mostly undetectable early time-point 
191,47.0,6.0,['cell bind covid-19'],525,conclusions findings suggest early cell binding antibody responses rather either receptor-blocking virus neutralizing activity induced early protection covid-19 
192,48.0,0.0,"['sars-cov-2 induce vaccine', 'sars-cov-2 induce infection', 'immunity induce vaccine', 'immunity induce infection']",527,rapid spread omicron sars-cov-2 variant b11529 resulted international efforts quickly assess escape immunity generated vaccines previous infections 
193,49.0,2.0,"['herein associate bacterial', 'balbc associate bacterial', 'mouse associate bacterial', 'pneumoniae associate bacterial', 'lipid-associated associate bacterial', 'lung associate bacterial']",536,herein report vaccination balbc mice m pneumoniae lipid-associated membrane proteins lamps induces lung lesions consistent exacerbated disease following challenge without reducing bacterial loads 
194,50.0,0.0,"['death induce covid-19', 'death induce immunity', 'death induce vaccine', 'death increase immunity', 'death increase vaccine', 'covid-19 increase immunity', 'covid-19 increase vaccine']",539,immune dysregulation individuals syndrome ds leads increased risk hospitalization death due covid-19 may impair generation protective immunity vaccine administration 
195,50.0,1.0,"['cellular receive one', 'cellular receive three', 'cellular receive six', 'patient receive one', 'patient receive three', 'patient receive six', 'sars-cov-2 receive one', 'sars-cov-2 receive three', 'sars-cov-2 receive six']",540,cellular humoral responses 55 ds patients received complete sars-cov-2 vaccination regime one three v1 six v2 months characterised 
196,50.0,3.0,"['one three circulate vaccine', 'sars-cov-2-specific circulate vaccine', 'ctfh circulate vaccine']",542,likewise sustained increase sars-cov-2-specific circulating tfh ctfh cells observed one three months vaccine administration 
197,50.0,4.0,"['antibody detect igg', 'sars-cov-2 detect igg']",543,specific igg antibodies sars-cov-2 protein detected 96 98 subjects v1 v2 respectively though igg titers decreased significantly timepoints 
198,51.0,3.0,"['covid-19 relate switzerland', 'covid-19 relate 2021']",547,methods investigated trends covid-19 related mortality in-hospital in-intermediateintensive-care time switzerland february 2020 may 2021 comparing particular first second wave 
199,51.0,6.0,"['ch-sur receive death', 'ch-sur receive covid-19', 'ch-sur receive 130']",550,results analysis included 16030 episodes recorded ch-sur 2320 reported deaths due covid-19 130 included episodes 
200,51.0,7.0,"['second compare p-value', 'second compare patient', 'covid-19 compare p-value', 'covid-19 compare patient']",551,found overall in-hospital mortality lower second wave covid-19 compared first wave hr 071 95 ci 069 - 072 p-value 0001 decrease apparently explained changes demographic characteristics patients 
201,51.0,8.0,"['148 compare 142', '148 compare 155', '148 compare p-value']",552,contrast mortality intermediate intensive care significantly increased second wave compared first wave hr 148 95 ci 142 - 155 p-value 0001 significant changes course hospitalisation first second wave 
202,51.0,9.0,"['switzerland receive person', 'switzerland receive patient', 'switzerland decrease patient', 'covid-19 decrease patient', 'person decrease patient']",553,conclusion found switzerland covid-19 mortality decreased among hospitalised persons whereas increased among patients admitted intermediate intensive care comparing second wave first wave 
203,52.0,1.0,['cell aim sars-cov-2'],557,virus entry cells depends receptor binding domain rbd sars-cov-2 spike protein 
204,52.0,5.0,"['plasma collect b cells', 'plasma collect symptom', 'plasma collect pseudovirus', 'plasma collect 150', 'plasma collect 1', 'plasma collect 15000', 'plasma collect clone', 'plasma collect antibody', 'plasma neutralize b cells', 'plasma neutralize 15000', 'plasma neutralize clone', 'plasma neutralize antibody', 'symptom neutralize b cells', 'symptom neutralize 15000', 'symptom neutralize clone', 'symptom neutralize antibody', 'pseudovirus neutralize b cells', 'pseudovirus neutralize 15000', 'pseudovirus neutralize clone', 'pseudovirus neutralize antibody', '150 neutralize b cells', '150 neutralize 15000', '150 neutralize clone', '150 neutralize antibody', '1 neutralize b cells', '1 neutralize 15000', '1 neutralize clone', '1 neutralize antibody']",561,plasmas collected average 39 days onset symptoms variable half-maximal pseudovirus neutralizing titres less 150 33 11000 79 1 showed titres 15000 antibody sequencing revealed expanded clones rbd-specific memory b cells expressing closely related antibodies different individuals 
205,52.0,6.0,"['plasma neutralize digit', 'antibody neutralize digit', 'three neutralize digit', 'epitope neutralize digit']",562,despite low plasma titres antibodies three distinct epitopes rbd neutralized half-maximal inhibitory concentrations ic50 values low single digit nanograms per millitre 
206,52.0,7.0,"['convalescent induce covid-19', 'plasma induce covid-19']",563,thus convalescent plasmas obtained individuals recover covid-19 contain high levels neutralizing activity 
207,52.0,8.0,"['rbd-specific receive antibody', 'vaccine receive antibody', 'rbd-specific recur vaccine', 'rbd-specific recur antibody']",564,nevertheless rare recurring rbd-specific antibodies potent antiviral activity found individuals tested suggesting vaccine designed elicit antibodies could broadly effective 
208,53.0,2.0,"['mosaic develop prrsv', 'vaccinia develop prrsv', 'vacv develop prrsv', 'vaccine develop prrsv']",567,mosaic dna vaccinia vacv vaccines developed order improve protection heterologous prrsv strains 
209,53.0,3.0,"['piglet prim gp5-mosaic', 'piglet prim vaccine', 'piglet prim gp5-mosaic', 'piglet prim vacv', 'piglet prim rgp5-mosaic', 'piglet boost gp5-mosaic', 'piglet boost vacv', 'piglet boost rgp5-mosaic', 'gp5-mosaic boost vacv', 'gp5-mosaic boost rgp5-mosaic']",568,methods piglets primed boosted gp5-mosaic dna vaccine recombinant gp5-mosaic vacv rgp5-mosaic vacv respectively 
210,53.0,4.0,"['pig vaccinate rgp5-wt', 'pig vaccinate rgp5-wt']",569,pigs vaccinated rgp5-wt vr2332 dna rgp5-wt vacv empty vector dna empty vacv respectively served controls 
211,53.0,7.0,"['gp5-mosaic-based base antibody', 'gp5-mosaic-based base mn184c', 'gp5-mosaic-based base prrsv', 'cellular base antibody', 'cellular base mn184c', 'cellular base prrsv', 'gp5-mosaic-based induce mn184c', 'gp5-mosaic-based induce prrsv', 'cellular induce mn184c', 'cellular induce prrsv', 'antibody induce mn184c', 'antibody induce prrsv']",572,results vaccination gp5-mosaic-based vaccines resulted cellular reactivity higher levels neutralizing antibodies vr2332 mn184c prrsv strains 
212,53.0,9.0,"['gp5-mosaic base bronchoalveolar lavage', 'gp5-mosaic base serum', 'gp5-mosaic base alveolar', 'gp5-mosaic base bal', 'gp5-mosaic base lung', 'vaccine base bronchoalveolar lavage', 'vaccine base serum', 'vaccine base alveolar', 'vaccine base bal', 'vaccine base lung', 'gp5-mosaic induce bronchoalveolar lavage', 'gp5-mosaic induce serum', 'gp5-mosaic induce alveolar', 'gp5-mosaic induce bal', 'gp5-mosaic induce lung', 'vaccine induce bronchoalveolar lavage', 'vaccine induce serum', 'vaccine induce alveolar', 'vaccine induce bal', 'vaccine induce lung', 'two induce bronchoalveolar lavage', 'two induce serum', 'two induce alveolar', 'two induce bal', 'two induce lung', 'gp5-mosaic show bronchoalveolar lavage', 'gp5-mosaic show bal', 'gp5-mosaic show lung', 'vaccine show bronchoalveolar lavage', 'vaccine show bal', 'vaccine show lung', 'two show bronchoalveolar lavage', 'two show bal', 'two show lung', 'serum show bronchoalveolar lavage', 'serum show bal', 'serum show lung', 'alveolar show bronchoalveolar lavage', 'alveolar show bal', 'alveolar show lung']",574,furthermore vaccination gp5-mosaic based vaccines resulted protection challenge two heterologous virus strains demonstrated significantly lower viral loads serum tissues porcine alveolar macrophages pams bronchoalveolar lavage bal fluids less severe lung lesions challenge either mn184c vr2332 85 identity 
213,53.0,11.0,"['gp5-mosaic use pig', 'vaccine use pig', 'dna-primevacv use pig', 'boost use pig']",576,conclusions gp5-mosaic vaccines using dna-primevacv boost regimen conferred protection pigs heterologous viruses 
214,54.0,3.0,"['covid-19 provide careoutpatient', 'vaccine provide covid-19', 'vaccine provide careoutpatient']",580,covid-19 vaccines provide good protection covid-19 presentation primary careoutpatient level particularly among fully vaccinated individuals 
215,55.0,1.0,"['one elapse sars-cov-2', 'one elapse researcher', 'one elapse patient', 'one elapse vaccine', 'one need patient', 'one need vaccine', 'covid-19 need patient', 'covid-19 need vaccine', 'sars-cov-2 need patient', 'sars-cov-2 need vaccine', 'researcher need patient', 'researcher need vaccine']",582,one year elapsed since beginning covid-19 pandemic multitude medical studies involving sars-cov-2 virus helped researchers medical practitioners understanding effects sorts patients effective vaccines finally developed distributed mass vaccination 
216,55.0,2.0,"['sars-cov-2 induce woman', 'patient induce woman']",583,still sars-cov-2 new variants remain potential threat towards categories patients including delicate group represented pregnant women 
217,55.0,4.0,"['cohort investigate woman', 'cohort investigate patient', 'cohort investigate covid-19-positive', 'cohort investigate mother', '1039 investigate woman', '1039 investigate patient', '1039 investigate covid-19-positive', '1039 investigate mother']",585,materials methods single-center prospective cohort study investigated pregnancy outcomes total 1039 eligible pregnant women 30 august 2020 30 january 2021 multiple patient characteristics obstetrical outcomes tested analyzed multivariate regression model establish potential risks determined covid-19-positive pregnancy towards mother newborn 
218,55.0,5.0,"['938 include covid-19', '101 include covid-19', 'woman include covid-19']",586,results study sample 938 pregnancies included without covid-19 101 pregnant women identified positive covid-19 infection 
219,55.0,6.0,"['covid-19 associate 2-fold', 'covid-19 associate rupture', 'covid-19 associate preterm', 'covid-19 associate apgar']",587,covid-19 significantly associated 2-fold increase risk premature rupture membranes 15 times higher risk preterm birth emergency c-sections lower apgar scores 
220,55.0,7.0,"['newborn receive mother', 'newborn receive sars-cov-2']",588,also significantly newborns given birth prematurely lower apgar scores mothers infected sars-cov-2 
221,56.0,1.0,"['influenza fragment india', 'ah1n1pdm09 fragment influenza', 'ah1n1pdm09 fragment india']",591,recurrent outbreaks pandemic influenza ah1n1pdm09 fragmented nationwide incidence data lack national policy influenza vaccination india underscores necessity generating regional level data 
222,56.0,2.0,"['2017-19 relate eastern india', '2017-19 relate ah1n1pdm09', 'patient relate eastern india', 'patient relate ah1n1pdm09', '2017-19 hospitalize ah1n1pdm09', 'patient hospitalize ah1n1pdm09']",592,thus 2017-19 4106 referred samples patients hospitalized severe acute respiratory illness sari eastern india tested ah1n1pdm09 infection 
223,56.0,5.0,"['vaccine strain eastern', 'vaccine strain indian']",595,vaccine strain ahumancalifornia072009 globally used 2017 clustered different lineage away representative eastern indian strains phylogenetic dendrogram 
224,56.0,6.0,"['vaccine strain india', 'vaccine strain isolates', 'vaccine strain lineage-6b', 'vaccine use isolates', 'vaccine use lineage-6b', 'india use isolates', 'india use lineage-6b']",596,vaccine strain ahumanmichigan452015 used india study period recommended strain ahumanbrisbane022018 2019-20 flu season northern hemisphere clustered circulating isolates lineage-6b 
225,56.0,7.0,"['amino acids see ahumancalifornia072009', 'epitope see ahumancalifornia072009', 'vaccine see ahumancalifornia072009', 'amino acids cover vaccine', 'amino acids cover ahumancalifornia072009']",597,dissimilarities amino acids encompassing antigenic epitopes seen highest vaccine strain- ahumancalifornia072009 
226,56.0,8.0,"['amino acid circulate vaccine', 'amino acid circulate ah1n1pdm09', 'amino acid recommend ah1n1pdm09', 'vaccine recommend ah1n1pdm09']",598,significant amino acid variations circulating strains current recommended vaccine strain implies exigency continuous pandemic ah1n1pdm09 surveillance studies epidemiological setting 
227,57.0,4.0,"['participant vaccinate mrna-1273', 'participant vaccinate bnt162b2', 'participant vaccinate elisa', 'participant vaccinate igg', 'participant vaccinate sars-cov-2', 'participant vaccinate interferon', 'participant vaccinate cohort', 'participant vaccinate worker', 'patient vaccinate mrna-1273', 'patient vaccinate bnt162b2', 'patient vaccinate elisa', 'patient vaccinate igg', 'patient vaccinate sars-cov-2', 'patient vaccinate interferon', 'patient vaccinate cohort', 'patient vaccinate worker', 'participant include sars-cov-2', 'participant include mrna-1273', 'participant include bnt162b2', 'participant include elisa', 'participant include igg', 'participant include sars-cov-2', 'participant include interferon', 'participant include cohort', 'participant include worker', 'patient include sars-cov-2', 'patient include mrna-1273', 'patient include bnt162b2', 'patient include elisa', 'patient include igg', 'patient include sars-cov-2', 'patient include interferon', 'patient include cohort', 'patient include worker']",604,participants study included patients fully vaccinated sars-cov-2 mrna-1273 bnt162b2 ad26cov2s underwent clinical testing anti-sars-sov-2 s1 igg elisa anti-s1 igg sars-cov-2 interferon gamma release assay igra january 1 2021 november 15 2021 cohort 18 immunocompetent volunteer healthcare workers included reference 
228,57.0,12.0,"['patient increase autoimmune', 'patient increase p009', '425 increase autoimmune', '425 increase p009', 'malignancy increase autoimmune', 'malignancy increase p009', 'malignancy increase autoimmune', 'malignancy increase p009', 'patient respond solid organ', 'patient respond 425', 'patient respond malignancy', 'patient respond malignancy', 'patient respond autoimmune', 'patient respond p009', 'patient develop solid organ', 'patient develop malignancy', 'patient develop autoimmune', 'patient develop p009', '425 develop solid organ', '425 develop malignancy', '425 develop autoimmune', '425 develop p009', 'malignancy develop solid organ', 'malignancy develop autoimmune', 'malignancy develop p009', 'solid organ dose p009', 'patient dose p009', '425 dose p009', 'malignancy dose p009', 'malignancy dose p009', 'autoimmune dose p009']",612,patients responded poorly primary vaccination 16 425 hematologic malignancy primary immunodeficiency developed significantly increased humoral response booster dose 52 1427 solid malignancy solid organ transplantation autoimmune disease developed increased response p009 
229,57.0,13.0,"['242 develop booster', 'patient develop booster']",613,5 242 immunosuppressed patients developed significantly increased cellular response following booster dose 
230,58.0,5.0,"['eclia-based base eclia', 'eclia-based base elisa', 'inter- base eclia', 'inter- base elisa', 'eclia-based characterize elisa', 'inter- characterize elisa', 'intra-assay characterize elisa', 'eclia characterize elisa']",621,methods current study describes development multiplex eclia-based assay characterizes sensitivity linear range inter- intra-assay variability eclia platform agreement traditional elisa 
231,58.0,8.0,['eclia provide elisa'],624,beyond practical advantages multiplexing eclia provides superior assay performance compared elisa 
232,58.0,9.0,['eclia show dilution'],625,eclia show good agreement elisa assay linear range eclia also sufficiently wide permit single-dilution measurements concentration without need serial dilutions 
233,58.0,10.0,['antigen relate cross-reactivitiesÃ\x83\x83Ã\x83\x82Ã\x83\x82or'],626,lack antigenic competition allows simultaneous testing closely related antigens plate antigens representing different alleles protein inform cross-reactivitiesÃÂÂor lack thereofÃÂÂof serological responses 
234,59.0,2.0,['patient induce cov'],630,patients methods conducted retrospective multicenter cohort study incidence mortality covidÃÂ 19 hemodialysis patients compared general adult population period beginning pandemic commencement sarsÃÂ cov 2 vaccination program 
235,59.0,3.0,"['patient receive pomerania', 'patient receive poland', 'patient receive 2021', 'patient receive 1567']",631,study population included patients receiving hemodialysis 14 dialysis units pomerania province poland december 31 2019 individuals starting longÃÂ term hemodialysis january 1 2020 january 31 2021 amounting total 1567 patients 
236,60.0,0.0,"['sars-cov-2 show adult', 'vaccine show adult', 'bbv152covaxin show adult', '778 show adult', '934 show adult', 'covid-19 show adult', 'sars-cov-2 induce covid-19', 'sars-cov-2 induce adult', 'vaccine induce covid-19', 'vaccine induce adult', 'bbv152covaxin induce covid-19', 'bbv152covaxin induce adult', '778 induce covid-19', '778 induce adult', '934 induce covid-19', '934 induce adult']",639,sars-cov-2 vaccine bbv152covaxin well-tolerated shown 778 efficacious symptomatic 934 efficacious severe symptomatic covid-19 disease adults 
237,60.0,1.0,"['covaxin vaccinate alpha', 'covaxin vaccinate delta', 'covaxin vaccinate zeta', 'covaxin vaccinate kappa', 'covaxin vaccinate sars-cov-2']",640,previous studies shown sera covaxin vaccinated individuals neutralizing activity b117 alpha b1351 beta b16172 delta b1128 zeta b16171 kappa sars-cov-2 variants 
238,60.0,4.0,"['omicron collect covaxin', '6- collect covaxin']",643,used live virus neutralization assay evaluate neutralizing activity omicron variant sera collected subjects received booster dose 6- month primary series last dose covaxin 
239,60.0,5.0,"['covaxin boost d614g', 'covaxin boost vaccine', 'covaxin boost delta', 'covaxin show vaccine', 'covaxin show delta']",644,found sera covaxin boosted individuals showed neutralizing activity d614g vaccine strain delta omicron variants 
240,60.0,6.0,['one hundred show delta'],645,one hundred percent boosted subjects showed neutralizing activity delta variant 90 boosted subjects showed neutralizing activity omicron variant 
241,60.0,7.0,"['booster generate omicron', 'covaxin generate omicron']",646,findings show booster dose covaxin generate robust neutralizing antibody responses omicron variant 
242,61.0,0.0,"['covid-19 show vaccine', 'covid-19 select vaccine']",647,background safety covid-19 vaccines demonstrated selected populations recent studies data specific groups needed inform vaccine choice health policy 
243,61.0,6.0,"['covid-19 associate 108', 'covid-19 associate 105-111', 'covid-19 associate fever', 'covid-19 associate 224', 'covid-19 associate 186-270', 'covid-19 associate breathlessness', 'covid-19 associate flu-like', 'covid-19 associate 178', 'covid-19 associate fatigue', 'covid-19 associate 134', 'covid-19 associate 106-115', 'covid-19 increase 108', 'covid-19 increase 105-111', 'covid-19 increase fever', 'covid-19 increase 224', 'covid-19 increase 186-270', 'covid-19 increase breathlessness', 'covid-19 increase flu-like', 'covid-19 increase 178', 'covid-19 increase fatigue', 'covid-19 increase 134', 'covid-19 increase 106-115']",653,prior covid-19 infection associated increased risk side effect risk ratio 108 95 confidence intervals 105-111 fever 224 186-270 breathlessness 205 128-329 flu-like illness 178 151-210 fatigue 134 120-149 local reactions 110 106-115 
244,61.0,8.0,"['mrna associate 106', 'mrna associate 101-111', 'mrna associate vector-based', 'mrna associate vaccine', 'vaccine associate 106', 'vaccine associate 101-111', 'vaccine associate vector-based']",655,mrna vaccines associated higher incidence side effect 106 101-111 compared viral vector-based vaccines generally milder p 0001 mostly local reactions 
245,61.0,9.0,"['mrna report anaphylaxis', 'mrna report swelling', 'mrna report flu-like', 'mrna report breathlessness', 'mrna report fatigue', 'vaccine-recipients report anaphylaxis', 'vaccine-recipients report swelling', 'vaccine-recipients report flu-like', 'vaccine-recipients report breathlessness', 'vaccine-recipients report fatigue', 'mrna include fatigue', 'vaccine-recipients include fatigue', 'anaphylaxis include fatigue', 'swelling include fatigue', 'flu-like include fatigue']",656,importantly mrna vaccine-recipients reported considerably lower incidence systemic reactions rr 06 including anaphylaxis swelling flu-like illness breathlessness fatigue side effects requiring hospital care 042 031-058 
246,61.0,10.0,['covid-19 increase vaccine'],657,conclusion first time study links prior covid-19 illness increased incidence vaccination side effects demonstrates mrna vaccines cause milder less frequent systemic side effects local reactions 
247,62.0,1.0,"['adult mediate fat', 'vaccine mediate fat']",659,hypothesized antibody cell-mediated immune responses t-cmi elderly adults vaccine intended intramuscular im administration would attenuated deposited sc fat independent confounding conditions 
248,62.0,2.0,"['fifty-two establish hbv', 'fifty-two establish senieur', 'adult establish hbv', 'adult establish senieur']",660,results fifty-two healthy community dwelling elderly adults 65ÃÂÂ82 years seronegative hbv enrolled senieur protocol strictly healthy population 
249,62.0,3.0,"['senior randomize alum-adjuvanted', 'senior randomize hbv', 'senior randomize vaccine', 'senior receive hbv', 'senior receive vaccine', 'alum-adjuvanted receive hbv', 'alum-adjuvanted receive vaccine']",661,seniors randomized receive licensed alum-adjuvanted recombinant hbv vaccine either sc im inoculum site verified imaging 
250,62.0,4.0,"['hepatitis b describe antibody', 'hepatitis b describe young', 'hepatitis b describe adult', 'hepatitis b describe volunteer']",662,response rates defined hepatitis b surface antibodies hbsab ÃÂÂ10 iul significantly lower elderly young adults group 12 healthy 21ÃÂÂ34-year-old volunteers 
251,63.0,1.0,"['serum collect vaccine', '133 collect vaccine', 'hcws collect vaccine', 'brazil collect vaccine', 'one collect vaccine']",671,methods serum samples 133 hcws southern brazil collected one day day 0 10 20 40 days administering vaccines first dose 
252,63.0,2.0,"['immunoglobulin use anti-n-protein', 'immunoglobulin use antibody', 'immunoglobulin use sligo', 'immunoglobulin use ireland', 'immunoglobulin use anti-s1', 'immunoglobulin use antibody', 'immunoglobulin use lubeck', 'immunoglobulin use germany', 'igg use anti-n-protein', 'igg use antibody', 'igg use sligo', 'igg use ireland', 'igg use anti-s1', 'igg use antibody', 'igg use lubeck', 'igg use germany']",672,immunoglobulin g igg quantified using immunoassays anti-n-protein antibodies abbott sligo ireland anti-s1 spike protein antibodies euroimmun lubeck germany 
253,63.0,3.0,['129 receive hcws'],673,results seroconversion 40 20 days second dose occurred 129 97 hcws s1 protein 69 5187 hcws n protein 
254,63.0,4.0,"['igg receive two', 'igg receive hcws', 'antibody receive two', 'antibody receive hcws', 'two receive hcws', 'hcws receive two', 'rituximab receive two', 'rituximab receive hcws']",674,absence igg antibodies methodologies occurred two 15 hcws undergoing semiannual rituximab administration also another two 15 hcws apparent reason 
255,63.0,5.0,['coronavac show hcw'],675,conclusion study showed coronavac high seroconversion rate evaluated hcw population 
256,64.0,2.0,"['cross-sectional use covid-19', 'cross-sectional use vaccine', 'cross-sectional use sinovacbutantan', 'cross-sectional use brazilian', 'cross-sectional use woman', 'cross-sectional use 2021', 'cross-sectional use covid-19', 'cross-sectional use vaccine', 'brazilian use covid-19', 'brazilian use vaccine', 'brazilian use sinovacbutantan', 'brazilian use woman', 'brazilian use 2021', 'brazilian use covid-19', 'brazilian use vaccine', 'cross-sectional characterize 2021', 'cross-sectional characterize covid-19', 'cross-sectional characterize vaccine', 'brazilian characterize 2021', 'brazilian characterize covid-19', 'brazilian characterize vaccine', 'covid-19 characterize 2021', 'covid-19 characterize vaccine', 'vaccine characterize 2021', 'vaccine characterize covid-19', 'sinovacbutantan characterize 2021', 'sinovacbutantan characterize covid-19', 'sinovacbutantan characterize vaccine', 'brazilian characterize 2021', 'brazilian characterize covid-19', 'brazilian characterize vaccine', 'woman characterize 2021', 'woman characterize covid-19', 'woman characterize vaccine']",678,methods observational cross-sectional study using data brazilian surveillance information system adverse events si-eapv characterize safety covid-19 vaccines available sinovacbutantan pfizerbiontech astrazeneca janssen brazilian pregnant postpartum women receiving april august 2021 descriptive analysis performed assess frequency incidence rate adverse events ae covid-19 vaccines 
257,64.0,4.0,['3094100000 receive 29723'],680,incidence ae found 3094100000 doses 95 ci 29723 32151 
258,64.0,6.0,"['8207 notify 1193', '8207 notify 474']",682,systemic events frequent notified group 8207 followed local 1193 maternal 474 classified non-severe 9065 
259,65.0,0.0,"['ae37 derive vaccine', 'gp2 derive vaccine', 'her2 derive vaccine']",685,purpose ae37 gp2 her2 derived peptide vaccines 
260,65.0,2.0,"['peptide test recurrence', 'peptide test her2', 'peptide test cancer', 'peptide test patient', 'peptide evaluate cancer', 'peptide evaluate patient', 'recurrence evaluate cancer', 'recurrence evaluate patient', 'her2 evaluate cancer', 'her2 evaluate patient']",687,peptides tested large randomized trial assess ability prevent recurrence her2 expressing breast cancer patients 
261,65.0,5.0,"['multi-center randomize node', 'multi-center randomize breast', 'multi-center randomize cancer', 'multi-center randomize patient']",690,methods 4-arm prospective randomized single-blinded multi-center phase ii trial disease-free node positive high-risk node negative breast cancer patients enrolled standard care therapy 
262,65.0,6.0,"['six receive 6-month', 'vaccine receive 6-month', 'cg receive 6-month', 'vaccine receive 6-month']",691,six monthly inoculations vaccine vg vs control cg given primary vaccine series 4 boosters 6-month intervals 
263,65.0,8.0,"['456 enrol patient', '456 enrol 147', '456 enrol cg', '456 enrol ae37', '456 enrol patient', '456 enrol cg', '456 enrol gp2', 'patient enrol 147', 'patient enrol cg', 'patient enrol ae37', 'patient enrol cg', 'patient enrol gp2']",693,results 456 patients enrolled 154 patients vg 147 cg ae37 89 patients vg 91 cg gp2 
264,65.0,9.0,"['ae37 compare ci 0275Ã\x83\x83Ã\x83\x82Ã\x83\x821193', 'ae37 compare her2', 'ae37 compare hr', 'ae37 compare hr', 'cg compare ci 0275Ã\x83\x83Ã\x83\x82Ã\x83\x821193', 'cg compare her2', 'cg compare hr', 'cg compare hr', 'pre-specified compare ci 0275Ã\x83\x83Ã\x83\x82Ã\x83\x821193', 'pre-specified compare her2', 'pre-specified compare hr', 'pre-specified compare hr', 'ae37 show her2', 'ae37 show hr', 'ae37 show hr', 'cg show her2', 'cg show hr', 'cg show hr', 'pre-specified show her2', 'pre-specified show hr', 'pre-specified show hr']",694,ae37 arm difference dfs compared cg pre-specified exploratory subgroup analyses showed trend towards benefit advanced stage p 0132 hr 0573 ci 0275ÃÂÂ1193 her2 under-expression p 0181 hr 0756 ci 0499ÃÂÂ1145 triple-negative breast cancer p 0266 hr 0443 ci 0114ÃÂÂ1717 
265,65.0,11.0,"['gp2 compare p 0052', 'gp2 compare patient', 'gp2 compare cg', 'cg compare p 0052', 'cg compare patient', 'her2 compare p 0052', 'her2 compare patient', 'her2 compare cg']",696,gp2 arm significant difference dfs compared cg subgroup analysis her2 positive patients recurrences trend toward improved dfs p 0052 vg compared cg 
266,65.0,12.0,"['ae37 associate subgroup', 'ae37 associate breast', 'ae37 associate cancer', 'ae37 associate patient', 'gp2 associate subgroup', 'gp2 associate breast', 'gp2 associate cancer', 'gp2 associate patient']",697,conclusions phase ii trial reveals ae37 gp2 safe possibly associated improved clinical outcomes dfs certain subgroups breast cancer patients 
267,65.0,13.0,"['ae37 observe breast', 'ae37 observe cancer', 'ae37 observe patient', 'gp2 observe breast', 'gp2 observe cancer', 'gp2 observe patient', 'vaccine observe breast', 'vaccine observe cancer', 'vaccine observe patient', 'ae37 receive patient', 'gp2 receive patient', 'vaccine receive patient', 'breast receive patient']",698,findings evaluations warranted ae37 gp2 vaccines given combination andor separately specific subsets breast cancer patients based disease biology 
268,66.0,1.0,"['adolescent induce nicklaus', 'adolescent induce perimyocarditis', 'adolescent induce bnt162b2', 'adolescent induce vaccine']",700,describe clinical characteristics 8 adolescents presented course 36 days nicklaus childrenÃÂÂs hospital perimyocarditis within 4 days receiving dose bnt162b2 vaccine 
269,67.0,0.0,"['immunity protect respiratory syndrome', 'immunity protect covid-19', 'immunity protect coronavirus', 'immunity protect sars-cov-2', 'patient protect respiratory syndrome', 'patient protect covid-19', 'patient protect coronavirus', 'patient protect sars-cov-2', 'respiratory syndrome cause sars-cov-2', 'immunity cause sars-cov-2', 'patient cause sars-cov-2', 'coronavirus cause sars-cov-2', 'covid-19 cause sars-cov-2', 'coronavirus cause sars-cov-2']",701,adaptive immunity protects patients coronavirus disease 2019 covid-19 caused severe acute respiratory syndrome coronavirus 2 sars-cov-2 well characterized 
270,67.0,1.0,"['patient receive sars-cov-2', 'patient receive immunity', 'patient induce immunity', 'sars-cov-2 induce immunity', 'sars-cov-2 induce patient']",702,particular asymptomatic patients found induce weak transient sars-cov-2 antibody responses underlying mechanisms remain unknown meanwhile protective immunity guide recovery asymptomatic patients also well studied 
271,67.0,2.0,"['b-cell t-cell characterize b cell', 'b-cell t-cell characterize patient', 'b-cell t-cell characterize patient', 'b-cell t-cell characterize n32', 'b-cell t-cell characterize patient', 'b-cell t-cell characterize gc', 'b-cell t-cell characterize long-term', 'b-cell t-cell characterize immunity', 'b-cell t-cell characterize gc', 'b-cell t-cell characterize indicator', 'b-cell t-cell characterize follicular', 'b-cell t-cell characterize serum', 'b-cell t-cell characterize cxcl13', 'sars-cov-2-specific characterize b cell', 'sars-cov-2-specific characterize patient', 'sars-cov-2-specific characterize patient', 'sars-cov-2-specific characterize n32', 'sars-cov-2-specific characterize patient', 'sars-cov-2-specific characterize gc', 'sars-cov-2-specific characterize long-term', 'sars-cov-2-specific characterize immunity', 'sars-cov-2-specific characterize gc', 'sars-cov-2-specific characterize indicator', 'sars-cov-2-specific characterize follicular', 'sars-cov-2-specific characterize serum', 'sars-cov-2-specific characterize cxcl13', 'b-cell t-cell receive serum', 'b-cell t-cell receive cxcl13', 'b cell receive serum', 'b cell receive cxcl13', 'sars-cov-2-specific receive serum', 'sars-cov-2-specific receive cxcl13', 'patient receive serum', 'patient receive cxcl13', 'patient receive serum', 'patient receive cxcl13', 'n32 receive serum', 'n32 receive cxcl13', 'patient receive serum', 'patient receive cxcl13', 'gc receive serum', 'gc receive cxcl13', 'long-term receive serum', 'long-term receive cxcl13', 'immunity receive serum', 'immunity receive cxcl13', 'gc receive serum', 'gc receive cxcl13', 'indicator receive serum', 'indicator receive cxcl13', 'b-cell t-cell die serum', 'b-cell t-cell die cxcl13', 'b cell die serum', 'b cell die cxcl13', 'sars-cov-2-specific die serum', 'sars-cov-2-specific die cxcl13', 'patient die serum', 'patient die cxcl13', 'patient die serum', 'patient die cxcl13', 'n32 die serum', 'n32 die cxcl13', 'patient die serum', 'patient die cxcl13', 'gc die serum', 'gc die cxcl13', 'long-term die serum', 'long-term die cxcl13', 'immunity die serum', 'immunity die cxcl13', 'gc die serum', 'gc die cxcl13', 'indicator die serum', 'indicator die cxcl13', 'follicular die serum', 'follicular die cxcl13']",703, characterized sars-cov-2-specific b-cell t-cell responses 10 asymptomatic patients 49 patients disease severity mild n10 moderate n32 severe n7 found asymptomatic mild symptomatic patients failed mount virus-specific germinal center gc b cell responses result robust long-term humoral immunity assessed gc response indicators including follicular helper tfh cell memory b cell responses well serum cxcl13 levels 
272,67.0,3.0,"['patient mount cd8 cell', 'patient mount th1']",704,alternatively patients mounted potent virus-specific th1 cd8 cell responses 
273,67.0,4.0,"['patient induce cd8 cells', 'patient induce virus-specific', 'patient induce th1', 'virus-specific induce cd8 cells', 'virus-specific induce th1', 'virus-specific induce patient', 'gc induce cd8 cells', 'gc induce virus-specific', 'gc induce th1', 'gc induce patient']",705,sharp contrast patients moderate severe disease induced vigorous virus-specific gc b cell responses associated tfh responses however virus-specific th1 cd8 cells minimally induced patients 
274,67.0,5.0,"['immunity receive cellular', 'immunity receive covid-19', 'immunity receive patient', 'immunity receive covid-19', 'immunity receive vaccine', 'patient receive cellular', 'patient receive covid-19', 'patient receive covid-19', 'patient receive vaccine']",706,results therefore uncovered protective immunity asymptomatic patients revealed strikingly dichotomous unbalanced humoral cellular immune responses covid-19 patients different disease severity providing important insights rational design covid-19 vaccines 
275,68.0,3.0,"['100 show immunocompromised', '100 show patient', '100 show ci594-772', 'ci806-100 show immunocompromised', 'ci806-100 show patient', 'ci806-100 show ci594-772', '100 mediate ci594-772', 'ci806-100 mediate ci594-772', 'ci404-596 mediate ci594-772', 'immunocompromised mediate ci594-772', 'patient mediate ci594-772']",710,find 100 ci806-100 immunocompetent individuals show positive cell-mediated humoral immune response post vaccination 50 ci404-596 immunocompromised patients show humoral immune response 69 ci594-772 positive cell-mediated immune response 
276,69.0,3.0,"['norwegian provide influenza', 'norwegian provide primary-health-care', 'norwegian provide date', 'norwegian provide influenza', 'norwegian provide h1n1', 'date provide influenza', 'date provide primary-health-care', 'date provide influenza', 'date provide h1n1', 'date provide norwegian']",716,norwegian directorate health provided dates clinical influenza diagnoses primary-health-care providers whereas dates laboratory-confirmed influenza h1n1 diagnoses provided norwegian surveillance system communicable diseases 
277,69.0,5.0,"['proportional-hazards match death', 'proportional-hazards match ci', 'proportional-hazards match woman']",718,cox proportional-hazards regression models fitted estimate hazard ratios hrs fetal death associated 95 confidence intervals cis comparing women without ili diagnosis pregnancy 
278,69.0,7.0,['ili associate death'],720,ili regular seasons associated increased risk fetal death adjusted hr 090 95 ci 064ÃÂÂ127 
279,69.0,8.0,['death increase 175'],721,contrast ili pandemic associated substantially increased risk fetal death adjusted hr 175 95 ci 121ÃÂÂ254 
280,69.0,9.0,['first-trimester follow 228'],722,risk highest following first-trimester ili adjusted hr 228 95 ci 145ÃÂÂ359 
281,70.0,0.0,"['salmonella use antigen', 'salmonella use pig', 'vaccine use antigen', 'vaccine use pig']",726,background recombinant salmonella enterica serotype choleraesuis s choleraesuis vaccine vector could used deliver heterologous antigens prevent control pig diseases 
282,70.0,1.0,"['vaccine attenuate crp Ã\x83\x83Ã\x83\x82pmi-2426', 'vaccine attenuate tt terminator', 'vaccine attenuate tt', 'vaccine attenuate laci', 'vaccine attenuate tt', 'vaccine attenuate saoa', 'vaccine attenuate serotypes', 'vaccine attenuate mouse', 'vaccine attenuate approximately', 'vaccine attenuate mouse', 'crp Ã\x83\x83Ã\x83\x82pmi-2426 induce serotypes', 'crp Ã\x83\x83Ã\x83\x82pmi-2426 induce mouse', 'crp Ã\x83\x83Ã\x83\x82pmi-2426 induce approximately', 'crp Ã\x83\x83Ã\x83\x82pmi-2426 induce mouse', 'tt terminator induce serotypes', 'tt terminator induce mouse', 'tt terminator induce approximately', 'tt terminator induce mouse', 'vaccine induce serotypes', 'vaccine induce mouse', 'vaccine induce approximately', 'vaccine induce mouse', 'tt induce serotypes', 'tt induce mouse', 'tt induce approximately', 'tt induce mouse', 'laci induce serotypes', 'laci induce mouse', 'laci induce approximately', 'laci induce mouse', 'tt induce serotypes', 'tt induce mouse', 'tt induce approximately', 'tt induce mouse', 'saoa induce serotypes', 'saoa induce mouse', 'saoa induce approximately', 'saoa induce mouse', 'crp Ã\x83\x83Ã\x83\x82pmi-2426 conserve mouse', 'crp Ã\x83\x83Ã\x83\x82pmi-2426 conserve approximately', 'crp Ã\x83\x83Ã\x83\x82pmi-2426 conserve mouse', 'tt terminator conserve mouse', 'tt terminator conserve approximately', 'tt terminator conserve mouse', 'vaccine conserve mouse', 'vaccine conserve approximately', 'vaccine conserve mouse', 'tt conserve mouse', 'tt conserve approximately', 'tt conserve mouse', 'laci conserve mouse', 'laci conserve approximately', 'laci conserve mouse', 'tt conserve mouse', 'tt conserve approximately', 'tt conserve mouse', 'saoa conserve mouse', 'saoa conserve approximately', 'saoa conserve mouse', 'serotypes conserve mouse', 'serotypes conserve approximately', 'serotypes conserve mouse', 'crp Ã\x83\x83Ã\x83\x82pmi-2426 provide mouse', 'tt terminator provide mouse', 'vaccine provide mouse', 'tt provide mouse', 'laci provide mouse', 'tt provide mouse', 'saoa provide mouse', 'serotypes provide mouse']",727,previously shown live-attenuated s choleraesuis vaccine candidate strain rsc0011 ÃÂp crp527 tt arac p bad crp ÃÂpmi-2426 ÃÂrela199 arac p bad laci tt ÃÂasda33 ÃÂ deletion tt terminator delivering saoa conserved surface protein s suis serotypes provided excellent protection s suis challenge occasionally lead morbidity enteritidis vaccinated mice approximately 1 every 10 mice 
283,70.0,3.0,"['herein observe symptom', 'tt observe symptom', 'arac observe symptom', 'fur observe symptom', 'bad observe symptom', 'laci observe symptom', 'tt observe symptom', 'herein describe tt', 'herein describe arac', 'herein describe fur', 'herein describe bad', 'herein describe laci', 'herein describe tt', 'herein describe symptom', 'herein attenuate tt', 'herein attenuate arac', 'herein attenuate fur', 'herein attenuate bad', 'herein attenuate laci', 'herein attenuate tt', 'herein attenuate symptom']",729,herein described another recombinant attenuated s choleraesuis vector rsc0012 ÃÂp fur88 tt arac p bad fur ÃÂpmi-2426 ÃÂrela199 arac p bad laci tt ÃÂasda33 regulated delayed fur mutation avoid inducing disease symptoms exhibiting high degree immunogenicity 
284,70.0,6.0,"['rsc0012 make rsc0011', 'pya3493 make rsc0011', 'spleen make rsc0011', 'liver make rsc0011']",732,rsc0012 either ps-saoa pya3493 cleared spleen liver tissues 7 days earlier rsc0011 vectors oral inoculation 
285,70.0,7.0,"['saoa induce mucosal iga', 'saoa induce antibody', 'saoa induce igg', 'saoa induce serum', 'saoa induce vaginal', 'saoa induce il-4', 'saoa induce th2-type', 'saoa induce mouse']",733,strain rsc0012 synthesizing saoa induced high titers anti-saoa antibodies systemic igg serum mucosal iga vaginal washes sites well increased level il-4 facilitator th2-type cell immune response mice 
286,70.0,8.0,"['vaccine confer suis', 'vaccine confer balbc', 'rsc0012 confer suis', 'rsc0012 confer balbc', 'ps-saoa confer suis', 'ps-saoa confer balbc']",734,recombinant vaccine rsc0012 ps-saoa conferred high percentage protection s suis s choleraesuis challenge balbc mice 
287,70.0,9.0,['salmonella attenuate vaccine'],735,conclusions live-attenuated salmonella enterica serotype choleraesuis vaccine rsc0012 ps-saoa regulated delayed fur mutation provides foundation development safe effective vaccine s choleraesuis s suis 
288,71.0,0.0,"['influenza induce adult', 'influenza induce adult']",736,despite widespread influenza vaccination programs influenza remains major cause morbidity mortality older adults 
289,71.0,1.0,"['influenza include senescence', 'influenza include senescence']",737,age-related changes multiple aspects adaptive immune response influenza well-documented including decline antibody responses influenza vaccination changes cell-mediated response associated immune senescence 
290,71.0,3.0,"['cd8 cell provide influenza', 'cd8 cell provide lung', 'pro- provide influenza', 'pro- provide lung', 'mediator provide influenza', 'mediator provide lung']",739, dysregulation production pro- anti-inflammatory mediators contributes decline generation effective cd8 cell response needed clear influenza virus lungs 
291,71.0,4.0,"['influenza provide cd8 cell', 'influenza provide virus']",740,current influenza vaccines provide weak stimulus arm adaptive immune response rely re-stimulation cd8 cell memory related prior exposure influenza virus 
292,72.0,1.0,"['antibody prevent cellular', 'antibody prevent surrogate']",743,new competitive immunoassays measuring antibodies preventing interaction spike protein cellular receptor proposed surrogate vnt svnt 
293,72.0,2.0,"['three receive igg', 'three receive biomerieux', 'three receive plaque', 'three receive prnt50', 'three receive 306', 'three receive patient', 'two receive igg', 'two receive biomerieux', 'two receive plaque', 'two receive prnt50', 'two receive 306', 'two receive patient', 'teco receive igg', 'teco receive biomerieux', 'teco receive plaque', 'teco receive prnt50', 'teco receive 306', 'teco receive patient']",744,tested three commercial svnt qualitative immunochromatographic test two quantitative immunoassays named yhlo teco together conventional anti-spike igg assay biomerieux comparison in-house plaque reduction neutralization test prnt50 using original 19a strain different variants concern voc panel 306 sera naturally-infected vaccinated patients 
294,72.0,4.0,"['8407 use biomerieux', '8407 use nab', 'p-value use biomerieux', 'p-value use nab', 'p-value use biomerieux', 'p-value use nab']",746,areas curve yhlo teco assays respectively 8583 8407 p-value 005 using positivity threshold 20 prnt50 9563 9035 p-value 002 using threshold 80 however performances yhlo biomerieux close thresholds demonstrating absence added value svnt compared conventional assay evaluation presence nab seropositive subjects 
295,73.0,1.0,"['168 million vaccinate two', '168 million vaccinate six', '168 million vaccinate vaccine', 'case-control vaccinate two', 'case-control vaccinate six', 'case-control vaccinate vaccine', '2021 vaccinate two', '2021 vaccinate six', '2021 vaccinate vaccine', '168 million cover case-control', '168 million cover 2021', '168 million cover two', '168 million cover six', '168 million cover vaccine', '168 million induce 2021', '168 million induce two', '168 million induce six', '168 million induce vaccine', 'case-control induce 2021', 'case-control induce two', 'case-control induce six', 'case-control induce vaccine', '168 million match 2021', '168 million match two', '168 million match six', '168 million match vaccine', 'case-control match 2021', 'case-control match two', 'case-control match six', 'case-control match vaccine']",750,methods using claims laboratory data covering 168 million lives conducted matched case-control study fully vaccinated individuals january 1 september 7 2021 odds ratios developing outcomes months two six following full vaccination estimated relative first month full vaccination vaccine separately 
296,73.0,4.0,"['ad26cov2s wan 125', 'ad26cov2s wan 180']",753,evidence waning protection hospitalization ad26cov2s 95 ci 125 086 180 month 5 
297,73.0,7.0,"['ad26cov2s show line', 'ad26cov2s show cellular', 'ad26cov2s show vaccine', 'ad26cov2s show single-dose', 'ad26cov2s show two-dose', 'ad26cov2s show mrna', 'ad26cov2s show vaccine', 'ad26cov2s emerge vaccine', 'ad26cov2s emerge single-dose', 'ad26cov2s emerge two-dose', 'ad26cov2s emerge mrna', 'ad26cov2s emerge vaccine', 'line emerge vaccine', 'line emerge single-dose', 'line emerge two-dose', 'line emerge mrna', 'line emerge vaccine', 'cellular emerge vaccine', 'cellular emerge single-dose', 'cellular emerge two-dose', 'cellular emerge mrna', 'cellular emerge vaccine']",756,ad26cov2s showed durable level protection breakthrough infections hospitalizations line published evidence durable antibody cellular immune response although vaccine effectiveness baseline single-dose lower two-dose mrna vaccines 
298,74.0,0.0,"['cancer include vaccine', 'cancer include patient', 'immunotherapy include vaccine', 'immunotherapy include cancer', 'immunotherapy include patient']",758,cancer immunotherapy including vaccine therapy promising modality cancer treatment patients show clinical benefits currently 
299,74.0,1.0,['patient receive immunotherapy'],759,identification biomarkers identify patients benefit cancer immunotherapy thus important 
300,74.0,2.0,"['cfdna circulate cell-derived', 'cfdna circulate fragment', 'cfdna circulate cell-derived', 'cfdna circulate fragment', 'cfdna circulate alu', 'cfdna circulate vaccine', 'cfdna circulate patient', 'cfdna circulate cancer', 'cfdna derive patient', 'cfdna derive cancer', 'necrotic derive patient', 'necrotic derive cancer', 'cell-derived derive patient', 'cell-derived derive cancer', 'fragment derive patient', 'fragment derive cancer', 'cell-derived derive patient', 'cell-derived derive cancer', 'fragment derive patient', 'fragment derive cancer', 'alu derive patient', 'alu derive cancer', 'vaccine derive patient', 'vaccine derive cancer']",760, investigated potential utility circulating cell-free dna cfdna integrityÃÂÂa ratio necrotic cell-derived longer dna fragments versus apoptotic cell-derived shorter fragments alu geneÃÂÂas biomarker vaccine therapy patients ovarian cancer 
301,74.0,4.0,"['cfdna decrease vaccine-induced', 'cfdna decrease 593', 'cfdna decrease igg-positive', 'cfdna decrease patient', 'cfdna decrease igg-positive', 'cfdna decrease patient', 'vaccine-induced decrease igg-positive', 'vaccine-induced decrease patient', 'cfdna decrease igg-positive', 'cfdna decrease patient']",762,observed 1 cfdna integrity decreased first cycle vaccination 2 decreased levels cfdna integrity correlated vaccine-induced immune responses ie decreased cfdna integrity observed 917 593 igg-positive negative patients respectively p 00445 
302,74.0,6.0,"['cfdna circulate cancer', 'cfdna circulate vaccine']",764,results suggest circulating cfdna integrity possible biomarker cancer vaccine therapy 
303,75.0,0.0,"['antibody neutralize pre-infected', 'antibody neutralize sars-cov-2', 'antibody neutralize three', 'antibody neutralize bnt162b2', 'antibody neutralize vaccine', 'wuhan neutralize pre-infected', 'wuhan neutralize sars-cov-2', 'wuhan neutralize three', 'wuhan neutralize bnt162b2', 'wuhan neutralize vaccine']",765,report levels neutralising antibodies wuhan delta omicron variants healthy individuals pre-infected sars-cov-2 immunized three doses bnt162b2 vaccine 
304,76.0,0.0,"['hematopoietic increase immune dysfunction', 'hematopoietic increase covid-19', 'hsct increase immune dysfunction', 'hsct increase covid-19', 'recipient increase immune dysfunction', 'recipient increase covid-19', 'coronavirus increase immune dysfunction', 'coronavirus increase covid-19']",767,background hematopoietic stem cell transplant hsct recipients increased risk mortality morbidity coronavirus disease 2019 covid-19 due severe immune dysfunction 
305,76.0,9.0,"['patient range men', '569 range men', '1-816 range men', 'year range men']",776,median age patients 569 range 1-816 years 63 patients men according 14 studies 
306,77.0,2.0,"['cohort vaccinate sars-cov-2', '1464 vaccinate cohort', '1464 vaccinate sars-cov-2', 'cohort aim 1464', 'cohort aim 231', 'cohort aim sars-cov-2', 'cohort compare 1464', 'cohort compare 231', 'cohort compare sars-cov-2']",785,methodsthis observational cohort study aimed comparing differences clinical biochemical parameters hospitalization outcomes 53 fully vaccinated individuals unvaccinated 1464 partially vaccinated 231 individuals among cohort 2080 individuals hospitalized sars-cov-2 infection 
307,77.0,3.0,"['covid-19 develop hypoxia', 'covid-19 develop death']",786,resultscompleting course vaccination protected individuals developing severe covid-19 evidence lower proportions hypoxia abnormal levels inflammatory markers requiring ventilatory support death compared unvaccinated partially vaccinated individuals 
308,77.0,7.0,"['studyc_st_absthe receive niv-2020-770', 'studyc_st_absthe receive covaxin', 'studyc_st_absthe receive chimpanzee', 'studyc_st_absthe receive adenovirus', 'studyc_st_absthe receive chadox1', 'studyc_st_absthe receive ncov-19', 'studyc_st_absthe receive corona', 'studyc_st_absthe receive vaccine', 'india receive niv-2020-770', 'india receive covaxin', 'india receive chimpanzee', 'india receive adenovirus', 'india receive chadox1', 'india receive ncov-19', 'india receive corona', 'india receive vaccine', 'citizen receive niv-2020-770', 'citizen receive covaxin', 'citizen receive chimpanzee', 'citizen receive adenovirus', 'citizen receive chadox1', 'citizen receive ncov-19', 'citizen receive corona', 'citizen receive vaccine', 'two receive niv-2020-770', 'two receive covaxin', 'two receive chimpanzee', 'two receive adenovirus', 'two receive chadox1', 'two receive ncov-19', 'two receive corona', 'two receive vaccine', 'vaccine receive niv-2020-770', 'vaccine receive covaxin', 'vaccine receive chimpanzee', 'vaccine receive adenovirus', 'vaccine receive chadox1', 'vaccine receive ncov-19', 'vaccine receive corona', 'covid-19 receive niv-2020-770', 'covid-19 receive covaxin', 'covid-19 receive chimpanzee', 'covid-19 receive adenovirus', 'covid-19 receive chadox1', 'covid-19 receive ncov-19', 'covid-19 receive corona', 'covid-19 receive vaccine', 'vaccine receive niv-2020-770', 'vaccine receive covaxin', 'vaccine receive chimpanzee', 'vaccine receive adenovirus', 'vaccine receive chadox1', 'vaccine receive ncov-19', 'vaccine receive corona', 'sars-cov-2 receive niv-2020-770', 'sars-cov-2 receive covaxin', 'sars-cov-2 receive chimpanzee', 'sars-cov-2 receive adenovirus', 'sars-cov-2 receive chadox1', 'sars-cov-2 receive ncov-19', 'sars-cov-2 receive corona', 'sars-cov-2 receive vaccine', 'studyc_st_absthe vaccinate two', 'studyc_st_absthe vaccinate vaccine', 'studyc_st_absthe vaccinate covid-19', 'studyc_st_absthe vaccinate vaccine', 'studyc_st_absthe vaccinate sars-cov-2', 'studyc_st_absthe vaccinate vaccine', 'studyc_st_absthe vaccinate niv-2020-770', 'studyc_st_absthe vaccinate covaxin', 'studyc_st_absthe vaccinate chimpanzee', 'studyc_st_absthe vaccinate adenovirus', 'studyc_st_absthe vaccinate chadox1', 'studyc_st_absthe vaccinate ncov-19', 'studyc_st_absthe vaccinate corona', 'studyc_st_absthe vaccinate vaccine', 'india vaccinate two', 'india vaccinate vaccine', 'india vaccinate covid-19', 'india vaccinate vaccine', 'india vaccinate sars-cov-2', 'india vaccinate vaccine', 'india vaccinate niv-2020-770', 'india vaccinate covaxin', 'india vaccinate chimpanzee', 'india vaccinate adenovirus', 'india vaccinate chadox1', 'india vaccinate ncov-19', 'india vaccinate corona', 'india vaccinate vaccine', 'citizen vaccinate two', 'citizen vaccinate vaccine', 'citizen vaccinate covid-19', 'citizen vaccinate vaccine', 'citizen vaccinate sars-cov-2', 'citizen vaccinate vaccine', 'citizen vaccinate niv-2020-770', 'citizen vaccinate covaxin', 'citizen vaccinate chimpanzee', 'citizen vaccinate adenovirus', 'citizen vaccinate chadox1', 'citizen vaccinate ncov-19', 'citizen vaccinate corona', 'citizen vaccinate vaccine', 'studyc_st_absthe base vaccine', 'india base vaccine', 'citizen base vaccine', 'two base vaccine', 'covid-19 base vaccine', 'sars-cov-2 base vaccine', 'niv-2020-770 base vaccine', 'covaxin base vaccine', 'chimpanzee base vaccine', 'adenovirus base vaccine', 'chadox1 base vaccine', 'ncov-19 base vaccine', 'corona base vaccine']",790,research contexto_st_absevidence studyc_st_absthe government india started vaccinating citizens 16th january 2021 emergency use authorization received use two vaccines bbv152 covid-19 vaccine based whole-virion sars-cov-2 vaccine strain niv-2020-770 covaxin recombinant replication-deficient chimpanzee adenovirus vector encoding spike protein chadox1 ncov-19 corona virus vaccine covishield 
309,77.0,9.0,['vaccine receive covid-19'],792,studies found vaccines led 90 reduction symptomatic covid-19 disease 
310,77.0,12.0,"['patient include 125', 'patient include 315', 'patient include cohort', 'sars-cov-2 include patient', 'sars-cov-2 include 125', 'sars-cov-2 include 315', 'sars-cov-2 include cohort', 'new include patient', 'new include 125', 'new include 315', 'new include cohort', 'delhi include patient', 'delhi include 125', 'delhi include 315', 'delhi include cohort']",795,study patients sars-cov-2 infection admitted tertiary care hospital new delhi found mortality fully vaccinated patients 125 compared 315 unvaccinated cohort 
311,77.0,13.0,"['studythis test patient', 'studythis test 714', 'cohort test patient', 'cohort test 714', 'patient test 714', 'sars-cov-2 test patient', 'sars-cov-2 test 714', 'second test patient', 'second test 714', 'covid-19 test patient', 'covid-19 test 714', 'india test patient', 'india test 714', 'studythis hospitalize second', 'studythis hospitalize covid-19', 'studythis hospitalize india', 'studythis hospitalize patient', 'studythis hospitalize 714', 'cohort hospitalize second', 'cohort hospitalize covid-19', 'cohort hospitalize india', 'cohort hospitalize patient', 'cohort hospitalize 714', 'patient hospitalize second', 'patient hospitalize covid-19', 'patient hospitalize india', 'patient hospitalize 714', 'sars-cov-2 hospitalize second', 'sars-cov-2 hospitalize covid-19', 'sars-cov-2 hospitalize india', 'sars-cov-2 hospitalize patient', 'sars-cov-2 hospitalize 714']",796,added-value studythis cohort hospitalized patients sars-cov-2 infection studied peak second wave covid-19 india delta variant concern predominant infecting strain 26 patients partially vaccinated 714 unvaccinated 
312,77.0,20.0,"['infection develop 228', 'illness develop 228', 'fatality develop 228']",803,3 individuals 57 53 developed breakthrough infection succumbed illness case fatality rates significantly higher unvaccinated 228 partially vaccinated 195 groups 
313,77.0,23.0,"['vaccine reduce death', 'covid-19 reduce death']",806,vaccines effective reducing incidence severe covid-19 hypoxia critical illness death 
314,78.0,1.0,"['sars-cov-2 need patient', 'infection need patient']",810,objective assess demographic clinical outcome variables patients requiring hospitalization severe sars-cov-2 infection comparing fully vaccinated boosted fv b unvaccinated uv patients 
315,78.0,2.0,"['cohort compare adult', 'cohort compare covid-19']",811,methods multicenter observational cohort analysis compared demographic clinical outcome variables fv b uv adults hospitalized covid-19 
316,78.0,3.0,"['fv perform two', 'patient perform two', 'fv need two', 'patient need two', 'fv describe two', 'patient describe two', 'fv test two', 'patient test two']",812,sub-analysis fv b patients requiring intensive care icu care versus non-icu care performed describe analyze common symptom presentations initial vital signs initial laboratory workup pertinent medication use two groups 
317,78.0,5.0,"['4571 need fv', '4571 need 2935']",814,4571 encounters requiring hospitalization 65 14 fv b 2935 64 uv 
318,78.0,7.0,"['in-hospital compare 121', 'in-hospital compare p038', 'in-hospital compare patient', 'fv compare 121', 'fv compare p038', 'fv compare patient']",816,despite significantly higher baseline risk in-hospital mortality fv b group compared uv elixhauser 16 vs 8 p 0001 trend toward lower in-hospital mortality 77 vs 121 p038 among fv b patients 
319,78.0,8.0,"['fv need p05', '111 need p05', 'patient need p05', '106 need p05', 'patient need p05']",817,severe outcomes followed trend 77 fv b vs 111 uv patients needing mechanical ventilation 46 vs 106 patients needing vasopressors group respectively p05 017 
320,79.0,1.0,"['booster lack nocebo', 'booster aim nocebo']",822,since booster studies lack comparators estimating extent nocebo effect difficult 
321,79.0,4.0,"['covid-19 make 2021', 'covid-19 make fda', 'vaccine make 2021', 'vaccine make fda', 'fda make 2021']",825,documents regarding covid-19 vaccines booster dose authorized fda cutoff date 19 november 2021 systematically searched pubmed fda website 
322,79.0,7.0,"['two receive participant', 'two receive mrna-1273', 'two receive one', 'two receive ad26cov2s']",828,findings two trials identified bnt162b2 n21785 participants two mrna-1273 n22324 one ad26cov2s n4085 
323,79.0,8.0,"['fever make booster', 'fever make vaccine', 'fever make ae']",829,fever cases dropped half booster dose vaccines whereas systemic ae frequencies similar preceding dose 
324,79.0,9.0,['fever receive aes'],830,almost fever cases occurred placebo firstsecond dose systemic aes occurred high frequencies 
325,79.0,14.0,"['nocebo provide aes', 'nocebo appear aes']",835,nocebo effect appears substantially contribute differences frequencies various systemic aes 
326,80.0,0.0,"['igg detect sars-cov-2', 'igg detect sars', 'igg detect mers', 'igg detect oc43', 'igg detect hku1', 'igg detect ifn-is', 'antibody detect sars-cov-2', 'antibody detect sars', 'antibody detect mers', 'antibody detect oc43', 'antibody detect hku1', 'antibody detect ifn-is']",836,microarray-based assay detect igg igm antibodies betacoronaviruses sars-cov-2 sars mers oc43 hku1 respiratory viruses type interferons ifn-is developed 
327,80.0,2.0,"['endocrine disorders receive cohort', 'endocrine disorders receive patient', '278 receive cohort', '278 receive patient', 'serum receive cohort', 'serum receive patient', 'convalescent receive cohort', 'convalescent receive patient', 'plasma receive cohort', 'plasma receive patient', 'donor receive cohort', 'donor receive patient', 'covid-19 receive cohort', 'covid-19 receive patient', 'pa-tients receive cohort', 'pa-tients receive patient', 'patient receive cohort', 'covid-19 receive cohort', 'covid-19 receive patient', 'vaccine receive cohort', 'vaccine receive patient', 'patient receive cohort', 'autoimmune receive cohort', 'autoimmune receive patient']",838,total 278 serum samples convalescent plasma donors covid-19 pa-tients intensive care unit icu patients recovered mildmoderate covid-19 vaccine recipients prepandemic pandemic patients autoimmune endocrine disorders heterogeneous prepandemic cohort including healthy individuals chronically ill patients analyzed 
328,80.0,4.0,"['patient detect antibody', 'patient detect two', 'ifn-is detect antibody', 'ifn-is detect two', '105 detect antibody', '105 detect two']",840,regarding icu patients autoantibodies ifn-is detected 105 samples 105 samples found simultaneously contain igm antibodies two different viruses 
329,81.0,1.0,"['bell report vaccine', 'palsy report vaccine', 'covid-19 report vaccine', 'bell follow vaccine', 'palsy follow vaccine']",844,cases bell s palsy following covid-19 vaccination reported disproportionately vaccine group phase 3 clinical trials reported multiple times post-licensure 
330,81.0,2.0,"['bell induce vaccine', 'bell induce vaccine', 'bell induce bnt162b2', 'bell induce covid-19', 'bell induce vaccine', 'bell induce patient', 'bell induce immunization', 'bell induce vaccine', 'bell induce bnt162b2', 'bell induce covid-19', 'bell induce vaccine', 'bell induce patient', 'bell induce immunization', 'vaccine induce bell', 'vaccine induce bnt162b2', 'vaccine induce covid-19', 'vaccine induce patient', 'vaccine induce immunization', 'bell induce vaccine', 'bell induce bnt162b2', 'bell induce covid-19', 'bell induce vaccine', 'bell induce patient', 'bell induce immunization', 'bell induce vaccine', 'bell induce bnt162b2', 'bell induce covid-19', 'bell induce vaccine', 'bell induce patient', 'bell induce immunization', 'bell recommend bnt162b2', 'bell recommend covid-19', 'bell recommend vaccine', 'bell recommend patient', 'bell recommend immunization', 'vaccine recommend bnt162b2', 'vaccine recommend covid-19', 'vaccine recommend patient', 'vaccine recommend immunization', 'bell recommend bnt162b2', 'bell recommend covid-19', 'bell recommend vaccine', 'bell recommend patient', 'bell recommend immunization', 'bell recommend bnt162b2', 'bell recommend covid-19', 'bell recommend vaccine', 'bell recommend patient', 'bell recommend immunization', 'vaccine recommend bnt162b2', 'vaccine recommend covid-19', 'vaccine recommend patient', 'vaccine recommend immunization', 'bell recommend bnt162b2', 'bell recommend covid-19', 'bell recommend vaccine', 'bell recommend patient', 'bell recommend immunization']",845,us food drug administration stated frequency bell s palsy vaccine group consistent expected background rate bell s palsy population recommends ÃÂÂsurveillance cases bell s palsy deployment vaccine larger populationsÃÂÂ 1 present case bell s palsy following pfizerbiontech bnt162b2 covid-19 vaccine administration hiv patient potential adverse event following immunization 
331,81.0,5.0,"['ed receive forehead', 'ed receive left', 'ed receive eyebrow', 'ed receive left', 'ed receive eye', 'ed receive extremity', 'ed elicit extremity', 'forehead elicit extremity', 'left elicit extremity', 'eyebrow elicit extremity', 'left elicit extremity', 'eye elicit extremity']",848,physical examination ed revealed left-sided facial weakness involvement forehead inability raise left eyebrow inability close left eye sensation strength intact bilateral upper lower extremities 
332,81.0,6.0,"['outpatient receive lagophthalmos', 'outpatient receive bell', 'outpatient receive left', 'outpatient receive eye', 'outpatient follow keratopathy', 'outpatient follow lagophthalmos', 'outpatient follow bell', 'outpatient follow left', 'outpatient follow eye']",849,physical examination outpatient ophthalmology clinic day 2 following symptom onset revealing mild exposure keratopathy 5 mm lagophthalmos poor bell s reflex left eye otherwise normal exam findings 
333,81.0,8.0,"['ointment lubricate tear', 'ointment lubricate goggles', 'ointment lubricate eyelid', 'ointment lubricate glucocorticoid', 'ointment use goggles', 'ointment use eyelid', 'ointment use glucocorticoid', 'ointment need glucocorticoid', 'tear need glucocorticoid', 'goggles need glucocorticoid']",851,provided ophthalmic lubricating ointment use hourly artificial tears needed moisture goggles suggested tape eyelids nightly addition standard systemic glucocorticoid antiviral therapy 
334,82.0,8.0,"['woman vaccinate gam-covid-vac', 'woman vaccinate sputnik', 'woman vaccinate vaccine']",863,prospective study included 51 women vaccinated covid-19 gam-covid-vac sputnik v vaccine 
335,82.0,18.0,['gam-covid-vac investigate apl antibody'],873,first study investigating effect gam-covid-vac vaccine ovarian reserve parameters apl antibody levels 
336,84.0,6.0,"['patient collate 2020', 'melanoma collate 2020', 'melanoma collate patient', 'cancer collate 2020', 'cancer collate patient', 'centre collate 2020', 'centre collate patient', '2019 collate 2020', '2019 collate patient', 'patient receive centre', 'patient receive 2019', 'patient receive 2020', 'melanoma receive centre', 'melanoma receive 2019', 'melanoma receive 2020', 'melanoma receive patient']",887,methods real world data patients 70 years age receiving io melanoma collated tertiary cancer centre oct 2019 - dec 2020 objective see older patients tolerated cpi adjuvant palliative settings global pandemic 
337,84.0,12.0,"['sixteen treat patient', 'sixteen treat palliative', 'patient treat palliative']",893,sixteen patients 29 treated adjuvant intent remaining 40 patients 71 treated palliative intent 
338,84.0,20.0,"['cpi explore patient', 'cpi explore covid-19']",901,conclusions real-world data explored use cpi older patients impact covid-19 pandemic management 
339,84.0,23.0,"['clinician make patient', 'clinician make patient', 'clinician make toxicity', 'clinician make covid-19', 'clinician observe patient', 'clinician observe toxicity', 'clinician observe covid-19', 'patient observe toxicity', 'patient observe covid-19']",904,however clinicians working partnership patients ensured safe delivery patients died toxicity therapy covid-19 time 
340,84.0,26.0,['patient receive covid-19'],907,patients received first covid-19 vaccinations ongoing assessement impact vaccination progress 
341,86.0,0.0,"['six use phytase', 'six use boulardii', 'six use intestinal', 'six use microflora', 'six use indicator', 'six use broiler', 'six use chicken', 'six use fed', 'six use diet', 'six use nonphytate', 'six use npp', 'six use 750', 'six use broiler', 'six use chicken', 'six use broiler', 'six use chicken', 'six use npp', 'six use 500', 'six use phy', 'six use boulardiikg', 'six treat boulardiikg', 'phytase treat boulardiikg', 'boulardii treat boulardiikg', 'intestinal treat boulardiikg', 'microflora treat boulardiikg', 'indicator treat boulardiikg', 'broiler treat boulardiikg', 'chicken treat boulardiikg', 'fed treat boulardiikg', 'diet treat boulardiikg', 'nonphytate treat boulardiikg', 'npp treat boulardiikg', '750 treat boulardiikg', 'broiler treat boulardiikg', 'chicken treat boulardiikg', 'broiler treat boulardiikg', 'chicken treat boulardiikg', 'npp treat boulardiikg', '500 treat boulardiikg', 'six observe intestinal', 'six observe microflora', 'six observe indicator', 'six observe broiler', 'six observe chicken', 'six observe fed', 'six observe diet', 'six observe nonphytate', 'six observe npp', 'six observe 750', 'six observe broiler', 'six observe chicken', 'six observe broiler', 'six observe chicken', 'six observe npp', 'six observe 500', 'six observe phy', 'six observe boulardiikg', 'phytase observe intestinal', 'phytase observe microflora', 'phytase observe indicator', 'phytase observe broiler', 'phytase observe chicken', 'phytase observe fed', 'phytase observe diet', 'phytase observe nonphytate', 'phytase observe npp', 'phytase observe 750', 'phytase observe broiler', 'phytase observe chicken', 'phytase observe broiler', 'phytase observe chicken', 'phytase observe npp', 'phytase observe 500', 'phytase observe phy', 'phytase observe boulardiikg', 'boulardii observe intestinal', 'boulardii observe microflora', 'boulardii observe indicator', 'boulardii observe broiler', 'boulardii observe chicken', 'boulardii observe fed', 'boulardii observe diet', 'boulardii observe nonphytate', 'boulardii observe npp', 'boulardii observe 750', 'boulardii observe broiler', 'boulardii observe chicken', 'boulardii observe broiler', 'boulardii observe chicken', 'boulardii observe npp', 'boulardii observe 500', 'boulardii observe phy', 'boulardii observe boulardiikg', 'six reduce npp', 'six reduce 500', 'six reduce phy', 'six reduce boulardiikg', 'phytase reduce npp', 'phytase reduce 500', 'phytase reduce phy', 'phytase reduce boulardiikg', 'boulardii reduce npp', 'boulardii reduce 500', 'boulardii reduce phy', 'boulardii reduce boulardiikg', 'intestinal reduce npp', 'intestinal reduce 500', 'intestinal reduce phy', 'intestinal reduce boulardiikg', 'microflora reduce npp', 'microflora reduce 500', 'microflora reduce phy', 'microflora reduce boulardiikg', 'indicator reduce npp', 'indicator reduce 500', 'indicator reduce phy', 'indicator reduce boulardiikg', 'broiler reduce npp', 'broiler reduce 500', 'broiler reduce phy', 'broiler reduce boulardiikg', 'chicken reduce npp', 'chicken reduce 500', 'chicken reduce phy', 'chicken reduce boulardiikg', 'fed reduce npp', 'fed reduce 500', 'fed reduce phy', 'fed reduce boulardiikg', 'diet reduce npp', 'diet reduce 500', 'diet reduce phy', 'diet reduce boulardiikg', 'nonphytate reduce npp', 'nonphytate reduce 500', 'nonphytate reduce phy', 'nonphytate reduce boulardiikg', 'npp reduce 500', 'npp reduce phy', 'npp reduce boulardiikg', '750 reduce npp', '750 reduce 500', '750 reduce phy', '750 reduce boulardiikg', 'broiler reduce npp', 'broiler reduce 500', 'broiler reduce phy', 'broiler reduce boulardiikg', 'chicken reduce npp', 'chicken reduce 500', 'chicken reduce phy', 'chicken reduce boulardiikg', 'broiler reduce npp', 'broiler reduce 500', 'broiler reduce phy', 'broiler reduce boulardiikg', 'chicken reduce npp', 'chicken reduce 500', 'chicken reduce phy', 'chicken reduce boulardiikg']",920,six dietary treatments applied 42-d study determine effect phytase butyric acid boulardii productive performance intestinal microflora immune response stress indicators gut morphology broiler chickens fed diets reduced content nonphytate p npp 0 total 750 male broiler chickens randomly allotted 6 treatments 5 pens 25 broiler chickens diet positive control pc adequate amounts npp negative control nc 0 1 reduction dietary npp content nc 500 ftu phytasekg phy nc 2 g butyric acidkg ba nc 1 10sup8sup cfu boulardiikg sb nc butyric acid boulardii ba sb considering entire study period body weight gain broiler chickens fed diets greater p 0 05 broiler chickens fed nc diet broiler chickens fed diets phy ba sb greatest value broiler chickens fed diets pc phy sb ba sb greater p 0 05 relative thymus weight primary secondary antibody response infectious bronchitis virus vaccine cutaneous basophil hypersensitivity phytohaemagglutinin-p lower p 0 05 mortality rate blood corticosterone concentration fed nc diet 42 feeding diet ba sb increased p 0 05 cecal lactobacillus spp counts 35 jejunal villus high crypt depth 42 decreased p 0 05 cecal clostridium spp counts 35 compared fed nc diet 35 phy ba sb ba sb treatments also lower p 0 05 population e coli clostridium spp ileum diets affected feed intake relative weights abdominal fat liver population total anaerobic bacteria bifidobacterium spp coliforms ileum ceca serum insulin concentration duodenal morphology conclusion combination butyric acid boulardii may synergistic effects improving productive performance immune response intestinal microflora gut morphology broiler chickens fed low-npp diet
342,87.0,1.0,"['mrna induce 160', 'mrna induce kidney', 'mrna induce recipient', 'mrna induce patient', 'mrna induce leukemia', 'covid-19 induce 160', 'covid-19 induce kidney', 'covid-19 induce recipient', 'covid-19 induce patient', 'covid-19 induce leukemia']",922,objective retrospective study characterize antibody responses induced third dose mrna covid-19 vaccine 160 kidney transplant recipients 20 patients treated chronic lymphocytic leukemia cll 
343,88.0,5.0,"['rna-seq induce five', 'rna-seq induce covid', 'rna-seq induce symptom', 'rna-seq induce jak-stat', 'rna-seq induce patient', 'rna-seq induce b117', 'pbmcs induce five', 'pbmcs induce covid', 'pbmcs induce symptom', 'pbmcs induce jak-stat', 'pbmcs induce patient', 'pbmcs induce b117', 'rna-seq show jak-stat', 'rna-seq show patient', 'rna-seq show b117', 'pbmcs show jak-stat', 'pbmcs show patient', 'pbmcs show b117', 'five show jak-stat', 'five show patient', 'five show b117', 'covid show jak-stat', 'covid show patient', 'covid show b117', 'symptom show jak-stat', 'symptom show patient', 'symptom show b117']",932,rna-seq conducted pbmcs isolated within five days onset covid symptoms demonstrated elevated activation specific immune pathways including jak-stat signaling b117e484k patients compared b117 
344,88.0,7.0,"['bnt162b reduce infection', 'bnt162b reduce patient', 'vaccine reduce infection', 'vaccine reduce patient', 'one reduce infection', 'one reduce patient', 'two reduce infection', 'two reduce patient']",934,prior vaccination bnt162b vaccine n8 one dose n1 two doses reduced transcriptome inflammatory response b117e484k infection relative unvaccinated patients 
345,88.0,8.0,['patient infect b11163'],935,lastly immune transcriptome patients infected additional variants b1258 b11163 b177 displayed reduced activation compared patients infected b117 
346,89.0,0.0,"['influenza decline south america', 'influenza decline lockdown', 'influenza decline covid-19', 'infection decline south america', 'infection decline lockdown', 'infection decline covid-19']",937,ÃÂÂ influenza infections declined drastically north south america lockdowns covid-19 
347,89.0,1.0,['vaccine do influenza'],938,ÃÂÂ selection influenza strains vaccine done early opposing hemisphere influenza season 
348,89.0,3.0,"['reliance base influenza', 'vaccine base influenza']",940,ÃÂÂ reliance egg-based influenza vaccines may result widespread influenza scenario 
349,90.0,0.0,"['prematurity observe human', 'prematurity observe mother', 'cereus observe human', 'cereus observe mother', 'enterotoxin observe human', 'enterotoxin observe mother', 's observe human', 's observe mother']",942,objective study aimed determine whether vaccination pregnancy prematurity staphylococci concentration influenced presence b cereus staphylococcal enterotoxins ses raw human milk healthy mothers 
350,90.0,1.0,"['human collect woman', 'milk collect woman']",943,study design human milk samples collected 152 healthy women 
351,90.0,5.0,"['prematurity affect staphylococci', 'prematurity affect human', 'prematurity affect milk', 'b affect staphylococci', 'b affect human', 'b affect milk']",947,prematurity affect b cereus staphylococci human milk 
352,90.0,8.0,['staphylococci reduce human milk'],950,conclusions vaccination pregnancy low concentration staphylococci could reduce risk b cereus raw human milk 
353,90.0,9.0,"['cereus perform cereus infection', 'cereus perform b', 'cereus perform preterm', 'cereus perform infant']",951,screening b cereus raw human milk must performed pasteurization reduce risk b cereus infection preterm infants 
354,91.0,0.0,"['purpura follow infant', 'itp follow infant']",952,caseÃÂÂcontrol study investigated immune thrombocytopenic purpura itp risk following live inactivated simultaneous vaccination focus infants aged 2 years 
355,91.0,8.0,['itp follow infant'],960,limited data suggest significant itp risk following vaccinations simultaneous vaccination age group including infants 
356,92.0,0.0,"['human compare egyptian', 'human compare stool', 'human compare specimen', 'human compare vaccine', 'rotavirus compare human', 'rotavirus compare egyptian', 'rotavirus compare stool', 'rotavirus compare specimen', 'rotavirus compare vaccine']",962,objective study compare prevalence human rotavirus group common g p genotypes human egyptian stool specimens raw sewage samples determine common genotypes future vaccine development 
357,92.0,1.0,"['1026 nest 2437', '1026 nest rotavirus', '1026 nest rotavirus', '1026 nest specimen', 'stool nest 2437', 'stool nest rotavirus', 'stool nest rotavirus', 'stool nest specimen', 'child nest 2437', 'child nest rotavirus', 'child nest rotavirus', 'child nest specimen', 'diarrhea nest 2437', 'diarrhea nest rotavirus', 'diarrhea nest rotavirus', 'diarrhea nest specimen', '1026 use specimen', 'stool use specimen', 'child use specimen', 'diarrhea use specimen', '2437 use specimen', 'rotavirus use specimen', 'rotavirus use specimen']",963,1026 stool specimens children acute diarrhea using nested rt-pcr 250 samples 2437 positive human rotavirus group a using multiplex rt-pcr rotavirus common p g genotypes detected 8920 4640 positive clinical specimens respectively 
358,92.0,2.0,"['oral attenuate rotavirus', 'oral attenuate rotavirus', 'oral attenuate g6p', 'oral attenuate specimen', 'oral attenuate 1200', 'rotavirus attenuate g6p', 'rotavirus attenuate specimen', 'rotavirus attenuate 1200', 'vaccine attenuate rotavirus', 'vaccine attenuate rotavirus', 'vaccine attenuate g6p', 'vaccine attenuate specimen', 'vaccine attenuate 1200']",964,low percentage common g genotypes frequency may affect efficiency available live attenuated oral rotavirus vaccines rotarixÃÂ human rotavirus g1p 8 rotateqÃÂ reassortant bovineÃÂÂhuman rotavirus g1-4p 5 g6p 8 however percentage clinical specimens negative common g genotypes positive p 8 genotype 1200 
359,92.0,3.0,"['rotavirus collect plant', 'rotavirus collect wwtps', 'rotavirus collect 5417', 'vp6 collect plant', 'vp6 collect wwtps', 'vp6 collect 5417', 'zenin collect plant', 'zenin collect wwtps', 'zenin collect 5417', 'el-gabal collect plant', 'el-gabal collect wwtps', 'el-gabal collect 5417']",965,24 positive raw sewage samples rotavirus group vp6 collected zenin el-gabal el-asfar wastewater treatment plants wwtps 21 samples 8750 typeable common p genotypes 13 samples 5417 typeable common g genotypes 
360,92.0,4.0,"['vp8 show two', 'vp8 show vaccine', 'p-typeable show two', 'p-typeable show vaccine', 'isolates show two', 'isolates show vaccine', 'sewage show two', 'sewage show vaccine']",966,phylogenetic analysis vp8 partial gene 45 p-typeable clinical isolates 20 p-typeable raw sewage samples showed high similarity reference strains majority mutations silent showed lower non-significant similarity two vaccine strains 
361,92.0,5.0,['antigen observe vaccine'],967,finding useful determining common antigens required future vaccine development 
362,93.0,0.0,"['immunocompromised show covid-19', 'immunocompromised show vaccine']",969,background shown immunocompromised patients significantly reduced immunologic responses covid-19 vaccines 
363,93.0,3.0,"['patient evaluate 673', 'antibody evaluate 673', 'cohort evaluate 673', '202 evaluate 673', 'cancer evaluate 673', 'patient evaluate 673', 'chemotherapy evaluate 673']",972,patients methods anti-sars-cov-2 s1s2 antibodies measured cohort 202 cancer patients active treatment chemotherapy 96 immunologic 52 biologic 46 hormonal 12 treatments early n66 327 metastatic disease n136 673 
364,93.0,4.0,"['172 receive covid-19', '172 receive 2030', '172 receive one', '172 receive vaccine', 'two receive covid-19', 'two receive 2030', 'two receive one', 'two receive vaccine', 'vaccine receive covid-19', 'vaccine receive 2030', 'vaccine receive one']",973, 172 received two vaccine doses 30 covid-19 infection 2030 also received one dose vaccine 
365,93.0,7.0,"['chemotherapy associate infection', 'chemotherapy associate 813', 'chemotherapy associate 962', 'chemotherapy associate patient', 'chemotherapy associate p0001', 'chemotherapy reduce infection', 'chemotherapy reduce 813', 'chemotherapy reduce 962', 'chemotherapy reduce patient', 'chemotherapy reduce p0001']",976,chemotherapy treatment independently associated significantly reduced humoral response infection vaccination 813 response rate compared 962 patients treatments p0001 
366,94.0,2.0,['vaccine select huang'],984,motivated need rank choose vaccine regimens based immunogenicity phase trials huang et al 
367,94.0,3.0,['algorithm range vaccine'],985, biostatistics 18 2 230ÃÂÂ243 2017 proposed rankingfilteringselection algorithm down-selects vaccine regimens satisfy superiority non-redundancy criteria based multiple immune response endpoints 
368,95.0,4.0,"['cell base gfp', 'cell base infection']",996,utilized new rapid neutralization assay based reporter cells become positive gfp overnight infection 
369,95.0,5.0,['convalescent collect symptom'],997,sera 58 convalescent individuals collected 9 months symptoms similarly neutralized b117 d614g 
370,95.0,7.0,"['serum test b1351', 'serum test d614g', '6 test b1351', '6 test d614g', 'serum vaccinate 6', 'serum vaccinate b1351', 'serum vaccinate d614g']",999,sera 19 individuals vaccinated twice pfizer cominarty longitudinally tested 6 weeks vaccination similarly potent b117 less efficacious b1351 compared d614g 
371,95.0,8.0,"['second dose b1351', 'vaccine dose b1351']",1000,neutralizing titers increased second vaccine dose remained 14-fold lower b1351 
372,95.0,10.0,"['antibody detect nasal', 'antibody detect swab', 'antibody detect vaccinee']",1002,neutralizing antibodies rarely detected nasal swabs vaccinees 
373,95.0,11.0,['sars-cov-2 circulate antibody'],1003,thus faster-spreading sars-cov-2 variants acquired partial resistance neutralizing antibodies generated natural infection vaccination frequently detected individuals low antibody levels 
374,96.0,1.0,"['first approve bnt162b2', 'first approve mrna', 'first approve worker', 'vaccine approve bnt162b2', 'vaccine approve mrna', 'vaccine approve worker']",1006,first vaccine approved poland bnt162b2 mrna preparation pfizerbiontech first vaccinated group healthcare workers 
375,96.0,2.0,"['post-vaccine evaluate vaccine', 'post-vaccine evaluate employee', 'post-vaccine evaluate poland']",1007,aim present study evaluate post-vaccine antibody titers 8 months second vaccine dose administered group employees hospital ministry interior administration olsztyn poland 
376,96.0,3.0,"['employee divide person', 'employee divide covid-19', 'employee divide 2021', 'employee divide person', 'employee divide covid-19']",1008,employees divided two groups persons covid-19 fourth quarter 2020 vaccinated januaryÃÂÂfebruary 2021 persons without history covid-19 vaccinated period 
377,96.0,4.0,"['blood collect employee', 'blood collect 2021', 'blood collect antibody', 'blood collect cobas', 'blood collect e411', 'blood collect eclia', 'serum collect employee', 'serum collect 2021', 'serum collect antibody', 'serum collect cobas', 'serum collect e411', 'serum collect eclia', '100 collect employee', '100 collect 2021', '100 collect antibody', '100 collect cobas', '100 collect e411', '100 collect eclia']",1009,analyzed material venous blood serum collected 100 hospital employees 23ÃÂÂ28 september 2021 level anti-sars-cov-2 antibodies measured roche cobas e411 analyzer using electrochemiluminescence eclia method 
378,96.0,5.0,"['person induce employee', 'person induce covid-19', 'sars-cov-2 induce employee', 'sars-cov-2 induce covid-19']",1010,study demonstrated persons history sars-cov-2 infection significantly higher antibody levels taking account gender age type work performed severity post-vaccination symptoms employees without history covid-19 
379,97.0,0.0,['covid-19 cause china'],1013,covid-19 pandemic caused sars-cov-2 started china december 2019 spread across several continents 
380,97.0,1.0,"['5th confirm antibody', 'covid-19 confirm antibody', 'death confirm antibody', '231 confirm antibody']",1014,5th december 2020 65257767 confirmed cases covid-19 worldwide 1513179 deaths 231 mortality humoral immune responses highly specific provide long-lasting protection reinfection titre antibodies persist directly related extent protection afforded 
381,97.0,2.0,"['vaccine continue immunity', 'vaccine continue antigen', 'sars-cov-2 continue immunity', 'sars-cov-2 continue antigen', 'antibody continue immunity', 'antibody continue antigen']",1015,research towards generating effective vaccines sars-cov-2 advanced stages need continued robust review available data various studies antibody response natural sars-cov-2 infection regards potential immunity re-infection following exposure antigens virus 
382,97.0,4.0,"['igg observe 4272', 'antibody observe 4272']",1017,igg antibodies observed last beyond 120days predicted seroreversion would happen 4272 months 
383,98.0,2.0,"['sars-cov-2 screen iga', 'sars-cov-2 screen antibody', 'sars-cov-2 screen polish', 'sars-cov-2 screen citizen', 'sars-cov-2 screen adult', 'sars-cov-2 screen n501']",1024,present population screening sars-cov-2 specific igg iga antibodies polish citizens healthy adults n501 never positively diagnosed vaccinated sars-cov-2 
384,98.0,3.0,"['blood collect silesia', 'blood collect covid-19', 'blood collect patient']",1025,blood samples collected wrocaw lower silesia 15th 22nd may 2021 sera covid-19 patients severe course hospitalized n43 vaccinated n14 served positive control 
385,98.0,4.0,"['patient test covid-19', 'patient test sars-cov-2', 'patient test antigen', 'patient test ncp', 'patient test ace2', 'patient test antigen', 'patient test coronaviruses', 'patient test mers-cov', 'patient test sars-cov', 'patient test hcov', 'patient test 229e', 'patient test np', 'patient test hcov', 'patient test nl63', 'patient test np', 'patient observe antigen', 'patient observe coronaviruses', 'patient observe mers-cov', 'patient observe sars-cov', 'patient observe hcov', 'patient observe 229e', 'patient observe np', 'patient observe hcov', 'patient observe nl63', 'patient observe np', 'covid-19 observe antigen', 'covid-19 observe coronaviruses', 'covid-19 observe mers-cov', 'covid-19 observe sars-cov', 'covid-19 observe hcov', 'covid-19 observe 229e', 'covid-19 observe np', 'covid-19 observe hcov', 'covid-19 observe nl63', 'covid-19 observe np', 'sars-cov-2 observe antigen', 'sars-cov-2 observe coronaviruses', 'sars-cov-2 observe mers-cov', 'sars-cov-2 observe sars-cov', 'sars-cov-2 observe hcov', 'sars-cov-2 observe 229e', 'sars-cov-2 observe np', 'sars-cov-2 observe hcov', 'sars-cov-2 observe nl63', 'sars-cov-2 observe np', 'antigen observe coronaviruses', 'antigen observe mers-cov', 'antigen observe sars-cov', 'antigen observe hcov', 'antigen observe 229e', 'antigen observe np', 'antigen observe hcov', 'antigen observe nl63', 'antigen observe np', 'ncp observe antigen', 'ncp observe coronaviruses', 'ncp observe mers-cov', 'ncp observe sars-cov', 'ncp observe hcov', 'ncp observe 229e', 'ncp observe np', 'ncp observe hcov', 'ncp observe nl63', 'ncp observe np']",1026,patients tested microblot-array covid-19 igg iga quantitative contain specific sars-cov-2 antigens ncp rbd spike s2 e ace2 plpro protein well antigens exclusion cross-reactivity coronaviruses mers-cov sars-cov hcov 229e np hcov nl63 np 
386,98.0,5.0,"['adult diagnose 525 263', 'adult diagnose sars-cov-2-specific', 'adult diagnose sars-cov-2-specific', 'adult diagnose 216', 'adult diagnose virus-specific', 'adult diagnose igg', 'sars-cov-2 diagnose 525 263', 'sars-cov-2 diagnose sars-cov-2-specific', 'sars-cov-2 diagnose sars-cov-2-specific', 'sars-cov-2 diagnose 216', 'sars-cov-2 diagnose virus-specific', 'sars-cov-2 diagnose igg', '355 178 vaccinate 525 263', '355 178 vaccinate sars-cov-2-specific', '355 178 vaccinate 216', '355 178 vaccinate virus-specific', '355 178 vaccinate igg', 'adult vaccinate 525 263', 'adult vaccinate sars-cov-2-specific', 'adult vaccinate 216', 'adult vaccinate virus-specific', 'adult vaccinate igg', 'sars-cov-2 vaccinate 525 263', 'sars-cov-2 vaccinate sars-cov-2-specific', 'sars-cov-2 vaccinate 216', 'sars-cov-2 vaccinate virus-specific', 'sars-cov-2 vaccinate igg', '355 178 receive 216', '355 178 receive virus-specific', '355 178 receive igg', '525 263 receive 216', '525 263 receive virus-specific', '525 263 receive igg', 'adult receive 216', 'adult receive virus-specific', 'adult receive igg', 'sars-cov-2 receive 216', 'sars-cov-2 receive virus-specific', 'sars-cov-2 receive igg', 'sars-cov-2-specific receive 216', 'sars-cov-2-specific receive virus-specific', 'sars-cov-2-specific receive igg', 'sars-cov-2-specific receive 216', 'sars-cov-2-specific receive virus-specific', 'sars-cov-2-specific receive igg']",1027,within investigated population healthy adults never positively diagnosed vaccinated sars-cov-2 found 355 178 501 positive sars-cov-2-specific igg 525 263 501 positive sars-cov-2-specific iga 216 investigated population developed virus-specific igg iga asymptomatic 
387,98.0,9.0,"['igg lack immunity', 'igg lack covid-19']",1031,note majority investigated population still lacked anti-rbd igg protection 744 thus positive fraction sufficient effective population immunity vaccination covid-19 still importance controlling pandemic 
388,99.0,0.0,"['clozapine confer infection', 'clozapine confer sarscov-2', 'clozapine confer covid-19', 'clozapine confer patient']",1032,background clozapine plus working group frequently consulted advice measures case infection sarscov-2 vaccination covid-19 patients receiving clozapine 
389,99.0,4.0,"['smi increase non-psychiatric', 'smi increase patient', 'patient increase non-psychiatric', 'ssd increase non-psychiatric', 'ssd increase patient', 'patient increase non-psychiatric', 'sars-cov-2 increase non-psychiatric', 'sars-cov-2 increase patient']",1036,results smi patients particular ssd patients increased risk infection sars-cov-2 hospitalizations higher mortality non-psychiatric patients 
390,99.0,5.0,"['patient use clozapine', 'patient use infection']",1037,patients using clozapine may greater risk infection 
391,99.0,6.0,"['sars-cov-2 cause clozapine', 'sars-cov-2 cause plasma', 'sars-cov-2 cause granulocytopenia', 'sars-cov-2 cause lymphocytopenia', 'sars-cov-2 cause clozapine', 'infection cause clozapine', 'infection cause plasma', 'infection cause granulocytopenia', 'infection cause lymphocytopenia', 'infection cause clozapine']",1038,sars-cov-2 infection may cause dangerous increase clozapine plasma levels generally mild short-term granulocytopenia lymphocytopenia usually result clozapine treatment 
392,99.0,7.0,"['covid-19 need ssd', 'patient need ssd', 'smi need ssd']",1039,conclusion case covid-19 extra alertness required patients smi especially ssd 
393,99.0,9.0,"['patient develop sars-cov-2', 'patient develop clozapine']",1041,patients develop granulocytopenia sars-cov-2 considered cause immediately clozapine 
394,100.0,0.0,"['patient need rrt', 'patient need covid-19', 'patient need mrna']",1043,background patients needing chronic rrt risk severe covid-19 mount lesser response mrna vaccination 
395,100.0,2.0,"['covid-19-centred focus booster', 'cohort focus booster', 'kidney focus booster']",1045,methods setting prospective covid-19-centred cohort study dialysis kidney transplant patients examined humoral responses booster vaccination subsequent infection risk 
396,100.0,5.0,"['antibody transition injection', 'antibody transition p', 'booster transition injection', 'booster transition p', 'injection transition p', 'vice transition injection', 'vice transition p']",1048,risk factors antibodies 60 auml despite booster injection transplant vs dialysis or184 p 00001 transitioning dialysis transplantation vice versa or157 p 001 days post injection or0953 p 005 
397,100.0,8.0,['auml associate p0048'],1051,antibody level ÃÂÂ 59 auml time point independently associated reduced risk infection surge or0264 p0048 
398,100.0,10.0,['patient make infection'],1053,patients reached antibody levels likely protect infection 
399,100.0,11.0,"['antibody hint patient', 'antibody compare patient']",1054,antibodies higher third dose compared previous peaks may hint latest immune response may robust sustainable even immune-compromised patients 
400,100.0,12.0,"['kidney show 55-fold', 'kidney show patient', 'recipient show 55-fold', 'recipient show patient', 'kidney show patient', 'recipient show patient', '55-fold show patient']",1055,kidney transplant recipients showed striking enhancement exhibiting 55-fold increase percentage patients protective antibody levels 
401,100.0,13.0,"['patient induce boost', 'patient induce injection']",1056,however many transplant patients remain threshold even boost injection necessitating boosting strategies 
402,101.0,0.0,"['adult induce coronavirus', 'adult induce covid-19', 'adult induce age-based', 'child induce coronavirus', 'child induce covid-19', 'child induce age-based']",1057,compared adults children tend lower incidence rate hospitalization rate mortality rate coronavirus disease 2019 covid-19 cause age-based differences disease severity remains unclear 
403,101.0,1.0,['child serve high-risk'],1058,investigation pathogenesis children may help analyze therapies high-risk population 
404,101.0,2.0,"['respiratory syndrome observe lung injury', 'respiratory syndrome observe acute', 'angiotensin-converting observe lung injury', 'angiotensin-converting observe acute', 'enzyme observe lung injury', 'enzyme observe acute', 'receptor observe lung injury', 'receptor observe acute', 'acute observe lung injury', 'coronavirus observe lung injury', 'coronavirus observe acute', 'pulmonary observe lung injury', 'pulmonary observe acute', 'inflammation observe lung injury', 'inflammation observe acute', 'angiotensin observe lung injury', 'angiotensin observe acute', 'angiotensin-converting modify respiratory syndrome', 'angiotensin-converting modify lung injury', 'angiotensin-converting modify receptor', 'angiotensin-converting modify acute', 'angiotensin-converting modify coronavirus', 'angiotensin-converting modify pulmonary', 'angiotensin-converting modify inflammation', 'angiotensin-converting modify angiotensin', 'angiotensin-converting modify acute', 'enzyme modify respiratory syndrome', 'enzyme modify lung injury', 'enzyme modify receptor', 'enzyme modify acute', 'enzyme modify coronavirus', 'enzyme modify pulmonary', 'enzyme modify inflammation', 'enzyme modify angiotensin', 'enzyme modify acute']",1059,human angiotensin-converting enzyme ÃÂ Â main receptor severe acute respiratory syndrome coronavirus 2 limit pulmonary capillary leakage inflammation mediated angiotensin 2 exert protective effect acute lung injury 
405,101.0,4.0,"['virus induce immunity', 'virus induce child', 'virus induce covid-19', 'infection induce immunity', 'infection induce child', 'infection induce covid-19', 'child induce immunity', 'child induce covid-19']",1061,regular vaccination frequent upper respiratory virus infection children lead regular immune activation combination strong innate immunity help achieve virus clearance early stage infection children covid-19 
406,101.0,6.0,"['cardiopulmonary diseases underlie child', 'obesity underlie child', 'smoking underlie child']",1063,addition risk factors underlying cardiopulmonary diseases obesity smoking relatively uncommon children 
407,101.0,7.0,"['quarantine serve child', 'infection serve child']",1064,social factors including home quarantine timely closure schools may help reduce infection rate children 
408,102.0,7.0,"['fatality hospitalize covid-19', 'fatality hospitalize influenza', 'fatality hospitalize 6', 'fatality hospitalize influenza']",1074,case fatality rate hospitalized patients covid-19 65 p 0001 influenza type 6 p 0001 influenza type b 3 p 0001 
409,103.0,1.0,['antibody induce immunity'],1078,however antibodies induced vaccine display differences specificity cross-reactivity dependent pre-existing immunity 
410,103.0,3.0,"['hemagglutinin aim vaccine', 'antibody aim vaccine']",1080,model predicts region virus hemagglutinin ha protein targeted antibodies vaccination well level cross-reactivity induced vaccine 
411,103.0,4.0,"['human subjects compare h1n1', 'human subjects compare influenza', 'human subjects compare vaccine', 'vaccine compare h1n1', 'vaccine compare influenza', 'human subjects bind vaccine', 'h1n1 bind vaccine']",1081,tested model simulating scenario similar 2009 pandemic vaccine compared results antibody binding data obtained human subjects vaccinated monovalent 2009 h1n1 influenza vaccine 
412,103.0,8.0,['serum show vaccine'],1085,comparison simulation data antibody binding data human serum samples demonstrated qualitative quantitative similarities model real-life immune responses 2009 vaccine 
413,103.0,10.0,['human report vaccine'],1087,model produced similar outcomes previously reported humans receiving 2009 influenza pandemic vaccine 
414,104.0,0.0,"['stem cell undergo sars-cov-2', 'stem cell undergo death', 'covid-19 undergo sars-cov-2', 'covid-19 undergo death', 'patient undergo sars-cov-2', 'patient undergo death']",1089,covid-19 scenario patients undergoing hematopoietic stem cell transplantation hsct infected sars-cov-2 may increased risk death 
415,104.0,1.0,"['covid-19 aim hsct', 'covid-19 aim recipient', 'covid-19 aim brazil', 'covid-19 describe brazil', 'hsct describe brazil']",1090,national multicenter study aimed describe impact covid-19 survival hsct recipients brazil 
416,104.0,3.0,"['child receive hsct', 'child receive malignant', 'adult receive hsct', 'adult receive malignant', 'autologous receive hsct', 'autologous receive malignant']",1092,24 children 62 adults receiving autologous n 25 allogeneic n 61 hsct malignant n 72 non-malignant n 14 disorders 
417,104.0,4.0,['twenty-six die patient'],1093,twenty-six patients died 10 autologous 38 16 patients 62 allogeneic group 
418,104.0,6.0,['adult compare child'],1095,adults decreased os compared children 66 vs 79 p 003 
419,104.0,8.0,"['recipient infect adult', 'recipient infect patient', 'recipient infect covid-19', 'sars-cov-2 infect adult', 'sars-cov-2 infect patient', 'sars-cov-2 infect covid-19']",1097,conclusion hsct recipients infected sars-cov-2 high mortality rate mainly adults patients critical initial covid-19 presentation 
420,105.0,2.0,['left provide vaccine'],1102,one choice left namely effective safe vaccine 
421,105.0,3.0,['people consider vaccine'],1103,many people ambivalent regarding corona vaccines also fear possible side effects vaccination 
422,105.0,5.0,"['cross-sectional induce bangladesh', 'cross-sectional induce five', 'cross-sectional induce 293', 'cross-sectional induce vaccine', 'cross-sectional induce recipient', 'cross-sectional induce two', 'cross-sectional induce vaccine', 'mymensingh induce bangladesh', 'mymensingh induce five', 'mymensingh induce 293', 'mymensingh induce vaccine', 'mymensingh induce recipient', 'mymensingh induce two', 'mymensingh induce vaccine']",1105,cross-sectional descriptive type observational study conducted mymensingh medical college mymensingh bangladesh period five months 1 february 2021 30 june 2021 among 293 purposively selected vaccine recipients received two doses oxford-astrazeneca vaccines 
423,105.0,27.0,"['217 dose vaccine', '741 dose vaccine', 'recipient dose vaccine', '162 dose vaccine', '553 dose vaccine']",1127,study results revealed 217 741 vaccine recipients side effects first dose 162 553 side effects second dose oxford-astrazeneca vaccine 
424,106.0,0.0,"['volunteer induce consortium', 'volunteer induce saccharomyces', 'volunteer induce selenium', 'volunteer induce zinc', 'volunteer induce influenza', 'volunteer induce chiromas', 'volunteer induce covid-19', 'yeast-based induce consortium', 'yeast-based induce saccharomyces', 'yeast-based induce selenium', 'yeast-based induce zinc', 'yeast-based induce influenza', 'yeast-based induce chiromas', 'yeast-based induce covid-19', 'volunteer observe consortium', 'volunteer observe saccharomyces', 'volunteer observe selenium', 'volunteer observe zinc', 'volunteer observe influenza', 'volunteer observe chiromas', 'volunteer observe covid-19', 'yeast-based observe consortium', 'yeast-based observe saccharomyces', 'yeast-based observe selenium', 'yeast-based observe zinc', 'yeast-based observe influenza', 'yeast-based observe chiromas', 'yeast-based observe covid-19', 'volunteer receive selenium', 'volunteer receive zinc', 'volunteer receive influenza', 'volunteer receive chiromas', 'volunteer receive covid-19', 'yeast-based receive selenium', 'yeast-based receive zinc', 'yeast-based receive influenza', 'yeast-based receive chiromas', 'yeast-based receive covid-19', 'consortium receive selenium', 'consortium receive zinc', 'consortium receive influenza', 'consortium receive chiromas', 'consortium receive covid-19', 'saccharomyces receive selenium', 'saccharomyces receive zinc', 'saccharomyces receive influenza', 'saccharomyces receive chiromas', 'saccharomyces receive covid-19', 'volunteer base influenza', 'volunteer base chiromas', 'volunteer base covid-19', 'yeast-based base influenza', 'yeast-based base chiromas', 'yeast-based base covid-19', 'consortium base influenza', 'consortium base chiromas', 'consortium base covid-19', 'saccharomyces base influenza', 'saccharomyces base chiromas', 'saccharomyces base covid-19', 'selenium base influenza', 'selenium base chiromas', 'selenium base covid-19', 'zinc base influenza', 'zinc base chiromas', 'zinc base covid-19']",1130,single-center randomized double-blind placebo-controlled study conducted 72 volunteers received synergistic combination yeast-based ingredients unique ÃÂ²-1316-glucan complex consortium heat-treated probiotic saccharomyces cerevisiae rich selenium zinc abb c1 ÃÂ placebo next day getting vaccinated influenza chiromas ÃÂ n 34 covid-19 comirnaty ÃÂ n 38 
425,106.0,2.0,"['cd4t cells increase covid-19', 'cd4t cells increase vaccine']",1132,mean levels cd4t cells increased 9107 baseline 10002 cellsÃÂµl second dose covid-19 vaccine abb c1 ÃÂ group whereas decrease 10551 9298 cellsÃÂµl placebo group 
426,107.0,0.0,"['patient treat vaccine', 'bowel treat vaccine', 'tnf treat vaccine', 'biologics treat vaccine']",1138,background patients inflammatory bowel diseases ibd specifically treated anti-tumor-necrosis-factor tnf ÃÂ biologics high risk vaccine preventable infections 
427,107.0,7.0,['vaccine dose patient'],1145,first vaccine dose hc seropositive ÃÂÂ7 patients ibd regardless treatment remained seronegative 
428,107.0,13.0,"['patient match two', 'patient match bnt162b2', 'patient match two', 'patient match bnt162b2']",1151,conclusions prospective study patients ibd stratified according treatment patients mounted serologic response two doses bnt162b2 
429,108.0,3.0,"['influenza confirm illness', 'influenza confirm u', 'influenza confirm canada', 'influenza randomize illness', 'influenza randomize u', 'influenza randomize canada', 'influenza observe illness', 'influenza observe u', 'influenza observe canada']",1158,methods use dynamic disease transmission model laboratory-confirmed influenza surveillance data randomized-controlled trial rct data quantify underestimation factor expansion factor symptomatic influenza illnesses us canada 2011-2012 2012-2013 influenza seasons 
430,109.0,0.0,"['swine cause csfv', 'swine cause pig']",1163,classical swine fever csf caused csf virus csfv one important swine diseases resulting huge economic losses pig industry worldwide 
431,109.0,3.0,"['taiwan report 70', 'csf report 70']",1166,taiwan csf cases reported since 2006 although systemic vaccination practiced 70 years 
432,109.0,4.0,"['piglet test sow', 'piglet test csfv', 'piglet test mlv', 'piglet test e2', 'piglet test vaccine', 'piglet test porcine', 'piglet test prrsv', 'piglet test csfv', 'piglet induce porcine', 'piglet induce prrsv', 'piglet induce csfv', 'sow induce porcine', 'sow induce prrsv', 'sow induce csfv', 'csfv induce porcine', 'csfv induce prrsv', 'mlv induce porcine', 'mlv induce prrsv', 'mlv induce csfv', 'e2 induce porcine', 'e2 induce prrsv', 'e2 induce csfv', 'vaccine induce porcine', 'vaccine induce prrsv', 'vaccine induce csfv', 'piglet receive prrsv', 'piglet receive csfv', 'sow receive prrsv', 'sow receive csfv', 'csfv receive prrsv', 'mlv receive prrsv', 'mlv receive csfv', 'e2 receive prrsv', 'e2 receive csfv', 'vaccine receive prrsv', 'vaccine receive csfv', 'porcine receive prrsv', 'porcine receive csfv']",1167, examined sero-dynamics piglets born sows received either csfv mlv e2 vaccine investigated field correlation porcine reproductive respiratory syndrome virus prrsv loads levels csfv antibody 
433,109.0,5.0,"['1398 evaluate csfv antibody', '1398 evaluate elisa', 'serum evaluate csfv antibody', 'serum evaluate elisa', 'prrsv evaluate csfv antibody', 'prrsv evaluate elisa', 'csfv antibody observe elisa', '1398 observe elisa', 'serum observe elisa', 'prrsv observe elisa']",1168,total 1398 serum samples 42 prrsv-positive farms evaluated determine prrsv loads real-time pcr detect csfv antibody levels commercial elisa 
434,109.0,6.0,"['two farrow csfv antibody', 'two farrow pre-farrowing', 'two farrow piglet', 'two farrow mlv', 'two farrow e2', 'csfv farrow csfv antibody', 'csfv farrow pre-farrowing', 'csfv farrow piglet', 'csfv farrow mlv', 'csfv farrow e2', 'mlv farrow csfv antibody', 'mlv farrow pre-farrowing', 'mlv farrow piglet', 'mlv farrow e2', 'e2 farrow csfv antibody', 'e2 farrow pre-farrowing', 'e2 farrow piglet', 'e2 farrow mlv', 'csfv antibody farrow mlv', 'csfv antibody farrow e2', 'two farrow mlv', 'two farrow e2', 'csfv farrow mlv', 'csfv farrow e2', 'mlv farrow e2', 'e2 farrow mlv', 'pre-farrowing farrow mlv', 'pre-farrowing farrow e2', 'piglet farrow mlv', 'piglet farrow e2']",1169,upon comparing two sow vaccination protocols csfv mlv vaccination 4 weeks post-farrowing versus e2 vaccination 4ÃÂÂ5 weeks pre-farrowing lowest levels csfv antibody found piglets 5ÃÂÂ8 9ÃÂÂ12 weeks age mlv e2 groups respectively 
435,110.0,0.0,"['kenya introduce vaccine', 'kenya introduce immunization', 'kenya introduce rotavirus', 'kenya introduce post-', 'kenya introduce july', 'kenya introduce rva', 'kenya introduce vaccine', 'kenya test post-', 'kenya test july', 'kenya test rva', 'kenya test vaccine', 'vaccine test post-', 'vaccine test july', 'vaccine test rva', 'immunization test post-', 'immunization test july', 'immunization test rva', 'immunization test vaccine', 'rotavirus test post-', 'rotavirus test july', 'rotavirus test rva', 'rotavirus test vaccine']",1175,background kenya introduced monovalent g1p 8 rotarixÃÂ vaccine infant immunization schedule july 2014 examined trends rotavirus group rva genotype distribution pre- january 2010ÃÂÂjune 2014 post- july 2014ÃÂÂdecember 2018 rva vaccine introduction 
436,110.0,1.0,"['stool collect four', 'stool collect kenya', 'stool collect kilifi', 'stool collect tabitha', 'stool collect nairobi', 'stool collect lwak', 'stool collect child', 'stool make child', 'stool make four', 'stool make kenya', 'stool make kilifi', 'stool make tabitha', 'stool make nairobi', 'stool make lwak', 'stool make child']",1176,methods stool samples collected children aged 13 years four surveillance sites across kenya kilifi county hospital tabitha clinic nairobi lwak mission hospital siaya county referral hospital children aged 5 years 
437,110.0,2.0,"['rva use immunosorbent', 'rva use elisa', 'rva use vp7', 'rva use vp4', 'enzyme use immunosorbent', 'enzyme use elisa', 'enzyme use vp7', 'enzyme use vp4', 'rva associate elisa', 'rva associate vp7', 'rva associate vp4', 'enzyme associate elisa', 'enzyme associate vp7', 'enzyme associate vp4', 'immunosorbent associate elisa', 'immunosorbent associate vp7', 'immunosorbent associate vp4']",1177,samples screened rva using enzyme linked immunosorbent assay elisa vp7 vp4 genes sequenced infer genotypes 
438,111.0,0.0,['sars-cov-2 show patient'],1190,objectives emergence strains sars-cov-2 exhibiting increase viral fitness immune escape potential delta variant b16172 raises concerns immunocompromised patients 
439,111.0,6.0,"['igg show rituximab', 'bnt162b2 show rituximab', 'vaccine show rituximab']",1196,kinetics anti-spike igg bnt162b2 vaccine showed lower delayed induction cases pronounced rituximab 
440,111.0,7.0,"['two generate alpha', 'two generate delta', 'two generate 100', 'two generate one', 'two generate rituximab-treated', 'two generate patient', 'two generate alpha', 'bnt162b2 generate alpha', 'bnt162b2 generate delta', 'bnt162b2 generate 100', 'bnt162b2 generate one', 'bnt162b2 generate rituximab-treated', 'bnt162b2 generate patient', 'bnt162b2 generate alpha']",1197,administration two doses bnt162b2 generated neutralising response alpha delta 100 controls sera one rituximab-treated patients neutralised alpha 5 none delta 
441,111.0,10.0,"['methotrexate abrogate one', 'methotrexate abrogate two', 'methotrexate abrogate bnt162b2', 'methotrexate dose two', 'methotrexate dose bnt162b2', 'one dose two', 'one dose bnt162b2']",1200,methotrexate abrogated t-cell responses one dose dramatically impaired t-cell responses two doses bnt162b2 
442,111.0,11.0,['vaccine improve patient'],1201,third dose vaccine improved immunogenicity patients low responses 
443,111.0,12.0,"['rituximab affect b-cell t-cell', 'rituximab affect bnt162b2', 'methotrexate affect b-cell t-cell', 'methotrexate affect bnt162b2']",1202,conclusion rituximab methotrexate differentially impact immunogenicity bnt162b2 impairing b-cell t-cell responses respectively 
444,111.0,13.0,['delta escape rituximab'],1203,delta fully escapes humoral response individuals treated rituximab 
445,111.0,14.0,['bnt162b2 improve immunocompromised'],1204,findings support efforts improve bnt162b2 immunogenicity immunocompromised individuals clinicaltrialsgov number nct04870411 
446,112.0,3.0,"['adem associate infection', 'adem associate covid-19']",1208,recently adem also associated covid-19 infection rarely covid-19 vaccination 
447,112.0,5.0,"['adem consider symptom', 'adem consider covid-19', 'patient consider symptom', 'patient consider covid-19']",1210,case demonstrates adem considered patients developing neurological symptoms post covid-19 vaccination although adverse reaction likely remain extremely rare 
448,113.0,1.0,"['bronchitis affect poultry', 'ib affect poultry', 'chicken affect poultry']",1214,infectious bronchitis ib affects chicken ages poses major economic loses poultry industry worldwide 
449,113.0,3.0,"['ibv detect flock', 'ibv detect india', 'ibv detect india']",1216,multiple lineages ibv strains detected chicken flocks india since 2003 aims detect ibv genotypes prevalent india 
450,113.0,4.0,"['organ use transcriptase-polymerase', 'flock use transcriptase-polymerase', 'sign use transcriptase-polymerase']",1217,methods organ samples 20 ibv-positive flocks variable clinical signs used amplification s1 gene ibv reverse transcriptase-polymerase chain reaction rt-pcr 
451,113.0,6.0,"['isolates belong two', 'isolates belong gi-13', 'isolates belong uk', 'isolates belong 491', 'isolates belong one', 'isolates belong isolate', 'isolates belong gv', 'isolates belong three', 'isolates belong india', 'isolates belong gi-24', 'isolates belong one', 'isolates belong isolate', 'isolates belong gv', 'isolates belong three', 'isolates belong india', 'isolates belong gi-24', 'gi-1 belong one', 'gi-1 belong isolate', 'gi-1 belong gv', 'gi-1 belong three', 'gi-1 belong india', 'gi-1 belong gi-24', 'two belong one', 'two belong isolate', 'two belong gv', 'two belong three', 'two belong india', 'two belong gi-24', 'isolates belong one', 'isolates belong isolate', 'isolates belong gv', 'isolates belong three', 'isolates belong india', 'isolates belong gi-24', 'gi-13 belong one', 'gi-13 belong isolate', 'gi-13 belong gv', 'gi-13 belong three', 'gi-13 belong india', 'gi-13 belong gi-24', 'uk belong one', 'uk belong isolate', 'uk belong gv', 'uk belong three', 'uk belong india', 'uk belong gi-24', '491 belong one', '491 belong isolate', '491 belong gv', '491 belong three', '491 belong india', '491 belong gi-24', 'isolates group gi-24', 'gi-1 group gi-24', 'two group gi-24', 'isolates group gi-24', 'gi-13 group gi-24', 'uk group gi-24', '491 group gi-24', 'one group gi-24', 'isolate group gi-24', 'gv group gi-24', 'three group gi-24']",1219,sequence analysis showed 14 field isolates belonged gi-1 genetic lineage mass 41 serotype two field isolates belonged gi-13 uk 491 variant ibv strain one field isolate grouped giii gv gvi genetic lineage three belonged variant genotype unique india gi-24 
452,113.0,8.0,"['fourteen isolate two', 'fourteen isolate gi-13', 'fourteen isolate one', 'fourteen isolate gv', 'gi-1 isolate two', 'gi-1 isolate gi-13', 'gi-1 isolate one', 'gi-1 isolate gv', 'isolates isolate two', 'isolates isolate gi-13', 'isolates isolate one', 'isolates isolate gv', 'fourteen isolate one', 'fourteen isolate gv', 'gi-1 isolate one', 'gi-1 isolate gv', 'isolates isolate one', 'isolates isolate gv', 'two isolate one', 'two isolate gv']",1221,among fourteen gi-1 isolates 12 isolated 2003 2006 two isolated 2009 2011 two field isolates belonging gi-13 isolated 2007 another one belonging giii gv gvi isolated 2010 three field isolates close reference ibv sequences isolated 2006 ind-tn-168-06 2010 ind-tn-280-10 2011 ind-tn-290-11 
453,115.0,0.0,"['hepatitis b affect people', '257 million affect people', 'hbv affect people']",1227,chronic hepatitis b virus hbv infection affects 257 million people globally 
454,115.0,2.0,"['hbv induce antigen', 'hbv induce vaccine', 'hbv induce chimpanzee', 'hbv induce adenovirus', 'hbv induce chad', 'hbv induce vaccinia', 'hbv induce ankara', 'hbv induce antigen', 'vaccine induce hbv', 'vaccine induce antigen', 'vaccine induce hbv', 'vaccine induce chimpanzee', 'vaccine induce adenovirus', 'vaccine induce chad', 'vaccine induce vaccinia', 'vaccine induce ankara', 'vaccine induce hbv', 'vaccine induce antigen', 'hbv develop ankara', 'hbv develop antigen', 'vaccine develop ankara', 'vaccine develop hbv', 'vaccine develop antigen', 'hbv develop ankara', 'hbv develop antigen', 'antigen develop ankara', 'antigen develop hbv', 'hbv develop ankara', 'hbv develop antigen', 'vaccine develop ankara', 'vaccine develop hbv', 'vaccine develop antigen', 'chimpanzee develop ankara', 'chimpanzee develop hbv', 'chimpanzee develop antigen', 'adenovirus develop ankara', 'adenovirus develop hbv', 'adenovirus develop antigen', 'chad develop ankara', 'chad develop hbv', 'chad develop antigen', 'hbv use antigen', 'vaccine use hbv', 'vaccine use antigen', 'hbv use antigen', 'antigen use hbv', 'hbv use antigen', 'vaccine use hbv', 'vaccine use antigen', 'chimpanzee use hbv', 'chimpanzee use antigen', 'adenovirus use hbv', 'adenovirus use antigen', 'chad use hbv', 'chad use antigen', 'vaccinia use hbv', 'vaccinia use antigen', 'ankara use hbv', 'ankara use antigen']",1229,develop therapeutic hbv vaccine induce high magnitude cells major hbv antigens developed novel hbv vaccine using chimpanzee adenovirus chad modified vaccinia ankara mva viral vectors encoding multiple hbv antigens 
455,115.0,3.0,"['chad generate hbv', 'chad generate cell', 'chad generate hbv', 'chad generate antigen', 'vaccine generate hbv', 'vaccine generate cell', 'vaccine generate hbv', 'vaccine generate antigen']",1230,chad vaccine alone generated high magnitude hbv specific cell responses hbv major antigens 
456,115.0,4.0,"['shark enhance antigen', 't-cells enhance antigen']",1231,inclusion shark invariant sii chain genetic adjuvant significantly enhanced magnitude t-cells hbv antigens 
457,115.0,5.0,"['chad follow vaccine', 'chad follow cell', 'chad-prime follow vaccine', 'chad-prime follow cell', 'mva-boost follow vaccine', 'mva-boost follow cell']",1232,compared chad alone vaccination chad-prime followed mva-boost vaccination enhanced magnitude breadth vaccine induced cell response 
458,115.0,6.0,"['intra-cellular show cd4 cells', 'intra-cellular show combinations ifnÃ\x83\x83Ã\x83\x82Ã\x82Â³', 'intra-cellular show cd8', 'intra-cellular show tnf-Ã\x83\x83Ã\x83\x82', 'intra-cellular show il-2', 'cytokine show cd4 cells', 'cytokine show combinations ifnÃ\x83\x83Ã\x83\x82Ã\x82Â³', 'cytokine show cd8', 'cytokine show tnf-Ã\x83\x83Ã\x83\x82', 'cytokine show il-2', 'hbv show cd4 cells', 'hbv show combinations ifnÃ\x83\x83Ã\x83\x82Ã\x82Â³', 'hbv show cd8', 'hbv show tnf-Ã\x83\x83Ã\x83\x82', 'hbv show il-2']",1233,intra-cellular cytokine staining study showed hbv specific cd8 cd4 cells polyfunctional producing combinations ifnÃÂ³ tnf-ÃÂ il-2 
459,115.0,8.0,"['pre-clinical pave hepatitis b', 'pre-clinical pave hbv', 'pre-clinical pave human']",1235,pre-clinical studies pave way new studies hbv therapeutic vaccination humans chronic hepatitis b infection 
460,116.0,2.0,"['animal models use influenza', 'animal models use pre-immune', 'animal models use human', 'animal models investigate pre-immune', 'animal models investigate human', 'influenza investigate pre-immune', 'influenza investigate human']",1238,animal models used investigate influenza pathogenesis vaccination recapitulate pre-immune history human population 
461,117.0,0.0,"['covid-19 explore tract', 'covid-19 explore macaque', 'covid-19 explore sars-cov-2', 'covid-19 explore four', 'covid-19 explore participant', 'sars-cov-2 explore tract', 'sars-cov-2 explore macaque', 'sars-cov-2 explore covid-19', 'sars-cov-2 explore four', 'sars-cov-2 explore participant', 'sars-cov-2 explore covid-19', 'covid-19 explore tract', 'covid-19 explore macaque', 'covid-19 explore sars-cov-2', 'covid-19 explore four', 'covid-19 explore participant', 'sars-cov-2 explore tract', 'sars-cov-2 explore macaque', 'sars-cov-2 explore covid-19', 'sars-cov-2 explore four', 'sars-cov-2 explore participant', 'sars-cov-2 explore covid-19', '2021 explore tract', '2021 explore macaque', '2021 explore sars-cov-2', '2021 explore covid-19', '2021 explore four', '2021 explore participant', '2021 explore covid-19', 'covid-19 explore tract', 'covid-19 explore macaque', 'covid-19 explore sars-cov-2', 'covid-19 explore four', 'covid-19 explore participant', 'covid-19 vaccinate sars-cov-2', 'covid-19 vaccinate sars-cov-2', 'covid-19 vaccinate 2021', 'covid-19 vaccinate tract', 'covid-19 vaccinate macaque', 'covid-19 vaccinate sars-cov-2', 'covid-19 vaccinate four', 'covid-19 vaccinate participant', 'covid-19 include sars-cov-2', 'covid-19 include 2021', 'covid-19 include tract', 'covid-19 include macaque', 'covid-19 include sars-cov-2', 'covid-19 include four', 'covid-19 include participant', 'covid-19 circulate sars-cov-2', 'covid-19 circulate 2021', 'covid-19 circulate tract', 'covid-19 circulate macaque', 'covid-19 circulate sars-cov-2', 'covid-19 circulate four', 'covid-19 circulate participant', 'sars-cov-2 circulate 2021', 'sars-cov-2 circulate covid-19', 'sars-cov-2 circulate tract', 'sars-cov-2 circulate macaque', 'sars-cov-2 circulate covid-19', 'sars-cov-2 circulate four', 'sars-cov-2 circulate participant', 'sars-cov-2 circulate covid-19', 'covid-19 observe tract', 'covid-19 observe macaque', 'covid-19 observe sars-cov-2', 'covid-19 observe four', 'covid-19 observe participant', 'sars-cov-2 observe covid-19', 'sars-cov-2 observe tract', 'sars-cov-2 observe macaque', 'sars-cov-2 observe covid-19', 'sars-cov-2 observe four', 'sars-cov-2 observe participant', 'sars-cov-2 observe covid-19', 'covid-19 observe tract', 'covid-19 observe macaque', 'covid-19 observe sars-cov-2', 'covid-19 observe four', 'covid-19 observe participant', 'sars-cov-2 observe covid-19', 'sars-cov-2 observe tract', 'sars-cov-2 observe macaque', 'sars-cov-2 observe covid-19', 'sars-cov-2 observe four', 'sars-cov-2 observe participant', 'sars-cov-2 observe covid-19', 'covid-19 vaccinate tract', 'covid-19 vaccinate macaque', 'covid-19 vaccinate sars-cov-2', 'covid-19 vaccinate four', 'covid-19 vaccinate participant', 'sars-cov-2 vaccinate covid-19', 'sars-cov-2 vaccinate tract', 'sars-cov-2 vaccinate macaque', 'sars-cov-2 vaccinate covid-19', 'sars-cov-2 vaccinate four', 'sars-cov-2 vaccinate participant', 'sars-cov-2 vaccinate covid-19', 'covid-19 vaccinate tract', 'covid-19 vaccinate macaque', 'covid-19 vaccinate sars-cov-2', 'covid-19 vaccinate four', 'covid-19 vaccinate participant', 'sars-cov-2 vaccinate covid-19', 'sars-cov-2 vaccinate tract', 'sars-cov-2 vaccinate macaque', 'sars-cov-2 vaccinate covid-19', 'sars-cov-2 vaccinate four', 'sars-cov-2 vaccinate participant', 'sars-cov-2 vaccinate covid-19', '2021 vaccinate covid-19', '2021 vaccinate tract', '2021 vaccinate macaque', '2021 vaccinate sars-cov-2', '2021 vaccinate covid-19', '2021 vaccinate four', '2021 vaccinate participant', '2021 vaccinate covid-19']",1240,fundamental rights probably given back earlier covid-19 vaccinated individuals assuming spread sars-cov-2 anymore objective study determine covid-19 vaccinated individuals still source sars-cov-2 transmission pubmed searched studies 4 april 2021 studies original data covid-19 cases among vaccinated individuals phase iii rcts viral load upper respiratory tract vaccinated macaques sars-cov-2 challenge included symptomatic covid-19 cases found four trials among vaccinated participants although less frequently among control subjects one study revealed asymptomatic covid-19 cases similar frequency among 2 168 azd1222-vaccinated subjects 1 0 compared 2 223 control subjects 1 0 15 studies vaccinated macaques found load sars-cov-2 rna subgenomic rna infectious virus upper respiratory tract variable sterilizing immunity found none animal studies major limitations animal studies sars-cov-2 challenge took place within weeks final vaccine dose viral challenge often high studies administered four routes based current knowledge seems clear covid-19 vaccinated individuals still source sars-cov-2 transmission
462,120.0,3.0,['participant relate symptom'],1259,participants questioned concerning symptoms bg determined 
463,120.0,4.0,"['fisher square mann', 'fisher square u']",1260,used descriptive statistics comparative analysis chi squared fisher s exact test student s mann whitney s u tests 
464,120.0,8.0,"['284 compare bg-a', 'bg-no-a compare bg-a']",1264,bg-a 284 compared bg-no-a 716 showed trend increased risk bg-a 1523 95 ci 0818-2837 p ns 
465,121.0,4.0,"['statin induce cholesterol', 'statin induce patient', 'statin induce cardiovascular']",1272,however often despite maximum allowed tolerated dosage statins able reach target cholesterol levels thus patients persist increased cardiovascular risk 
466,121.0,6.0,"['pcsk9 play ldl receptor', 'pcsk9 play ldl', 'pcsk9 play particle', 'pcsk9 play cell']",1274,pcsk9 plays essential role metabolism ldl particles inhibiting ldl receptor recirculation cell surface 
467,121.0,8.0,"['antibody treat two', 'antibody treat patient']",1276,however treatment procedure administering anti-pcsk9 antibodies frequently two times month limitations terms time patient adherence nevertheless cost 
468,122.0,1.0,['gastrointestinal elicit arthritis'],1281,gastrointestinal genitourinary respiratory tract infections generally provoke reactive arthritis 
469,122.0,3.0,"['arthritis report hepatitis b', 'arthritis report tetanus', 'arthritis report diphteria-poliomyelitis-tetanus', 'arthritis report toxoid', 'arthritis report influenza', 'hepatitis b combine influenza', 'arthritis combine influenza', 'tetanus combine influenza', 'diphteria-poliomyelitis-tetanus combine influenza', 'toxoid combine influenza']",1283,reactive arthritis cases reported tetanus combined diphteria-poliomyelitis-tetanus toxoid hepatitis b influenza vaccination 
470,122.0,5.0,"['two induce 2019', 'two induce covid-19', 'two induce coronavac', 'two induce sinovac']",1285,present two cases rea induced inactivated coronavirus 2019 covid-19 vaccination coronavac sinovac 
471,123.0,2.0,"['341 elicit vaccine', '341 elicit adv', 'serum elicit vaccine', 'serum elicit adv', 'specimen elicit vaccine', 'specimen elicit adv', 'full-course elicit vaccine', 'full-course elicit adv', 'iav elicit vaccine', 'iav elicit adv', 'prv elicit vaccine', 'prv elicit adv']",1290,investigated cross-neutralizing activities 341 human serum specimens elicited full-course vaccinations iav prv adv various vaccine boosters following prime iav adv vaccinations 
472,123.0,3.0,['vaccine induce omicron'],1291,found types vaccines induced significantly lower neutralizing antibody titers omicron variant prototype strain 
473,123.0,5.0,"['mrna derive immunization', 'mrna derive vaccine', 'vaccine derive immunization', 'vaccine derive mrna', 'booster derive immunization', 'booster derive mrna', 'booster derive vaccine', 'mrna encode immunization', 'mrna encode vaccine', 'vaccine encode immunization', 'vaccine encode mrna', 'booster encode immunization', 'booster encode mrna', 'booster encode vaccine']",1293,mouse model demonstrated among series variant-derived rbd-encoding mrna vaccine boosters omicron booster significantly enhanced omicron neutralizing antibody titers compared prototype booster following prime immunization prototype s-encoding mrna vaccine candidate 
474,123.0,6.0,['vaccine inform omicron'],1294,summary systematical investigations various vaccine boosters inform potential booster administrations future combat omicron variant 
475,124.0,2.0,"['worker receive aes', 'sars-cov-2 receive aes', 'bnt162b2 receive aes']",1297,healthcare workers without prior sars-cov-2 infection received prime-boost vaccination bnt162b2 completed standardized electronic questionnaire duration severity aes 
476,124.0,3.0,"['serum collect two', 'serum collect four', 'serum collect boost', 'serum collect covid-19', 'serum collect elisa', 'serum collect vircell-igg', 'serum collect sars-cov-2', 'serum collect igg', 'serum collect diasorin-igg', 'serum collect nab', 'serum collect surrogate', 'serum collect yhlo-nab', 'specimen collect two', 'specimen collect four', 'specimen collect boost', 'specimen collect covid-19', 'specimen collect elisa', 'specimen collect vircell-igg', 'specimen collect sars-cov-2', 'specimen collect igg', 'specimen collect diasorin-igg', 'specimen collect nab', 'specimen collect surrogate', 'specimen collect yhlo-nab', 'serum test sars-cov-2', 'serum test igg', 'serum test diasorin-igg', 'serum test nab', 'serum test surrogate', 'serum test yhlo-nab', 'specimen test sars-cov-2', 'specimen test igg', 'specimen test diasorin-igg', 'specimen test nab', 'specimen test surrogate', 'specimen test yhlo-nab', 'two test sars-cov-2', 'two test igg', 'two test diasorin-igg', 'two test nab', 'two test surrogate', 'two test yhlo-nab', 'four test sars-cov-2', 'four test igg', 'four test diasorin-igg', 'four test nab', 'four test surrogate', 'four test yhlo-nab', 'boost test sars-cov-2', 'boost test igg', 'boost test diasorin-igg', 'boost test nab', 'boost test surrogate', 'boost test yhlo-nab', 'covid-19 test sars-cov-2', 'covid-19 test igg', 'covid-19 test diasorin-igg', 'covid-19 test nab', 'covid-19 test surrogate', 'covid-19 test yhlo-nab', 'elisa test sars-cov-2', 'elisa test igg', 'elisa test diasorin-igg', 'elisa test nab', 'elisa test surrogate', 'elisa test yhlo-nab', 'vircell-igg test sars-cov-2', 'vircell-igg test igg', 'vircell-igg test diasorin-igg', 'vircell-igg test nab', 'vircell-igg test surrogate', 'vircell-igg test yhlo-nab']",1298,serum specimens collected two four weeks boost vaccination tested covid-19 elisa igg vircell-igg liaison ÃÂ sars-cov-2 s1s2 igg clia diasorin-igg iflash-2019-ncov nab surrogate neutralization assay yhlo-nab 
477,124.0,7.0,"['sars-cov-2 evaluate vircell-igg', 'sars-cov-2 evaluate yhlo-nab', '925 evaluate vircell-igg', '925 evaluate yhlo-nab']",1302,elevated sars-cov-2 igg antibody levels measured 925 subjects vircell-igg subjects diasorin-igg yhlo-nab 
478,125.0,0.0,"['vaccine develop covid-19', 'sars-cov-2 develop covid-19']",1308,objectives exceptional research efforts several vaccines developed sars-cov-2 sustains pandemic covid-19 
479,125.0,2.0,['vaccine dose antibody'],1310,evaluated immune response induced first vaccine dose different sexage groups subjects without naturally present anti-sars-cov-2 antibodies 
480,125.0,3.0,"['italian test siemens-healthineers', 'covidiagnostix test siemens-healthineers', 'serum test siemens-healthineers', '4290 test siemens-healthineers', 'health-professionals test siemens-healthineers', 'two test siemens-healthineers']",1311,methods part italian multicenter project covidiagnostix serum samples 4290 health-professionals serologically tested day first vaccination dose 21 days later using two different instrumentations siemens-healthineers roche 
481,125.0,4.0,['antibody show non-responders'],1312,results total 97 samples showed presence specific antibodies 21 days vaccination dose percentage non-responders increased age genders 
482,126.0,1.0,"['death provide hepatitis', 'death provide vaccine', 'death provide one', 'woman provide hepatitis', 'woman provide vaccine', 'woman provide one']",1319,despite high risk death among infected pregnant women scarce incidence data contributing factor global policy recommendations introduction licensed hepatitis e vaccines one effective prevention tools 
483,126.0,2.0,"['serum test bangladesh', 'serum test immunoglobulin']",1320,methods tested serum nationally representative serosurvey bangladesh anti-hev immunoglobulin g estimated seroprevalence 
484,126.0,3.0,"['bayesian generate household-level', 'bayesian generate community-level']",1321,used bayesian geostatistical models generate high-resolution maps seropositivity examined variability seropositivity individual-level household-level community-level risk factors using spatial logistic regression 
485,126.0,4.0,"['serum test community', 'serum test bangladesh']",1322,results tested serum samples 2924 individuals 70 communities representing divisions bangladesh estimated national seroprevalence 20 95 confidence interval ci 17 ÃÂÂ24 
486,126.0,6.0,['seroprevalence range dhaka'],1324,community-level seroprevalence ranged widely 0ÃÂÂ78 higher seroprevalence urban areas including dhaka 30-fold 95 credible interval 23ÃÂÂ37 higher seroprevalence rest country 
487,127.0,0.0,"['immunity investigate coronavirus', 'immunity investigate sars-cov-2', 'immunity investigate chinese']",1327,verify reliability antibody detection investigate population immunity severe acute respiratory syndrome-related coronavirus 2 sars-cov-2 local chinese population 
488,127.0,1.0,"['cross-sectional induce immunoglobulin', 'cross-sectional induce igg', 'cross-sectional induce immunoglobulin', 'cross-sectional induce immunoglobulin', 'shenzhen induce immunoglobulin', 'shenzhen induce igg', 'shenzhen induce immunoglobulin', 'shenzhen induce immunoglobulin', 'anti-coronavirus antibodies detect immunoglobulin', 'anti-coronavirus antibodies detect immunoglobulin', 'cross-sectional detect immunoglobulin', 'cross-sectional detect immunoglobulin', 'shenzhen detect immunoglobulin', 'shenzhen detect immunoglobulin']",1328,cross-sectional study conducted shenzhen detect anti-coronavirus antibodies including immunoglobulin g igg immunoglobulin igm immunoglobulin iga 
489,128.0,2.0,"['cell observe death', 'cell observe patient', 'cell observe covid-19']",1339,aim present study determine function phenotype cell populations associated survival death patients covid-19 intensive care result phenotypic functional profiling mass cytometry 
490,128.0,3.0,"['stem cell decrease patient', 'memory cells decrease patient', 'cd4 decrease patient', 'cxcr5 decrease patient', 'hla-dr decrease patient', 'memory decrease patient', 'granzyme decrease patient', 'perforin-expressing decrease patient']",1340,increased frequencies circulating polyfunctional cd4 cxcr5 hla-dr stem cell memory cells tscms decreased proportions granzyme bÃÂÂexpressing perforin-expressing effector memory cells detected recovered deceased patients respectively 
491,128.0,5.0,['imbalance show patient'],1342,results principal component analysis show imbalance cell compartment allowed separation recovered deceased patients 
492,128.0,6.0,"['pd-l1 circulate cd8 cells', 'pd-l1 circulate cd8', 'pd-l1 circulate nc-specific']",1343,paucity circulating pd-l1 cxcr3 cd8 teffs nc-specific cd8 cells accurately forecasts fatal disease outcome 
493,128.0,7.0,"['cell need vaccine', 'covid-19 need vaccine']",1344,study provides insight nature cell populations involved control covid-19 therefore might impact cellÃÂÂbased vaccine designs infectious disease 
494,129.0,0.0,"['respiratory infect lri', 'respiratory infect infant', 'syncytial infect lri', 'syncytial infect infant', 'rsv infect lri', 'rsv infect infant', 'one infect lri', 'one infect infant', 'child infect lri', 'child infect infant']",1345,respiratory syncytial virus rsv one common viruses infect children worldwide leading cause lower respiratory tract illness lri infants 
495,129.0,1.0,"['rsv review east', 'rsv review africa', 'rsv review mena', 'rsv emerge mena', 'east emerge mena']",1346,study aimed conduct systematic review collecting reviewing published knowledge epidemiology rsv middle east north africa mena region 
496,129.0,6.0,['rsv report israel'],1351,highest rsv prevalence reported jordan 64 2006ÃÂÂ2007 israel 56 2005ÃÂÂ2006 
497,130.0,1.0,"['vaccine-related aim thoracic', 'vaccine-related aim malignancy', 'vaccine-related aim covid-19', 'axillary aim thoracic', 'axillary aim malignancy', 'axillary aim covid-19', 'lymphadenopathy aim thoracic', 'lymphadenopathy aim malignancy', 'lymphadenopathy aim covid-19', 'vaccine-related relate covid-19', 'axillary relate covid-19', 'lymphadenopathy relate covid-19', 'patient relate covid-19', 'thoracic relate covid-19', 'malignancy relate covid-19']",1357,present study investigated incidence predisposing factors imaging characteristics vaccine-related axillary lymphadenopathy patients thoracic malignancy underwent ct scans covid-19 vaccinations 
498,130.0,2.0,"['patient receive covid-19', 'patient receive pre-vaccine', 'patient receive post-vaccine', 'patient receive chest', 'thoracic receive covid-19', 'thoracic receive pre-vaccine', 'thoracic receive post-vaccine', 'thoracic receive chest', 'two receive covid-19', 'two receive pre-vaccine', 'two receive post-vaccine', 'two receive chest']",1358,methods study included patients thoracic malignancies received two doses mrna-based covid-19 vaccinations pre-vaccine post-vaccine chest ct scans 
499,130.0,3.0,"['post-vaccine review axillarysubpectoral lymph', 'post-vaccine review pre-vaccine', 'chest review axillarysubpectoral lymph', 'chest review pre-vaccine']",1359,post-vaccine chest ct scans reviewed increase size axillarysubpectoral lymph nodes comparing pre-vaccine scans 
500,130.0,4.0,"['axillarysubpectoral review lymphadenopathy', 'two review lymphadenopathy', 'radiologist review lymphadenopathy']",1360,cases axillarysubpectoral lymphadenopathy reviewed independently two radiologists referring clinical information determine lymphadenopathy attributed vaccinations 
501,130.0,5.0,"['vaccine-related relate 232', 'vaccine-related relate patient']",1361,results vaccine-related axillarysubpectoral lymphadenopathy noted 21 232 patients 90 
502,130.0,7.0,['node increase 1-10'],1363,median number increased nodes 4 range 1-10 
503,130.0,9.0,"['vaccine-related observe men', 'vaccine-related observe 125', 'vaccine-related observe 388', 'vaccine-related observe p0019', 'vaccine-related observe mrna-1273', 'vaccine-related observe vaccine', 'vaccine-related observe bnt162b2', 'vaccine-related observe vaccine', 'vaccine-related observe 15204', 'vaccine-related observe p0026', 'lymphadenopathy observe men', 'lymphadenopathy observe 125', 'lymphadenopathy observe 388', 'lymphadenopathy observe p0019', 'lymphadenopathy observe mrna-1273', 'lymphadenopathy observe vaccine', 'lymphadenopathy observe bnt162b2', 'lymphadenopathy observe vaccine', 'lymphadenopathy observe 15204', 'lymphadenopathy observe p0026', 'vaccine-related relate woman', 'vaccine-related relate men', 'vaccine-related relate 125', 'vaccine-related relate 388', 'vaccine-related relate p0019', 'vaccine-related relate mrna-1273', 'vaccine-related relate vaccine', 'vaccine-related relate bnt162b2', 'vaccine-related relate vaccine', 'vaccine-related relate 15204', 'vaccine-related relate p0026', 'lymphadenopathy relate woman', 'lymphadenopathy relate men', 'lymphadenopathy relate 125', 'lymphadenopathy relate 388', 'lymphadenopathy relate p0019', 'lymphadenopathy relate mrna-1273', 'lymphadenopathy relate vaccine', 'lymphadenopathy relate bnt162b2', 'lymphadenopathy relate vaccine', 'lymphadenopathy relate 15204', 'lymphadenopathy relate p0026']",1365,vaccine-related lymphadenopathy noted commonly woman men 18144 125 vs 388 34 respectively p0019 mrna-1273 vaccines bnt162b2 vaccines 628 21 vs 15204 74 respectively p0026 
504,130.0,11.0,"['vaccine associate cohort', 'mrna-1273 associate cohort', 'vaccine associate cohort']",1367,female sex vaccine type mrna-1273 vaccine associated higher frequency lymphadenopathy providing initial observations inform investigations larger cohorts 
505,131.0,0.0,"['igm follow igg', 'igm follow iga', 'igm associate igg', 'igm associate iga']",1368,humoral immune responses typically characterized primary igm antibody responses followed secondary antibody responses associated immune memory comprised igg iga ige 
506,131.0,1.0,"['sars-cov-2 include broncho-alveolar fluid', 'sars-cov-2 include antibody', 'sars-cov-2 include serum', 'sars-cov-2 include saliva', 'sars-cov-2 include 159', 'sars-cov-2 include patient', 'sars-cov-2 include covid-19', 'cell include broncho-alveolar fluid', 'cell include antibody', 'cell include serum', 'cell include saliva', 'cell include 159', 'cell include patient', 'cell include covid-19', 'sars-cov-2-specific include broncho-alveolar fluid', 'sars-cov-2-specific include antibody', 'sars-cov-2-specific include serum', 'sars-cov-2-specific include saliva', 'sars-cov-2-specific include 159', 'sars-cov-2-specific include patient', 'sars-cov-2-specific include covid-19', 'broncho-alveolar fluid make patient', 'broncho-alveolar fluid make covid-19', 'sars-cov-2 make patient', 'sars-cov-2 make covid-19', 'cell make patient', 'cell make covid-19', 'sars-cov-2-specific make patient', 'sars-cov-2-specific make covid-19', 'antibody make patient', 'antibody make covid-19', 'serum make patient', 'serum make covid-19', 'saliva make patient', 'saliva make covid-19']",1369,measured acute humoral responses sars-cov-2 including frequency antibody-secreting cells presence sars-cov-2-specific neutralizing antibodies serum saliva broncho-alveolar fluid 159 patients covid-19 
507,131.0,3.0,"['peripheral home symptom', 'mucosal-homing home symptom']",1371,peripheral expansion iga plasmablasts mucosal-homing potential detected shortly onset symptoms peaked third week disease 
508,131.0,4.0,"['igg include iga', 'igm include iga', 'igm include igg']",1372,virus-specific antibody responses included igg igm iga iga contributed virus neutralization greater extent compared igg 
509,131.0,5.0,"['iga decrease one', 'iga decrease symptom', 'iga decrease saliva', 'iga decrease symptom', 'serum decrease one', 'serum decrease symptom', 'serum decrease iga', 'serum decrease saliva', 'serum decrease symptom', 'iga neutralize symptom', 'serum neutralize symptom', 'one neutralize symptom', 'iga neutralize symptom', 'saliva neutralize symptom', 'iga induce symptom', 'serum induce symptom', 'one induce symptom', 'iga induce symptom', 'saliva induce symptom']",1373,specific iga serum concentrations decreased notably one month onset symptoms neutralizing iga remained detectable saliva longer time days 49 73 post symptoms 
510,131.0,6.0,"['antibody associate iga', 'vaccine associate iga']",1374,results represent critical observation given emerging information types antibodies associated optimal protection re-infection whether vaccine regimens consider targeting potent potentially short-lived iga response 
511,132.0,1.0,"['embase explore cochrane', 'cnki explore cochrane', 'wanfang explore cochrane', 'china explore cochrane', 'china explore cochrane', 'covid-19 explore cochrane', 'vaccine explore cochrane']",1376,methods pubmed embase cochrane library clinicaltrialgov cnki wanfang data china biomedical literature service system china clinical trial registry searched randomized controlled trials covid-19 vaccines published december 31 2020 cochrane bias risk assessment tool used assess quality studies 
512,132.0,3.0,"['thirteen randomize covid-19', 'thirteen randomize vaccine', 'thirteen blind covid-19', 'thirteen blind vaccine', 'thirteen observe covid-19', 'thirteen observe vaccine', 'thirteen need vaccine']",1378,results thirteen randomized blinded controlled trials involved safety efficacy 11 covid-19 vaccines included 
513,133.0,0.0,['vaccine include second'],1392,objective first protective dose vaccine may allow delaying second dose context low supply 
514,133.0,3.0,"['hcp include sars-cov-2', 'covid-19 include sars-cov-2', 'hcp include sars-cov-2', 'covid-19 include sars-cov-2', 'hcp suspect covid-19', 'hcp suspect sars-cov-2']",1395,hcp suspected covid-19 hcp close contacts covid-19 cases included january 27 february 7 2021 pcr tested sars-cov-2 positive pcr considered cases negative pcr considered controls 
515,133.0,4.0,"['vea use 261', 'vea use 739', 'vaccine use 261', 'vaccine use 739', 'covid-19 use 261', 'covid-19 use 739', '100 use 261', '100 use 739', '268 use 261', '268 use 739', 'hcp use 261', 'hcp use 739', 'vea adjust 100', 'vea adjust 268', 'vea adjust hcp', 'vea adjust 261', 'vea adjust 739', 'vaccine adjust 100', 'vaccine adjust 268', 'vaccine adjust hcp', 'vaccine adjust 261', 'vaccine adjust 739', 'vea prevent 100', 'vea prevent 268', 'vea prevent hcp', 'vea prevent 261', 'vea prevent 739', 'vaccine prevent 100', 'vaccine prevent 268', 'vaccine prevent hcp', 'vaccine prevent 261', 'vaccine prevent 739', 'covid-19 prevent 100', 'covid-19 prevent 268', 'covid-19 prevent hcp', 'covid-19 prevent 261', 'covid-19 prevent 739']",1396,crude adjusted vea vaccine effectiveness prevent covid-19 cases 95 confidence interval calculated using formula 1-odds ratio x 100 results 268 hcp included 70 261 considered cases 198 739 controls 
516,133.0,7.0,"['vea test 384-895', 'hcp test 384-895', '746 test 384-895']",1399,vea subgroup hcp studied suspected disease 746 ci95 384-895 
517,133.0,9.0,"['second defer vaccine', 'second defer people']",1401,data could considered adapt strategies consider postponing second dose situations limited vaccine supply order achieve maximum number people covered first dose 
518,134.0,1.0,"['covid-19 recommend vaccine', 'covid-19 recommend patient', 'covid-19 recommend solid', 'covid-19 recommend tumour', 'covid-19 recommend cancer']",1403,vaccination prevent covid-19 recommended data immunogenicity safety covid-19 vaccines patients solid tumours receiving systemic cancer treatment scarce 
519,134.0,2.0,"['immunotherapy evaluate madrid', 'immunotherapy evaluate spain', 'immunotherapy evaluate covid-19', 'immunotherapy evaluate vaccine', 'immunotherapy evaluate covid', 'immunotherapy evaluate cancer']",1404,therefore aimed assess impact immunotherapy chemotherapy chemoimmunotherapy immunogenicity safety mrna-1273 moderna biotech madrid spain covid-19 vaccine part vaccination covid cancer voice trial 
520,134.0,4.0,"['four enrol cohort', 'four enrol patient', 'four enrol solid', 'four enrol tumour', 'four enrol immunotherapy', 'four enrol cohort', 'four enrol chemotherapy', 'four enrol cohort', 'four enrol chemoimmunotherapy', 'four enrol cohort', 'cohort enrol patient', 'cohort enrol solid', 'cohort enrol tumour', 'cohort enrol immunotherapy', 'cohort enrol chemotherapy', 'cohort enrol chemoimmunotherapy', 'cancer enrol cohort', 'cancer enrol patient', 'cancer enrol solid', 'cancer enrol tumour', 'cancer enrol immunotherapy', 'cancer enrol cohort', 'cancer enrol chemotherapy', 'cancer enrol cohort', 'cancer enrol chemoimmunotherapy', 'cancer enrol cohort']",1406,individuals aged 18 years older life expectancy 12 months enrolled four cohorts individuals without cancer cohort control cohort patients solid tumours regardless stage histology treated immunotherapy cohort b chemotherapy cohort c chemoimmunotherapy cohort 
521,134.0,5.0,"['participant receive two', 'participant receive mrna-1273', 'participant receive 100', 'participant receive 28']",1407,participants received two mrna-1273 vaccinations 100 ÃÂg 0ÃÂ5 ml intramuscularly 28 days apart 
522,134.0,6.0,"['patient exclude bau', 'patient exclude sars-cov-2', 'patient exclude sars-cov-2', 'patient exclude igg', 'patient exclude serum', 'patient exclude sars-cov-2-binding', 'patient exclude bauml', 'patient bind sars-cov-2', 'patient bind igg', 'patient bind serum', 'patient bind sars-cov-2-binding', 'patient bind bauml', 'bau bind sars-cov-2', 'bau bind igg', 'bau bind serum', 'bau bind sars-cov-2-binding', 'bau bind bauml', 'patient indicate sars-cov-2-binding', 'patient indicate bauml', 'bau indicate sars-cov-2-binding', 'bau indicate bauml', 'sars-cov-2 indicate sars-cov-2-binding', 'sars-cov-2 indicate bauml', 'sars-cov-2 indicate sars-cov-2-binding', 'sars-cov-2 indicate bauml', 'igg indicate sars-cov-2-binding', 'igg indicate bauml']",1408,primary endpoint analysed per protocol excluding patients positive baseline sample 10 binding antibody units bau ml indicating previous sars-cov-2 infection defined sars-cov-2 spike s1-specific igg serum antibody response ie sars-cov-2-binding antibody concentration 10 bauml 28 days second vaccination 
523,134.0,8.0,"['patient receive participant', 'patient receive one', 'one receive participant']",1410,also assessed adverse events patients received least one vaccination recorded solicited adverse events participants received least one vaccination excluding already seroconversion 10 bauml baseline 
524,134.0,10.0,"['feb enrol 128', 'march enrol 128', '791 enrol 128', 'participant enrol 128', '122 enrol 128']",1412,findings feb 17 march 12 2021 791 participants enrolled followed median 122 days iqr 118 128 
525,134.0,11.0,"['sars-cov-2-binding receive 100', 'sars-cov-2-binding receive 240', 'sars-cov-2-binding receive participant', 'sars-cov-2-binding receive cohort', 'sars-cov-2-binding receive 130', 'sars-cov-2-binding receive 131', 'sars-cov-2-binding receive patient', 'sars-cov-2-binding receive cohort', 'sars-cov-2-binding receive 229', 'sars-cov-2-binding receive patient', 'sars-cov-2-binding receive cohort', 'sars-cov-2-binding receive 143', 'sars-cov-2-binding receive 100', 'sars-cov-2-binding receive 100', 'sars-cov-2-binding receive patient', 'sars-cov-2-binding receive cohort', 'sars-cov-2-binding receive patient', 'sars-cov-2-binding receive cohort', 'sars-cov-2-binding receive non-inferior', 'sars-cov-2-binding receive cohort', '240 receive 100', '240 receive participant', '240 receive cohort', '240 receive 130', '240 receive 131', '240 receive patient', '240 receive cohort', '240 receive 229', '240 receive patient', '240 receive cohort', '240 receive 143', '240 receive 100', '240 receive 100', '240 receive patient', '240 receive cohort', '240 receive sars-cov-2-binding', '240 receive patient', '240 receive cohort', '240 receive non-inferior', '240 receive cohort', '100 receive 240', '100 receive participant', '100 receive cohort', '100 receive 130', '100 receive 131', '100 receive patient', '100 receive cohort', '100 receive 229', '100 receive patient', '100 receive cohort', '100 receive 143', '100 receive patient', '100 receive cohort', '100 receive sars-cov-2-binding', '100 receive patient', '100 receive cohort', '100 receive non-inferior', '100 receive cohort', 'sars-cov-2-binding bind 100', 'sars-cov-2-binding bind 240', 'sars-cov-2-binding bind participant', 'sars-cov-2-binding bind cohort', 'sars-cov-2-binding bind 130', 'sars-cov-2-binding bind 131', 'sars-cov-2-binding bind patient', 'sars-cov-2-binding bind cohort', 'sars-cov-2-binding bind 229', 'sars-cov-2-binding bind patient', 'sars-cov-2-binding bind cohort', 'sars-cov-2-binding bind 143', 'sars-cov-2-binding bind 100', 'sars-cov-2-binding bind 100', 'sars-cov-2-binding bind patient', 'sars-cov-2-binding bind cohort', 'sars-cov-2-binding bind patient', 'sars-cov-2-binding bind cohort', 'sars-cov-2-binding bind non-inferior', 'sars-cov-2-binding bind cohort', '240 bind 100', '240 bind participant', '240 bind cohort', '240 bind 130', '240 bind 131', '240 bind patient', '240 bind cohort', '240 bind 229', '240 bind patient', '240 bind cohort', '240 bind 143', '240 bind 100', '240 bind 100', '240 bind patient', '240 bind cohort', '240 bind sars-cov-2-binding', '240 bind patient', '240 bind cohort', '240 bind non-inferior', '240 bind cohort']",1413,sars-cov-2-binding antibody response found 240 100 95 ci 98 100 240 evaluable participants cohort 130 99 96 99 131 evaluable patients cohort b 223 97 94 99 229 evaluable patients cohort c 143 100 97 100 143 evaluable patients cohort d sars-cov-2-binding antibody response patient cohort non-inferior compared cohort a new safety signals observed 
526,134.0,14.0,"['solid tumour receive mrna-1273', 'solid tumour receive covid-19', 'solid tumour receive vaccine', 'patient receive mrna-1273', 'patient receive covid-19', 'patient receive vaccine', 'cancer receive mrna-1273', 'cancer receive covid-19', 'cancer receive vaccine', 'immunotherapy receive mrna-1273', 'immunotherapy receive covid-19', 'immunotherapy receive vaccine']",1416,interpretation patients cancer develop receiving chemotherapy immunotherapy solid tumour adequate antibody response vaccination mrna-1273 covid-19 vaccine 
527,135.0,1.0,"['coronavac inactivate coronavirus', 'coronavac inactivate sars-cov-2', 'sinovac inactivate coronavirus', 'sinovac inactivate sars-cov-2', 'beijing inactivate coronavirus', 'beijing inactivate sars-cov-2', 'china inactivate coronavirus', 'china inactivate sars-cov-2', 'vaccine inactivate coronavirus', 'vaccine inactivate sars-cov-2', 'covid-19 inactivate coronavirus', 'covid-19 inactivate sars-cov-2']",1421,investigated coronavac sinovac life sciences beijing china inactivated vaccine candidate covid-19 containing inactivated severe acute respiratory syndrome coronavirus 2 sars-cov-2 safety tolerability immunogenicity 
528,135.0,2.0,"['adult observe suining county', 'adult observe jiangsu province', 'adult observe china']",1422,methods randomised double-blind placebo-controlled phase 12 clinical trial healthy adults aged 18ÃÂÂ59 years recruited community suining county jiangsu province china 
529,135.0,4.0,"['vaccine use cell', 'vaccine use wujiang', 'vaccine use china', 'vaccine use ge', 'vaccine use umea', 'vaccine use sweden', 'cell use wujiang', 'cell use china', 'cell use ge', 'cell use umea', 'cell use sweden']",1424,experimental vaccine phase 1 trial manufactured using cell factory process cellstack cell culture chamber 10 corning wujiang china whereas phase 2 trial produced bioreactor process readytoprocess wave 25 ge umea sweden 
530,135.0,6.0,"['participant receive aluminium hydroxide', 'participant receive aluminium hydroxide', 'participant receive two', 'participant receive cohort', 'participant receive cohort', 'participant receive cohort', 'participant receive cohort', 'participant receive coronavac', 'participant receive coronavc', 'aluminium hydroxide indicate coronavc', 'participant indicate aluminium hydroxide', 'participant indicate coronavc', 'two indicate aluminium hydroxide', 'two indicate coronavc', 'cohort indicate aluminium hydroxide', 'cohort indicate coronavc', 'cohort indicate aluminium hydroxide', 'cohort indicate coronavc', 'cohort indicate aluminium hydroxide', 'cohort indicate coronavc', 'cohort indicate aluminium hydroxide', 'cohort indicate coronavc', 'participant indicate aluminium hydroxide', 'participant indicate coronavc', 'coronavac indicate aluminium hydroxide', 'coronavac indicate coronavc', 'participant dose aluminium hydroxide', 'two dose aluminium hydroxide', 'cohort dose aluminium hydroxide', 'cohort dose aluminium hydroxide', 'cohort dose aluminium hydroxide', 'cohort dose aluminium hydroxide', 'participant dose aluminium hydroxide', 'coronavac dose aluminium hydroxide', 'coronavc dose aluminium hydroxide', 'participant block aluminium hydroxide', 'two block aluminium hydroxide', 'cohort block aluminium hydroxide', 'cohort block aluminium hydroxide', 'cohort block aluminium hydroxide', 'cohort block aluminium hydroxide', 'participant block aluminium hydroxide', 'coronavac block aluminium hydroxide', 'coronavc block aluminium hydroxide']",1426,screening participants initially separated 11 specific randomisation two vaccination schedule cohorts days 0 14 vaccination cohort days 0 28 vaccination cohort within cohort first 36 participants assigned block 1 low dose coronavac 3 ÃÂg per 0ÃÂ5 ml aluminium hydroxide diluent per dose another 36 assigned block 2 high-dose coronavc 6 ÃÂg per 0ÃÂ5 ml aluminium hydroxide diluent per dse 
531,135.0,7.0,"['participant indicate six', 'participant indicate two', 'participant indicate coronavac', 'participant indicate two', 'participant use two', 'participant use coronavac', 'participant use two', 'six use two', 'six use coronavac', 'six use two']",1427,within block participants randomly assigned 21 using block randomisation block size six either two doses coronavac two doses placebo 
532,135.0,8.0,"['participant receive cohort', 'participant receive cohort', 'participant receive five', 'participant receive two', 'participant receive low-dose']",1428,phase 2 trial screening participants initially separated 11 specific randomisation days 0 14 vaccination cohort days 0 28 vaccination cohort participants randomly assigned 221 using block randomisation block size five receive two doses either low-dose coronavac high-dose coronavac placebo 
533,135.0,11.0,"['antibody neutralize cohort', 'antibody neutralize cohort', 'antibody neutralize participant', 'antibody neutralize two-dose', 'antibody induce cohort', 'antibody induce cohort', 'antibody induce participant', 'antibody induce two-dose', 'sars-cov-2 induce cohort', 'sars-cov-2 induce cohort', 'sars-cov-2 induce participant', 'sars-cov-2 induce two-dose']",1431,primary immunogenic outcome seroconversion rates neutralising antibodies live sars-cov-2 day 14 last dose days 0 14 cohort day 28 last dose days 0 28 cohort participants completed allocated two-dose vaccination schedule per-protocol population 
534,135.0,13.0,"['144 enrol 600', '144 enrol participant', 'participant enrol 600']",1433,findings april 16 april 25 2020 144 participants enrolled phase 1 trial may 3 may 5 2020 600 participants enrolled phase 2 trial 
535,135.0,14.0,"['743 receive one', '743 receive n143', '743 receive n600', 'participant receive one', 'participant receive n143', 'participant receive n600']",1434,743 participants received least one dose investigational product n143 phase 1 n600 phase 2 safety population 
536,135.0,16.0,"['antibody see one', 'participant see one', 'antibody neutralize participant', 'antibody neutralize one']",1436,seroconversion neutralising antibodies day 14 days 0 14 vaccination schedule seen 11 46 24 participants 3 ÃÂg group 12 50 24 6 ÃÂg group none 0 24 placebo group whereas day 28 days 0 28 vaccination schedule seroconversion seen 20 83 24 3 ÃÂg group 19 79 24 6 ÃÂg group one 4 24 placebo group 
537,135.0,18.0,"['antibody see participant', 'antibody see 117', 'antibody see 119', 'antibody see two', 'antibody see 117', 'antibody see 118', 'antibody see 100', 'antibody see 118']",1438,seroconversion neutralising antibodies seen 109 92 118 participants 3 ÃÂg group 117 98 119 6 ÃÂg group two 3 60 placebo group day 14 days 0 14 schedule whereas day 28 days 0 28 schedule seroconversion seen 114 97 117 3 ÃÂg group 118 100 118 6 ÃÂg group none 0 59 placebo group 
538,136.0,3.0,"['126 vaccinate vaccine', 'patient vaccinate vaccine', 'covid-19 vaccinate vaccine', 'two vaccinate vaccine']",1444,resultsoverall 126 patients chronic maintenance dialysis without prior covid-19 diagnosis vaccinated two doses mrna-1273 vaccine 
539,136.0,6.0,"['aes swell diarrhoea', 'aes swell shiver', 'aes swell vertigo', 'injection-site swell diarrhoea', 'injection-site swell shiver', 'injection-site swell vertigo', '619 swell diarrhoea', '619 swell shiver', '619 swell vertigo', 'erythema swell diarrhoea', 'erythema swell shiver', 'erythema swell vertigo', 'swelling swell diarrhoea', 'swelling swell shiver', 'swelling swell vertigo', '167 swell diarrhoea', '167 swell shiver', '167 swell vertigo', 'axillary swell diarrhoea', 'axillary swell shiver', 'axillary swell vertigo', 'fever swell diarrhoea', 'fever swell shiver', 'fever swell vertigo', '175 swell diarrhoea', '175 swell shiver', '175 swell vertigo', 'headache swell diarrhoea', 'headache swell shiver', 'headache swell vertigo', 'fatigue swell diarrhoea', 'fatigue swell shiver', 'fatigue swell vertigo', '238 swell diarrhoea', '238 swell shiver', '238 swell vertigo', 'myalgia swell diarrhoea', 'myalgia swell shiver', 'myalgia swell vertigo', '175 swell diarrhoea', '175 swell shiver', '175 swell vertigo', 'arthralgia swell diarrhoea', 'arthralgia swell shiver', 'arthralgia swell vertigo', '127 swell diarrhoea', '127 swell shiver', '127 swell vertigo', 'dyspnoea swell diarrhoea', 'dyspnoea swell shiver', 'dyspnoea swell vertigo']",1447,common aes injection-site pain 619 erythema 48 itching 48 swelling 167 axillary swellingtenderness 24 fever 175 headache 79 fatigue 238 myalgia 175 arthralgia 127 dyspnoea 24 nauseavomiting 71 diarrhoea 56 shivers 4 vertigo 16 
540,136.0,11.0,"['vaccine associate aes', 'vaccine associate 579', 'vaccine associate 619', 'vaccine associate patient', 'vaccine associate hemodialysis']",1452,conclusionrna-1273 vaccine associated development transient aes first 579 second doses 619 patients chronic maintenance hemodialysis 
541,137.0,3.0,"['eighteen receive covid-19', 'eighteen receive vaccine', 'patient receive covid-19', 'patient receive vaccine']",1458,eighteen months radiotherapy patient received 2 doses mrna covid-19 vaccine 
542,137.0,4.0,"['fdg show lymphadenopathy', 'fdg show radiation', 'fdg show pneumonitis', 'petct show lymphadenopathy', 'petct show radiation', 'petct show pneumonitis', 'vaccine show lymphadenopathy', 'vaccine show radiation', 'vaccine show pneumonitis', 'fdg-avid show lymphadenopathy', 'fdg-avid show radiation', 'fdg-avid show pneumonitis', 'fdg perform vaccine', 'fdg perform fdg-avid', 'fdg perform lymphadenopathy', 'fdg perform radiation', 'fdg perform pneumonitis', 'petct perform vaccine', 'petct perform fdg-avid', 'petct perform lymphadenopathy', 'petct perform radiation', 'petct perform pneumonitis', 'fdg follow fdg-avid', 'fdg follow lymphadenopathy', 'fdg follow radiation', 'fdg follow pneumonitis', 'petct follow fdg-avid', 'petct follow lymphadenopathy', 'petct follow radiation', 'petct follow pneumonitis']",1459,fdg petct performed 4 days following second vaccine dose showed fdg-avid multistation lymphadenopathy radiation recall pneumonitis likely vaccination-induced mimicking recurrent disease 
543,138.0,4.0,"['patient match dcm', 'myocardial match dcm']",1465,subsequently performed propensity score ps matched analysis patients acute myocardial infarction ami complicated rcs non-ischaemic cardiomyopathy dcm related rcs 
544,138.0,5.0,"['seven relate influenza', 'patient relate influenza', 'influenza-related relate influenza', 'myocarditis relate influenza']",1466,results describe series seven patients rcs-complicated influenza-related myocarditis mean age 56ÃÂ10 years 58 male influenza n2 influenza b n5 
545,138.0,6.0,['patient vaccinate influenza'],1467,patient vaccinated prior influenza season 
546,138.0,10.0,['patient base influenza-related'],1471,ps-based comparison patients ami- dcm-related rcs combined mcs 30-day mortality significantly higher influenza-related rcs 
547,138.0,12.0,"['virus infection affect organ', 'virus infection affect heart', 'influenza affect organ', 'influenza affect heart']",1473,influenza virus infection potentially critically affects organs besides heart leading irreversible end-organ damage mcs compensate therefore results devastating outcome 
548,139.0,0.0,['respiratory syndrome associate patient'],1474,background sarsÃÂÂcovÃÂÂ2-induced severe acute respiratory syndrome associated high mortality general population however data chronic haemodialysis hd patients currently scarce 
549,139.0,1.0,"['respiratory distress evaluate ards', 'respiratory distress evaluate patient', 'respiratory distress evaluate interstitial', 'respiratory distress evaluate pneumonia', 'respiratory distress evaluate hrct']",1475,methods performed retrospective analysis evaluate onset acute respiratory distress syndrome ards patients sarsÃÂÂcovÃÂÂ2-induced interstitial pneumonia diagnosed pcr test detected high resolution computed tomography hrct 
550,139.0,2.0,['patient aim pneumonia'],1476,patient calculated ct score 0 24 based severity pneumonia 
551,139.0,4.0,"['5790 treat patient', '665 treat patient', '614 treat patient', '421 treat patient', 'diabetic treat patient', '526 treat patient', 'naples treat patient', 'italy treat patient']",1478,included 5790 hd patients age 665 ÃÂ134 years 614 males 421 diabetics 526 cv disease treated cardarelli hospital naples italy 1st september 2020 31st march 2021 patients treated intermittent hd 
552,139.0,9.0,"['patient affect ards', 'sars-cov-2 affect ards', 'pneumonia affect ards']",1483,conclusions retrospective analysis highlights hd patients affected sars-cov-2 pneumonia show increased risk developing ards dependent severity ct presentation 
553,140.0,1.0,"['covid-19 protect people', 'death protect people', 'infection protect people']",1486,vaccination significantly protects severe covid-19 hospitalization death also protects symptomatic infection reduces risk transmission people 
554,140.0,5.0,"['people prompt adult', 'child prompt adult']",1490,order achieve adequate vaccination coverage necessary motivate groups people vaccinated including children 12 years age young adults 
555,140.0,7.0,"['vaccine recommend second', 'vaccine recommend booster', 'vaccine recommend second', 'vaccine dose second', 'booster dose second']",1492,selected groups vaccines third dose vaccination recommended additional third dose 4 weeks second dose booster dose 8 12 months second dose 
556,140.0,8.0,"['thrombosis syndrome include guillain-barrÃ\x83\x83Ã\x83\x82', 'thrombosis syndrome include capillary', 'anaphylaxis include guillain-barrÃ\x83\x83Ã\x83\x82', 'anaphylaxis include capillary', 'thrombocytopenia include guillain-barrÃ\x83\x83Ã\x83\x82', 'thrombocytopenia include capillary']",1493,side effects usually mild serious complications including anaphylaxis thrombocytopenia thrombosis syndrome myocarditis guillain-barrÃÂ syndrome capillary leak syndrome rare 
557,141.0,3.0,"['hepatitis virus investigate tunisia', 'hepatitis virus investigate hepatitis']",1497,aim study investigate current seroprevalence hepatitis virus antibodies central-west tunisia assess impact hepatitis virus vaccination hepatitis epidemiology 
558,141.0,6.0,"['vaccine construct hepatitis', 'vaccine construct one', 'vaccine construct 12-months', 'vaccine construct one', 'vaccine construct 12-months', 'vaccine evaluate one', 'vaccine evaluate 12-months', 'vaccine evaluate one', 'vaccine evaluate 12-months', 'hepatitis evaluate one', 'hepatitis evaluate 12-months', 'hepatitis evaluate one', 'hepatitis evaluate 12-months']",1500,vaccine model constructed assess impact hepatitis virus epidemiology 3 scenarios vaccination strategies one dose 12-months age one dose 6-years one dose 12-months another 6-years age 6 years 
559,141.0,9.0,['vaccine show susceptibles'],1503,vaccine model showed 3-scenarios lead significant reduction fraction susceptibles 
560,141.0,11.0,"['single-dose provide 12-months', 'single-dose provide susceptibles', 'single-dose provide child', 'school-aged provide 12-months', 'school-aged provide susceptibles', 'school-aged provide child']",1505,single-dose vaccination 6-years age provides rapid decrease disease burden school-aged children compared single-dose vaccination 12-months keeps non-negligible fraction susceptibles among children 6-years 
561,142.0,1.0,"['970 diagnose connective tissue', '970 diagnose ra', '970 diagnose axial', '970 diagnose spondyloarthritis', '970 diagnose psoriasis', '970 diagnose arthritis', '970 diagnose psa', '970 diagnose ctd', 'patient diagnose connective tissue', 'patient diagnose ra', 'patient diagnose axial', 'patient diagnose spondyloarthritis', 'patient diagnose psoriasis', 'patient diagnose arthritis', 'patient diagnose psa', 'patient diagnose ctd', 'rheumatoid diagnose connective tissue', 'rheumatoid diagnose ra', 'rheumatoid diagnose axial', 'rheumatoid diagnose spondyloarthritis', 'rheumatoid diagnose psoriasis', 'rheumatoid diagnose arthritis', 'rheumatoid diagnose psa', 'rheumatoid diagnose ctd']",1508,methods total 970 cird patients diagnosed rheumatoid arthritis ra axial spondyloarthritis axspa psoriasis arthritis psa connective tissue diseases ctd selected records presented hospital least twice last year contacted telephone asked medication changes health status therapy satisfaction 
562,142.0,7.0,"['197 report 354', '197 report bdmards', '197 report 218', '197 report cdmards', '197 report corticosteroid', '197 include corticosteroid', 'patient include corticosteroid', '354 include corticosteroid', 'bdmards include corticosteroid', '218 include corticosteroid', 'cdmards include corticosteroid']",1514,recent change medication reported 197 patients 354 512 admitted decision mainly made due pandemic changes occurring bdmards 218 cdmards 66 corticosteroids 54 
563,142.0,8.0,"['patient modify depression', 'patient modify anxiety', 'patient modify 313', 'patient modify 475', 'patient modify 225', 'patient modify 350', 'patient modify 489', 'patient modify 277', 'patient modify 341', 'patient report 313', 'patient report 475', 'patient report 225', 'patient report 350', 'patient report 489', 'patient report 277', 'patient report 341', 'patient report 313', 'patient report 475', 'patient report 225', 'patient report 350', 'patient report 489', 'patient report 277', 'patient report 341', 'depression report 313', 'depression report 475', 'depression report 225', 'depression report 350', 'depression report 489', 'depression report 277', 'depression report 341', 'patient modify 489', 'patient modify 277', 'patient modify 341', 'patient modify 489', 'patient modify 277', 'patient modify 341', 'depression modify 489', 'depression modify 277', 'depression modify 341', 'anxiety modify 489', 'anxiety modify 277', 'anxiety modify 341', '313 modify 489', '313 modify 277', '313 modify 341', '475 modify 489', '475 modify 277', '475 modify 341', '225 modify 489', '225 modify 277', '225 modify 341', '350 modify 489', '350 modify 277', '350 modify 341', 'patient consider 341', 'patient consider 341', 'depression consider 341', 'anxiety consider 341', '313 consider 341', '475 consider 341', '225 consider 341', '350 consider 341', '489 consider 341']",1515,major difference patients changed pandemic self-reported inactive disease versus patients change therapy regarding disease activity depression anxiety 41 172 313 vs 475 225 350 vs 489 277 341 
564,142.0,10.0,"['patient vaccinate pneumococcus', 'patient vaccinate 613', 'influenza vaccinate pneumococcus', 'influenza vaccinate 613']",1517,majority patients vaccinated influenza 553 pneumococci 613 respectively 
565,142.0,11.0,"['anxiety play patient', 'depression play patient']",1518,conclusions anxiety depression disease activity play important role decisions favouring change therapy even though many patients changed medication due pandemic 
566,143.0,1.0,"['sars-cov-2 amplify vaccine', 'sars-cov-2 amplify covid-19', 'sars-cov-2 amplify patient', 'sars-cov-2 encode vaccine', 'sars-cov-2 encode covid-19', 'sars-cov-2 encode patient', 'sars-cov-2 encapsulate covid-19', 'sars-cov-2 encapsulate patient', 'vaccine encapsulate covid-19', 'vaccine encapsulate patient']",1522, present self-amplifying rna encoding sars-cov-2 spike protein encapsulated within lipid nanoparticle vaccine demonstrate induction robust neutralization pseudo-virus proportional quantity specific igg higher quantities recovered covid-19 patients 
567,144.0,0.0,['cd8 cell play infection'],1524,background memory cd8 cell responses play essential role protection persistent infection 
568,144.0,6.0,"['myeloid cells infect pd-l1-l2', 'myeloid cells infect cd8', 'myeloid cells expand pd-l1-l2', 'myeloid cells expand cd8', 'myeloid cells show cd8', 'pd-l1-l2 show cd8']",1530,myeloid cells infected rapidly expanded exhibiting elevated pd-l1-l2 expression cell suppressive function day 7 resistant cd8 cell-mediated apoptosis 
569,144.0,7.0,['myeloid-derived derive infection'],1531,depletion myeloid-derived suppressor cells mdscs reduced ecohiv infection boosted cell responses 
570,144.0,9.0,"['mdscs observe vaccine', 'mdscs observe human', 'cell observe mdscs', 'cell observe vaccine', 'cell observe human']",1533,identify mdscs critical gatekeepers restrain antiviral cell memory responses highlight mdscs important target developing effective vaccines chronic human infections 
571,145.0,6.0,"['fourteen receive three', 'fourteen receive quality']",1541,fourteen eligible studies found three higher quality 
572,145.0,7.0,"['parvum increase herd', 'infection increase herd', 'calf increase herd', 'calf increase herd']",1542,consistent evidence suggested risk c parvum infection increased calves contact calves larger herds organic production 
573,146.0,1.0,"['covid-19 match singapore', 'covid-19 match mrna', 'covid-19 match vaccine', 'covid-19 match worker', 'covid-19 match hcws', 'covid-19 match singapore', 'vaccine match singapore', 'vaccine match mrna', 'vaccine match covid-19', 'vaccine match covid-19', 'vaccine match worker', 'vaccine match hcws', 'vaccine match singapore', 'covid-19 emerge worker', 'covid-19 emerge hcws', 'covid-19 emerge singapore', 'vaccine emerge covid-19', 'vaccine emerge worker', 'vaccine emerge hcws', 'vaccine emerge singapore', 'singapore emerge covid-19', 'singapore emerge worker', 'singapore emerge hcws', 'mrna emerge covid-19', 'mrna emerge worker', 'mrna emerge hcws', 'mrna emerge singapore', 'covid-19 emerge worker', 'covid-19 emerge hcws', 'covid-19 emerge singapore', 'vaccine emerge covid-19', 'vaccine emerge worker', 'vaccine emerge hcws', 'vaccine emerge singapore', 'covid-19 focus singapore', 'vaccine focus singapore', 'mrna focus singapore', 'covid-19 focus singapore', 'vaccine focus singapore', 'covid-19 focus singapore', 'worker focus singapore']",1549,pfizer-biontech covid-19 vaccine first granted interim authorisation use singapore december 2020 overseas studies published safety side effect profiles mrna covid-19 vaccines focusing mainly non-asian populations described side effects pfizer-biontech covid-19 vaccination experienced healthcare workers hcws tertiary hospital singapore 
574,146.0,3.0,"['cross-sectional use atopic disorders', 'hcws use atopic disorders']",1551,cross-sectional study among vaccinated hcws conducted using online survey established basic demographics histories allergies atopic disorders adverse events encountered dose 1 dose 2 vaccination 
575,146.0,8.0,"['injection ache hcws', 'headache ache hcws', 'ache ache hcws', 'pain ache hcws', 'unwell ache hcws']",1556,feverchills injection site reactions headache aches pains feeling unwell significantly common hcws 60 years compared ÃÂÂ60 years 
576,147.0,0.0,"['patient receive hepatitis b', 'patient receive coronavirus', 'patient receive covid-19', 'patient receive b-cell', 'malignancy receive hepatitis b', 'malignancy receive coronavirus', 'malignancy receive covid-19', 'malignancy receive b-cell', 'autoimmune receive hepatitis b', 'autoimmune receive coronavirus', 'autoimmune receive covid-19', 'autoimmune receive b-cell']",1559,proposed patients hematologic malignancy autoimmune diseases receiving anti-cd20 monoclonal antibody mab therapy particularly risk severe coronavirus disease covid-19 profound long-lasting b-cell depletion induced anti-cd20 mab may impair virus clearance may also contribute reactivation latent viruses especially hepatitis b jc viruses 
577,147.0,1.0,"['covid-19 report milan', 'covid-19 report brescia', 'covid-19 report italian', 'italian report milan', 'italian report brescia', 'italian report covid-19', '245000 report milan', '245000 report brescia', '245000 report italian', '245000 report covid-19', 'covid-19 make italian', 'italian make covid-19', '245000 make italian', '245000 make covid-19', 'milan make italian', 'milan make covid-19', 'brescia make italian', 'brescia make covid-19']",1560,july 20 2020 total number covid-19 cases reported italian authorities reached 245000 north country mostly hit milan brescia among italian provinces registered highest number covid-19 cases 
578,147.0,2.0,"['hematological disorders affect 137', 'hematological disorders affect multiple', 'hematological disorders affect brescia', 'covid-19 affect 137', 'covid-19 affect multiple', 'covid-19 affect brescia', 'patient affect 137', 'patient affect multiple', 'patient affect brescia']",1561,consistent high number covid-19 patients affected multiple types hematological disorders n 137 multiple sclerosis ms n 114 referred asst spedali civili di brescia 
579,147.0,3.0,"['antibody test hematologic disease', 'antibody test patient', 'antibody test patient', 'antibody test rituximab', 'antibody test ocrelizumab', 'antibody test two', 'antibody test mabs', 'antibody test covid-19', 'sars-cov-2 test hematologic disease', 'sars-cov-2 test patient', 'sars-cov-2 test patient', 'sars-cov-2 test rituximab', 'sars-cov-2 test ocrelizumab', 'sars-cov-2 test two', 'sars-cov-2 test mabs', 'sars-cov-2 test covid-19', 'patient test hematologic disease', 'patient test rituximab', 'patient test ocrelizumab', 'patient test two', 'patient test mabs', 'patient test covid-19']",1562,antibodies sars-cov-2 analyzed 70 patients hematological disease patients ms among 10 patients 7 hematologic disease 3 ms received treatment rituximab ocrelizumab two anti-cd20 mabs within 3 months prior covid-19 onset 
580,147.0,4.0,"['cd20-depleting deplete b cell', 'cd20-depleting deplete hodgkin lymphoma', 'cd20-depleting deplete nhl', 'patient deplete b cell', 'patient deplete hodgkin lymphoma', 'patient deplete nhl', 'b cell include hodgkin lymphoma', 'b cell include nhl', 'cd20-depleting include hodgkin lymphoma', 'cd20-depleting include nhl', 'patient include hodgkin lymphoma', 'patient include nhl']",1563,clinical indication cd20-depleting treatment patients hematological disorders included diffuse large b cell lymphoma dlbcl follicular non hodgkin lymphoma nhl 
581,147.0,5.0,"['anti-nucleocapsid test lip', 'sars-cov-2 test lip', 'symptom test lip', 'plasma test lip', 'serum test lip', 'antibody test lip', 'luciferase test lip']",1564,anti-spike protein anti-s anti-nucleocapsid anti-n antibodies sars-cov-2 analyzed acute phase infection 3 months since onset symptoms quantitative measurements plasma serum antibodies luciferase immune precipitation assay systems lips 
582,147.0,6.0,"['anti-s show immunocompromised', 'anti-s show patient', 'anti-s show medrxiv', 'anti-n show immunocompromised', 'anti-n show patient', 'anti-n show medrxiv', 'antibody show immunocompromised', 'antibody show patient', 'antibody show medrxiv', 'symptom show immunocompromised', 'symptom show patient', 'symptom show medrxiv']",1565,technique production anti-s anti-n antibodies demonstrated day 8 day 14 onset symptoms immunocompetent individuals whereas specific antibody production delayed days immunocompromised patients burbelo pd et al medrxiv 
583,147.0,8.0,"['patient induce sars-cov-2', 'patient induce symptom']",1567,10 patients remained seronegative sars-cov-2 first 20 days since onset symptoms 
584,147.0,12.0,"['three die death', 'patient die death', 'three die death']",1571,three 10 patients died three sars-cov-2 rt-qpcr seronegative time death 
585,147.0,13.0,"['sars-cov-2 report autoimmune diseases', 'sars-cov-2 report people', 'sars-cov-2 report immunotherapy', 'sars-cov-2 make immunotherapy', 'people make immunotherapy']",1572,reported sars-cov-2 cleared without significant problems majority people ms autoimmune diseases immunotherapy data indicate treatment anti-cd20 mab may significantly alter humoral responses virus 
586,148.0,0.0,"['three compare canine', 'three compare parvovirus', 'parvovirus compare canine', 'parvovirus compare canine']",1581,study three different diagnostic tests parvovirus compared vaccination status parvovirus genotype suspected canine parvovirus cases 
587,148.0,3.0,"['parvovirus suspect dog', 'parvovirus suspect three']",1584,addition suspected parvovirus samples 21 faecal samples apparently healthy dogs tested three diagnostic tests evaluate sensitivity specificity tests 
588,148.0,6.0,"['type-2c detect dog', 'type-2c detect cpv-2b', 'type-2c detect 517', 'type-2c detect dog', 'type-2c detect one', 'type-2c detect two', 'type-2c detect cpv-2a', 'type-2c detect 172', 'cpv-2c detect dog', 'cpv-2c detect cpv-2b', 'cpv-2c detect 517', 'cpv-2c detect dog', 'cpv-2c detect one', 'cpv-2c detect two', 'cpv-2c detect cpv-2a', 'cpv-2c detect 172', '8275 detect dog', '8275 detect cpv-2b', '8275 detect 517', '8275 detect dog', '8275 detect one', '8275 detect two', '8275 detect cpv-2a', '8275 detect 172', 'type-2c vaccinate one', 'type-2c vaccinate two', 'type-2c vaccinate cpv-2a', 'type-2c vaccinate 172', 'cpv-2c vaccinate one', 'cpv-2c vaccinate two', 'cpv-2c vaccinate cpv-2a', 'cpv-2c vaccinate 172', '8275 vaccinate one', '8275 vaccinate two', '8275 vaccinate cpv-2a', '8275 vaccinate 172', 'dog vaccinate one', 'dog vaccinate two', 'dog vaccinate cpv-2a', 'dog vaccinate 172', 'dog vaccinate one', 'dog vaccinate two', 'dog vaccinate cpv-2a', 'dog vaccinate 172', 'cpv-2b vaccinate one', 'cpv-2b vaccinate two', 'cpv-2b vaccinate cpv-2a', 'cpv-2b vaccinate 172', '517 vaccinate one', '517 vaccinate two', '517 vaccinate cpv-2a', '517 vaccinate 172']",1587,cpv type-2c cpv-2c detected 8275 dogs 12 vaccinated 36 unvaccinated dogs cpv-2b detected 517 dogs one vaccinated two unvaccinated cpv-2a 172 vaccinated dog 
589,148.0,9.0,"['antigen die cpv-2c', 'antigen die dog', 'antigen receive cpv-2c', 'antigen receive dog']",1590,faecal antigen testing failed identify substantial proportion cpv-2c infected dogs likely due low sensitivity 
590,149.0,0.0,['adult hospitalize high-'],1593,background stormy course reported among hospitalized adults covid-19 high- middle-income countries 
591,149.0,2.0,"['patient include n501', 'covid-19 include n501']",1595,methods developed case registry successive patients admitted suspected covid-19 infection hospital n501 
592,149.0,3.0,"['covid-19 use reverse', 'covid-19 use transcriptase', 'covid-19 use polymerase']",1596,covid-19 diagnosed using reverse transcriptase polymerase chain reaction rt-pcr 
593,149.0,6.0,"['covid-19 diagnose 234', 'covid-19 diagnose 467', 'covid-19 diagnose 267', 'covid-19 diagnose 533']",1599,results covid-19 diagnosed 234 467 data compared 267 533 negative controls 
594,149.0,13.0,"['covid-19 receive hydroxychloroquine', 'covid-19 receive azithromycin', 'patient receive hydroxychloroquine', 'patient receive azithromycin']",1606,covid-19 patients received hydroxychloroquine azithromycin according prevalent guidelines 
595,149.0,14.0,"['one need oxygen', 'patient need oxygen']",1607,one patient needed oxygen support hospital course uncomplicated rest 
596,150.0,3.0,"['eclia assay igg', 'eclia assay elisa', 'eclia assay igg', 'immunoglobulin assay igg', 'immunoglobulin assay elisa', 'immunoglobulin assay igg']",1614,virus neutralizing tests used well eclia assay roche total immunoglobulins cmia assay abbott igg elisa assay euroimmun igg iga 
597,150.0,5.0,"['antibody correlate immunoglobulin', 'antibody correlate igg', 'antibody correlate second', 'antibody correlate czech']",1616,high levels neutralizing antibodies correlated higher levels immunoglobulins good predictor increase igg autumn second wave epidemic czech republic 
598,150.0,8.0,"['antibody follow infection', 'senior follow infection']",1619,study shows senior population production protective antibodies follows normal pattern seniors probably immune repeated infection least 8 months first infection 
599,151.0,0.0,"['covid-19 follow vaccine', 'covid-19 follow coronavac', 'covid-19 follow sinovac', 'covid-19 follow paulo', 'covid-19 follow brazil']",1621,objective estimate change odds covid-19 time following primary series completion inactivated whole virus vaccine coronavac sinovac biotech sÃÂo paulo state brazil 
600,151.0,3.0,"['participant age paulo', 'participant age covid-19', 'participant age two', 'participant age coronavac', 'participant age sars-cov-2', 'participant age covid-19', 'participant age death', 'adult age paulo', 'adult age covid-19', 'adult age two', 'adult age coronavac', 'adult age sars-cov-2', 'adult age covid-19', 'adult age death', 'participant confirm sars-cov-2', 'participant confirm covid-19', 'participant confirm death', 'adult confirm sars-cov-2', 'adult confirm covid-19', 'adult confirm death', 'paulo confirm sars-cov-2', 'paulo confirm covid-19', 'paulo confirm death', 'covid-19 confirm sars-cov-2', 'covid-19 confirm death', 'two confirm sars-cov-2', 'two confirm covid-19', 'two confirm death', 'coronavac confirm sars-cov-2', 'coronavac confirm covid-19', 'coronavac confirm death', 'participant receive sars-cov-2', 'participant receive covid-19', 'participant receive death', 'adult receive sars-cov-2', 'adult receive covid-19', 'adult receive death', 'paulo receive sars-cov-2', 'paulo receive covid-19', 'paulo receive death', 'covid-19 receive sars-cov-2', 'covid-19 receive death', 'two receive sars-cov-2', 'two receive covid-19', 'two receive death', 'coronavac receive sars-cov-2', 'coronavac receive covid-19', 'coronavac receive death']",1624,participants adults aged 18ÃÂÂ120 years residents sÃÂo paulo state without previous laboratory-confirmed covid-19 infection received two doses coronavac underwent reverse transcription polymerase chain reaction rt-pcr testing sars-cov-2 17 january 30 september 2021 main outcome measures rt-pcr-confirmed symptomatic covid-19 associated hospital admissions deaths 
601,151.0,4.0,['5-year test hcw'],1625,cases pair-matched test-negative controls age 5-year bands municipality residence healthcare worker hcw status date rt-pcr test ÃÂ3 days 
602,151.0,7.0,['covid-19 increase hcws'],1628,adjusted odds ratios symptomatic covid-19 increased time since series completion increase greater younger individuals among hcws compared non-hcws 
603,151.0,8.0,"['covid-19 increase 140', 'covid-19 increase 109', 'covid-19 increase 179', 'covid-19 increase 155', 'covid-19 increase 116', 'covid-19 increase 207', 'covid-19 increase 112', 'covid-19 increase 218', 'covid-19 increase 212', 'death increase 140', 'death increase 109', 'death increase 179', 'death increase 155', 'death increase 116', 'death increase 207', 'death increase 112', 'death increase 218', 'death increase 212', 'covid-19 compare 140', 'covid-19 compare 109', 'covid-19 compare 179', 'covid-19 compare 155', 'covid-19 compare 116', 'covid-19 compare 207', 'covid-19 compare 112', 'covid-19 compare 218', 'covid-19 compare 212', 'death compare 140', 'death compare 109', 'death compare 179', 'death compare 155', 'death compare 116', 'death compare 207', 'death compare 112', 'death compare 218', 'death compare 212', 'covid-19 vaccinate 109', 'covid-19 vaccinate 179', 'covid-19 vaccinate 155', 'covid-19 vaccinate 116', 'covid-19 vaccinate 207', 'covid-19 vaccinate 112', 'covid-19 vaccinate 218', 'covid-19 vaccinate 212', 'death vaccinate 109', 'death vaccinate 179', 'death vaccinate 155', 'death vaccinate 116', 'death vaccinate 207', 'death vaccinate 112', 'death vaccinate 218', 'death vaccinate 212', '140 vaccinate 109', '140 vaccinate 179', '140 vaccinate 155', '140 vaccinate 116', '140 vaccinate 207', '140 vaccinate 112', '140 vaccinate 218', '140 vaccinate 212']",1629,adjusted odds ratios covid-19 hospitalisation death significantly increased 98 days since series completion compared individuals vaccinated 14ÃÂÂ41 days previously 140 95 confidence interval 109 179 98ÃÂÂ125 days 155 116 207 126ÃÂÂ153 days 156 112 218 154ÃÂÂ181 days 212 139ÃÂÂ322 182 days 
604,152.0,0.0,"['covid-19 start worker', 'covid-19 start hcw']",1631,italy covid-19 vaccination campaign started december 2020 vaccination healthcare workers hcw 
605,152.0,2.0,"['ppr observe hcw', 'ppr observe hcw', 'ppr observe hcws', 'ppr observe august-7', 'ppr report hcws', 'ppr report august-7', 'hcw report hcws', 'hcw report august-7', 'hcw report hcws', 'hcw report august-7']",1633,week 22ÃÂÂ28 march observed 74 reduction ppr 026 95 ci 022ÃÂÂ029 proportion cases reported hcw 81 reduction proportion symptomatic cases reported hcw compared week lowest proportion cases among hcws prior vaccination campaign 31 august-7 september 
606,153.0,0.0,"['patient test covid-19', 'vaccine include patient', 'covid-19 include patient']",1635,background aim study analyze percentage patients admitted icu received vaccine covid-19 describe clinical profile vaccinated patients admitted icu assess humoral immune response vaccination 
607,153.0,1.0,"['critically ill confirm sars-cov-2', 'critically ill confirm vaccine', 'cohort confirm sars-cov-2', 'cohort confirm vaccine', 'patient confirm sars-cov-2', 'patient confirm vaccine', 'sars-cov-2 confirm vaccine', 'pneumonia confirm sars-cov-2', 'pneumonia confirm vaccine']",1636,methods multicenter prospective descriptive cohort study consecutive critically ill patients confirmed sars-cov-2 pneumonia received least one dose sars-cov-2 vaccine included 
608,153.0,3.0,['patient include sars-cov-2'],1638,patient admitted previously sars-cov-2 infection 
609,153.0,6.0,"['fifteen include respiratory distress', 'fifteen include ards', 'fifteen include patient', 'patient include respiratory distress', 'patient include ards', 'respiratory distress complete patient', 'fifteen complete patient', 'ards complete patient']",1641,fifteen patients admitted icu acute respiratory distress syndrome ards without completed vaccination clinical profile younger less comorbidities compared patients full vaccination 
610,153.0,8.0,"['patient include serum', 'vaccine include patient', 'vaccine include serum', 'vaccine include patient', 'patient receive serum', 'vaccine receive serum', 'vaccine receive patient', 'patient receive serum']",1643,conclusions patients admitted icu received dose vaccine optimally vaccinated fully vaccinated patients obtain optimal serum antibody levels patients considered immunocompromised 
611,155.0,0.0,"['two document b1526', 'two document one', 'two document sars-cov-2', 'two document antibody', 'two document south', 'two document africa', 'two document brazil', 'two cause brazil', 'b1526 cause brazil', 'one cause brazil', 'sars-cov-2 cause brazil', 'antibody cause brazil', 'south cause brazil', 'africa cause brazil']",1648,recent studies documented emergence rapid growth b1526 novel variant interest voi sars-cov-2 virus causes covid-19 new york city nyc area identification nyc november 2020 1-3 
612,155.0,1.0,"['nyc department receive b1526', 'nyc department receive infection', 'nyc department receive person', 'mental receive b1526', 'mental receive infection', 'mental receive person', 'nyc department observe infection', 'nyc department observe person', 'mental observe infection', 'mental observe person', 'nyc department bind person', 'mental bind person', 'b1526 bind person', 'infection bind person', 'nyc department attenuate person', 'mental attenuate person', 'b1526 attenuate person', 'infection attenuate person']",1649,two predominant subclades within b1526 lineage identified one containing e484k mutation receptor-binding domain 12 attenuates vitro neutralization multiple sars-cov-2 antibodies present variants concern vocs first identified south africa b1351 4 brazil p1 
613,155.0,3.0,"['specimen induce infection', 'specimen induce infection']",1651,preliminary data suggest b1526 variant lead severe disease associated increased risk infection vaccination breakthrough infection reinfection 
614,156.0,0.0,"['vaccine approve allergic', 'vaccine approve patient']",1654,background along newly approved vaccines coronavirus disease 2019 covid-19 first reports allergic intolerance reactions published 
615,156.0,1.0,"['allergic develop covid-19', 'allergic develop vaccine', 'allergic induce vaccine', 'covid-19 induce vaccine', 'allergic increase vaccine', 'covid-19 increase vaccine']",1655,subsequently questions arose whether vaccines pose increased risk intolerance reactions whether allergic patients may higher risk 
616,156.0,2.0,['allergic follow vaccine'],1656,results allergic reactions following covid-19 vaccinations reported mostly mild severity normal modernaÃÂ slightly increased frequency biontechpfizerÃÂ compared established conventional vaccines 
617,156.0,3.0,"['allergic diseases show vaccine', 'patient show vaccine', 'atopic show vaccine', 'patient show vaccine']",1657,risk allergic reaction newly licensed vector vaccines astrazenecaÃÂ johnson johnsonÃÂ conclusively assessed yet also appears low 
618,156.0,5.0,"['glycol include polysorbate', 'glycol include vaccine']",1659,currently assumed intolerance reactions immediate-type either type allergic ige-mediated reactions occur via complement activation carpa ÃÂÂcomplement activation-related pseudoallergyÃÂÂ 
619,156.0,9.0,"['igg suspect sars-cov-2', 'igg suspect saliva', 'igg suspect mrna-based', 'igg suspect vaccine', 'igg mediate mrna-based', 'igg mediate vaccine', 'sars-cov-2 mediate mrna-based', 'sars-cov-2 mediate vaccine', 'saliva mediate mrna-based', 'saliva mediate vaccine']",1663,standardized follow-up tests suspected allergic reactions carpa-mediated reactions currently limited 
620,157.0,2.0,"['salivary collect 2-wk', 'salivary collect 10-20', 'sars-cov-2 collect 2-wk', 'sars-cov-2 collect 10-20', 'igg collect 2-wk', 'igg collect 10-20', 'salivary test 10-20', 'sars-cov-2 test 10-20', 'igg test 10-20']",1666, 840 samples collected analyzed 
621,157.0,3.0,"['20 develop two', '20 develop patient']",1667,individuals salivary sars-cov-2 s1 igg ab levels rose sharply 2-wk period second vaccination peak ab levels seen 10-20 vaccination 
622,157.0,5.0,"['nab include coronavirus', 'nab include sars-cov-2']",1669,use noninvasive quantitative salivary ab measurement allow widespread cost-effective monitoring vaccine response 
623,158.0,0.0,['outpatient circulate nab'],1670,durability circulating neutralizing antibody nab responses severe acute respiratory syndrome coronavirus 2 sars-cov-2 infection boosting vaccination remains defined 
624,158.0,1.0,"['nab hospitalize patient', 'nab hospitalize infection']",1671,show outpatient hospitalized sars-cov-2 seropositive individuals mount robust neutralizing antibody nab response peaks days 23 27 post-symptom onset respectively 
625,158.0,2.0,"['nab induce b cell', 'immunization induce b cell', 'two induce b cell', 'coronavac induce b cell', 'sinovac induce b cell', 'one induce b cell', 'bnt162b2 induce b cell', 'nab induce b cell', 'nab induce immunization', 'nab induce two', 'nab induce coronavac', 'nab induce sinovac', 'nab induce one', 'nab induce bnt162b2', 'nab hospitalize b cell', 'nab hospitalize immunization', 'nab hospitalize two', 'nab hospitalize coronavac', 'nab hospitalize sinovac', 'nab hospitalize one', 'nab hospitalize bnt162b2', 'nab show b cell', 'nab show bnt162b2', 'immunization show b cell', 'immunization show bnt162b2', 'two show b cell', 'two show bnt162b2', 'coronavac show b cell', 'coronavac show bnt162b2', 'sinovac show b cell', 'sinovac show bnt162b2', 'nab induce b cell', 'immunization induce b cell', 'two induce b cell', 'coronavac induce b cell', 'sinovac induce b cell', 'one induce b cell', 'bnt162b2 induce b cell']",1672,although nab titers remained higher hospitalized patients study groups showed long-lasting nab responses persist 12 months natural infection 
626,158.0,4.0,"['immunization die bnt162b2', 'immunization die vaccine', 'immunization die nabs', 'immunization die 133', 'immunization die sars-cov-2', 'two die bnt162b2', 'two die vaccine', 'two die nabs', 'two die 133', 'two die sars-cov-2', 'vaccine die bnt162b2', 'vaccine die nabs', 'vaccine die 133', 'vaccine die sars-cov-2', 'immunization observe 133', 'immunization observe sars-cov-2', 'two observe 133', 'two observe sars-cov-2', 'vaccine observe 133', 'vaccine observe sars-cov-2', 'one observe 133', 'one observe sars-cov-2', 'bnt162b2 observe 133', 'bnt162b2 observe sars-cov-2', 'vaccine observe 133', 'vaccine observe sars-cov-2', 'nabs observe 133', 'nabs observe sars-cov-2']",1674,noteworthy three obese previously seropositive individuals failed mount booster response upon vaccination warranting studies population 
627,158.0,6.0,['worker induce covid-19'],1676,thus preliminary evidence suggests seropositive naÃÂve individuals require two doses coronavac ensure induction robust nab titers 
628,159.0,1.0,"['castilla include immunity', 'castilla include worker', 'castilla include sars-cov-2']",1678,workers centres included priority group vaccination sars-cov-2 
629,159.0,2.0,"['antibody make 1085', 'antibody make worker', 'antibody make bnt162b2', 'antibody make vaccine', 'antibody evaluate 1085', 'antibody evaluate worker', 'antibody evaluate bnt162b2', 'antibody evaluate vaccine']",1679,family ministry castilla leÃÂ³n realized seroprevalence survey measuring humoral immunity workers vaccination sars-cov-2 
630,159.0,3.0,"['elisa evaluate cero', 'elisa evaluate one', 'elisa evaluate two', 'elisa evaluate subgroup', 'elisa evaluate covid-19', 'anti-nucleocapsid evaluate cero', 'anti-nucleocapsid evaluate one', 'anti-nucleocapsid evaluate two', 'anti-nucleocapsid evaluate subgroup', 'anti-nucleocapsid evaluate covid-19', 'sars-cov-2 evaluate cero', 'sars-cov-2 evaluate one', 'sars-cov-2 evaluate two', 'sars-cov-2 evaluate subgroup', 'sars-cov-2 evaluate covid-19', 'igg evaluate cero', 'igg evaluate one', 'igg evaluate two', 'igg evaluate subgroup', 'igg evaluate covid-19']",1680,methods february march 2021 igmigg antibodies measured 7 social health care centers total 1085 workers least 15 days completing vaccination bnt162b2 vaccine pfizerbiontech 
631,159.0,7.0,"['covid-19 notify 259', 'covid-19 notify 894', 'covid-19 notify 601', 'covid-19 notify 1085', 'covid-19 notify p', 'covid-19 notify auml']",1684,7 cases covid-19 notified least 15 days full vaccination 
632,159.0,8.0,"['998 die bnt162b2', '998 die vaccine', '998 die immunity', '998 die igg', 'worker die bnt162b2', 'worker die vaccine', 'worker die immunity', 'worker die igg', '998 vaccinate immunity', '998 vaccinate igg', 'worker vaccinate immunity', 'worker vaccinate igg', 'bnt162b2 vaccinate immunity', 'bnt162b2 vaccinate igg', 'vaccine vaccinate immunity', 'vaccine vaccinate igg']",1685,titers significantly higher covid-19 passed group vaccinated 1 2 doses 259 vs 894 601 vs 1085 auml respectively p 005 unvaccinated group 53 vs 34 auml p 005 
633,159.0,10.0,"['covid-19 induce one', 'covid-19 induce two', 'covid-19 induce vaccine']",1687,64 unvaccinated workers presented humoral immunity 
634,159.0,11.0,['sars-cov-2 induce immunity'],1688,history passed covid-19 produces important booster effect one two doses vaccine 
635,159.0,12.0,"['b consider meningococcal disease', 'neisseria consider meningococcal disease', 'meningitidis consider meningococcal disease']",1689,measurement humoral immunity sars-cov-2 could considered parameter sufficient immunity 
636,160.0,1.0,"['vaccine aim menb', 'vaccine induce menb']",1691,menb vaccine directed polysaccharide capsule remains elusive due poor immunogenicity safety concerns 
637,160.0,4.0,"['teenager reduce conjugate', 'teenager reduce vaccine', 'vaccine reduce conjugate', 'herd reduce conjugate', 'herd reduce vaccine', 'vaccine reduce conjugate', 'teenager disrupt vaccine', 'herd disrupt vaccine']",1694,beginning late 1990s immunisation age group meningococcal group c conjugate vaccine reduced asymptomatic carriage disrupted transmission organism resulting lower group c imd incidence across age groups 
638,160.0,5.0,"['4cmenb vaccinate capsular', '4cmenb vaccinate commensal', '4cmenb vaccinate neisseria', '4cmenb base commensal', '4cmenb base neisseria', 'capsular base commensal', 'capsular base neisseria']",1695,whether vaccinating teenagers novel ÃÂÂmenbÃÂÂ protein-based vaccines prevent acquisition reduce duration carriage generate herd protection unknown time vaccine introduction could inferred effects conjugate vaccines 
639,160.0,6.0,"['oropharyngeal cause menb', 'meningococci cause menb', 'teenager cause menb', 'vaccine cause menb']",1696,4cmenb menb-fhbp may also impact non-menb disease-causing capsular groups well commensal neisseria spp 
640,160.0,9.0,"['meningococci follow 12', 'meningococci follow 12', 'meningococci follow vaccine', 'meningococci follow vaccine', 'vaccine follow 12', 'vaccine follow 12']",1699,culture-confirmed oropharyngeal carriage assessed baseline 12 months following control group eligible 4cmenb vaccination 
641,160.0,10.0,"['b describe vaccine', 'b describe antigen', 'b describe neisseria', 'meningococci describe vaccine', 'meningococci describe antigen', 'meningococci describe neisseria']",1700,primary outcome carriage prevalence potentially pathogenic meningococci defined genogroups b c w x vaccine group compared separately control group 12 months post-enrolment 12 months first vaccine dose 6 months second vaccine dose 
642,160.0,11.0,"['meningococci induce 2021', 'meningococci induce uk', 'meningococci induce immunisation', 'meningococci induce vaccine']",1701,secondary outcomes include impact carriage genogroup b meningococci hyperinvasive meningococci meningococci meningococci expressing vaccine antigens neisseria spp 
643,160.0,12.0,"['south central provide uk', 'south central provide medicine', 'south central detect uk', 'south central detect medicine']",1702,sample size 8000 arm provide 80 power detect 30 reduction meningococcal carriage assuming genogroup b c w x meningococci carriage 343 design effect 15 retention rate 80 significance level 005 study results available 2021 inform uk international immunisation policy future vaccine development 
644,161.0,1.0,"['steroid receive dexamethasone', 'steroid receive vaccine']",1708,methods literature search performed identify information pertinent steroid administration subsequent downstream effects vaccine efficacy 
645,161.0,3.0,"['six observe steroid', 'six observe vaccine']",1710,studies limited articles english language 
646,161.0,5.0,"['one use influenza', 'steroid use influenza', 'one indicate influenza', 'steroid indicate influenza']",1712,three 6 studies indicated steroids could used periÃÂÂvaccine period without significant suppression immune response 
647,161.0,7.0,"['one induce patient', 'one induce dexamethasone', 'one induce prednisolone', 'one induce mount', 'one induce igg']",1714,remaining 2 studies mixed findings 
648,161.0,8.0,"['vaccine receive steroid', 'vaccine receive steroid', 'vaccine receive steroid']",1715,one study showed patients received dexamethasone prednisolone able mount immune response resulting increased igg 
649,161.0,10.0,"['sars-cov-2 treat covid-19', 'vaccine treat covid-19']",1717,conclusions although shared consensus studies reviewed one study noted scenarios patients receiving steroids still successfully vaccinated 
650,162.0,0.0,"['viral infection consider organ', 'viral infection consider recipient', 'viral infection consider patient']",1718,sars-cov-2 vaccine considered primary health strategy able end current covid-19 pandemic 
651,162.0,2.0,"['plaque induce sars-cov-2', 'plaque induce antibody', 'plaque induce serum', 'plaque induce surrogate', 'plaque induce enzyme-linked', 'plaque induce immunosorbent', 'plaque induce elisa', 'plaque induce ace2', 'plaque induce antibody', 'plaque induce three', 'plaque induce surrogate', 'plaque induce sars-cov-2', 'plaque induce surrogate', 'plaque induce piscataway', 'plaque induce sars-cov-2']",1720,preliminary reports suggest lower antibody production bnt162b2 pfizerbiontech mrna-vaccine1234 data currently available elicited virus-specific cell responses 
652,164.0,1.0,"['participant enrol covid-19', 'participant enrol sars-cov-2', 'two enrol covid-19', 'two enrol sars-cov-2']",1723,methods seroepidemiological research enrolled 118 residents one nursing home zagreb 
653,164.0,3.0,"['sars-cov-2 test croatian', 'sars-cov-2 test covid-19', 'sars-cov-2 test patient']",1725,samples tested presence neutralizing antibodies using virus neutralization test 
654,164.0,9.0,"['almost half correlate six', 'participant correlate six', 'almost half neutralize six', 'participant neutralize six']",1731,age negatively significantly correlated neutralizing antibody titer spearman s rho -0132 p0155 
655,165.0,1.0,"['ninety-seven observe dog', 'ninety-seven observe cav-2', 'ninety-seven observe vaccine']",1736,study determined anti-cav antibodies within 28 days re-vaccination factors associated absence antibodies vaccination response 
656,165.0,5.0,"['ci 8561Ã\x83\x83Ã\x83\x82Ã\x83\x829670 perform antibody', 'dog perform antibody']",1740,fisherÃÂÂs exact test multivariate regression analysis performed determine factors associated absence antibodies vaccination response 
657,165.0,11.0,"['dog respond 3', 'dog respond antibody']",1746,dogs respond re-vaccination 
658,165.0,12.0,"['autoimmune vaccinate aiha', 'autoimmune vaccinate thrombocytopenia', 'autoimmune vaccinate itp', 'hemolytic vaccinate aiha', 'hemolytic vaccinate thrombocytopenia', 'hemolytic vaccinate itp']",1747,based study dogs re-vaccinated every 3 years antibodies determined 
659,166.0,1.0,"['herein associate covid-19', 'herein associate 53-year-old', 'herein associate woman', 'sle associate covid-19', 'sle associate 53-year-old', 'sle associate woman', 'bnt162b2 associate covid-19', 'bnt162b2 associate 53-year-old', 'bnt162b2 associate woman', 'mrna associate covid-19', 'mrna associate 53-year-old', 'mrna associate woman', 'coronavirus associate covid-19', 'coronavirus associate 53-year-old', 'coronavirus associate woman']",1749,systemic lupus erythematosus sle frequent autoimmune disorder associated evans syndrome 
660,166.0,3.0,"['hypocomplementemia show sle', 'lupus show sle', 'anticoagulant show sle']",1751,blood examination diagnosis showed hemolytic anemia positive coombs test thrombocytopenia 
661,166.0,6.0,"['physician cause recipient', 'mrna cause recipient', 'covid-19 cause recipient', 'physician induce mrna', 'physician induce covid-19', 'physician induce recipient']",1754,case suggests mrna covid-19 vaccination may cause autoimmune disorder 
662,167.0,1.0,"['thirty-four generate memory b', 'thirty-four generate two', 'thirty-four generate bnt162b2', 'thirty-four generate vaccine', 'thirty-four generate sars-cov-2', 'thirty-four generate convalescent', 'thirty-four generate bnt162b2', 'cvid generate memory b', 'cvid generate two', 'cvid generate bnt162b2', 'cvid generate vaccine', 'cvid generate sars-cov-2', 'cvid generate convalescent', 'cvid generate bnt162b2', 'convalescent generate memory b', 'convalescent generate two', 'convalescent generate bnt162b2', 'convalescent generate vaccine', 'convalescent generate sars-cov-2', 'convalescent generate bnt162b2', 'patient generate memory b', 'patient generate two', 'patient generate bnt162b2', 'patient generate vaccine', 'patient generate sars-cov-2', 'patient generate convalescent', 'patient generate bnt162b2', 'sars-cov-2 generate memory b', 'sars-cov-2 generate two', 'sars-cov-2 generate bnt162b2', 'sars-cov-2 generate vaccine', 'sars-cov-2 generate convalescent', 'sars-cov-2 generate bnt162b2', 'patient generate memory b', 'patient generate two', 'patient generate bnt162b2', 'patient generate vaccine', 'patient generate sars-cov-2', 'patient generate convalescent', 'patient generate bnt162b2']",1757,specifically patients common variable immunodeficiency cvid generated poor spike-specific antibody cell responses immunization 
663,167.0,4.0,"['patient boost b cells', 'patient boost b cells', 'patient boost memory', 'patient boost extra-follicular', 'patient boost convalescent', 'patient boost infection', 'patient boost memory', 'patient boost immunization']",1760,antibody response boosted convalescents vaccination 
664,167.0,6.0,"['sars-cov-2 evaluate b cell', 'sars-cov-2 evaluate bnt162b2', 'sars-cov-2 evaluate vaccine']",1762,poor spike-specific cell responses measured independently immunological challenge 
665,167.0,7.0,"['infection prim vaccine', 'infection prim cvid', 'immunization prim vaccine', 'immunization prim cvid']",1763,conclusions sars-cov-2 infection primed efficient classical memory b cell response whereas bnt162b2 vaccine induced non-canonical b cell responses cvid 
666,167.0,8.0,"['mrna induce sars-cov2', 'vaccine induce sars-cov2']",1764,natural infection responses boosted subsequent immunization suggesting possibility stimulate immune response additional vaccine doses cvid 
667,168.0,0.0,"['mrna show sars-cov2', 'mrna show infection', 'mrna show covid-19', 'mrna show bologna', 'mrna show ht', 'mrna show italy', 'mrna show bologna', 'mrna show ht', 'mrna show 2020', 'mrna show cox', 'vaccine show sars-cov2', 'vaccine show infection', 'vaccine show covid-19', 'vaccine show bologna', 'vaccine show ht', 'vaccine show italy', 'vaccine show bologna', 'vaccine show ht', 'vaccine show 2020', 'vaccine show cox', 'mrna prevent bologna', 'mrna prevent ht', 'mrna prevent italy', 'mrna prevent bologna', 'mrna prevent ht', 'mrna prevent 2020', 'mrna prevent cox', 'vaccine prevent bologna', 'vaccine prevent ht', 'vaccine prevent italy', 'vaccine prevent bologna', 'vaccine prevent ht', 'vaccine prevent 2020', 'vaccine prevent cox', 'sars-cov2 prevent bologna', 'sars-cov2 prevent ht', 'sars-cov2 prevent italy', 'sars-cov2 prevent bologna', 'sars-cov2 prevent ht', 'sars-cov2 prevent 2020', 'sars-cov2 prevent cox', 'infection prevent bologna', 'infection prevent ht', 'infection prevent italy', 'infection prevent bologna', 'infection prevent ht', 'infection prevent 2020', 'infection prevent cox', 'covid-19 prevent bologna', 'covid-19 prevent ht', 'covid-19 prevent italy', 'covid-19 prevent bologna', 'covid-19 prevent ht', 'covid-19 prevent 2020', 'covid-19 prevent cox']",1765,background aim randomized controlled trials shown mrna vaccines highly effective preventing sars-cov2 infection 
668,168.0,1.0,"['vaccine evaluate 855', 'vaccine evaluate 759-913', 'vaccine evaluate 848', 'vaccine evaluate 732-914', 'sars-cov2 evaluate 855', 'sars-cov2 evaluate 759-913', 'sars-cov2 evaluate 848', 'sars-cov2 evaluate 732-914']",1766,conducted study assess real-world effectiveness mrna vaccines pfizer-biontech moderna preventing symptomatic sars-cov2 infections covid-19 related hospitalizations staff bologna health trust ht italy methods followed retrospectively 9839 staff bologna ht december 27 2020 april 3 2020 calculated effectiveness partially fully vaccinated subjects applying multivariable cox proportional hazard model 
669,168.0,2.0,"['infection prevent 627-910', 'infection prevent 871', 'infection prevent 693-946', '817 prevent 627-910', '817 prevent 871', '817 prevent 693-946']",1767,results vaccine effectiveness preventing sars-cov2 infections 855 95 ci 759-913 partially vaccinated 848 95 ci 732-914 fully vaccinated 
670,168.0,3.0,['covid-19-related prevent cohort'],1768,preventing symptomatic infection effectiveness 817 95 ci 627-910 partially 871 95 ci 693-946 fully vaccinated 
671,168.0,4.0,['mrna relate northern italy'],1769,covid-19-related hospitalizations partially fully vaccinated vs 15 hospitalization unvaccinated cohort 
672,169.0,0.0,"['sars-cov-2 exist covid-19', 'sars-cov-2 exist woman', 'sars-cov-2 exist newborn', 'igg exist covid-19', 'igg exist woman', 'igg exist newborn']",1771,importance contribution study variability exists passage sars-cov-2 igg asymptomatic covid-19 mothers newly born infants 
673,169.0,1.0,"['covid provide woman', 'covid provide infant']",1772,awareness sars-cov-2 igg may contribute management asymptomatic rt pcr covid-19 positive pregnant women newborns future vaccination practices 
674,169.0,5.0,"['woman review covid-19', 'woman review dyad', 'woman review covid-19', 'woman review mother37', 'woman review dyad', 'woman review one', 'woman review twin', 'infant review covid-19', 'infant review dyad', 'infant review covid-19', 'infant review mother37', 'infant review dyad', 'infant review one', 'infant review twin', 'university review covid-19', 'university review dyad', 'university review covid-19', 'university review mother37', 'university review dyad', 'university review one', 'university review twin', 'louisville review covid-19', 'louisville review dyad', 'louisville review covid-19', 'louisville review mother37', 'louisville review dyad', 'louisville review one', 'louisville review twin', 'louisville review covid-19', 'louisville review dyad', 'louisville review covid-19', 'louisville review mother37', 'louisville review dyad', 'louisville review one', 'louisville review twin', 'woman collect dyad', 'woman collect covid-19', 'woman collect mother37', 'woman collect dyad', 'woman collect one', 'woman collect twin', 'infant collect dyad', 'infant collect covid-19', 'infant collect mother37', 'infant collect dyad', 'infant collect one', 'infant collect twin', 'university collect dyad', 'university collect covid-19', 'university collect mother37', 'university collect dyad', 'university collect one', 'university collect twin', 'louisville collect dyad', 'louisville collect covid-19', 'louisville collect mother37', 'louisville collect dyad', 'louisville collect one', 'louisville collect twin', 'louisville collect dyad', 'louisville collect covid-19', 'louisville collect mother37', 'louisville collect dyad', 'louisville collect one', 'louisville collect twin', 'participant collect dyad', 'participant collect covid-19', 'participant collect mother37', 'participant collect dyad', 'participant collect one', 'participant collect twin', 'covid-19 collect dyad', 'covid-19 collect mother37', 'covid-19 collect dyad', 'covid-19 collect one', 'covid-19 collect twin']",1776,clinical demographicscovid-19 testing maternalinfant dyads reviewedcollected reporting purposes 
675,169.0,10.0,"['mother observe igg', 'mother observe antibody', 'covid-19 observe igg', 'covid-19 observe antibody', 'infant observe igg', 'infant observe antibody', 'mother receive infant', 'mother receive sars-cov-2', 'mother receive igg', 'mother receive antibody', 'covid-19 receive infant', 'covid-19 receive sars-cov-2', 'covid-19 receive igg', 'covid-19 receive antibody']",1781,required intensive care recovered pregnancies maintained 37w4d 39w3d gestation respectively 
676,169.0,14.0,"['neonatology aim listserv', 'loma aim listserv', 'linda aim listserv']",1785,investigation immune system s response sars-cov-2 virus pregnancy direct future managementtreatment pregnancy especially wake vaccination virus pregnancy emerging variants 
677,170.0,1.0,"['participant investigate sweden', 'participant investigate immunity', 'participant investigate covid-19', 'participant investigate 2021']",1793,objective investigate association risk covid-19 nonimmune individuals number family members known immunity acquired previous covid-19 infection full vaccination 2 vaccine doses 
678,170.0,3.0,"['family members match family', 'family members match immunity', 'family members match covid-19', 'family members match bnt162b2', 'family members match mrna', 'family members match chadox1', 'family members match ncov-19', 'family members match vaccine', 'family members receive bnt162b2', 'family members receive mrna', 'family members receive chadox1', 'family members receive ncov-19', 'family members receive vaccine', 'family receive bnt162b2', 'family receive mrna', 'family receive chadox1', 'family receive ncov-19', 'family receive vaccine', 'immunity receive bnt162b2', 'immunity receive mrna', 'immunity receive chadox1', 'immunity receive ncov-19', 'immunity receive vaccine', 'family members establish bnt162b2', 'family members establish mrna', 'family members establish chadox1', 'family members establish ncov-19', 'family members establish vaccine', 'family establish bnt162b2', 'family establish mrna', 'family establish chadox1', 'family establish ncov-19', 'family establish vaccine', 'immunity establish bnt162b2', 'immunity establish mrna', 'immunity establish chadox1', 'immunity establish ncov-19', 'immunity establish vaccine', 'covid-19 establish bnt162b2', 'covid-19 establish mrna', 'covid-19 establish chadox1', 'covid-19 establish ncov-19', 'covid-19 establish vaccine']",1795,person immunity matched 11 individual without immunity identified cohort individuals families comprising 2 5 members 
679,170.0,4.0,"['family members acquire family', 'covid-19 acquire family', 'infection acquire family', 'nonimmune acquire family', '2021 acquire family', '789 acquire family', '728 acquire family', '814 acquire family']",1796,exposures number immune family members family april 14 2021 index date acquired immunity previous covid-19 infection full vaccination 2 doses mrna-1273 bnt162b2 mrna chadox1 ncov-19 vaccine 
680,170.0,7.0,"['immune members follow family members', 'immune members follow covid-19', 'immune members follow nonimmune']",1799,mean range follow-up time 263 1-40 days 88 797 1 549 989 57 nonimmune family members mean sd age 516 177 years 790 276 men 510 diagnosed covid-19 
681,170.0,9.0,"['family members contract p', 'family members contract p', 'family contract family members', 'family contract family members', 'family contract p', 'family contract p']",1801,nonimmune families 1 immune family member 45 61 lower risk contracting covid-19 hazard ratio hr 039-055 95 ci 037-061 p 001 
682,171.0,0.0,"['enzyme dose participant', 'ace2 dose participant', 'receptor dose participant']",1806,background recent reports suggested among individuals previously infected sars-cov-2 single mrna vaccine dose sufficient elicit high levels immunity 
683,171.0,1.0,"['participant compare mrna-1273moderna', 'participant compare chicago', 'participant compare covid-19', 'mrna compare mrna-1273moderna', 'mrna compare chicago', 'mrna compare covid-19', 'participant bind covid-19', 'mrna bind covid-19', 'mrna-1273moderna bind covid-19', 'chicago bind covid-19']",1807,methods compared anti-sars-cov-2 spike receptor binding domain rbd igg antibody concentrations antibody-mediated neutralization spike-angiotensin-converting enzyme ace2 receptor binding vitro following vaccination non-hospitalized participants sero-status acute virus diagnosis history 
684,171.0,2.0,"['covid-19 base igg', 'covid-19 collect igg']",1808,participants analysed mrna vaccination bnt162b2pfizer mrna-1273moderna community-based home-collected longitudinal serosurvey chicago area usa none reported hospitalization covid-19 
685,171.0,7.0,"['one evaluate post-vaccine', 'one evaluate igg', 'one evaluate surrogate', 'one evaluate covid-19', 'one evaluate igg', 'one evaluate 999', 'one evaluate igg', 'one evaluate 565', 'one evaluate igg']",1813,responses evaluated one n 142 two n 191 doses bnt162b2 mrna-1273 vaccine 
686,171.0,9.0,"['one make covid-19', 'one make surrogate', 'mrna make covid-19', 'mrna make surrogate', 'one dose surrogate', 'mrna dose surrogate', 'vaccine dose surrogate', 'covid-19 dose surrogate']",1815,latter two groups reached 95 neutralization second vaccine dose 
687,171.0,10.0,"['one diagnose sars-cov-2', 'one diagnose covid-19', 'one diagnose person', 'mrna diagnose sars-cov-2', 'mrna diagnose covid-19', 'mrna diagnose person', 'vaccine diagnose sars-cov-2', 'vaccine diagnose covid-19', 'vaccine diagnose person', 'one respond covid-19', 'one respond person', 'mrna respond covid-19', 'mrna respond person', 'vaccine respond covid-19', 'vaccine respond person', 'person respond covid-19', 'sars-cov-2 respond covid-19', 'sars-cov-2 respond person']",1816,interpretation one dose mrna vaccine individuals previously diagnosed covid-19 responded high levels anti-rbd igg surrogate neutralization spike-ace2 interaction 
688,172.0,7.0,"['patient consider covid-19', 'patient consider infectious']",1826,conclusions stiko vaccination recommendations considered medical standard 
689,172.0,8.0,"['coxsackievirus emerge serotypes', 'coxsackievirus emerge myocarditis', 'coxsackievirus emerge pancreatitis', 'six emerge serotypes', 'six emerge myocarditis', 'six emerge pancreatitis', 'organ emerge serotypes', 'organ emerge myocarditis', 'organ emerge pancreatitis']",1827,published current instructions vaccination immunodeficient patients recently published recommendation covid-19 vaccination together scientific backgrounds reasons represent valuable basis medical action field vaccination infectious diseases 
690,173.0,2.0,"['cvb3 desire wild-type', 'mt10 desire wild-type', 'mt10 desire cvb3', 'myocarditis desire wild-type', 'myocarditis desire cvb3', 'pancreatitis desire wild-type', 'pancreatitis desire cvb3', 'cvb3 induce mt10', 'cvb3 induce myocarditis', 'cvb3 induce pancreatitis', 'cvb3 induce wild-type']",1830,translationally derivation vaccines offer protection multiple serotypes highly desired 
691,173.0,3.0,"['mt10 report serotypes', 'mt10 report cvb4', 'vaccine report serotypes', 'vaccine report cvb4']",1831,direction recently reported generation attenuated strain cvb3 termed mt10 completely protects myocarditis pancreatitis induced homologous wild-type cvb3 strain 
692,173.0,5.0,"['cvb4 induce heart', 'cvb4 induce pancreas', 'mt10 induce heart', 'mt10 induce pancreas', 'vaccine induce heart', 'vaccine induce pancreas']",1833,note mt10 vaccine could induce cross-reactive neutralizing antibodies nabs cvb1 cvb4 
693,173.0,7.0,['vp1 indicate antibody'],1835,antibody responses induced mt10cvb4 challenged animals indicated persistence cross-reactive nabs cvb1 cvb3 cvb4 
694,173.0,8.0,"['histocompatibility receive cd4 cells', 'histocompatibility receive vp1-specific', 'histocompatibility receive cytokine', 'histocompatibility receive interferon-Ã\x83\x83Ã\x83\x82Ã\x82Â³']",1836,evaluation antigen-specific immune responses revealed viral protein 1 vp1 -reactive antibodies predominantly igg2a igg2b igg3 igg1 
695,173.0,9.0,"['vaccine use nucleic acid', 'vaccine use cvb4', 'vaccine use heart', 'vaccine use pancreas']",1837,similarly using major histocompatibility complex class ii tetramers noted induction vp1-specific cd4 cells capable producing multiple cell cytokines interferon-ÃÂ³ predominant 
696,173.0,10.0,"['mt10 challenge vaccine', 'mt10 challenge heart', 'mt10 challenge enteroviral', 'vaccine challenge heart', 'vaccine challenge enteroviral', 'mt10 receive vaccine', 'mt10 receive heart', 'mt10 receive enteroviral', 'vaccine receive heart', 'vaccine receive enteroviral']",1838,finally none vaccine recipients challenged cvb4 revealed presence viral nucleic acid heart pancreas 
697,173.0,11.0,['vaccine-acquired induce immunity'],1839,taken together data suggest mt10 vaccine prevent infections caused multiple cvb serotypes paving way development monovalent cvb vaccines prevent heart pancreatic diseases enteroviral origin 
698,174.0,1.0,"['vaccine undergo sars-cov-2', '10-months undergo sars-cov-2', 'immunity undergo sars-cov-2']",1841,investigated large prospective cohort uk healthcare workers undergoing routine asymptomatic pcr testing 
699,174.0,6.0,"['immunity decrease two', 'immunity decrease vaccine', 'immunity decrease 15-months']",1846,adjusted ave decreased 81 95 ci 68 -89 14-73 days dose-2 46 95 ci 22 -63 6-months significant difference short-interval bnt162b2 significantly lower ave 50 95 ci 18 -70 14-73 days dose-2 chadox1 
700,174.0,7.0,"['conclusiontwo acquire sars-cov-2', 'conclusiontwo acquire six', 'bnt162b2 acquire sars-cov-2', 'bnt162b2 acquire six', 'conclusiontwo show sars-cov-2', 'conclusiontwo show six', 'bnt162b2 show sars-cov-2', 'bnt162b2 show six', 'conclusiontwo wan six', 'bnt162b2 wan six', 'sars-cov-2 wan six']",1847,protection infection-acquired immunity showed evidence waning unvaccinated follow-up remained consistently 90 received two doses vaccine even infected 15-months ago 
701,174.0,8.0,"['infection-acquired induce infection', 'immunity induce infection']",1848,conclusiontwo doses bnt162b2 vaccination induce high short-term protection sars-cov-2 infection wanes significantly six months 
702,174.0,9.0,['vaccinee induce infection'],1849,infection-acquired immunity boosted vaccination remains high year infection 
703,175.0,1.0,"['patient evaluate allergic', 'patient evaluate vaccine', 'patient evaluate polysorbate', 'patient evaluate skin', 'patient vaccinate polysorbate', 'patient vaccinate skin', 'allergic vaccinate polysorbate', 'allergic vaccinate skin']",1853,aimed evaluate possibility vaccinating patients peg andor polysorbate allergy covidÃÂÂ19 
704,175.0,2.0,"['patient observe vaccine', '2021 observe vaccine', 'four observe vaccine', 'patient observe vaccine', 'skin observe vaccine', 'basophil observe vaccine', 'histamine observe vaccine', 'bahr observe vaccine', 'polysorbates observe vaccine']",1854,methods twentyÃÂÂfive patients history allergic reaction drugs vaccines mouth hygiene products containing peg polysorbate sensitization skin test vitro test positive challenge included 
705,175.0,9.0,"['eleven vaccinate vaccine', 'eleven vaccinate four', 'eleven vaccinate seven']",1861,three vaccinated referral 
706,175.0,10.0,"['six induce polysorbate', 'six induce vaccine']",1862,eleven offered johnsonÃÂÂjohnson vaccine four vaccinated successfully seven abstained 
707,175.0,11.0,"['hypersensitivity vaccinate patient', 'hypersensitivity vaccinate allergy', 'hypersensitivity vaccinate peg', 'hypersensitivity vaccinate polysorbates', 'hypersensitivity observe polysorbates', 'vaccine observe polysorbates', 'patient observe polysorbates', 'allergy observe polysorbates']",1863,six patients could vaccinated peg polysorbate containing vaccines 
708,175.0,12.0,['patient establish vaccine'],1864,conclusion hypersensitivity excipients covidÃÂÂ19 vaccines constitutes risk patients allergy peg polysorbates 
709,175.0,13.0,"['coronavac induce sars-cov-2', 'vaccine induce sars-cov-2', 'coronavac await sars-cov-2', 'vaccine await sars-cov-2', 'coronavac observe sars-cov-2', 'vaccine observe sars-cov-2']",1865,diagnostic evaluation safe covidÃÂÂ19 vaccine could offered patients remainders await new vaccines containing different excipients 
710,176.0,2.0,"['volunteer randomize sars-cov-2', 'volunteer randomize turkey', 'covid-19 randomize sars-cov-2', 'covid-19 randomize turkey', 'volunteer observe turkey', 'covid-19 observe turkey', 'sars-cov-2 observe turkey']",1868,methods double-blind randomised placebo-controlled phase 3 trial 
711,176.0,4.0,"['k1 include health-care', 'k1 include worker', 'k1 include health-care', 'k1 include worker', 'k1 include k2', 'k1 include cohort', 'cohort include health-care', 'cohort include worker', 'cohort include health-care', 'cohort include worker', 'cohort include k2', 'k1 include cohort', 'health-care include cohort', 'worker include cohort', 'health-care include cohort', 'worker include cohort']",1870,exclusion criteria included limited immunosuppressive therapy including steroids within past 6 months bleeding disorders asplenia receipt blood products immunoglobulins within past 3 months 
712,176.0,5.0,"['vaccine establish aluminium hydroxide', 'vaccine establish sars-cov-2', 'vaccine establish virion', 'vaccine establish suspension', 'aluminium hydroxide randomize suspension', 'vaccine randomize suspension', 'sars-cov-2 randomize suspension', 'virion randomize suspension']",1871,k1 cohort consisted health-care workers randomised 11 ratio individuals health-care workers also recruited k2 cohort randomised 21 ratio using interactive web response system 
713,176.0,6.0,"['participant inactivate covid-19', 'vaccine inactivate covid-19', 'participant adsorb covid-19', 'vaccine adsorb covid-19', 'vaccine adsorb covid-19']",1872,study vaccine 3 ÃÂg inactivated sars-cov-2 virion adsorbed aluminium hydroxide 0ÃÂ5 ml aqueous suspension 
714,176.0,10.0,"['four allocate participant', 'four allocate two', 'four allocate vaccine', 'participant allocate two', 'participant allocate vaccine', 'vaccine allocate participant', 'vaccine allocate two', '10 allocate participant', '10 allocate two', '10 allocate vaccine', '214 allocate participant', '214 allocate two', '214 allocate vaccine', 'participant allocate two', 'participant allocate vaccine', 'vaccine allocate participant', 'vaccine allocate two', '3568 allocate participant', '3568 allocate two', '3568 allocate vaccine', 'four screen 10', 'four screen 214', 'four screen participant', 'four screen vaccine', 'four screen 3568', 'four screen participant', 'four screen two', 'four screen vaccine', 'participant screen 10', 'participant screen 214', 'participant screen vaccine', 'participant screen 3568', 'participant screen two', 'participant screen vaccine', 'vaccine screen 10', 'vaccine screen 214', 'vaccine screen participant', 'vaccine screen 3568', 'vaccine screen participant', 'vaccine screen two']",1876,findings among 11 303 volunteers screened sept 14 2020 jan 5 2021 10 218 randomly allocated 
715,176.0,11.0,"['nine establish person-years', 'nine establish vaccine', 'covid-19 establish person-years', 'covid-19 establish vaccine', 'vaccine establish person-years', 'person-years establish vaccine']",1877,exclusion four participants vaccine group protocol deviations intention-to-treat group consisted 10 214 participants 6646 65ÃÂ1 vaccine group 3568 34ÃÂ9 placebo group per protocol group consisted 10 029 participants 6559 65ÃÂ4 3470 34ÃÂ6 received two doses vaccine placebo 
716,177.0,0.0,"['patient consider covid-19', 'patient consider vaccine']",1884,background rationale government guidance regarding covid-19 vaccination lists food allergy drug allergy history anaphylaxis contraindications receiving vaccination 
717,177.0,2.0,"['18 mine one', '18 mine covid-19', '18 mine vaccine', 'allergic mine one', 'allergic mine covid-19', 'allergic mine vaccine']",1886,methods data n255 patients mined 
718,177.0,6.0,"['allergy andor induce ae', 'andor induce ae', 'anaphylaxis induce ae']",1890,eighty one took first dose 33 took doses 
719,177.0,8.0,"['two see one', 'aes see one']",1892,three aes seen allergic diathesis 
720,177.0,10.0,"['allergy make compound', 'polyethylene make compound', 'glycolpeg make compound', 'allergy make compound']",1894,female patient itching palmar erythema post covishieldÃÂÂ subsided week s treatment antihistamine 
721,177.0,11.0,"['patient observe allergic', 'covid-19 observe allergic', 'indian observe allergic']",1895,history allergy radiocontrast media containing polyethylene glycolpeg indicating possible allergy polysorbate 80 peg related compound contained covishieldÃÂÂ 
722,178.0,0.0,"['europe induce 2021', 'europe induce covid-19', 'europe induce death', 'europe induce uk', 'europe induce cancer', 'europe induce patient', 'europe induce eu', 'uk induce 2021', 'uk induce covid-19', 'uk induce death', 'uk induce cancer', 'uk induce patient', 'uk induce eu', 'death induce 2021', 'death induce covid-19', 'death induce uk', 'death induce cancer', 'death induce patient', 'death induce eu']",1898,background despite high contagiousness rapid spread sars-cov-2 led heterogeneous outcomes across affected nations 
723,178.0,1.0,"['cancer affect covid-19', 'cancer affect 2020', 'cancer affect death', 'cancer affect uk', 'cancer affect eu', 'patient affect covid-19', 'patient affect 2020', 'patient affect death', 'patient affect uk', 'patient affect eu', 'cancer aim uk', 'cancer aim eu', 'patient aim uk', 'patient aim eu', 'covid-19 aim uk', 'covid-19 aim eu', '2020 aim uk', '2020 aim eu', 'death aim uk', 'death aim eu', 'cancer compare uk', 'cancer compare eu', 'patient compare uk', 'patient compare eu', 'covid-19 compare uk', 'covid-19 compare eu', '2020 compare uk', '2020 compare eu', 'death compare uk', 'death compare eu']",1899,within europe united kingdom uk severely affected country death toll excess 100000 january 2021 aimed compare national impact covid-19 risk death uk cancer patients versus continental europe eu 
724,178.0,2.0,"['patient diagnose cox', 'covid-19 diagnose cox', 'uk diagnose cox', 'eu diagnose cox', 'cohort diagnose cox', 'patient perform covid-19', 'patient perform uk', 'patient perform eu', 'patient perform cohort', 'patient perform cox']",1900,methods performed retrospective analysis oncovid study database european registry cancer patients consecutively diagnosed covid-19 27 centres february 27 september 10 2020 analysed case fatality rates risk death 30 days 6 months stratified region origin uk versus eu 
725,178.0,3.0,"['eu include 265', 'eu include p', 'eu include death', 'eu include 164', 'eu include 136-199', 'eu include covid-19', 'eu include 4764', 'eu include 159', 'eu include 133-188', 'uk include 265', 'uk include p', 'uk include death', 'uk include 164', 'uk include 136-199', 'uk include covid-19', 'uk include 4764', 'uk include 159', 'uk include 133-188', 'patient include 265', 'patient include p', 'patient include death', 'patient include 164', 'patient include 136-199', 'patient include covid-19', 'patient include 4764', 'patient include 159', 'patient include 133-188', 'n468 include 265', 'n468 include p', 'n468 include death', 'n468 include 164', 'n468 include 136-199', 'n468 include covid-19', 'n468 include 4764', 'n468 include 159', 'n468 include 133-188', 'eu evaluate 164', 'eu evaluate 136-199', 'eu evaluate covid-19', 'eu evaluate 4764', 'eu evaluate 159', 'eu evaluate 133-188', 'uk evaluate 164', 'uk evaluate 136-199', 'uk evaluate covid-19', 'uk evaluate 4764', 'uk evaluate 159', 'uk evaluate 133-188', 'patient evaluate 164', 'patient evaluate 136-199', 'patient evaluate covid-19', 'patient evaluate 4764', 'patient evaluate 159', 'patient evaluate 133-188', 'n468 evaluate 164', 'n468 evaluate 136-199', 'n468 evaluate covid-19', 'n468 evaluate 4764', 'n468 evaluate 159', 'n468 evaluate 133-188', '265 evaluate 164', '265 evaluate 136-199', '265 evaluate covid-19', '265 evaluate 4764', '265 evaluate 159', '265 evaluate 133-188', 'p evaluate 164', 'p evaluate 136-199', 'p evaluate covid-19', 'p evaluate 4764', 'p evaluate 159', 'p evaluate 133-188']",1901,compared patient characteristics baseline including oncological covid-19 specific therapy across uk eu cohorts evaluated association factors risk adverse outcome multivariable cox regression models 
726,178.0,4.0,"['uk compare eu', 'patient compare eu']",1902,findings compared eu n924 uk patients n468 characterised higher case fatality rates 4038 versus 265 p 00001 higher risk death 30 days hazard ratio hr 164 95 ci 136-199 6 months covid-19 diagnosis 4764 versus 3333 p 00001 hr 159 95 ci 133-188 
727,178.0,7.0,"['uk receive covid-19', 'uk receive anticancer', 'cohort receive covid-19', 'cohort receive anticancer', 'death receive covid-19', 'death receive anticancer', 'tumour receive covid-19', 'tumour receive anticancer']",1905,despite equal proportions complicated covid-19 rates intensive care admission use mechanical ventilation uk cancer patients less likely receive anti-covid-19 therapies including corticosteroids anti-virals interleukin-6 antagonists p 00001 
728,178.0,8.0,"['anticancer confirm uk', 'anticancer confirm eu', 'covid-19 confirm uk', 'covid-19 confirm eu']",1906,multivariable analyses adjusted imbalanced prognostic factors confirmed uk cohort characterised worse risk death 30 days 6 months independent patientÃÂÂs age gender tumour stage status number co-morbidities covid-19 severity receipt anticancer anti-covid-19 therapy 
729,178.0,12.0,"['five observe chadox1', 'five observe ncov-19', 'five observe adenoviral', 'five observe vaccine', 'five observe coronavirus', 'five observe covid-19', 'patient observe chadox1', 'patient observe ncov-19', 'patient observe adenoviral', 'patient observe vaccine', 'patient observe coronavirus', 'patient observe covid-19', 'venous observe chadox1', 'venous observe ncov-19', 'venous observe adenoviral', 'venous observe vaccine', 'venous observe coronavirus', 'venous observe covid-19', 'thrombosis observe chadox1', 'thrombosis observe ncov-19', 'thrombosis observe adenoviral', 'thrombosis observe vaccine', 'thrombosis observe coronavirus', 'thrombosis observe covid-19']",1910,continued evaluation long-term outcomes warranted 
730,179.0,3.0,"['woman receive axillary', 'woman receive lymphadenopathy', 'woman receive malignancy', 'covid-19 receive axillary', 'covid-19 receive lymphadenopathy', 'covid-19 receive malignancy']",1914,five cases occurred population 130000 vaccinated persons propose represent rare vaccine-related variant spontaneous heparin-induced thrombocytopenia refer vaccine-induced immune thrombotic thrombocytopenia 
731,180.0,0.0,"['axillary display mammogram', 'axillary display woman', 'axillary display pfizer-biontech', 'axillary display covid-19', 'axillary display vaccine', 'axillary display woman', 'lymphadenopathy display mammogram', 'lymphadenopathy display woman', 'lymphadenopathy display pfizer-biontech', 'lymphadenopathy display covid-19', 'lymphadenopathy display vaccine', 'lymphadenopathy display woman', 'axillary appear vaccine', 'axillary appear woman', 'lymphadenopathy appear vaccine', 'lymphadenopathy appear woman', 'mammogram appear vaccine', 'mammogram appear woman', 'woman appear vaccine', 'pfizer-biontech appear vaccine', 'pfizer-biontech appear woman', 'axillary screen pfizer-biontech', 'axillary screen covid-19', 'axillary screen vaccine', 'axillary screen woman', 'lymphadenopathy screen pfizer-biontech', 'lymphadenopathy screen covid-19', 'lymphadenopathy screen vaccine', 'lymphadenopathy screen woman', 'mammogram screen pfizer-biontech', 'mammogram screen covid-19', 'mammogram screen vaccine', 'mammogram screen woman', 'woman screen pfizer-biontech', 'woman screen covid-19', 'woman screen vaccine']",1915,background women received covid-19 vaccination may display subclinical unilateral axillary lymphadenopathy screening mammography appear suspicious malignancy leading additional diagnostic evaluation 
732,180.0,4.0,"['woman retrieve n15', 'woman retrieve 349', 'woman retrieve 209', 'covid-19 retrieve n15', 'covid-19 retrieve 349', 'covid-19 retrieve 209', 'slad retrieve n15', 'slad retrieve 349', 'slad retrieve 209', 'n19 retrieve n15', 'n19 retrieve 349', 'n19 retrieve 209']",1919,results 1027 women 43 recalled unilateral slad 
733,180.0,7.0,"['vaccine receive 637', 'vaccine receive 597']",1922,132 patients received pfizer vaccine 95 patients received moderna vaccine developed slad 
734,180.0,8.0,"['vaccine elicit 465', 'vaccine elicit covid-19', 'vaccine elicit p044', 'slad elicit 465', 'slad elicit covid-19', 'slad elicit vaccine', 'slad elicit p044']",1923,moderna s vaccine elicited robust reaction elderly moderna 637 years vs pfizer 597 years 
735,180.0,9.0,"['woman resolve vaccine', 'mrna resolve vaccine']",1924,vaccines slad resolved average 465 days last covid-19 vaccine p044 
736,180.0,11.0,"['lad elicit covid-19', 'lad elicit axillary', 'lad elicit lymphadenopathy', 'lad elicit woman', 'lad elicit vaccine', 'lymphadenopathy elicit covid-19', 'lymphadenopathy elicit axillary', 'lymphadenopathy elicit woman', 'lymphadenopathy elicit vaccine', 'lymphadenopathy elicit covid-19', 'lymphadenopathy elicit axillary', 'lymphadenopathy elicit woman', 'lymphadenopathy elicit vaccine', 'mammogram elicit covid-19', 'mammogram elicit axillary', 'mammogram elicit lymphadenopathy', 'mammogram elicit woman', 'mammogram elicit vaccine', 'summary elicit covid-19', 'summary elicit axillary', 'summary elicit lymphadenopathy', 'summary elicit woman', 'summary elicit vaccine']",1926,pfizer may overall robust immune response moderna may elicit stronger immune response elderly women 
737,180.0,14.0,"['lymphadenopathy receive 507', 'lymphadenopathy receive 415', 'mammogram receive 507', 'mammogram receive 415', '465 receive 507', '465 receive 415', 'lymphadenopathy induce 415', 'mammogram induce 415', '465 induce 415']",1929,12 receive vaccine presented subclinical unilateral axillary lymphadenopathy 
738,181.0,1.0,"['body observe kidney disease', 'body observe ckd', 'body observe covid-19']",1932,although adverse reactions observed mild emergence serious vaccine-associated adverse events closely monitored 
739,182.0,1.0,"['large-scale prevent patient', 'large-scale prevent ckd', 'large-scale prevent uraemia', 'large-scale prevent cdk', 'large-scale prevent patient', 'herd prevent patient', 'herd prevent ckd', 'herd prevent uraemia', 'herd prevent cdk', 'herd prevent patient', 'immunity prevent patient', 'immunity prevent ckd', 'immunity prevent uraemia', 'immunity prevent cdk', 'immunity prevent patient', 'large-scale reduce uraemia', 'large-scale reduce cdk', 'large-scale reduce patient', 'herd reduce uraemia', 'herd reduce cdk', 'herd reduce patient', 'immunity reduce uraemia', 'immunity reduce cdk', 'immunity reduce patient', 'patient reduce uraemia', 'patient reduce cdk', 'ckd reduce uraemia', 'ckd reduce cdk', 'ckd reduce patient']",1934,preventive measures rapid monitoring organ function interventions capable preventing multiorgan failures great importance reduce adverse outcomes covid-19 patients ckd 
740,183.0,0.0,"['human milk receive san diego', 'woman receive san diego', 'two receive san diego', 'mrna receive san diego', 'vaccine receive san diego']",1938,background december 2020 two novel messenger rna mrna vaccines severe acute respiratory syndrome coronavirus-2 received emergency use authorization us food drug administration however early trials excluded lactating women 
741,183.0,1.0,"['180 receive mrna', '180 receive vaccine', 'woman receive mrna', 'woman receive vaccine', 'two receive mrna', 'two receive vaccine']",1939,methods breastfeeding women residing united states received either two mrna vaccines enrolled mommy s milk human milk research biorepository university california san diego 
742,183.0,5.0,"['woman receive milk', 'woman receive second', 'woman receive moderna', 'first receive woman', 'first receive milk', 'first receive second', 'first receive moderna', 'vaccine receive woman', 'vaccine receive milk', 'vaccine receive second', 'vaccine receive moderna']",1943,however following second dose vaccine women received moderna brand significantly likely report symptoms 
743,183.0,7.0,"['woman follow mrna', 'woman follow covid-19', 'woman follow vaccine', 'woman dose covid-19', 'woman dose vaccine', 'child dose covid-19', 'child dose vaccine']",1945,infant events reported either vaccine brand following either dose serious adverse events reported 
744,183.0,8.0,"['steer consider 271', 'steer consider bovine', 'steer consider herpesvirus', 'steer consider bovine', 'steer consider parainfluenza', 'steer consider coronavirus', 'steer consider vaccine', 'steer lactate bovine', 'steer lactate herpesvirus', 'steer lactate bovine', 'steer lactate parainfluenza', 'steer lactate coronavirus', 'steer lactate vaccine', 'calf lactate bovine', 'calf lactate herpesvirus', 'calf lactate bovine', 'calf lactate parainfluenza', 'calf lactate coronavirus', 'calf lactate vaccine', '271 lactate bovine', '271 lactate herpesvirus', '271 lactate bovine', '271 lactate parainfluenza', '271 lactate coronavirus', '271 lactate vaccine']",1946,conclusions data reassuring regarding safety vaccination breastfeeding women breastfed children either mrna covid-19 vaccines 
745,184.0,0.0,"['saline use 136', '135 use 136']",1947,abruptly weaned crossbred steer calves n 271 used randomized blinded 2-arm clinical trial assess impact long-acting non-steroidal anti-inflammatory drug bovine herpesvirus type 1 bovine respiratory syncytial virus parainfluenza virus type 3 coronavirus titers health outcomes administered concurrently modified live respiratory vaccine upon arrival feedlot 
746,184.0,3.0,['meloxicam associate vaccine'],1950,interestingly use meloxicam associated increased treatment risk p 005 
747,185.0,1.0,"['patient repeat sars-cov-2', 'patient repeat pakistan']",1953,report case series repeated infections sars-cov-2 
748,185.0,7.0,['covid-19 vaccinate sars-cov-2'],1959,none vaccinated 
749,186.0,3.0,"['adult induce child', 'adult induce vaccine', 'adult induce adr', 'adult induce aes']",1964,methods passive enhanced safety surveillance study conducted belgium germany spain 
750,186.0,4.0,"['1082 receive two', 'participant receive two', 'gsk receive two', '115 receive two', 'child receive two']",1965,adults received gsk s iiv4 parent guardian legally acceptable representative children given vaccine invited complete adverse drug reaction adr card document aes experienced within 7 days post vaccination 
751,186.0,5.0,"['970 receive participant', '970 receive belgium', '970 receive germany', '970 receive adult', '100 receive participant', '100 receive belgium', '100 receive germany', '100 receive adult', '115 receive participant', '115 receive belgium', '115 receive germany', '115 receive adult']",1966,results total 1082 participants 516 females received gsk s iiv4 including 115 children 9 years age received two doses 
752,186.0,8.0,['aes report gdasc'],1969,dose 1 392 reported one ae 
753,186.0,15.0,"['mumps observe child', 'mumps observe one-dose', 'mumps observe measles-mumps-rubella', 'vaccine-preventable observe mumps', 'vaccine-preventable observe child', 'vaccine-preventable observe one-dose', 'vaccine-preventable observe measles-mumps-rubella', 'mumps observe child', 'mumps observe one-dose', 'mumps observe measles-mumps-rubella']",1976,supplementary information online version contains supplementary material available 101007s40264-021-01121-8 
754,187.0,0.0,"['mumps-containing cause mumps', 'mumps-containing cause cox-proportional', 'vaccine cause mumps', 'vaccine cause cox-proportional']",1977,mumps vaccine-preventable disease caused mumps virus incidence mumps increased among children vaccinated one-dose measles-mumps-rubella mmr recent years 
755,187.0,1.0,"['909 test mucv', '909 test quzhou', 'mumps test mucv', 'mumps test quzhou', 'child test mucv', 'child test quzhou']",1978,study analyzed influence different doses mumps-containing vaccine mucv mumps using cox-proportional hazard model 
756,187.0,2.0,['kaplan-meier collect cox-proportional'],1979,collected 909 mumps cases children born 2006 2010 vaccinated different doses mucv quzhou 2006-2018 clinically diagnosed 
757,187.0,5.0,"['mumps induce china', 'mumps induce china']",1982,cox-proportional hazard regression suggested onset sia born 2006 vaccinated two-dose mucv protective factors infection even adjusting potential confounding effects 
758,187.0,6.0,"['two revise immunization', 'mmr revise immunization']",1983,study showed necessary revise diagnostic criteria mumps identify rt-pcr standard mumps diagnosis china 
759,187.0,7.0,"['covid-19 perform greek', 'covid-19 perform patient', 'covid-19 perform 512', 'covid-19 perform patient', 'covid-19 perform greece', 'covid-19 perform patient', 'covid-19 perform influenza', 'covid-19 perform death', 'covid-19 perform patient', 'covid-19 perform patient', 'covid-19 perform hypertension', 'covid-19 perform gastrointestinal', 'death perform greek', 'death perform covid-19', 'death perform patient', 'death perform 512', 'death perform covid-19', 'death perform patient', 'death perform greece', 'death perform patient', 'death perform influenza', 'death perform patient', 'death perform patient', 'death perform hypertension', 'death perform gastrointestinal', 'covid-19 introduce death', 'covid-19 introduce infection', 'covid-19 introduce greek', 'covid-19 introduce patient', 'covid-19 introduce 512', 'covid-19 introduce patient', 'covid-19 introduce greece', 'covid-19 introduce patient', 'covid-19 introduce influenza', 'covid-19 introduce death', 'covid-19 introduce patient', 'covid-19 introduce patient', 'covid-19 introduce hypertension', 'covid-19 introduce gastrointestinal']",1984,suggested routine immunization schedule introduce two doses mmr prevaccination screening performed booster immunization vaccinated populations 
760,188.0,0.0,"['cellular circulate hiv-1', 'cellular circulate vaccine', 'mucosal circulate hiv-1', 'mucosal circulate vaccine', 'immunity circulate hiv-1', 'immunity circulate vaccine']",1985,background epidemic covid-19 rapidly spread worldwide millions confirmed cases related deaths numerous efforts made clarify infection progresses potential factors associated disease severity mortality investigated mortality greek hospitalized covid-19 patients also predictors mortality objective importantly may assist implementation efficient protective measures public healthcare policies methodology study population included 512 covid-19 patients admitted hospitals attica region greece patients demographic characteristics comorbidities allergies previous vaccination seasonal influenza virus admission icu intubation death recorded potential predictors in-hospital mortality identified regression analysis results mean age hospitalized patients 60 4 years higher patients deceased common comorbidities respiratory diseases hypertension gastrointestinal disorders dyslipidemia mental health diseases asthma diabetes mellitus cardiovascular diseases need icu care intubation significantly higher among patients died mortality rate 15 8 81 512 age gt 65 years cancer chronic kidney disease endocrine diseases central nervous system disorders anemia intubation independently associated increased in-hospital mortality allergies previous influenza vaccination associated decreased in-hospital mortality conclusion finding beneficial effect allergies influenza vaccination covid-19 infection merits investigation may shed light mechanisms underlying disease progression severity
761,189.0,1.0,"['fowl test fpv', 'fowl test pol', 'fowl test antagonist', 'pox test fpv', 'pox test pol', 'pox test antagonist']",1987, tested vaccine regimen pigtail macaques using intranasal in 
762,189.0,4.0,"['booster observe cellular', 'booster observe hiv-specific', 'booster observe cellular', 'gp140-specific observe cellular', 'gp140-specific observe hiv-specific', 'gp140-specific observe cellular', 'igg observe cellular', 'igg observe hiv-specific', 'igg observe cellular', 'adcc antibody-dependent aim hiv-specific', 'adcc antibody-dependent aim cellular', 'booster aim hiv-specific', 'booster aim cellular', 'gp140-specific aim hiv-specific', 'gp140-specific aim cellular', 'igg aim hiv-specific', 'igg aim cellular', 'cellular aim hiv-specific']",1990,viral vectorÃÂÂexpressed il-4r antagonist transiently inhibited il-4il-13 signalling vaccination site 
763,189.0,7.0,"['cd8 cells associate mucosal', 'cd4 associate mucosal']",1993,systemic compartment elevated granzyme k expression linked cd4 cells whilst granzyme btia-1 cd8 cells 
764,189.0,8.0,"['mucosal match antibody', 'mucosal match blood', 'mucosal match hiv-1', 'antagonistsosip match antibody', 'antagonistsosip match blood', 'antagonistsosip match mucosal', 'antagonistsosip match hiv-1', 'mucosal match antibody', 'mucosal match blood', 'mucosal match hiv-1', 'cd4 match antibody', 'cd4 match blood', 'cd4 match mucosal', 'cd4 match hiv-1', 'line match antibody', 'line match blood', 'line match mucosal', 'line match hiv-1', 'cd4 match antibody', 'cd4 match blood', 'cd4 match mucosal', 'cd4 match hiv-1']",1994,contrast cytotoxic marker expression mucosal cd4 cd8 cells differed according mucosal compartment 
765,190.0,6.0,"['115 deem 113', '115 deem 108', '115 deem participant', '115 deem two', '115 deem participant', '115 deem n35', '115 deem n2', '115 deem n2', '115 follow n35', '115 follow n2', '115 follow n2', '113 follow n35', '113 follow n2', '113 follow n2', '108 follow n35', '108 follow n2', '108 follow n2', 'participant follow n35', 'participant follow n2', 'participant follow n2', 'two follow n35', 'two follow n2', 'two follow n2']",2002,results lfia deemed suitable clinical advice decision making following evaluation 310 serum samples sars-cov-2 pcr positive patients 300 pre-pandemic samples giving sensitivity specificity 961 993 respectively 
766,190.0,9.0,"['pims-ts activate n40', 'pims-ts activate sars-cov-2', 'pulmonary activate n40', 'pulmonary activate sars-cov-2', 'n5 activate n40', 'n5 activate sars-cov-2']",2005,three main indications serology new acute presentations potentially triggered recent covid-19 infection eg 
767,190.0,10.0,"['sars-cov-2 make adult', 'sars-cov-2 make child']",2006,pims-ts n26 pulmonary embolism n5 potential missed diagnoses context recent compatible illness n40 making infection control immunosuppression treatment decisions persistently sars-cov-2 rna pcr positive individuals n6 
768,190.0,14.0,"['antibody exist first-wave', 'infection exist first-wave']",2010,experience thus far volume requests hospital referral routes manageable within existing clinical laboratory services however demand community referrals yet assessed 
769,190.0,15.0,"['nh follow infection', 'nh follow patient', 'patient follow infection']",2011,given recent evidence rapid decline antibodies particularly following mild infection likely limited window opportunity realise benefit serology testing individuals infected first-wave potentially fall measurable threshold 
770,190.0,16.0,"['cattle receive high-throughput', 'infection receive high-throughput', 'immunopathology receive high-throughput']",2012,rapidly expanding availability serology services nhs patients also help understand long-term implications serostatus prior infection different patient groups particularly emergence second-wave outbreak introduction vaccination programme 
771,191.0,1.0,['cell use cattle'],2014,report longitudinal innate immune response profiles cattle using low-blood volume whole blood stimulation systemÃÂÂthe immunochek ichek assay 
772,191.0,2.0,"['cytokine enable r848', 'cytokine enable pamps', 'il-1Ã\x83\x83Ã\x83\x82Ã\x82Â² enable r848', 'il-1Ã\x83\x83Ã\x83\x82Ã\x82Â² enable pamps', 'il-6 enable r848', 'il-6 enable pamps', 'chemokine enable r848', 'chemokine enable pamps', 'il-8 enable r848', 'il-8 enable pamps']",2015,minimizing cell manipulation standardized system minimizes potential artefactual results enables repeatable temporal comparative analysis cattle 
773,191.0,5.0,"['monocyte match r848', 'il-6 match r848', 'neutrophil match r848', 'cytokine match r848']",2018,correlation coefficients immune response read-outs il-1ÃÂ² il-6 il-8 varied according pamp 
774,191.0,7.0,"['dna-primehuman receive malaria infection', 'dna-primehuman receive cd8 cell', 'dna-primehuman receive membrane', 'dna-primehuman receive antigen-1', 'dna-primehuman receive pfama1', 'dna-primehuman receive 415', 'dna-primehuman receive chmi', 'adenovirus receive malaria infection', 'adenovirus receive cd8 cell', 'adenovirus receive membrane', 'adenovirus receive antigen-1', 'adenovirus receive pfama1', 'adenovirus receive 415', 'adenovirus receive chmi', 'huad5 receive malaria infection', 'huad5 receive cd8 cell', 'huad5 receive membrane', 'huad5 receive antigen-1', 'huad5 receive pfama1', 'huad5 receive 415', 'huad5 receive chmi', 'boost receive malaria infection', 'boost receive cd8 cell', 'boost receive membrane', 'boost receive antigen-1', 'boost receive pfama1', 'boost receive 415', 'boost receive chmi', 'vaccine receive malaria infection', 'vaccine receive cd8 cell', 'vaccine receive membrane', 'vaccine receive antigen-1', 'vaccine receive pfama1', 'vaccine receive 415', 'vaccine receive chmi', 'plasmodium receive malaria infection', 'plasmodium receive cd8 cell', 'plasmodium receive membrane', 'plasmodium receive antigen-1', 'plasmodium receive pfama1', 'plasmodium receive 415', 'plasmodium receive chmi', 'dna-primehuman associate malaria infection', 'dna-primehuman associate cd8 cell', 'dna-primehuman associate membrane', 'dna-primehuman associate antigen-1', 'dna-primehuman associate pfama1', 'dna-primehuman associate 415', 'dna-primehuman associate chmi', 'adenovirus associate malaria infection', 'adenovirus associate cd8 cell', 'adenovirus associate membrane', 'adenovirus associate antigen-1', 'adenovirus associate pfama1', 'adenovirus associate 415', 'adenovirus associate chmi', 'huad5 associate malaria infection', 'huad5 associate cd8 cell', 'huad5 associate membrane', 'huad5 associate antigen-1', 'huad5 associate pfama1', 'huad5 associate 415', 'huad5 associate chmi', 'boost associate malaria infection', 'boost associate cd8 cell', 'boost associate membrane', 'boost associate antigen-1', 'boost associate pfama1', 'boost associate 415', 'boost associate chmi', 'vaccine associate malaria infection', 'vaccine associate cd8 cell', 'vaccine associate membrane', 'vaccine associate antigen-1', 'vaccine associate pfama1', 'vaccine associate 415', 'vaccine associate chmi', 'plasmodium associate malaria infection', 'plasmodium associate cd8 cell', 'plasmodium associate membrane', 'plasmodium associate antigen-1', 'plasmodium associate pfama1', 'plasmodium associate 415', 'plasmodium associate chmi']",2020,standardized assay facilitates high-throughput bovine innate immune response profiling identify phenotypes associated disease susceptibility responses vaccination 
775,192.0,1.0,"['huad5 exist two-antigen', 'huad5 exist ama1', 'huad5 exist vaccine', 'huad5 exist three-antigen', 'huad5 exist ama1', 'huad5 exist cat', 'huad5 exist vaccine', 'huad5 exist antigen', 'huad5 exist malaria', 'huad5 exist epitope', 'huad5 exist trap', 'chimpanzee exist two-antigen', 'chimpanzee exist ama1', 'chimpanzee exist vaccine', 'chimpanzee exist three-antigen', 'chimpanzee exist ama1', 'chimpanzee exist cat', 'chimpanzee exist vaccine', 'chimpanzee exist antigen', 'chimpanzee exist malaria', 'chimpanzee exist epitope', 'chimpanzee exist trap', 'adenovirus exist two-antigen', 'adenovirus exist ama1', 'adenovirus exist vaccine', 'adenovirus exist three-antigen', 'adenovirus exist ama1', 'adenovirus exist cat', 'adenovirus exist vaccine', 'adenovirus exist antigen', 'adenovirus exist malaria', 'adenovirus exist epitope', 'adenovirus exist trap', 'chad63 exist two-antigen', 'chad63 exist ama1', 'chad63 exist vaccine', 'chad63 exist three-antigen', 'chad63 exist ama1', 'chad63 exist cat', 'chad63 exist vaccine', 'chad63 exist antigen', 'chad63 exist malaria', 'chad63 exist epitope', 'chad63 exist trap', 'huad5 protect vaccine', 'huad5 protect three-antigen', 'huad5 protect ama1', 'huad5 protect cat', 'huad5 protect vaccine', 'huad5 protect antigen', 'huad5 protect malaria', 'huad5 protect epitope', 'huad5 protect trap', 'chimpanzee protect vaccine', 'chimpanzee protect three-antigen', 'chimpanzee protect ama1', 'chimpanzee protect cat', 'chimpanzee protect vaccine', 'chimpanzee protect antigen', 'chimpanzee protect malaria', 'chimpanzee protect epitope', 'chimpanzee protect trap', 'adenovirus protect vaccine', 'adenovirus protect three-antigen', 'adenovirus protect ama1', 'adenovirus protect cat', 'adenovirus protect vaccine', 'adenovirus protect antigen', 'adenovirus protect malaria', 'adenovirus protect epitope', 'adenovirus protect trap', 'chad63 protect vaccine', 'chad63 protect three-antigen', 'chad63 protect ama1', 'chad63 protect cat', 'chad63 protect vaccine', 'chad63 protect antigen', 'chad63 protect malaria', 'chad63 protect epitope', 'chad63 protect trap', 'two-antigen protect vaccine', 'two-antigen protect three-antigen', 'two-antigen protect ama1', 'two-antigen protect cat', 'two-antigen protect vaccine', 'two-antigen protect antigen', 'two-antigen protect malaria', 'two-antigen protect epitope', 'two-antigen protect trap', 'ama1 protect vaccine', 'ama1 protect three-antigen', 'ama1 protect cat', 'ama1 protect vaccine', 'ama1 protect antigen', 'ama1 protect malaria', 'ama1 protect epitope', 'ama1 protect trap', 'huad5 induce three-antigen', 'huad5 induce ama1', 'huad5 induce cat', 'huad5 induce vaccine', 'huad5 induce antigen', 'huad5 induce malaria', 'huad5 induce epitope', 'huad5 induce trap', 'chimpanzee induce three-antigen', 'chimpanzee induce ama1', 'chimpanzee induce cat', 'chimpanzee induce vaccine', 'chimpanzee induce antigen', 'chimpanzee induce malaria', 'chimpanzee induce epitope', 'chimpanzee induce trap', 'adenovirus induce three-antigen', 'adenovirus induce ama1', 'adenovirus induce cat', 'adenovirus induce vaccine', 'adenovirus induce antigen', 'adenovirus induce malaria', 'adenovirus induce epitope', 'adenovirus induce trap', 'chad63 induce three-antigen', 'chad63 induce ama1', 'chad63 induce cat', 'chad63 induce vaccine', 'chad63 induce antigen', 'chad63 induce malaria', 'chad63 induce epitope', 'chad63 induce trap', 'two-antigen induce three-antigen', 'two-antigen induce ama1', 'two-antigen induce cat', 'two-antigen induce vaccine', 'two-antigen induce antigen', 'two-antigen induce malaria', 'two-antigen induce epitope', 'two-antigen induce trap', 'ama1 induce three-antigen', 'ama1 induce cat', 'ama1 induce vaccine', 'ama1 induce antigen', 'ama1 induce malaria', 'ama1 induce epitope', 'ama1 induce trap', 'vaccine induce three-antigen', 'vaccine induce ama1', 'vaccine induce cat', 'vaccine induce antigen', 'vaccine induce malaria', 'vaccine induce epitope', 'vaccine induce trap']",2022,subjects high level pre-existing immunity huad5 protected suggesting adverse effect vaccine efficacy 
776,192.0,3.0,"['cat evaluate chad63', 'cat evaluate boost']",2024,methodology open label randomized phase 1 trial assessing safety tolerability chmi healthy malaria naÃÂve adults 
777,192.0,4.0,"['four receive mosquito', 'four receive pf3d7', 'boost receive mosquito', 'boost receive pf3d7']",2025,forty subjects 20 group receive three monthly ca cat dna priming immunizations followed corresponding chad63 boost four months later 
778,192.0,5.0,"['parasitemia vaccinate blood', 'parasitemia vaccinate cochran-mantel-haenszel', 'parasitemia use cochran-mantel-haenszel', 'blood use cochran-mantel-haenszel']",2026,four weeks boost immunized subjects 12 infectivity controls underwent chmi mosquito bite using pf3d7 strain 
779,192.0,8.0,"['938 develop parasitemia', '938 develop 120', '938 indicate 120']",2029,eleven 12 infectivity controls developed parasitemia mean 117 days 
780,192.0,11.0,"['cat compare cellular', 'cat compare ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'cat compare fluorospot', 'cat compare ama1', 'cat compare trap', 'vaccine compare cellular', 'vaccine compare ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'vaccine compare fluorospot', 'vaccine compare ama1', 'vaccine compare trap', 'elisa compare cellular', 'elisa compare ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'elisa compare fluorospot', 'elisa compare ama1', 'elisa compare trap', 'antibody compare cellular', 'antibody compare ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'antibody compare fluorospot', 'antibody compare ama1', 'antibody compare trap', 'ama1 compare cellular', 'ama1 compare ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'ama1 compare fluorospot', 'ama1 compare trap', 'trap compare cellular', 'trap compare ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'trap compare fluorospot', 'trap compare ama1', 'sporozoite compare cellular', 'sporozoite compare ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'sporozoite compare fluorospot', 'sporozoite compare ama1', 'sporozoite compare trap', 'pf3d7 compare cellular', 'pf3d7 compare ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'pf3d7 compare fluorospot', 'pf3d7 compare ama1', 'pf3d7 compare trap']",2032, 1 minus risk ratio cat group 25 compared -2 ca group 
781,192.0,12.0,"['chad63 induce antigen', 'chad63 induce two-antigen', 'cat induce antigen', 'cat induce two-antigen']",2033,ca cat vaccines induced robust humoral elisa antibodies csp ama1 trap ifa responses sporozoites pf3d7 blood stages cellular responses ifn-ÃÂ³ fluorospot responses csp ama1 trap associated protection 
782,192.0,13.0,"['chad63-cat afford ama1', 'vaccine afford ama1', 'aes afford ama1', 'vaccine afford ama1', 'huad5 afford ama1', 'malaria afford ama1', 'vaccine afford ama1', 'chad63-cat show aes', 'chad63-cat show vaccine', 'chad63-cat show huad5', 'chad63-cat show malaria', 'chad63-cat show vaccine', 'chad63-cat show csp', 'chad63-cat show ama1', 'vaccine show aes', 'vaccine show huad5', 'vaccine show malaria', 'vaccine show csp', 'vaccine show ama1', 'chad63-cat show huad5', 'chad63-cat show malaria', 'chad63-cat show vaccine', 'chad63-cat show csp', 'chad63-cat show ama1', 'vaccine show huad5', 'vaccine show malaria', 'vaccine show csp', 'vaccine show ama1', 'aes show huad5', 'aes show malaria', 'aes show vaccine', 'aes show csp', 'aes show ama1', 'chad63-cat confirm csp', 'chad63-cat confirm ama1', 'vaccine confirm csp', 'vaccine confirm ama1', 'aes confirm csp', 'aes confirm ama1', 'vaccine confirm csp', 'vaccine confirm ama1', 'huad5 confirm csp', 'huad5 confirm ama1', 'malaria confirm csp', 'malaria confirm ama1']",2034,conclusions study demonstrated chad63 cat vaccine exhibited significant protective efficacy confirmed protection afforded adding third antigen two-antigen ca formulation achieve increased 
783,193.0,2.0,"['cross-sectional aim two', 'cross-sectional aim sindh', 'cross-sectional aim pakistan', 'cross-sectional observe sindh', 'cross-sectional observe pakistan']",2038,study aims determine association prior pulmonary tuberculosis covid-19 pneumonia 
784,193.0,3.0,"['521 induce covid-19', 'hrct induce covid-19', 'chest induce covid-19']",2039,methods cross-sectional study conducted two centres sindh pakistan 
785,193.0,4.0,"['761 include tuberculosis', 'hrct include tuberculosis', 'chest include tuberculosis', 'six include tuberculosis', '761 perform six', '761 perform tuberculosis', 'hrct perform six', 'hrct perform tuberculosis', 'chest perform six', 'chest perform tuberculosis']",2040,521 hrct chest performed 1st may 31st july 2020 included marked covid-19 group 
786,193.0,5.0,"['pulmonary perform att', 'tuberculosis perform att']",2041,761 hrct chest performed first six months 2019 retrospectively evaluated determine prevalence prior pulmonary tuberculosis marked pre-covid-19 group 
787,193.0,6.0,"['chi-square document pulmonary', 'chi-square document tuberculosis', 'chi-square document covid-19', 'chi-square document pneumonia', 'chi-square show tuberculosis', 'chi-square show covid-19', 'chi-square show pneumonia']",2042,previous pulmonary tuberculosis documented evidenced clinical history att intake hrct findings 
788,193.0,8.0,"['covid-19 consider pulmonary', 'covid-19 consider tuberculosis', 'patient consider pulmonary', 'patient consider tuberculosis']",2044,p-value ÃÂÂ001 considered statistically significant 
789,193.0,11.0,"['pulmonary induce pneumonia', 'pulmonary induce antibody', 'pulmonary induce tuberculosis', 'pulmonary induce bcg', 'tuberculosis induce pneumonia', 'tuberculosis induce antibody', 'tuberculosis induce bcg']",2047,significant p-value 0001 obtained confidence interval 99 
790,194.0,4.0,"['2015-2019 circulate ci', '2015-2019 circulate 861', '2015-2019 circulate 875', '2015-2019 circulate thrombosis', '2015-2019 circulate 637100000', '2015-2019 circulate embolism', '2015-2019 circulate idiopathic', '2015-2019 circulate thrombocytopenia', '2015-2019 circulate 16100000', '2015-2019 circulate 15100000', '223 circulate ci', '223 circulate 861', '223 circulate 875', '223 circulate thrombosis', '223 circulate 637100000', '223 circulate embolism', '223 circulate idiopathic', '223 circulate thrombocytopenia', '223 circulate 16100000', '223 circulate 15100000', 'intracerebral haemorrhage average embolism', 'intracerebral haemorrhage average idiopathic', 'intracerebral haemorrhage average thrombocytopenia', 'intracerebral haemorrhage average 16100000', 'intracerebral haemorrhage average 15100000', '2015-2019 average embolism', '2015-2019 average idiopathic', '2015-2019 average thrombocytopenia', '2015-2019 average 16100000', '2015-2019 average 15100000', '223 average embolism', '223 average idiopathic', '223 average thrombocytopenia', '223 average 16100000', '223 average 15100000', 'ci average embolism', 'ci average idiopathic', 'ci average thrombocytopenia', 'ci average 16100000', 'ci average 15100000', '861 average embolism', '861 average idiopathic', '861 average thrombocytopenia', '861 average 16100000', '861 average 15100000', '875 average embolism', '875 average idiopathic', '875 average thrombocytopenia', '875 average 16100000', '875 average 15100000', 'thrombosis average embolism', 'thrombosis average idiopathic', 'thrombosis average thrombocytopenia', 'thrombosis average 16100000', 'thrombosis average 15100000', '637100000 average embolism', '637100000 average idiopathic', '637100000 average thrombocytopenia', '637100000 average 16100000', '637100000 average 15100000']",2054,primary outcome measures incidence rates stroke deep vein thrombosis pulmonary embolism idiopathic thrombocytopenia disseminated intravascular coagulation cerebral venous thrombosis five pre-pandemic years 2015-2019 annually averaged monthly average 2020 results average annual population 14 million 51 female 
791,194.0,9.0,"['aplastic aim stem cells', 'aplastic aim anemia', 'aplastic aim defect', 'anemia aim stem cells', 'anemia aim defect', 'aplastic serve stem cells', 'aplastic serve defect', 'anemia serve stem cells', 'anemia serve defect', 'anemia serve stem cells', 'anemia serve defect']",2059,conclusions estimated background rates help contextualize observed events potential adverse events special interest detect potential safety signals related covid-19 vaccines 
792,195.0,3.0,"['covid-19 induce thrombocytopenia', 'covid-19 induce agranulocytosis', 'covid-19 induce monocytopenia']",2063,infection covid-19 expected patient developed fever respiratory manifestations leukopenia lymphopenia together history suggestive exposure infection 
793,195.0,11.0,"['vaccine-induced induce sars-cov-2', 'immunity induce sars-cov-2']",2071,conclusion study proposed next step combating covid-19 infection mass survey high risk people application specific precautions perhaps could candidate future vaccine prophylactic treatment 
794,196.0,0.0,['sars-cov-2 induce immunity'],2072,background natural vaccine-induced immunity play key role controlling sars-cov-2 pandemic 
795,196.0,1.0,"['cohort induce sars-cov-2', 'cohort induce infection', 'cohort induce bnt162b2', 'cohort induce chadox1', 'cohort induce ncov-19', 'worker induce sars-cov-2', 'worker induce infection', 'worker induce bnt162b2', 'worker induce chadox1', 'worker induce ncov-19', 'hcws induce sars-cov-2', 'hcws induce infection', 'hcws induce bnt162b2', 'hcws induce chadox1', 'hcws induce ncov-19', 'oxfordshire induce sars-cov-2', 'oxfordshire induce infection', 'oxfordshire induce bnt162b2', 'oxfordshire induce chadox1', 'oxfordshire induce ncov-19', 'uk induce sars-cov-2', 'uk induce infection', 'uk induce bnt162b2', 'uk induce chadox1', 'uk induce ncov-19']",2073,sars-cov-2 variants potential evade natural vaccine-induced immunity 
796,196.0,3.0,"['hcws confer vaccine 1407', 'hcws confer 8285', 'hcws confer two', 'hcws confer 2738', 'hcws confer vaccine', 'hcws confer two']",2075,estimated protection conferred one versus two vaccinations infections b117 variant identified using whole genome sequencing 
797,196.0,4.0,"['hcws receive hcw', 'immunity receive hcw', 'immunity receive hcws']",2076,results 13109 hcws participated 8285 received pfizer-biontech vaccine 1407 two doses 2738 oxford-astrazeneca vaccine 49 two doses 
798,196.0,5.0,"['two provide 015', 'vaccine provide 015', 'pcr-positive provide 015', 'symptom provide 015', '010 provide 015']",2077,compared unvaccinated seronegative hcws natural immunity two vaccination doses provided similar protection symptomatic infection hcw vaccinated twice symptomatic infection incidence 98 lower seropositive hcws adjusted incidence rate ratio 002 95 ci 001-018 
799,196.0,8.0,"['infection induce sars-cov-2', 'antibody induce sars-cov-2', 'antibody induce infection', 'two induce sars-cov-2', 'two induce infection']",2080,evidence differences immunity induced natural infection vaccination infections s-gene target failure b117 
800,197.0,0.0,"['patient provide 487', 'patient provide child', 'patient provide ukraine', 'artis provide 487', 'artis provide child', 'artis provide ukraine']",2082,objective aim provide data presence potential pathogens artis children ukraine 
801,197.0,1.0,"['seven investigate adv', 'seven investigate metapneumovirus', 'seven investigate mpv', 'seven investigate rhinovirus', 'seven investigate bocavirus', 'seven investigate coronavirus', 'seven investigate cov', 'rsv investigate adv', 'rsv investigate metapneumovirus', 'rsv investigate mpv', 'rsv investigate rhinovirus', 'rsv investigate bocavirus', 'rsv investigate coronavirus', 'rsv investigate cov', 'parainfluenza investigate adv', 'parainfluenza investigate metapneumovirus', 'parainfluenza investigate mpv', 'parainfluenza investigate rhinovirus', 'parainfluenza investigate bocavirus', 'parainfluenza investigate coronavirus', 'parainfluenza investigate cov']",2083,patients methods materials methods etiology artis investigated 487 children mc eurolab kyiv ukraine 2018-2020 years 
802,197.0,5.0,"['400 collect child', '400 collect influenza', '400 collect strep', '821 collect child', '821 collect influenza', '821 collect strep', '319 collect child', '319 collect influenza', '319 collect strep', 'swab collect child', 'swab collect influenza', 'swab collect strep', 'one collect child', 'one collect influenza', 'one collect strep']",2087,results results 487 nasal throat swabs children arvi collected 
803,197.0,7.0,"['271 receive iva', '271 receive 107', 'adv receive iva', 'adv receive 107', '134 receive iva', '134 receive 107', 'rsv receive iva', 'rsv receive 107']",2089,total 403 viruses identified 
804,198.0,2.0,"['igg receive memory', 'iga receive memory', 'igg show memory', 'iga show memory']",2094,vast majority covid-19 recovered individuals showed sars-cov-2 rbd-specific igg iga igm antibodies 3842 9047 2142 50 3342 7857 respectively half appreciable neutralizing antibody titers 
805,198.0,3.0,"['donor correlate antibody', 'donor correlate india', 'plasma correlate antibody', 'plasma correlate india', 'igg correlate antibody', 'igg correlate india', 'donor neutralize antibody', 'donor neutralize india', 'plasma neutralize antibody', 'plasma neutralize india', 'igg neutralize antibody', 'igg neutralize india', 'surrogate neutralize antibody', 'surrogate neutralize india']",2095,rbd-specific igg iga igm titers correlated neutralizing antibody titers rbd-specific memory b cell frequencies 
806,198.0,4.0,"['large-scale use sars', 'large-scale use cov-2', 'large-scale use vaccine']",2096,findings timely significance identifying potential donors plasma therapy using rbd-specific igg assays surrogate measurement neutralizing antibodies india 
807,199.0,0.0,"['covid-19 set respiratory failure', 'covid-19 set symptom', 'covid-19 set human', 'covid-19 set cough', 'covid-19 set fever', 'sars-cov-2 set respiratory failure', 'sars-cov-2 set symptom', 'sars-cov-2 set human', 'sars-cov-2 set cough', 'sars-cov-2 set fever']",2098,ongoing covid-19 pandemic placed overwhelming burden healthcare system caused major disruption world economy 
808,199.0,1.0,['sars-cov-2 cause antibody'],2099,covid-19 caused sars-cov-2 novel coronavirus leads variety symptoms humans including cough fever respiratory failure 
809,199.0,10.0,"['respiratory disease provide mycoplasmal infection', 'respiratory disease provide pcv2', 'mycoplasma hyopneumoniae provide mycoplasmal infection', 'mycoplasma hyopneumoniae provide pcv2', 'reproductive provide mycoplasmal infection', 'reproductive provide pcv2', 'prrsv provide mycoplasmal infection', 'prrsv provide pcv2']",2108,furthermore discuss examples successful applications serological tests contact tracing community-level sero-surveying provide invaluable information pandemic management assessment 
810,200.0,2.0,"['pig select hyopneumoniae', 'pig select prrsv', 'pig select pcv2', 'four select hyopneumoniae', 'four select prrsv', 'four select pcv2']",2111,four separate vaccine regimen groups selected 
811,200.0,3.0,"['prrsv challenge one', 'prrsv challenge hyopneumoniae', 'prrsv challenge vaccine', 'prrsv challenge pig', 'prrsv challenge hyopneumoniae', 'prrsv challenge vaccine', 'pcv2 challenge one', 'pcv2 challenge hyopneumoniae', 'pcv2 challenge vaccine', 'pcv2 challenge pig', 'pcv2 challenge hyopneumoniae', 'pcv2 challenge vaccine', 'pig challenge one', 'pig challenge hyopneumoniae', 'pig challenge vaccine', 'pig challenge hyopneumoniae', 'pig challenge vaccine', 'prrsv follow pig', 'prrsv follow hyopneumoniae', 'prrsv follow vaccine', 'pcv2 follow pig', 'pcv2 follow hyopneumoniae', 'pcv2 follow vaccine', 'pig follow hyopneumoniae', 'pig follow vaccine', 'one follow pig', 'one follow hyopneumoniae', 'one follow vaccine', 'hyopneumoniae follow pig', 'hyopneumoniae follow vaccine', 'vaccine follow pig', 'vaccine follow hyopneumoniae']",2112,pigs four vaccinated groups challenged m hyopneumoniae 28 days old followed challenge prrsv pcv2 49 days old 
812,200.0,4.0,"['pig vaccinate lung lesions', 'pig vaccinate prrsv', 'pig vaccinate viremia', 'pig vaccinate hyopneumoniae', 'pig vaccinate prrsv', 'hyopneumoniae vaccinate lung lesions', 'hyopneumoniae vaccinate prrsv', 'hyopneumoniae vaccinate viremia', 'hyopneumoniae vaccinate pig', 'hyopneumoniae vaccinate prrsv', 'prrsv vaccinate lung lesions', 'prrsv vaccinate viremia', 'prrsv vaccinate pig', 'prrsv vaccinate hyopneumoniae']",2113,results regardless prrsv pcv2 vaccination pigs vaccinated one m hyopneumoniae vaccines 7 days old significantly better growth performance whole length study compared pigs vaccinated second m hyopneumoniae vaccine 21 days old 
813,200.0,6.0,"['hyopneumoniae observe hyopneumoniae infection', 'hyopneumoniae observe prrsv', 'hyopneumoniae observe infection', 'vaccine observe hyopneumoniae infection', 'vaccine observe prrsv', 'vaccine observe infection']",2115,conclusions efficacy prrsv mlv vaccine influenced different timing m hyopneumoniae vaccination whereas efficacy pcv2 vaccine 
814,200.0,7.0,"['new zealand show infection', 'australia show infection']",2116,experiment study demonstrated early vaccination m hyopneumoniae vaccine highest priority order control m hyopneumoniae prrsv infection cases early m hyopneumoniae infection 
815,201.0,2.0,"['tct expedite patient', 'worker expedite tct', 'worker expedite patient']",2119,recommendation tct patients expedited access highÃÂÂefficacy covidÃÂÂ19 vaccines given patients high risk morbidity mortality covidÃÂÂ19 infection 
816,202.0,0.0,"['vaccine age convalescent sera', 'vaccine age roche', 'vaccine age two', 'vaccine evaluate convalescent sera', 'vaccine evaluate two', 'roche evaluate convalescent sera', 'roche evaluate two']",2123,sera collected 185 adults aged ÃÂÂ 70 years london evaluate immune response covid-19 vaccines 
817,202.0,1.0,"['united induce covid-19', 'united induce vaccine']",2124,single dose pfizerbiontech vaccine resulted 94 seropositivity 3 weeks naÃÂve individuals using roche spike antibody assay two doses produced high spike antibody levels significantly higher convalescent sera mild-to-moderate pcr-confirmed adult cases 
818,203.0,2.0,"['gse evaluate aprv', 'gse evaluate vaccine', 'gse evaluate neonate']",2128,present study evaluate gse effect immune response aprv vaccine neonatal mice matab 
819,203.0,4.0,['gse-enhanced treat immunization'],2130,gse co-administered aprv vaccine ap-gse specific gb antibody th1 cytokines il-2 il-12 ifn-ÃÂ³ th2 cytokines il-4 il-6 il-10 responses significantly increased association enhanced protection vaccinated neonates lethal prv challenge even though matab existed compared neonates immunized aprv vaccine alone 
820,203.0,6.0,"['neonate relate 5959', 'neonate relate aprv', 'ap-gse relate 5959', 'ap-gse relate aprv', 'saline relate 5959', 'saline relate aprv', '3976 relate 5959', '3976 relate aprv', 'neonate activate aprv', 'ap-gse activate aprv', 'saline activate aprv', '3976 activate aprv', 'ap-gse activate aprv']",2132,mechanisms underlying adjuvant effect gse may due innate immune related pathways activated gse 
821,203.0,7.0,"['kyoto induce ap-gse', 'kyoto induce cell', 'kyoto induce th2', 'kyoto induce cell', 'kegg induce ap-gse', 'kegg induce cell', 'kegg induce th2', 'kegg induce cell', 'innate induce ap-gse', 'innate induce cell', 'innate induce th2', 'innate induce cell', 'immune induce ap-gse', 'immune induce cell', 'immune induce th2', 'immune induce cell', 'cytokine induce ap-gse', 'cytokine induce cell', 'cytokine induce th2', 'cytokine induce cell', 'kyoto vaccinate kegg', 'kyoto vaccinate innate', 'kyoto vaccinate immune', 'kyoto vaccinate cytokine', 'kyoto vaccinate ap-gse', 'kyoto vaccinate cell', 'kyoto vaccinate th2', 'kyoto vaccinate cell', 'kyoto show ap-gse', 'kyoto show cell', 'kyoto show th2', 'kyoto show cell', 'kegg show ap-gse', 'kegg show cell', 'kegg show th2', 'kegg show cell', 'innate show ap-gse', 'innate show cell', 'innate show th2', 'innate show cell', 'immune show ap-gse', 'immune show cell', 'immune show th2', 'immune show cell', 'cytokine show ap-gse', 'cytokine show cell', 'cytokine show th2', 'cytokine show cell', 'kyoto compare th2', 'kyoto compare cell', 'kegg compare th2', 'kegg compare cell', 'innate compare th2', 'innate compare cell', 'immune compare th2', 'immune compare cell', 'cytokine compare th2', 'cytokine compare cell', 'ap-gse compare th2', 'ap-gse compare cell', 'cell compare th2']",2133,transcriptome analysis splenocytes neonates immunized ap-gse aprv saline solution showed 3976 differentially expressed genes degs ap-gse group 5959 degs aprv group compared control 
822,204.0,0.0,"['specimen detect multipathogen', 'sari detect multipathogen', 'patient detect multipathogen']",2136,april 2017 surveillance detected surge severe acute respiratory infections sari bangladesh 
823,204.0,1.0,['influenza collect vaccine'],2137,collected specimens sari patients asymptomatic controls analysis multipathogen diagnostic tests 
824,205.0,0.0,"['therapy acquire multiple', 'therapy acquire neuromyelitis', 'therapy acquire optica', 'therapy acquire chronic', 'therapy acquire polyneuropathy', 'therapy acquire cidp', 'therapy acquire myasthenia', 'therapy acquire gravis', 'therapy acquire myositis', 'therapy acquire encephalitis', 'therapy receive neuromyelitis', 'therapy receive optica', 'therapy receive chronic', 'therapy receive polyneuropathy', 'therapy receive cidp', 'therapy receive myasthenia', 'therapy receive gravis', 'therapy receive myositis', 'therapy receive encephalitis', 'multiple receive neuromyelitis', 'multiple receive optica', 'multiple receive chronic', 'multiple receive polyneuropathy', 'multiple receive cidp', 'multiple receive myasthenia', 'multiple receive gravis', 'multiple receive myositis', 'multiple receive encephalitis']",2139,secondary immunodeficiencies sids acquired conditions may occur sequelae immune therapy 
825,205.0,1.0,['therapeutic modify sid'],2140,recent years number disease-modifying therapies dmts approved multiple sclerosis related disorders neuromyelitis optica spectrum disorders frequently also used in- off-label treat conditions chronic inflammatory demyelinating polyneuropathy cidp myasthenia gravis myositis encephalitis 
826,205.0,2.0,"['long-term provide rituximab', 'long-term provide sid', 'long-term provide secondary', 'long-term provide rituximab', 'long-term provide sid', 'long-term provide secondary', 'long-term explore rituximab', 'long-term explore sid', 'long-term explore secondary']",2141,review focus currently available immune therapeutics neurology explore specific modes action might contribute sid particular emphasis potential induce secondary antibody deficiency 
827,205.0,5.0,"['sid induce pre-existing', 'sid induce immunoglobulin']",2144,date evidence suggesting treatment fingolimod dimethyl fumarate natalizumab leads antibody deficiency 
828,205.0,8.0,"['therapy reduce sid', 'therapy reduce neurologist', 'therapy reduce healthcare', 'therapy reduce professional', 'therapy associate neurologist', 'therapy associate healthcare', 'therapy associate professional', 'sid associate neurologist', 'sid associate healthcare', 'sid associate professional']",2147,immune supplementation employing ig replacement therapy might reduce morbidity mortality associated sids neurological conditions 
829,206.0,0.0,"['cross-sectional test 141', 'cross-sectional test child', 'cross-sectional test sars-cov-2', 'cross-sectional test infection']",2149,objective study association routine childhood vaccination severity covid-19 among children 
830,206.0,1.0,"['covid-19 assay vaccine', 'covid-19 assay 571']",2150,methods cross-sectional study undertaken among 141 children aged ÃÂÂ15 years tested positive sars-cov-2 infection 
831,206.0,3.0,['child vaccinate infection'],2152,disease severity partially immunized children 167 compared fully immunized children 70 
832,206.0,4.0,['covid-19 receive vaccine'],2153,conclusions children receive doses mr vaccine severe infection compared vaccinated 
833,207.0,1.0,"['participant evaluate emirate', 'participant evaluate bahrain', 'participant evaluate adult', 'participant evaluate 18', 'participant evaluate covid-19', 'participant inactivate emirate', 'participant inactivate bahrain', 'participant inactivate adult', 'participant inactivate 18', 'participant inactivate covid-19']",2155,objective evaluate efficacy adverse events 2 inactivated covid-19 vaccines 
834,207.0,3.0,"['participant use aluminum hydroxide', 'participant use alum', 'participant use 458', 'vaccine use aluminum hydroxide', 'vaccine use alum', 'vaccine use 458', 'sars-cov-2 use aluminum hydroxide', 'sars-cov-2 use alum', 'sars-cov-2 use 458', 'wiv04 use aluminum hydroxide', 'wiv04 use alum', 'wiv04 use 458', '459 use aluminum hydroxide', '459 use alum', '459 use 458', 'hb02 use aluminum hydroxide', 'hb02 use alum', 'hb02 use 458', '4 use aluminum hydroxide', '4 use alum', '4 use 458', 'participant start aluminum hydroxide', 'participant start vaccine', 'participant start sars-cov-2', 'participant start wiv04', 'participant start 459', 'participant start hb02', 'participant start 4', 'participant start 465', 'participant start alum', 'participant start 458', 'participant use aluminum hydroxide', 'participant use 459', 'participant use hb02', 'participant use 4', 'participant use 465', 'participant use alum', 'participant use 458', 'vaccine use aluminum hydroxide', 'vaccine use 459', 'vaccine use hb02', 'vaccine use 4', 'vaccine use 465', 'vaccine use alum', 'vaccine use 458', 'sars-cov-2 use aluminum hydroxide', 'sars-cov-2 use 459', 'sars-cov-2 use hb02', 'sars-cov-2 use 4', 'sars-cov-2 use 465', 'sars-cov-2 use alum', 'sars-cov-2 use 458', 'wiv04 use aluminum hydroxide', 'wiv04 use 459', 'wiv04 use hb02', 'wiv04 use 4', 'wiv04 use 465', 'wiv04 use alum', 'wiv04 use 458']",2157,study enrollment began july 16 2020 data sets used interim analysis efficacy adverse events locked december 20 2020 december 31 2020 respectively 
835,207.0,4.0,"['covid-19 inactivate vaccine', 'covid-19 inactivate participant', 'covid-19 inactivate sars-cov-2', 'covid-19 develop vaccine', 'covid-19 develop participant', 'covid-19 develop sars-cov-2']",2158,interventions participants randomized receive 1 2 inactivated vaccines developed sars-cov-2 wiv04 5 microgdose n 13 459 hb02 4 microgdose n 13 465 strains aluminum hydroxide alum -only control n 13 458 received 2 intramuscular injections 21 days apart 
836,207.0,7.0,"['382 collect vaccine', '382 collect alum-only', '382 collect 361', '382 collect 261', '382 collect 844', '382 collect men', '382 collect 206', '382 collect 946', '382 collect second', '382 collect transcriptase-polymerase', 'participant collect vaccine', 'participant collect alum-only', 'participant collect 361', 'participant collect 261', 'participant collect 844', 'participant collect men', 'participant collect 206', 'participant collect 946', 'participant collect second', 'participant collect transcriptase-polymerase', '382 receive alum-only', '382 receive 361', '382 receive 261', '382 receive 844', '382 receive men', '382 receive 206', '382 receive 946', '382 receive second', '382 receive transcriptase-polymerase', 'participant receive alum-only', 'participant receive 361', 'participant receive 261', 'participant receive 844', 'participant receive men', 'participant receive 206', 'participant receive 946', 'participant receive second', 'participant receive transcriptase-polymerase', '382 dose 361', '382 dose 261', '382 dose 844', '382 dose men', '382 dose 206', '382 dose 946', '382 dose second', '382 dose transcriptase-polymerase', 'participant dose 361', 'participant dose 261', 'participant dose 844', 'participant dose men', 'participant dose 206', 'participant dose 946', 'participant dose second', 'participant dose transcriptase-polymerase', 'vaccine dose 361', 'vaccine dose 261', 'vaccine dose 844', 'vaccine dose men', 'vaccine dose 206', 'vaccine dose 946', 'vaccine dose second', 'vaccine dose transcriptase-polymerase', 'alum-only dose 361', 'alum-only dose 261', 'alum-only dose 844', 'alum-only dose men', 'alum-only dose 206', 'alum-only dose 946', 'alum-only dose second', 'alum-only dose transcriptase-polymerase']",2161,incidence adverse events reactions collected among participants received least 1 dose 
837,207.0,8.0,"['1-121 randomize covid-19', '1-121 randomize participant', '1-121 randomize wiv04', '1-121 randomize 121', '1-121 randomize person-years', '1-121 randomize hb02', '1-121 randomize person-years', '1-121 randomize alum-only', '1-121 randomize 366-546', '1-121 randomize person-years', '1-121 randomize vaccine', '1-121 randomize alum-only', '1-121 randomize 648', '1-121 randomize hb02', '1-121 receive participant', '1-121 receive wiv04', '1-121 receive 121', '1-121 receive person-years', '1-121 receive hb02', '1-121 receive person-years', '1-121 receive alum-only', '1-121 receive 366-546', '1-121 receive person-years', '1-121 receive vaccine', '1-121 receive alum-only', '1-121 receive 648', '1-121 receive hb02', '1-121 dose 121', '1-121 dose person-years', '1-121 dose hb02', '1-121 dose person-years', '1-121 dose alum-only', '1-121 dose 366-546', '1-121 dose person-years', '1-121 dose vaccine', '1-121 dose alum-only', '1-121 dose 648', '1-121 dose hb02', 'covid-19 dose 121', 'covid-19 dose person-years', 'covid-19 dose hb02', 'covid-19 dose person-years', 'covid-19 dose alum-only', 'covid-19 dose 366-546', 'covid-19 dose person-years', 'covid-19 dose vaccine', 'covid-19 dose alum-only', 'covid-19 dose 648', 'covid-19 dose hb02', 'participant dose 121', 'participant dose person-years', 'participant dose hb02', 'participant dose person-years', 'participant dose alum-only', 'participant dose 366-546', 'participant dose person-years', 'participant dose vaccine', 'participant dose alum-only', 'participant dose 648', 'participant dose hb02', '1-121 receive alum-only', '1-121 receive 648', '1-121 receive hb02', 'covid-19 receive alum-only', 'covid-19 receive 648', 'covid-19 receive hb02', 'participant receive alum-only', 'participant receive 648', 'participant receive hb02', 'wiv04 receive alum-only', 'wiv04 receive 648', 'wiv04 receive hb02', '121 receive alum-only', '121 receive 648', '121 receive hb02', 'person-years receive alum-only', 'person-years receive 648', 'person-years receive hb02', 'hb02 receive alum-only', 'hb02 receive 648', 'person-years receive alum-only', 'person-years receive 648', 'person-years receive hb02', 'alum-only receive 648', 'alum-only receive hb02', '366-546 receive alum-only', '366-546 receive 648', '366-546 receive hb02', 'person-years receive alum-only', 'person-years receive 648', 'person-years receive hb02', 'vaccine receive alum-only', 'vaccine receive 648', 'vaccine receive hb02', '1-121 provide 648', '1-121 provide hb02', 'covid-19 provide 648', 'covid-19 provide hb02', 'participant provide 648', 'participant provide hb02', 'wiv04 provide 648', 'wiv04 provide hb02', '121 provide 648', '121 provide hb02', 'person-years provide 648', 'person-years provide hb02', 'hb02 provide 648', 'person-years provide 648', 'person-years provide hb02', 'alum-only provide 648', 'alum-only provide hb02', '366-546 provide 648', '366-546 provide hb02', 'person-years provide 648', 'person-years provide hb02', 'vaccine provide 648', 'vaccine provide hb02', 'alum-only provide 648', 'alum-only provide hb02', '1-121 follow 648', '1-121 follow hb02', 'covid-19 follow 648', 'covid-19 follow hb02', 'participant follow 648', 'participant follow hb02', 'wiv04 follow 648', 'wiv04 follow hb02', '121 follow 648', '121 follow hb02', 'person-years follow 648', 'person-years follow hb02', 'hb02 follow 648', 'person-years follow 648', 'person-years follow hb02', 'alum-only follow 648', 'alum-only follow hb02', '366-546 follow 648', '366-546 follow hb02', 'person-years follow 648', 'person-years follow hb02', 'vaccine follow 648', 'vaccine follow hb02', 'alum-only follow 648', 'alum-only follow hb02']",2162,results among 40 382 participants randomized receive least 1 dose 2 vaccines alum-only control mean age 361 years 32 261 844 men 38 206 946 received 2 doses contributed least 1 follow-up measure day 14 following second dose negative reverse transcriptase-polymerase chain reaction test results enrollment included primary efficacy analysis 
838,207.0,9.0,"['covid-19 follow vaccine', 'alum-only follow vaccine']",2163,median range follow-up duration 77 1-121 days symptomatic covid-19 identified 26 participants wiv04 group 121 95 ci 83-178 per 1000 person-years 21 hb02 group 98 95 ci 64-150 per 1000 person-years 95 alum-only group 447 95 ci 366-546 per 1000 person-years resulting vaccine efficacy compared alum-only 728 95 ci 581 -824 wiv04 781 95 ci 648 -863 hb02 p lt 001 
839,207.0,10.0,"['injection receive 417', 'injection receive 465', 'injection receive participant', 'injection receive wiv04', 'injection receive hb02', 'injection receive alum-only', 'injection receive wiv04', 'injection receive hb02', 'injection receive alum-only', '417 receive wiv04', '417 receive hb02', '417 receive alum-only', '465 receive wiv04', '465 receive hb02', '465 receive alum-only', 'participant receive wiv04', 'participant receive hb02', 'participant receive alum-only']",2164,two severe cases covid-19 occurred alum-only group none occurred vaccine groups 
840,208.0,2.0,['death become sars-cov-2'],2171,even though covid-19 vaccine become available since december 2020 main preventive measures still include social distancing hand washing use protective face masks 
841,208.0,13.0,"['patient diagnose globulin', 'patient diagnose tacrolimus', 'patient diagnose mycophenolate', 'patient diagnose mofetil', 'patient diagnose steroid', '67-year-old diagnose globulin', '67-year-old diagnose tacrolimus', '67-year-old diagnose mycophenolate', '67-year-old diagnose mofetil', '67-year-old diagnose steroid', 'woman diagnose globulin', 'woman diagnose tacrolimus', 'woman diagnose mycophenolate', 'woman diagnose mofetil', 'woman diagnose steroid', 'kidney diagnose globulin', 'kidney diagnose tacrolimus', 'kidney diagnose mycophenolate', 'kidney diagnose mofetil', 'kidney diagnose steroid', 'renal diagnose globulin', 'renal diagnose tacrolimus', 'renal diagnose mycophenolate', 'renal diagnose mofetil', 'renal diagnose steroid', 'allograft diagnose globulin', 'allograft diagnose tacrolimus', 'allograft diagnose mycophenolate', 'allograft diagnose mofetil', 'allograft diagnose steroid', 'donor diagnose globulin', 'donor diagnose tacrolimus', 'donor diagnose mycophenolate', 'donor diagnose mofetil', 'donor diagnose steroid', '2014 diagnose globulin', '2014 diagnose tacrolimus', '2014 diagnose mycophenolate', '2014 diagnose mofetil', '2014 diagnose steroid', 'patient develop renal', 'patient develop allograft', 'patient develop donor', 'patient develop 2014', 'patient develop globulin', 'patient develop tacrolimus', 'patient develop mycophenolate', 'patient develop mofetil', 'patient develop steroid', '67-year-old develop renal', '67-year-old develop allograft', '67-year-old develop donor', '67-year-old develop 2014', '67-year-old develop globulin', '67-year-old develop tacrolimus', '67-year-old develop mycophenolate', '67-year-old develop mofetil', '67-year-old develop steroid', 'woman develop renal', 'woman develop allograft', 'woman develop donor', 'woman develop 2014', 'woman develop globulin', 'woman develop tacrolimus', 'woman develop mycophenolate', 'woman develop mofetil', 'woman develop steroid']",2182,herein present two rtrs developed skin cancers covid-19 pandemic tumors diagnosed significant delay 
842,208.0,23.0,"['patient excise chronic glomerulonephritis', 'patient excise renal', 'patient excise allograft', 'patient excise donor', 'patient treat chronic glomerulonephritis', 'woman treat chronic glomerulonephritis', 'renal treat chronic glomerulonephritis', 'allograft treat chronic glomerulonephritis', 'donor treat chronic glomerulonephritis']",2192,scc situ excised actinic keratosis treated cryosurgery 
843,208.0,26.0,"['patient receive eyeglass', 'wound receive eyeglass']",2195,june 2020 erosion occurred left infraocular area heal instead gradually enlarged 
844,208.0,27.0,"['six suspect nephrologist', 'six suspect erosion']",2196,patient suspected wound developed due friction rim eyeglasses 
845,208.0,30.0,"['patient confirm physician', 'patient confirm skin']",2199,pathohistological analysis confirmed clinical diagnosis 
846,208.0,33.0,"['skin cancers recognize melanoma', 'canadian recognize skin cancers', 'canadian recognize melanoma', 'author recognize skin cancers', 'author recognize melanoma']",2202,problem diagnostic delay skin cancers covid-19 pandemic recognized several studies 
847,208.0,35.0,"['skin cancers show 2020', 'skin cancers show author', 'italy show skin cancers', 'italy show 2020', 'italy show author', 'advanced show skin cancers', 'advanced show 2020', 'advanced show author', 'skin cancers make author', 'italy make skin cancers', 'italy make author', 'advanced make skin cancers', 'advanced make author', '2020 make skin cancers', '2020 make author', 'italy compare skin cancers', 'advanced compare skin cancers', '2020 compare skin cancers', 'author compare skin cancers']",2204,multicenter study performed northern-central italy showed number skin cancer nmsc melanoma diagnoses fell 567 weeks 11 20 2020 compared average number noted periods 2018 2019 7 
848,208.0,38.0,"['skin associate follow-up', 'skin associate follow-up', 'cancer associate follow-up']",2207,namely skin cancers rtrs aggressive associated higher incidence rate metastases recurrences general population 9 
849,208.0,39.0,"['covid-19 notify people', 'covid-19 observe people']",2208,therefore rtrs advised regularly check skin potential skin cancer includes self-examinations dermatologic follow-ups 
850,209.0,6.0,['coronavirus-2 develop fda'],2215,understanding adjuvant mechanism increase vaccine effectiveness needed develop stronger vaccine response elderly individuals 
851,210.0,1.0,"['coronavirus use nucleic acid', 'coronavirus use covid-19', 'coronavirus use sars-cov-2', 'coronavirus use soldier', 'nucleic acid observe soldier', 'coronavirus observe soldier', 'covid-19 observe soldier', 'nucleic acid bind soldier', 'coronavirus bind soldier', 'covid-19 bind soldier', 'sars-cov-2 bind soldier', 'nucleic acid associate soldier', 'coronavirus associate soldier', 'covid-19 associate soldier', 'sars-cov-2 associate soldier']",2217,antibody detection uses purified proteins sars-cov-2 determine antibody binding via enzyme-linked immunosorbent assay chemiluminescent immunoassay clia colloidal gold-based immunochromatographic assay 
852,210.0,3.0,"['18 observe serum', '18 observe joint', '18 observe lewis']",2219,purpose surveillance survey determine prevalence prior sars-cov-2 infection symptoms covid-19 within mechanized infantry brigade 
853,210.0,4.0,"['symptom provide participant', 'covid-19 provide participant']",2220,materials methods active-duty military servicemembers 18 years mechanized infantry brigade provided serum samples testing elecsysÃÂ anti-sars-cov-2 qualitative antibody test june september 2020 joint base lewis mcchord jblm 
854,210.0,5.0,"['264 fill one', '264 fill sars-cov-2', 'participant fill one', 'participant fill sars-cov-2']",2221,addition participants filled questionnaire symptoms exposure covid-19 january september 2020 surveillance team collected analyzed antibody testing results questionnaires participants antibody positivity rates symptom prevalence 
855,210.0,6.0,"['144 test symptom', '144 test headache', '144 test rhinorrhea', '144 test cough', '144 test sore', '144 test throat', '545 test symptom', '545 test headache', '545 test rhinorrhea', '545 test cough', '545 test sore', '545 test throat', 'symptom test headache', 'symptom test rhinorrhea', 'symptom test cough', 'symptom test sore', 'symptom test throat']",2222,results total 264 participants tested one 04 participant testing positive sars-cov-2 antibody 
856,211.0,0.0,"['64 million exist patient', '64 million exist cirrhosis', 'covid exist patient', 'covid exist cirrhosis', 'cohort exist patient', 'cohort exist cirrhosis', 'n3c exist patient', 'n3c exist cirrhosis', 'sars-cov-2 exist patient', 'sars-cov-2 exist cirrhosis']",2230,background aims chronic liver disease cld patients without cirrhosis existing studies outcomes sars-cov-2 infection limited generalizability 
857,211.0,3.0,['cld associate patient'],2233,used survival analyses associate sars-cov-2 infection presence cirrhosis clinical factors primary outcome 30-day mortality 
858,211.0,8.0,"['gender-balanced increase sars-cov-2', 'gender-balanced increase patient', 'gender-balanced increase cirrhosis', 'gender-balanced increase cirrhosis', 'gender-balanced increase cld', 'gender-balanced increase patient', 'gender-balanced increase sars-cov-2', 'gender-balanced increase 331-times', 'patient increase sars-cov-2', 'patient increase cirrhosis', 'patient increase cirrhosis', 'patient increase cld', 'patient increase sars-cov-2', 'patient increase 331-times']",2238,stratified analyses among patients cirrhosis increased age obesity comorbid conditions diabetes heart failure pulmonary disease sars-cov-2 infection associated increased adjusted hazards death 
859,211.0,10.0,"['people increase mrna', 'people increase covid-19', 'people increase vaccine', 'people increase greece', 'people consider greece', 'mrna consider greece', 'covid-19 consider greece']",2240,results provide additional impetus increasing vaccination uptake research regarding immune responses vaccines patients severe liver disease 
860,212.0,5.0,"['hydroxychloroquine highlight prophylaxis', 'hydroxychloroquine highlight covid-19', 'hydroxychloroquine highlight worker', 'hydroxychloroquine highlight hcws', 'hydroxychloroquine highlight cohort', 'hydroxychloroquine highlight indian', 'hydroxychloroquine highlight participant', 'hydroxychloroquine highlight doctor', 'hydroxychloroquine highlight nurse', 'hydroxychloroquine highlight ancillary', 'hydroxychloroquine highlight covid-19', 'hydroxychloroquine highlight patient', 'hydroxychloroquine highlight prophylaxis', 'hcq highlight prophylaxis', 'hcq highlight covid-19', 'hcq highlight worker', 'hcq highlight hcws', 'hcq highlight cohort', 'hcq highlight indian', 'hcq highlight participant', 'hcq highlight doctor', 'hcq highlight nurse', 'hcq highlight ancillary', 'hcq highlight covid-19', 'hcq highlight patient', 'hcq highlight prophylaxis', 'hydroxychloroquine receive cohort', 'hydroxychloroquine receive indian', 'hydroxychloroquine receive participant', 'hydroxychloroquine receive doctor', 'hydroxychloroquine receive nurse', 'hydroxychloroquine receive ancillary', 'hydroxychloroquine receive covid-19', 'hydroxychloroquine receive patient', 'hydroxychloroquine receive prophylaxis', 'hcq receive cohort', 'hcq receive indian', 'hcq receive participant', 'hcq receive doctor', 'hcq receive nurse', 'hcq receive ancillary', 'hcq receive covid-19', 'hcq receive patient', 'hcq receive prophylaxis', 'prophylaxis receive cohort', 'prophylaxis receive indian', 'prophylaxis receive participant', 'prophylaxis receive doctor', 'prophylaxis receive nurse', 'prophylaxis receive ancillary', 'prophylaxis receive covid-19', 'prophylaxis receive patient', 'covid-19 receive cohort', 'covid-19 receive indian', 'covid-19 receive participant', 'covid-19 receive doctor', 'covid-19 receive nurse', 'covid-19 receive ancillary', 'covid-19 receive patient', 'covid-19 receive prophylaxis', 'worker receive cohort', 'worker receive indian', 'worker receive participant', 'worker receive doctor', 'worker receive nurse', 'worker receive ancillary', 'worker receive covid-19', 'worker receive patient', 'worker receive prophylaxis', 'hcws receive cohort', 'hcws receive indian', 'hcws receive participant', 'hcws receive doctor', 'hcws receive nurse', 'hcws receive ancillary', 'hcws receive covid-19', 'hcws receive patient', 'hcws receive prophylaxis', 'hydroxychloroquine neutralize cohort', 'hydroxychloroquine neutralize indian', 'hydroxychloroquine neutralize participant', 'hydroxychloroquine neutralize doctor', 'hydroxychloroquine neutralize nurse', 'hydroxychloroquine neutralize ancillary', 'hydroxychloroquine neutralize covid-19', 'hydroxychloroquine neutralize patient', 'hydroxychloroquine neutralize prophylaxis', 'hcq neutralize cohort', 'hcq neutralize indian', 'hcq neutralize participant', 'hcq neutralize doctor', 'hcq neutralize nurse', 'hcq neutralize ancillary', 'hcq neutralize covid-19', 'hcq neutralize patient', 'hcq neutralize prophylaxis', 'prophylaxis neutralize cohort', 'prophylaxis neutralize indian', 'prophylaxis neutralize participant', 'prophylaxis neutralize doctor', 'prophylaxis neutralize nurse', 'prophylaxis neutralize ancillary', 'prophylaxis neutralize covid-19', 'prophylaxis neutralize patient', 'covid-19 neutralize cohort', 'covid-19 neutralize indian', 'covid-19 neutralize participant', 'covid-19 neutralize doctor', 'covid-19 neutralize nurse', 'covid-19 neutralize ancillary', 'covid-19 neutralize patient', 'covid-19 neutralize prophylaxis', 'worker neutralize cohort', 'worker neutralize indian', 'worker neutralize participant', 'worker neutralize doctor', 'worker neutralize nurse', 'worker neutralize ancillary', 'worker neutralize covid-19', 'worker neutralize patient', 'worker neutralize prophylaxis', 'hcws neutralize cohort', 'hcws neutralize indian', 'hcws neutralize participant', 'hcws neutralize doctor', 'hcws neutralize nurse', 'hcws neutralize ancillary', 'hcws neutralize covid-19', 'hcws neutralize patient', 'hcws neutralize prophylaxis', 'hydroxychloroquine induce cohort', 'hydroxychloroquine induce indian', 'hydroxychloroquine induce participant', 'hydroxychloroquine induce doctor', 'hydroxychloroquine induce nurse', 'hydroxychloroquine induce ancillary', 'hydroxychloroquine induce covid-19', 'hydroxychloroquine induce patient', 'hydroxychloroquine induce prophylaxis', 'hcq induce cohort', 'hcq induce indian', 'hcq induce participant', 'hcq induce doctor', 'hcq induce nurse', 'hcq induce ancillary', 'hcq induce covid-19', 'hcq induce patient', 'hcq induce prophylaxis', 'prophylaxis induce cohort', 'prophylaxis induce indian', 'prophylaxis induce participant', 'prophylaxis induce doctor', 'prophylaxis induce nurse', 'prophylaxis induce ancillary', 'prophylaxis induce covid-19', 'prophylaxis induce patient', 'covid-19 induce cohort', 'covid-19 induce indian', 'covid-19 induce participant', 'covid-19 induce doctor', 'covid-19 induce nurse', 'covid-19 induce ancillary', 'covid-19 induce patient', 'covid-19 induce prophylaxis', 'worker induce cohort', 'worker induce indian', 'worker induce participant', 'worker induce doctor', 'worker induce nurse', 'worker induce ancillary', 'worker induce covid-19', 'worker induce patient', 'worker induce prophylaxis', 'hcws induce cohort', 'hcws induce indian', 'hcws induce participant', 'hcws induce doctor', 'hcws induce nurse', 'hcws induce ancillary', 'hcws induce covid-19', 'hcws induce patient', 'hcws induce prophylaxis']",2246,conclusion taken together findings highlighted high fold change 4118 recorded titers neutralizing antibodies second dose suggesting need timely administration elderly individuals 
861,213.0,3.0,"['covid adjust non-diabetics', 'covid adjust person', 'covid adjust hcq', 'covid adjust 1-65']",2250,however adjusted risk factors hcq dose per government recommendations 2-3 4-5 6 weeks reduced probability covid positivity 34 48 72 respectively 
862,213.0,5.0,"['hcws stop hcq', 'hcws stop 800', 'hcws stop 400', 'hcws stop covid-19', 'hcws stop vaccine']",2252,major adverse events reported gi disorder palpitation giddiness 140 persons discontinued due adverse events 
863,214.0,0.0,"['metabolic disease relate diabetes', 'metabolic disease relate heart', 'metabolic disease relate immunization', 'metabolic disease relate obesity', 'metabolic disease relate high-risk', 'metabolic disease relate covid-19', 'metabolic disease relate vaccine', 'obesity relate diabetes', 'obesity relate heart', 'obesity relate immunization', 'obesity relate high-risk', 'obesity relate covid-19', 'obesity relate vaccine', '424 relate diabetes', '424 relate heart', '424 relate immunization', '424 relate obesity', '424 relate high-risk', '424 relate covid-19', '424 relate vaccine', 'adult relate diabetes', 'adult relate heart', 'adult relate immunization', 'adult relate obesity', 'adult relate high-risk', 'adult relate covid-19', 'adult relate vaccine', 'metabolic disease recognize 424', 'metabolic disease recognize adult', 'metabolic disease recognize diabetes', 'metabolic disease recognize heart', 'metabolic disease recognize immunization', 'metabolic disease recognize obesity', 'metabolic disease recognize high-risk', 'metabolic disease recognize covid-19', 'metabolic disease recognize vaccine', 'obesity recognize 424', 'obesity recognize adult', 'obesity recognize diabetes', 'obesity recognize heart', 'obesity recognize immunization', 'obesity recognize high-risk', 'obesity recognize covid-19', 'obesity recognize vaccine']",2255,obesity recognized risk factor severe covid-19 12 possibly related chronic inflammation disrupts immune thrombogenic responses pathogens 3 well impaired lung function excess weight 4 
864,214.0,1.0,"['premier affect phd-sr', 'premier affect body', 'premier affect covid-19', 'premier affect death', 'covid-19 affect phd-sr', 'covid-19 affect body', 'covid-19 affect death', 'premier include death', 'covid-19 include death', 'phd-sr include death', 'body include death', 'covid-19 include death']",2256,obesity common metabolic disease affecting 424 us adults 5 risk factor chronic diseases including type 2 diabetes heart disease cancersÃÂ advisory committee immunization practices considers obesity high-risk medical condition covid-19 vaccine prioritization 6 
865,214.0,2.0,"['adult evaluate 283', 'adult evaluate 508', 'adult evaluate obesity', 'covid-19 evaluate 283', 'covid-19 evaluate 508', 'covid-19 evaluate obesity', '238 evaluate 283', '238 evaluate 508', '238 evaluate obesity', 'u evaluate 283', 'u evaluate 508', 'u evaluate obesity']",2257,using data premier healthcare database special covid-19 release phd-sr ÃÂ cdc assessed association body mass index bmi risk severe covid-19 outcomes ie hospitalization intensive care unit icu stepdown unit admission invasive mechanical ventilation death 
866,214.0,3.0,"['overweight receive obesity', 'overweight receive death', 'overweight receive adult', 'obesity receive death', 'obesity receive adult']",2258,among 148494 adults received covid-19 diagnosis emergency department ed inpatient visit 238 us hospitals march-december 2020 283 overweight 508 obesity 
867,214.0,6.0,"['clinician increase patient', 'clinician increase obesity', 'covid-19 increase patient', 'covid-19 increase obesity']",2261,risk invasive mechanical ventilation increased full range bmis 15 kgm2 60 kgm2 
868,214.0,7.0,"['bmi consider covid-19', 'bmi consider obesity', 'bmi consider covid-19', 'bmi consider vaccine']",2262,clinicians develop care plans covid-19 patients consider risk severe outcomes patients higher bmis especially severe obesity 
869,215.0,0.0,['obesity know covid-19-associated'],2264,already known topic 
870,215.0,7.0,"['oral include parenteral', 'rabies include oral', 'rabies include parenteral', 'gasgas include oral', 'gasgas include parenteral', 'immunity include oral', 'immunity include parenteral', 'oral associate parenteral', 'rabies associate oral', 'rabies associate parenteral', 'gasgas associate oral', 'gasgas associate parenteral', 'immunity associate oral', 'immunity associate parenteral', 'fox associate oral', 'fox associate parenteral']",2271,findings highlight clinical public health implications higher bmis including need intensive management covid-19-associated illness continued vaccine prioritization masking policies support healthy behaviors 
871,216.0,0.0,"['antibody aim igg', 'antibody aim fox']",2272,live genetically-engineered oral rabies virus rabv variant spbn gasgas induces long-lasting immunity foxes protection challenge otherwise lethal dose rabv field strains experimental oral parenteral routes administration 
872,216.0,2.0,"['rabies-specific observe immunity', 'rabies-specific observe gasgas', 'rabies-specific neutralize immunity', 'rabies-specific neutralize gasgas', 'antibody neutralize immunity', 'antibody neutralize gasgas']",2274,differences observed induction virus-neutralizing vna titers significantly higher parenterally vaccinated group 
873,216.0,5.0,"['parenteral cause fox', 'parenteral cause oral', 'parenteral cause rabies', 'parenteral cause vaccine', 'gasgas cause fox', 'gasgas cause oral', 'gasgas cause rabies', 'gasgas cause vaccine']",2277,interestingly vaccination spbn gasgas cause significant differences inducible ifn-ÃÂ³ production vaccinated animals indicating relatively weak cellular immune response challenge 
874,217.0,2.0,"['132 retrieve vaccinee', 'bell retrieve vaccinee', '152 retrieve vaccinee']",2281,methods using database largest healthcare provider israel retrieved data different periods 2018-2021 observed cases bell s palsy occurring within 21-days first vaccine dose within 30-days second vaccine dose compared expected cases based experience population 2019 standardized incidence ratios sirs attributable risks ars computed 
875,217.0,3.0,"['sir report vaccine', '136 report vaccine']",2282,findings overall 132 cases bell s palsy reported 2594990 vaccinees first dose 152 cases 2434674 vaccinees second dose 
876,217.0,4.0,"['sir weight second', 'sir weight vaccine']",2283,age sex weighted sirs 136 95 ci 114-161 116 099-136 first second vaccine dose respectively 
877,217.0,7.0,"['patient detect 7567', 'patient detect vaccinee', 'patient detect vaccinee', 'bell detect 7567', 'bell detect vaccinee', 'bell detect vaccinee', 'patient age 7567', 'patient age vaccinee', 'patient age vaccinee', 'bell age 7567', 'bell age vaccinee', 'bell age vaccinee', 'bell age 7567', 'bell age vaccinee', 'bell age vaccinee']",2286,highest ar 446 per 100000 vaccinees detected females aged ÃÂÂ65 years 
878,217.0,9.0,"['bnt162b2 weight covid-19', 'bnt162b2 weight vaccine', 'bnt162b2 weight bell']",2288,age sex weighted sirs 115 036-276 215 109-383 first second vaccine dose respectively 
879,218.0,0.0,"['multi-centre induce oral', 'multi-centre induce angiotensin', 'multi-centre induce receptor', 'multi-centre induce agonist', 'multi-centre induce patient', 'multi-centre induce covid-19', 'multi-centre induce crp', 'multi-centre induce 50-150', 'multi-centre induce eight', 'multi-centre induce nct04452435', 'multi-centre continue receptor', 'multi-centre continue agonist', 'multi-centre continue patient', 'multi-centre continue covid-19', 'multi-centre continue crp', 'multi-centre continue 50-150', 'multi-centre continue eight', 'multi-centre continue nct04452435', 'oral continue receptor', 'oral continue agonist', 'oral continue patient', 'oral continue covid-19', 'oral continue crp', 'oral continue 50-150', 'oral continue eight', 'oral continue nct04452435', 'angiotensin continue receptor', 'angiotensin continue agonist', 'angiotensin continue patient', 'angiotensin continue covid-19', 'angiotensin continue crp', 'angiotensin continue 50-150', 'angiotensin continue eight', 'angiotensin continue nct04452435']",2293,background covid-19 morbidity mortality remains high need safe effective drugs continues despite vaccines 
880,218.0,4.0,"['crp randomize 126', 'c21 randomize 126', '085 randomize 126']",2297,study period 21 july 13 october 2020 findings 106 patients randomised included analysis 51 c21 55 placebo 
881,218.0,6.0,"['725 reduce 220', '725 reduce 112', '725 reduce 441', '545 reduce 220', '545 reduce 112', '545 reduce 441', 'patient reduce 220', 'patient reduce 112', 'patient reduce 441', 'oxygen reduce 220', 'oxygen reduce 112', 'oxygen reduce 441', 'c21 reduce 220', 'c21 reduce 112', 'c21 reduce 441', '725 need patient', '725 need oxygen', '725 need c21', '725 need 220', '725 need 112', '725 need 441']",2299,secondary analysis patients requiring supplemental oxygen randomisation crp reduced c21 group compared placebo 
882,218.0,8.0,"['patient show one', 'patient show four', 'patient show one', 'patient show three', 'patient need one', 'patient need three', 'one need three', 'four need one', 'four need three', 'patient need one', 'patient need three']",2301,post hoc analysis showed day 14 proportion patients requiring supplemental oxygen 98 80 c21 group compared placebo 125 90 ci 29 126 
883,218.0,10.0,"['patient induce crp', 'covid-19 induce crp']",2303,treatment c21 safe well tolerated 
884,218.0,11.0,['post-hoc hospitalize oxygen'],2304,interpretation among hospitalised patients covid-19 receiving c21 7 days reduction crp compared placebo 
885,219.0,0.0,['b1617 detect india'],2307,recently multiple sars-cov-2 variants detected across globe 
886,219.0,2.0,"['b16172 observe b16171', 'b16172 observe b6173']",2309,high transmissibility observed lineage led daily increase number sars-cov-2 infections 
887,219.0,4.0,['b1351 describe vaccine'],2311, world health organization described b16172 variant concern 
888,219.0,6.0,"['covid-19 evaluate vaccinee', 'two evaluate covid-19', 'two evaluate vaccinee']",2313,increasing threat sars-cov-2 variants imperative assess efficacy currently available vaccines variants 
889,219.0,7.0,"['b1351 collect sars-cov-2', 'b1351 collect vaccine', 'b1351 collect bbv152', 'b1351 collect voc', 'whole-virion collect sars-cov-2', 'whole-virion collect vaccine', 'whole-virion collect bbv152', 'whole-virion collect voc', 'whole-virion collect b1351', 'b1351 receive voc', 'whole-virion receive voc', 'whole-virion receive b1351', 'sars-cov-2 receive voc', 'sars-cov-2 receive b1351', 'vaccine receive voc', 'vaccine receive b1351']",2314, evaluated neutralization potential sera collected covid-19 recovered cases n20 vaccinees two doses bbv152 n17 b1351 b16172 compared prototype b1 d614g variantthe finding study demonstrated reduction neutralization titers sera covid-19 recovered cases 33-fold 46-fold bbv152 vaccinees 3 
890,221.0,4.0,"['second reduce p', 'second reduce vaccine', 'second reduce p', 'second reduce sars-cov-2', 'second reduce two', 'second reduce vaccine', 'second reduce infection']",2335,results odds new sars-cov-2 infection reduced 65 95 ci 60 70 p 0001 ÃÂÂ 21 days since first vaccination second dose versus unvaccinated individuals without evidence prior infection rt-pcr antibody 
891,221.0,5.0,"['sars-cov-2 see two', 'sars-cov-2 see symptom', 'sars-cov-2 see two', 'sars-cov-2 see p']",2336,vaccinated largest reduction odds seen post second dose 70 95 ci 62 77 p 0001 there evidence benefits varied oxford-astrazeneca pfizer-biontech vaccines p 09 there evidence difference odds new sars-cov-2 infection individuals received two vaccine doses evidence prior infection vaccinated p089 
892,221.0,6.0,"['pfizer-biontech reduce two', 'pfizer-biontech reduce sars-cov-2']",2337,vaccination greater impact reducing sars-cov-2 infections evidence high viral shedding ct 30 88 reduction two doses 95 ci 80 93 p 0001 self-reported symptoms 90 reduction two doses 95 ci 82 94 p 0001 effects similar different gene positivity patterns 
893,222.0,3.0,"['coronavirus treat 2020', 'coronavirus treat measles-mumps-rubella', 'coronavirus treat mid-april', 'coronavirus treat 2020', 'covid-19 treat 2020', 'covid-19 treat measles-mumps-rubella', 'covid-19 treat mid-april', 'covid-19 treat 2020']",2344,due limitation ecological study design interpretation results treated caution 
894,223.0,0.0,"['one evaluate antibody', 'immunity evaluate antibody']",2345,using electronic health records assessed early impact coronavirus disease covid-19 routine childhood vaccination england 26 april 2020 measles-mumps-rubella vaccination counts fell february 2020 3 weeks introduction physical distancing measures 19 8 lower 95 confidence interval ÃÂÂ20 7 ÃÂÂ18 9 period 2019 improving mid-april gradual decline hexavalent vaccination counts throughout 2020 accentuated physical distancing
895,224.0,4.0,"['immunity circulate four', 'immunity circulate czech', 'immunity circulate antibody', 'immunity circulate one', 'sars-cov-2 circulate four', 'sars-cov-2 circulate czech', 'sars-cov-2 circulate antibody', 'sars-cov-2 circulate one']",2350,information repeatedly questions antibody measurement significance circulating among professionals general public 
896,224.0,7.0,"['immunization vaccinate sputnik', 'immunization vaccinate v', 'immunization vaccinate vaccine', 'worker vaccinate sputnik', 'worker vaccinate v', 'worker vaccinate vaccine']",2353,acknowledging naturally acquired anti-infective immunity addition vaccinated individuals significantly increase perceived level collective immunity 
897,225.0,1.0,"['2021 base 707', '2021 base worker', 'buenos base 707', 'buenos base worker', 'aire base 707', 'aire base worker']",2355,safety 72 h post-immunization analyzed based self-reported form 
898,225.0,5.0,"['muscle pain report diarrhea', '968 report diarrhea', 'participant report diarrhea', 'fever report diarrhea']",2359,total number esavis 1434 total 469 local reactions reported 57 participants reported pain injection site 11 redness swelling 
899,225.0,6.0,['five inform one'],2360,total 968 systemic reactions informed including new worsened muscle pain referred 58 participants fever referred 40 diarrhea referred 5 
900,225.0,7.0,"['hr 138 hospitalize 630', 'hr 138 hospitalize 280', 'hr 138 hospitalize 132-538', '113-538 hospitalize 630', '113-538 hospitalize 280', '113-538 hospitalize 132-538', 'worker hospitalize 630', 'worker hospitalize 280', 'worker hospitalize 132-538']",2361,five percent n 34 serious adverse events one participant hospitalized 
901,225.0,11.0,"['fatality need death', 'inpatient need death', 'covid-19 need death', 'fatality stratify inpatient', 'fatality stratify covid-19', 'fatality stratify patient', 'fatality stratify death']",2365,studies long-term safety stratified sex age needed 
902,226.0,3.0,['second base june'],2369,methods retrospective study based administrative health data electronic case records inpatients consecutively admitted niguarda hospital 21 february 8 november 2020 results overall cfr 18 observed 
903,226.0,10.0,"['vaccine design inpatient', 'vaccine design fatality', 'multi-wave design inpatient', 'multi-wave design fatality']",2376,reasons improvement investigated plan exit strategy case future outbreaks 
904,226.0,19.0,"['south observe covid-19', 'south observe 2021', 'south observe 173', 'south observe anaphylaxis', 'south observe immunisation', 'south observe anaphylaxis', 'korea observe covid-19', 'korea observe 2021', 'korea observe 173', 'korea observe anaphylaxis', 'korea observe immunisation', 'korea observe anaphylaxis']",2385,supplementary information online version contains supplementary material available 101007s10389-021-01675-y 
905,227.0,0.0,['182 treat vaxzevria'],2386,south korea mass vaccination programme administered 38 million doses covid-19 vaccinations 26 february 30 april 2021 173 suspected anaphylaxis reports nationwide monitoring system adverse events following immunisation 44 anaphylaxis cases confirmed using brighton collaboration case definitions 
906,227.0,2.0,"['coronavirus receive covid-19', 'sars receive covid-19', 'cov-2 receive covid-19']",2388,median time onset 14 min vaccination cases recovered time review 
907,228.0,1.0,"['africa need immunodeficiency', 'africa need adult', 'africa need people', 'africa need plwh', 'africa need two', 'africa need vaccine', 'africa need matrix-m1', 'africa inform adult', 'africa inform people', 'africa inform plwh', 'africa inform two', 'africa inform vaccine', 'africa inform matrix-m1', 'human inform adult', 'human inform people', 'human inform plwh', 'human inform two', 'human inform vaccine', 'human inform matrix-m1', 'immunodeficiency inform adult', 'immunodeficiency inform people', 'immunodeficiency inform plwh', 'immunodeficiency inform two', 'immunodeficiency inform vaccine', 'immunodeficiency inform matrix-m1']",2390,evaluation covid-19 vaccine efficacy sars-cov-2 variants urgently needed inform vaccine development use 
908,228.0,2.0,"['vaccine randomize covid-19', 'vaccine randomize sars-cov-2', 'vaccine randomize participant', 'vaccine blind sars-cov-2', 'vaccine blind participant']",2391,methods phase 2ab multicenter randomized observer-blinded placebo-controlled trial south africa healthy human immunodeficiency virus hiv -negative adults 18 84 years medically stable people living hiv plwh 18 84 years randomized 11 ratio receive two doses administered 21 days apart either nvx-cov2373 nanoparticle vaccine 5 micrograms recombinant spike protein 50 micrograms matrix-m1 adjuvant placebo 
909,229.0,1.0,"['cohort compare spike-protein', 'cohort compare diasorin', 'cohort compare roche', 'cohort compare 194', 'cohort compare patient', 'cohort compare 141', 'cohort compare cirrhosis', 'cohort compare a-c', 'cohort induce diasorin', 'cohort induce roche', 'cohort induce 194', 'cohort induce patient', 'cohort induce 141', 'cohort induce cirrhosis', 'cohort induce a-c', 'spike-protein induce diasorin', 'spike-protein induce roche', 'spike-protein induce 194', 'spike-protein induce patient', 'spike-protein induce 141', 'spike-protein induce cirrhosis', 'spike-protein induce a-c']",2404,aimed comparing vaccine-induced humoral t-cell responses vulnerable patient groups 
910,229.0,5.0,"['recipient perform cirrhotic', 'recipient perform patient']",2408,results second vaccination seroconversion achieved 63 lt recipients 100 cirrhotic patients controls using anti-s trimer assay 
911,229.0,8.0,"['recipient develop 457', 'recipient develop arterial', 'recipient develop hypertension', 'recipient develop calcineurin', 'recipient develop inhibitor']",2411,altogether 28 lt recipients neither develop humoral t-cell response second vaccination 
912,230.0,2.0,"['brain aim adenosine', 'brain aim triphosphate', 'brain aim atp']",2417,persons targeted one aims prevent ad 
913,230.0,3.0,"['cerebral need beta aÃ\x83\x83Ã\x83\x82Ã\x82Â²', 'cerebral need amyloid', 'cerebral need pyroglutamate', 'cerebral need synaptic', 'cerebral need atp', 'cerebral need hypometabolism', 'synaptic need beta aÃ\x83\x83Ã\x83\x82Ã\x82Â²', 'synaptic need amyloid', 'synaptic need pyroglutamate', 'synaptic need atp', 'synaptic need hypometabolism', 'hypometabolism need beta aÃ\x83\x83Ã\x83\x82Ã\x82Â²', 'hypometabolism need amyloid', 'hypometabolism need pyroglutamate', 'hypometabolism need synaptic', 'hypometabolism need atp', 'hypometabolism need beta aÃ\x83\x83Ã\x83\x82Ã\x82Â²', 'hypometabolism need amyloid', 'hypometabolism need pyroglutamate', 'hypometabolism need synaptic', 'hypometabolism need atp']",2418,synaptic hypometabolism implies brain s availability adenosine triphosphate atp inadequate performance required synaptic functions 
914,230.0,4.0,"['cyclophilin confirm atp', 'cyclophilin confirm atp', 'cyclophilin reduce atp']",2419,review first describes basis asserting reduced cerebral uptake 18 fÃÂÂfdg accurately reflects synaptic hypometabolism second explains basis asserting hypometabolism implies inadequate atp third shows amyloid beta aÃÂ² aÃÂ² modified pyroglutamate become molecule termed pe 3 aÃÂ² cyclophilinÃÂÂd concert main contributors inadequate synaptic atp therefore reducing levels would neutralize combined effect correct hypometabolism 
915,230.0,5.0,"['mrna reduce person', 'vaccine reduce person', 'brain reduce person', 'atp reduce person']",2420,pe 3 aÃÂ² neurotoxic unmodified aÃÂ² cyclophilin inhibits atp synthase reduces atp formation 
916,230.0,6.0,"['sars-cov-2 describe covid-19', 'immunity describe covid-19']",2421,finally review describes mrna selfÃÂÂreplicating vaccine raise brain levels atp reducing aÃÂ² pyroglutamateÃÂÂmodified aÃÂ² cyclophilinÃÂÂd therebyÃÂÂin cognitively normal elderly persons synaptic hypometabolismÃÂÂprevent initiation process terminates ad 
917,231.0,0.0,"['sars-cov-2 base 963', 'sars-cov-2 base covid-19']",2422,understanding antibody-based sars-cov-2 immunity critical overcoming covid-19 pandemic informing vaccination strategies 
918,231.0,5.0,"['half-lives observe igg', 'half-lives observe igg', '147 observe igg', '147 observe igg', 'serum observe igg', 'serum observe igg']",2427,loss reactivity virus spike protein observed 13 individuals 10 months infection 
919,232.0,2.0,"['plasmodium inform msp1', 'plasmodium inform vaccine', 'plasmodium inform igg', 'plasmodium inform plasma']",2432,serological assays provide population-level infection history inform elimination campaigns 
920,232.0,3.0,"['236 use human', '236 use plasmodium', '236 use plasmodium', '236 use plasmodium', '236 use malariae', '236 use plasmodium', '236 use igg', '236 use pvrmc-msp1', '236 use four', '236 use msp1-19', '236 use isoforms', '236 use plasmodium', 'traveller use human', 'traveller use plasmodium', 'traveller use plasmodium', 'traveller use plasmodium', 'traveller use malariae', 'traveller use plasmodium', 'traveller use igg', 'traveller use pvrmc-msp1', 'traveller use four', 'traveller use msp1-19', 'traveller use isoforms', 'traveller use plasmodium', 'four use human', 'four use plasmodium', 'four use plasmodium', 'four use plasmodium', 'four use malariae', 'four use plasmodium', 'four use igg', 'four use pvrmc-msp1', 'four use msp1-19', 'four use isoforms', 'four use plasmodium', '236 base four', '236 base plasmodium', '236 base human', '236 base plasmodium', '236 base plasmodium', '236 base plasmodium', '236 base malariae', '236 base plasmodium', '236 base igg', '236 base pvrmc-msp1', '236 base four', '236 base msp1-19', '236 base isoforms', '236 base plasmodium', 'traveller base four', 'traveller base plasmodium', 'traveller base human', 'traveller base plasmodium', 'traveller base plasmodium', 'traveller base plasmodium', 'traveller base malariae', 'traveller base plasmodium', 'traveller base igg', 'traveller base pvrmc-msp1', 'traveller base four', 'traveller base msp1-19', 'traveller base isoforms', 'traveller base plasmodium', '236 evaluate plasmodium', '236 evaluate plasmodium', '236 evaluate plasmodium', '236 evaluate malariae', '236 evaluate plasmodium', '236 evaluate igg', '236 evaluate pvrmc-msp1', '236 evaluate four', '236 evaluate msp1-19', '236 evaluate isoforms', '236 evaluate plasmodium', 'traveller evaluate plasmodium', 'traveller evaluate plasmodium', 'traveller evaluate plasmodium', 'traveller evaluate malariae', 'traveller evaluate plasmodium', 'traveller evaluate igg', 'traveller evaluate pvrmc-msp1', 'traveller evaluate four', 'traveller evaluate msp1-19', 'traveller evaluate isoforms', 'traveller evaluate plasmodium', 'four evaluate plasmodium', 'four evaluate plasmodium', 'four evaluate plasmodium', 'four evaluate malariae', 'four evaluate plasmodium', 'four evaluate igg', 'four evaluate pvrmc-msp1', 'four evaluate msp1-19', 'four evaluate isoforms', 'four evaluate plasmodium', 'plasmodium evaluate malariae', 'plasmodium evaluate igg', 'plasmodium evaluate pvrmc-msp1', 'plasmodium evaluate four', 'plasmodium evaluate msp1-19', 'plasmodium evaluate isoforms', '236 design igg', '236 design pvrmc-msp1', '236 design four', '236 design msp1-19', '236 design isoforms', '236 design plasmodium', 'traveller design igg', 'traveller design pvrmc-msp1', 'traveller design four', 'traveller design msp1-19', 'traveller design isoforms', 'traveller design plasmodium', 'four design igg', 'four design pvrmc-msp1', 'four design msp1-19', 'four design isoforms', 'four design plasmodium', 'plasmodium design igg', 'plasmodium design pvrmc-msp1', 'plasmodium design four', 'plasmodium design msp1-19', 'plasmodium design isoforms', 'human design igg', 'human design pvrmc-msp1', 'human design four', 'human design msp1-19', 'human design isoforms', 'human design plasmodium', 'plasmodium design igg', 'plasmodium design pvrmc-msp1', 'plasmodium design four', 'plasmodium design msp1-19', 'plasmodium design isoforms', 'plasmodium design igg', 'plasmodium design pvrmc-msp1', 'plasmodium design four', 'plasmodium design msp1-19', 'plasmodium design isoforms', 'plasmodium design igg', 'plasmodium design pvrmc-msp1', 'plasmodium design four', 'plasmodium design msp1-19', 'plasmodium design isoforms', 'malariae design igg', 'malariae design pvrmc-msp1', 'malariae design four', 'malariae design msp1-19', 'malariae design isoforms', 'malariae design plasmodium', '236 play isoforms', '236 play plasmodium', 'traveller play isoforms', 'traveller play plasmodium', 'four play isoforms', 'four play plasmodium', 'plasmodium play isoforms', 'human play isoforms', 'human play plasmodium', 'plasmodium play isoforms', 'plasmodium play isoforms', 'plasmodium play isoforms', 'malariae play isoforms', 'malariae play plasmodium', 'plasmodium play isoforms', 'igg play isoforms', 'igg play plasmodium', 'pvrmc-msp1 play isoforms', 'pvrmc-msp1 play plasmodium', 'four play isoforms', 'four play plasmodium']",2433,methods bead-based multiplex antibody detection assay used evaluate chimeric plasmodium vivax msp1 protein pvrmc-msp1 designed broadly immunogenic use vaccine studies act pan-malaria serological tool based ability capture igg plasma samples obtained naturally exposed individuals 
921,232.0,4.0,"['plasmodium confirm plasma', 'plasmodium confirm sample', 'plasmodium confirm traveller', 'plasmodium confirm pvrmc-msp1', 'plasmodium confirm 115', 'plasmodium confirm 236', 'plasmodium confirm 487', 'plasmodium infect 115', 'plasmodium infect 236', 'plasmodium infect 487', 'plasma infect 115', 'plasma infect 236', 'plasma infect 487', 'sample infect 115', 'sample infect 236', 'sample infect 487', 'traveller infect 115', 'traveller infect 236', 'traveller infect 487']",2434,samples 236 us travellers pcr confirmed infection status four major plasmodium species infecting humans plasmodium falciparum n 181 plasmodium vivax n 38 plasmodium malariae n 4 plasmodium ovale n 13 tested igg capture using pvrmc-msp1 well four recombinant msp1-19 kd isoforms representative plasmodium species 
922,232.0,5.0,"['infection infect falciparum-', 'infection infect vivax-', 'infection infect 750', 'infection infect malariae-', '387 infect falciparum-', '387 infect vivax-', '387 infect 750', '387 infect malariae-']",2435,results regardless infecting plasmodium species large proportion plasma samples infected us travellers provided high assay signal pvrmc-msp1 chimeric protein 115 high responders 236 samples assessed 487 
923,232.0,7.0,"['pvrmc-msp1 increase pvmsp1', 'pvrmc-msp1 increase 387', 'pvrmc-msp1 increase falciparum-infected', 'pvrmc-msp1 increase traveller', 'pvrmc-msp1 increase pvmsp1', 'antibody increase pvmsp1', 'antibody increase 387', 'antibody increase falciparum-infected', 'antibody increase traveller', 'antibody increase pvmsp1', 'pvrmc-msp1 infect pvmsp1', 'pvrmc-msp1 infect 387', 'pvrmc-msp1 infect falciparum-infected', 'pvrmc-msp1 infect traveller', 'pvrmc-msp1 infect pvmsp1', 'antibody infect pvmsp1', 'antibody infect 387', 'antibody infect falciparum-infected', 'antibody infect traveller', 'antibody infect pvmsp1', 'pvrmc-msp1 compare pvmsp1', 'antibody compare pvmsp1', '387 compare pvmsp1', 'falciparum-infected compare pvmsp1', 'traveller compare pvmsp1']",2437,also determined plasma p vivax-infected individuals produced increased assay signals response pvrmc-msp1 chimera compared recombinant pvmsp1 895 34 38 individuals 
924,232.0,8.0,"['antigen include plasmodium', 'antigen infect plasmodium', 'antigen compare plasmodium']",2438,pvrmc-msp1 also showed improved ability capture igg antibodies p falciparum-infected individuals compared capture recombinant pvmsp1 high assay signals observed 387 p falciparum-infected travellers response pvrmc-msp1 igg capture compared 11 high responders capture recombinant pvmsp1 protein 
925,232.0,9.0,"['plasmodium bind seroestimates', 'bead bind seroestimates', 'igg bind seroestimates', 'plasmodium design igg', 'plasmodium design seroestimates', 'bead design igg', 'bead design seroestimates', 'plasmodium increase igg', 'plasmodium increase seroestimates', 'bead increase igg', 'bead increase seroestimates']",2439,conclusions results support study designed antigens approach increasing sensitivity broadening binding capacity improve existing serological tools determining population-level exposure plasmodium species 
926,232.0,10.0,['malaria coat vivax'],2440,including broad-reacting plasmodium species-specific antigen-coated beads assay panel could provide nuanced view population-level exposure histories extensive igg profile detailed seroestimates 
927,233.0,0.0,"['vaccine approve syndrome', 'vaccine approve coronavirus', 'vaccine approve sars-cov-2', 'vaccine approve 2-dose', 'covid-19 approve syndrome', 'covid-19 approve coronavirus', 'covid-19 approve sars-cov-2', 'covid-19 approve vaccine', 'covid-19 approve 2-dose', 'vaccine need syndrome', 'vaccine need coronavirus', 'vaccine need sars-cov-2', 'vaccine need 2-dose', 'covid-19 need syndrome', 'covid-19 need coronavirus', 'covid-19 need sars-cov-2', 'covid-19 need vaccine', 'covid-19 need 2-dose', 'vaccine treat sars-cov-2', 'vaccine treat 2-dose', 'covid-19 treat sars-cov-2', 'covid-19 treat vaccine', 'covid-19 treat 2-dose', 'syndrome treat sars-cov-2', 'syndrome treat vaccine', 'syndrome treat 2-dose']",2442,two coronavirus disease 2019 covid-19 vaccines currently approved united states require 2 doses administered 3 4 weeks apart 
928,233.0,2.0,"['vaccine base 173', 'vaccine base infection', 'vaccine base cri', 'vaccine base cri', 'vaccine base death', 'vaccine compare 173', 'vaccine compare infection', 'vaccine compare cri', 'vaccine compare cri', 'vaccine compare death', 'vaccine vary infection', 'vaccine vary cri', 'vaccine vary cri', 'vaccine vary death', '173 vary infection', '173 vary cri', '173 vary cri', '173 vary death', 'vaccine follow cri', 'vaccine follow death', '173 follow cri', '173 follow death', 'infection follow cri', 'infection follow death', 'cri follow death']",2444,developed agent-based model covid-19 transmission compare impact 2 vaccination strategies varying temporal waning vaccine efficacy following first dose level preexisting immunity population 
929,233.0,3.0,"['vaccine maximize second', 'vaccine maximize dsd', 'vaccine maximize 3-week', 'cri maximize second', 'cri maximize dsd', 'cri maximize 3-week', 'cri maximize second', 'cri maximize dsd', 'cri maximize 3-week', 'death maximize second', 'death maximize dsd', 'death maximize 3-week', 'vaccine show cri', 'vaccine show cri', 'vaccine show death', 'vaccine show second', 'vaccine show dsd', 'vaccine show 3-week']",2445,results show moderna vaccines delay least 9 weeks could maximize vaccination program effectiveness avert least additional 173 95 credible interval cri 78-297 infections 069 95 cri 052-097 hospitalizations 034 95 cri 025-044 deaths per 10000 population compared recommended 4-week interval 2 doses 
930,233.0,5.0,['vaccine-induced observe optimal'],2447,however clear advantage delaying second dose pfizer-biontech vaccines reducing infections unless efficacy first dose wane time 
931,233.0,6.0,"['vaccine induce brucella', 'vaccine induce outer', 'vaccine induce omp', 'vaccine induce sod', 'human induce brucella', 'human induce outer', 'human induce omp', 'human induce sod', 'brucellosis induce brucella', 'brucellosis induce outer', 'brucellosis induce omp', 'brucellosis induce sod', 'influenza induce brucella', 'influenza induce outer', 'influenza induce omp', 'influenza induce sod', 'rivv induce brucella', 'rivv induce outer', 'rivv induce omp', 'rivv induce sod', 'vaccine observe sod', 'human observe sod', 'brucellosis observe sod', 'influenza observe sod', 'rivv observe sod', 'h5n1 observe sod', 'brucella observe sod', 'outer observe sod', 'omp observe sod']",2448,findings underscore importance quantifying characteristics durability vaccine-induced protection first dose order determine optimal time interval 2 doses 
932,234.0,2.0,"['guinea provide pig', 'guinea provide weight-gain', 'pig provide guinea', 'pig provide weight-gain']",2451,provided data novel vaccine candidate contribute movement preclinical stage study 
933,234.0,3.0,"['vaccine base conjunctival', 'vaccine base 10', 'vaccine base eid', 'vaccine base 10', 'vaccine base eid', 'vaccine base eid', 'vaccine base boost', 'vaccine base animal']",2452,methods general states guinea pigs assessed based behavior dynamics guinea pig weight-gain test 
934,234.0,6.0,"['body evaluate guinea', 'body evaluate pig', 'body evaluate booster', 'body evaluate immunization', 'body evaluate vaccine', 'body evaluate conjunctival', 'body evaluate vaccine', 'body compare vaccine', 'guinea compare vaccine', 'pig compare vaccine', 'booster compare vaccine', 'immunization compare vaccine', 'conjunctival compare vaccine']",2455,protective properties vaccines assessed quantitation brucella colonization organs tissues infected animals compared control groups 
935,234.0,7.0,"['vaccine use infection', 'vaccine use p', 'immunization use infection', 'immunization use p', 'immunization use vaccine', 'guinea use infection', 'guinea use p', 'guinea use vaccine', 'pig use infection', 'pig use p', 'pig use vaccine', 'eid use infection', 'eid use p', 'eid use vaccine', 'guinea use infection', 'guinea use p', 'guinea use vaccine', 'pig use infection', 'pig use p', 'pig use vaccine']",2456,results observed gradual increase body weight guinea pigs prime booster immunization vaccine using conjunctival intranasal sublingual routes administration well using various doses vaccine 
936,234.0,8.0,"['vaccine establish pig', 'brucellosis establish pig', 'vaccine use brucellosis', 'vaccine use immunization', 'vaccine use pig']",2457,optimal way using vaccine established double intranasal immunization guinea pigs dose 10 6 eid 50 provides 80 protection guinea pigs b melitensis 16 infection p 005 comparable results effectiveness commercial b melitensis rev1 vaccine 
937,234.0,11.0,"['czech see coronavirus', 'czech see approximately', 'czech see 2-3', 'czech see people', 'czech see infection', 'republic see coronavirus', 'republic see approximately', 'republic see 2-3', 'republic see people', 'republic see infection', 'one see coronavirus', 'one see approximately', 'one see 2-3', 'one see people', 'one see infection']",2460, image see text 
938,235.0,2.0,['antigen test immunity'],2463,purpose appropriate examine igg antibodies 
939,235.0,4.0,['covid-19 observe antigen'],2465,aim pilot study determine number immune individuals infection three clinics gennet sro 
940,235.0,6.0,"['people vaccinate igg', 'people vaccinate antibody', 'people vaccinate infection', 'people vaccinate 209', 'people vaccinate antibody', 'people vaccinate igg', 'people vaccinate antibody', 'people vaccinate infection', 'people vaccinate 209', 'people vaccinate antibody']",2467,cohort included 297 subjects 182 vaccinated 613 115 subjects 387 vaccination 
941,235.0,8.0,"['people test 581', 'people test liberec', 'people test immune', 'people test infection', 'people test 581', 'people test liberec', 'people test immune', 'people test infection', 'antibody test 581', 'antibody test liberec', 'antibody test immune', 'antibody test infection', '743 test 581', '743 test liberec', '743 test immune', '743 test infection', 'employee test 581', 'employee test liberec', 'employee test immune', 'employee test infection']",2469,far 55 persons 302 examined 
942,235.0,13.0,"['people test infection', 'antibody test infection']",2474,person antibodies tested positive antigen 
943,235.0,16.0,"['influenza vaccines include vaccine', 'low-dose include vaccine']",2477,based study recommend including antibody testing antiepidemic measures limit antigen testing seronegative individuals 
944,236.0,1.0,"['embase inform influenza', '2020 inform influenza', 'age inform influenza']",2479,objective compare immunogenicity safety influenza vaccine reduced full intradermal doses full intramuscular doses inform policy design event vaccine shortages 
945,236.0,7.0,"['75-Ã\x83\x83Ã\x83\x82Ã\x82Âµg include vaccine', '75-Ã\x83\x83Ã\x83\x82Ã\x82Âµg include 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', '75-Ã\x83\x83Ã\x83\x82Ã\x82Âµg include vaccine', '75-Ã\x83\x83Ã\x83\x82Ã\x82Âµg include h1n1', '75-Ã\x83\x83Ã\x83\x82Ã\x82Âµg include h3n2', '75-Ã\x83\x83Ã\x83\x82Ã\x82Âµg include b', '75-Ã\x83\x83Ã\x83\x82Ã\x82Âµg include 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', '75-Ã\x83\x83Ã\x83\x82Ã\x82Âµg include 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', '75-Ã\x83\x83Ã\x83\x82Ã\x82Âµg include 101-120', '75-Ã\x83\x83Ã\x83\x82Ã\x82Âµg randomize vaccine', '75-Ã\x83\x83Ã\x83\x82Ã\x82Âµg randomize h1n1', '75-Ã\x83\x83Ã\x83\x82Ã\x82Âµg randomize h3n2', '75-Ã\x83\x83Ã\x83\x82Ã\x82Âµg randomize b', '75-Ã\x83\x83Ã\x83\x82Ã\x82Âµg randomize 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', '75-Ã\x83\x83Ã\x83\x82Ã\x82Âµg randomize 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', '75-Ã\x83\x83Ã\x83\x82Ã\x82Âµg randomize 101-120', 'vaccine randomize h1n1', 'vaccine randomize h3n2', 'vaccine randomize b', 'vaccine randomize 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'vaccine randomize 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'vaccine randomize 101-120', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg randomize vaccine', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg randomize h1n1', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg randomize h3n2', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg randomize b', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg randomize 101-120']",2485,results total 30 relevant studies included 29 studies randomized clinical trials 13 759 total participants 1 study cohort study 164 021 participants 
946,236.0,9.0,"['adverse compare ci', 'adverse compare 9-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'adverse compare 456', 'adverse compare 305-682', 'adverse compare 319-425', 'adverse compare swelling', 'adverse compare 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'adverse compare 347', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg compare ci', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg compare 9-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg compare 456', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg compare 305-682', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg compare 319-425', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg compare swelling', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg compare 347', 'intramuscular compare ci', 'intramuscular compare 9-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'intramuscular compare 456', 'intramuscular compare 305-682', 'intramuscular compare 319-425', 'intramuscular compare swelling', 'intramuscular compare 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'intramuscular compare 347', 'adverse dose 9-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'adverse dose 456', 'adverse dose 305-682', 'adverse dose 319-425', 'adverse dose swelling', 'adverse dose 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'adverse dose 347', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg dose 9-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg dose 456', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg dose 305-682', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg dose 319-425', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg dose swelling', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg dose 347', 'intramuscular dose 9-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'intramuscular dose 456', 'intramuscular dose 305-682', 'intramuscular dose 319-425', 'intramuscular dose swelling', 'intramuscular dose 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'intramuscular dose 347', '962 dose 9-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', '962 dose 456', '962 dose 305-682', '962 dose 319-425', '962 dose swelling', '962 dose 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', '962 dose 347', 'adverse dose 319-425', 'adverse dose swelling', 'adverse dose 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'adverse dose 347', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg dose 319-425', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg dose swelling', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg dose 347', 'intramuscular dose 319-425', 'intramuscular dose swelling', 'intramuscular dose 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'intramuscular dose 347', '962 dose 319-425', '962 dose swelling', '962 dose 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', '962 dose 347', 'ci dose 319-425', 'ci dose swelling', 'ci dose 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'ci dose 347', '9-Ã\x83\x83Ã\x83\x82Ã\x82Âµg dose 319-425', '9-Ã\x83\x83Ã\x83\x82Ã\x82Âµg dose swelling', '9-Ã\x83\x83Ã\x83\x82Ã\x82Âµg dose 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', '9-Ã\x83\x83Ã\x83\x82Ã\x82Âµg dose 347', '456 dose 319-425', '456 dose swelling', '456 dose 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', '456 dose 347', '305-682 dose 319-425', '305-682 dose swelling', '305-682 dose 15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', '305-682 dose 347']",2487,seroprotection rates 9-ÃÂµg 15-ÃÂµg intradermal doses vary significantly compared 15-ÃÂµg intramuscular dose 3 strains except 15-ÃÂµg intradermal dose h1n1 strain rates significantly higher rr 105 95 ci 101-109 
947,236.0,10.0,"['fever dose 103-150', 'chill dose 103-150', '9-Ã\x83\x83Ã\x83\x82Ã\x82Âµg dose 103-150', 'intradermal dose 103-150', '15-Ã\x83\x83Ã\x83\x82Ã\x82Âµg dose 103-150', 'fever dose 103-150', '136 dose 103-150', 'ci dose 103-150', '103-180 dose 103-150']",2488,local adverse events significantly higher intradermal doses 15-ÃÂµg intramuscular dose particularly erythema 3-ÃÂµg dose rr 962 95 ci 107-8656 6-ÃÂµg dose rr 2379 95 ci 1442-3923 9-ÃÂµg dose rr 456 95 ci 305-682 15-ÃÂµg dose rr 368 95 ci 319-425 swelling 3-ÃÂµg dose rr 2016 95 ci 468-8682 9-ÃÂµg dose rr 523 95 ci 358-762 15-ÃÂµg dose rr 347 95 ci 221-545 
948,237.0,1.0,"['patient repeat sars-cov-2', 'patient repeat pakistan']",2492,report case series repeated infections sars-cov-2 
949,237.0,2.0,"['infection receive transcriptase-polymerase', 'sars-cov-2 receive transcriptase-polymerase']",2493,methods total 12 patients identified repeated infections sars-cov-2 25 april 2020 16 march 2021 pakistan 
950,237.0,7.0,['covid-19 vaccinate sars-cov-2'],2498,none vaccinated 
951,238.0,4.0,"['vaccine compare patient', 'vaccine compare lip', 'vaccine compare 081', 'vaccine compare rba', 'vaccine compare 472', 'vaccine compare 491']",2504,ha antibodies increased nt1 patients compared controls exploratory lips p 00295 rba p 00369 confirmatory cohort lips p 055 rba p 0625 
952,238.0,5.0,['lip evaluate hla-dqb1'],2505,ha antibody affinity assessed competition pandemrix vaccine comparable patients controls lips 48 vs 39 ngml p 081 rba 472 vs 491 ngml p 065 
953,238.0,6.0,"['antibody associate patient', 'antibody associate nt1']",2506,lips assay also detected higher ha antibody titres associated hla-dqb1 060201 p 002 
954,239.0,2.0,['medrxiv induce 2021'],2510,complied prisma guidelines conducting meta-analysis 
955,239.0,7.0,"['schizophrenia induce mood disorders', 'schizophrenia induce patient', 'schizophrenia induce patient', 'schizotypal induce mood disorders', 'schizotypal induce patient', 'schizotypal induce patient']",2515,increase risk covid-19 mortality severity remained significant model included studies adjusted confounding variables 
956,239.0,8.0,"['two observe mental disorders', 'two observe covid-19', 'two observe patient', 'two observe covid-19', 'two observe vaccine', 'two include mental disorders', 'two include patient', 'two include covid-19', 'two include vaccine']",2516,furthermore higher mortality noticed included studies among schizophrenia schizotypal delusional disorders patients compared mood disorders patients 
957,239.0,9.0,"['worker provide sars-cov-2', 'worker provide covid-19', 'hcws provide sars-cov-2', 'hcws provide covid-19', 'line provide sars-cov-2', 'line provide covid-19']",2517,meta-analysis provided two models reported significant increase risk covid-19 severity mortality among patients mental disorders upcoming covid-19 vaccines recommend give category priority vaccination campaigns along medical health providers elderly 
958,240.0,1.0,"['2021 evaluate sars-cov-2', '2021 evaluate hcws']",2519,conducted systematic review meta-analysis assess incidence postvaccination sars-cov-2 infection among vaccinated hcws 
959,240.0,2.0,['meta-analysis explore covid-19'],2520,methodswe searched multiple databases inception august 2021 identify studies reported incidence postvaccination sars-cov-2 infection among hcws 
960,240.0,5.0,"['covid-19 vaccinate hcws', 'infection vaccinate hcws']",2523,total number partially vaccinated fully vaccinated unvaccinated hcws 132922 155673 17505 respectively 
961,240.0,6.0,['hcws vaccinate 101'],2524,overall pooled proportion covid-19 infections among partiallyfully vaccinated unvaccinated hcws 21 95 ci 12-35 
962,240.0,9.0,"['influenza vaccinate influenza-related', 'influenza induce influenza-related']",2527,remains urgent need frontline hcws vaccinated sars-cov-2 infection 
963,241.0,1.0,['influenza induce antigen'],2529,two antigenically distinct lineages co-circulate worldwide often resulting mismatches vaccine coverage vaccine predictions fail 
964,242.0,0.0,"['vaccine receive headache', 'vaccine receive tiredness']",2533,first covid-19 vaccination given december 2020 effort vaccinate international population massive scale 
965,242.0,2.0,"['two describe supraclavicular', 'two describe lymphadenopathy', 'two describe patient', 'two describe covid']",2535,regional lymphadenopathy described relation vaccines 
966,243.0,0.0,"['patient test transcarpathian', 'patient test diphtheria', 'patient test diphtheria', 'patient test immunity']",2538,objective aim study dynamics incidence diphtheria transcarpathian region ukraine 
967,244.0,0.0,"['leumit increase 183', 'leumit increase patient', 'leumit increase diabetes', 'leumit increase pre-covid-19', 'leumit increase hba1c', 'lh increase 183', 'lh increase patient', 'lh increase diabetes', 'lh increase pre-covid-19', 'lh increase hba1c', 'leumit develop pre-covid-19', 'leumit develop hba1c', 'lh develop pre-covid-19', 'lh develop hba1c', '183 develop pre-covid-19', '183 develop hba1c', 'patient develop pre-covid-19', 'patient develop hba1c']",2541,introduction people diabetes mellitus increased risk developing severe disease death contracting coronavirus disease 2019 covid-19 effect pre-covid-19 infection glycemic control disease outcomes still unclear 
968,244.0,1.0,"['patient emerge covid-19', 'patient emerge lh', 'patient emerge hba1c']",2542,previous study published leumit health services lhs including 183 patients diabetes pre-covid-19 infection hba1c 9 associated need hospitalization disease 
969,244.0,2.0,"['patient die diabetes', 'patient die pre-diabetes', 'lh die diabetes', 'lh die pre-diabetes', 'covid-19 die diabetes', 'covid-19 die pre-diabetes']",2543,current study present clinical characteristics patients died covid-19 lhs demonstrate significant link pre-infection hba1c 
970,244.0,3.0,"['covid-19 consider patient', 'covid-19 consider survivor', 'covid-19 observe patient', 'covid-19 observe survivor']",2544,methods collected demographic clinical laboratory information regarding patients insured lhs contracted covid-19 1st february 31st may 2020 diabetes pre-diabetes 
971,244.0,5.0,"['patient receive dementia cerebrovascular', 'patient receive heart failure', 'patient receive hba1c', 'patient receive creatinine', 'patient receive hemoglobin', 'patient receive iron', 'patient receive vitamin', 'patient receive obesity', 'patient receive sglt-2', 'patient receive inhibitor', 'patient die dementia cerebrovascular', 'patient die heart failure', 'patient die obesity', 'patient die sglt-2', 'patient die inhibitor', 'hba1c die dementia cerebrovascular', 'hba1c die heart failure', 'hba1c die patient', 'hba1c die obesity', 'hba1c die sglt-2', 'hba1c die inhibitor', 'creatinine die dementia cerebrovascular', 'creatinine die heart failure', 'creatinine die patient', 'creatinine die obesity', 'creatinine die sglt-2', 'creatinine die inhibitor', 'hemoglobin die dementia cerebrovascular', 'hemoglobin die heart failure', 'hemoglobin die patient', 'hemoglobin die obesity', 'hemoglobin die sglt-2', 'hemoglobin die inhibitor', 'iron die dementia cerebrovascular', 'iron die heart failure', 'iron die patient', 'iron die obesity', 'iron die sglt-2', 'iron die inhibitor', 'vitamin die dementia cerebrovascular', 'vitamin die heart failure', 'vitamin die patient', 'vitamin die obesity', 'vitamin die sglt-2', 'vitamin die inhibitor']",2546,results identified 888 patients 24 27 died covid-19 
972,244.0,8.0,"['covid-19 associate vaccine', 'covid-19 associate at-risk']",2549,conclusions pre- covid-19 hba1c levels prior cerebrovascular disease associated increased risk mortality 
973,244.0,10.0,"['covid-19 need vaccine', 'vaccine need covid-19', 'vaccine receive covid-19', 'vaccine receive covid-19']",2551,study needed understand potential mechanism causality poor glycemic control covid-19 death 
974,245.0,2.0,"['author receive metabolic syndrome', 'author receive covid-19', 'author receive vaccine', 'author receive recipient', 'blood receive metabolic syndrome', 'blood receive covid-19', 'blood receive vaccine', 'blood receive recipient']",2554,thrombosis problem might occur covid-19 vaccination increased blood viscosity pathomechanism 
975,246.0,2.0,"['immunity use patient', 'immunity use hepcidin', 'immunity use serum', 'immunity use iron', 'immunity use tmprss6']",2562,methods used hepcidin mimetic several genetic models examine effect low iron availability cells vitro immune responses vaccines viral infection mice 
976,246.0,3.0,"['iron elicit iron deficiency', 'immunity elicit iron deficiency', 'piglet elicit iron deficiency']",2563,examined humoral immunity human patients raised hepcidin low serum iron caused mutant tmprss6 
977,246.0,4.0,"['serum induce immunization', 'iron induce immunization', 'hypoferremia induce immunization', 'hepcidin induce immunization']",2564,tested effect iron supplementation vaccination-induced humoral immunity piglets natural model iron deficiency 
978,246.0,6.0,"['iron facilitate antibody', 'mouse facilitate antibody', 'piglet facilitate antibody', 'hypoferremic facilitate antibody', 'human facilitate antibody', 'iron activate mouse', 'iron activate piglet', 'iron activate hypoferremic', 'iron activate human', 'iron activate hepcidin', 'iron activate antibody', 'iron need mouse', 'iron need piglet', 'iron need hypoferremic', 'iron need human', 'iron need hepcidin', 'iron need antibody']",2566,intensified metabolism activated lymphocytes requires support enhanced iron acquisition facilitated irp12 tfrc 
979,246.0,7.0,"['hypoferremia provide b cell', 'hypoferremia provide cell', 'hypoferremia provide influenza', 'hypoferremia provide mouse', 'hypoferremia provide lung', 'hypoferremia provide inflammation', 'b cell improve influenza', 'b cell improve mouse', 'b cell improve lung', 'b cell improve inflammation', 'hypoferremia improve influenza', 'hypoferremia improve mouse', 'hypoferremia improve lung', 'hypoferremia improve inflammation', 'cell improve influenza', 'cell improve mouse', 'cell improve lung', 'cell improve inflammation']",2567,accordingly providing extra iron improved response vaccination hypoferremic mice piglets conversely hypoferremic humans chronically increased hepcidin reduced concentrations antibodies specific certain pathogens 
980,246.0,8.0,"['hypoferremia blunt infection', 'hypoferremia blunt immunity']",2568,imposing hypoferremia blunted cell b cell neutralizing antibody responses influenza virus infection mice allowing virus persist exacerbating lung inflammation morbidity 
981,246.0,9.0,"['nutrient conserve inflammatory disorders', 'nutrient conserve vaccine', 'nutrient conserve iron', 'immune conserve inflammatory disorders', 'immune conserve vaccine', 'immune conserve iron']",2569,conclusions hypoferremia well-conserved physiological innate response infection counteract development adaptive immunity 
982,247.0,0.0,"['protean infect symptom', 'protean infect multiorgan', 'protean infect failure', 'protean infect death']",2572,sars-cov-2 covid-19 infected 124 million people worldwide total amount casualties sits staggering 27 million 
983,247.0,2.0,"['kidney emerge death', 'kidney emerge death']",2574,chronic kidney disease ckd emerged primary risk factor severe patients apart age 
984,247.0,3.0,"['italian correlate patient', '10-fold correlate patient']",2575,kidney disease acute kidney injury correlated higher risk death 
985,247.0,5.0,"['three need vaccine', 'three need two', 'three need mrna']",2577,dramatic numbers require immediate response 
986,247.0,9.0,"['melanoma mandate patient', 'melanoma mandate therapy', 'last mandate patient', 'last mandate therapy', 'immunotherapy mandate patient', 'immunotherapy mandate therapy', 'melanoma contract patient', 'melanoma contract therapy', 'last contract patient', 'last contract therapy']",2581,high mortality ckd dialysis patients contracting covid-19 mandate top priority vaccination 
987,248.0,0.0,"['vaccine modify tumor', 'vaccine modify immunotherapy', 'vaccine modify melanoma']",2582,background melanoma therapy changed dramatically last decade improvements immunotherapy yet many patients respond current therapies 
988,248.0,2.0,"['patient randomize yeast', 'patient randomize cell', 'vaccine randomize yeast', 'vaccine randomize cell']",2584,methods prospective randomized double-blind placebo-controlled phase iib trial tumor lysate particle-loaded dendritic cell tlpldc vaccine administered prevent recurrence patients resected stage iiiiv melanoma 
989,248.0,4.0,"['144 treat vaccine', 'patient treat vaccine']",2586,intention-to-treat itt per treatment pt analyses predefined pt analysis including patients remained disease-free primary vaccineplacebo series 6 months 
990,248.0,9.0,"['inhibitor recur patient', 'inhibitor recur melanoma', 'inhibitor prevent melanoma', 'inhibitor prevent melanoma', 'patient prevent melanoma']",2591,suggests patients recur early benefit tlpldc preventing future recurrence melanoma 
991,248.0,12.0,"['respiratory observe sars-cov-2', 'syndrome observe sars-cov-2']",2594,supplementary information online version contains supplementary material available 101245s10434-021-09709-1 
992,249.0,0.0,"['infection induce sars-cov-2', 'immunity induce sars-cov-2', 'igg induce sars-cov-2', 'antibody induce sars-cov-2']",2595,immune response severe acute respiratory syndrome coronavirus 2 sars-cov-2 infection current pandemic remains field immense interest active research worldwide 
993,249.0,1.0,"['igg aim infection', 'igg aim sars-cov-2', 'igg aim antigen', 'igg aim patient', 'igg induce sars-cov-2', 'igg induce antigen', 'igg induce patient', 'infection induce igg', 'infection induce sars-cov-2', 'infection induce antigen', 'infection induce patient']",2596,although severity acute infection may depend intensity innate adaptive immunity leading higher morbidity mortality longevity igg antibodies including neutralizing activity sars-cov-2 viewed key correlate immune protection 
994,249.0,3.0,"['igg bind coronaviruses', 'igg bind sars', 'igg bind east', 'mo bind coronaviruses', 'mo bind sars', 'mo bind east', 'immunity bind coronaviruses', 'immunity bind sars', 'immunity bind east', 'igg neutralize east', 'mo neutralize east', 'immunity neutralize east', 'covid-19 neutralize east', 'coronaviruses neutralize east']",2598,herein show correlation igg anti-spike protein s1 subunit receptor binding domain nucleocapsid virus neutralizing antibody titers clinical features length severity covid-19 illness 
995,249.0,4.0,"['mrna use pancreatic adenocarcinoma', 'mrna use paad', 'mrna receive paad', 'vaccine receive paad']",2599,importantly using orthogonal measurements found igg titers persist 4 mo post symptom onset implying long-lasting immunity covid-19 infection vaccination might observed seen coronaviruses sars middle east respiratory syndrome 
996,250.0,2.0,"['239 receive rna-seq', '239 receive 103', '239 receive tcga']",2602,aim study identify potent antigens paad mrna vaccine development distinguish immune subtypes paad construct immune landscape selecting suitable patients vaccination 
997,250.0,5.0,"['six use tumor', 'six use paad', 'six use adam9', 'six use efnb2', 'six use tmod3', 'six use tpx2', 'six use wnt7a', 'six use paad', 'six use adam9', 'six use efnb2', 'six use tmod3', 'six use tpx2', 'six use wnt7a', 'tumor use paad', 'tumor use adam9', 'tumor use efnb2', 'tumor use tmod3', 'tumor use tpx2', 'tumor use wnt7a']",2605,consensus cluster used consistency matrix construction data clustering david used functional annotation graph learning-based dimensional reduction used depict immune landscape 
998,250.0,6.0,"['five mutate paad', 'five mutate patient', 'five mutate cohort', 'five associate paad', 'five associate patient', 'five associate cohort', 'nine associate paad', 'nine associate patient', 'nine associate cohort']",2606,results six overexpressed mutated tumor antigens associated poor prognosis infiltration antigen presenting cells identified paad including adam9 efnb2 met tmod3 tpx2 wnt7a 
999,250.0,9.0,"['is5 show tumor', 'is5 activate tumor']",2609,is1 is2 exhibited immune-activated phenotypes correlated better survival compared subtypes 
1000,250.0,10.0,"['death associate five', 'ca125 associate five']",2610,is4 is5 tumors immunologically cold associated higher tumor mutation burden 
1001,250.0,12.0,"['adam9 show antigen', 'adam9 show anti-paad', 'adam9 show mrna', 'adam9 show vaccine', 'adam9 show patient', 'adam9 show is5', 'adam9 show tumor', 'efnb2 show antigen', 'efnb2 show anti-paad', 'efnb2 show mrna', 'efnb2 show vaccine', 'efnb2 show patient', 'efnb2 show is5', 'efnb2 show tumor', 'tmod3 show antigen', 'tmod3 show anti-paad', 'tmod3 show mrna', 'tmod3 show vaccine', 'tmod3 show patient', 'tmod3 show is5', 'tmod3 show tumor', 'wnt7a show antigen', 'wnt7a show anti-paad', 'wnt7a show mrna', 'wnt7a show vaccine', 'wnt7a show patient', 'wnt7a show is5', 'wnt7a show tumor']",2612,finally immune landscape paad showed high degree heterogeneity individual patients 
1002,250.0,13.0,['sars-cov-2 meet vaccine'],2613,conclusions adam9 efnb2 met tmod3 tpx2 wnt7a potent antigens developing anti-paad mrna vaccine patients is4 is5 tumors suitable vaccination 
1003,251.0,2.0,"['worker experience sars-cov-2', 'hcws experience sars-cov-2', 'two experience sars-cov-2']",2616,report case series 9 covid-19 patients experienced two clinically- andor virologically-confirmed episodes covid-19 
1004,251.0,6.0,"['sars-cov-2 induce second', 'sars-cov-2 induce patient', 'sars-cov-2 become patient', 'second become patient']",2620,negative correlation numbers days patients took become sars-cov-2 negative rt-cpr andor clinically recover first episode second episode irrespective time spent remission 
1005,251.0,7.0,"['respiratory associate child', 'rsv associate child']",2621,conclusion shorter durations sars-cov-2 infection first episode associated longer time recovery second episode patients re-infectionreactivation 
1006,252.0,1.0,['rsv associate premature'],2623,majority rsv-associated lower respiratory tract infections lrti mortality occurs developing countries associated various sociodemographic risk factors 
1007,252.0,2.0,"['rsv include high-risk', 'rsv include infant']",2624,independent risk factors severe rsv disease include age premature birth 
1008,252.0,3.0,"['rsv develop caregiver', 'lrti develop caregiver', 'rsv develop caregiver', 'lrti develop caregiver']",2625,rsv mortality developed countries lower relative developing countries high-risk infants comorbidities experience higher rates mortality 
1009,252.0,5.0,['vaccine receive antibody'],2627,overall factors translate higher health care resource utilization costs factored consideration rsv prophylaxis 
1010,252.0,6.0,"['palivizumab play high-risk', 'rsv play high-risk', 'immunoprophylaxis play high-risk']",2628,multiple vaccine candidates long-acting monoclonal antibodies various stages clinical development 
1011,252.0,8.0,"['sars-cov-2 relate covid-19', 'sars-cov-2 relate convalescent', 'sars-cov-2 relate patient', 'covid-19 relate convalescent', 'covid-19 relate patient']",2630,review discuss socioeconomic impact health care resource utilization rsv-related hospitalization rsvh well various sociodemographic risk factors used identify children high risk developing severe rsv disease 
1012,253.0,1.0,['sars-cov-2-specific focus antibody'],2632,currently assessment sars-cov-2-specific immunity mainly focused measurement antibody titers analysis neutralizing capacity 
1013,253.0,2.0,"['cellular lack covid-t', 'cellular lack sars-cov-2-specific', 'cellular lack cell', 'convalescent lack covid-t', 'convalescent lack sars-cov-2-specific', 'convalescent lack cell', 'patient lack covid-t', 'patient lack sars-cov-2-specific', 'patient lack cell', 'cellular show sars-cov-2-specific', 'cellular show cell', 'convalescent show sars-cov-2-specific', 'convalescent show cell', 'patient show sars-cov-2-specific', 'patient show cell', 'covid-t show sars-cov-2-specific', 'covid-t show cell']",2633,however considerable proportion individuals lack humoral responses show progressive decline sars-cov-2-specific neutralizing antibodies 
1014,253.0,5.0,"['influenza receive noninfluenza', 'influenza receive canadian', 'influenza receive sentinel', 'influenza receive vaccine', 'influenza receive coronaviruses', 'vaccine receive noninfluenza', 'vaccine receive canadian', 'vaccine receive sentinel', 'vaccine receive influenza', 'vaccine receive coronaviruses', 'influenza test canadian', 'influenza test sentinel', 'influenza test vaccine', 'influenza test coronaviruses', 'vaccine test canadian', 'vaccine test sentinel', 'vaccine test influenza', 'vaccine test coronaviruses', 'influenza test canadian', 'influenza test sentinel', 'influenza test vaccine', 'influenza test coronaviruses', 'noninfluenza test canadian', 'noninfluenza test sentinel', 'noninfluenza test vaccine', 'noninfluenza test influenza', 'noninfluenza test coronaviruses', 'influenza emerge canadian', 'influenza emerge sentinel', 'influenza emerge vaccine', 'influenza emerge coronaviruses', 'vaccine emerge canadian', 'vaccine emerge sentinel', 'vaccine emerge influenza', 'vaccine emerge coronaviruses', 'influenza emerge canadian', 'influenza emerge sentinel', 'influenza emerge vaccine', 'influenza emerge coronaviruses', 'noninfluenza emerge canadian', 'noninfluenza emerge sentinel', 'noninfluenza emerge vaccine', 'noninfluenza emerge influenza', 'noninfluenza emerge coronaviruses', 'influenza receive vaccine', 'influenza receive coronaviruses', 'vaccine receive influenza', 'vaccine receive coronaviruses', 'influenza receive vaccine', 'influenza receive coronaviruses', 'noninfluenza receive vaccine', 'noninfluenza receive influenza', 'noninfluenza receive coronaviruses', 'canadian receive vaccine', 'canadian receive influenza', 'canadian receive coronaviruses']",2636,moreover gives opportunity study cellular responses emerging coronavirus variants identify individuals cross-reactive immunity seasonal coronaviruses 
1015,255.0,1.0,"['serum compare 197', 'serum compare toddler', 'serum compare microfluidic', 'serum compare 110', 'serum compare antigen', 'igm compare 197', 'igm compare toddler', 'igm compare microfluidic', 'igm compare 110', 'igm compare antigen', 'igg compare 197', 'igg compare toddler', 'igg compare microfluidic', 'igg compare 110', 'igg compare antigen', 'serum receive 110', 'serum receive antigen', 'igm receive 110', 'igm receive antigen', 'igg receive 110', 'igg receive antigen', '197 receive 110', '197 receive antigen', 'toddler receive 110', 'toddler receive antigen', 'microfluidic receive 110', 'microfluidic receive antigen']",2639,specificity antibody responses compared among cohort toddlers identify differences seropositive versus seronegative responses 
1016,255.0,5.0,['igg know toddler'],2643,clinical presentations previously known genetic risk alleles various immune system conditions investigated relation igg responses 
1017,255.0,8.0,"['il2rb associate two', 'il2rb associate cytokine', 'il2rb associate eczema', 'il2rb associate asthma', 'tnfsf4 associate two', 'tnfsf4 associate cytokine', 'tnfsf4 associate eczema', 'tnfsf4 associate asthma']",2646,high group likely associated gestational diabetes older age 
1018,255.0,9.0,"['serum receive toddler', 'serum receive vaccine', 'serum receive autoantigens']",2647,genetic analyses identified polymorphisms il2rb tnfsf4 ins genes two high responder individuals associated elevated cytokine levels clinical history eczema asthma 
1019,255.0,11.0,"['serum include nile virus', 'serum include west', 'serum include parvovirus', 'serum include tuberculosis', 'igg include nile virus', 'igg include west', 'igg include parvovirus', 'igg include tuberculosis']",2649,low responder group much weaker responses overall including vaccines 
1020,255.0,14.0,"['rsv observe pneumonia', 'rsv observe bronchiolitis']",2652,supplementary information online version contains supplementary material available 101007s10875-021-00993-w 
1021,256.0,2.0,"['rsv develop quality life', 'rsv develop wheezing', 'rsv develop asthma', 'rsv include quality life', 'wheezing include quality life', 'asthma include quality life']",2655,populations higher susceptibility developing severe rsv include premature infants children chronic lung disease prematurity cldp congenital heart disease chd elderly individuals aged 65 years immunocompromised individuals 
1022,256.0,6.0,"['palivizumab prevent infant', 'rsv prevent infant', 'rsvh prevent infant', 'high-risk prevent infant']",2659,currently palivizumab immunoprophylaxis ip available prevent severe rsv specific high-risk pediatric populations 
1023,256.0,7.0,"['aap 2014 establish rsv', 'aap 2014 establish infant', 'american establish rsv', 'american establish infant', 'american observe aap 2014', 'american observe rsv', 'american observe infant', 'american randomize rsv', 'american randomize infant', 'aap 2014 reduce infant', 'american reduce infant', 'rsv reduce infant']",2660,well-controlled randomized clinical trials established efficacy palivizumab reducing rsv hospitalization rsvh high-risk infants including moderate- late-preterm infants 
1024,256.0,11.0,"['patient aim covid-19', 'patient aim immunity']",2664,aap recommendations drive insurance reimbursements rsv ip revised help mitigate rsv disease burden 
1025,257.0,0.0,"['sars-cov-2 follow hcw', 'sars-cov-2 follow convalescent', 'sars-cov-2 follow serum', 'patient follow hcw', 'patient follow convalescent', 'patient follow serum', 'covid-19 follow hcw', 'covid-19 follow convalescent', 'covid-19 follow serum', 'health follow hcw', 'health follow convalescent', 'health follow serum', 'sars-cov-2 induce serum', 'patient induce serum', 'covid-19 induce serum', 'health induce serum', 'worker induce serum', 'hcw induce serum']",2665,background hemodialysis hd patients high mortality covid-19 immunity following vaccination remains uncertain 
1026,257.0,1.0,"['centre follow bnt162b2', 'centre follow vaccine', 'cohort follow bnt162b2', 'cohort follow vaccine', '142 follow bnt162b2', '142 follow vaccine', 'patient follow bnt162b2', 'patient follow vaccine']",2666,study evaluated sars-cov-2 antibody response hd patients following bnt162b2 covid-19 vaccination compared health care workers hcw convalescent serum 
1027,257.0,2.0,"['sars-cov-2 enrol nucleocapsid', 'sars-cov-2 enrol anti-np', 'sars-cov-2 enrol patient', 'sars-cov-2 enrol one', 'sars-cov-2 enrol vaccine', 'sars-cov-2 enrol patient', 'sars-cov-2 enrol two', 'sars-cov-2 enrol vaccine', 'sars-cov-2 enrol two', 'sars-cov-2 enrol vaccine', 'antibody enrol nucleocapsid', 'antibody enrol anti-np', 'antibody enrol patient', 'antibody enrol one', 'antibody enrol vaccine', 'antibody enrol patient', 'antibody enrol two', 'antibody enrol vaccine', 'antibody enrol two', 'antibody enrol vaccine', 'receptor enrol nucleocapsid', 'receptor enrol anti-np', 'receptor enrol patient', 'receptor enrol one', 'receptor enrol vaccine', 'receptor enrol patient', 'receptor enrol two', 'receptor enrol vaccine', 'receptor enrol two', 'receptor enrol vaccine', 'sars-cov-2 receive patient', 'sars-cov-2 receive one', 'sars-cov-2 receive vaccine', 'sars-cov-2 receive patient', 'sars-cov-2 receive two', 'sars-cov-2 receive vaccine', 'sars-cov-2 receive two', 'sars-cov-2 receive vaccine', 'antibody receive patient', 'antibody receive one', 'antibody receive vaccine', 'antibody receive patient', 'antibody receive two', 'antibody receive vaccine', 'antibody receive two', 'antibody receive vaccine', 'receptor receive patient', 'receptor receive one', 'receptor receive vaccine', 'receptor receive patient', 'receptor receive two', 'receptor receive vaccine', 'receptor receive two', 'receptor receive vaccine', 'nucleocapsid receive patient', 'nucleocapsid receive one', 'nucleocapsid receive vaccine', 'nucleocapsid receive patient', 'nucleocapsid receive two', 'nucleocapsid receive vaccine', 'nucleocapsid receive two', 'nucleocapsid receive vaccine', 'anti-np receive patient', 'anti-np receive one', 'anti-np receive vaccine', 'anti-np receive patient', 'anti-np receive two', 'anti-np receive vaccine', 'anti-np receive two', 'anti-np receive vaccine']",2667,methods single centre observational cohort study enrolled 142 hd patients 35 hcw receiving bnt162b2 vaccine 
1028,257.0,3.0,"['patient evaluate convalescent', 'patient evaluate serum', 'bnt162b2 evaluate convalescent', 'bnt162b2 evaluate serum', '5366 evaluate convalescent', '5366 evaluate serum', '466 evaluate convalescent', '466 evaluate serum', 'patient bind 466', 'patient bind convalescent', 'patient bind serum', 'bnt162b2 bind 466', 'bnt162b2 bind convalescent', 'bnt162b2 bind serum', '5366 bind 466', '5366 bind convalescent', '5366 bind serum']",2668,sars-cov-2 igg antibodies spike protein anti-spike receptor binding domain anti-rbd nucleocapsid protein anti-np measured 66 hd patients receiving one vaccine dose 76 hd patients receiving two vaccine doses 35 hcw receiving two vaccine doses 
1029,257.0,4.0,"['patient receive 6972', 'patient receive 6372', 'patient receive second', 'patient receive 4372', 'patient receive convalescent', 'patient receive serum', 'two receive 6972', 'two receive 6372', 'two receive second', 'two receive 4372', 'two receive convalescent', 'two receive serum', 'bnt162b2 receive 6972', 'bnt162b2 receive 6372', 'bnt162b2 receive second', 'bnt162b2 receive 4372', 'bnt162b2 receive convalescent', 'bnt162b2 receive serum', 'patient receive second', 'patient receive 4372', 'patient receive convalescent', 'patient receive serum', 'two receive second', 'two receive 4372', 'two receive convalescent', 'two receive serum', 'bnt162b2 receive second', 'bnt162b2 receive 4372', 'bnt162b2 receive convalescent', 'bnt162b2 receive serum', 'vaccine receive second', 'vaccine receive 4372', 'vaccine receive convalescent', 'vaccine receive serum', '6972 receive second', '6972 receive 4372', '6972 receive convalescent', '6972 receive serum', '6372 receive second', '6372 receive 4372', '6372 receive convalescent', '6372 receive serum']",2669,results hd patients receiving single bnt162b2 dose seroconversion occurred 5366 80 anti-spike 3566 55 anti-rbd 28 days post dose 1566 23 466 6 respectively attained robust response defined reaching median level anti-spike anti-rbd convalescent serum 
1030,257.0,5.0,"['hcw receive convalescent', 'hcw receive serum', 'hcw receive 2-4']",2670,patients receiving two doses bnt162b2 vaccine seroconversion occurred 6972 96 anti-spike 6372 88 anti-rbd 2 weeks following second dose 5272 72 4372 60 reached median convalescent serum levels anti-spike anti-rbd 
1031,257.0,7.0,"['argentine receive covid', 'argentine receive 2021', 'argentine follow 2021', 'covid follow 2021']",2672,conclusions study found poor immunogenicity 28 days following single dose bnt162b2 vaccine hd patients supporting adherence recommended vaccination schedules avoiding delay second dose population 
1032,258.0,1.0,"['covid-19 receive 550', 'covid-19 receive patient', '3709 receive 550', '3709 receive patient', 'patient receive 550', 'patient receive 550', '1675 receive 550', '1675 receive patient', 'patient receive 550', '452 receive 550', '452 receive patient']",2674,study period 36 918 prevalent patients chronic dialysis registered 
1033,258.0,5.0,['argentina associate covid'],2678,multivariate analysis showed factors associated mortality covid dialysis patients age greater 60 years 26 95 ci 22-31 diabetes 15 95 ci 13-18 time dialysis greater 55 months 15 95 ci 12-17 cerebrovascular disease 16 95 ci 11-23 neoplasia 17 95 ci 11-26 hospitalization requirement 34 95 ci 28-39 icu admission 18 95 ci 13-25 need mv 118 95 ci 69-202 
1034,260.0,0.0,"['streptococcus induce nthi', 'pneumoniae induce nthi', 'haemophilus induce nthi']",2682,background aboriginal children living australian remote communities high risk early persistent otitis media hearing loss social disadvantage 
1035,260.0,5.0,"['ear combine otitis', 'ear combine aom', 'ear combine suppurative', 'ear combine otitis', 'ear combine csom']",2687,ears assessed using tympanometry 1 2 months combined otoscopy 4 6 7 months 
1036,260.0,6.0,"['425 match 141', '425 match 141', 'infant match 141', 'infant match 141', '143 match 141', '143 match 141']",2688,worst ear diagnosis made child visit according severity hierarchy normal otitis media effusion ome acute otitis media without perforation aomwop aom perforation aomwip chronic suppurative otitis media csom 
1037,260.0,15.0,['covid-19 observe new zealand'],2697,supplementary information online version contains supplementary material available 101186s12887-021-02552-z 
1038,262.0,4.0,"['papillomavirus recommend cervical', 'papillomavirus recommend cancer', 'papillomavirus recommend woman']",2706,aspirin longer recommended primary prevention cardiovascular disease 
1039,262.0,5.0,"['woman associate fragility fracture', 'woman associate three', 'bone associate fragility fracture', 'bone associate three', 'woman reduce fragility fracture', 'woman reduce three', 'bone reduce fragility fracture', 'bone reduce three', 'mineral reduce fragility fracture', 'mineral reduce three']",2707,human papillomavirus vaccination strongly associated reduced risk invasive cervical cancer especially women vaccinated 17 years age 
1040,262.0,7.0,"['one associate glucocorticoid', 'one associate knee', 'one associate acetaminophen', 'one associate acute', 'one associate hip', 'one associate muscle', 'one associate ibuprofen', 'one associate people']",2709,higher daily step count associated lower all-cause mortality 
1041,262.0,10.0,"['patient perform allergy', 'penicillin perform allergy']",2712,successful communication patients seeking antibiotic flulike illness achieved combinations messaging including information antibiotic resistance self-limiting nature illness 
1042,262.0,11.0,['low-value receive patient'],2713,new prediction rule effectively identifies patients history penicillin allergy low likelihood positive findings allergy testing 
1043,263.0,1.0,"['cohort investigate covid-19', 'cohort investigate 01032020-30042020', 'cohort induce covid-19', 'cohort induce 01032020-30042020', 'cohort underlie 01032020-30042020', 'covid-19 underlie 01032020-30042020']",2718,study investigated incidence risk suffer covid-19 baseline underlying conditions people ÃÂÂ50 years tarragona region across march-april 2020 methods population-based retrospective cohort study involving 79071 adults ÃÂÂ50 years-old tarragona region southern catalonia spain 
1044,263.0,3.0,"['1547 adjust 367', 'cohort adjust 367', 'member adjust 367']",2720,cox regression analysis calculating hazard ratios hrs adjusted age sex comorbidities used estimate risk covid-19 
1045,263.0,4.0,"['covid-19 test 141', 'covid-19 test 424', 'covid-19 test 3135', 'covid-19 test men', 'covid-19 test 497', 'covid-19 test woman', 'covid-19 test 259', 'persons-period test 141', 'persons-period test 424', 'persons-period test 3135', 'persons-period test men', 'persons-period test 497', 'persons-period test woman', 'persons-period test 259', '441 test 141', '441 test 424', '441 test 3135', '441 test men', '441 test 497', '441 test woman', '441 test 259', 'covid-19 test woman', 'covid-19 test 259', 'persons-period test woman', 'persons-period test 259', '441 test woman', '441 test 259', '248 test woman', '248 test 259', '141 test woman', '141 test 259', '424 test woman', '424 test 259', '3135 test woman', '3135 test 259', 'men test woman', 'men test 259']",2721,results across study period 1547 cohort members pcr tested 226 positive 367 presumptive cases without pcr tested 
1046,263.0,6.0,['rheumatic diseases emerge 180'],2723,comorbidities maximum incidence emerged among persons neurological disease 2723 atrial fibrillation 1348 chronic renal failure 1050 cardiac disease 856 respiratory disease 798 diabetes 706 
1047,263.0,9.0,"['covid-19 appear two', 'infection appear two', 'adult appear two', 'tarragona appear two', 'catalonia appear two', 'spain appear two']",2726,conclusions apart increasing age nursing-home residence chronic respiratory cardiac disease appear increased risk suffering covid19 
1048,263.0,10.0,"['pox-protein investigate rv144', 'pox-protein investigate vaccine', 'pox-protein investigate hiv-1', 'pox-protein base hiv-1', 'rv144 base hiv-1']",2727,study investigated population-based incidence covid-19 infection underlying conditions among adults ÃÂÂ50 years tarragona southern catalonia spain across two first months pandemic period 
1049,264.0,0.0,['cellular test infection'],2728,pox-protein regimen tested rv144 trial vaccine strategy demonstrated prevent hiv-1 infection 
1050,264.0,2.0,"['specimen provide south africans', 'specimen provide hiv-1-uninfected', 'specimen provide hvtn', 'specimen provide alvac-hiv', 'specimen provide immunization', '1b provide south africans', '1b provide hiv-1-uninfected', '1b provide hvtn', '1b provide alvac-hiv', '1b provide immunization', 'south africans induce alvac-hiv', 'south africans induce immunization', 'specimen induce alvac-hiv', 'specimen induce immunization', '1b induce alvac-hiv', '1b induce immunization', 'hiv-1-uninfected induce alvac-hiv', 'hiv-1-uninfected induce immunization', 'hvtn induce alvac-hiv', 'hvtn induce immunization', 'south africans aim alvac-hiv', 'south africans aim immunization', 'specimen aim alvac-hiv', 'specimen aim immunization', '1b aim alvac-hiv', '1b aim immunization', 'hiv-1-uninfected aim alvac-hiv', 'hiv-1-uninfected aim immunization', 'hvtn aim alvac-hiv', 'hvtn aim immunization']",2730,early predictors cors could provide insight vaccine-induced protection guide efforts enhance vaccine efficacy 
1051,264.0,5.0,"['two activate cor', 'two activate 4-dose', 'two aim cor', 'two aim 4-dose']",2733,type ii interferon signaling pathways activated innate pathways critical adaptive immune priming 
1052,264.0,6.0,"['cellular associate cd4 cell', 'cellular associate cd4 t-cell', 'cellular associate env-specific']",2734,identified two innate immune transcriptional signatures strongly associated adaptive immune cor completion 4-dose regimen 
1053,264.0,8.0,"['vaccine report sars-cov-2', 'vaccine report sars-cov-2', 'vaccine report bbv152a', 'vaccine report bbv152c', 'vaccine report syrian', 'vaccine report hamster', 'vaccine report three', 'vaccine report sars-cov-2', 'vaccine report igg', 'vaccine report antibody', 'vaccine report hamster', 'vaccine report lung', 'vaccine report hamster', 'vaccine induce sars-cov-2', 'vaccine induce bbv152a', 'vaccine induce bbv152c', 'vaccine induce syrian', 'vaccine induce hamster', 'vaccine induce three', 'vaccine induce sars-cov-2', 'vaccine induce igg', 'vaccine induce antibody', 'vaccine induce hamster', 'vaccine induce lung', 'vaccine induce hamster', 'sars-cov-2 induce vaccine', 'sars-cov-2 induce bbv152a', 'sars-cov-2 induce bbv152c', 'sars-cov-2 induce syrian', 'sars-cov-2 induce hamster', 'sars-cov-2 induce three', 'sars-cov-2 induce vaccine', 'sars-cov-2 induce igg', 'sars-cov-2 induce antibody', 'sars-cov-2 induce vaccine', 'sars-cov-2 induce hamster', 'sars-cov-2 induce lung', 'sars-cov-2 induce hamster', 'vaccine associate sars-cov-2', 'vaccine associate bbv152a', 'vaccine associate bbv152c', 'vaccine associate syrian', 'vaccine associate hamster', 'vaccine associate three', 'vaccine associate sars-cov-2', 'vaccine associate igg', 'vaccine associate antibody', 'vaccine associate hamster', 'vaccine associate lung', 'vaccine associate hamster', 'sars-cov-2 associate vaccine', 'sars-cov-2 associate bbv152a', 'sars-cov-2 associate bbv152c', 'sars-cov-2 associate syrian', 'sars-cov-2 associate hamster', 'sars-cov-2 associate three', 'sars-cov-2 associate vaccine', 'sars-cov-2 associate igg', 'sars-cov-2 associate antibody', 'sars-cov-2 associate vaccine', 'sars-cov-2 associate hamster', 'sars-cov-2 associate lung', 'sars-cov-2 associate hamster', 'vaccine induce hamster', 'vaccine induce three', 'vaccine induce sars-cov-2', 'vaccine induce igg', 'vaccine induce antibody', 'vaccine induce hamster', 'vaccine induce lung', 'vaccine induce hamster', 'sars-cov-2 induce hamster', 'sars-cov-2 induce three', 'sars-cov-2 induce vaccine', 'sars-cov-2 induce igg', 'sars-cov-2 induce antibody', 'sars-cov-2 induce vaccine', 'sars-cov-2 induce hamster', 'sars-cov-2 induce lung', 'sars-cov-2 induce hamster', 'sars-cov-2 induce hamster', 'sars-cov-2 induce three', 'sars-cov-2 induce vaccine', 'sars-cov-2 induce igg', 'sars-cov-2 induce antibody', 'sars-cov-2 induce vaccine', 'sars-cov-2 induce hamster', 'sars-cov-2 induce lung', 'sars-cov-2 induce hamster', 'vaccine induce hamster', 'vaccine induce three', 'vaccine induce sars-cov-2', 'vaccine induce igg', 'vaccine induce antibody', 'vaccine induce hamster', 'vaccine induce lung', 'vaccine induce hamster', 'bbv152a induce hamster', 'bbv152a induce three', 'bbv152a induce vaccine', 'bbv152a induce sars-cov-2', 'bbv152a induce igg', 'bbv152a induce antibody', 'bbv152a induce vaccine', 'bbv152a induce hamster', 'bbv152a induce lung', 'bbv152a induce hamster', 'bbv152c induce hamster', 'bbv152c induce three', 'bbv152c induce vaccine', 'bbv152c induce sars-cov-2', 'bbv152c induce igg', 'bbv152c induce antibody', 'bbv152c induce vaccine', 'bbv152c induce hamster', 'bbv152c induce lung', 'bbv152c induce hamster', 'vaccine improve sars-cov-2', 'vaccine improve igg', 'vaccine improve antibody', 'vaccine improve hamster', 'vaccine improve lung', 'vaccine improve hamster', 'sars-cov-2 improve vaccine', 'sars-cov-2 improve igg', 'sars-cov-2 improve antibody', 'sars-cov-2 improve vaccine', 'sars-cov-2 improve hamster', 'sars-cov-2 improve lung', 'sars-cov-2 improve hamster', 'sars-cov-2 improve vaccine', 'sars-cov-2 improve igg', 'sars-cov-2 improve antibody', 'sars-cov-2 improve vaccine', 'sars-cov-2 improve hamster', 'sars-cov-2 improve lung', 'sars-cov-2 improve hamster', 'vaccine improve sars-cov-2', 'vaccine improve igg', 'vaccine improve antibody', 'vaccine improve hamster', 'vaccine improve lung', 'vaccine improve hamster', 'bbv152a improve vaccine', 'bbv152a improve sars-cov-2', 'bbv152a improve igg', 'bbv152a improve antibody', 'bbv152a improve vaccine', 'bbv152a improve hamster', 'bbv152a improve lung', 'bbv152a improve hamster', 'bbv152c improve vaccine', 'bbv152c improve sars-cov-2', 'bbv152c improve igg', 'bbv152c improve antibody', 'bbv152c improve vaccine', 'bbv152c improve hamster', 'bbv152c improve lung', 'bbv152c improve hamster', 'syrian improve vaccine', 'syrian improve sars-cov-2', 'syrian improve igg', 'syrian improve antibody', 'syrian improve vaccine', 'syrian improve hamster', 'syrian improve lung', 'syrian improve hamster', 'hamster improve vaccine', 'hamster improve sars-cov-2', 'hamster improve igg', 'hamster improve antibody', 'hamster improve vaccine', 'hamster improve lung', 'three improve vaccine', 'three improve sars-cov-2', 'three improve igg', 'three improve antibody', 'three improve vaccine', 'three improve hamster', 'three improve lung', 'three improve hamster']",2736,first-reported early immune biomarkers vaccine-induced responses associated hiv-1 acquisition risk humans suggest hypotheses improve hiv-1 vaccine regimens 
1054,266.0,2.0,"['hpv induce cervical', 'hpv induce cancer', 'vaccine induce cervical', 'vaccine induce cancer', 'tanzania induce cervical', 'tanzania induce cancer']",2740,however costs setting multi-dose hpv vaccination programme remain barrier introduction 
1055,266.0,3.0,"['930 induce tanzania', '930 induce one', '930 induce 2-valent', '930 induce cervarix', '930 induce gardasil-9', '930 induce hpv', '930 induce vaccine', 'girl induce tanzania', 'girl induce one', 'girl induce 2-valent', 'girl induce cervarix', 'girl induce gardasil-9', 'girl induce hpv', 'girl induce vaccine', '930 randomize 2-valent', '930 randomize cervarix', '930 randomize gardasil-9', '930 randomize hpv', '930 randomize vaccine', 'girl randomize 2-valent', 'girl randomize cervarix', 'girl randomize gardasil-9', 'girl randomize hpv', 'girl randomize vaccine', 'mwanza randomize 2-valent', 'mwanza randomize cervarix', 'mwanza randomize gardasil-9', 'mwanza randomize hpv', 'mwanza randomize vaccine', 'tanzania randomize 2-valent', 'tanzania randomize cervarix', 'tanzania randomize gardasil-9', 'tanzania randomize hpv', 'tanzania randomize vaccine', '930 observe 2-valent', '930 observe cervarix', '930 observe gardasil-9', '930 observe hpv', '930 observe vaccine', 'girl observe 2-valent', 'girl observe cervarix', 'girl observe gardasil-9', 'girl observe hpv', 'girl observe vaccine', 'mwanza observe 2-valent', 'mwanza observe cervarix', 'mwanza observe gardasil-9', 'mwanza observe hpv', 'mwanza observe vaccine', 'tanzania observe 2-valent', 'tanzania observe cervarix', 'tanzania observe gardasil-9', 'tanzania observe hpv', 'tanzania observe vaccine', 'one observe 2-valent', 'one observe cervarix', 'one observe gardasil-9', 'one observe hpv', 'one observe vaccine', '930 reduce 2-valent', '930 reduce cervarix', '930 reduce gardasil-9', '930 reduce hpv', '930 reduce vaccine', 'girl reduce 2-valent', 'girl reduce cervarix', 'girl reduce gardasil-9', 'girl reduce hpv', 'girl reduce vaccine', 'mwanza reduce 2-valent', 'mwanza reduce cervarix', 'mwanza reduce gardasil-9', 'mwanza reduce hpv', 'mwanza reduce vaccine', 'tanzania reduce 2-valent', 'tanzania reduce cervarix', 'tanzania reduce gardasil-9', 'tanzania reduce hpv', 'tanzania reduce vaccine', 'one reduce 2-valent', 'one reduce cervarix', 'one reduce gardasil-9', 'one reduce hpv', 'one reduce vaccine']",2741,methodsdesign conducting randomised-controlled trial reduced dose schedules hpv vaccine tanzania establish whether single dose produces immune responses effective preventing cervical cancer 
1056,266.0,10.0,"['sars-cov-2 induce antibody', 'sars-cov-2 induce immunity', 'sars-cov-2 emerge antibody', 'sars-cov-2 emerge immunity', 'covid-19 emerge antibody', 'covid-19 emerge immunity']",2748,initial results 24 months expected published early 2021 
1057,267.0,0.0,"['convalescent become igg', 'plasma become igg', 'covid-19 become igg', 'patient become igg']",2749,soon commencement sars-cov-2 disease outbreak 2019 covid-19 became evident receptor-binding domain viral spike protein target neutralizing antibodies comprise critical element protective immunity virus 
1058,268.0,0.0,"['meta-analysis acquire hai', 'quantify acquire hai']",2754,background hospital-acquired influenza hai usually contributed severe outcomes among inpatients 
1059,268.0,1.0,"['embase evaluate china', 'embase evaluate cnki', 'embase evaluate wanfang']",2755, performed meta-analysis summarize quantify epidemiological clinical characteristics hai 
1060,268.0,3.0,"['1483 use 71849', '1483 use non-hospital-acquired', '1483 use influenza', '1483 use hai', '1483 use influenza', '1483 use 519', '1483 use 615', '1483 induce hai', '1483 induce influenza', '1483 induce 519', '1483 induce 615', 'hai induce influenza', 'hai induce 519', 'hai induce 615', '71849 induce hai', '71849 induce influenza', '71849 induce 519', '71849 induce 615', 'non-hospital-acquired induce hai', 'non-hospital-acquired induce influenza', 'non-hospital-acquired induce 519', 'non-hospital-acquired induce 615', '1483 weight 519', '1483 weight 615', 'hai weight 519', 'hai weight 615', '71849 weight 519', '71849 weight 615', 'non-hospital-acquired weight 519', 'non-hospital-acquired weight 615', 'influenza weight 519', 'influenza weight 615', 'hai weight 519', 'hai weight 615', 'influenza weight 519', 'influenza weight 615']",2757,randomfix-effects models used obtain pooled proportion odds ratio weighted mean difference wmd 
1061,268.0,4.0,"['hai need patient', 'hai need 185', 'wmd need patient', 'wmd need 185']",2758,results total 14 studies involving 1483 hai 71849 non-hospital-acquired influenza infections nhai cases includedthe proportion hai among influenza cases 1138 95 confidence interval ci 519 ÃÂÂ1955 increased 2012 615 vs 1272 
1062,268.0,5.0,"['metabolic disorders increase renal diseases', 'metabolic disorders increase heart', 'metabolic disorders increase 152', 'metabolic disorders increase ci', 'metabolic disorders increase diabetes', 'metabolic disorders increase 122', 'ci 108Ã\x83\x83Ã\x83\x82Ã\x83\x82931 increase renal diseases', 'ci 108Ã\x83\x83Ã\x83\x82Ã\x83\x82931 increase heart', 'ci 108Ã\x83\x83Ã\x83\x82Ã\x83\x82931 increase 152', 'ci 108Ã\x83\x83Ã\x83\x82Ã\x83\x82931 increase ci', 'ci 108Ã\x83\x83Ã\x83\x82Ã\x83\x82931 increase diabetes', 'ci 108Ã\x83\x83Ã\x83\x82Ã\x83\x82931 increase 122', '810 increase renal diseases', '810 increase heart', '810 increase 152', '810 increase ci', '810 increase diabetes', '810 increase 122', 'malignancy increase renal diseases', 'malignancy increase heart', 'malignancy increase 152', 'malignancy increase ci', 'malignancy increase diabetes', 'malignancy increase 122', '318 increase renal diseases', '318 increase heart', '318 increase 152', '318 increase ci', '318 increase diabetes', '318 increase 122', '213 increase renal diseases', '213 increase heart', '213 increase 152', '213 increase ci', '213 increase diabetes', '213 increase 122']",2759,hai cases significantly older wmd 951 95 ci 004ÃÂÂ1898 patients chronic medical diseases increased risk hai 185 95 ci 157ÃÂÂ219 
1063,268.0,6.0,"['hai range 299', '1023 range 299']",2760,among metabolic disorders 810 95 ci 246ÃÂÂ2664 ranked highest danger followed malignancy 318 95 ci 212ÃÂÂ476 chronic diseases 281 95 ci 108ÃÂÂ931 immunosuppression 213 95 ci 125ÃÂÂ364 renal diseases 172 95 ci140ÃÂÂ210 heart diseases 152 95 ci 103ÃÂÂ144 diabetes 122 95 ci 103ÃÂÂ144 
1064,269.0,0.0,"['cancer underlie adult', 'survivor underlie adult', 'survivor underlie cancer']",2765,cancer underlying medical conditions including chronic obstructive pulmonary disease heart diseases diabetes chronic kidney disease obesity associated increased risk severe covid-19 illness 
1065,269.0,1.0,"['survivor receive 8805', 'survivor receive 564', 'survivor receive 548', 'survivor receive 579', 'survivor receive 416', 'survivor receive 409', 'survivor receive 422', 'survivor receive adult', 'survivor receive cancer', 'survivor receive one-quarter', 'survivor receive 229', 'survivor receive 216', 'survivor receive 243', 'survivor receive 8805', 'survivor receive cancer', 'survivor test 216', 'survivor test 243', 'survivor test 8805', 'survivor test cancer', '8805 test 216', '8805 test 243', '8805 test cancer', '8805 test survivor', '564 test 216', '564 test 243', '564 test 8805', '564 test cancer', '564 test survivor', '548 test 216', '548 test 243', '548 test 8805', '548 test cancer', '548 test survivor', '579 test 216', '579 test 243', '579 test 8805', '579 test cancer', '579 test survivor', '416 test 216', '416 test 243', '416 test 8805', '416 test cancer', '416 test survivor', '409 test 216', '409 test 243', '409 test 8805', '409 test cancer', '409 test survivor', '422 test 216', '422 test 243', '422 test 8805', '422 test cancer', '422 test survivor', 'adult test 216', 'adult test 243', 'adult test 8805', 'adult test cancer', 'adult test survivor', 'cancer test 216', 'cancer test 243', 'cancer test 8805', 'cancer test survivor', 'one-quarter test 216', 'one-quarter test 243', 'one-quarter test 8805', 'one-quarter test cancer', 'one-quarter test survivor', 'survivor associate cancer', '8805 associate cancer', '8805 associate survivor', '564 associate cancer', '564 associate survivor', '548 associate cancer', '548 associate survivor', '579 associate cancer', '579 associate survivor', '416 associate cancer', '416 associate survivor', '409 associate cancer', '409 associate survivor', '422 associate cancer', '422 associate survivor', 'adult associate cancer', 'adult associate survivor', 'cancer associate survivor', 'one-quarter associate cancer', 'one-quarter associate survivor', '229 associate cancer', '229 associate survivor', '216 associate cancer', '216 associate survivor', '243 associate cancer', '243 associate survivor']",2766,identified 6411 cancer survivors 77748 adults without cancer history 2016-2018 national health interview survey examined prevalence sociodemographic factors associated conditions us 
1066,271.0,0.0,"['infectious diseases associate hcw', 'infectious diseases associate hcw', 'infectious diseases associate covid-19', 'bcg associate hcw', 'bcg associate hcw', 'bcg associate covid-19', 'covid-19 associate hcw', 'covid-19 associate hcw']",2775,objectives bacille calmette-guÃÂrin bcg vaccine tuberculosis associated non- specific protective effects infections significant reductions all-cause morbidity mortality reported 
1067,271.0,1.0,"['hcw reduce covid-19', 'sars-cov-2 reduce hcw', 'sars-cov-2 reduce covid-19']",2776,aim test whether bcg vaccination may reduce susceptibility andor severity covid-19 infectious diseases health care workers hcw thus prevent work absenteeismthe primary objective reduce absenteeism due illness among hcw covid-19 pandemic 
1068,271.0,4.0,"['bcg observe one', 'bcg observe danish', 'bcg observe medicine', 'vaccine observe one', 'vaccine observe danish', 'vaccine observe medicine']",2779,trial design placebo-controlled single-blinded randomised controlled trial recruiting study participants several geographic locations 
1069,271.0,5.0,"['participant approve bacterial infection', 'participant approve allergy', 'participant approve bcg', 'participant approve vaccine', 'participant approve bcg', 'participant approve infection', 'participant approve mycobacterium', 'participant approve tuberculosis', 'participant approve tuberculosis', 'participant approve covid-19', 'participant approve fever', 'participant approve vaccine', 'participant approve immunocompromised', '1500 approve bacterial infection', '1500 approve allergy', '1500 approve bcg', '1500 approve vaccine', '1500 approve bcg', '1500 approve infection', '1500 approve mycobacterium', '1500 approve tuberculosis', '1500 approve tuberculosis', '1500 approve covid-19', '1500 approve fever', '1500 approve vaccine', '1500 approve immunocompromised', 'hcw approve bacterial infection', 'hcw approve allergy', 'hcw approve bcg', 'hcw approve vaccine', 'hcw approve bcg', 'hcw approve infection', 'hcw approve mycobacterium', 'hcw approve tuberculosis', 'hcw approve tuberculosis', 'hcw approve covid-19', 'hcw approve fever', 'hcw approve vaccine', 'hcw approve immunocompromised', 'danish approve bacterial infection', 'danish approve allergy', 'danish approve bcg', 'danish approve vaccine', 'danish approve bcg', 'danish approve infection', 'danish approve mycobacterium', 'danish approve tuberculosis', 'danish approve tuberculosis', 'danish approve covid-19', 'danish approve fever', 'danish approve vaccine', 'danish approve immunocompromised', '8805 approve bacterial infection', '8805 approve allergy', '8805 approve bcg', '8805 approve vaccine', '8805 approve bcg', '8805 approve infection', '8805 approve mycobacterium', '8805 approve tuberculosis', '8805 approve tuberculosis', '8805 approve covid-19', '8805 approve fever', '8805 approve vaccine', '8805 approve immunocompromised', 'participant use bacterial infection', 'participant use hcw', 'participant use danish', 'participant use 8805', 'participant use allergy', 'participant use bcg', 'participant use vaccine', 'participant use bcg', 'participant use infection', 'participant use mycobacterium', 'participant use tuberculosis', 'participant use tuberculosis', 'participant use covid-19', 'participant use fever', 'participant use vaccine', 'participant use immunocompromised', 'participant classify bacterial infection', 'participant classify allergy', 'participant classify bcg', 'participant classify vaccine', 'participant classify bcg', 'participant classify infection', 'participant classify mycobacterium', 'participant classify tuberculosis', 'participant classify tuberculosis', 'participant classify covid-19', 'participant classify fever', 'participant classify vaccine', 'participant classify immunocompromised', '1500 classify bacterial infection', '1500 classify allergy', '1500 classify bcg', '1500 classify vaccine', '1500 classify bcg', '1500 classify infection', '1500 classify mycobacterium', '1500 classify tuberculosis', '1500 classify tuberculosis', '1500 classify covid-19', '1500 classify fever', '1500 classify vaccine', '1500 classify immunocompromised', 'hcw classify bacterial infection', 'hcw classify allergy', 'hcw classify bcg', 'hcw classify vaccine', 'hcw classify bcg', 'hcw classify infection', 'hcw classify mycobacterium', 'hcw classify tuberculosis', 'hcw classify tuberculosis', 'hcw classify covid-19', 'hcw classify fever', 'hcw classify vaccine', 'hcw classify immunocompromised', 'danish classify bacterial infection', 'danish classify allergy', 'danish classify bcg', 'danish classify vaccine', 'danish classify bcg', 'danish classify infection', 'danish classify mycobacterium', 'danish classify tuberculosis', 'danish classify tuberculosis', 'danish classify covid-19', 'danish classify fever', 'danish classify vaccine', 'danish classify immunocompromised', '8805 classify bacterial infection', '8805 classify allergy', '8805 classify bcg', '8805 classify vaccine', '8805 classify bcg', '8805 classify infection', '8805 classify mycobacterium', '8805 classify tuberculosis', '8805 classify tuberculosis', '8805 classify covid-19', '8805 classify fever', '8805 classify vaccine', '8805 classify immunocompromised']",2780,bcg vaccine used study different indication one approved danish medicines agency therefore classified phase iii study 
1070,271.0,6.0,"['solid organ exclude bcg-denmark-covid', 'solid organ exclude participant', 'solid organ exclude bcg', 'solid organ exclude vaccine', 'solid organ exclude bcg-denmark', 'solid organ exclude vaccine', 'solid organ exclude denmark', 'solid organ exclude saline', 'human exclude bcg-denmark-covid', 'human exclude participant', 'human exclude bcg', 'human exclude vaccine', 'human exclude bcg-denmark', 'human exclude vaccine', 'human exclude denmark', 'human exclude saline', 'immunodeficiency exclude bcg-denmark-covid', 'immunodeficiency exclude participant', 'immunodeficiency exclude bcg', 'immunodeficiency exclude vaccine', 'immunodeficiency exclude bcg-denmark', 'immunodeficiency exclude vaccine', 'immunodeficiency exclude denmark', 'immunodeficiency exclude saline', 'hiv-1 exclude bcg-denmark-covid', 'hiv-1 exclude participant', 'hiv-1 exclude bcg', 'hiv-1 exclude vaccine', 'hiv-1 exclude bcg-denmark', 'hiv-1 exclude vaccine', 'hiv-1 exclude denmark', 'hiv-1 exclude saline', 'bone exclude bcg-denmark-covid', 'bone exclude participant', 'bone exclude bcg', 'bone exclude vaccine', 'bone exclude bcg-denmark', 'bone exclude vaccine', 'bone exclude denmark', 'bone exclude saline', 'marrow exclude bcg-denmark-covid', 'marrow exclude participant', 'marrow exclude bcg', 'marrow exclude vaccine', 'marrow exclude bcg-denmark', 'marrow exclude vaccine', 'marrow exclude denmark', 'marrow exclude saline', 'chemotherapy exclude bcg-denmark-covid', 'chemotherapy exclude participant', 'chemotherapy exclude bcg', 'chemotherapy exclude vaccine', 'chemotherapy exclude bcg-denmark', 'chemotherapy exclude vaccine', 'chemotherapy exclude denmark', 'chemotherapy exclude saline', 'immunodeficiency exclude bcg-denmark-covid', 'immunodeficiency exclude participant', 'immunodeficiency exclude bcg', 'immunodeficiency exclude vaccine', 'immunodeficiency exclude bcg-denmark', 'immunodeficiency exclude vaccine', 'immunodeficiency exclude denmark', 'immunodeficiency exclude saline', 'anti-cytokine exclude bcg-denmark-covid', 'anti-cytokine exclude participant', 'anti-cytokine exclude bcg', 'anti-cytokine exclude vaccine', 'anti-cytokine exclude bcg-denmark', 'anti-cytokine exclude vaccine', 'anti-cytokine exclude denmark', 'anti-cytokine exclude saline', 'oral exclude bcg-denmark-covid', 'oral exclude participant', 'oral exclude bcg', 'oral exclude vaccine', 'oral exclude bcg-denmark', 'oral exclude vaccine', 'oral exclude denmark', 'oral exclude saline', 'steroid exclude bcg-denmark-covid', 'steroid exclude participant', 'steroid exclude bcg', 'steroid exclude vaccine', 'steroid exclude bcg-denmark', 'steroid exclude vaccine', 'steroid exclude denmark', 'steroid exclude saline', 'prednisone exclude bcg-denmark-covid', 'prednisone exclude participant', 'prednisone exclude bcg', 'prednisone exclude vaccine', 'prednisone exclude bcg-denmark', 'prednisone exclude vaccine', 'prednisone exclude denmark', 'prednisone exclude saline', 'solid exclude bcg-denmark-covid', 'solid exclude participant', 'solid exclude bcg', 'solid exclude vaccine', 'solid exclude bcg-denmark', 'solid exclude vaccine', 'solid exclude denmark', 'solid exclude saline', 'solid organ meet chemotherapy', 'solid organ meet immunodeficiency', 'solid organ meet anti-cytokine', 'solid organ meet oral', 'solid organ meet steroid', 'solid organ meet prednisone', 'solid organ meet solid', 'solid organ meet bcg-denmark-covid', 'solid organ meet participant', 'solid organ meet bcg', 'solid organ meet vaccine', 'solid organ meet bcg-denmark', 'solid organ meet vaccine', 'solid organ meet denmark', 'solid organ meet saline', 'human meet chemotherapy', 'human meet immunodeficiency', 'human meet anti-cytokine', 'human meet oral', 'human meet steroid', 'human meet prednisone', 'human meet solid', 'human meet bcg-denmark-covid', 'human meet participant', 'human meet bcg', 'human meet vaccine', 'human meet bcg-denmark', 'human meet vaccine', 'human meet denmark', 'human meet saline', 'immunodeficiency meet chemotherapy', 'immunodeficiency meet anti-cytokine', 'immunodeficiency meet oral', 'immunodeficiency meet steroid', 'immunodeficiency meet prednisone', 'immunodeficiency meet solid', 'immunodeficiency meet bcg-denmark-covid', 'immunodeficiency meet participant', 'immunodeficiency meet bcg', 'immunodeficiency meet vaccine', 'immunodeficiency meet bcg-denmark', 'immunodeficiency meet vaccine', 'immunodeficiency meet denmark', 'immunodeficiency meet saline', 'hiv-1 meet chemotherapy', 'hiv-1 meet immunodeficiency', 'hiv-1 meet anti-cytokine', 'hiv-1 meet oral', 'hiv-1 meet steroid', 'hiv-1 meet prednisone', 'hiv-1 meet solid', 'hiv-1 meet bcg-denmark-covid', 'hiv-1 meet participant', 'hiv-1 meet bcg', 'hiv-1 meet vaccine', 'hiv-1 meet bcg-denmark', 'hiv-1 meet vaccine', 'hiv-1 meet denmark', 'hiv-1 meet saline', 'bone meet chemotherapy', 'bone meet immunodeficiency', 'bone meet anti-cytokine', 'bone meet oral', 'bone meet steroid', 'bone meet prednisone', 'bone meet solid', 'bone meet bcg-denmark-covid', 'bone meet participant', 'bone meet bcg', 'bone meet vaccine', 'bone meet bcg-denmark', 'bone meet vaccine', 'bone meet denmark', 'bone meet saline', 'solid organ follow immunodeficiency', 'solid organ follow anti-cytokine', 'solid organ follow oral', 'solid organ follow steroid', 'solid organ follow prednisone', 'solid organ follow solid', 'solid organ follow bcg-denmark-covid', 'solid organ follow participant', 'solid organ follow bcg', 'solid organ follow vaccine', 'solid organ follow bcg-denmark', 'solid organ follow vaccine', 'solid organ follow denmark', 'solid organ follow saline', 'human follow immunodeficiency', 'human follow anti-cytokine', 'human follow oral', 'human follow steroid', 'human follow prednisone', 'human follow solid', 'human follow bcg-denmark-covid', 'human follow participant', 'human follow bcg', 'human follow vaccine', 'human follow bcg-denmark', 'human follow vaccine', 'human follow denmark', 'human follow saline', 'immunodeficiency follow anti-cytokine', 'immunodeficiency follow oral', 'immunodeficiency follow steroid', 'immunodeficiency follow prednisone', 'immunodeficiency follow solid', 'immunodeficiency follow bcg-denmark-covid', 'immunodeficiency follow participant', 'immunodeficiency follow bcg', 'immunodeficiency follow vaccine', 'immunodeficiency follow bcg-denmark', 'immunodeficiency follow vaccine', 'immunodeficiency follow denmark', 'immunodeficiency follow saline', 'hiv-1 follow immunodeficiency', 'hiv-1 follow anti-cytokine', 'hiv-1 follow oral', 'hiv-1 follow steroid', 'hiv-1 follow prednisone', 'hiv-1 follow solid', 'hiv-1 follow bcg-denmark-covid', 'hiv-1 follow participant', 'hiv-1 follow bcg', 'hiv-1 follow vaccine', 'hiv-1 follow bcg-denmark', 'hiv-1 follow vaccine', 'hiv-1 follow denmark', 'hiv-1 follow saline', 'bone follow immunodeficiency', 'bone follow anti-cytokine', 'bone follow oral', 'bone follow steroid', 'bone follow prednisone', 'bone follow solid', 'bone follow bcg-denmark-covid', 'bone follow participant', 'bone follow bcg', 'bone follow vaccine', 'bone follow bcg-denmark', 'bone follow vaccine', 'bone follow denmark', 'bone follow saline', 'marrow follow immunodeficiency', 'marrow follow anti-cytokine', 'marrow follow oral', 'marrow follow steroid', 'marrow follow prednisone', 'marrow follow solid', 'marrow follow bcg-denmark-covid', 'marrow follow participant', 'marrow follow bcg', 'marrow follow vaccine', 'marrow follow bcg-denmark', 'marrow follow vaccine', 'marrow follow denmark', 'marrow follow saline', 'solid organ make oral', 'solid organ make steroid', 'solid organ make prednisone', 'solid organ make solid', 'solid organ make bcg-denmark-covid', 'solid organ make participant', 'solid organ make bcg', 'solid organ make vaccine', 'solid organ make bcg-denmark', 'solid organ make vaccine', 'solid organ make denmark', 'solid organ make saline', 'human make oral', 'human make steroid', 'human make prednisone', 'human make solid', 'human make bcg-denmark-covid', 'human make participant', 'human make bcg', 'human make vaccine', 'human make bcg-denmark', 'human make vaccine', 'human make denmark', 'human make saline', 'immunodeficiency make oral', 'immunodeficiency make steroid', 'immunodeficiency make prednisone', 'immunodeficiency make solid', 'immunodeficiency make bcg-denmark-covid', 'immunodeficiency make participant', 'immunodeficiency make bcg', 'immunodeficiency make vaccine', 'immunodeficiency make bcg-denmark', 'immunodeficiency make vaccine', 'immunodeficiency make denmark', 'immunodeficiency make saline', 'hiv-1 make oral', 'hiv-1 make steroid', 'hiv-1 make prednisone', 'hiv-1 make solid', 'hiv-1 make bcg-denmark-covid', 'hiv-1 make participant', 'hiv-1 make bcg', 'hiv-1 make vaccine', 'hiv-1 make bcg-denmark', 'hiv-1 make vaccine', 'hiv-1 make denmark', 'hiv-1 make saline', 'bone make oral', 'bone make steroid', 'bone make prednisone', 'bone make solid', 'bone make bcg-denmark-covid', 'bone make participant', 'bone make bcg', 'bone make vaccine', 'bone make bcg-denmark', 'bone make vaccine', 'bone make denmark', 'bone make saline', 'marrow make oral', 'marrow make steroid', 'marrow make prednisone', 'marrow make solid', 'marrow make bcg-denmark-covid', 'marrow make participant', 'marrow make bcg', 'marrow make vaccine', 'marrow make bcg-denmark', 'marrow make vaccine', 'marrow make denmark', 'marrow make saline', 'chemotherapy make oral', 'chemotherapy make steroid', 'chemotherapy make prednisone', 'chemotherapy make solid', 'chemotherapy make bcg-denmark-covid', 'chemotherapy make participant', 'chemotherapy make bcg', 'chemotherapy make vaccine', 'chemotherapy make bcg-denmark', 'chemotherapy make vaccine', 'chemotherapy make denmark', 'chemotherapy make saline', 'immunodeficiency make oral', 'immunodeficiency make steroid', 'immunodeficiency make prednisone', 'immunodeficiency make solid', 'immunodeficiency make bcg-denmark-covid', 'immunodeficiency make participant', 'immunodeficiency make bcg', 'immunodeficiency make vaccine', 'immunodeficiency make bcg-denmark', 'immunodeficiency make vaccine', 'immunodeficiency make denmark', 'immunodeficiency make saline', 'anti-cytokine make oral', 'anti-cytokine make steroid', 'anti-cytokine make prednisone', 'anti-cytokine make solid', 'anti-cytokine make bcg-denmark-covid', 'anti-cytokine make participant', 'anti-cytokine make bcg', 'anti-cytokine make vaccine', 'anti-cytokine make bcg-denmark', 'anti-cytokine make vaccine', 'anti-cytokine make denmark', 'anti-cytokine make saline', 'solid organ enrol steroid', 'solid organ enrol prednisone', 'solid organ enrol solid', 'solid organ enrol bcg-denmark-covid', 'solid organ enrol participant', 'solid organ enrol bcg', 'solid organ enrol vaccine', 'solid organ enrol bcg-denmark', 'solid organ enrol vaccine', 'solid organ enrol denmark', 'solid organ enrol saline', 'human enrol steroid', 'human enrol prednisone', 'human enrol solid', 'human enrol bcg-denmark-covid', 'human enrol participant', 'human enrol bcg', 'human enrol vaccine', 'human enrol bcg-denmark', 'human enrol vaccine', 'human enrol denmark', 'human enrol saline', 'immunodeficiency enrol steroid', 'immunodeficiency enrol prednisone', 'immunodeficiency enrol solid', 'immunodeficiency enrol bcg-denmark-covid', 'immunodeficiency enrol participant', 'immunodeficiency enrol bcg', 'immunodeficiency enrol vaccine', 'immunodeficiency enrol bcg-denmark', 'immunodeficiency enrol vaccine', 'immunodeficiency enrol denmark', 'immunodeficiency enrol saline', 'hiv-1 enrol steroid', 'hiv-1 enrol prednisone', 'hiv-1 enrol solid', 'hiv-1 enrol bcg-denmark-covid', 'hiv-1 enrol participant', 'hiv-1 enrol bcg', 'hiv-1 enrol vaccine', 'hiv-1 enrol bcg-denmark', 'hiv-1 enrol vaccine', 'hiv-1 enrol denmark', 'hiv-1 enrol saline', 'bone enrol steroid', 'bone enrol prednisone', 'bone enrol solid', 'bone enrol bcg-denmark-covid', 'bone enrol participant', 'bone enrol bcg', 'bone enrol vaccine', 'bone enrol bcg-denmark', 'bone enrol vaccine', 'bone enrol denmark', 'bone enrol saline', 'marrow enrol steroid', 'marrow enrol prednisone', 'marrow enrol solid', 'marrow enrol bcg-denmark-covid', 'marrow enrol participant', 'marrow enrol bcg', 'marrow enrol vaccine', 'marrow enrol bcg-denmark', 'marrow enrol vaccine', 'marrow enrol denmark', 'marrow enrol saline', 'chemotherapy enrol steroid', 'chemotherapy enrol prednisone', 'chemotherapy enrol solid', 'chemotherapy enrol bcg-denmark-covid', 'chemotherapy enrol participant', 'chemotherapy enrol bcg', 'chemotherapy enrol vaccine', 'chemotherapy enrol bcg-denmark', 'chemotherapy enrol vaccine', 'chemotherapy enrol denmark', 'chemotherapy enrol saline', 'immunodeficiency enrol steroid', 'immunodeficiency enrol prednisone', 'immunodeficiency enrol solid', 'immunodeficiency enrol bcg-denmark-covid', 'immunodeficiency enrol participant', 'immunodeficiency enrol bcg', 'immunodeficiency enrol vaccine', 'immunodeficiency enrol bcg-denmark', 'immunodeficiency enrol vaccine', 'immunodeficiency enrol denmark', 'immunodeficiency enrol saline', 'anti-cytokine enrol steroid', 'anti-cytokine enrol prednisone', 'anti-cytokine enrol solid', 'anti-cytokine enrol bcg-denmark-covid', 'anti-cytokine enrol participant', 'anti-cytokine enrol bcg', 'anti-cytokine enrol vaccine', 'anti-cytokine enrol bcg-denmark', 'anti-cytokine enrol vaccine', 'anti-cytokine enrol denmark', 'anti-cytokine enrol saline', 'solid organ meet solid', 'solid organ meet bcg-denmark-covid', 'solid organ meet participant', 'solid organ meet bcg', 'solid organ meet vaccine', 'solid organ meet bcg-denmark', 'solid organ meet vaccine', 'solid organ meet denmark', 'solid organ meet saline', 'human meet solid', 'human meet bcg-denmark-covid', 'human meet participant', 'human meet bcg', 'human meet vaccine', 'human meet bcg-denmark', 'human meet vaccine', 'human meet denmark', 'human meet saline', 'immunodeficiency meet solid', 'immunodeficiency meet bcg-denmark-covid', 'immunodeficiency meet participant', 'immunodeficiency meet bcg', 'immunodeficiency meet vaccine', 'immunodeficiency meet bcg-denmark', 'immunodeficiency meet vaccine', 'immunodeficiency meet denmark', 'immunodeficiency meet saline', 'hiv-1 meet solid', 'hiv-1 meet bcg-denmark-covid', 'hiv-1 meet participant', 'hiv-1 meet bcg', 'hiv-1 meet vaccine', 'hiv-1 meet bcg-denmark', 'hiv-1 meet vaccine', 'hiv-1 meet denmark', 'hiv-1 meet saline', 'bone meet solid', 'bone meet bcg-denmark-covid', 'bone meet participant', 'bone meet bcg', 'bone meet vaccine', 'bone meet bcg-denmark', 'bone meet vaccine', 'bone meet denmark', 'bone meet saline', 'marrow meet solid', 'marrow meet bcg-denmark-covid', 'marrow meet participant', 'marrow meet bcg', 'marrow meet vaccine', 'marrow meet bcg-denmark', 'marrow meet vaccine', 'marrow meet denmark', 'marrow meet saline', 'chemotherapy meet solid', 'chemotherapy meet bcg-denmark-covid', 'chemotherapy meet participant', 'chemotherapy meet bcg', 'chemotherapy meet vaccine', 'chemotherapy meet bcg-denmark', 'chemotherapy meet vaccine', 'chemotherapy meet denmark', 'chemotherapy meet saline', 'immunodeficiency meet solid', 'immunodeficiency meet bcg-denmark-covid', 'immunodeficiency meet participant', 'immunodeficiency meet bcg', 'immunodeficiency meet vaccine', 'immunodeficiency meet bcg-denmark', 'immunodeficiency meet vaccine', 'immunodeficiency meet denmark', 'immunodeficiency meet saline', 'anti-cytokine meet solid', 'anti-cytokine meet bcg-denmark-covid', 'anti-cytokine meet participant', 'anti-cytokine meet bcg', 'anti-cytokine meet vaccine', 'anti-cytokine meet bcg-denmark', 'anti-cytokine meet vaccine', 'anti-cytokine meet denmark', 'anti-cytokine meet saline', 'oral meet solid', 'oral meet bcg-denmark-covid', 'oral meet participant', 'oral meet bcg', 'oral meet vaccine', 'oral meet bcg-denmark', 'oral meet vaccine', 'oral meet denmark', 'oral meet saline', 'steroid meet solid', 'steroid meet bcg-denmark-covid', 'steroid meet participant', 'steroid meet bcg', 'steroid meet vaccine', 'steroid meet bcg-denmark', 'steroid meet vaccine', 'steroid meet denmark', 'steroid meet saline', 'prednisone meet solid', 'prednisone meet bcg-denmark-covid', 'prednisone meet participant', 'prednisone meet bcg', 'prednisone meet vaccine', 'prednisone meet bcg-denmark', 'prednisone meet vaccine', 'prednisone meet denmark', 'prednisone meet saline', 'solid organ follow bcg-denmark-covid', 'solid organ follow participant', 'solid organ follow bcg', 'solid organ follow vaccine', 'solid organ follow bcg-denmark', 'solid organ follow vaccine', 'solid organ follow denmark', 'solid organ follow saline', 'human follow bcg-denmark-covid', 'human follow participant', 'human follow bcg', 'human follow vaccine', 'human follow bcg-denmark', 'human follow vaccine', 'human follow denmark', 'human follow saline', 'immunodeficiency follow bcg-denmark-covid', 'immunodeficiency follow participant', 'immunodeficiency follow bcg', 'immunodeficiency follow vaccine', 'immunodeficiency follow bcg-denmark', 'immunodeficiency follow vaccine', 'immunodeficiency follow denmark', 'immunodeficiency follow saline', 'hiv-1 follow bcg-denmark-covid', 'hiv-1 follow participant', 'hiv-1 follow bcg', 'hiv-1 follow vaccine', 'hiv-1 follow bcg-denmark', 'hiv-1 follow vaccine', 'hiv-1 follow denmark', 'hiv-1 follow saline', 'bone follow bcg-denmark-covid', 'bone follow participant', 'bone follow bcg', 'bone follow vaccine', 'bone follow bcg-denmark', 'bone follow vaccine', 'bone follow denmark', 'bone follow saline', 'marrow follow bcg-denmark-covid', 'marrow follow participant', 'marrow follow bcg', 'marrow follow vaccine', 'marrow follow bcg-denmark', 'marrow follow vaccine', 'marrow follow denmark', 'marrow follow saline', 'chemotherapy follow bcg-denmark-covid', 'chemotherapy follow participant', 'chemotherapy follow bcg', 'chemotherapy follow vaccine', 'chemotherapy follow bcg-denmark', 'chemotherapy follow vaccine', 'chemotherapy follow denmark', 'chemotherapy follow saline', 'immunodeficiency follow bcg-denmark-covid', 'immunodeficiency follow participant', 'immunodeficiency follow bcg', 'immunodeficiency follow vaccine', 'immunodeficiency follow bcg-denmark', 'immunodeficiency follow vaccine', 'immunodeficiency follow denmark', 'immunodeficiency follow saline', 'anti-cytokine follow bcg-denmark-covid', 'anti-cytokine follow participant', 'anti-cytokine follow bcg', 'anti-cytokine follow vaccine', 'anti-cytokine follow bcg-denmark', 'anti-cytokine follow vaccine', 'anti-cytokine follow denmark', 'anti-cytokine follow saline', 'oral follow bcg-denmark-covid', 'oral follow participant', 'oral follow bcg', 'oral follow vaccine', 'oral follow bcg-denmark', 'oral follow vaccine', 'oral follow denmark', 'oral follow saline', 'steroid follow bcg-denmark-covid', 'steroid follow participant', 'steroid follow bcg', 'steroid follow vaccine', 'steroid follow bcg-denmark', 'steroid follow vaccine', 'steroid follow denmark', 'steroid follow saline', 'prednisone follow bcg-denmark-covid', 'prednisone follow participant', 'prednisone follow bcg', 'prednisone follow vaccine', 'prednisone follow bcg-denmark', 'prednisone follow vaccine', 'prednisone follow denmark', 'prednisone follow saline', 'solid follow bcg-denmark-covid', 'solid follow participant', 'solid follow bcg', 'solid follow vaccine', 'solid follow bcg-denmark', 'solid follow vaccine', 'solid follow denmark', 'solid follow saline', 'solid organ know participant', 'solid organ know bcg', 'solid organ know vaccine', 'solid organ know bcg-denmark', 'solid organ know vaccine', 'solid organ know denmark', 'solid organ know saline', 'human know participant', 'human know bcg', 'human know vaccine', 'human know bcg-denmark', 'human know vaccine', 'human know denmark', 'human know saline', 'immunodeficiency know participant', 'immunodeficiency know bcg', 'immunodeficiency know vaccine', 'immunodeficiency know bcg-denmark', 'immunodeficiency know vaccine', 'immunodeficiency know denmark', 'immunodeficiency know saline', 'hiv-1 know participant', 'hiv-1 know bcg', 'hiv-1 know vaccine', 'hiv-1 know bcg-denmark', 'hiv-1 know vaccine', 'hiv-1 know denmark', 'hiv-1 know saline', 'bone know participant', 'bone know bcg', 'bone know vaccine', 'bone know bcg-denmark', 'bone know vaccine', 'bone know denmark', 'bone know saline', 'marrow know participant', 'marrow know bcg', 'marrow know vaccine', 'marrow know bcg-denmark', 'marrow know vaccine', 'marrow know denmark', 'marrow know saline', 'chemotherapy know participant', 'chemotherapy know bcg', 'chemotherapy know vaccine', 'chemotherapy know bcg-denmark', 'chemotherapy know vaccine', 'chemotherapy know denmark', 'chemotherapy know saline', 'immunodeficiency know participant', 'immunodeficiency know bcg', 'immunodeficiency know vaccine', 'immunodeficiency know bcg-denmark', 'immunodeficiency know vaccine', 'immunodeficiency know denmark', 'immunodeficiency know saline', 'anti-cytokine know participant', 'anti-cytokine know bcg', 'anti-cytokine know vaccine', 'anti-cytokine know bcg-denmark', 'anti-cytokine know vaccine', 'anti-cytokine know denmark', 'anti-cytokine know saline', 'oral know participant', 'oral know bcg', 'oral know vaccine', 'oral know bcg-denmark', 'oral know vaccine', 'oral know denmark', 'oral know saline', 'steroid know participant', 'steroid know bcg', 'steroid know vaccine', 'steroid know bcg-denmark', 'steroid know vaccine', 'steroid know denmark', 'steroid know saline', 'prednisone know participant', 'prednisone know bcg', 'prednisone know vaccine', 'prednisone know bcg-denmark', 'prednisone know vaccine', 'prednisone know denmark', 'prednisone know saline', 'solid know participant', 'solid know bcg', 'solid know vaccine', 'solid know bcg-denmark', 'solid know vaccine', 'solid know denmark', 'solid know saline']",2781,participants trial recruit 1500 hcw danish hospitalsto eligible participation subject must meet following criteria adult 8805 18 years hospital personnel working participating hospital 22 hours per weeka potential subject meets following criteria excluded participation study known allergy components bcg vaccine serious adverse events prior bcg administration known prior active latent infection mycobacterium tuberculosis m tuberculosis mycobacterial species previous confirmed covid-19 fever 38 c within past 24 hours suspicion active viral bacterial infection pregnancy breastfeeding vaccination live attenuated vaccine within last 4 weeks severely immunocompromised subjects 
1071,271.0,9.0,"['180 induce covid-19', '180 induce participant', 'endpoint induce covid-19', 'endpoint induce participant']",2784,participants receive one injection inclusion treatment study participants take place 
1072,271.0,11.0,"['injection need physician', 'injection need n1500', 'injection describe n1500', 'vaccine describe n1500', 'physician describe n1500', 'injection provide physician', 'injection provide n1500', 'vaccine provide physician', 'vaccine provide n1500', 'injection allocate n1500', 'vaccine allocate n1500', 'physician allocate n1500']",2786,participant asked leave room allocated treatment prepared 
1073,271.0,12.0,"['1500 aim participant', '1500 aim 2020', '1500 aim eudract', '1500 aim 2020', '1500 aim eudract', '1500 aim 2020-001888-90', 'participant aim 2020', 'participant aim eudract', 'participant aim 2020', 'participant aim eudract', 'participant aim 2020-001888-90', 'bcg aim participant', 'bcg aim 2020', 'bcg aim eudract', 'bcg aim 2020', 'bcg aim eudract', 'bcg aim 2020-001888-90', '750 aim participant', '750 aim 2020', '750 aim eudract', '750 aim 2020', '750 aim eudract', '750 aim 2020-001888-90', 'participant aim 2020', 'participant aim eudract', 'participant aim 2020', 'participant aim eudract', 'participant aim 2020-001888-90', '1500 randomize eudract', '1500 randomize 2020', '1500 randomize eudract', '1500 randomize 2020-001888-90', 'participant randomize eudract', 'participant randomize 2020', 'participant randomize eudract', 'participant randomize 2020-001888-90', 'bcg randomize eudract', 'bcg randomize 2020', 'bcg randomize eudract', 'bcg randomize 2020-001888-90', '750 randomize eudract', '750 randomize 2020', '750 randomize eudract', '750 randomize 2020-001888-90', 'participant randomize eudract', 'participant randomize 2020', 'participant randomize eudract', 'participant randomize 2020-001888-90', 'participant randomize eudract', 'participant randomize 2020', 'participant randomize eudract', 'participant randomize 2020-001888-90', '2020 randomize eudract', '2020 randomize eudract', '2020 randomize 2020-001888-90', '1500 receive 2020', '1500 receive eudract', '1500 receive 2020', '1500 receive eudract', '1500 receive 2020-001888-90', 'participant receive 2020', 'participant receive eudract', 'participant receive 2020', 'participant receive eudract', 'participant receive 2020-001888-90', 'bcg receive 2020', 'bcg receive eudract', 'bcg receive 2020', 'bcg receive eudract', 'bcg receive 2020-001888-90', '750 receive 2020', '750 receive eudract', '750 receive 2020', '750 receive eudract', '750 receive 2020-001888-90', 'participant receive 2020', 'participant receive eudract', 'participant receive 2020', 'participant receive eudract', 'participant receive 2020-001888-90', 'participant receive 2020', 'participant receive eudract', 'participant receive 2020', 'participant receive eudract', 'participant receive 2020-001888-90', '1500 treat eudract', '1500 treat 2020', '1500 treat eudract', '1500 treat 2020-001888-90', 'participant treat eudract', 'participant treat 2020', 'participant treat eudract', 'participant treat 2020-001888-90', 'bcg treat eudract', 'bcg treat 2020', 'bcg treat eudract', 'bcg treat 2020-001888-90', '750 treat eudract', '750 treat 2020', '750 treat eudract', '750 treat 2020-001888-90', 'participant treat eudract', 'participant treat 2020', 'participant treat eudract', 'participant treat 2020-001888-90', 'participant treat eudract', 'participant treat 2020', 'participant treat eudract', 'participant treat 2020-001888-90', '2020 treat eudract', '2020 treat eudract', '2020 treat 2020-001888-90']",2787,ready injection vaccine placebo look similar participant able tell differencethe physicians administering treatment blindednumbers randomised sample size sample size n1500 
1074,271.0,14.0,['rash eliminate vaccine'],2789,interest expediting dissemination material familiar formatting eliminated letter serves summary key elements full protocol 
1075,272.0,3.0,"['mrna declare vaccine', 'mrna declare allergy', 'mrna declare one', 'mrna declare vaccine', 'vaccine declare allergy', 'vaccine declare one']",2793,conflict interest financial support none declared 
1076,274.0,2.0,['vaccinee show wh1 strain'],2802,data show parameters natural infection time infection nature infecting variant determined cross-neutralization 
1077,274.0,3.0,"['b117 compare boost', 'b117 compare infection']",2803,uninfected vaccinees showed small reduction neutralization b117 variant compared wh1 strain d614g mutant 
1078,275.0,1.0,"['cross-sectional evaluate 2021', 'cross-sectional evaluate greater', 'cross-sectional evaluate pittsburgh']",2806,objective quantify presence magnitude antibody response vaccinated older adult residents assisted living personal care independent living communities 
1079,275.0,2.0,"['participant induce community', 'participant induce mrna-based', 'participant induce covid-19', 'participant induce vaccine']",2807,design cross-sectional quality improvement study conducted march 15 - april 1 2021 greater pittsburgh region 
1080,275.0,7.0,"['participant aim two', 'participant aim antibody']",2812,spearman correlations calculated antibody levels neutralization titers 
1081,275.0,9.0,"['pseudovirus reduce d614', 'pseudovirus reduce uk']",2814,antibody levels trended lower males advanced age current use steroids longer length time vaccination 
1082,275.0,14.0,"['imiquimod reopen body', 'imiquimod reopen cytokine', 'imiquimod reopen cell', 'imiquimod reopen vaccine', 'imiquimod reopen vaccine-only', 'imiquimod reopen influenza', 'imiquimod reopen lung', 'influenza reopen body', 'influenza reopen cytokine', 'influenza reopen cell', 'influenza reopen vaccine', 'influenza reopen vaccine-only', 'influenza reopen lung', 'vaccine reopen body', 'vaccine reopen cytokine', 'vaccine reopen cell', 'vaccine reopen vaccine-only', 'vaccine reopen influenza', 'vaccine reopen lung', 'fda-approved reopen body', 'fda-approved reopen cytokine', 'fda-approved reopen cell', 'fda-approved reopen vaccine', 'fda-approved reopen vaccine-only', 'fda-approved reopen influenza', 'fda-approved reopen lung', 'miltefosine reopen body', 'miltefosine reopen cytokine', 'miltefosine reopen cell', 'miltefosine reopen vaccine', 'miltefosine reopen vaccine-only', 'miltefosine reopen influenza', 'miltefosine reopen lung', 'mtf reopen body', 'mtf reopen cytokine', 'mtf reopen cell', 'mtf reopen vaccine', 'mtf reopen vaccine-only', 'mtf reopen influenza', 'mtf reopen lung', 'vaccine reopen body', 'vaccine reopen cytokine', 'vaccine reopen cell', 'vaccine reopen vaccine-only', 'vaccine reopen influenza', 'vaccine reopen lung', 'mouse reopen body', 'mouse reopen cytokine', 'mouse reopen cell', 'mouse reopen vaccine', 'mouse reopen vaccine-only', 'mouse reopen influenza', 'mouse reopen lung', 'influenza reopen body', 'influenza reopen cytokine', 'influenza reopen cell', 'influenza reopen vaccine', 'influenza reopen vaccine-only', 'influenza reopen lung', 'vaccine reopen body', 'vaccine reopen cytokine', 'vaccine reopen cell', 'vaccine reopen vaccine-only', 'vaccine reopen influenza', 'vaccine reopen lung', 'mtf reopen body', 'mtf reopen cytokine', 'mtf reopen cell', 'mtf reopen vaccine', 'mtf reopen vaccine-only', 'mtf reopen influenza', 'mtf reopen lung', 'imiquimod induce influenza', 'imiquimod induce body', 'imiquimod induce cytokine', 'imiquimod induce cell', 'imiquimod induce vaccine', 'imiquimod induce vaccine-only', 'imiquimod induce influenza', 'imiquimod induce lung', 'influenza induce body', 'influenza induce cytokine', 'influenza induce cell', 'influenza induce vaccine', 'influenza induce vaccine-only', 'influenza induce lung', 'vaccine induce influenza', 'vaccine induce body', 'vaccine induce cytokine', 'vaccine induce cell', 'vaccine induce vaccine-only', 'vaccine induce influenza', 'vaccine induce lung', 'fda-approved induce influenza', 'fda-approved induce body', 'fda-approved induce cytokine', 'fda-approved induce cell', 'fda-approved induce vaccine', 'fda-approved induce vaccine-only', 'fda-approved induce influenza', 'fda-approved induce lung', 'miltefosine induce influenza', 'miltefosine induce body', 'miltefosine induce cytokine', 'miltefosine induce cell', 'miltefosine induce vaccine', 'miltefosine induce vaccine-only', 'miltefosine induce influenza', 'miltefosine induce lung', 'mtf induce influenza', 'mtf induce body', 'mtf induce cytokine', 'mtf induce cell', 'mtf induce vaccine', 'mtf induce vaccine-only', 'mtf induce influenza', 'mtf induce lung', 'vaccine induce influenza', 'vaccine induce body', 'vaccine induce cytokine', 'vaccine induce cell', 'vaccine induce vaccine-only', 'vaccine induce influenza', 'vaccine induce lung', 'mouse induce influenza', 'mouse induce body', 'mouse induce cytokine', 'mouse induce cell', 'mouse induce vaccine', 'mouse induce vaccine-only', 'mouse induce influenza', 'mouse induce lung', 'influenza induce body', 'influenza induce cytokine', 'influenza induce cell', 'influenza induce vaccine', 'influenza induce vaccine-only', 'influenza induce lung', 'vaccine induce influenza', 'vaccine induce body', 'vaccine induce cytokine', 'vaccine induce cell', 'vaccine induce vaccine-only', 'vaccine induce influenza', 'vaccine induce lung', 'mtf induce influenza', 'mtf induce body', 'mtf induce cytokine', 'mtf induce cell', 'mtf induce vaccine', 'mtf induce vaccine-only', 'mtf induce influenza', 'mtf induce lung']",2819,study provides important preliminary results level population risk older adult residents assisted living personal care independent living communities inform reopening strategies likely translatable residents nursing homes 
1083,276.0,0.0,"['respiratory syndrome improve sars-cov-2', 'respiratory syndrome improve corona', 'respiratory syndrome improve covid-19', 'coronavirus improve sars-cov-2', 'coronavirus improve corona', 'coronavirus improve covid-19']",2820,previously reported topical imiquimod improve immunogenicity influenza vaccine study investigated another fda-approved drug miltefosine mtf vaccine adjuvant mice immunized influenza vaccine without mtf adjuvant challenged lethal dose influenza virus 3 7 days vaccination survival body weight antibody response histopathological changes viral loads cytokine levels cell frequencies compared mtf-adjuvanted vaccine mtf-vac group significantly better survival rate vaccine-only vac group administered 3 days 80 vs 26 7 p 0 0063 7 days 96 vs 65 p 0 0041 influenza virus challenge lung damage significantly ameliorated mtf-vac group antibody response significantly augmented mtf-vac group homologous heterologous influenza strains greater follicular helper cell tfh response enhanced germinal center gc reaction mtf-vac group mtf-vac also induced th1 th2 antigen-specific cytokine responses mtf improved efficacy influenza vaccine homologous heterologous viruses improving tfh antibody responses miltefosine may also used vaccines including upcoming vaccines covid-19
1084,277.0,1.0,"['sputnik match covid-19', 'sputnik match covid-19', 'sputnik match people']",2822,two vaccines granted emergency use central drugs standard control organization cdsco india covishieldÃÂ astrazeneca s vaccine manufactured serum institute india covaxinÃÂ manufactured bharat biotech limited 
1085,277.0,3.0,"['1028 base covid', '1028 base 146', '1028 base 146', '1028 base 100', 'covid base 146', 'covid base 146', 'covid base 100', '1028 do 146', '1028 do 146', '1028 do 100', 'covid do 146', 'covid do 146', 'covid do 100', 'covid do 146', 'covid do 146', 'covid do 100', '1028 associate 100', 'covid associate 100', 'covid associate 100', '146 associate 100', '146 associate 100']",2824,methods hospital based prospective cohort study done march june 2021 pbm associated group hospitals agh bikaner raj 
1086,277.0,5.0,"['4286 infect infection', '4286 infect infection', '4286 receive infection', 'mild receive infection', '4286 induce infection', 'mild induce infection']",2826,results among 100 covid-19 infected cases 49 received first dose rest got doses 
1087,277.0,7.0,"['1020 dose 898', '1020 dose covid', '1020 dose 7347', '1020 dose 1633']",2828,evaluation hrct chest first dose 816 normal 4082 severe category got doses 5282 392 respectively 
1088,277.0,8.0,"['6667 receive 2549', '6667 receive 784', '6667 base 784', '3333 base 784', '2549 base 784']",2829,among 49 got first dose 1020 recovered home based treatment without need hospitalization 898 got admitted dedicated covid hospital 7347 got recovered 1633 died 
1089,277.0,9.0,['vaccine receive infection'],2830,among 51 got doses 6667 recovered home based treatment 3333 required hospitalization 2549 got recovered 784 died 
1090,277.0,10.0,"['covid-19 dose influenza', 'covid-19 dose vaccine', 'covid-19 dose death', 'covid-19 dose patient', 'covid-19 dose brindisi', 'covid-19 dose patient', 'covid-19 dose influenza', 'covid-19 dose vaccine', 'covid-19 dose influenza', 'covid-19 dose 2020', 'covid-19 dose 3872', 'covid-19 dose sars-cov-2', 'covid-19 dose 664', 'coronavirus dose influenza', 'coronavirus dose vaccine', 'coronavirus dose death', 'coronavirus dose covid-19', 'coronavirus dose patient', 'coronavirus dose covid-19', 'coronavirus dose brindisi', 'coronavirus dose patient', 'coronavirus dose influenza', 'coronavirus dose vaccine', 'coronavirus dose influenza', 'coronavirus dose 2020', 'coronavirus dose 3872', 'coronavirus dose sars-cov-2', 'coronavirus dose 664', 'sars-cov-2 dose influenza', 'sars-cov-2 dose vaccine', 'sars-cov-2 dose death', 'sars-cov-2 dose covid-19', 'sars-cov-2 dose patient', 'sars-cov-2 dose covid-19', 'sars-cov-2 dose brindisi', 'sars-cov-2 dose patient', 'sars-cov-2 dose influenza', 'sars-cov-2 dose vaccine', 'sars-cov-2 dose influenza', 'sars-cov-2 dose 2020', 'sars-cov-2 dose 3872', 'sars-cov-2 dose 664', 'influenza dose vaccine', 'influenza dose death', 'influenza dose covid-19', 'influenza dose patient', 'influenza dose covid-19', 'influenza dose brindisi', 'influenza dose patient', 'influenza dose vaccine', 'influenza dose 2020', 'influenza dose 3872', 'influenza dose sars-cov-2', 'influenza dose 664', 'vaccine dose influenza', 'vaccine dose death', 'vaccine dose covid-19', 'vaccine dose patient', 'vaccine dose covid-19', 'vaccine dose brindisi', 'vaccine dose patient', 'vaccine dose influenza', 'vaccine dose influenza', 'vaccine dose 2020', 'vaccine dose 3872', 'vaccine dose sars-cov-2', 'vaccine dose 664', 'covid-19 dose influenza', 'covid-19 dose vaccine', 'covid-19 dose death', 'covid-19 dose patient', 'covid-19 dose brindisi', 'covid-19 dose patient', 'covid-19 dose influenza', 'covid-19 dose vaccine', 'covid-19 dose influenza', 'covid-19 dose 2020', 'covid-19 dose 3872', 'covid-19 dose sars-cov-2', 'covid-19 dose 664', 'covid-19 induce influenza', 'covid-19 induce vaccine', 'covid-19 induce influenza', 'covid-19 induce vaccine', 'covid-19 induce death', 'covid-19 induce patient', 'covid-19 induce brindisi', 'covid-19 induce patient', 'covid-19 induce influenza', 'covid-19 induce vaccine', 'covid-19 induce influenza', 'covid-19 induce 2020', 'covid-19 induce 3872', 'covid-19 induce sars-cov-2', 'covid-19 induce 664', 'coronavirus induce influenza', 'coronavirus induce vaccine', 'coronavirus induce covid-19', 'coronavirus induce influenza', 'coronavirus induce vaccine', 'coronavirus induce death', 'coronavirus induce covid-19', 'coronavirus induce patient', 'coronavirus induce covid-19', 'coronavirus induce brindisi', 'coronavirus induce patient', 'coronavirus induce influenza', 'coronavirus induce vaccine', 'coronavirus induce influenza', 'coronavirus induce 2020', 'coronavirus induce 3872', 'coronavirus induce sars-cov-2', 'coronavirus induce 664', 'sars-cov-2 induce influenza', 'sars-cov-2 induce vaccine', 'sars-cov-2 induce covid-19', 'sars-cov-2 induce influenza', 'sars-cov-2 induce vaccine', 'sars-cov-2 induce death', 'sars-cov-2 induce covid-19', 'sars-cov-2 induce patient', 'sars-cov-2 induce covid-19', 'sars-cov-2 induce brindisi', 'sars-cov-2 induce patient', 'sars-cov-2 induce influenza', 'sars-cov-2 induce vaccine', 'sars-cov-2 induce influenza', 'sars-cov-2 induce 2020', 'sars-cov-2 induce 3872', 'sars-cov-2 induce 664', 'covid-19 compare influenza', 'covid-19 compare vaccine', 'covid-19 compare death', 'covid-19 compare patient', 'covid-19 compare brindisi', 'covid-19 compare patient', 'covid-19 compare influenza', 'covid-19 compare vaccine', 'covid-19 compare influenza', 'covid-19 compare 2020', 'covid-19 compare 3872', 'covid-19 compare sars-cov-2', 'covid-19 compare 664', 'coronavirus compare influenza', 'coronavirus compare vaccine', 'coronavirus compare death', 'coronavirus compare covid-19', 'coronavirus compare patient', 'coronavirus compare covid-19', 'coronavirus compare brindisi', 'coronavirus compare patient', 'coronavirus compare influenza', 'coronavirus compare vaccine', 'coronavirus compare influenza', 'coronavirus compare 2020', 'coronavirus compare 3872', 'coronavirus compare sars-cov-2', 'coronavirus compare 664', 'sars-cov-2 compare influenza', 'sars-cov-2 compare vaccine', 'sars-cov-2 compare death', 'sars-cov-2 compare covid-19', 'sars-cov-2 compare patient', 'sars-cov-2 compare covid-19', 'sars-cov-2 compare brindisi', 'sars-cov-2 compare patient', 'sars-cov-2 compare influenza', 'sars-cov-2 compare vaccine', 'sars-cov-2 compare influenza', 'sars-cov-2 compare 2020', 'sars-cov-2 compare 3872', 'sars-cov-2 compare 664', 'influenza compare vaccine', 'influenza compare death', 'influenza compare covid-19', 'influenza compare patient', 'influenza compare covid-19', 'influenza compare brindisi', 'influenza compare patient', 'influenza compare vaccine', 'influenza compare 2020', 'influenza compare 3872', 'influenza compare sars-cov-2', 'influenza compare 664', 'vaccine compare influenza', 'vaccine compare death', 'vaccine compare covid-19', 'vaccine compare patient', 'vaccine compare covid-19', 'vaccine compare brindisi', 'vaccine compare patient', 'vaccine compare influenza', 'vaccine compare influenza', 'vaccine compare 2020', 'vaccine compare 3872', 'vaccine compare sars-cov-2', 'vaccine compare 664']",2831,conclusion 2nd dose vaccine significant risk reduction need hospitalization getting severe infection mortality compared first dose 
1091,279.0,1.0,"['enzyme-linked embed elisa', 'enzyme-linked embed infection', 'immunosorbent embed elisa', 'immunosorbent embed infection']",2834,methodswe used ongoing household cohort embedded transmission study closely monitors participants regardless symptom status 
1092,279.0,6.0,"['692 dominate infection', '692 dominate 794', '692 dominate 649', 'infection dominate 794', 'infection dominate 649', '607 dominate infection', '607 dominate 794', '607 dominate 649']",2839,march 2021 gamma delta variants predominated 
1093,279.0,8.0,"['second associate rr', 'second associate 133-273', 'infection associate rr', 'infection associate 133-273', 'infection associate rr', 'infection associate 133-273']",2841,anti-spike titers 327 2551 associated 50 80 protection infection titers 284 656 sufficient protection moderate severe disease 
1094,280.0,0.0,"['low-risk reduce immunity', 'one reduce immunity', 'sars-cov-2 reduce immunity']",2847,many countries extensive vaccination programme substantially reduced public-health impact sars-cov-2 limiting number hospital admissions deaths compared unmitigated epidemic 
1095,280.0,3.0,"['booster use infection', 'booster use vaccine']",2850, using data models england consider dynamics covid-19 two-year time-frame role booster vaccinations play mitigating worst effects 
1096,280.0,6.0,['second follow booster'],2853,protection boosters wanes slowly akin protection following infection single booster dose 50s may needed next two-years 
1097,281.0,2.0,"['dry-powder need t-laiv', 'dry-powder need delta', 'dry-powder need inulin', 'dry-powder need ferret', 'laiv need t-laiv', 'laiv need delta', 'laiv need inulin', 'laiv need ferret', 'dry-powder observe t-laiv', 'dry-powder observe delta', 'dry-powder observe inulin', 'dry-powder observe ferret', 'laiv observe t-laiv', 'laiv observe delta', 'laiv observe inulin', 'laiv observe ferret', 't-laiv observe delta', 't-laiv observe inulin', 't-laiv observe ferret']",2857,however laivs require reconstitution cold-chain requirements restrict storage distribution influenza vaccines 
1098,281.0,4.0,"['ferret show inulin', 'ferret show mucosal', 'ferret show serum', 't-laiv store ferret', 'inulin store ferret', 'mucosal store ferret']",2859,stability assays demonstrated minimal loss t-laiv titer stored 25 ÃÂc 1 year 
1099,282.0,0.0,"['liposome show liposomal', 'vaccine show liposomal', 'phospholipase-a show liposomal', 'pla show liposomal', 'wll show liposomal']",2863,objective whole leishmania lysate antigens wll shown effective tackle leishmaniasis murine models 
1100,282.0,1.0,['lipid promise pla'],2864,although liposomes considered promising vaccines activity phospholipase-a pla wll breeds difficulties preparing stable liposomal wll 
1101,282.0,2.0,['liposome use vaccine'],2865,one strategy overcome shortcoming use lipids sphingomyelin sm resistant pla 
1102,282.0,3.0,"['leishmania formulate liposome', 'leishmania formulate balbc']",2866,study aim formulating stable sm liposomes containing wll comparing adjuvant effects another first generation vaccine ie 
1103,282.0,7.0,"['liposomal evaluate mouse', 'liposomal evaluate liposome-wll', 'liposomal evaluate footpad', 'liposomal evaluate swelling']",2870,factors used assess response immune system means igg subclasses il-4 ifn-ÃÂ³ levels intracellular cytokine assay cultured splenocytes 
1104,282.0,12.0,"['covid-19 observe coronavirus', 'covid-19 observe sars-cov-2', 'covid-19 receive coronavirus', 'covid-19 receive sars-cov-2']",2875,also studies warranted fully understand role sphingomyelin inducing immune response 
1105,283.0,0.0,"['covid-19 prevent household', 'covid-19 prevent bnt162b2', 'covid-19 prevent chadox1', 'covid-19 prevent ncov-19', 'covid-19 prevent chadox1', 'covid-19 prevent vaccine', 'covid-19 prevent sars-cov-2', 'covid-19 prevent symptom', 'covid-19 prevent 8805', 'covid-19 prevent surrogate', 'covid-19 prevent b117']",2876,effectiveness covid-19 vaccination preventing new severe acute respiratory syndrome coronavirus 2 sars-cov-2 infections general community still unclear 
1106,283.0,1.0,"['nose select sars-cov-2', 'nose select infection', 'nose select 8805', 'nose select ci', 'nose select 54-68', 'nose select 95', 'nose select 60-71', 'nose select second', 'throat select sars-cov-2', 'throat select infection', 'throat select 8805', 'throat select ci', 'throat select 54-68', 'throat select 95', 'throat select 60-71', 'throat select second', 'swab select sars-cov-2', 'swab select infection', 'swab select 8805', 'swab select ci', 'swab select 54-68', 'swab select 95', 'swab select 60-71', 'swab select second', 'participant select sars-cov-2', 'participant select infection', 'participant select 8805', 'participant select ci', 'participant select 54-68', 'participant select 95', 'participant select 60-71', 'participant select second', 'chadox1 select sars-cov-2', 'chadox1 select infection', 'chadox1 select 8805', 'chadox1 select ci', 'chadox1 select 54-68', 'chadox1 select 95', 'chadox1 select 60-71', 'chadox1 select second', 'bnt162b2 select sars-cov-2', 'bnt162b2 select infection', 'bnt162b2 select 8805', 'bnt162b2 select ci', 'bnt162b2 select 54-68', 'bnt162b2 select 95', 'bnt162b2 select 60-71', 'bnt162b2 select second', 'vaccine select sars-cov-2', 'vaccine select infection', 'vaccine select 8805', 'vaccine select ci', 'vaccine select 54-68', 'vaccine select 95', 'vaccine select 60-71', 'vaccine select second', 'nose base chadox1', 'nose base bnt162b2', 'nose base vaccine', 'nose base sars-cov-2', 'nose base infection', 'nose base 8805', 'nose base ci', 'nose base 54-68', 'nose base 95', 'nose base 60-71', 'nose base second', 'throat base chadox1', 'throat base bnt162b2', 'throat base vaccine', 'throat base sars-cov-2', 'throat base infection', 'throat base 8805', 'throat base ci', 'throat base 54-68', 'throat base 95', 'throat base 60-71', 'throat base second', 'swab base chadox1', 'swab base bnt162b2', 'swab base vaccine', 'swab base sars-cov-2', 'swab base infection', 'swab base 8805', 'swab base ci', 'swab base 54-68', 'swab base 95', 'swab base 60-71', 'swab base second', 'participant base chadox1', 'participant base bnt162b2', 'participant base vaccine', 'participant base sars-cov-2', 'participant base infection', 'participant base 8805', 'participant base ci', 'participant base 54-68', 'participant base 95', 'participant base 60-71', 'participant base second', 'nose induce sars-cov-2', 'nose induce infection', 'nose induce 8805', 'nose induce ci', 'nose induce 54-68', 'nose induce 95', 'nose induce 60-71', 'nose induce second', 'throat induce sars-cov-2', 'throat induce infection', 'throat induce 8805', 'throat induce ci', 'throat induce 54-68', 'throat induce 95', 'throat induce 60-71', 'throat induce second', 'swab induce sars-cov-2', 'swab induce infection', 'swab induce 8805', 'swab induce ci', 'swab induce 54-68', 'swab induce 95', 'swab induce 60-71', 'swab induce second', 'participant induce sars-cov-2', 'participant induce infection', 'participant induce 8805', 'participant induce ci', 'participant induce 54-68', 'participant induce 95', 'participant induce 60-71', 'participant induce second', 'chadox1 induce sars-cov-2', 'chadox1 induce infection', 'chadox1 induce 8805', 'chadox1 induce ci', 'chadox1 induce 54-68', 'chadox1 induce 95', 'chadox1 induce 60-71', 'chadox1 induce second', 'bnt162b2 induce sars-cov-2', 'bnt162b2 induce infection', 'bnt162b2 induce 8805', 'bnt162b2 induce ci', 'bnt162b2 induce 54-68', 'bnt162b2 induce 95', 'bnt162b2 induce 60-71', 'bnt162b2 induce second', 'nose evaluate ci', 'nose evaluate 54-68', 'nose evaluate 95', 'nose evaluate 60-71', 'nose evaluate second', 'throat evaluate ci', 'throat evaluate 54-68', 'throat evaluate 95', 'throat evaluate 60-71', 'throat evaluate second', 'swab evaluate ci', 'swab evaluate 54-68', 'swab evaluate 95', 'swab evaluate 60-71', 'swab evaluate second', 'participant evaluate ci', 'participant evaluate 54-68', 'participant evaluate 95', 'participant evaluate 60-71', 'participant evaluate second', 'chadox1 evaluate ci', 'chadox1 evaluate 54-68', 'chadox1 evaluate 95', 'chadox1 evaluate 60-71', 'chadox1 evaluate second', 'bnt162b2 evaluate ci', 'bnt162b2 evaluate 54-68', 'bnt162b2 evaluate 95', 'bnt162b2 evaluate 60-71', 'bnt162b2 evaluate second', 'vaccine evaluate ci', 'vaccine evaluate 54-68', 'vaccine evaluate 95', 'vaccine evaluate 60-71', 'vaccine evaluate second', 'sars-cov-2 evaluate ci', 'sars-cov-2 evaluate 54-68', 'sars-cov-2 evaluate 95', 'sars-cov-2 evaluate 60-71', 'sars-cov-2 evaluate second', 'infection evaluate ci', 'infection evaluate 54-68', 'infection evaluate 95', 'infection evaluate 60-71', 'infection evaluate second', '8805 evaluate ci', '8805 evaluate 54-68', '8805 evaluate 95', '8805 evaluate 60-71', '8805 evaluate second']",2877, used office national statistics covid-19 infection survey-a large community-based survey individuals living randomly selected private households across united kingdom-to assess effectiveness bnt162b2 pfizer-biontech chadox1 ncov-19 oxford-astrazeneca chadox1 vaccines new sars-cov-2 pcr-positive tests split according self-reported symptoms cycle threshold value 30 versus 8805 30 surrogate viral load gene positivity pattern compatible b117 
1107,283.0,3.0,"['covid-19 observe sars-cov-2', 'covid-19 observe two', 'covid-19 observe viral', 'covid-19 observe bnt162b2', 'covid-19 observe chadox1', 'covid-19 observe vaccine']",2879,largest reductions observed symptomatic infections andor infections higher viral burden 
1108,283.0,4.0,"['patient reduce covid-19', 'patient reduce mrna', 'patient reduce vaccine', 'cancer reduce covid-19', 'cancer reduce mrna', 'cancer reduce vaccine']",2880,overall covid-19 vaccination reduced number new sars-cov-2 infections largest benefit received two vaccinations symptomatic high viral burden infections evidence difference bnt162b2 chadox1 vaccines 
1109,284.0,0.0,"['cytokine prioritize mrna', 'cytokine prioritize vaccine', 'cr prioritize mrna', 'cr prioritize vaccine']",2881,patients cancer currently prioritized coronavirus disease 2019 covid-19 vaccination programs globally includes administration mrna vaccines 
1110,284.0,1.0,"['cr report pfizer-biontech', 'cr report mrna', 'cr report covid-19', 'cr report vaccine-in', 'cr report patient', 'cr report cancer', 'btn162b2 report pfizer-biontech', 'btn162b2 report mrna', 'btn162b2 report covid-19', 'btn162b2 report vaccine-in', 'btn162b2 report patient', 'btn162b2 report cancer', 'tozinameran report pfizer-biontech', 'tozinameran report mrna', 'tozinameran report covid-19', 'tozinameran report vaccine-in', 'tozinameran report patient', 'tozinameran report cancer']",2882,cytokine release syndrome crs reported mrna vaccines extremely rare immune-related adverse event immune checkpoint inhibitors 
1111,284.0,2.0,"['cr receive ifn-Ã\x83\x83Ã\x83\x82Ã\x83\x83Ã\x83\x82Ã\x82Â³il-2ril-18il-16il-10', 'cr receive steroid', 'thrombocytopenia receive ifn-Ã\x83\x83Ã\x83\x82Ã\x83\x83Ã\x83\x82Ã\x82Â³il-2ril-18il-16il-10', 'thrombocytopenia receive steroid']",2883,present case crs occurred 5 vaccination btn162b2 tozinameran -the pfizer-biontech mrna covid-19 vaccine-in patient colorectal cancer long-standing anti-pd-1 monotherapy 
1112,284.0,3.0,"['cr boost blockade', 'cr boost blockade', 'vaccine-related boost blockade']",2884,crs evidenced raised inflammatory markers thrombocytopenia elevated cytokine levels ifn-ÃÂÃÂ³il-2ril-18il-16il-10 steroid responsiveness 
1113,284.0,5.0,"['patient need high-risk', 'patient need sars-cov-2', 'worker need high-risk', 'worker need sars-cov-2']",2886,overall prospective pharmacovigillence data needed patients cancer benefit-risk profile remains strongly favor covid-19 vaccination population 
1114,285.0,0.0,"['worker consider bnt162b2', 'worker consider biontech-pfizer', 'worker consider vaccine', '216 consider bnt162b2', '216 consider biontech-pfizer', '216 consider vaccine']",2887,background hemodialysis patients well healthcare workers considered high-risk category sars-cov-2 infection priority vaccination 
1115,285.0,5.0,"['100 report worker', '100 report igg', '100 report second', '100 report 917', '100 report patient']",2892,lymphadenopathy reported health workers 
1116,285.0,6.0,"['patient develop p001', 'patient develop r', 'patient develop p0005', 'patient develop first', 'patient develop p0028', 'patient develop p0018', 'patient compare first', 'patient compare p0028', 'patient compare p0018', 'p001 compare first', 'p001 compare p0028', 'p001 compare p0018', 'r compare first', 'r compare p0028', 'r compare p0018', 'p0005 compare first', 'p0005 compare p0028', 'p0005 compare p0018']",2893, 100 individuals healthcare workers group developed positive antibody response anti-s igg second dose compared 917 patients 
1117,285.0,12.0,"['b recommend vaccine', 'streptococcus recommend vaccine', 'b consider vaccine', 'streptococcus consider vaccine']",2899,however 91 response believe vaccination recommended strongly hemodialysis population 
1118,286.0,2.0,"['isolates collect hvga ermb', 'isolates collect pi-2b', 'isolates collect lnub', 'capsular collect hvga ermb', 'capsular collect pi-2b', 'capsular collect lnub']",2902,total number 72 colonizing invasive gbs collected pregnant non-pregnant women 
1119,286.0,6.0,"['375 follow 305', '375 follow pi-2b', '375 follow 291', '375 follow pi-2b']",2906,frequency capsular serotypes follows iii 263 ia 2083 ib v 152 iv 97 ii 83 vii 27 vi 13 
1120,286.0,8.0,"['erythromycin belong 233', 'erythromycin belong mefa', 'isolates belong 233', 'isolates belong mefa']",2908,two maternal colonizing gbs 26 hvga positive belonged st-17cps-iiipi-1 pi-2b lineage 
1121,286.0,10.0,"['five harbor complex', 'five harbor nine', 'five harbor sts', 'five harbor cc-19st-335', 'five harbor st-19', 'five harbor st-197', 'five harbor cc-12st-43', 'five harbor st-12', 'five harbor cc-23st-163', 'five harbor st-23', 'five harbor cc-17st-17', 'five harbor cc-4st-16']",2910,one clindamycin-resistant isolate harbored lnub gene 
1122,286.0,12.0,"['st-335cps-iii show tetracycline', 'st-335cps-iii show erythromycin']",2912,conclusion study shows alarmingly high prevalence erythromycin-resistant gbs iran 
1123,287.0,3.0,"['influenza induce vaccine', 'influenza induce riv', 'influenza induce laiv', 'vaccine induce influenza', 'vaccine induce riv', 'vaccine induce influenza', 'vaccine induce laiv']",2918,thus categories represent target flu vaccine strategies countries 
1124,288.0,3.0,"['lymph nodes test 20 -', 'lymph nodes test patient', 'lymph nodes test 173', 'fdg test 20 -', 'fdg test patient', 'fdg test 173', 'petct test 20 -', 'petct test patient', 'petct test 173', 'vaccine test 20 -', 'vaccine test patient', 'vaccine test 173', 'lymph nodes evaluate 173', '20 - evaluate 173', 'fdg evaluate 173', 'petct evaluate 173', 'vaccine evaluate 173', 'injection evaluate 173', 'patient evaluate 173']",2924,assuming knowledge prior vaccination metastatic risk analyzed two readers clinical impact evaluated 
1125,288.0,4.0,"['lymph nodes show 3990', 'patient show 3990']",2925,results fdg petct showed fdg-avid lymph nodes ipsilateral vaccine injection 75140 54 patients mean suvmax 51 range 20 - 173 
1126,288.0,10.0,"['axillary lymph induce vaccine', 'axillary lymph induce injection', 'axillary lymph induce 140', 'axillary lymph induce patient', 'axillary lymph induce covid-19', 'petct induce vaccine', 'petct induce injection', 'petct induce 140', 'petct induce patient', 'petct induce covid-19']",2931,avoid relatively frequent clinical dilemmas recommend carefully taking history prior vaccination patients undergoing fdg petct administering vaccine contralateral primary cancer 
1127,288.0,11.0,"['fdg-avid show patient', 'fdg-avid show pfizer-biontech-vaccines', 'lymphadenopathy show patient', 'lymphadenopathy show pfizer-biontech-vaccines']",2932,key points ÃÂÃÂÃÂ petct showed fdg-avid axillary lymph nodes ipsilateral vaccine injection site 54 140 oncological patients covid-19 vaccination 
1128,288.0,12.0,"['patient observe petct', 'covid-19 observe petct']",2933,ÃÂÃÂÃÂ fdg-avid lymphadenopathy observed significantly frequently moderna compared patients receiving pfizer-biontech-vaccines 
1129,288.0,13.0,"['swine undergo animal', 'pig undergo animal', 'boar undergo animal']",2934,ÃÂÃÂÃÂ patients screened prior covid-19 vaccination undergoing petct enable individually tailored recommendations clinical management 
1130,289.0,6.0,['infection observe animal'],2941,results observed faster csf infection spread wild boar population japan compared csf epidemics european countries 
1131,289.0,9.0,"['boar increase piglet', 'boar increase infection']",2944,decrease increase proportion infected immune animals respectively however immunization piglets remained insufficient vaccination 1 year 
1132,290.0,3.0,"['coronavirus explore 2019', 'coronavirus explore covid-19']",2951,method systematically searched pubmed europe pmc databases 19 january 2021 using specific keywords related aims 
1133,290.0,7.0,"['covid-19 evaluate 101-139', 'random-effects evaluate 101-139', '119 evaluate 101-139', 'covid-19 include 119', 'covid-19 include 101-139', 'random-effects include 119', 'random-effects include 101-139']",2955,results total 28 studies including 18 255 040 covid-19 patients assessed meta-analysis 
1134,290.0,8.0,"['meta-regression associate p 0208', 'meta-regression associate cd4 cell', 'meta-regression associate 0353']",2956,overall hiv associated higher mortality covid-19 random-effects modelling odds ratio 119 95 confidence interval ci 101-139 p 003 lt sup gt 2 lt sup gt 72 
1135,290.0,9.0,"['africa observe 130', '113 observe 130']",2957,meta-regression confirmed association influenced age p 0208 cd4 cell count p 0353 presence antiretroviral therapy art p 0647 
1136,290.0,10.0,"['person indicate sars-cov-2', 'person indicate vaccine', 'person indicate plwh', 'person indicate death', 'person indicate covid-19']",2958,subgroup analysis indicated association statistically significant studies africa 113 p 0004 united states 130 p 0006 
1137,291.0,0.0,"['cohort aim kidney', 'cohort aim recipient', 'cohort aim centre', 'cohort evaluate kidney', 'cohort evaluate recipient', 'cohort evaluate centre']",2961,objectives aimed evaluate rates antibody response severe acute respiratory syndrome coronavirus 2 sars-cov-2 mrna vaccine among kidney transplant recipients identify factors associated reduced immunogenicity 
1138,291.0,4.0,"['308 induce 112', '308 induce 364', '308 induce antibody', '308 induce 2-4', '308 induce bnt162b2', '308 induce vaccine', 'kidney induce 112', 'kidney induce 364', 'kidney induce antibody', 'kidney induce 2-4', 'kidney induce bnt162b2', 'kidney induce vaccine', '308 receive antibody', '308 receive 2-4', '308 receive bnt162b2', '308 receive vaccine', 'kidney receive antibody', 'kidney receive 2-4', 'kidney receive bnt162b2', 'kidney receive vaccine', 'recipient receive antibody', 'recipient receive 2-4', 'recipient receive bnt162b2', 'recipient receive vaccine', '112 receive antibody', '112 receive 2-4', '112 receive bnt162b2', '112 receive vaccine', '308 associate antibody', '308 associate 2-4', '308 associate bnt162b2', '308 associate vaccine', 'kidney associate antibody', 'kidney associate 2-4', 'kidney associate bnt162b2', 'kidney associate vaccine', 'recipient associate antibody', 'recipient associate 2-4', 'recipient associate bnt162b2', 'recipient associate vaccine', '112 associate antibody', '112 associate 2-4', '112 associate bnt162b2', '112 associate vaccine', '364 associate antibody', '364 associate 2-4', '364 associate bnt162b2', '364 associate vaccine']",2965,univariate multivariate analyses conducted identify factors associated seropositivity 
1139,291.0,8.0,"['kidney report mrna', 'recipient report mrna', 'kidney induce sars-cov-2', 'kidney induce mrna', 'recipient induce sars-cov-2', 'recipient induce mrna']",2969,serious adverse events resulting vaccine reported 
1140,291.0,11.0,"['convalescent test respiratory syndrome', 'convalescent test vaccine', 'convalescent test coronavirus', 'convalescent test covid-19', 'plasma test respiratory syndrome', 'plasma test vaccine', 'plasma test coronavirus', 'plasma test covid-19', 'convalescent improve respiratory syndrome', 'convalescent improve vaccine', 'convalescent improve coronavirus', 'convalescent improve covid-19']",2972,strategies improve immunogenicity examined future studies 
1141,292.0,2.0,"['plasma use patient', 'plasma use infection', 'plasma use sars-cov-2']",2975,methods cp treatment applied 26 covid-19 patients intensive care unit quantitative reverse transcriptase-polymerase chain reaction positive sars-cov-2 infection 
1142,292.0,5.0,"['neutrophil compare bilirubin', 'lymphocyte compare bilirubin', 'platelet compare bilirubin', 'crp compare bilirubin', 'ferritin compare bilirubin', 'ldh compare bilirubin']",2978,laboratory values patients cp 7 days compared 
1143,292.0,7.0,"['patient receive 746', 'patient receive 6185', 'patient receive lymphopenia', 'patient receive 118', 'patient induce 118', '746 induce 118', '6185 induce 118', 'lymphopenia induce 118']",2980,statistically significant difference found age lymphocyte values living dying patients 
1144,293.0,0.0,"['thymus make atherosclerosis', 'thymus make hypertension', 'thymus make diabetes', 'thymus play atherosclerosis', 'thymus play hypertension', 'thymus play diabetes']",2984,thymus largely neglected organ plays significant role regulation adaptive immune responses 
1145,293.0,2.0,"['thymus associate thymic', 'thymus associate covid-19', 'thymus associate thymic', 'thymus associate covid-19', 'thymus predispose covid-19', 'thymic predispose covid-19', 'thymic predispose covid-19']",2986,aging diseases inflammaging associated severe covid-19 disease dysfunctional thymus may predisposing factor 
1146,293.0,3.0,"['thymic induce covid-19', 'thymic induce vaccine', 'convalescent induce covid-19', 'convalescent induce vaccine', 'serum induce covid-19', 'serum induce vaccine']",2987,addition insults thymus childhood may lead abnormal thymic function may explain severe covid-19 disease among younger individuals therefore measurement thymic function may assist covid-19 care 
1147,293.0,4.0,"['thymic treat patient', 'thymic treat covid-19']",2988,poor thymic function may treated prophylactically convalescent serum recombinant antibodies may respond better high-dose adjuvanted covid-19 vaccines 
1148,293.0,5.0,"['vaccine observe immunity', 'vaccine observe coronavirus', 'vaccine observe sars-cov-2', 'vaccine improve immunity', 'vaccine improve coronavirus', 'vaccine improve sars-cov-2']",2989,treatments inducing thymic regeneration may improve patients overall health may incorporated covid-19 management 
1149,294.0,0.0,['two dose infection'],2990,given vaccine dose shortages logistical challenges various deployment strategies proposed increase population immunity levels severe acute respiratory syndrome coronavirus 2 sars-cov-2 
1150,294.0,2.0,"['immuno-epidemiological elicit infection', 'immuno-epidemiological elicit longer-term']",2992,hinge robustness immune response elicited single dose compared natural two-dose immunity 
1151,294.0,3.0,"['three exist one-dose', 'three exist immunity', 'three receive immunity', 'one-dose receive immunity']",2993,building existing immuno-epidemiological model find short term focusing one dose generally decreases infections longer-term outcomes depend relative immune robustness 
1152,294.0,5.0,['fentanyl test sud'],2995,highlight critical need test viral loads quantify immune responses one vaccine dose ramp vaccination efforts globally 
1153,295.0,3.0,"['anti-fentanyl derive antibody', 'anti-fentanyl derive bone-marrow', 'anti-fentanyl derive alum', 'anti-fentanyl derive dmlt', 'anti-fentanyl derive lta1', 'anti-fentanyl include alum', 'anti-fentanyl include dmlt', 'anti-fentanyl include lta1', 'serum include alum', 'serum include dmlt', 'serum include lta1', 'antibody include alum', 'antibody include dmlt', 'antibody include lta1', 'bone-marrow include alum', 'bone-marrow include dmlt', 'bone-marrow include lta1']",2999,tested adjuvants derived heat-labile toxin e coli including dmlt lta1 intramuscular sublingual intranasal delivery 
1154,295.0,4.0,"['vaccine show dmlt', 'vaccine show antibody', 'vaccine show alum']",3000,results show anti-fentanyl serum antibodies antibody secreting cells bone-marrow vaccination highest levels observed adjuvant alum dmlt lta1 
1155,295.0,5.0,"['dmlt elicit blockade', 'dmlt elicit fentanyl-induced', 'dmlt elicit cns', 'lta1 elicit blockade', 'lta1 elicit fentanyl-induced', 'lta1 elicit cns']",3001,vaccine adjuvanted lta1 dmlt elicited highest levels anti-fentanyl antibodies whereas alum achieved highest levels carrier protein 
1156,295.0,6.0,"['dmlt provide vaccine', 'dmlt provide sud', 'lta1 provide vaccine', 'lta1 provide sud']",3002,vaccination sublingual dmlt intranasal lta1 provided robust blockade fentanyl-induced analgesia cns penetration correlating strongly anti-fen iga 
1157,295.0,7.0,"['cancer-patients show covid-19', 'cancer-patients show death', 'cancer-patients show covid-19']",3003,conclusion study demonstrates dmlt lta1 adjuvant well mucosal delivery may attractive strategies improving efficacy vaccines sud 
1158,296.0,4.0,"['20th2021 treat 102', '20th2021 treat 112', '914 treat 102', '914 treat 112']",3008,reasons refusal collected administrating 6-items-multiple-choice questionnaire 
1159,296.0,5.0,"['vaccine-related decline 267', 'vaccine-related decline allergic', '481 decline 267', '481 decline allergic']",3009,results march 1st 20th2021 914 eligible pts 102 refused vaccination 112 95 ci91-132 
1160,296.0,6.0,"['suspension report 197', 'suspension report ci169-399', 'suspension report fig1b', 'suspension relate fig1b', '197 relate fig1b']",3010,frequent gt 10 reasons reported concerns vaccine-related adverse events 481 negative interaction concomitant antitumor therapy 267 fear allergic reaction 107 
1161,297.0,1.0,"['vaccine receive infant', 'vaccine receive low-income']",3016,however reasons still poorly understood immune responses vaccination highly variable different individuals different populations 
1162,297.0,4.0,['sars-cov-2 discuss child'],3019,review synthesize evidence discuss immunological mechanisms potentially mediate effects consider potential microbiota-targeted interventions optimize vaccine effectiveness 
1163,298.0,1.0,"['child consider parent', 'child consider sars-cov-2', 'sars-cov-2 consider parent']",3021,therefore crucial clarify aspect considering implications development successful surveillance strategies therapies vaccinations 
1164,298.0,2.0,"['child evaluate t30', 'child evaluate blood', 'child evaluate anti-sars-cov-2', 'child evaluate igm', 'child evaluate igg', 'parent evaluate child', 'parent evaluate t30', 'parent evaluate blood', 'parent evaluate anti-sars-cov-2', 'parent evaluate igm', 'parent evaluate igg', 'covid-19 evaluate child', 'covid-19 evaluate t30', 'covid-19 evaluate blood', 'covid-19 evaluate anti-sars-cov-2', 'covid-19 evaluate igm', 'covid-19 evaluate igg', 'child compare t30', 'child compare blood', 'child compare anti-sars-cov-2', 'child compare igm', 'child compare igg', 'parent compare t30', 'parent compare blood', 'parent compare anti-sars-cov-2', 'parent compare igm', 'parent compare igg', 'covid-19 compare t30', 'covid-19 compare blood', 'covid-19 compare anti-sars-cov-2', 'covid-19 compare igm', 'covid-19 compare igg', 'child compare t30', 'child compare blood', 'child compare anti-sars-cov-2', 'child compare igm', 'child compare igg', 'child affect blood', 'child affect anti-sars-cov-2', 'child affect igm', 'child affect igg', 'parent affect blood', 'parent affect anti-sars-cov-2', 'parent affect igm', 'parent affect igg', 'covid-19 affect blood', 'covid-19 affect anti-sars-cov-2', 'covid-19 affect igm', 'covid-19 affect igg', 'child affect blood', 'child affect anti-sars-cov-2', 'child affect igm', 'child affect igg']",3022,aim study assess antibody response children group sars-cov-2 infection compare parents affected sars-cov-2 infection 
1165,298.0,6.0,"['igg relate child', 'igg relate antibody', 'igg relate sars-cov-2', 'igg relate t180', 'igg relate child', 'igg relate sars-cov-2', 'igg relate parent', 't30 relate child', 't30 relate antibody', 't30 relate sars-cov-2', 't30 relate t180', 't30 relate child', 't30 relate sars-cov-2', 't30 relate parent']",3026,significant differences igg level related age sex clinical manifestations 
1166,298.0,10.0,"['sars-cov-2 decline child', 'sars-cov-2 decline adult', 'child decline adult']",3030,ÃÂÃÂÃÂ recent reports adults suggest antibodies sars-cov-2 declined several months infection data missing pediatric age 
1167,298.0,12.0,"['covid-19 use itp', 'covid-19 use patient']",3032,ÃÂÃÂÃÂ context serological tests used caution surveillance strategies 
1168,299.0,1.0,"['fifteen follow symptom', 'fifteen follow platelet', 'symptom follow platelet', 'platelet follow symptom']",3034,fifty-two consecutive chronic itp patients prospectively followed covid-19 vaccination 
1169,299.0,5.0,"['vaccine dose coronavirus', 'vaccine dose sars-cov-2']",3038,safety second vaccine dose needs careful assessment 
1170,300.0,0.0,"['vaccine match b cell', 'vaccine match toxicity', 'vaccine match patient', 'vaccine match immunodeficiency', 'vaccine match malignancy']",3039,background multiple vaccines granted emergency use authorization food drug administration severe acute respiratory syndrome coronavirus 2 sars-cov-2 
1171,300.0,1.0,"['vaccine test solid organ', 'vaccine test hematologic', 'vaccine test malignancy', 'covid-19 test solid organ', 'covid-19 test hematologic', 'covid-19 test malignancy']",3040,currently available vaccines none systematically studied efficacy toxicity patients immunodeficiency immunosuppressed states b cell malignancy 
1172,300.0,2.0,"['patient evaluate solid organ', 'patient evaluate nhl']",3041,purpose study evaluate immune response currently available vaccines covid-19 patients hematologic solid organ malignancies 
1173,300.0,3.0,"['igg enrol sars-cov-2', 'igg enrol nucleocapsid', 'igg enrol enzyme', 'igg enrol immunoassay']",3042,methods prospective study enrolled 53 patients 12 cll 10 multiple myeloma mm 11 non-hodgkin s lymphoma nhl 21 solid organ malignancy 
1174,300.0,6.0,"['910 report organ malignancy', '910 report patient', '910 report 611', '910 report 541', '910 report patient', '910 report nhl', '910 report 809', '910 report patient', '910 report solid', 'patient report organ malignancy', 'patient report 611', 'patient report 541', 'patient report nhl', 'patient report 809', 'patient report solid']",3045,predesigned survey patients also self-reported side effects dose vaccination 
1175,300.0,9.0,['patient treat p0030'],3048,among patients hematological malignancies 513 383 patients treated rituximab 27 285 patients immunoglobulin replacement igr therapy responded vaccination 
1176,300.0,10.0,"['patient reduce chemotherapy', 'patient reduce p0320', 'patient reduce immunotherapy', 'patient reduce 457', 'patient reduce p0169', 'patient reduce endocrine', 'solid reduce chemotherapy', 'solid reduce p0320', 'solid reduce immunotherapy', 'solid reduce 457', 'solid reduce p0169', 'solid reduce endocrine']",3049,corresponded reduced odds seroconversion 018 95 ci 0047-069 p 0013 patients treated rituximab 014 95 ci 0024-0826 p0030 patients igr 
1177,300.0,13.0,"['patient report organ', 'patient report malignancy', 'patient report parsonage', 'patient report turner']",3052,injection site soreness commonly reported side effect 
1178,300.0,16.0,"['patient include organ malignancies', 'patient include solid', 'covid-19 include organ malignancies', 'covid-19 include solid', 'patient include organ malignancies', 'patient include solid', 'patient receive organ malignancies', 'covid-19 receive organ malignancies', 'patient receive organ malignancies', 'nhl receive organ malignancies']",3055,majority patients mm solid organ malignancies including receiving active treatment responded adequately immunization 
1179,300.0,17.0,"['rituximab appear hematologic', 'rituximab appear malignancy', 'rituximab respond hematologic', 'rituximab respond malignancy']",3056,patients cll appear less likely respond vaccination covid-19 compared patients nhl mm solid organ malignancies 
1180,300.0,20.0,"['galaxosmithkline speakers provide regeneron', 'speaker provide regeneron']",3059,future research needed investigate approaches provide protective igg sars-cov-2 at-risk population 
1181,301.0,2.0,"['ccp design covid-19', 'ccp design patient', 'ccp design blood', 'ccp design donor', 'ccp design line', 'ccp design fda', 'ccp receive line', 'ccp receive fda', 'covid-19 receive line', 'covid-19 receive fda', 'patient receive line', 'patient receive fda', 'blood receive line', 'blood receive fda']",3065,designed open label study received investigational new drug ind number food drug administration study april 11 2020 methods patients severe covid-19 enrolled identical abo ccp administered 
1182,301.0,3.0,"['patient collect three', 'patient collect ccp', 'patient collect donor', 'patient receive ccp', 'patient receive donor', 'three receive ccp', 'three receive donor']",3066,ccp collected recovered covid-19 patients hospital blood donor services line fda guidelines 
1183,301.0,8.0,"['twenty-six receive ccp', 'twenty-six receive blood', 'twenty-six receive donor', 'twenty-six inhale blood', 'twenty-six inhale donor', 'recipient inhale blood', 'recipient inhale donor', 'ccp inhale blood', 'ccp inhale donor']",3071,patients also received supplemental therapies remdesivir tocilizumab dexamethasone inhaled nitric oxide 
1184,301.0,12.0,"['two follow diphenhydramine', 'two follow furosemide', 'patient follow diphenhydramine', 'patient follow furosemide']",3075,28 day follow 14 patients deceased 31 4 9 still hospitalized 27 60 discharged home 
1185,301.0,13.0,['patient resolve covid-19'],3076,two patients suspected transfusion related reaction resolved supportive care including diphenhydramine furosemide 
1186,301.0,14.0,"['sixty percent design discharge', 'sixty percent use discharge']",3077,conclusion designed implemented pragmatic study provide treatment option patients hospitalized covid-19 
1187,301.0,16.0,"['left axillary evaluate ipsilateral', 'left axillary evaluate injection', 'left axillary evaluate covid-19', 'left axillary evaluate patient', 'left axillary evaluate osteosarcoma', 'petct evaluate ipsilateral', 'petct evaluate injection', 'petct evaluate covid-19', 'petct evaluate patient', 'petct evaluate osteosarcoma', 'supraclavicular evaluate ipsilateral', 'supraclavicular evaluate injection', 'supraclavicular evaluate covid-19', 'supraclavicular evaluate patient', 'supraclavicular evaluate osteosarcoma', 'left axillary lay patient', 'left axillary lay osteosarcoma', 'petct lay patient', 'petct lay osteosarcoma', 'supraclavicular lay patient', 'supraclavicular lay osteosarcoma', 'lymphadenopathy lay patient', 'lymphadenopathy lay osteosarcoma', 'ipsilateral lay patient', 'ipsilateral lay osteosarcoma', 'injection lay patient', 'injection lay osteosarcoma', 'covid-19 lay patient', 'covid-19 lay osteosarcoma']",3079,larger studies control group necessary clearly evaluate benefit ccp covid-19 study lays foundation rapid implementation convalescent plasma program possible future pandemics bridge vaccine therapeutic trials 
1188,303.0,3.0,"['recipient develop safevac', 'influenza develop safevac', 'recipient observe safevac', 'influenza observe safevac', 'recipient observe safevac', 'influenza observe safevac']",3085,objective goal research determine factors influencing adherence correct use newly developed app individuals report aefi 3 months using regular reminder functions identify determinants aefi occurrence define reported aefi types 
1189,303.0,4.0,['cox develop app'],3086,methods developed app safevac offered recipients influenza vaccination 3 occupational settings fall 2018 prospective longitudinal feasibility study data aefis generated safevac 3 months 
1190,303.0,5.0,"['safevac evaluate 3-month', '614 evaluate 3-month', '207337 evaluate 3-month']",3087,using logistic cox regression assessed associations app adherence correct app entry aefis sociodemographic parameters 
1191,303.0,10.0,['safevac generate vaccine'],3092,conclusions digital aefi reporting feasible safevac generated plausible results observation period setting 
1192,304.0,0.0,"['danish show thrombotic', 'danish show adenoviral', 'danish show chadox1', 'danish show covid-19', 'danish show vaccine', 'danish prevent adenoviral', 'danish prevent chadox1', 'danish prevent covid-19', 'danish prevent vaccine', 'thrombotic prevent adenoviral', 'thrombotic prevent chadox1', 'thrombotic prevent covid-19', 'thrombotic prevent vaccine']",3095,although primary infection shown prevent reinfection sars-cov2 severe acute respiratory syndrome coronavirus 2 animal models gaps understanding immune response virus adequately addressed cases possible reinfection reported however frequency relevance proof events yet determined report cases two doctors two episodes covid-19 positive rt-pcr reverse transcriptase polymerase chain reaction test results raising probability reinfection case 1 40-year-old male physician presented fever respiratory symptoms april 10 positive rtpcr test sars-cov-2 complete improvement symptoms five days 44 days patient presented symptoms previous episode associated anosmia dysgeusia results new rt-pcr test performed two days later positive sars-cov-2 case 2 44-year-old female physician worked reference clinic covid-19 coronavirus disease 2019 onset symptoms indicative disease april 30 rt-pcr test positive sars-cov-2 improvement symptoms six days may 24 patient presented fever cough sore throat accompanied headache asthenia myalgia diarrhea new episode anosmia dysgeusia also present new rt-pcr test nasopharyngeal swabs performed positive result two patients described patients possible reinfection observed clinical practice reinforce need expand investigation risk reinfection confirmed findings relevant clinical-epidemiological perspective define isolation strategies develop vaccines
1193,305.0,0.0,"['60-year-old include vaccine', 'woman include vaccine']",3096,describe first danish case presumed inflammatory thrombotic response vaccination adenoviral chadox1 vector-based covid-19 vaccine azd1222 
1194,305.0,4.0,"['blood deem 118000 5000', 'blood deem platelet', 'blood deem d-dimer', 'blood induce d-dimer', 'platelet induce d-dimer']",3100,ischemic area deemed large offer reperfusion therapy 
1195,305.0,6.0,"['blood die platelet', 'blood die antibody', 'blood die heparin-induced', 'blood die thrombocytopenia']",3102,patient died sixth day hospitalization 
1196,306.0,0.0,"['cellular acknowledge influenza', 'cellular acknowledge vaccine', 'cellular acknowledge two', 'cellular acknowledge influenza', 'cellular acknowledge singaporegp19082015', 'cellular acknowledge h3n2', 'cellular acknowledge north', 'cellular acknowledge two', 'cellular acknowledge influenza', 'cellular acknowledge singaporeinftt-16-06102016', 'cellular acknowledge peripheral', 'cellular acknowledge blood', 'cellular acknowledge peptide', 'cellular acknowledge influenza']",3105,role cell immunity acknowledged recent vaccine development evaluation 
1197,306.0,2.0,"['cd4 cell detect hana', 'cd4 cell detect influenza', 'cd4 cell detect b', 'cd4 cell detect npm1m2ns1nep', 'cd4 cell detect influenza']",3107,baseline reactivity detected four strains level cd4 cd8 responses targeting different proteins 
1198,306.0,4.0,"['cd4 aim th1', 'cd8 aim th1', 'influenza aim th1', 'antigen aim th1', 'cd4 conserve th1', 'cd8 conserve th1', 'influenza conserve th1', 'antigen conserve th1']",3109,cd8 responses influenza b viruses preferentially targeted conserved core viral proteins 
1199,306.0,5.0,"['vaccine increase antigen', 'four increase antigen', 'cd4 increase antigen']",3110,following vaccination cd4 cd8 responses various influenza antigens increased day 15 day 91 post vaccination period maintained th1 polarized profile 
1200,306.0,6.0,"['respiratory include vaccine', 'respiratory include messenger', 'respiratory include mrna-1273', 'syndrome include vaccine', 'syndrome include messenger', 'syndrome include mrna-1273', 'coronavirus include vaccine', 'coronavirus include messenger', 'coronavirus include mrna-1273']",3111,importantly vaccine interference detected increased responses balanced across four included viral strains cd4 cd8 cells targeting ha multiple additional viral antigens 
1201,307.0,1.0,['animal receive boost'],3113,evaluated immune responses nonhuman primates received primary vaccination series mrna-1273 boosted 6 months later either homologous mrna-1273 heterologous mrna-1273b encompasses spike sequence b1351 beta variant 
1202,307.0,2.0,"['nine neutralize sars-cov-2', 'boost neutralize sars-cov-2', 'animal neutralize sars-cov-2']",3114,boost animals increased neutralizing antibody responses across vocs sustained least 8 weeks boost 
1203,307.0,3.0,"['bronchoalveolar lavage challenge nasal swabs', 'bronchoalveolar lavage challenge animal', 'bronchoalveolar lavage challenge booster', 'bronchoalveolar lavage challenge immunity']",3115,nine weeks boost animals challenged sars-cov-2 beta variant 
1204,307.0,4.0,['american reduce listserv'],3116,viral replication low undetectable bronchoalveolar lavage significantly reduced nasal swabs boosted animals suggesting booster vaccinations may required sustain immunity protection 
1205,308.0,0.0,"['blood-borne improve viral', 'blood-borne improve hepatitis']",3123,background objectives regular blood transfusion improved overall survival quality life patients hereditary hemolytic anemias 
1206,308.0,1.0,"['hepatitis c induce hereditary hemolytic', 'hepatitis c induce cytomegalovirus', 'hepatitis c induce cmv', 'hepatitis c induce egyptian', 'hepatitis c induce child', 'hepatitis c induce egypt', 'egyptian induce hereditary hemolytic', 'egyptian induce cytomegalovirus', 'egyptian induce cmv', 'egyptian induce child', 'egyptian induce egypt', 'blood-borne induce hereditary hemolytic', 'blood-borne induce cytomegalovirus', 'blood-borne induce cmv', 'blood-borne induce egyptian', 'blood-borne induce child', 'blood-borne induce egypt', 'hcv induce hereditary hemolytic', 'hcv induce cytomegalovirus', 'hcv induce cmv', 'hcv induce egyptian', 'hcv induce child', 'hcv induce egypt']",3124,nevertheless carries real risk acquisition blood-borne virus infections especially viral hepatitis 
1207,308.0,2.0,"['hemolytic anemias induce zagazig', 'hemolytic anemias induce egypt', 'patient induce zagazig', 'patient induce egypt', 'patient induce zagazig', 'patient induce egypt', 'hereditary induce zagazig', 'hereditary induce egypt', 'blood induce zagazig', 'blood induce egypt']",3125,purpose current study present egyptian update blood-borne hepatitis c b viruses hcv hbv cytomegalovirus cmv among multi-transfused egyptian children hereditary hemolytic anemias especially implementation national preventive programs egypt 
1208,308.0,5.0,"['seventy-seven confirm hemolytic anemia', 'seventy-seven confirm patient']",3128,positive results confirmed real-time polymerase chain reaction pcr 
1209,308.0,7.0,['hcvab range 147'],3130,ages ranged 2 18 years 549 males 
1210,308.0,10.0,"['hcv associate hemolytic anemias', 'hcv associate patient', 'hcv associate hereditary', 'cmv associate hemolytic anemias', 'cmv associate patient', 'cmv associate hereditary']",3133,seropositivity hcv significantly associated older age patients higher transfusion frequency longer disease duration higher mean serum ferritin 
1211,308.0,12.0,['hbv observe infection'],3135,nationwide plans taken ensure meticulous highly sensitive methods blood screening transfusion 
1212,308.0,13.0,"['vaccine follow scb-2019', 'vaccine follow spike', 'vaccine follow two', 'respiratory follow scb-2019', 'respiratory follow vaccine', 'respiratory follow spike', 'respiratory follow two', 'syndrome follow scb-2019', 'syndrome follow vaccine', 'syndrome follow spike', 'syndrome follow two', 'coronavirus follow scb-2019', 'coronavirus follow vaccine', 'coronavirus follow spike', 'coronavirus follow two', 'vaccine aim respiratory', 'vaccine aim syndrome', 'vaccine aim coronavirus', 'vaccine aim sars-cov-2', 'vaccine aim scb-2019', 'vaccine aim spike', 'vaccine aim two', 'vaccine eliminate scb-2019', 'vaccine eliminate spike', 'vaccine eliminate two', 'respiratory eliminate scb-2019', 'respiratory eliminate vaccine', 'respiratory eliminate spike', 'respiratory eliminate two', 'syndrome eliminate scb-2019', 'syndrome eliminate vaccine', 'syndrome eliminate spike', 'syndrome eliminate two', 'coronavirus eliminate scb-2019', 'coronavirus eliminate vaccine', 'coronavirus eliminate spike', 'coronavirus eliminate two', 'sars-cov-2 eliminate scb-2019', 'sars-cov-2 eliminate vaccine', 'sars-cov-2 eliminate spike', 'sars-cov-2 eliminate two']",3136,hand seems hbv compulsory vaccination succeeded eliminate hbv infection 
1213,309.0,1.0,"['volunteer randomize adult', 'volunteer randomize 55-75', 'two randomize adult', 'two randomize 55-75', 'adult randomize 55-75']",3138,methods study phase 1 randomised double-blind placebo-controlled trial specialised clinical trials centre australia 
1214,309.0,2.0,['participant enrol vaccine'],3139,enrolled healthy adult volunteers two age groups younger adults aged 18-54 years older adults aged 55-75 years 
1215,309.0,3.0,"['participant allocate scb-2019', 'participant allocate nacl', 'participant use nacl', 'scb-2019 use nacl', 'participant describe nacl', 'scb-2019 describe nacl']",3140,participants randomly allocated either vaccine placebo using list prepared study funder 
1216,309.0,4.0,['scb-2019 receive as03'],3141,participants receive two doses scb-2019 either 3 ÃÂµg 9 ÃÂµg 30 ÃÂµg placebo 0ÃÂ9 nacl 21 days apart 
1217,309.0,8.0,"['cellular evaluate peptide', 'cellular evaluate intracellular', 'cellular evaluate cytokine', 'cellular bind intracellular', 'cellular bind cytokine', 'peptide bind intracellular', 'peptide bind cytokine']",3145,humoral responses measured scb-2019 binding igg antibodies ace2-competitive blocking igg antibodies elisa neutralising antibodies wild-type sars-cov-2 microneutralisation assay 
1218,309.0,10.0,"['151 continue adenoma', 'volunteer continue adenoma', 'three continue adenoma', 'people continue adenoma', 'two continue adenoma', 'one continue adenoma']",3147,trial registered clinicaltrialsgov nct04405908 interim analysis study continuing 
1219,309.0,11.0,"['148 enrol 2020', 'participant enrol 2020', 'lock enrol 2020', 'oct enrol 2020']",3148,findings june 19 sept 23 2020 151 volunteers enrolled three people withdrew two personal reasons one unrelated serious adverse event pituitary adenoma 
1220,309.0,12.0,"['two dose cpgalum-adjuvanted', 'pain dose cpgalum-adjuvanted']",3149,148 participants least 4 weeks follow-up dose two included analysis database lock oct 23 2020 
1221,309.0,13.0,"['injection-site solicit as03', 'injection-site solicit cpgalum', 'injection-site solicit 3-13', 'pain solicit as03', 'pain solicit cpgalum', 'pain solicit 3-13']",3150,vaccination well tolerated two grade 3 solicited adverse events pain 9 ÃÂµg as03-adjuvanted 9 ÃÂµg cpgalum-adjuvanted groups 
1222,309.0,15.0,"['scb-2019 increase adult', 'scb-2019 increase igg', 'three increase adult', 'three increase igg', 'scb-2019 increase adult', 'scb-2019 increase igg', 'cpgalum increase adult', 'cpgalum increase igg', 'antibody increase adult', 'antibody increase igg']",3152,systemic adverse events frequent younger adults 38 older adults 17 first dose increased similar levels age groups second dose 30 older 34 younger adults 
1223,309.0,18.0,"['scb-2019 elicit cpgalum', 'scb-2019 elicit cellular', 'scb-2019 elicit sars-cov-2', 'vaccine elicit cpgalum', 'vaccine elicit cellular', 'vaccine elicit sars-cov-2']",3155,adjuvanted scb-2019 formulations elicited t-helper-1-biased cd4 t-cell responses 
1224,310.0,0.0,"['rhesus suspect vaccine', 'rhesus suspect vaccine', 'rhesus suspect lav', 'macaque suspect vaccine', 'macaque suspect vaccine', 'macaque suspect lav']",3159,antibody-dependent enhancement ade suspected influence dengue virus denv infection role ade plays vaccination strategies incorporating live attenuated virus components less clear 
1225,310.0,1.0,"['low-level test ade', 'antibody test ade', 'nab test ade']",3160,using heterologous prime-boost strategy rhesus macaques examine effect priming denv purified inactivated vaccines pivs tetravalent live attenuated vaccine lav 
1226,310.0,3.0,['nab show lav'],3162,following lav administration piv primed groups exhibited denv-2 lav peak viremias 1176-fold higher mock primed group peak viremia correlated vitro ade 
1227,311.0,0.0,"['influenza induce inhibitor', 'influenza induce patient', 'influenza induce cancer', 'influenza induce icis', 'influenza induce italian', 'influenza induce 2020', 'influenza induce influenza-like', 'influenza induce 2020', 'influenza induce vaccine', 'vaccine induce inhibitor', 'vaccine induce influenza', 'vaccine induce patient', 'vaccine induce cancer', 'vaccine induce icis', 'vaccine induce italian', 'vaccine induce 2020', 'vaccine induce influenza-like', 'vaccine induce 2020', 'influenza receive italian', 'influenza receive 2020', 'influenza receive influenza-like', 'influenza receive 2020', 'influenza receive vaccine', 'vaccine receive italian', 'vaccine receive 2020', 'vaccine receive influenza-like', 'vaccine receive 2020', 'inhibitor receive italian', 'inhibitor receive 2020', 'inhibitor receive influenza-like', 'inhibitor receive 2020', 'inhibitor receive vaccine', 'influenza receive italian', 'influenza receive 2020', 'influenza receive influenza-like', 'influenza receive 2020', 'influenza receive vaccine', 'patient receive italian', 'patient receive 2020', 'patient receive influenza-like', 'patient receive 2020', 'patient receive vaccine', 'cancer receive italian', 'cancer receive 2020', 'cancer receive influenza-like', 'cancer receive 2020', 'cancer receive vaccine']",3165,background robust data supported efficacy safety recommendation influenza vaccination patients cancer receiving immune checkpoint inhibitors icis 
1228,311.0,7.0,"['ili-related receive 298', 'ili-related receive p0027', 'intravenous receive 298', 'intravenous receive p0027', 'therapy receive 298', 'therapy receive p0027', 'patient receive 298', 'patient receive p0027']",3172,ili complications significantly less frequent patients receiving vaccination 118 vs 383 unvaccinated p0002 
1229,311.0,8.0,['ili relate patient'],3173,ili-related intravenous therapies significantly less frequent vaccinated patients unvaccinated 118 vs 298 p0027 
1230,311.0,11.0,"['canada receive 2020-2021', 'canada receive influenza', 'canada receive influenza', 'canada receive influenza', 'canada receive influenza', 'canada receive influenza', 'canada receive influenza', 'canada receive sentinel', 'canada receive influenza', 'canada receive influenza', 'canada receive influenza', 'canada receive vaccine', 'influenza receive 2020-2021', 'influenza receive canada', 'influenza receive sentinel', 'influenza receive vaccine', 'influenza receive 2020-2021', 'influenza receive canada', 'influenza receive sentinel', 'influenza receive vaccine']",3176,conclusion invidia-2 study results support positive recommendation influenza vaccination patients advanced cancer receiving immunotherapy 
1231,312.0,0.0,"['woman start coronavirus', 'woman start covid-19', 'axillary start coronavirus', 'axillary start covid-19', 'adenopathy start coronavirus', 'adenopathy start covid-19']",3177,canada s national influenza season typically starts latter half november week 47 defined week least 5 influenza tests positive minimum 15 positive tests observed december 12 2020 week 50 2020-2021 influenza season begun 47 laboratory-confirmed influenza detections reported august 23 december 12 2020 unprecedentedly low number despite higher usual levels influenza testing small number detections 64 influenza 36 influenza b influenza activity canada historically low levels compared previous five seasons provinces territories reported influenza-associated adult hospitalizations fewer five hospitalizations reported paediatric sentinel hospitalization network little influenza circulating national microbiology laboratory yet received samples influenza viruses collected 2020-2021 season strain characterization antiviral resistance testing assessment influenza vaccine effectiveness typically available mid-march expected similarly limited low seasonal influenza circulation persists nevertheless canada s influenza surveillance system remains robust pivoted syndromic virologic severe outcomes system components support coronavirus disease 2019 covid-19 surveillance despite covid-19 pandemic threat influenza epidemics pandemics persists imperative 1 maintain surveillance influenza 2 remain alert unusual unexpected events 3 prepared mitigate influenza epidemics resurge
1232,313.0,2.0,"['radiologist indicate adenopathy', 'radiologist indicate covid-19']",3180,bi-rads 2 assigned one woman bi-rads 3 21 ultrasound 4-24 weeks bi-rads 4 one 
1233,313.0,3.0,"['bronchitis need vaccine based', 'bronchitis need ib h120', 'bronchitis need vaccine', 'bronchitis need h120', 'bronchitis need vaccine', 'bronchitis need immunity', 'bronchitis need h120', 'bronchitis need h120', 'bronchitis need european', 'bronchitis need immunity', 'bronchitis need seven', 'bronchitis need chicken', 'bronchitis need chicken', 'bronchitis need chicken', 'poultry need vaccine based', 'poultry need ib h120', 'poultry need vaccine', 'poultry need h120', 'poultry need vaccine', 'poultry need immunity', 'poultry need h120', 'poultry need h120', 'poultry need european', 'poultry need immunity', 'poultry need seven', 'poultry need chicken', 'poultry need chicken', 'poultry need chicken', 'bronchitis base vaccine based', 'bronchitis base ib h120', 'bronchitis base vaccine', 'bronchitis base h120', 'bronchitis base vaccine', 'bronchitis base immunity', 'bronchitis base h120', 'bronchitis base h120', 'bronchitis base european', 'bronchitis base immunity', 'bronchitis base seven', 'bronchitis base chicken', 'bronchitis base chicken', 'bronchitis base chicken', 'bronchitis avoid vaccine based', 'bronchitis avoid ib h120', 'bronchitis avoid h120', 'bronchitis avoid vaccine', 'bronchitis avoid immunity', 'bronchitis avoid h120', 'bronchitis avoid h120', 'bronchitis avoid european', 'bronchitis avoid immunity', 'bronchitis avoid seven', 'bronchitis avoid chicken', 'bronchitis avoid chicken', 'bronchitis avoid chicken', 'poultry avoid vaccine based', 'poultry avoid ib h120', 'poultry avoid h120', 'poultry avoid vaccine', 'poultry avoid immunity', 'poultry avoid h120', 'poultry avoid h120', 'poultry avoid european', 'poultry avoid immunity', 'poultry avoid seven', 'poultry avoid chicken', 'poultry avoid chicken', 'poultry avoid chicken', 'vaccine avoid vaccine based', 'vaccine avoid ib h120', 'vaccine avoid h120', 'vaccine avoid immunity', 'vaccine avoid h120', 'vaccine avoid h120', 'vaccine avoid european', 'vaccine avoid immunity', 'vaccine avoid seven', 'vaccine avoid chicken', 'vaccine avoid chicken', 'vaccine avoid chicken']",3181,radiologist familiarity evidence-based guidelines needed avoid follow-up imaging biopsies reactive adenopathy covid-19 vaccination 
1234,315.0,1.0,"['plasmodium provide human', 'plasmodium provide erythrocyte', 'plasmodium provide human', 'vivax provide human', 'vivax provide erythrocyte', 'vivax provide human', 'reticulocyte provide human', 'reticulocyte provide erythrocyte', 'reticulocyte provide human']",3184,better understanding human immunity parasite provide new insights vaccine development 
1235,315.0,3.0,"['igg characterize plasma', 'igg characterize vivax', 'igg characterize malaria', 'igg characterize patient', 'igg characterize 525', 'igg characterize villager']",3186,aim study characterize human antibody response rbp2p1 recently described member rbp family 
1236,315.0,10.0,['infection correlate rbp2p1'],3193,higher level igg3 correlated higher vitro rbp2p1-mediated complement fixing activity 
1237,315.0,12.0,"['measles-mumps-rubella correlate covid-19', 'vaccine correlate covid-19', 'sars-cov-2 correlate covid-19']",3195,predominance cytophilic subtypes elevated level igg3 correlating complement fixing activity suggest possible role anti-rbp2p1 antibodies immunity p vivax 
1238,316.0,0.0,"['measles afford sars-cov-2', 'measles afford 805', 'measles afford 5100', 'worker afford sars-cov-2', 'worker afford 805', 'worker afford 5100', 'mmr afford sars-cov-2', 'mmr afford 805', 'mmr afford 5100', 'vaccine afford sars-cov-2', 'vaccine afford 805', 'vaccine afford 5100', 'measles provide 5100', 'worker provide 5100', 'mmr provide 5100', 'vaccine provide 5100', 'sars-cov-2 provide 5100', '805 provide 5100']",3196,background hypothesised measles-mumps-rubella mmr vaccine may afford cross-protection sars-cov-2 may contribute wide variability disease severity covid-19 
1239,316.0,1.0,['sars-cov-2 use 109'],3197,methods employed test negative case-control study utilising recent measles outbreak many healthcare workers received mmr vaccine investigate potential protective effect mmr sars-cov-2 5905 subjects n 805 males n 5100 females 
1240,317.0,0.0,"['plaque need serum', 'plaque need antibody', 'plaque evaluate antibody']",3202,backgroundtests sars-cov-2 immunity needed help assess responses vaccination heterogeneous may wane time 
1241,317.0,1.0,"['enzyme consider receptor', 'enzyme consider receptor', 'enzyme consider angiotensin', 'enzyme consider receptor', 'enzyme consider infection', 'enzyme consider vaccine', 'elisa consider receptor', 'elisa consider receptor', 'elisa consider angiotensin', 'elisa consider enzyme', 'elisa consider receptor', 'elisa consider infection', 'elisa consider vaccine', 'sars-cov-2 consider receptor', 'sars-cov-2 consider receptor', 'sars-cov-2 consider angiotensin', 'sars-cov-2 consider enzyme', 'sars-cov-2 consider receptor', 'sars-cov-2 consider infection', 'sars-cov-2 consider vaccine', 'enzyme evaluate receptor', 'enzyme evaluate angiotensin', 'enzyme evaluate receptor', 'enzyme evaluate infection', 'enzyme evaluate vaccine', 'elisa evaluate receptor', 'elisa evaluate angiotensin', 'elisa evaluate enzyme', 'elisa evaluate receptor', 'elisa evaluate infection', 'elisa evaluate vaccine', 'sars-cov-2 evaluate receptor', 'sars-cov-2 evaluate angiotensin', 'sars-cov-2 evaluate enzyme', 'sars-cov-2 evaluate receptor', 'sars-cov-2 evaluate infection', 'sars-cov-2 evaluate vaccine', 'receptor evaluate angiotensin', 'receptor evaluate enzyme', 'receptor evaluate infection', 'receptor evaluate vaccine', 'enzyme neutralize angiotensin', 'enzyme neutralize receptor', 'enzyme neutralize infection', 'enzyme neutralize vaccine', 'elisa neutralize angiotensin', 'elisa neutralize enzyme', 'elisa neutralize receptor', 'elisa neutralize infection', 'elisa neutralize vaccine', 'sars-cov-2 neutralize angiotensin', 'sars-cov-2 neutralize enzyme', 'sars-cov-2 neutralize receptor', 'sars-cov-2 neutralize infection', 'sars-cov-2 neutralize vaccine', 'receptor neutralize angiotensin', 'receptor neutralize enzyme', 'receptor neutralize infection', 'receptor neutralize vaccine', 'enzyme need receptor', 'enzyme need infection', 'enzyme need vaccine', 'elisa need receptor', 'elisa need infection', 'elisa need vaccine', 'sars-cov-2 need receptor', 'sars-cov-2 need infection', 'sars-cov-2 need vaccine', 'receptor need infection', 'receptor need vaccine', 'receptor need infection', 'receptor need vaccine', 'angiotensin need receptor', 'angiotensin need infection', 'angiotensin need vaccine', 'enzyme induce infection', 'enzyme induce vaccine', 'elisa induce infection', 'elisa induce vaccine', 'sars-cov-2 induce infection', 'sars-cov-2 induce vaccine', 'receptor induce infection', 'receptor induce vaccine', 'receptor induce infection', 'receptor induce vaccine', 'angiotensin induce infection', 'angiotensin induce vaccine', 'enzyme induce infection', 'enzyme induce vaccine', 'receptor induce infection', 'receptor induce vaccine']",3203,plaque reduction neutralization test prnt considered gold standard measuring serum neutralizing antibodies requires high level biosafety live viral cultures days complete 
1242,317.0,2.0,"['elisa associate vaccine', 'elisa associate serum', 'elisa base vaccine', 'elisa base serum']",3204,hypothesized competitive enzyme linked immunoassays elisas based sars-cov-2 spike proteins receptor binding domain rbd attachment host receptor angiotensin converting enzyme 2 receptor ace2r would correlate prnt given central role rbd-ace2r interactions infection published studies date enable evaluation vaccine responses 
1243,317.0,3.0,"['elisa bind ic50', 'n32 bind ic50', 'covid-19 bind ic50', 'patient bind ic50']",3205,methods findingsconfiguration development competitive elisa plate-bound rbd soluble biotinylated ace2r accomplished using pairs prepost vaccine serum 
1244,317.0,4.0,"['elisa use covid-19', 'elisa use patient', 'elisa use covid-19', 'elisa use vaccine', 'elisa test covid-19', 'elisa test vaccine', 'covid-19 test vaccine', 'patient test covid-19', 'patient test vaccine', 'elisa evaluate covid-19', 'elisa evaluate patient', 'elisa evaluate covid-19', 'elisa evaluate vaccine']",3206,competitive elisa used evaluate n32 samples covid-19 patients previously tested prnt excellent correlation ic50 results observed rs 83 p 00001 
1245,317.0,5.0,"['200 use vaccine', '200 use surrogate', '200 use booster', '200 use vaccine', '200 evaluate booster', '200 evaluate vaccine', 'vaccine evaluate booster', '200 vaccinate booster', '200 vaccinate vaccine', 'vaccine vaccinate booster', 'surrogate vaccinate booster', 'surrogate vaccinate vaccine']",3207,competitive elisa used evaluate n41 vaccinated individuals additional n14 unvaccinated recovered covid-19 patients significant differences rbd-ace2r inhibitory activity associated prior history covid-19 type vaccine received 
1246,317.0,6.0,"['elisa neutralize vaccine', 'elisa neutralize recipient', 'elisa neutralize covid', 'elisa neutralize surrogate', 'elisa increase recipient', 'elisa increase covid', 'elisa increase surrogate']",3208,longitudinal analyses pre 200 days post vaccine surrogate neutralizing activity increased markedly primary booster vaccine doses fell substantially 12 maximal levels within 6 months 
1247,318.0,1.0,"['testing-on-a-probe test sars-cov-2', 'testing-on-a-probe test surrogate', 'testing-on-a-probe test snab', 'testing-on-a-probe test igg', 'top-plus test sars-cov-2', 'top-plus test surrogate', 'top-plus test snab', 'top-plus test igg', 'testing-on-a-probe receive surrogate', 'testing-on-a-probe receive snab', 'testing-on-a-probe receive igg', 'top-plus receive surrogate', 'top-plus receive snab', 'top-plus receive igg', 'sars-cov-2 receive surrogate', 'sars-cov-2 receive snab', 'sars-cov-2 receive igg']",3212,antibody levels avidity antibody-antigen interaction examined understand quality antibody response 
1248,318.0,8.0,"['precise vaccinate sars-cov-2', 'precise vaccinate snab', 'precise vaccinate igg', 'precise vaccinate one', 'precise vaccinate sars-cov-2-infected', 'precise vaccinate patient', 'precise vaccinate covid-19', 'precise evaluate sars-cov-2-infected', 'precise evaluate patient', 'precise evaluate covid-19', 'sars-cov-2 evaluate sars-cov-2-infected', 'sars-cov-2 evaluate patient', 'sars-cov-2 evaluate covid-19', 'snab evaluate sars-cov-2-infected', 'snab evaluate patient', 'snab evaluate covid-19', 'igg evaluate sars-cov-2-infected', 'igg evaluate patient', 'igg evaluate covid-19', 'one evaluate sars-cov-2-infected', 'one evaluate patient', 'one evaluate covid-19']",3219,antibody avidity 10 sars-cov-2 vaccinated individuals median 28 days post-vaccination comparable measured antibody avidity infected individuals median 26 days post-infection 
1249,319.0,1.0,"['participant evaluate solid tumors', 'participant evaluate cohort', 'participant evaluate 102', 'participant evaluate patient', 'participant evaluate anticancer', 'participant evaluate bnt162b2', 'participant evaluate vaccine']",3222,objective evaluate rates antispike anti-s antibody response bnt162b2 vaccine patients cancer undergoing systemic treatment vs healthy controls 
1250,319.0,4.0,['blood induce participant'],3225,study conducted february 22 2021 march 15 2021 davidoff cancer center beilinson hospital petah tikva israel 
1251,319.0,5.0,"['serum describe antibody', 'serum describe sars-cov-2']",3226,interventions blood samples drawn study participants 
1252,319.0,9.0,"['180 associate 56-72', '180 associate men', '180 associate men', 'participant associate 56-72', 'participant associate men', 'participant associate men', '102 associate 56-72', '102 associate men', '102 associate men', 'patient associate 56-72', 'patient associate men', 'patient associate men', 'cancer associate 56-72', 'cancer associate men', 'cancer associate men', '180 receive 56-72', '180 receive men', '180 receive men', 'participant receive 56-72', 'participant receive men', 'participant receive men', '102 receive 56-72', '102 receive men', '102 receive men', 'patient receive 56-72', 'patient receive men', 'patient receive men', '180 use men', '180 use men', 'participant use men', 'participant use men', '102 use men', '102 use men', 'patient use men', 'patient use men', 'cancer use men', 'cancer use men']",3230,secondary outcomes included comparisons igg titers identifying factors associated seropositivity using univariatemultivariable analyses 
1253,319.0,14.0,"['cohort associate patient', 'cohort associate bnt162b2', 'cohort associate vaccine', 'patient associate bnt162b2', 'patient associate vaccine', 'cancer associate patient', 'cancer associate bnt162b2', 'cancer associate vaccine']",3235,multivariable analysis variable significantly associated lower igg titers treatment chemotherapy plus immunotherapy ÃÂ -35 95 ci -56 -15 
1254,319.0,17.0,"['respiratory syndrome vaccinate 2-induced', 'respiratory syndrome vaccinate coronavirus', 'respiratory syndrome vaccinate covid-19']",3238,nonetheless data support vaccinating patients cancer high priority even therapy 
1255,320.0,3.0,"['woman report joint', 'woman report covid-19', 'left report joint', 'left report covid-19']",3242,reactive arthritis rea vaccination reported however rea covid-19 vaccination reported 
1256,320.0,4.0,"['left knee induce coronavac', 'left knee induce vaccine', 'left knee induce injection', 'swollen induce coronavac', 'swollen induce vaccine', 'swollen induce injection', 'joint induce coronavac', 'joint induce vaccine', 'joint induce injection']",3243,reported 23-year-old woman suffered acute rea left knee joint covid-19 vaccination discussed etiology preventive strategy 
1257,320.0,6.0,"['swelling diagnose 1month', 'pain diagnose 1month']",3245,finally diagnosed rea coronavac vaccination administered single intra-articular injection 1 ml compound betamethasone 
1258,320.0,11.0,"['infection explore respiratory', 'infection explore death', 'influenza explore respiratory', 'influenza explore death']",3250,versatile safer vaccines explored 
1259,321.0,0.0,"['influenza cause vaccine', 'influenza cause egg', 'vaccine cause influenza', 'vaccine cause egg']",3251,globally infection seasonal influenza viruses causes 3ÃÂÂ5 million cases severe illness 290000ÃÂÂ650000 respiratory deaths year 
1260,321.0,4.0,"['influenza induce cell', 'influenza induce vaccine', 'influenza induce antigen', 'influenza improve vaccine', 'influenza improve antigen', 'vaccine improve influenza', 'vaccine improve antigen', 'vaccine improve influenza']",3255, suggest future directions improving effectiveness influenza vaccines age groups 
1261,321.0,6.0,['2019 envisage covid-19'],3257,brighter future envisaged development adjuvant safe effective realized 
1262,322.0,0.0,"['death report 15811', 'death report ecuador']",3258,background december 2019 first covid-19 disease cases reported 
1263,322.0,4.0,"['oxygen follow los', 'oxygen follow symptom', 'oxygen follow los', 'oxygen follow symptom']",3262,patients followed since february first 2020 31 january 2021 patients covid-19 symptoms identified diagnosis made exclusively positive nasopharyngeal swabs pcr testing 
1264,322.0,6.0,"['205 collect p003', 'patient collect p003', 'covid-19 collect p003', 'symptom collect p003', '115 collect p003']",3264,hospital-stay time negative pcr mortality laboratory findings collected 
1265,322.0,7.0,['64 years induce pulmonary'],3265,results total 205 patients 29 presented covid-19 symptoms 115 tested positive 16 60 men p003 25 subjects died 22 
1266,322.0,13.0,"['respiratory include patient', 'respiratory include coronavirus', 'respiratory include covid-19', 'respiratory include vaccine', 'syndrome include patient', 'syndrome include coronavirus', 'syndrome include covid-19', 'syndrome include vaccine', 'coronavirus include patient', 'coronavirus include covid-19', 'coronavirus include vaccine', 'sars-cov-2 include patient', 'sars-cov-2 include coronavirus', 'sars-cov-2 include covid-19', 'sars-cov-2 include vaccine', 'respiratory induce t-cell', 'respiratory induce patient', 'respiratory induce coronavirus', 'respiratory induce covid-19', 'respiratory induce vaccine', 'syndrome induce t-cell', 'syndrome induce patient', 'syndrome induce coronavirus', 'syndrome induce covid-19', 'syndrome induce vaccine', 'coronavirus induce t-cell', 'coronavirus induce patient', 'coronavirus induce covid-19', 'coronavirus induce vaccine', 'respiratory need covid-19', 'respiratory need vaccine', 'syndrome need covid-19', 'syndrome need vaccine', 'coronavirus need covid-19', 'coronavirus need vaccine', 'sars-cov-2 need covid-19', 'sars-cov-2 need vaccine', 't-cell need covid-19', 't-cell need vaccine', 'patient need covid-19', 'patient need vaccine', 'coronavirus need covid-19', 'coronavirus need vaccine']",3271,health care burden due covid-19 high dialysis population suggesting vaccination programs must include dialysis patients staff involved care diminish mortality infections health care burden 
1267,323.0,1.0,"['963 neutralize symptom', 'patient neutralize symptom']",3273,methods conducted combined assessment changes neutralising antibody levels sars-cov-2-specific t-cell responses time 27 patients 7 months infection 
1268,323.0,3.0,"['cd4 cells include covid-19', 'cd4 cells include patient', 'cd8 cells include covid-19', 'cd8 cells include patient']",3275,however humoral responses including titres spike receptor-binding domain igg neutralising antibody decreased significantly compared first clinic visit 
1269,323.0,5.0,['sars-cov-2-specific observe antibody'],3277,significant change observed proportion spike-specific cd4 cells patients recovered covid-19 within 7 months 
1270,323.0,7.0,['covid-19 neutralize state'],3279,studies needed extend longevity neutralising antibodies evaluate whether cells sufficient protect patients reinfection 
1271,324.0,0.0,['vaccine include sars-cov-2'],3280,background nursing home residents staff included first phase covid-19 vaccination united states 
1272,324.0,3.0,"['three use infection', 'three use symptom']",3283,methods use stochastic agent-based seir model nursing home simulate sars-cov-2 transmission 
1273,324.0,10.0,"['vaccine reduce woman', 'covid-19 reduce woman', 'vaccine protect woman', 'vaccine protect woman', 'covid-19 protect woman', 'covid-19 protect vaccine', 'covid-19 protect woman']",3290,conclusions encouraging staff vaccination important protecting staff might also reduce symptomatic cases residents vaccine confers least protection infection infectiousness 
1274,325.0,0.0,"['covid-induced activate covid-19', 'covid-induced activate symptom', 'covid-induced activate patient', 'woman activate covid-19', 'woman activate symptom', 'woman activate patient']",3291,aim recent availability vaccines covid-19 sparked national international debate feasibility administering pregnant lactating women given vaccines tested assess safety efficacy women 
1275,325.0,1.0,"['vaccine emerge woman', 'vaccine emerge diabetes', 'vaccine emerge obesity', 'vaccine show woman', 'vaccine show diabetes', 'vaccine show obesity', 'covid-19 show woman', 'covid-19 show diabetes', 'covid-19 show obesity', 'vaccine develop woman', 'vaccine develop diabetes', 'vaccine develop obesity', 'covid-19 develop woman', 'covid-19 develop diabetes', 'covid-19 develop obesity']",3292,concerns risks covid-induced disease published data show pregnant women develop covid-19 fewer symptoms patients pregnant likely need hospitalization intensive care neonatal morbidity 
1276,325.0,5.0,"['woman consider healthcare', 'woman consider professional']",3296,considered pregnant women high risk exposure covid-19 
1277,325.0,6.0,"['covid-19 evaluate woman', 'covid-19 evaluate sars-cov-2', 'covid-19 evaluate mrna', 'covid-19 evaluate immunity', 'covid-19 evaluate woman', 'mrna evaluate woman', 'mrna evaluate sars-cov-2', 'mrna evaluate immunity', 'mrna evaluate woman', 'covid-19 care immunity', 'covid-19 care woman', 'mrna care immunity', 'mrna care woman', 'woman care immunity', 'sars-cov-2 care immunity', 'sars-cov-2 care woman', 'mrna care immunity', 'mrna care woman']",3297,women potential benefits risks assessed healthcare professionals caring 
1278,325.0,9.0,"['pneumocystis induce carinii', 'pneumocystis induce infection', 'pneumocystis induce immunocompromised', 'pneumonia induce pneumocystis', 'pneumonia induce carinii', 'pneumonia induce infection', 'pneumonia induce immunocompromised', 'pcp induce pneumocystis', 'pcp induce carinii', 'pcp induce infection', 'pcp induce immunocompromised', 'pneumocystis boost infection', 'pneumocystis boost immunocompromised', 'pneumonia boost infection', 'pneumonia boost immunocompromised', 'pcp boost infection', 'pcp boost immunocompromised', 'pneumocystis boost infection', 'pneumocystis boost immunocompromised', 'carinii boost infection', 'carinii boost immunocompromised']",3300,important run campaigns promote vaccination particular pregnant women high risk severe covid infection diabetics andor obese 
1279,326.0,3.0,"['immunization vaccinate secretion', 'immunization vaccinate lymphocyte', 'immunization vaccinate lung', 'immunization vaccinate mouse', 'serum vaccinate secretion', 'serum vaccinate lymphocyte', 'serum vaccinate lung', 'serum vaccinate mouse', 'immunization detect lung', 'immunization detect mouse', 'serum detect lung', 'serum detect mouse', 'igg detect lung', 'igg detect mouse', 'secretion detect lung', 'secretion detect mouse']",3304,methods used recombinant a12 1ÃÂÂ85 antigen immunized mice detected serum titer igg expression inflammatory factors eilsa qrt-pcr flow cytometry 
1280,326.0,4.0,"['a12 show vaccine', 'a12 show pneumocystis', 'a12 show carinii']",3305,results results showed immunization recombinant a12 1ÃÂÂ85 increased serum titer igg promoted secretion lymphocytes increased expression inflammatory factors elevated lung inflammatory injury mice 
1281,327.0,0.0,['infectious induce toxin'],3309,introduction etiology myocarditis often remains undetermined 
1282,327.0,6.0,"['left induce one-month', 'ventricular induce one-month', 'ejection induce one-month']",3315,patient hemodynamic status remained stable hospitalization 
1283,328.0,2.0,"['seven evaluate two', 'seven evaluate peptide', 'seven evaluate cellular', 'seven evaluate 681', 'seven evaluate vivax-infected', 'seven evaluate people', 'seven evaluate rok', 'seven acquire cellular', 'seven acquire 681', 'seven acquire vivax-infected', 'seven acquire people', 'seven acquire rok', 'two acquire cellular', 'two acquire 681', 'two acquire vivax-infected', 'two acquire people', 'two acquire rok', 'peptide acquire cellular', 'peptide acquire 681', 'peptide acquire vivax-infected', 'peptide acquire people', 'peptide acquire rok', 'seven infect 681', 'seven infect vivax-infected', 'seven infect people', 'seven infect rok', 'two infect 681', 'two infect vivax-infected', 'two infect people', 'two infect rok', 'peptide infect 681', 'peptide infect vivax-infected', 'peptide infect people', 'peptide infect rok']",3321,thus study evaluated naturally-acquired immune response vir proteins vivax malaria-infected individuals republic korea rok 
1284,328.0,5.0,"['cellular use mononuclear cells', 'cellular use vivax-infected', 'antigen use mononuclear cells', 'antigen use vivax-infected', 'cellular use mononuclear cells', 'cellular use vivax-infected', 'cytokine use mononuclear cells', 'cytokine use vivax-infected', 'cellular know mononuclear cells', 'cellular know antigen', 'cellular know cytokine', 'cellular know vivax-infected']",3324,pvmsp1-19 known promising vaccine candidate p vivax used positive control immune response assessment 
1285,328.0,7.0,"['antigen detect 278', 'antigen detect 292', 'antigen detect pvmsp1-19', 'antigen detect igg', 'vir25 detect 278', 'vir25 detect 292', 'vir25 detect pvmsp1-19', 'vir25 detect igg']",3326,results igm igg detected 524 population 
1286,328.0,8.0,"['cellular elicit cell', 'cellular elicit il-2', 'cellular elicit il-6', 'cellular elicit il-10', 'cellular elicit g-csf', 'cellular elicit vivax-infected', 'cellular elicit pvmsp1-19', 'pvlp2 elicit cell', 'pvlp2 elicit il-2', 'pvlp2 elicit il-6', 'pvlp2 elicit il-10', 'pvlp2 elicit g-csf', 'pvlp2 elicit vivax-infected', 'pvlp2 elicit pvmsp1-19', 'pvmsp1-19 elicit cell', 'pvmsp1-19 elicit il-2', 'pvmsp1-19 elicit il-6', 'pvmsp1-19 elicit il-10', 'pvmsp1-19 elicit g-csf', 'pvmsp1-19 elicit vivax-infected']",3327,among vir antigens vir25 elicited highest humoral immune response whole population igg igm prevalence 278 292 respectively pvmsp1-19 elicited even higher prevalence 92 igg population 
1287,328.0,10.0,"['cellular observe malaria', 'cellular observe patient']",3329,however significant proliferation response antigens observed malaria-infected healthy groups 
1288,328.0,12.0,['human conserve antigen'],3331,interesting immune response vir antigens conserved among malaria parasites different countries considering vir genes highly polymorphic 
1289,328.0,14.0,"['immunity observe vaccine', 'immunity observe antigen', 'immunity observe vaccine']",3333,supplementary information online version contains supplementary material available 101186s12936-021-03810-2 
1290,329.0,0.0,"['two include mouse', 'two include conjugate', 'two include vaccine', 'two include prevnar', 'booster include mouse', 'booster include conjugate', 'booster include vaccine', 'booster include prevnar', 'two dose conjugate', 'two dose vaccine', 'two dose prevnar', 'booster dose conjugate', 'booster dose vaccine', 'booster dose prevnar', 'cd-1 dose conjugate', 'cd-1 dose vaccine', 'cd-1 dose prevnar', 'mouse dose conjugate', 'mouse dose vaccine', 'mouse dose prevnar']",3334,achieving durable protective immunity following vaccination dependent many factors including vaccine composition antigen dose investigated various types vaccines 
1291,329.0,1.0,"['immunization use immunity', 'immunization use cmi', 'immunization use cytokine', 'immunization use antigen', 'immunization use polysaccharide', 'two use immunity', 'two use cmi', 'two use cytokine', 'two use antigen', 'two use polysaccharide', 'pcv13 use immunity', 'pcv13 use cmi', 'pcv13 use cytokine', 'pcv13 use antigen', 'pcv13 use polysaccharide', 'two use immunity', 'two use cmi', 'two use cytokine', 'two use antigen', 'two use polysaccharide', 'booster use immunity', 'booster use cmi', 'booster use cytokine', 'booster use antigen', 'booster use polysaccharide', 'immunization investigate booster', 'immunization investigate immunity', 'immunization investigate cmi', 'immunization investigate cytokine', 'immunization investigate antigen', 'immunization investigate polysaccharide', 'two investigate booster', 'two investigate immunity', 'two investigate cmi', 'two investigate cytokine', 'two investigate antigen', 'two investigate polysaccharide', 'pcv13 investigate booster', 'pcv13 investigate immunity', 'pcv13 investigate cmi', 'pcv13 investigate cytokine', 'pcv13 investigate antigen', 'pcv13 investigate polysaccharide', 'two investigate booster', 'two investigate immunity', 'two investigate cmi', 'two investigate cytokine', 'two investigate antigen', 'two investigate polysaccharide', 'immunization elicit immunity', 'immunization elicit cmi', 'immunization elicit cytokine', 'immunization elicit antigen', 'immunization elicit polysaccharide', 'two elicit immunity', 'two elicit cmi', 'two elicit cytokine', 'two elicit antigen', 'two elicit polysaccharide', 'pcv13 elicit immunity', 'pcv13 elicit cmi', 'pcv13 elicit cytokine', 'pcv13 elicit antigen', 'pcv13 elicit polysaccharide', 'two elicit immunity', 'two elicit cmi', 'two elicit cytokine', 'two elicit antigen', 'two elicit polysaccharide', 'immunization exploit immunity', 'immunization exploit cmi', 'immunization exploit cytokine', 'immunization exploit antigen', 'immunization exploit polysaccharide', 'two exploit immunity', 'two exploit cmi', 'two exploit cytokine', 'two exploit antigen', 'two exploit polysaccharide', 'pcv13 exploit immunity', 'pcv13 exploit cmi', 'pcv13 exploit cytokine', 'pcv13 exploit antigen', 'pcv13 exploit polysaccharide', 'two exploit immunity', 'two exploit cmi', 'two exploit cytokine', 'two exploit antigen', 'two exploit polysaccharide', 'booster exploit immunity', 'booster exploit cmi', 'booster exploit cytokine', 'booster exploit antigen', 'booster exploit polysaccharide']",3335,aim present study investigate overall immune response elicited two different booster doses cd-1 mice exploiting largely used 13-valent pneumococcal conjugate vaccine prevnar 13ÃÂ pcv13 
1292,329.0,3.0,"['il-5 induce booster', 'il-5 induce ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'il-5 induce cell', 'il-5 induce polysaccharide', 'il-5 induce antigen', 'il-5 induce il-2', 'il-5 induce cell', 'il-2 induce booster', 'il-2 induce ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'il-2 induce cell', 'il-2 induce polysaccharide', 'il-2 induce antigen', 'il-2 induce il-5', 'il-2 induce cell', 'cell induce booster', 'cell induce ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'cell induce polysaccharide', 'cell induce antigen', 'cell induce il-5', 'cell induce il-2', 'mouse induce booster', 'mouse induce ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'mouse induce cell', 'mouse induce polysaccharide', 'mouse induce antigen', 'mouse induce il-5', 'mouse induce il-2', 'mouse induce cell', 'il-5 characterize booster', 'il-5 characterize ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'il-5 characterize cell', 'il-5 characterize polysaccharide', 'il-5 characterize antigen', 'il-5 characterize il-2', 'il-5 characterize cell', 'il-2 characterize booster', 'il-2 characterize ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'il-2 characterize cell', 'il-2 characterize polysaccharide', 'il-2 characterize antigen', 'il-2 characterize il-5', 'il-2 characterize cell', 'cell characterize booster', 'cell characterize ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'cell characterize polysaccharide', 'cell characterize antigen', 'cell characterize il-5', 'cell characterize il-2', 'mouse characterize booster', 'mouse characterize ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'mouse characterize cell', 'mouse characterize polysaccharide', 'mouse characterize antigen', 'mouse characterize il-5', 'mouse characterize il-2', 'mouse characterize cell']",3337,data showed regardless booster dose comparable humoral response produced characterized similar amounts serotype-specific antibodies analog avidity opsonophagocytic properties 
1293,329.0,4.0,"['pcv13 evaluate th2', 'pcv13 evaluate booster', 'pcv13 evaluate one', 'pcv13 evaluate th1th2', 'pcv13 evaluate cmi', 'pcv13 evaluate antibody', 'pcv13 evaluate vaccine', 'pcv13 induce cmi', 'pcv13 induce antibody', 'pcv13 induce vaccine', 'mouse induce cmi', 'mouse induce antibody', 'mouse induce vaccine', 'th2 induce cmi', 'th2 induce antibody', 'th2 induce vaccine', 'booster induce cmi', 'booster induce antibody', 'booster induce vaccine', 'one induce cmi', 'one induce antibody', 'one induce vaccine', 'pcv13 vaccinate antibody', 'pcv13 vaccinate vaccine', 'mouse vaccinate antibody', 'mouse vaccinate vaccine', 'th2 vaccinate antibody', 'th2 vaccinate vaccine', 'booster vaccinate antibody', 'booster vaccinate vaccine', 'one vaccinate antibody', 'one vaccinate vaccine', 'th1th2 vaccinate antibody', 'th1th2 vaccinate vaccine', 'cmi vaccinate antibody', 'cmi vaccinate vaccine']",3338,hand cmi evaluated presence crm197-specific il-5 il-2 producing cells evident splenocytes mice immunized full dose immunized fractional booster dose ifn-ÃÂ³ producing cells responsive protein polysaccharide antigens significantly increased whereas number il-5 il-2 positive cells remained unaffected 
1294,329.0,5.0,"['coronavirus associate covid-19', 'coronavirus associate syndrome', 'coronavirus associate sars-cov-2']",3339,overall present findings show pcv13 humoral response mice associated th2 predominant response full booster dose fractional one favors mixed th1th2 response suggesting important role cmi besides measurement functional protective antibodies additional important key information vaccine development 
1295,330.0,2.0,"['immunization induce vaccine', 'immunization induce element', 'sars-cov-2 induce vaccine', 'sars-cov-2 induce element', 'antibody induce vaccine', 'antibody induce element']",3342,divergence frequency comorbidities males females differences hormonal profile chromosomal composition gender behavior proposed potential causative factors 
1296,330.0,3.0,"['sars-cov-2 induce covid-19', 'sars-cov-2 induce healthcare', 'sars-cov-2 induce professional', 'sars-cov-2 induce patient']",3343,data deriving immunization process indirectly support existence sex-specific response sars-cov-2 since females apparently produce higher numbers antibodies simultaneously exhibiting higher rates side effects indicating stronger immune reactivity vaccine s elements 
1297,330.0,5.0,"['coronaviruses discuss respiratory infection', 'coronaviruses discuss human', 'coronaviruses discuss hcovs', 'coronaviruses discuss oc43', 'coronaviruses discuss 229e', 'coronaviruses discuss patient', 'coronaviruses discuss belgium', 'coronaviruses discuss influenza', 'coronaviruses discuss belgium', 'coronaviruses discuss 2015-20', 'coronaviruses discuss specimen', 'coronaviruses discuss influenza-like', 'coronaviruses discuss patient', 'coronaviruses discuss fever', 'coronaviruses discuss cough', 'coronaviruses discuss dyspnoea', 'coronaviruses discuss patient', 'coronaviruses discuss one', 'coronaviruses discuss patient', 'hcovs discuss respiratory infection', 'hcovs discuss human', 'hcovs discuss coronaviruses', 'hcovs discuss oc43', 'hcovs discuss 229e', 'hcovs discuss patient', 'hcovs discuss belgium', 'hcovs discuss influenza', 'hcovs discuss belgium', 'hcovs discuss 2015-20', 'hcovs discuss specimen', 'hcovs discuss influenza-like', 'hcovs discuss patient', 'hcovs discuss fever', 'hcovs discuss cough', 'hcovs discuss dyspnoea', 'hcovs discuss patient', 'hcovs discuss one', 'hcovs discuss patient', 'coronaviruses observe respiratory infection', 'coronaviruses observe hcovs', 'coronaviruses observe oc43', 'coronaviruses observe 229e', 'coronaviruses observe patient', 'coronaviruses observe belgium', 'coronaviruses observe influenza', 'coronaviruses observe belgium', 'coronaviruses observe 2015-20', 'coronaviruses observe specimen', 'coronaviruses observe influenza-like', 'coronaviruses observe patient', 'coronaviruses observe fever', 'coronaviruses observe cough', 'coronaviruses observe dyspnoea', 'coronaviruses observe patient', 'coronaviruses observe one', 'coronaviruses observe patient', 'hcovs observe respiratory infection', 'hcovs observe oc43', 'hcovs observe 229e', 'hcovs observe patient', 'hcovs observe belgium', 'hcovs observe influenza', 'hcovs observe belgium', 'hcovs observe 2015-20', 'hcovs observe specimen', 'hcovs observe influenza-like', 'hcovs observe patient', 'hcovs observe fever', 'hcovs observe cough', 'hcovs observe dyspnoea', 'hcovs observe patient', 'hcovs observe one', 'hcovs observe patient', 'human observe respiratory infection', 'human observe hcovs', 'human observe oc43', 'human observe 229e', 'human observe patient', 'human observe belgium', 'human observe influenza', 'human observe belgium', 'human observe 2015-20', 'human observe specimen', 'human observe influenza-like', 'human observe patient', 'human observe fever', 'human observe cough', 'human observe dyspnoea', 'human observe patient', 'human observe one', 'human observe patient', 'coronaviruses observe respiratory infection', 'coronaviruses observe hcovs', 'coronaviruses observe oc43', 'coronaviruses observe 229e', 'coronaviruses observe patient', 'coronaviruses observe belgium', 'coronaviruses observe influenza', 'coronaviruses observe belgium', 'coronaviruses observe 2015-20', 'coronaviruses observe specimen', 'coronaviruses observe influenza-like', 'coronaviruses observe patient', 'coronaviruses observe fever', 'coronaviruses observe cough', 'coronaviruses observe dyspnoea', 'coronaviruses observe patient', 'coronaviruses observe one', 'coronaviruses observe patient']",3345,narrative review aims discuss pathophysiological behavioral basis disproportionate male morbidity mortality observed covid-19 context research findings field 
1298,331.0,0.0,"['summary make hcovs', 'summary make oc43', 'summary make nl63', 'summary make 229e', 'summary make patient', 'summary make belgium', 'summary make influenza', 'summary make belgium', 'summary make respiratory', 'summary make specimen', 'summary make respiratory', 'summary make infection', 'summary make influenza-like', 'summary make patient', 'summary make fever', 'summary make cough', 'summary make dyspnoea', 'summary make patient', 'summary make one', 'summary make patient', 'summary make death', 'coronaviruses make hcovs', 'coronaviruses make oc43', 'coronaviruses make nl63', 'coronaviruses make 229e', 'coronaviruses make patient', 'coronaviruses make belgium', 'coronaviruses make influenza', 'coronaviruses make belgium', 'coronaviruses make respiratory', 'coronaviruses make specimen', 'coronaviruses make respiratory', 'coronaviruses make infection', 'coronaviruses make influenza-like', 'coronaviruses make patient', 'coronaviruses make fever', 'coronaviruses make cough', 'coronaviruses make dyspnoea', 'coronaviruses make patient', 'coronaviruses make one', 'coronaviruses make patient', 'coronaviruses make death', 'hcovs make oc43', 'hcovs make nl63', 'hcovs make 229e', 'hcovs make patient', 'hcovs make belgium', 'hcovs make influenza', 'hcovs make belgium', 'hcovs make respiratory', 'hcovs make specimen', 'hcovs make respiratory', 'hcovs make infection', 'hcovs make influenza-like', 'hcovs make patient', 'hcovs make fever', 'hcovs make cough', 'hcovs make dyspnoea', 'hcovs make patient', 'hcovs make one', 'hcovs make patient', 'hcovs make death', 'human make hcovs', 'human make oc43', 'human make nl63', 'human make 229e', 'human make patient', 'human make belgium', 'human make influenza', 'human make belgium', 'human make respiratory', 'human make specimen', 'human make respiratory', 'human make infection', 'human make influenza-like', 'human make patient', 'human make fever', 'human make cough', 'human make dyspnoea', 'human make patient', 'human make one', 'human make patient', 'human make death', 'coronaviruses make hcovs', 'coronaviruses make oc43', 'coronaviruses make nl63', 'coronaviruses make 229e', 'coronaviruses make patient', 'coronaviruses make belgium', 'coronaviruses make influenza', 'coronaviruses make belgium', 'coronaviruses make respiratory', 'coronaviruses make specimen', 'coronaviruses make respiratory', 'coronaviruses make infection', 'coronaviruses make influenza-like', 'coronaviruses make patient', 'coronaviruses make fever', 'coronaviruses make cough', 'coronaviruses make dyspnoea', 'coronaviruses make patient', 'coronaviruses make one', 'coronaviruses make patient', 'coronaviruses make death', 'summary circulate human', 'summary circulate coronaviruses', 'summary circulate hcovs', 'summary circulate oc43', 'summary circulate nl63', 'summary circulate 229e', 'summary circulate patient', 'summary circulate belgium', 'summary circulate influenza', 'summary circulate belgium', 'summary circulate respiratory', 'summary circulate specimen', 'summary circulate respiratory', 'summary circulate infection', 'summary circulate influenza-like', 'summary circulate patient', 'summary circulate fever', 'summary circulate cough', 'summary circulate dyspnoea', 'summary circulate patient', 'summary circulate one', 'summary circulate patient', 'summary circulate death', 'coronaviruses circulate human', 'coronaviruses circulate hcovs', 'coronaviruses circulate oc43', 'coronaviruses circulate nl63', 'coronaviruses circulate 229e', 'coronaviruses circulate patient', 'coronaviruses circulate belgium', 'coronaviruses circulate influenza', 'coronaviruses circulate belgium', 'coronaviruses circulate respiratory', 'coronaviruses circulate specimen', 'coronaviruses circulate respiratory', 'coronaviruses circulate infection', 'coronaviruses circulate influenza-like', 'coronaviruses circulate patient', 'coronaviruses circulate fever', 'coronaviruses circulate cough', 'coronaviruses circulate dyspnoea', 'coronaviruses circulate patient', 'coronaviruses circulate one', 'coronaviruses circulate patient', 'coronaviruses circulate death', 'hcovs circulate human', 'hcovs circulate coronaviruses', 'hcovs circulate oc43', 'hcovs circulate nl63', 'hcovs circulate 229e', 'hcovs circulate patient', 'hcovs circulate belgium', 'hcovs circulate influenza', 'hcovs circulate belgium', 'hcovs circulate respiratory', 'hcovs circulate specimen', 'hcovs circulate respiratory', 'hcovs circulate infection', 'hcovs circulate influenza-like', 'hcovs circulate patient', 'hcovs circulate fever', 'hcovs circulate cough', 'hcovs circulate dyspnoea', 'hcovs circulate patient', 'hcovs circulate one', 'hcovs circulate patient', 'hcovs circulate death', 'summary test fever', 'summary test cough', 'summary test dyspnoea', 'summary test patient', 'summary test one', 'summary test patient', 'summary test death', 'coronaviruses test fever', 'coronaviruses test cough', 'coronaviruses test dyspnoea', 'coronaviruses test patient', 'coronaviruses test one', 'coronaviruses test patient', 'coronaviruses test death', 'hcovs test fever', 'hcovs test cough', 'hcovs test dyspnoea', 'hcovs test patient', 'hcovs test one', 'hcovs test patient', 'hcovs test death', 'human test fever', 'human test cough', 'human test dyspnoea', 'human test patient', 'human test one', 'human test patient', 'human test death', 'coronaviruses test fever', 'coronaviruses test cough', 'coronaviruses test dyspnoea', 'coronaviruses test patient', 'coronaviruses test one', 'coronaviruses test patient', 'coronaviruses test death', 'hcovs test fever', 'hcovs test cough', 'hcovs test dyspnoea', 'hcovs test patient', 'hcovs test one', 'hcovs test patient', 'hcovs test death', 'oc43 test fever', 'oc43 test cough', 'oc43 test dyspnoea', 'oc43 test patient', 'oc43 test one', 'oc43 test patient', 'oc43 test death', 'nl63 test fever', 'nl63 test cough', 'nl63 test dyspnoea', 'nl63 test patient', 'nl63 test one', 'nl63 test patient', 'nl63 test death', '229e test fever', '229e test cough', '229e test dyspnoea', '229e test patient', '229e test one', '229e test patient', '229e test death', 'patient test fever', 'patient test cough', 'patient test dyspnoea', 'patient test one', 'patient test death', 'belgium test fever', 'belgium test cough', 'belgium test dyspnoea', 'belgium test patient', 'belgium test one', 'belgium test patient', 'belgium test death', 'influenza test fever', 'influenza test cough', 'influenza test dyspnoea', 'influenza test patient', 'influenza test one', 'influenza test patient', 'influenza test death', 'belgium test fever', 'belgium test cough', 'belgium test dyspnoea', 'belgium test patient', 'belgium test one', 'belgium test patient', 'belgium test death', 'respiratory test fever', 'respiratory test cough', 'respiratory test dyspnoea', 'respiratory test patient', 'respiratory test one', 'respiratory test patient', 'respiratory test death', 'specimen test fever', 'specimen test cough', 'specimen test dyspnoea', 'specimen test patient', 'specimen test one', 'specimen test patient', 'specimen test death', 'respiratory test fever', 'respiratory test cough', 'respiratory test dyspnoea', 'respiratory test patient', 'respiratory test one', 'respiratory test patient', 'respiratory test death', 'infection test fever', 'infection test cough', 'infection test dyspnoea', 'infection test patient', 'infection test one', 'infection test patient', 'infection test death', 'influenza-like test fever', 'influenza-like test cough', 'influenza-like test dyspnoea', 'influenza-like test patient', 'influenza-like test one', 'influenza-like test patient', 'influenza-like test death', 'patient test fever', 'patient test cough', 'patient test dyspnoea', 'patient test one', 'patient test death', 'summary collect patient', 'summary collect death', 'coronaviruses collect patient', 'coronaviruses collect death', 'hcovs collect patient', 'hcovs collect death', 'human collect patient', 'human collect death', 'coronaviruses collect patient', 'coronaviruses collect death', 'hcovs collect patient', 'hcovs collect death', 'oc43 collect patient', 'oc43 collect death', 'nl63 collect patient', 'nl63 collect death', '229e collect patient', '229e collect death', 'patient collect death', 'belgium collect patient', 'belgium collect death', 'influenza collect patient', 'influenza collect death', 'belgium collect patient', 'belgium collect death', 'respiratory collect patient', 'respiratory collect death', 'specimen collect patient', 'specimen collect death', 'respiratory collect patient', 'respiratory collect death', 'infection collect patient', 'infection collect death', 'influenza-like collect patient', 'influenza-like collect death', 'patient collect death', 'fever collect patient', 'fever collect death', 'cough collect patient', 'cough collect death', 'dyspnoea collect patient', 'dyspnoea collect death', 'patient collect death', 'one collect patient', 'one collect death', 'summary emerge hcovs', 'summary emerge oc43', 'summary emerge nl63', 'summary emerge 229e', 'summary emerge patient', 'summary emerge belgium', 'summary emerge influenza', 'summary emerge belgium', 'summary emerge respiratory', 'summary emerge specimen', 'summary emerge respiratory', 'summary emerge infection', 'summary emerge influenza-like', 'summary emerge patient', 'summary emerge fever', 'summary emerge cough', 'summary emerge dyspnoea', 'summary emerge patient', 'summary emerge one', 'summary emerge patient', 'summary emerge death', 'coronaviruses emerge hcovs', 'coronaviruses emerge oc43', 'coronaviruses emerge nl63', 'coronaviruses emerge 229e', 'coronaviruses emerge patient', 'coronaviruses emerge belgium', 'coronaviruses emerge influenza', 'coronaviruses emerge belgium', 'coronaviruses emerge respiratory', 'coronaviruses emerge specimen', 'coronaviruses emerge respiratory', 'coronaviruses emerge infection', 'coronaviruses emerge influenza-like', 'coronaviruses emerge patient', 'coronaviruses emerge fever', 'coronaviruses emerge cough', 'coronaviruses emerge dyspnoea', 'coronaviruses emerge patient', 'coronaviruses emerge one', 'coronaviruses emerge patient', 'coronaviruses emerge death', 'hcovs emerge oc43', 'hcovs emerge nl63', 'hcovs emerge 229e', 'hcovs emerge patient', 'hcovs emerge belgium', 'hcovs emerge influenza', 'hcovs emerge belgium', 'hcovs emerge respiratory', 'hcovs emerge specimen', 'hcovs emerge respiratory', 'hcovs emerge infection', 'hcovs emerge influenza-like', 'hcovs emerge patient', 'hcovs emerge fever', 'hcovs emerge cough', 'hcovs emerge dyspnoea', 'hcovs emerge patient', 'hcovs emerge one', 'hcovs emerge patient', 'hcovs emerge death', 'human emerge hcovs', 'human emerge oc43', 'human emerge nl63', 'human emerge 229e', 'human emerge patient', 'human emerge belgium', 'human emerge influenza', 'human emerge belgium', 'human emerge respiratory', 'human emerge specimen', 'human emerge respiratory', 'human emerge infection', 'human emerge influenza-like', 'human emerge patient', 'human emerge fever', 'human emerge cough', 'human emerge dyspnoea', 'human emerge patient', 'human emerge one', 'human emerge patient', 'human emerge death', 'coronaviruses emerge hcovs', 'coronaviruses emerge oc43', 'coronaviruses emerge nl63', 'coronaviruses emerge 229e', 'coronaviruses emerge patient', 'coronaviruses emerge belgium', 'coronaviruses emerge influenza', 'coronaviruses emerge belgium', 'coronaviruses emerge respiratory', 'coronaviruses emerge specimen', 'coronaviruses emerge respiratory', 'coronaviruses emerge infection', 'coronaviruses emerge influenza-like', 'coronaviruses emerge patient', 'coronaviruses emerge fever', 'coronaviruses emerge cough', 'coronaviruses emerge dyspnoea', 'coronaviruses emerge patient', 'coronaviruses emerge one', 'coronaviruses emerge patient', 'coronaviruses emerge death', 'summary aim belgium', 'summary aim influenza', 'summary aim belgium', 'summary aim respiratory', 'summary aim specimen', 'summary aim respiratory', 'summary aim infection', 'summary aim influenza-like', 'summary aim patient', 'summary aim fever', 'summary aim cough', 'summary aim dyspnoea', 'summary aim patient', 'summary aim one', 'summary aim patient', 'summary aim death', 'coronaviruses aim belgium', 'coronaviruses aim influenza', 'coronaviruses aim belgium', 'coronaviruses aim respiratory', 'coronaviruses aim specimen', 'coronaviruses aim respiratory', 'coronaviruses aim infection', 'coronaviruses aim influenza-like', 'coronaviruses aim patient', 'coronaviruses aim fever', 'coronaviruses aim cough', 'coronaviruses aim dyspnoea', 'coronaviruses aim patient', 'coronaviruses aim one', 'coronaviruses aim patient', 'coronaviruses aim death', 'hcovs aim belgium', 'hcovs aim influenza', 'hcovs aim belgium', 'hcovs aim respiratory', 'hcovs aim specimen', 'hcovs aim respiratory', 'hcovs aim infection', 'hcovs aim influenza-like', 'hcovs aim patient', 'hcovs aim fever', 'hcovs aim cough', 'hcovs aim dyspnoea', 'hcovs aim patient', 'hcovs aim one', 'hcovs aim patient', 'hcovs aim death', 'human aim belgium', 'human aim influenza', 'human aim belgium', 'human aim respiratory', 'human aim specimen', 'human aim respiratory', 'human aim infection', 'human aim influenza-like', 'human aim patient', 'human aim fever', 'human aim cough', 'human aim dyspnoea', 'human aim patient', 'human aim one', 'human aim patient', 'human aim death', 'coronaviruses aim belgium', 'coronaviruses aim influenza', 'coronaviruses aim belgium', 'coronaviruses aim respiratory', 'coronaviruses aim specimen', 'coronaviruses aim respiratory', 'coronaviruses aim infection', 'coronaviruses aim influenza-like', 'coronaviruses aim patient', 'coronaviruses aim fever', 'coronaviruses aim cough', 'coronaviruses aim dyspnoea', 'coronaviruses aim patient', 'coronaviruses aim one', 'coronaviruses aim patient', 'coronaviruses aim death', 'hcovs aim belgium', 'hcovs aim influenza', 'hcovs aim belgium', 'hcovs aim respiratory', 'hcovs aim specimen', 'hcovs aim respiratory', 'hcovs aim infection', 'hcovs aim influenza-like', 'hcovs aim patient', 'hcovs aim fever', 'hcovs aim cough', 'hcovs aim dyspnoea', 'hcovs aim patient', 'hcovs aim one', 'hcovs aim patient', 'hcovs aim death', 'oc43 aim belgium', 'oc43 aim influenza', 'oc43 aim belgium', 'oc43 aim respiratory', 'oc43 aim specimen', 'oc43 aim respiratory', 'oc43 aim infection', 'oc43 aim influenza-like', 'oc43 aim patient', 'oc43 aim fever', 'oc43 aim cough', 'oc43 aim dyspnoea', 'oc43 aim patient', 'oc43 aim one', 'oc43 aim patient', 'oc43 aim death', 'nl63 aim belgium', 'nl63 aim influenza', 'nl63 aim belgium', 'nl63 aim respiratory', 'nl63 aim specimen', 'nl63 aim respiratory', 'nl63 aim infection', 'nl63 aim influenza-like', 'nl63 aim patient', 'nl63 aim fever', 'nl63 aim cough', 'nl63 aim dyspnoea', 'nl63 aim patient', 'nl63 aim one', 'nl63 aim patient', 'nl63 aim death', '229e aim belgium', '229e aim influenza', '229e aim belgium', '229e aim respiratory', '229e aim specimen', '229e aim respiratory', '229e aim infection', '229e aim influenza-like', '229e aim patient', '229e aim fever', '229e aim cough', '229e aim dyspnoea', '229e aim patient', '229e aim one', '229e aim patient', '229e aim death']",3346,background seasonal human coronaviruses hcovs broadly circulate humans epidemiology effect spread emerging coronaviruses neglected thus far aimed elucidate epidemiology burden disease seasonal hcovs oc43 nl63 229e patients primary care hospitals belgium 2015 2020 methods retrospectively analysed data national influenza surveillance networks belgium winter seasons 2015-20 respiratory specimens collected severe acute respiratory infection sari influenza-like illness networks patients acute respiratory illness onset within previous 10 days measured reported fever 38 degrees c greater cough dyspnoea patients admitted hospital least one night potential risk factors recorded patients admitted hospital followed occurrence complications death length hospital stay samples analysed multiplex quantitative rt-pcrs respiratory viruses including seasonal hcovs oc43 nl63 229e estimated prevalence incidence seasonal hcov infection without co-infection respiratory viruses evaluated association co-infections potential risk factors complications death patients admitted hospital seasonal hcov infections age group samples received week 8 2020 tested severe acute respiratory syndrome coronavirus 2 sars-cov-2 findings 2573 primary care 6494 hospital samples included study 161 6 3 2573 patients primary care 371 5 7 6494 patients admitted hospital infected seasonal hcov oc43 seasonal hcov highest prevalence across age groups highest incidence children admitted hospital younger 5 years incidence 9 0 95 ci 7 2-11 2 per 100 000 person-months adults older 65 years 2 6 2 1-3 2 per 100 000 person-months among 262 patients admitted hospital seasonal hcov infection complete information potential risk factors 66 73 3 90 patients complications died also least one potential risk factor p0 0064 complications children younger 5 years associated co-infection 24 36 4 66 p0 017 teenagers adults gt 15 years complications arose patients single hcov infection 49 45 0 109 p0 0097 early 2020 belgian sari surveillance detected first sars-cov-2-positive sample concomitantly first confirmed covid-19 case travel history china interpretation main burden severe seasonal hcov infection lies children younger 5 years co-infections adults aged 65 years older pre-existing comorbidities age patient groups targeted enhanced observation medical care possible future vaccination strategies co-infections children younger 5 years considered diagnosis treatment findings support use national influenza surveillance systems seasonal hcov monitoring early detection monitoring emerging coronaviruses sars-cov-2 copyright c 2021 author published elsevier ltd open access article cc by-nc-nd 4 0 license
1299,333.0,1.0,"['one inform age', 'one inform 188', 'one inform injury', 'one inform un', 'one inform 2020', 'one inform covid-19', 'one inform gbd', 'one inform uk', 'one inform usa', 'covid-19 inform age', 'covid-19 inform 188', 'covid-19 inform injury', 'covid-19 inform un', 'covid-19 inform 2020', 'covid-19 inform gbd', 'covid-19 inform uk', 'covid-19 inform usa', 'one vary covid-19', 'one vary age', 'one vary 188', 'one vary injury', 'one vary un', 'one vary 2020', 'one vary covid-19', 'one vary gbd', 'one vary uk', 'one vary usa', 'one harbor injury', 'one harbor un', 'one harbor 2020', 'one harbor covid-19', 'one harbor gbd', 'one harbor uk', 'one harbor usa', 'covid-19 harbor injury', 'covid-19 harbor un', 'covid-19 harbor 2020', 'covid-19 harbor gbd', 'covid-19 harbor uk', 'covid-19 harbor usa', 'age harbor injury', 'age harbor un', 'age harbor 2020', 'age harbor covid-19', 'age harbor gbd', 'age harbor uk', 'age harbor usa', 'one vaccinate injury', 'one vaccinate un', 'one vaccinate 2020', 'one vaccinate covid-19', 'one vaccinate gbd', 'one vaccinate uk', 'one vaccinate usa', 'covid-19 vaccinate injury', 'covid-19 vaccinate un', 'covid-19 vaccinate 2020', 'covid-19 vaccinate gbd', 'covid-19 vaccinate uk', 'covid-19 vaccinate usa', 'age vaccinate injury', 'age vaccinate un', 'age vaccinate 2020', 'age vaccinate covid-19', 'age vaccinate gbd', 'age vaccinate uk', 'age vaccinate usa', '188 vaccinate injury', '188 vaccinate un', '188 vaccinate 2020', '188 vaccinate covid-19', '188 vaccinate gbd', '188 vaccinate uk', '188 vaccinate usa']",3349,understanding number individuals increased risk severe covid-19 varies countries inform design possible strategies shield vaccinate highest risk 
1300,333.0,2.0,"['two aim multimorbidity', 'two aim multimorbidity', 'two increase multimorbidity']",3350,methods estimated number individuals increased risk severe disease defined least one condition listed increased risk severe covid-19 current guidelines age 5-year age groups sex country 188 countries using prevalence data global burden diseases injuries risk factors study gbd 2017 un population estimates 2020 list underlying conditions relevant covid-19 determined mapping conditions listed gbd 2017 listed guidelines published public health agencies uk usa 
1301,333.0,7.0,"['people induce covid-19', '15-28 induce covid-19', 'people use covid-19', '15-28 use covid-19']",3355,generated uncertainty intervals uis estimates running low high scenarios using lower upper 95 confidence limits country population size disease prevalences multimorbidity fractions infection-hospitalisation ratios plausible low high estimates degree clustering informed multimorbidity studies 
1302,333.0,8.0,"['349 million aim people', '349 million aim 3-9', '349 million aim covid-19']",3356,findings estimated 1ÃÂ7 billion ui 1ÃÂ0-2ÃÂ4 people comprising 22 ui 15-28 global population least one underlying condition puts increased risk severe covid-19 infected ranging 5 younger 20 years 66 aged 70 years older 
1303,333.0,10.0,"['african compare diabetes', 'hivaids compare diabetes']",3358,estimated 6 3-12 males high risk compared 3 2-7 females 
1304,333.0,12.0,"['one increase covid-19', 'five increase covid-19']",3360,estimates number individuals increased risk sensitive prevalence chronic kidney disease diabetes cardiovascular disease chronic respiratory disease 
1305,334.0,4.0,"['cellular fold b1351', 'phagocytosis fold b1351', 'complement fold b1351', 'cell fold b1351']",3368,median binding antibody titres 29-fold 27-fold lower b1351 p1 variants respectively compared wa12020 
1306,334.0,6.0,['ad26cov2s include sars-cov-2'],3370,cd8 cd4 cell responses including central effector memory responses comparable among wa12020 b117 b1351 p1 cal20c variants 
1307,335.0,0.0,"['influenza vaccinate child', 'influenza vaccinate cohort', 'vaccine vaccinate child', 'vaccine vaccinate cohort']",3373,background second-grade pupils israel vaccinated influenza since winter 2016ÃÂÂ2017 
1308,335.0,2.0,"['parent perform influenza', 'parent perform influenza-like', 'parent perform ili', 'parent perform child', 'nine perform influenza', 'nine perform influenza-like', 'nine perform ili', 'nine perform child']",3375,methods retrospective cohort study performed winter 2016ÃÂÂ2017 tel-aviv district israel compared second-grade pupils vaccinated school third-grade pupils- vaccinated school 
1309,335.0,4.0,"['527 describe 359', '527 describe 681', '527 describe 168', '527 describe 319']",3377,rate reduction defined ili among unvaccinated ÃÂÂ ili among vaccinated ili among vaccinated 
1310,335.0,6.0,"['child report 357', 'child report 149', 'child report 429', 'child report 256', 'child compare 357', 'child compare 149', 'child compare 429', 'child compare 256']",3379,unvaccinated children reported ili compared vaccinated children 195 vs 77 yielding rate reduction 605 
1311,335.0,7.0,"['345 make child', '250 make child']",3380,unvaccinated children also greater number physiciansÃÂÂ visits missed school days 357 vs 149 429 vs 256 respectively 
1312,335.0,8.0,"['cohort compare 446', 'child compare 446', 'second compare 446', 'cohort compare 446', 'child compare 446']",3381,rate ili among household members unvaccinated children 345 compared 250 among household members vaccinated children 
1313,335.0,9.0,"['pupil describe 320', 'pupil describe cohort', 'pupil describe 354', 'pupil describe 273', 'cohort describe 320', 'cohort describe 354', 'cohort describe 273', 'pupil report cohort', 'pupil report 354', 'pupil report 273', 'cohort report 354', 'cohort report 273', '320 report cohort', '320 report 354', '320 report 273', 'pupil compare cohort', 'pupil compare 354', 'pupil compare 273', 'cohort compare 354', 'cohort compare 273', '320 compare cohort', '320 compare 354', '320 compare 273', 'pupil describe 273', 'cohort describe 273', '320 describe 273', 'cohort describe 273', '354 describe 273']",3382,vaccinated cohort defined children second grade reported less ili compared unvaccinated cohort defined children third grade rate reduction 446 
1314,335.0,10.0,"['influenza make cohort', 'influenza make member', 'influenza make 605', 'influenza make 275', 'influenza make cohort', 'vaccine make cohort', 'vaccine make member', 'vaccine make 605', 'vaccine make 275', 'vaccine make cohort']",3383,pupils unvaccinated cohort likely miss school days 421 vs 320 respectively higher rate ili reported among household members unvaccinated cohort 354 vs 273 respectively 
1315,336.0,2.0,"['blood use malaria-naÃ\x83\x83Ã\x83\x82ve', 'blood use participant', 'blood use participant', 'blood use bspzv1', 'immunization use malaria-naÃ\x83\x83Ã\x83\x82ve', 'immunization use participant', 'immunization use participant', 'immunization use bspzv1', 'falciparum use malaria-naÃ\x83\x83Ã\x83\x82ve', 'falciparum use participant', 'falciparum use participant', 'falciparum use bspzv1', 'sporozoite use malaria-naÃ\x83\x83Ã\x83\x82ve', 'sporozoite use participant', 'sporozoite use participant', 'sporozoite use bspzv1', 'blood attenuate falciparum', 'blood attenuate sporozoite', 'blood attenuate malaria-naÃ\x83\x83Ã\x83\x82ve', 'blood attenuate participant', 'blood attenuate participant', 'blood attenuate bspzv1', 'immunization attenuate falciparum', 'immunization attenuate sporozoite', 'immunization attenuate malaria-naÃ\x83\x83Ã\x83\x82ve', 'immunization attenuate participant', 'immunization attenuate participant', 'immunization attenuate bspzv1', 'blood receive participant', 'blood receive participant', 'blood receive bspzv1', 'immunization receive participant', 'immunization receive participant', 'immunization receive bspzv1', 'falciparum receive participant', 'falciparum receive participant', 'falciparum receive bspzv1', 'sporozoite receive participant', 'sporozoite receive participant', 'sporozoite receive bspzv1']",3388,work two recent radiation-attenuated sporozoite vaccination studies used identify potential transcriptional correlates vaccination-induced protection 
1316,336.0,7.0,['blood receive cell'],3393,results analysis comparable time points 1 week first vaccination revealed shared cross-study transcriptional response programme despite large differences number magnitude differentially expressed genes trials 
1317,336.0,10.0,"['summary protect malaria', 'two protect malaria']",3396,individuals except non-protected bspzv1 participants showed robust upregulation cell-cycle associated transcriptional responses post vaccination 
1318,336.0,12.0,"['interferon follow bspzv1', 'failure follow bspzv1']",3398,comprised moderate early interferon response peaking 2 days post vaccination followed later proliferative cell cycle response steadily increasing first 7 days post vaccination 
1319,336.0,14.0,"['pneumococcus observe vaccine-preventable', 'pneumococcus observe death', 'pneumonia observe vaccine-preventable', 'pneumonia observe death']",3400,supplementary information online version contains supplementary material available 101186s12936-021-03839-3 
1320,337.0,5.0,"['german eliminate stiko', 'german eliminate ppv23']",3406,eradicating healthy pneumococcal carriers thus herd-protective effects 
1321,337.0,6.0,"['renal failure recommend pcv13', 'renal failure recommend ppv23', 'renal failure recommend infection', 'liver failure recommend pcv13', 'liver failure recommend ppv23', 'liver failure recommend infection', 'patient recommend pcv13', 'patient recommend ppv23', 'patient recommend infection']",3407,german standing commission vaccination practices stiko currently recommends ppv23 indication vaccination various comorbidities standard vaccination 60 years repeat vaccination 6 years earliest 
1322,338.0,1.0,"['methodsin affect serum', '101 affect serum', 'people affect serum', 'igg affect serum', 'covid-19 affect serum']",3410,whether disease modifying therapies dmts multiple sclerosis ms also impact cell immune response vaccination unknown 
1323,338.0,2.0,"['cell evaluate pbmcs', 'cell evaluate peptide', 'cell evaluate genscript', 'cell evaluate 158', 'cell evaluate peptide', 'ifn- evaluate pbmcs', 'ifn- evaluate peptide', 'ifn- evaluate genscript', 'ifn- evaluate 158', 'ifn- evaluate peptide', 'sweden evaluate pbmcs', 'sweden evaluate peptide', 'sweden evaluate genscript', 'sweden evaluate 158', 'sweden evaluate peptide', 'cell evaluate ifn-', 'cell evaluate sweden', 'cell evaluate pbmcs', 'cell evaluate peptide', 'cell evaluate genscript', 'cell evaluate 158', 'cell evaluate peptide']",3411,methodsin 101 people ms measured humoral responses via immunoassay measure igg covid-19 spike s1 glycoprotein serum 
1324,338.0,5.0,"['findingshumoral test 564', 'findingshumoral test participant', 'findingshumoral test 5963', 'findingshumoral test 936', 'findingshumoral test participant']",3414,tested differences immune responses across dmts using linear models 
1325,338.0,7.0,"['anticd20 detect 859', 'ifn- detect anticd20', 'ifn- detect 859', 'anticd20 detect 859', 'anticd20 include 859', 'ifn- include 859', 'anticd20 include 859', 'anticd20 include 859']",3416,subset immune cell phenotyping n88 87 cell responses detected 7688 86 including 3233 969 participants anti-cd20 therapies 
1326,338.0,10.0,"['covid-19 need people', 'covid-19 need pwms', 'covid-19 need vaccine', 'covid-19 need sars-cov2', 'covid-19 need covid-', 'covid-19 need pwms', 'covid-19 observe pwms', 'covid-19 observe vaccine', 'covid-19 observe sars-cov2', 'covid-19 observe covid-', 'covid-19 observe pwms', 'covid-19 receive vaccine', 'covid-19 receive sars-cov2', 'covid-19 receive covid-', 'covid-19 receive pwms', 'people receive vaccine', 'people receive sars-cov2', 'people receive covid-', 'people receive pwms']",3419,follow studies needed determine translates protection covid-19 infection 
1327,339.0,0.0,"['patient respond pwms', 'patient respond proven', 'patient respond covid-19', 'patient respond 91', 'patient respond ocrelizumab', 'patient respond rituximab', 'patient respond interferon', 'covid-19 respond pwms', 'covid-19 respond patient', 'covid-19 respond proven', 'covid-19 respond patient', 'covid-19 respond 91', 'covid-19 respond patient', 'covid-19 respond ocrelizumab', 'covid-19 respond rituximab', 'covid-19 respond interferon', 'antibody respond pwms', 'antibody respond patient', 'antibody respond proven', 'antibody respond covid-19', 'antibody respond patient', 'antibody respond 91', 'antibody respond patient', 'antibody respond ocrelizumab', 'antibody respond rituximab', 'antibody respond interferon', 'sars-cov-2 respond pwms', 'sars-cov-2 respond patient', 'sars-cov-2 respond proven', 'sars-cov-2 respond covid-19', 'sars-cov-2 respond patient', 'sars-cov-2 respond 91', 'sars-cov-2 respond patient', 'sars-cov-2 respond ocrelizumab', 'sars-cov-2 respond rituximab', 'sars-cov-2 respond interferon', 'patient respond pwms', 'patient respond proven', 'patient respond covid-19', 'patient respond 91', 'patient respond ocrelizumab', 'patient respond rituximab', 'patient respond interferon', 'covid-19 respond pwms', 'covid-19 respond patient', 'covid-19 respond proven', 'covid-19 respond patient', 'covid-19 respond 91', 'covid-19 respond patient', 'covid-19 respond ocrelizumab', 'covid-19 respond rituximab', 'covid-19 respond interferon', 'co-morbid respond pwms', 'co-morbid respond patient', 'co-morbid respond proven', 'co-morbid respond covid-19', 'co-morbid respond patient', 'co-morbid respond 91', 'co-morbid respond patient', 'co-morbid respond ocrelizumab', 'co-morbid respond rituximab', 'co-morbid respond interferon', 'patient elicit covid-19', 'patient elicit antibody', 'patient elicit sars-cov-2', 'patient elicit covid-19', 'patient elicit co-morbid', 'patient elicit pwms', 'patient elicit proven', 'patient elicit covid-19', 'patient elicit 91', 'patient elicit ocrelizumab', 'patient elicit rituximab', 'patient elicit interferon', 'patient affect 91', 'patient affect ocrelizumab', 'patient affect rituximab', 'patient affect interferon', 'covid-19 affect patient', 'covid-19 affect 91', 'covid-19 affect patient', 'covid-19 affect ocrelizumab', 'covid-19 affect rituximab', 'covid-19 affect interferon', 'antibody affect patient', 'antibody affect 91', 'antibody affect patient', 'antibody affect ocrelizumab', 'antibody affect rituximab', 'antibody affect interferon', 'sars-cov-2 affect patient', 'sars-cov-2 affect 91', 'sars-cov-2 affect patient', 'sars-cov-2 affect ocrelizumab', 'sars-cov-2 affect rituximab', 'sars-cov-2 affect interferon', 'patient affect 91', 'patient affect ocrelizumab', 'patient affect rituximab', 'patient affect interferon', 'covid-19 affect patient', 'covid-19 affect 91', 'covid-19 affect patient', 'covid-19 affect ocrelizumab', 'covid-19 affect rituximab', 'covid-19 affect interferon', 'co-morbid affect patient', 'co-morbid affect 91', 'co-morbid affect patient', 'co-morbid affect ocrelizumab', 'co-morbid affect rituximab', 'co-morbid affect interferon', 'pwms affect patient', 'pwms affect 91', 'pwms affect patient', 'pwms affect ocrelizumab', 'pwms affect rituximab', 'pwms affect interferon', 'patient affect 91', 'patient affect ocrelizumab', 'patient affect rituximab', 'patient affect interferon', 'proven affect patient', 'proven affect 91', 'proven affect patient', 'proven affect ocrelizumab', 'proven affect rituximab', 'proven affect interferon', 'patient cause ocrelizumab', 'patient cause rituximab', 'patient cause interferon', 'covid-19 cause patient', 'covid-19 cause ocrelizumab', 'covid-19 cause rituximab', 'covid-19 cause interferon', 'antibody cause patient', 'antibody cause ocrelizumab', 'antibody cause rituximab', 'antibody cause interferon', 'sars-cov-2 cause patient', 'sars-cov-2 cause ocrelizumab', 'sars-cov-2 cause rituximab', 'sars-cov-2 cause interferon', 'patient cause ocrelizumab', 'patient cause rituximab', 'patient cause interferon', 'covid-19 cause patient', 'covid-19 cause ocrelizumab', 'covid-19 cause rituximab', 'covid-19 cause interferon', 'co-morbid cause patient', 'co-morbid cause ocrelizumab', 'co-morbid cause rituximab', 'co-morbid cause interferon', 'pwms cause patient', 'pwms cause ocrelizumab', 'pwms cause rituximab', 'pwms cause interferon', 'patient cause ocrelizumab', 'patient cause rituximab', 'patient cause interferon', 'proven cause patient', 'proven cause ocrelizumab', 'proven cause rituximab', 'proven cause interferon', 'covid-19 cause patient', 'covid-19 cause ocrelizumab', 'covid-19 cause rituximab', 'covid-19 cause interferon', 'patient cause ocrelizumab', 'patient cause rituximab', 'patient cause interferon', '91 cause patient', '91 cause ocrelizumab', '91 cause rituximab', '91 cause interferon']",3420,background covid-19 pandemic raised novel questions people multiple sclerosis pwms worldwide registries help answer one question - disease modifying treatment dmt use affect efficacy future vaccine sars-cov2 virus causes covid- 19 pwms 
1328,340.0,0.0,"['optimal induce vaccine', 'combination induce vaccine', 'optimal follow covid-19', 'optimal follow vaccine', 'combination follow covid-19', 'combination follow vaccine', 'optimal associate covid-19', 'optimal associate vaccine', 'combination associate covid-19', 'combination associate vaccine']",3423,objectives diagnostic work-up following covid-19 associated symptom lead extensive testing potentially overwhelming laboratory capacity whilst primarily yielding negative results 
1329,340.0,1.0,"['uk receive covid-19', 'uk receive symptom', 'uk receive seven', 'u receive covid-19', 'u receive symptom', 'u receive seven', 'uk include symptom', 'uk include seven', 'u include symptom', 'u include seven', 'user include symptom', 'user include seven', 'covid-19 include symptom', 'covid-19 include seven', 'uk use seven', 'u use seven', 'user use seven', 'covid-19 use seven', 'symptom use seven']",3424,aimed identify optimal symptom combinations capture cases using fewer tests implications covid-19 vaccine developers across different resource settings public health 
1330,340.0,2.0,['one report combination'],3425,methods uk us users covid-19 symptom study app reported new-onset symptoms rt-pcr test within seven days symptom onset included 
1331,340.0,4.0,"['uk use 3162', 'u use 3162', 'cohort use 3162', '122305 use 3162']",3427,multi-objective evolutionary algorithm applied generate combinations optimal trade-offs sensitivity specificity 
1332,340.0,5.0,"['three include cough', 'three include dyspnoea', 'three include fever', 'three include anosmiaageusia', 'covid-19 include cough', 'covid-19 include dyspnoea', 'covid-19 include fever', 'covid-19 include anosmiaageusia']",3428,findings uk us cohorts included 122305 1202 positives 3162 79 positive individuals 
1333,341.0,1.0,"['holyoke receive sars-cov-2', 'holyoke receive antibody']",3433,information critical identifying hotspots high-risk groups informing public health responses covid-19 pandemic 
1334,341.0,8.0,"['207 receive age', '207 receive age', '207 receive 102', '207 receive age', '207 receive 100', '207 receive age', 'age receive 102', 'age receive 100', '138 receive age', '138 receive age', '138 receive 102', '138 receive age', '138 receive 100', '138 receive age', '207 compare age', '207 compare 102', '207 compare age', '207 compare 100', '207 compare age', 'age compare 102', 'age compare 100', '138 compare age', '138 compare 102', '138 compare age', '138 compare 100', '138 compare age', '207 receive 102', '207 receive age', '207 receive 100', '207 receive age', 'age receive 102', 'age receive 100', '138 receive 102', '138 receive age', '138 receive 100', '138 receive age', 'age receive 102', 'age receive 100', 'age receive 102', 'age receive 100']",3440,seroprevalence 168 95 ci 57 ÃÂÂ 280 among individuals identifying hispanic compared 89 95 ci 30 - 147 among identifying white 
1335,342.0,1.0,"['methylprednisolone dose covid-19', 'methylprednisolone dose patient']",3448,furthermore appropriate corticosteroid dose treatment covid-19 remained uncertain 
1336,342.0,2.0,"['covid-19 hospitalize iran', 'patient hospitalize iran']",3449,conducted study assess effectiveness methylprednisolone treatment versus dexamethasone hospitalized covid-19 patients 
1337,342.0,3.0,"['patient blind mgkgday', 'patient blind dexamethasone', 'two blind mgkgday', 'two blind dexamethasone', 'patient observe dexamethasone', 'two observe dexamethasone', 'methylprednisolone observe dexamethasone']",3450,methods prospective triple-blinded randomized controlled trial enrolled 86 hospitalized covid-19 patients august november 2020 shiraz iran 
1338,342.0,4.0,['9-point receive death'],3451,patients randomly allocated two groups receive either methylprednisolone 2 mgkgday intervention group dexamethasone 6 mgday control group 
1339,343.0,5.0,"['patient enrol plasma', 'patient enrol 223', 'patient enrol 112-445', 'patient enrol ci', 'patient enrol q-value', 'patient enrol 611', 'patient enrol beggs']",3466,results total 15 eligible articles enrolled current quantitative synthesis 
1340,343.0,6.0,"['discharge compare egger', 'discharge compare beggs', 'patient compare egger', 'patient compare beggs', '292 compare egger', '292 compare beggs', '148-577 compare egger', '148-577 compare beggs', 'ci compare egger', 'ci compare beggs', 'q-value compare egger', 'q-value compare beggs', '432 compare egger', '432 compare beggs', 'discharge receive q-value', 'discharge receive 432', 'discharge receive egger', 'discharge receive beggs', 'patient receive q-value', 'patient receive 432', 'patient receive egger', 'patient receive beggs', '292 receive q-value', '292 receive 432', '292 receive egger', '292 receive beggs', '148-577 receive q-value', '148-577 receive 432', '148-577 receive egger', '148-577 receive beggs', 'ci receive q-value', 'ci receive 432', 'ci receive egger', 'ci receive beggs']",3467,statistical analysis showed clinical improvement group patients received convalescent plasma significantly increased compared control group 223 112-445 95 cis p value 0022 q-value 611 2 8364 eggers p value 0064 beggs p value 0093 
1341,344.0,2.0,"['immunisation emerge antibody', 'immunisation emerge t-cell', 'immunisation collect t-cell']",3472,contrast previously published approaches cvncov exclusively composed naturally occurring nucleotides 
1342,344.0,4.0,['hamster protect vaccine-enhanced'],3474,cvncov vaccination protected hamsters challenge wild-type sars-cov-2 demonstrated absence viral replication lungs 
1343,344.0,5.0,"['cvncov induce vaccine', 'cvncov induce sars-cov-2']",3475,hamsters vaccinated suboptimal dose cvncov leading breakthrough viral replication exhibited evidence vaccine-enhanced disease 
1344,345.0,0.0,"['influenza receive obstructive pulmonary', 'influenza receive renal failure', 'influenza receive people', 'influenza receive 8805', 'influenza receive patient', 'influenza receive copd', 'influenza receive hepatopathies', 'influenza receive inflammatory', 'influenza receive bowel', 'influenza die obstructive pulmonary', 'influenza die renal failure', 'influenza die patient', 'influenza die copd', 'influenza die hepatopathies', 'influenza die inflammatory', 'influenza die bowel', 'people die obstructive pulmonary', 'people die renal failure', 'people die patient', 'people die copd', 'people die hepatopathies', 'people die inflammatory', 'people die bowel', '8805 die obstructive pulmonary', '8805 die renal failure', '8805 die patient', '8805 die copd', '8805 die hepatopathies', '8805 die inflammatory', '8805 die bowel', 'influenza relate obstructive pulmonary', 'influenza relate renal failure', 'influenza relate copd', 'influenza relate hepatopathies', 'influenza relate inflammatory', 'influenza relate bowel', 'people relate obstructive pulmonary', 'people relate renal failure', 'people relate copd', 'people relate hepatopathies', 'people relate inflammatory', 'people relate bowel', '8805 relate obstructive pulmonary', '8805 relate renal failure', '8805 relate copd', '8805 relate hepatopathies', '8805 relate inflammatory', '8805 relate bowel', 'patient relate obstructive pulmonary', 'patient relate renal failure', 'patient relate copd', 'patient relate hepatopathies', 'patient relate inflammatory', 'patient relate bowel']",3477,based data updated 20 may 2020 total recorded number patients died due covid-19-related reasons italy 31851 demographic clinical characteristics patients died including number comorbidities extremely relevant especially define higher risk mortality 
1345,345.0,3.0,"['ili relate two', 'covid-19 relate two']",3480,hence peak seasonal flu influenza-like illness-related ili deaths started grow 
1346,345.0,6.0,"['people perform patient', 'people perform covid-19', 'people perform influenza', 'people die patient', 'people die covid-19', 'people die influenza', 'people relate patient', 'people relate covid-19', 'people relate influenza']",3483,characterization died due virus-related reasons performed cross-linking data stored different warehouses geographical area developing electronic health records 
1347,345.0,8.0,"['bordetella prioritize antigen', 'bordetella prioritize mlva', 'bordetella prioritize tandem', 'bordetella prioritize lung', 'bordetella prioritize mouse', 'bordetella prioritize mouse', 'bordetella prioritize pertussis', 'bordetella prioritize vaccine', 'bordetella prioritize acellular', 'bordetella prioritize pertussis', 'bordetella prioritize vaccine', 'bordetella prioritize pertussis', 'bordetella prioritize vaccine', 'pertussis prioritize antigen', 'pertussis prioritize mlva', 'pertussis prioritize tandem', 'pertussis prioritize lung', 'pertussis prioritize mouse', 'pertussis prioritize mouse', 'pertussis prioritize vaccine', 'pertussis prioritize acellular', 'pertussis prioritize vaccine', 'pertussis prioritize vaccine', 'bordetella use mlva', 'bordetella use tandem', 'bordetella use lung', 'bordetella use mouse', 'bordetella use mouse', 'bordetella use pertussis', 'bordetella use vaccine', 'bordetella use acellular', 'bordetella use pertussis', 'bordetella use vaccine', 'bordetella use pertussis', 'bordetella use vaccine', 'pertussis use mlva', 'pertussis use tandem', 'pertussis use lung', 'pertussis use mouse', 'pertussis use mouse', 'pertussis use vaccine', 'pertussis use acellular', 'pertussis use vaccine', 'pertussis use vaccine', 'antigen use mlva', 'antigen use tandem', 'antigen use lung', 'antigen use mouse', 'antigen use mouse', 'antigen use pertussis', 'antigen use vaccine', 'antigen use acellular', 'antigen use pertussis', 'antigen use vaccine', 'antigen use pertussis', 'antigen use vaccine']",3485,description subgroup people higher risk mortality crucial prioritizing implementing future public health prevention treatment programs 
1348,346.0,0.0,['pertussis compare vaccine'],3486,aim study compare elimination bordetella pertussis clinical isolates representing different genotypes relation alleles encoding virulence factors mlstÃÂÂmulti-locus antigen sequence typing mlva type multi-locus variable-number tandem repeat analysis pfge group pulsed-field gel electrophoresis lungs naive mice mice immunised commercial whole-cell pertussis vaccine acellular pertussis vaccine experimental whole-cell pertussis vaccine 
1349,346.0,3.0,"['mouse show suspension', 'mouse show approximately', 'mouse show cfuml', 'mouse show pertussis', 'mouse use cfuml', 'mouse use pertussis', 'suspension use cfuml', 'suspension use pertussis', 'approximately use cfuml', 'approximately use pertussis']",3489,shown one isolates used prn deficient 
1350,346.0,4.0,"['vaccine challenge haemagglutinin fim', 'vaccine challenge pertussis', 'vaccine challenge prn', 'vaccine challenge pertactin', 'vaccine observe haemagglutinin fim', 'pertussis observe haemagglutinin fim', 'prn observe haemagglutinin fim', 'pertactin observe haemagglutinin fim']",3490,mice intranasally challenged bacterial suspension containing approximately 5 ÃÂ 10 7 cfuml b pertussis 
1351,346.0,5.0,"['whole-cell test immunity', 'whole-cell test b', 'whole-cell test pertussis', 'whole-cell test isolates', 'whole-cell test lung', 'acellular test immunity', 'acellular test b', 'acellular test pertussis', 'acellular test isolates', 'acellular test lung', 'pertussis test immunity', 'pertussis test b', 'pertussis test isolates', 'pertussis test lung']",3491,immunogenicity tested vaccines pt pertussis toxin prn pertactin fha filamentous haemagglutinin fim fimbriae types 2 3 examined 
1352,346.0,6.0,"['prn-deficient induce prn', 'prn-deficient induce isolate', 'prn-deficient induce isolates', 'prn-deficient induce vaccine', 'isolate induce prn', 'isolate induce isolates', 'isolate induce vaccine', 'lung induce prn', 'lung induce isolate', 'lung induce isolates', 'lung induce vaccine', 'mouse induce prn', 'mouse induce isolate', 'mouse induce isolates', 'mouse induce vaccine', 'vaccine induce prn', 'vaccine induce isolate', 'vaccine induce isolates', 'prn-deficient eliminate isolates', 'prn-deficient eliminate vaccine', 'isolate eliminate isolates', 'isolate eliminate vaccine', 'lung eliminate isolates', 'lung eliminate vaccine', 'mouse eliminate isolates', 'mouse eliminate vaccine', 'vaccine eliminate isolates', 'prn eliminate isolates', 'prn eliminate vaccine', 'isolate eliminate isolates', 'isolate eliminate vaccine']",3492,commercial whole-cell acellular pertussis vaccines induced immunity effective eliminating genetically different b pertussis isolates lungs 
1353,347.0,1.0,"['china cause adenovirus', 'china cause seven', 'china cause hadvs', 'china cause patient', 'china cause tract', 'china cause infection', 'china cause rtis']",3496,particularly cause frequent morbidity among children 
1354,347.0,2.0,"['hadv cause specimen', 'rtis cause specimen', 'rtis cause hadv', 'china cause specimen', 'china cause hadv', 'nasal cause specimen', 'nasal cause hadv', 'patient cause specimen', 'patient cause hadv', 'guangzhou cause specimen', 'guangzhou cause hadv']",3497,china human adenovirus types 3 4 7 11 14 21 55 caused least seven outbreaks since 2000 however limited studies available regarding epidemiological patterns diversity hadvs types among hospitalized patients respiratory tract infections rtis 
1355,347.0,3.0,"['hadv receive specimen', 'hadv receive child', 'hadv receive age', 'hadv associate child', 'hadv associate age', 'specimen associate child', 'specimen associate age', 'hadv associate child', 'hadv associate age']",3498,methods understand epidemiology subtype distribution hadv infections associated rtis china nasal swab ns clinical samples collected 4129 patients guangzhou hospital august 2017 october 2019 pcr sequencing phylogenetic analysis performed specimens identify hadv subtypes 
1356,347.0,4.0,"['specimen sequence hadv-b3', 'specimen sequence 556', 'specimen sequence hadv-b7', 'specimen sequence 253']",3499,results hadv successfully sequenced 99 24 4129 ns specimens highest hadv prevalence 63 found children ages 5 10 years 
1357,347.0,7.0,"['age detect adenovirus infections', 'age detect child']",3502,hadv infections detected throughout year relatively higher prevalence summer 
1358,347.0,11.0,"['conjugate observe cohort', 'conjugate observe pneumococcal', 'conjugate observe seven', 'vaccine observe cohort', 'vaccine observe pneumococcal', 'vaccine observe seven', 'pcv7 observe cohort', 'pcv7 observe pneumococcal', 'pcv7 observe seven']",3506,supplementary information online version contains supplementary material available 101186s12879-021-06412-0 
1359,348.0,0.0,"['1278 introduce sweden', 'patient introduce sweden']",3507,background pneumococcal conjugate vaccine pcv7 introduced southwest sweden child vaccination program 2009 followed pcv13 2010 pcv10 2015 retrospective cohort study assessed pneumococcal serotype distribution relation predisposing factors clinical manifestations outcome seven years pcv introduction 
1360,348.0,3.0,"['pcv13 evaluate p 0001', 'pcv13 evaluate cardiovascular disease', 'pcv13 evaluate pulmonary disease', 'pcv13 evaluate p 0001', 'pcv13 evaluate patient', 'pcv13 evaluate patient', 'serotypes evaluate p 0001', 'serotypes evaluate cardiovascular disease', 'serotypes evaluate pulmonary disease', 'serotypes evaluate p 0001', 'serotypes evaluate patient', 'serotypes evaluate patient', 'p 0001 test pulmonary disease', 'pcv13 test pulmonary disease', 'pcv13 test p 0001', 'serotypes test pulmonary disease', 'serotypes test p 0001', 'patient test pulmonary disease', 'patient test p 0001', 'patient test pulmonary disease', 'patient test p 0001', 'p 0001 cause cardiovascular disease', 'p 0001 cause pulmonary disease', 'p 0001 cause patient', 'pcv13 cause cardiovascular disease', 'pcv13 cause pulmonary disease', 'pcv13 cause p 0001', 'pcv13 cause patient', 'serotypes cause cardiovascular disease', 'serotypes cause pulmonary disease', 'serotypes cause p 0001', 'serotypes cause patient', 'patient cause cardiovascular disease', 'patient cause pulmonary disease', 'patient cause p 0001']",3510,associations serotypes clinical characteristics statistically evaluated use fisherÃÂÂs exact test mann-whitney u test logistic regression analysis whereas ipd episodes caused serotypes time analyzed mantel-haenszel chi-square test 
1361,348.0,4.0,"['patient decrease vaccine-included', 'malignancy decrease vaccine-included', 'renal decrease vaccine-included', 'ipd decrease vaccine-included']",3511,results exception serotype 3 prevalence pcv13 serotypes decreased study period 76 n 157 ipd episodes 2009 25 n 42 2015 p 0001 non-pcv13 serotypes increased mainly among patients ÃÂÂ65 years patients predisposing factors including cardiovascular disease pulmonary disease malignancy p 0001 
1362,348.0,6.0,"['pcv13 associate pneumonia', 'pcv13 associate serotypes', 'pcv13 associate bacteremia', 'pcv13 associate pneumonia', 'pcv13 associate meningitis', 'serotypes associate pneumonia', 'serotypes associate bacteremia', 'serotypes associate pneumonia', 'serotypes associate meningitis']",3513,serotype 3 associated intensive care unit admissions serotype 1 7f caused ipd among healthier younger patients 
1363,348.0,10.0,"['respiratory disease observe people', 'influenza observe people']",3517,supplementary information online version contains supplementary material available 101186s12879-021-06430-y 
1364,349.0,0.0,"['influenza affect antibody', 'influenza affect hemagglutinin']",3518,influenza highly contagious viral respiratory disease affects million people worldwide year 
1365,349.0,3.0,"['b cell establish vaccine', 'b cell establish recipient', 'b cell establish influenza', 'b cell induce vaccine', 'b cell induce recipient', 'b cell induce influenza']",3521,however remains unclear b cell memory shaped recurrent annual vaccination course multiple seasons especially high-risk elderly populations 
1366,349.0,5.0,"['strain-specific profile pre-existing', 'strain-specific profile memory', 'strain-specific profile b-cells', 'antibody profile pre-existing', 'antibody profile memory', 'antibody profile b-cells']",3523,specifically antibody serological memory b-cell compartments profiled reactivity current historical influenza virus strains 
1367,349.0,6.0,"['influenza receive participant', 'influenza receive vaccine']",3524,moreover multiparametric analysis antibody landscape profiling revealed transient increase strain-specific antibodies elderly impaired recall response pre-existing memory b-cells plasmablast pb differentiation long-lasting serological changes 
1368,349.0,7.0,"['coronavirus compare covid-19', 'coronavirus compare vaccine', 'coronavirus compare syndrome', 'coronavirus compare sars-cov-2', 'coronavirus compare patient', 'disease-2019 compare covid-19', 'disease-2019 compare vaccine', 'disease-2019 compare syndrome', 'disease-2019 compare coronavirus', 'disease-2019 compare sars-cov-2', 'disease-2019 compare patient', 'covid-19 compare vaccine', 'covid-19 compare syndrome', 'covid-19 compare coronavirus', 'covid-19 compare sars-cov-2', 'covid-19 compare patient', 'coronavirus receive syndrome', 'coronavirus receive sars-cov-2', 'coronavirus receive patient', 'disease-2019 receive syndrome', 'disease-2019 receive coronavirus', 'disease-2019 receive sars-cov-2', 'disease-2019 receive patient', 'covid-19 receive syndrome', 'covid-19 receive coronavirus', 'covid-19 receive sars-cov-2', 'covid-19 receive patient', 'covid-19 receive syndrome', 'covid-19 receive coronavirus', 'covid-19 receive sars-cov-2', 'covid-19 receive patient', 'vaccine receive syndrome', 'vaccine receive coronavirus', 'vaccine receive sars-cov-2', 'vaccine receive patient']",3525,study thoroughly profiles compares immune response recurrent influenza virus vaccination young elderly participants unveiling pitfalls current influenza virus vaccines high-risk populations 
1369,350.0,3.0,['vaccine indicate booster'],3529,moreover immunogenicity indicated booster dose viral vector mrna vaccine achieved significant proportion ig anti-receptor binding domain rbd igg anti-rbd iga anti-s1 booster response 
1370,350.0,4.0,['serum perform sars-cov-2'],3530,contrast inactivated vaccine achieved lower booster response others 
1371,350.0,5.0,"['igg vaccinate booster', 'anti-nucleocapsid vaccinate booster']",3531,consequently neutralization activity vaccinated serum high inhibition 90 sars-cov-2 wild-type variants b117-alpha b1351-beta b16172-delta 
1372,350.0,6.0,['interferon observe mrna'],3532,addition igg anti-nucleocapsid observed among group received bbibp booster 
1373,350.0,7.0,"['azd1222 make vaccine', 'azd1222 make coronavac', 'mrna make vaccine', 'mrna make coronavac', 'bnt162b2 make vaccine', 'bnt162b2 make coronavac']",3533,study found significant increase levels interferon gamma-secreting t-cell response additional viral vector mrna booster vaccination 
1374,351.0,0.0,"['chitosan show extracellular proteins', 'chitosan show ecp c', 'chitosan show toxoid', 'chitosan show salmonella', 'extracellular proteins cause salmonella', 'ecp c cause salmonella', 'chitosan cause salmonella', 'cn cause salmonella', 'toxoid cause salmonella']",3535,currently licensed vaccines clostridium perfringens causes necrotic enteritis poultry 
1375,351.0,2.0,"['cn assay pb', 'cn assay chicken', 'cn assay hemoglobin', 'cn make pb', 'cn make chicken', 'cn make hemoglobin']",3537,ph stability assay cn ct nanoparticles released 6 0 protein 80 ph 
1376,351.0,4.0,"['bird indicate vaccine', 'bird indicate pb', 'bird indicate pb', 'bird vaccinate pb', 'vaccine vaccinate pb']",3539,ninety broilers randomly assigned treatments sham-vaccinated control cn-vaccinated cn ct-vaccinated ct 
1377,351.0,13.0,"['chitosan vaccinate necrotic enteritis', 'clostridium vaccinate necrotic enteritis', 'perfringens vaccinate necrotic enteritis', 'extracellular vaccinate necrotic enteritis']",3548,pooled serum 28 age cn-vaccinated birds also partially neutralized toxins 50 ÃÂµg ecp 
1378,351.0,14.0,"['coronavirus reduce worker', 'coronavirus reduce hcws', 'covid-19 reduce worker', 'covid-19 reduce hcws', 'mrna-1273 reduce worker', 'mrna-1273 reduce hcws']",3549,result study indicates potential chitosan loaded clostridium perfringens extracellular proteins applied necrotic enteritis challenge studies 
1379,352.0,1.0,['cross-sectional investigate hcws'],3551,objective study investigate side effects mrna-1273 vaccine detailed review organ systems 
1380,352.0,2.0,['participant randomize 11161271'],3552,randomized cross-sectional study using independent online survey questionnaire conducted collect responses hcws 
1381,352.0,3.0,"['387 provide mrna-1273', '387 provide vaccine', '387 provide recipient', '387 provide one', '387 provide symptom', '4321116 provide mrna-1273', '4321116 provide vaccine', '4321116 provide recipient', '4321116 provide one', '4321116 provide symptom', 'mrna-1273 provide vaccine', 'mrna-1273 provide recipient', 'mrna-1273 provide one', 'mrna-1273 provide symptom', 'vaccine provide mrna-1273', 'vaccine provide recipient', 'vaccine provide one', 'vaccine provide symptom', '425 provide mrna-1273', '425 provide vaccine', '425 provide recipient', '425 provide one', '425 provide symptom']",3553,participants 878 11161271 provided complete responses 
1382,352.0,6.0,"['2778 continue 394', '2778 continue outpatient', '2778 continue 1432']",3556, 254432 588 able continue daily routine activities 
1383,352.0,7.0,"['symptom perform vaccine', '9702 perform vaccine', 'hcws perform vaccine']",3557,108432 25 temporarily trouble perform daily activities 120432 2778 required transient time work 17432 394 required help outpatient provider 1432 023 required help emergency department none hospitalized 
1384,352.0,8.0,"['symptom report muscle spasm', 'symptom report myalgia', 'symptom report chill', 'symptom report fever', 'symptom report nausea', 'symptom report joint', 'symptom report pain', 'symptom report swelling', 'symptom report injection', 'symptom report dizziness', 'symptom report rash', 'symptom report appetite', 'symptom report brain', 'weakness report muscle spasm', 'weakness report myalgia', 'weakness report chill', 'weakness report fever', 'weakness report nausea', 'weakness report joint', 'weakness report pain', 'weakness report swelling', 'weakness report injection', 'weakness report dizziness', 'weakness report rash', 'weakness report appetite', 'weakness report brain', 'weakness report symptom', 'symptom indicate muscle spasm', 'symptom indicate dizziness', 'symptom indicate rash', 'symptom indicate appetite', 'symptom indicate brain', 'weakness indicate muscle spasm', 'weakness indicate dizziness', 'weakness indicate rash', 'weakness indicate appetite', 'weakness indicate brain', 'weakness indicate symptom', 'headache indicate muscle spasm', 'headache indicate dizziness', 'headache indicate rash', 'headache indicate appetite', 'headache indicate brain', 'headache indicate symptom', 'myalgia indicate muscle spasm', 'myalgia indicate dizziness', 'myalgia indicate rash', 'myalgia indicate appetite', 'myalgia indicate brain', 'myalgia indicate symptom', 'chill indicate muscle spasm', 'chill indicate dizziness', 'chill indicate rash', 'chill indicate appetite', 'chill indicate brain', 'chill indicate symptom', 'fever indicate muscle spasm', 'fever indicate dizziness', 'fever indicate rash', 'fever indicate appetite', 'fever indicate brain', 'fever indicate symptom', 'nausea indicate muscle spasm', 'nausea indicate dizziness', 'nausea indicate rash', 'nausea indicate appetite', 'nausea indicate brain', 'nausea indicate symptom', 'joint indicate muscle spasm', 'joint indicate dizziness', 'joint indicate rash', 'joint indicate appetite', 'joint indicate brain', 'joint indicate symptom', 'pain indicate muscle spasm', 'pain indicate dizziness', 'pain indicate rash', 'pain indicate appetite', 'pain indicate brain', 'pain indicate symptom', 'swelling indicate muscle spasm', 'swelling indicate dizziness', 'swelling indicate rash', 'swelling indicate appetite', 'swelling indicate brain', 'swelling indicate symptom', 'symptom understudy muscle spasm', 'symptom understudy rash', 'symptom understudy appetite', 'symptom understudy brain', 'weakness understudy muscle spasm', 'weakness understudy rash', 'weakness understudy appetite', 'weakness understudy brain', 'weakness understudy symptom', 'headache understudy muscle spasm', 'headache understudy rash', 'headache understudy appetite', 'headache understudy brain', 'headache understudy symptom', 'myalgia understudy muscle spasm', 'myalgia understudy rash', 'myalgia understudy appetite', 'myalgia understudy brain', 'myalgia understudy symptom', 'chill understudy muscle spasm', 'chill understudy rash', 'chill understudy appetite', 'chill understudy brain', 'chill understudy symptom', 'fever understudy muscle spasm', 'fever understudy rash', 'fever understudy appetite', 'fever understudy brain', 'fever understudy symptom', 'nausea understudy muscle spasm', 'nausea understudy rash', 'nausea understudy appetite', 'nausea understudy brain', 'nausea understudy symptom', 'joint understudy muscle spasm', 'joint understudy rash', 'joint understudy appetite', 'joint understudy brain', 'joint understudy symptom', 'pain understudy muscle spasm', 'pain understudy rash', 'pain understudy appetite', 'pain understudy brain', 'pain understudy symptom', 'swelling understudy muscle spasm', 'swelling understudy rash', 'swelling understudy appetite', 'swelling understudy brain', 'swelling understudy symptom', 'injection understudy muscle spasm', 'injection understudy rash', 'injection understudy appetite', 'injection understudy brain', 'injection understudy symptom']",3558,despite wide array self-reported symptoms 9702 hcws intend skip second dose vaccine 
1385,352.0,10.0,['symptom threaten vaccine'],3560,symptoms reported nonlife threatening 
1386,352.0,11.0,"['covid-19 report vaccine', 'covid-19 report worker', 'covid-19 report hcws', 'covid-19 report vaccine', 'covid-19 report organ', 'covid-19 report cross-sectional', 'covid-19 report hcws', 'covid-19 report participant', 'covid-19 report 878', 'covid-19 appear hcws', 'covid-19 appear vaccine', 'covid-19 appear organ', 'covid-19 appear cross-sectional', 'covid-19 appear hcws', 'covid-19 appear participant', 'covid-19 appear 878', 'mrna-1273 appear hcws', 'mrna-1273 appear vaccine', 'mrna-1273 appear organ', 'mrna-1273 appear cross-sectional', 'mrna-1273 appear hcws', 'mrna-1273 appear participant', 'mrna-1273 appear 878', 'vaccine appear hcws', 'vaccine appear organ', 'vaccine appear cross-sectional', 'vaccine appear hcws', 'vaccine appear participant', 'vaccine appear 878']",3561,despite wide array self-reported symptoms appears higher acceptance vaccine 
1387,353.0,1.0,"['425 receive symptom', '432 receive symptom', 'mrna-1273 receive symptom', 'vaccine receive symptom', 'recipient receive symptom']",3563, 387 4321116 received mrna-1273 vaccine among 8935 females 
1388,353.0,4.0,"['2778 continue 394', '2778 continue outpatient', '2778 continue 1432']",3566, 254432 588 able continue daily routine activities 
1389,353.0,5.0,"['symptom perform muscle spasm', 'symptom perform vaccine', 'symptom perform headache', 'symptom perform myalgia', 'symptom perform chill', 'symptom perform fever', 'symptom perform nausea', 'symptom perform joint', 'symptom perform pain', 'symptom perform swelling', 'symptom perform injection', 'symptom perform dizziness', 'symptom perform rash', 'symptom perform appetite', 'symptom perform brain', '9702 perform muscle spasm', '9702 perform vaccine', '9702 perform symptom', '9702 perform headache', '9702 perform myalgia', '9702 perform chill', '9702 perform fever', '9702 perform nausea', '9702 perform joint', '9702 perform pain', '9702 perform swelling', '9702 perform injection', '9702 perform dizziness', '9702 perform rash', '9702 perform appetite', '9702 perform brain', '9702 perform symptom', 'hcws perform muscle spasm', 'hcws perform vaccine', 'hcws perform symptom', 'hcws perform headache', 'hcws perform myalgia', 'hcws perform chill', 'hcws perform fever', 'hcws perform nausea', 'hcws perform joint', 'hcws perform pain', 'hcws perform swelling', 'hcws perform injection', 'hcws perform dizziness', 'hcws perform rash', 'hcws perform appetite', 'hcws perform brain', 'hcws perform symptom', 'symptom need muscle spasm', 'symptom need headache', 'symptom need myalgia', 'symptom need chill', 'symptom need fever', 'symptom need nausea', 'symptom need joint', 'symptom need pain', 'symptom need swelling', 'symptom need injection', 'symptom need dizziness', 'symptom need rash', 'symptom need appetite', 'symptom need brain', '9702 need muscle spasm', '9702 need headache', '9702 need myalgia', '9702 need chill', '9702 need fever', '9702 need nausea', '9702 need joint', '9702 need pain', '9702 need swelling', '9702 need injection', '9702 need dizziness', '9702 need rash', '9702 need appetite', '9702 need brain', '9702 need symptom', 'hcws need muscle spasm', 'hcws need headache', 'hcws need myalgia', 'hcws need chill', 'hcws need fever', 'hcws need nausea', 'hcws need joint', 'hcws need pain', 'hcws need swelling', 'hcws need injection', 'hcws need dizziness', 'hcws need rash', 'hcws need appetite', 'hcws need brain', 'hcws need symptom', 'vaccine need muscle spasm', 'vaccine need headache', 'vaccine need myalgia', 'vaccine need chill', 'vaccine need fever', 'vaccine need nausea', 'vaccine need joint', 'vaccine need pain', 'vaccine need swelling', 'vaccine need injection', 'vaccine need dizziness', 'vaccine need rash', 'vaccine need appetite', 'vaccine need brain', 'vaccine need symptom', 'symptom need muscle spasm', 'symptom need headache', 'symptom need myalgia', 'symptom need chill', 'symptom need fever', 'symptom need nausea', 'symptom need joint', 'symptom need pain', 'symptom need swelling', 'symptom need injection', 'symptom need dizziness', 'symptom need rash', 'symptom need appetite', 'symptom need brain', 'symptom need muscle spasm', 'symptom need dizziness', 'symptom need rash', 'symptom need appetite', 'symptom need brain', '9702 need muscle spasm', '9702 need dizziness', '9702 need rash', '9702 need appetite', '9702 need brain', '9702 need symptom', 'hcws need muscle spasm', 'hcws need dizziness', 'hcws need rash', 'hcws need appetite', 'hcws need brain', 'hcws need symptom', 'vaccine need muscle spasm', 'vaccine need dizziness', 'vaccine need rash', 'vaccine need appetite', 'vaccine need brain', 'vaccine need symptom', 'symptom need muscle spasm', 'symptom need dizziness', 'symptom need rash', 'symptom need appetite', 'symptom need brain', 'headache need muscle spasm', 'headache need dizziness', 'headache need rash', 'headache need appetite', 'headache need brain', 'headache need symptom', 'myalgia need muscle spasm', 'myalgia need dizziness', 'myalgia need rash', 'myalgia need appetite', 'myalgia need brain', 'myalgia need symptom', 'chill need muscle spasm', 'chill need dizziness', 'chill need rash', 'chill need appetite', 'chill need brain', 'chill need symptom', 'fever need muscle spasm', 'fever need dizziness', 'fever need rash', 'fever need appetite', 'fever need brain', 'fever need symptom', 'nausea need muscle spasm', 'nausea need dizziness', 'nausea need rash', 'nausea need appetite', 'nausea need brain', 'nausea need symptom', 'joint need muscle spasm', 'joint need dizziness', 'joint need rash', 'joint need appetite', 'joint need brain', 'joint need symptom', 'pain need muscle spasm', 'pain need dizziness', 'pain need rash', 'pain need appetite', 'pain need brain', 'pain need symptom', 'swelling need muscle spasm', 'swelling need dizziness', 'swelling need rash', 'swelling need appetite', 'swelling need brain', 'swelling need symptom', 'muscle spasm need symptom', '9702 need symptom', 'hcws need symptom', 'vaccine need symptom', 'headache need symptom', 'myalgia need symptom', 'chill need symptom', 'fever need symptom', 'nausea need symptom', 'joint need symptom', 'pain need symptom', 'swelling need symptom', 'injection need symptom', 'dizziness need symptom', 'rash need symptom', 'appetite need symptom']",3567,108432 25 temporarily unable perform daily activities 120432 2778 required transient time work 17432 394 required help outpatient provider 1432 023 required help emergency department none hospitalized 
1390,353.0,9.0,"['bronchitis include ibc', 'bronchitis include gammacoronavirus', 'bronchitis include ibv', 'bronchitis include chicken', 'bronchitis include sars', 'bronchitis include cov2', 'bronchitis include human', 'bronchitis include triviron', 'bronchitis include argovit', 'bronchitis include chicken', 'bronchitis include vaccine', 'bronchitis include h120', 'bronchitis include chicken', 'bronchitis include intestine', 'bronchitis include lung', 'bronchitis include thymus', 'bronchitis include infection', 'bronchitis include thymus', 'bronchitis include lung', 'bronchitis include ibv', 'bronchitis include trivirone', 'bronchitis include ecocide']",3571,rights reserved 
1391,355.0,4.0,"['967 provide 227', 'pertussis provide 227']",3577,particular summarize clinical features severe patients aggravation 
1392,355.0,6.0,"['patient report hypoxemia', 'patient report pneumonia', 'patient report 3-month-old', 'vomiting report hypoxemia', 'vomiting report pneumonia', 'vomiting report 3-month-old', 'cyanosis report hypoxemia', 'cyanosis report pneumonia', 'cyanosis report 3-month-old', 'heart report hypoxemia', 'heart report pneumonia', 'heart report 3-month-old', 'patient receive 3-month-old', 'vomiting receive 3-month-old', 'cyanosis receive 3-month-old', 'heart receive 3-month-old', 'hypoxemia receive 3-month-old', 'pneumonia receive 3-month-old']",3579,onset age younger 3 months old accounted highest proportion 126 patients received hospitalization 
1393,355.0,9.0,"['cough paroxysms include cough', 'cough paroxysms include chest', 'cough paroxysms include pneumoniaconsolidationatelectasis', 'cough paroxysms include pertussis', 'vomiting include cough', 'vomiting include chest', 'vomiting include pneumoniaconsolidationatelectasis', 'vomiting include pertussis']",3582,risk factors severe patients included early age onset pathogen exposure unvaccinated status 
1394,355.0,13.0,"['tumor treat solid cancers', 'tumor treat vaccine', 'tumor treat glioma', 'tumor treat lgg', 'tumor recommend solid cancers', 'tumor recommend glioma', 'tumor recommend lgg', 'immunotherapy recommend solid cancers', 'immunotherapy recommend glioma', 'immunotherapy recommend lgg', 'tumor recommend solid cancers', 'tumor recommend glioma', 'tumor recommend lgg', 'vaccine recommend solid cancers', 'vaccine recommend glioma', 'vaccine recommend lgg']",3586,pediatricians must detect treat severe cases promptly recommend timely vaccination eligible children 
1395,356.0,1.0,"['tumor evaluate cancer', 'antigen evaluate cancer', 'lgg evaluate cancer']",3588,immunophenotyping tumors essential tool evaluate immune function patients immunodeficiency autoimmunity 
1396,356.0,2.0,"['529 receive tcga', '529 receive brain', 'patient receive tcga', 'patient receive brain']",3589,therefore study aims find potential tumor antigen lgg identify suitable population cancer vaccination based immune landscape 
1397,356.0,3.0,"['antigen induce patient', 'k-m induce antigen', 'k-m induce patient']",3590,method genomic clinical data 529 patients lgg obtained tcga mrna_seq data normal brain tissue downloaded gtex 
1398,356.0,8.0,"['prognosis- cluster lgg', 'immune-related cluster lgg', 'four cluster lgg', 'tumor cluster lgg']",3595,weighted gene co-expression network analysis wgcna clustered immune-related genes screened hub genes pathway enrichment analyses performed hub modules related immune subtype wgcna 
1399,356.0,10.0,"['three associate is1', 'three associate is2', 'three associate is3']",3597,also significantly positively associated antigen-presenting immune cells apcs 
1400,356.0,11.0,"['tumor mutation induce tumor', '1p19q induce tumor']",3598,three robust immune subtypes is1 is2 is3 represented immune status desert immune inhibition inflamed respectively might serve predictive parameter 
1401,356.0,12.0,"['fcgbp include antigen', 'fcgbp include cancer', 'fcgbp include patient', 'fcgbp include is3', 'fcgbp include lgg', 'tlr7 include antigen', 'tlr7 include cancer', 'tlr7 include patient', 'tlr7 include is3', 'tlr7 include lgg', 'csf2ra include antigen', 'csf2ra include cancer', 'csf2ra include patient', 'csf2ra include is3', 'csf2ra include lgg']",3599,subsequently clinicopathological features including codeletion status 1p19q idh mutation status tumor mutation burden tumor stemness etc significantly different among subtypes 
1402,356.0,14.0,"['inhibitor observe t-cell', 'inhibitor observe immunotherapeutic', 'inhibitor observe prostate', 'inhibitor observe cancer', 'tumor observe t-cell', 'tumor observe immunotherapeutic', 'tumor observe prostate', 'tumor observe cancer']",3601,supplementary information online version contains supplementary material available 101186s12967-021-03014-x 
1403,357.0,1.0,"['tumor receive atezolizumab', 'tumor receive sipuleucel-t', 'tumor follow atezolizumab', 'tumor follow sipuleucel-t']",3603,methods subjects asymptomatic minimally symptomatic mcrpc randomly assigned 11 ratio receive either atezolizumab followed sipuleucel-t arm 1 sipuleucel-t followed atezolizumab arm 2 
1404,357.0,2.0,"['750 include ngml', '750 include three', 'prostate include ngml', 'prostate include three', 'antigen include ngml', 'antigen include three', 'psa include ngml', 'psa include three']",3604,primary endpoint safety secondary endpoints included preliminary clinical activity objective tumor response systemic immune responses could identify key molecular immunological changes associated sequential administration atezolizumab sipuleucel-t results total 37 subjects enrolled 
1405,359.0,0.0,"['sars-cov-2 cause agonism', 'sars-cov-2 cause vaccine', 'vaccine cause agonism']",3615,background infectious diseases vaccines occasionally cause new-onset flare immune-mediated diseases imds 
1406,359.0,1.0,"['imd base five', 'imd base three', 'imd base israel', 'imd base one', 'imd base uk', 'imd base usa']",3616,adjuvanticity available sars-cov-2 vaccines based either tlr-78 tlr-9 agonism distinct previous vaccines common pathogenic mechanism imds 
1407,359.0,5.0,"['2327 include vaccine', '2327 include mrna-1273', '2327 include 227', '2327 include chadox1', '2327 include vaccine']",3620,findings 27 cases included 17 flares 10 new onset imds 
1408,359.0,9.0,"['patient receive second-dose', 'two receive second-dose', 'one receive second-dose', 'patient receive second-dose']",3624,among patients flare activation four episodes occurred receiving second-dose one patient occurred first second-dose 
1409,359.0,14.0,"['815 mediate immunization', '815 mediate patient', '815 include immunization', '815 include patient']",3629,immune-mediated conditions included idiopathic pericarditis n 2 neurosarcoidosis small fiber neuropathy n 1 demyelination n 1 myasthenia gravis n 2 
1410,360.0,0.0,"['sars-cov-2 confer smi', 'sars-cov-2 confer patient', 'sars-cov-2 confer schizophrenia', 'sars-cov-2 confer ssd', 'sars-cov-2 confer patient', 'sars-cov-2 confer clozapine', 'patient confer smi', 'patient confer schizophrenia', 'patient confer ssd', 'patient confer clozapine']",3636,background clozapine plus working group frequently consulted advice measures case infection sarscov-2 vaccination covid-19 patients receiving clozapine 
1411,361.0,7.0,"['respiratory infection induce rsv', 'respiratory infection induce poc', 'child induce rsv', 'child induce poc', 'symptom induce rsv', 'symptom induce poc']",3646,methods rsv gold-iiiÃÂÂicu network study international prospective observational multicenter study conducted 10 gavi-eligible countries pediatric intensive care units high-dependency units picushdus local viral respiratory seasons 2 years 
1412,362.0,6.0,"['panama city evaluate west', 'panama city evaluate 232', 'panama city evaluate 167', 'panama city evaluate influenza', 'influenza evaluate west', 'influenza evaluate 232', 'influenza evaluate 167', '796 evaluate west', '796 evaluate 232', '796 evaluate 167', '796 evaluate influenza', '204 evaluate west', '204 evaluate 232', '204 evaluate 167', '204 evaluate influenza', 'influenza recommend panama city', 'influenza recommend 547', 'influenza recommend west', 'influenza recommend 232', 'influenza recommend 167', '796 recommend panama city', '796 recommend 547', '796 recommend west', '796 recommend 232', '796 recommend 167', '796 recommend influenza', '204 recommend panama city', '204 recommend 547', '204 recommend west', '204 recommend 232', '204 recommend 167', '204 recommend influenza']",3659,percentage level mismatch circulating vaccine-recommended b lineage assessed mayÃÂÂoctober influenza season 
1413,362.0,11.0,"['influenza circulate less 2', 'influenza circulate panama city', 'influenza circulate age', 'influenza circulate child']",3664,influenza type circulated every year influenza b circulated 2012 2014 2017 2012 mayÃÂÂoctober influenza b season predominant lineage bvictoria switch byamagata observed 2014 lineages co-circulated 2017 leading 389 b-lineage-level vaccine mismatch 
1414,363.0,1.0,"['sars-cov-2 observe rhesus', 'sars-cov-2 observe macaque']",3670,safe effective vaccines needed overcome crisis 
1415,363.0,2.0,"['twenty develop animal', 'macaque develop animal', 'twenty evaluate animal', 'macaque evaluate animal']",3671, develop assess protective efficacy immunogenicity inactivated sars-cov-2 vaccine rhesus macaques 
1416,363.0,3.0,"['one divide three', 'one divide three', 'one divide vaccine', 'one divide bbv152']",3672,twenty macaques divided four groups five animals 
1417,363.0,4.0,['macaque treat fourteen'],3673,one group administered placebo three groups immunized three different vaccine candidates bbv152 0 14 days 
1418,363.0,6.0,"['bronchoalveolar lavage increase throat', 'bronchoalveolar lavage increase lung']",3675,protective response observed increasing sars-cov-2 specific igg neutralizing antibody titers 3rd-week post-immunization 
1419,363.0,7.0,"['pneumonia observe alveolar epithelium', 'pneumonia observe antigen', 'pneumonia observe macrophage']",3676,viral clearance observed bronchoalveolar lavage fluid nasal swab throat swab lung tissues 7 days post-infection vaccinated groups 
1420,363.0,8.0,"['vaccine observe nct04471519', 'vaccine observe india', 'bbv152 observe nct04471519', 'bbv152 observe india', 'bbv152 observe vaccine', 'bbv152 show vaccine', 'nct04471519 show vaccine', 'india show vaccine']",3677,evidence pneumonia observed histopathological examination vaccinated groups unlike placebo group exhibited interstitial pneumonia localization viral antigen alveolar epithelium macrophages immunohistochemistry 
1421,363.0,9.0,"['salmonid complete intracellular', 'salmonid complete bacterium', 'rickettsial complete intracellular', 'rickettsial complete bacterium', 'septicaemia complete intracellular', 'septicaemia complete bacterium']",3678,vaccine candidate bbv152 completed phase iii nct04471519 clinical trials india presently phase iii data study substantiates immunogenicity protective efficacy vaccine candidates 
1422,364.0,3.0,['vaccine show cellular'],3682,unfortunately commercially available srs vaccines shown significant effect reducing mortality 
1423,364.0,4.0,"['sr observe salmo', 'sr observe salar', 'sr observe atlantic', 'sr observe salmon']",3683,vaccines contain whole inactivated bacteria results decreased efficacy due limited ability vaccine evoke cellular mediated immune response eliminate pathogen infected cells 
1424,364.0,5.0,"['vaccine evaluate death', 'mykiss evaluate death']",3684,addition srs vaccine efficacy evaluated primarily salmo salar atlantic salmon 
1425,364.0,6.0,"['injectable induce cd8', 'injectable induce immunity', 'vaccine induce cd8', 'vaccine induce immunity', 'vaccine induce cd8', 'vaccine induce immunity']",3685,vaccine studies using oncorhynchus mykiss rainbow trout scarce despite srs leading cause infectious death species 
1426,364.0,10.0,"['mykiss induce salmonis', 'mykiss induce proteoliposome-based', 'mykiss induce vaccine']",3689,transcriptional profile suggests vaccine capable inducing cellular immunity 
1427,364.0,12.0,"['pertussis observe vaccine', 'pertussis observe infant', 'pertussis observe child', 'cough observe vaccine', 'cough observe infant', 'cough observe child']",3691,supplementary information online version contains supplementary material available 101186s13567-021-00982-2 
1428,365.0,0.0,"['pertussis induce vaccine', 'pertussis induce immunity', 'pertussis induce adolescent', 'pertussis induce adult']",3692,pertussis whooping cough epidemics persist globally despite high vaccine coverage among infants young children 
1429,365.0,2.0,"['embase indicate child', 'embase indicate adolescent', 'embase indicate adult', 'embase indicate europe', 'pertussis indicate child', 'pertussis indicate adolescent', 'pertussis indicate adult', 'pertussis indicate europe']",3694,however pertussis generally less severe adolescents adults difference presentation means often unrecognised healthcare professionals meaning largely under-diagnosed older populations 
1430,365.0,7.0,"['pertussis report adolescent', 'pertussis report adult', 'pertussis report europe', 'pertussis report pertussis-related', 'pertussis report infant', 'pertussis report adult', 'pertussis report 50', 'pertussis report year', 'pertussis notify pertussis-related', 'pertussis notify infant', 'pertussis notify adult', 'pertussis notify 50', 'pertussis notify year', 'adolescent notify pertussis-related', 'adolescent notify infant', 'adolescent notify adult', 'adolescent notify 50', 'adolescent notify year', 'adult notify pertussis-related', 'adult notify infant', 'adult notify 50', 'adult notify year']",3699,past decade reported incidence notified pertussis cases varied widely european countries likely associated differences surveillance systems diagnostic techniques reporting regulations 
1431,365.0,8.0,"['portugal circulate pertussis', 'portugal circulate infant', 'portugal circulate pertussis', 'portugal relate pertussis', 'infant relate pertussis']",3700,however several studies show pertussis circulating among adolescents adults europe although pertussis-related morbidity mortality highest infants evidence adults aged 50 years increased risk 
1432,365.0,9.0,"['pertussis boosters base immunisation', 'european base immunisation', 'adult base immunisation']",3701,example hospital-based surveillance study portugal 2000 2015 94 hospitalised pertussis cases infants aged 1 year case fatality rate cfr 08 however among hospitalised adult cases pertussis cfrs 115 aged 18ÃÂÂ64 years 174 aged 65 years 
1433,365.0,10.0,"['pertussis include adolescent', 'pertussis include adult', 'pertussis include european']",3702,european countries currently include pertussis boosters adults national immunisation strategy 
1434,365.0,12.0,"['c-x-c observe b cell', 'c-x-c observe cerebrospinal', 'c-x-c observe nervous', 'c-x-c observe cns', 'c-x-c observe meningeal', 'c-x-c observe brain', 'c-x-c observe patient', 'c-x-c observe cns', 'chemokine observe b cell', 'chemokine observe cerebrospinal', 'chemokine observe nervous', 'chemokine observe cns', 'chemokine observe meningeal', 'chemokine observe brain', 'chemokine observe patient', 'chemokine observe cns', 'ligand observe b cell', 'ligand observe cerebrospinal', 'ligand observe nervous', 'ligand observe cns', 'ligand observe meningeal', 'ligand observe brain', 'ligand observe patient', 'ligand observe cns', 'cxcl13 observe b cell', 'cxcl13 observe cerebrospinal', 'cxcl13 observe nervous', 'cxcl13 observe cns', 'cxcl13 observe meningeal', 'cxcl13 observe brain', 'cxcl13 observe patient', 'cxcl13 observe cns']",3704,supplementary information online version contains supplementary material available 101007s40121-021-00520-9 
1435,366.0,0.0,"['tfh boost cxcr5', 'tfh boost lymphoid', 'c-x-c boost cxcr5', 'c-x-c boost lymphoid', 'chemokine boost cxcr5', 'chemokine boost lymphoid']",3705,background c-x-c chemokine ligand 13 cxcl13 frequently elevated cerebrospinal fluid csf variety inflammatory central nervous system cns diseases detected meningeal b cell aggregates brain tissues multiple sclerosis patients proposedly recruits b cells inflamed cns 
1436,366.0,1.0,"['b cell induce autoimmune', 'b cell induce autoimmune']",3706,besides b cells also follicular helper tfh cells express cognate receptor c-x-c chemokine receptor type 5 cxcr5 follow cxcl13 gradients lymphoid tissues 
1437,366.0,6.0,"['patient retrieve neurological diseases', 'patient retrieve non-inflammatory', 'pyogenicaseptic retrieve neurological diseases', 'pyogenicaseptic retrieve non-inflammatory', 'meningoencephalitis retrieve neurological diseases', 'meningoencephalitis retrieve non-inflammatory']",3711,discharge diagnoses csf laboratory parameters retrieved records 
1438,366.0,8.0,"['cxcl13 use cohort', 'cxcl13 use patient', 'cxcr5cd4 use cohort', 'cxcr5cd4 use patient']",3713,anova models spearmanÃÂÂs rank-order correlation used group comparisons associations cxcl13 levels immune phenotyping data 
1439,366.0,9.0,"['csf-to-peripheral correlate cxcl13', 'csf-to-peripheral correlate cohort', 'csf-to-peripheral correlate p', 'csf-to-peripheral correlate p', 'csf-to-peripheral correlate 050', 'blood correlate cxcl13', 'blood correlate cohort', 'blood correlate p', 'blood correlate p', 'blood correlate 050', 'csfpb correlate cxcl13', 'csfpb correlate cohort', 'csfpb correlate p', 'csfpb correlate p', 'csfpb correlate 050', 'cxcr5cd4 correlate cxcl13', 'cxcr5cd4 correlate cohort', 'cxcr5cd4 correlate p', 'cxcr5cd4 correlate p', 'cxcr5cd4 correlate 050', 'cell correlate cxcl13', 'cell correlate cohort', 'cell correlate p', 'cell correlate p', 'cell correlate 050']",3714,results fact intrathecal cxcl13 elevations strongly correlated cxcr5cd4 cell frequencies total cohort p 00001 r 059 p 0003 r 054 nimm p 0043 r 044 patients 
1440,366.0,11.0,['cxcl13 differ cell'],3716, nimm nind groups differed regard csf cell counts albumin quotient intrathecal igg cxcl13 elevations cxcr5cd4 cells higher inflammatory subgroups 
1441,366.0,12.0,"['cxcr5cd4 show infection', 'cxcr5cd4 show inflammation', 'cxcr5cd4 show cns', 'cxcr5cd4 show autoimmunity', 'cxcr5cd4 induce inflammation', 'cxcr5cd4 induce cns', 'cxcr5cd4 induce autoimmunity']",3717,conclusion observed link intrathecal cxcl13 elevations cxcr5cd4 cell frequencies prove suggests recruitment possible professional b cell helpers inflamed csf 
1442,367.0,1.0,"['nine test asd id', 'covid-19 test asd id', 'infection test asd id', 'six test asd id', 'nine receive asd id', 'covid-19 receive asd id', 'infection receive asd id', 'six receive asd id']",3721,data fair health s fhÃÂ npic national private insurance claims database one nation s largest databases private insurance claim records analyzed understand experiences individuals asd covid-19 pandemic 
1443,367.0,4.0,"['pertussis toxin illustrate cough', 'pertussis toxin illustrate pertussis']",3724,first study illustrate higher likelihood hospitalization elevated length hospital stay covid-19 individuals asd comorbidities 
1444,368.0,2.0,['serum create antibody'],3727,human immune system creates good response pt measured quantity 
1445,368.0,6.0,"['line provide antibody', 'serum provide antibody']",3731,review summarize findings functional pt antibody bmem studies 
1446,369.0,1.0,"['nasopharyngeal investigate covid-19', 'nasopharyngeal investigate patient', 'nasopharyngeal investigate six']",3737,therefore investigated implications viral bacterial co-infection covid-19 clinical outcomes 
1447,369.0,2.0,"['co-infection induce covid-19', 'co-infection induce patient']",3738,methods nasopharyngeal samples obtained 48 covid-19 patients 29 icu 71 non-icu screened presence 24 respiratory pathogens using six multiplex pcr panels 
1448,369.0,3.0,"['influenza receive chlamydia', 'influenza receive pneumoniae', 'influenza receive adenovirus', 'h1n1 receive chlamydia', 'h1n1 receive pneumoniae', 'h1n1 receive adenovirus']",3739,results found evidence co-infection 34 covid-19 patients 71 
1449,369.0,5.0,"['two thirds associate patient', 'two thirds associate influenza', 'two thirds associate h1n1', 'covid-19 associate patient', 'covid-19 associate influenza', 'covid-19 associate h1n1', 'two thirds increase influenza', 'two thirds increase h1n1', 'covid-19 increase influenza', 'covid-19 increase h1n1', 'patient increase influenza', 'patient increase h1n1']",3741,viral co-infection associated increased icu admission r 01 higher mortality 178 ci 038-828 compared bacterial co-infections 044 ci 008-245 
1450,369.0,6.0,['covid-19 die death'],3742,two thirds covid-19 critically ill patients died co-infection influenza h1n1 pathogen direct relationship mortality seen r 02 
1451,369.0,7.0,"['influenza screen covid-19', 'co-infection screen influenza', 'co-infection screen covid-19']",3743,conclusions study highlights importance screening co-infecting viruses covid-19 patients could leading cause disease severity death 
1452,370.0,1.0,"['belgium test cv7202', 'belgium test 10', 'belgium test rabies', 'belgium test vaccine', 'belgium test rabipur', 'belgium test rabv-g-specific', 'belgium test igg', 'belgium test elisa', 'germany test cv7202', 'germany test 10', 'germany test rabies', 'germany test vaccine', 'germany test rabipur', 'germany test rabv-g-specific', 'germany test igg', 'germany test elisa', '18-40-year-olds test cv7202', '18-40-year-olds test 10', '18-40-year-olds test rabies', '18-40-year-olds test vaccine', '18-40-year-olds test rabipur', '18-40-year-olds test rabv-g-specific', '18-40-year-olds test igg', '18-40-year-olds test elisa']",3746,following successful preclinical studies mrna encapsulated lipid nanoparticles lnp tested mrna-lnp formulation cv7202 
1453,370.0,5.0,"['two dose recipient', 'two dose 8805', 'two dose iuml', 'two dose rabipur', 'two dose vaccinee']",3750,low dose-dependent vnt responses detectable day 15 day 29 31 22 1 2 5 ÃÂµg groups respectively vnts 8805 0ÃÂ5 iuml considered adequate response 
1454,370.0,7.0,"['two correlate cv7202', 'two correlate rabies', 'two correlate recipient', 'two correlate vaccine', 'two elicit cv7202', 'two elicit rabies', 'two elicit recipient', 'two elicit vaccine']",3752,cv7202-elicited vnt significantly correlated rabv-g-specific igg antibodies r2 08319 p 00001 
1455,371.0,1.0,"['siavs show swine', 'siavs show herd']",3756,monovalent inactivated h1n1pdm09 vaccine licensed brazil 2014 however concerns efficacy due limited vaccine cross-protection heterologous viruses potential exacerbated reactions vaccine strains 
1456,371.0,2.0,"['brazilian use influenza', 'brazilian use 117', '167 use influenza', '167 use 117']",3757,thus monitoring siavs subtypeslineages circulating brazilian swine population important applying fast efficient diagnostic test herd field samples 
1457,371.0,3.0,"['h1n1pdm develop h3n2', 'h1n1pdm develop h1hu', 'h1n1pdm develop serum', 'h1n1pdm use serum', 'h3n2 use serum']",3758,rt-pcr assay developed using primers specific ha subtyping brazilian siav used evaluate occurrence subtypes samples collected 2012 2019 167 field samples positive influenza 117 subtyped nested rt-pcr assay 
1458,371.0,4.0,"['h1hu observe vaccine', 'h1hu observe human']",3759,higher occurrence h1n1pdm observed 2012 2015 h3n2 2017 h1hu 2017 2019 hemagglutination inhibition test performed serum samples received 2017 2019 confirming data 
1459,372.0,0.0,"['canadian modify patient', 'american modify patient']",3764,background aims effectiveness safety vaccinations altered immunosuppressive therapies perhaps inflammatory bowel disease ibd 
1460,372.0,11.0,"['patient follow immunization', 'ibd follow immunization']",3775,recommendations address following vaccines haemophilus influenzae type b recombinant zoster hepatitis b influenza pneumococcus meningococcus tetanus-diphtheria-pertussis human papillomavirus 
1461,372.0,14.0,['patient make vaccine-preventable'],3778,consensus reached recommendations made 5 statements due largely lack evidence including double-dose hepatitis b vaccine timing influenza immunization patients biologics pneumococcal meningococcal vaccines adult patients without risk factors human papillomavirus vaccine patients aged 27ÃÂÂ45 years 
1462,372.0,16.0,"['ibd observe vaccine', 'ibd observe vaccine']",3780,therefore maintaining appropriate vaccination status patients critical optimize patient outcomes 
1463,373.0,1.0,"['pre-exposed aim covid-19', 'pre-exposed aim delta', 'pre-exposed aim epsilon', 'pre-exposed possess covid-19', 'pre-exposed possess delta', 'pre-exposed possess epsilon']",3783,delta variant seems possess enhanced transmissibility clear evidence suggests increased virulence 
1464,373.0,4.0,"['one vaccinate antibody', 'one vaccinate delta', 'one show antibody', 'one show delta', 'vaccine show antibody', 'vaccine show delta']",3786,healthy vaccinated individuals showed limited breadth neutralization 
1465,373.0,6.0,['vaccine expand antibody'],3788,however even two doses capacity expanded epsilon variant 
1466,374.0,0.0,"['mucosal observe gastrointestinal', 'mucosal observe oral', 'mucosal observe one', 'mucosal observe three', 'mucosal observe vaccine', 'mucosal observe immunogen', 'mucosal observe cellular', 'mucosal induce three', 'mucosal induce vaccine', 'mucosal induce immunogen', 'mucosal induce cellular', 'gastrointestinal induce three', 'gastrointestinal induce vaccine', 'gastrointestinal induce immunogen', 'gastrointestinal induce cellular', 'gastrointestinal induce mucosal', 'oral induce three', 'oral induce vaccine', 'oral induce immunogen', 'oral induce cellular', 'oral induce mucosal', 'mucosal neutralize vaccine', 'mucosal neutralize immunogen', 'mucosal neutralize cellular', 'gastrointestinal neutralize vaccine', 'gastrointestinal neutralize immunogen', 'gastrointestinal neutralize cellular', 'gastrointestinal neutralize mucosal', 'oral neutralize vaccine', 'oral neutralize immunogen', 'oral neutralize cellular', 'oral neutralize mucosal', 'one neutralize vaccine', 'one neutralize immunogen', 'one neutralize cellular', 'one neutralize mucosal', 'three neutralize vaccine', 'three neutralize immunogen', 'three neutralize cellular', 'three neutralize mucosal']",3789,attempts develop protective hiv vaccine limited success especially terms inducing protective antibodies capable neutralizing different viral strains 
1467,374.0,1.0,"['twenty-four receive provirus', 'twenty-four receive booster', 'twenty-four receive heat-labile', 'twenty-four receive dmlt', 'twenty-four receive poliovirus', 'cynomolgus receive provirus', 'cynomolgus receive booster', 'cynomolgus receive heat-labile', 'cynomolgus receive dmlt', 'cynomolgus receive poliovirus', 'macaque receive provirus', 'macaque receive booster', 'macaque receive heat-labile', 'macaque receive dmlt', 'macaque receive poliovirus', 'twenty-four replicate booster', 'twenty-four replicate heat-labile', 'twenty-four replicate dmlt', 'twenty-four replicate poliovirus', 'cynomolgus replicate booster', 'cynomolgus replicate heat-labile', 'cynomolgus replicate dmlt', 'cynomolgus replicate poliovirus', 'macaque replicate booster', 'macaque replicate heat-labile', 'macaque replicate dmlt', 'macaque replicate poliovirus', 'provirus replicate booster', 'provirus replicate heat-labile', 'provirus replicate dmlt', 'provirus replicate poliovirus', 'twenty-four use poliovirus', 'cynomolgus use poliovirus', 'macaque use poliovirus', 'provirus use poliovirus', 'booster use poliovirus', 'heat-labile use poliovirus', 'twenty-four explore poliovirus', 'cynomolgus explore poliovirus', 'macaque explore poliovirus', 'provirus explore poliovirus', 'booster explore poliovirus', 'heat-labile explore poliovirus', 'dmlt explore poliovirus']",3790,hiv transmission occurs mainly via mucosal surfaces hiv replicates significantly gastrointestinal tract oral route vaccination convenient one implement worldwide explored three siv vaccine modalities administered orally composed siv dna priming different boosting immunogens goal evaluating whether could provide lasting humoral cellular responses including mucosal surfaces sites hiv entry 
1468,374.0,3.0,['mucosal t-cell use gag'],3792,cell-mediated responses measured using blood lymph node rectal vaginal mononuclear cells 
1469,374.0,8.0,"['enzyme-linked elicit pertussis', 'enzyme-linked elicit vaccine', 'immunosorbent elicit pertussis', 'immunosorbent elicit vaccine', 'elisa elicit pertussis', 'elisa elicit vaccine', 'pertussis elicit vaccine', 'enzyme-linked test pertussis', 'enzyme-linked test pertussis', 'enzyme-linked test vaccine', 'immunosorbent test pertussis', 'immunosorbent test pertussis', 'immunosorbent test vaccine', 'elisa test pertussis', 'elisa test pertussis', 'elisa test vaccine', 'enzyme-linked mediate pertussis', 'enzyme-linked mediate vaccine', 'immunosorbent mediate pertussis', 'immunosorbent mediate vaccine', 'elisa mediate pertussis', 'elisa mediate vaccine', 'pertussis mediate vaccine']",3797,conclude oral cavity vaccination tested regimens stimulate cell-mediated immunity systemically mucosally humoral response stimulation limited doses vaccine platforms used 
1470,375.0,0.0,"['ecl associate two', 'ecl associate bordetella', 'ecl associate pertussis', 'ecl associate elisa', 'ecl associate elisa', 'ecl design elisa', 'two design elisa', 'bordetella design elisa', 'pertussis design elisa']",3798,introduction commercially available enzyme-linked immunosorbent assay elisa kits designed pertussis diagnostic purposes frequently used assess antibody responses pertussis vaccines clinical trials limited accuracy calibrated international standards 
1471,375.0,1.0,"['ecl compare prn fimbrial', 'ecl compare pertussis', 'ecl compare hemagglutinin', 'serum compare prn fimbrial', 'serum compare pertussis', 'serum compare hemagglutinin', 'antibody compare prn fimbrial', 'antibody compare pertussis', 'antibody compare hemagglutinin', 'four compare prn fimbrial', 'four compare pertussis', 'four compare hemagglutinin', 'b compare prn fimbrial', 'b compare pertussis', 'b compare hemagglutinin', 'pertussis compare prn fimbrial', 'pertussis compare hemagglutinin']",3799,developed new electrochemiluminescence ecl -based multiplexed assay compared performance two commercial bordetella pertussis elisa kits historical in-house elisas 
1472,375.0,4.0,"['serum use elisa', 'four use elisa', 'nct02587520 use elisa', 'nct00255047 use elisa', 'nct00347958 use elisa', 'nct01346293 use elisa', 'serum compare elisa', 'four compare elisa', 'nct02587520 compare elisa', 'nct00255047 compare elisa', 'nct00347958 compare elisa', 'nct01346293 compare elisa']",3802,sera clinical trial ctri201611007434 used compare ecl assay two commercial elisa kits available genway biotech demeditec diagnostics accuracy linearity specificity concordance internal wwo-2-043 international nibsc 06140 references 
1473,375.0,10.0,"['ecl recognize two', 'ecl recognize elisa', 'anti-fim recognize two', 'anti-fim recognize elisa', 'antibody recognize two', 'antibody recognize elisa']",3808,concordance ecl commercial kits low ecl assay better distinguished pre- post-vaccination clinical samples 
1474,376.0,1.0,"['aindonesia52005 ind05 receive vie04 virus', 'aindonesia52005 ind05 receive vie04 virus', 'aindonesia52005 ind05 receive kong1561997', 'aindonesia52005 ind05 receive ind05', 'aindonesia52005 ind05 receive year', 'aindonesia52005 ind05 receive ind05', 'aindonesia52005 ind05 receive h5-naive', 'aindonesia52005 ind05 receive two', 'aindonesia52005 ind05 receive ind05', 'aindonesia52005 ind05 receive vaccine', 'igg receive vie04 virus', 'igg receive vie04 virus', 'igg receive kong1561997', 'igg receive ind05', 'igg receive year', 'igg receive ind05', 'igg receive h5-naive', 'igg receive two', 'igg receive ind05', 'igg receive vaccine', 'h5 receive vie04 virus', 'h5 receive vie04 virus', 'h5 receive kong1561997', 'h5 receive ind05', 'h5 receive year', 'h5 receive ind05', 'h5 receive h5-naive', 'h5 receive two', 'h5 receive ind05', 'h5 receive vaccine', 'influenza receive vie04 virus', 'influenza receive vie04 virus', 'influenza receive kong1561997', 'influenza receive ind05', 'influenza receive year', 'influenza receive ind05', 'influenza receive h5-naive', 'influenza receive two', 'influenza receive ind05', 'influenza receive vaccine', 'three receive vie04 virus', 'three receive vie04 virus', 'three receive kong1561997', 'three receive ind05', 'three receive year', 'three receive ind05', 'three receive h5-naive', 'three receive two', 'three receive ind05', 'three receive vaccine', 'cohort receive vie04 virus', 'cohort receive vie04 virus', 'cohort receive kong1561997', 'cohort receive ind05', 'cohort receive year', 'cohort receive ind05', 'cohort receive h5-naive', 'cohort receive two', 'cohort receive ind05', 'cohort receive vaccine', 'two receive vie04 virus', 'two receive vie04 virus', 'two receive kong1561997', 'two receive ind05', 'two receive year', 'two receive ind05', 'two receive h5-naive', 'two receive ind05', 'two receive vaccine', 'h5 receive vie04 virus', 'h5 receive vie04 virus', 'h5 receive kong1561997', 'h5 receive ind05', 'h5 receive year', 'h5 receive ind05', 'h5 receive h5-naive', 'h5 receive two', 'h5 receive ind05', 'h5 receive vaccine']",3811,however effect individualÃÂÂs h5 exposure history antibody responses subsequent h5 vaccination poorly understood 
1475,376.0,2.0,"['ha -reactive test h5', 'ha -reactive test h1', 'ha -reactive test h3', 'ha -reactive test h7', 'ha -reactive test h9', 'igg test h5', 'igg test h1', 'igg test h3', 'igg test h7', 'igg test h9']",3812,investigate analyzed igg responses h5 influenza aindonesia52005 ind05 virus vaccination three cohorts doubly primed group received two h5 virus vaccinations namely influenza avietnam2032004 vie04 virus 5 years prior ahong kong1561997 hk97 11 years prior ind05 vaccination ii singly primed group received vaccination vie04 virus 5 years prior ind05 vaccination iii h5-naive group received two doses ind05 vaccine 28 days apart 
1476,376.0,4.0,"['short-interval generate vaccine', 'short-interval generate anti-h5', 'short-interval test anti-h5', 'ind05 test anti-h5', 'vaccine test anti-h5']",3814,relative ha antibody landscapes generated quantitatively analyze magnitude breadth antibody binding vaccination 
1477,376.0,6.0,"['igg generate h5', 'igg generate influenza', 'igg generate virus']",3816,primed groups generated robust antibody responses reactive broad range h5 strains receiving booster injection ind05 vaccine igg antibody levels persisted longer subjects doubly primed years ago 
1478,377.0,0.0,['rat describe vaccine'],3819,methods prepare anti-pcsk9 vaccine peptide construct called immunogenic fused pcsk9-tetanus ifpt linked surface nanoliposome carriers 
1479,377.0,1.0,"['two receive pcsk9', 'two receive lipoprotein', 'two receive ldlr']",3820,healthy rats received four subcutaneous injections vaccine biweekly intervals 
1480,377.0,2.0,"['rat aim mellitus', 'streptozotocin aim mellitus']",3821,two weeks last vaccination anti-pcsk9 antibody titers pcsk9 targeting inhibition pcsk9ÃÂÂlow-density lipoprotein receptor ldlr interaction evaluated 
1481,377.0,3.0,"['blood treat insulin', 'glucose treat insulin', 'fbg treat insulin', 'oral treat insulin', 'glucose treat insulin', 'blood vaccinate insulin', 'glucose vaccinate insulin', 'fbg vaccinate insulin', 'oral vaccinate insulin']",3822,verification antibody generation immunized rats intraperitoneally treated single dose 45 mgkg streptozotocin stz induce diabetes mellitus 
1482,377.0,4.0,"['ldl-c evaluate cholesterol', 'triglyceride evaluate cholesterol']",3823,levels fasting blood glucose fbg measured oral glucose tolerance test ogtt well insulin tolerance test itt carried assess glycemic status 
1483,377.0,6.0,"['vaccine use rat', 'anti-pcsk9 use rat']",3825,histopathology examination liver pancreas also performed using hematoxylin-eosin staining method 
1484,377.0,7.0,['injection induce diabetic'],3826,results prepared nanoliposomal vaccine could strongly induce anti-pcsk9 antibodies vaccinated rats 
1485,377.0,8.0,"['rat follow glucose', 'rat follow blood', 'rat follow glucose', 'rat follow 180', 'rat follow diabetic']",3827,within one week following stz injection fbg level lower vaccinated group vs diabetic control group 49 ÃÂÂ1717 ÃÂ 35 mgdl p 0001 
1486,377.0,9.0,"['insulin inject glucose', 'insulin inject 493', 'insulin inject diabetic', 'injection inject glucose', 'injection inject 493', 'injection inject diabetic', 'insulin show 493', 'insulin show diabetic', 'injection show 493', 'injection show diabetic', 'blood show 493', 'blood show diabetic', 'glucose show 493', 'glucose show diabetic', 'insulin reflect diabetic', 'injection reflect diabetic', 'blood reflect diabetic', 'glucose reflect diabetic', '493 reflect diabetic']",3828,ogtt injected rats showed improved glucose tolerance reflected reduction blood glucose levels 180 min compared diabetic controls 
1487,377.0,10.0,"['rat show plasma', 'rat show ldl-c', 'rat show diabetic']",3829,moreover itt demonstrated insulin injection blood glucose concentration declined 493 vaccinated group vs diabetic control group 
1488,377.0,11.0,"['pancreas show rat', 'tissue show rat']",3830,expectedly vaccinated rats exhibited lower -2665 p 003 plasma ldl-c levels compared diabetic controls 
1489,377.0,12.0,['liver show rat'],3831,histopathology examination pancreas tissue demonstrated pancreatic islets vaccinated rats slight decline population ÃÂ²-cells ÃÂ-cells 
1490,377.0,13.0,"['pcsk9 observe vaccine', 'pcsk9 observe glucose', 'pcsk9 observe insulin', 'pcsk9 observe lipid', 'pcsk9 observe diabetes', 'liposomal observe vaccine', 'liposomal observe glucose', 'liposomal observe insulin', 'liposomal observe lipid', 'liposomal observe diabetes']",3832,normal liver histology also observed vaccinated rats 
1491,377.0,14.0,"['typhoid fever improve africa', 'salmonella typhi improve africa', 'multidrug-resistant improve africa', 'h58 improve africa']",3833,conclusion pcsk9 inhibition liposomal ifpt vaccine improve glucose insulin tolerance impairments well lipid profile diabetes 
1492,378.0,4.0,"['typhoid fever treat 469', 'typhoid fever treat person-years', 'typhoid fever treat child', 'typhoid fever treat 243', 'blood treat 469', 'blood treat person-years', 'blood treat child', 'blood treat 243', 'child treat 469', 'child treat person-years', 'child treat 243', 'typhoid fever include child', 'typhoid fever include 243', 'blood include child', 'blood include 243', 'child include 243', 'vi-tcv include child', 'vi-tcv include 243', '469 include child', '469 include 243', 'typhoid fever establish 243', 'blood establish 243', 'child establish 243', 'vi-tcv establish 243', '469 establish 243', 'person-years establish 243', 'child establish 243']",3838,results intention-to-treat itt analysis included 28130 children comprising 14069 children received vi-tcv 14061 children received mena 
1493,378.0,5.0,"['807 confirm ci', '807 confirm 896', '807 confirm itt', '807 confirm 837', '807 confirm per-protocol', '807 receive 896', '807 receive itt', '807 receive 837', '807 receive per-protocol', 'ci receive 896', 'ci receive itt', 'ci receive 837', 'ci receive per-protocol']",3839,blood culture-confirmed typhoid fever occurred 12 children vi-tcv group 469 per 100000 person-years 62 children mena group 243 per 100000 person-years 
1494,378.0,8.0,"['blood consider typhoid fever', 'blood consider malawian', 'blood consider child']",3842,serious adverse event considered investigator related study vaccination 
1495,378.0,10.0,['influenza fund senior'],3844, funded bill melinda gates foundation clinicaltrialsgov number nct03299426 
1496,379.0,1.0,"['high-dose dose vaccine', 'high-dose dose senior']",3846,uncertain whether standard-dose sd quadrivalent vaccine offers better protection formulations elderly 
1497,379.0,3.0,"['two select influenza', 'two select pneumonia']",3848,selected 200000 individuals 6 influenza seasons 2012 2018 using marketscanÃÂ databases 
1498,379.0,5.0,"['hd-trivalent relate ahr', 'hd-trivalent relate hospitalizeder', 'hd-trivalent relate pneumonia', '116 relate ahr', '116 relate hospitalizeder', '116 relate pneumonia', 'hospitalizeder relate ahr', 'hospitalizeder relate pneumonia', 'hd-trivalent adjust pneumonia', '116 adjust pneumonia', 'hospitalizeder adjust pneumonia', 'influenza adjust pneumonia', 'ahr adjust pneumonia']",3850, sd-quadrivalent associated higher risk influenza-related hospitalizationer visit adjusted hazard ratio ahr 114 95 confidence interval 95 ci 105ÃÂÂ124 pneumonia-related hospitalizationer visit ahr 104 95 ci 101ÃÂÂ107 vs hd-trivalent 
1499,379.0,6.0,"['vaccine compare one', 'vaccine compare three']",3851,sd-trivalent followed similar trends compared hd-trivalent ahr 116 95 ci 106ÃÂÂ127 hospitalizeder visit influenza ahr 107 95 ci 105ÃÂÂ110 hospitalizeder visit pneumonia 
1500,380.0,1.0,"['sars-cov-2 aim spain', 'sars-cov-2 aim cohort', 'sars-cov-2 aim worker', 'sars-cov-2 aim andor', 'sars-cov-2 aim infection', 'sars-cov-2 evaluate cohort', 'sars-cov-2 evaluate worker', 'sars-cov-2 evaluate andor', 'sars-cov-2 evaluate infection']",3856,study aims evaluate influenza vaccination 2019-2020 season effect risk sars-cov-2 confirmed infection cohort health workers 
1501,380.0,3.0,"['890 test influenza', 'worker test influenza', 'sars-cov-2 test influenza']",3858,later june 8665 tested total antibodies serum 
1502,380.0,4.0,"['influenza confirm cohort', 'sars-cov-2 confirm cohort', 'infection confirm cohort', '107 confirm cohort']",3859,total 890 79 health workers laboratory-confirmed sars-cov-2 infection type test case influenza detected 
1503,380.0,6.0,['influenza test sars-cov-2'],3861,among symptomatic patients tested rt-qpcr comparison positive cases negative controls showed adjusted odds ratio 086 95 ci 068-108 
1504,381.0,0.0,"['elisa cover serum', 'elisa cover igm', 'elisa cover igg', 'elisa cover antibody', 'elisa cover sars-cov-2', 'elisa cover covid-19', 'elisa cover patient', 'elisa cover antibody', 'sars-cov-2 cover serum', 'sars-cov-2 cover igm', 'sars-cov-2 cover igg', 'sars-cov-2 cover antibody', 'sars-cov-2 cover covid-19', 'sars-cov-2 cover patient', 'sars-cov-2 cover antibody']",3864,objective sars-cov-2 sweeping world since end 2019 titer change antibodies sars-cov-2 needs clarified clinical preventive value antibodies still needs investigated 
1505,381.0,1.0,"['elisa establish 100', 'elisa coat 100', 'sars-cov-2 coat 100']",3865,method elisa established coating sars-cov-2 recombinant spike protein used detect serum igm igg antibodies sars-cov-2 covid-19 patients evaluate pattern changes antibodies 
1506,381.0,9.0,"['plasmodium include antigen', 'plasmodium include human', 'plasmodium include liver', 'plasmodium include pre-erythrocytic', 'plasmodium include vaccine', 'plasmodium include erythrocytic']",3873,rights reserved 
1507,382.0,0.0,['falciparum establish iga'],3874,knowledge plasmodium falciparum antigens comprise human liver stage immunoproteome important pre-erythrocytic vaccine development compared erythrocytic stage immunoproteome challenging classify 
1508,382.0,2.0,"['igg evaluate two', 'igg evaluate chmi', 'igg evaluate malian', 'igg evaluate child']",3876,assessed igg iga antibody responses adult sera collected two controlled human malaria infection chmi studies malaria-naÃÂve volunteers 1- 6-year-old malaria-exposed malian children 251 p falciparum antigen protein microarray 
1509,382.0,5.0,"['iga describe pre-erythrocytic', 'iga describe antigen', 'iga describe vaccine', 'iga receive vaccine', 'pre-erythrocytic receive vaccine']",3879,describe immunoproteome differences naÃÂve vs exposed individuals report pre-erythrocytic proteins recognized immune system 
1510,383.0,2.0,"['nasopharyngeal-oropharyngeal describe autolysin', 'blood describe autolysin', 'nasopharyngeal-oropharyngeal hospitalize blood', 'nasopharyngeal-oropharyngeal hospitalize autolysin']",3883,methods cases 1ÃÂÂ59 months age hospitalized world health organization clinically defined severevery severe pneumonia frequency-matched age season community controls 
1511,383.0,5.0,"['805 derive child', 'pneumonia derive child', '165 derive child']",3886,population etiologic fractions ef pneumonia radiologic evidence consolidationinfiltrate derived pathogen bayesian analysis 
1512,383.0,6.0,"['hiv-exposed base cri', 'hiv-exposed base 248', 'hiv-exposed base 364', 'hiv-exposed base 305', 'child base cri', 'child base 248', 'child base 364', 'child base 305', 'efs base cri', 'efs base 248', 'efs base 364', 'efs base 305', 'hiv-exposed confirm 364', 'hiv-exposed confirm 305', 'child confirm 364', 'child confirm 305', 'efs confirm 364', 'efs confirm 305', 'cri confirm 364', 'cri confirm 305', '248 confirm 364', '248 confirm 305']",3887,results 805 hiv-uninfected cases enrolled based clinical criteria radiologically confirmed pneumonia evident 165 hiv-exposed -uninfected 246 hiv-unexposed children 
1513,383.0,7.0,"['tuberculosis receive cri', 'tuberculosis receive child', 'tuberculosis receive hiv-exposed', 'tuberculosis receive child']",3888,hiv-exposed hiv-unexposed children respiratory syncytial virus important pathogen efs 316 95 credible interval cri 248 ÃÂÂ388 364 95 cri 305 ÃÂÂ431 respectively 
1514,383.0,8.0,"['bacteremia provide hiv-exposed', 'bacteremia provide child']",3889,m tuberculosis contributed efs 116 95 cri 61 ÃÂÂ188 hiv-exposed 83 95 cri 45 ÃÂÂ138 hiv-unexposed children including ef 163 95 cri 61 ÃÂÂ333 hiv-exposed children ÃÂÂ12 months age 
1515,383.0,10.0,"['tuberculosis prioritize community-acquired', 'tuberculosis prioritize pneumonia']",3891,conclusions vaccination strategies targeting respiratory syncytial virus prioritized prevention pneumonia children 
1516,383.0,11.0,"['pneumonia need perch', 'pneumonia need bamako', 'pneumonia need mali']",3892,furthermore interventions required address high burden tuberculosis pathogenesis acute community-acquired pneumonia settings 
1517,384.0,2.0,"['nasopharyngeal match streptococcus', 'nasopharyngeal match pneumoniae', 'oropharyngeal match streptococcus', 'oropharyngeal match pneumoniae', 'swab match streptococcus', 'swab match pneumoniae']",3895,community controls frequency matched age 
1518,384.0,4.0,"['pleural fluid induce polymerase', 'lung aspirates induce polymerase']",3897,cases underwent blood culture induced sputum culture mycobacterium tuberculosis 
1519,384.0,5.0,['participant collect chest'],3898,subset pleural fluid lung aspirates collected culture polymerase chain reaction 
1520,384.0,10.0,"['240 devastate cri 95Ã\x83\x83Ã\x83\x82Ã\x83\x82216', '240 devastate metapneumovirus', '240 devastate cri', '240 devastate parainfluenza', '240 devastate cri', '183 devastate cri 95Ã\x83\x83Ã\x83\x82Ã\x83\x82216', '183 devastate metapneumovirus', '183 devastate cri', '183 devastate parainfluenza', '183 devastate cri', 'pneumoniae devastate cri 95Ã\x83\x83Ã\x83\x82Ã\x83\x82216', 'pneumoniae devastate metapneumovirus', 'pneumoniae devastate cri', 'pneumoniae devastate parainfluenza', 'pneumoniae devastate cri', '152 devastate cri 95Ã\x83\x83Ã\x83\x82Ã\x83\x82216', '152 devastate metapneumovirus', '152 devastate cri', '152 devastate parainfluenza', '152 devastate cri', 'cri 95Ã\x83\x83Ã\x83\x82Ã\x83\x82216 stunt cri', '240 stunt cri', '183 stunt cri', 'pneumoniae stunt cri', '152 stunt cri', 'metapneumovirus stunt cri', 'parainfluenza stunt cri']",3903,compared controls cases likely moderate-to-severe wasting 431 vs 141 p 0001 stunting 266 vs 94 p 0001 
1521,384.0,12.0,"['perch dominate virus', 'perch dominate vaccine', 'perch dominate vaccine', 'child dominate virus', 'child dominate vaccine', 'child dominate vaccine', 'pneumonia dominate virus', 'pneumonia dominate vaccine', 'pneumonia dominate vaccine', 'mali dominate virus', 'mali dominate vaccine', 'mali dominate vaccine']",3905,case fatality 133 staphylococcus aureus pneumocystis jirovecii haemophilus influenzae type b predominating 40 fatal cases 
1522,384.0,13.0,"['pneumonia receive death', 'pneumonia receive child']",3906,conclusions perch uncovered high case fatality among children severe pneumonia mali highlighting role new interventions eg respiratory syncytial virus vaccines need improve vaccine coverage strengthen healthcare delivery 
1523,385.0,1.0,"['gambia modify conjugate vaccines-vaccinated', 'gambia modify pneumonia', 'gambia modify haemophilus', 'gambia modify influenzae', 'gambia modify west', 'gambia modify african', 'gambia modify pneumonia', 'gambia modify perch', 'gambia need conjugate vaccines-vaccinated', 'gambia need pneumonia', 'gambia need haemophilus', 'gambia need influenzae', 'gambia need west', 'gambia need african', 'gambia need pneumonia', 'gambia need perch', 'gambia aim conjugate vaccines-vaccinated', 'gambia aim influenzae', 'gambia aim west', 'gambia aim african', 'gambia aim pneumonia', 'gambia aim perch', 'pneumonia aim conjugate vaccines-vaccinated', 'pneumonia aim influenzae', 'pneumonia aim west', 'pneumonia aim african', 'pneumonia aim perch']",3908,changing epidemiology pneumonia requires up-to-date data guide case management prevention programs 
1524,385.0,2.0,"['perch provide pneumonia', 'perch provide child']",3909,gambia study site contributed high child mortality high pneumonia incidence low hiv prevalence haemophilus influenzae type b pneumococcal conjugate vaccines-vaccinated rural west african setting pneumonia etiology research child health perch study 
1525,385.0,5.0,"['gambia observe pneumonia', 'gambia observe 286', 'gambia observe chest', 'gambia observe 654', 'gambia use chest', 'gambia use 654', '638 use chest', '638 use 654', 'pneumonia use chest', 'pneumonia use 654', 'gambia observe 654', '638 observe 654', 'pneumonia observe 654', '286 observe 654', 'chest observe 654', 'gambia base 654', '638 base 654', 'pneumonia base 654', '286 base 654', 'chest base 654']",3912,etiology determined integrating case control data multiple specimens using perch integrated analysis based bayesian probabilistic methods 
1526,385.0,6.0,"['rsv describe 37', 'rsv describe streptococcus', 'rsv describe pneumoniae', 'rsv describe parainfluenza']",3913,results gambia study site 638 cases world health organization-defined severe severe pneumonia 286 chest radiograph cxr -positive hiv-negative 654 age-frequency matched controls enrolled 
1527,385.0,12.0,"['people induce vaccine', 'sars-cov-2 induce vaccine']",3919,continued emphasis appropriate case management severe pneumonia remains important 
1528,386.0,1.0,"['vaccine continue adult', 'vaccine continue sars-cov-2', 'viral continue adult', 'viral continue sars-cov-2', 'virus continue adult', 'virus continue sars-cov-2', 'vaccine emerge sars-cov-2', 'viral emerge sars-cov-2', 'virus emerge sars-cov-2', 'cohort emerge sars-cov-2', 'adult emerge sars-cov-2']",3921,questions become even urgent new variants concern enhanced transmissibility delta continue emerge 
1529,387.0,5.0,['five review 6537'],3931,reviewed literature aberrancies b-cell composition function influence immune responses vaccinations 
1530,387.0,13.0,"['intestine provide colostrum-derived', 'intestine provide immunoglobulin', 'intestine provide macromolecule', 'piglet provide colostrum-derived', 'piglet provide immunoglobulin', 'piglet provide macromolecule', 'intestine optimize colostrum-derived', 'intestine optimize immunoglobulin', 'intestine optimize macromolecule', 'piglet optimize colostrum-derived', 'piglet optimize immunoglobulin', 'piglet optimize macromolecule']",3939,hope overview contribute optimizing vaccination strategies especially immunocompromised patients 
1531,388.0,0.0,['precise develop pig'],3940,small intestine piglet evolved permeable immediately birth facilitate uptake colostrum-derived immunoglobulins well macromolecules cells 
1532,388.0,2.0,"['cy5-ova aim endosomal', 'cy5-ova aim rab7', 'endosome aim endosomal', 'endosome aim rab7']",3942,gavaged piglets immediately birth 1-h birth cy5-labeled ovalbumin cy5-ova harvested small intestineÃÂÂs 6ÃÂÂ7 h later 
1533,388.0,3.0,"['cy5-ova evaluate rab7', 'cy5-ova evaluate duodenum', 'cy5-ova evaluate jejunum', 'cy5-ova evaluate piglet', 'cy5-ova evaluate ileum', 'cy5-ova evaluate piglet']",3943,assess localization cy5-ova small intestinal epithelial cells performed immunohistochemistry using basolateral surface marker recycling endosome marker called pigr late endosomal marker rab7 lysosomal marker lamp-1 
1534,388.0,5.0,"['cy5-ova induce epithelial', 'cy5-ova induce cell', 'cy5-ova induce digestive', 'cy5-ova induce 0-h', 'cy5-ova induce piglet']",3945,data suggest movement cy5-ova late endosomes lysosomes much reduced ileum 1-h gavaged piglets 
1535,388.0,8.0,"['adult provide enzyme ii', 'adult provide acute respiratory', 'adult provide pulmonary capillary', 'adult provide angiotensin 2', 'adult provide lung injury', 'adult provide age-based', 'adult provide child', 'adult provide high-risk', 'adult provide human', 'adult provide receptor', 'adult provide coronavirus', 'adult provide inflammation', 'adult provide acute', 'adult provide decrease', 'adult provide infection', 'adult provide child', 'adult provide immunity', 'adult provide infection', 'adult provide child', 'adult provide covid-19', 'adult provide alveolar', 'child provide enzyme ii', 'child provide acute respiratory', 'child provide pulmonary capillary', 'child provide angiotensin 2', 'child provide lung injury', 'child provide age-based', 'child provide high-risk', 'child provide human', 'child provide receptor', 'child provide coronavirus', 'child provide inflammation', 'child provide acute', 'child provide decrease', 'child provide infection', 'child provide immunity', 'child provide infection', 'child provide covid-19', 'child provide alveolar', 'coronavirus provide enzyme ii', 'coronavirus provide acute respiratory', 'coronavirus provide pulmonary capillary', 'coronavirus provide angiotensin 2', 'coronavirus provide lung injury', 'coronavirus provide age-based', 'coronavirus provide child', 'coronavirus provide high-risk', 'coronavirus provide human', 'coronavirus provide receptor', 'coronavirus provide inflammation', 'coronavirus provide acute', 'coronavirus provide decrease', 'coronavirus provide infection', 'coronavirus provide child', 'coronavirus provide immunity', 'coronavirus provide infection', 'coronavirus provide child', 'coronavirus provide covid-19', 'coronavirus provide alveolar', 'adult capitalize enzyme ii', 'adult capitalize acute respiratory', 'adult capitalize pulmonary capillary', 'adult capitalize angiotensin 2', 'adult capitalize lung injury', 'adult capitalize high-risk', 'adult capitalize human', 'adult capitalize receptor', 'adult capitalize coronavirus', 'adult capitalize inflammation', 'adult capitalize acute', 'adult capitalize decrease', 'adult capitalize infection', 'adult capitalize child', 'adult capitalize immunity', 'adult capitalize infection', 'adult capitalize child', 'adult capitalize covid-19', 'adult capitalize alveolar', 'child capitalize enzyme ii', 'child capitalize acute respiratory', 'child capitalize pulmonary capillary', 'child capitalize angiotensin 2', 'child capitalize lung injury', 'child capitalize high-risk', 'child capitalize human', 'child capitalize receptor', 'child capitalize coronavirus', 'child capitalize inflammation', 'child capitalize acute', 'child capitalize decrease', 'child capitalize infection', 'child capitalize immunity', 'child capitalize infection', 'child capitalize covid-19', 'child capitalize alveolar', 'coronavirus capitalize enzyme ii', 'coronavirus capitalize acute respiratory', 'coronavirus capitalize pulmonary capillary', 'coronavirus capitalize angiotensin 2', 'coronavirus capitalize lung injury', 'coronavirus capitalize high-risk', 'coronavirus capitalize human', 'coronavirus capitalize receptor', 'coronavirus capitalize inflammation', 'coronavirus capitalize acute', 'coronavirus capitalize decrease', 'coronavirus capitalize infection', 'coronavirus capitalize child', 'coronavirus capitalize immunity', 'coronavirus capitalize infection', 'coronavirus capitalize child', 'coronavirus capitalize covid-19', 'coronavirus capitalize alveolar', 'covid-19 capitalize enzyme ii', 'covid-19 capitalize acute respiratory', 'covid-19 capitalize pulmonary capillary', 'covid-19 capitalize angiotensin 2', 'covid-19 capitalize lung injury', 'covid-19 capitalize high-risk', 'covid-19 capitalize human', 'covid-19 capitalize receptor', 'covid-19 capitalize coronavirus', 'covid-19 capitalize inflammation', 'covid-19 capitalize acute', 'covid-19 capitalize decrease', 'covid-19 capitalize infection', 'covid-19 capitalize child', 'covid-19 capitalize immunity', 'covid-19 capitalize infection', 'covid-19 capitalize child', 'covid-19 capitalize alveolar', 'age-based capitalize enzyme ii', 'age-based capitalize acute respiratory', 'age-based capitalize pulmonary capillary', 'age-based capitalize angiotensin 2', 'age-based capitalize lung injury', 'age-based capitalize high-risk', 'age-based capitalize human', 'age-based capitalize receptor', 'age-based capitalize coronavirus', 'age-based capitalize inflammation', 'age-based capitalize acute', 'age-based capitalize decrease', 'age-based capitalize infection', 'age-based capitalize child', 'age-based capitalize immunity', 'age-based capitalize infection', 'age-based capitalize child', 'age-based capitalize covid-19', 'age-based capitalize alveolar', 'adult establish enzyme ii', 'adult establish acute respiratory', 'adult establish pulmonary capillary', 'adult establish angiotensin 2', 'adult establish lung injury', 'adult establish child', 'adult establish high-risk', 'adult establish human', 'adult establish receptor', 'adult establish coronavirus', 'adult establish inflammation', 'adult establish acute', 'adult establish decrease', 'adult establish infection', 'adult establish child', 'adult establish immunity', 'adult establish infection', 'adult establish child', 'adult establish covid-19', 'adult establish alveolar', 'child establish enzyme ii', 'child establish acute respiratory', 'child establish pulmonary capillary', 'child establish angiotensin 2', 'child establish lung injury', 'child establish high-risk', 'child establish human', 'child establish receptor', 'child establish coronavirus', 'child establish inflammation', 'child establish acute', 'child establish decrease', 'child establish infection', 'child establish immunity', 'child establish infection', 'child establish covid-19', 'child establish alveolar', 'coronavirus establish enzyme ii', 'coronavirus establish acute respiratory', 'coronavirus establish pulmonary capillary', 'coronavirus establish angiotensin 2', 'coronavirus establish lung injury', 'coronavirus establish child', 'coronavirus establish high-risk', 'coronavirus establish human', 'coronavirus establish receptor', 'coronavirus establish inflammation', 'coronavirus establish acute', 'coronavirus establish decrease', 'coronavirus establish infection', 'coronavirus establish child', 'coronavirus establish immunity', 'coronavirus establish infection', 'coronavirus establish child', 'coronavirus establish covid-19', 'coronavirus establish alveolar', 'covid-19 establish enzyme ii', 'covid-19 establish acute respiratory', 'covid-19 establish pulmonary capillary', 'covid-19 establish angiotensin 2', 'covid-19 establish lung injury', 'covid-19 establish child', 'covid-19 establish high-risk', 'covid-19 establish human', 'covid-19 establish receptor', 'covid-19 establish coronavirus', 'covid-19 establish inflammation', 'covid-19 establish acute', 'covid-19 establish decrease', 'covid-19 establish infection', 'covid-19 establish child', 'covid-19 establish immunity', 'covid-19 establish infection', 'covid-19 establish child', 'covid-19 establish alveolar', 'age-based establish enzyme ii', 'age-based establish acute respiratory', 'age-based establish pulmonary capillary', 'age-based establish angiotensin 2', 'age-based establish lung injury', 'age-based establish child', 'age-based establish high-risk', 'age-based establish human', 'age-based establish receptor', 'age-based establish coronavirus', 'age-based establish inflammation', 'age-based establish acute', 'age-based establish decrease', 'age-based establish infection', 'age-based establish child', 'age-based establish immunity', 'age-based establish infection', 'age-based establish child', 'age-based establish covid-19', 'age-based establish alveolar', 'enzyme ii boost acute respiratory', 'enzyme ii boost pulmonary capillary', 'enzyme ii boost angiotensin 2', 'enzyme ii boost lung injury', 'enzyme ii boost receptor', 'enzyme ii boost coronavirus', 'enzyme ii boost inflammation', 'enzyme ii boost acute', 'enzyme ii boost decrease', 'enzyme ii boost infection', 'enzyme ii boost child', 'enzyme ii boost immunity', 'enzyme ii boost infection', 'enzyme ii boost child', 'enzyme ii boost covid-19', 'enzyme ii boost alveolar', 'adult boost acute respiratory', 'adult boost pulmonary capillary', 'adult boost angiotensin 2', 'adult boost lung injury', 'adult boost receptor', 'adult boost coronavirus', 'adult boost inflammation', 'adult boost acute', 'adult boost decrease', 'adult boost infection', 'adult boost child', 'adult boost immunity', 'adult boost infection', 'adult boost child', 'adult boost covid-19', 'adult boost alveolar', 'child boost acute respiratory', 'child boost pulmonary capillary', 'child boost angiotensin 2', 'child boost lung injury', 'child boost receptor', 'child boost coronavirus', 'child boost inflammation', 'child boost acute', 'child boost decrease', 'child boost infection', 'child boost immunity', 'child boost infection', 'child boost covid-19', 'child boost alveolar', 'coronavirus boost acute respiratory', 'coronavirus boost pulmonary capillary', 'coronavirus boost angiotensin 2', 'coronavirus boost lung injury', 'coronavirus boost receptor', 'coronavirus boost inflammation', 'coronavirus boost acute', 'coronavirus boost decrease', 'coronavirus boost infection', 'coronavirus boost child', 'coronavirus boost immunity', 'coronavirus boost infection', 'coronavirus boost child', 'coronavirus boost covid-19', 'coronavirus boost alveolar', 'covid-19 boost acute respiratory', 'covid-19 boost pulmonary capillary', 'covid-19 boost angiotensin 2', 'covid-19 boost lung injury', 'covid-19 boost receptor', 'covid-19 boost coronavirus', 'covid-19 boost inflammation', 'covid-19 boost acute', 'covid-19 boost decrease', 'covid-19 boost infection', 'covid-19 boost child', 'covid-19 boost immunity', 'covid-19 boost infection', 'covid-19 boost child', 'covid-19 boost alveolar', 'age-based boost acute respiratory', 'age-based boost pulmonary capillary', 'age-based boost angiotensin 2', 'age-based boost lung injury', 'age-based boost receptor', 'age-based boost coronavirus', 'age-based boost inflammation', 'age-based boost acute', 'age-based boost decrease', 'age-based boost infection', 'age-based boost child', 'age-based boost immunity', 'age-based boost infection', 'age-based boost child', 'age-based boost covid-19', 'age-based boost alveolar', 'child boost acute respiratory', 'child boost pulmonary capillary', 'child boost angiotensin 2', 'child boost lung injury', 'child boost receptor', 'child boost coronavirus', 'child boost inflammation', 'child boost acute', 'child boost decrease', 'child boost infection', 'child boost immunity', 'child boost infection', 'child boost covid-19', 'child boost alveolar', 'high-risk boost acute respiratory', 'high-risk boost pulmonary capillary', 'high-risk boost angiotensin 2', 'high-risk boost lung injury', 'high-risk boost receptor', 'high-risk boost coronavirus', 'high-risk boost inflammation', 'high-risk boost acute', 'high-risk boost decrease', 'high-risk boost infection', 'high-risk boost child', 'high-risk boost immunity', 'high-risk boost infection', 'high-risk boost child', 'high-risk boost covid-19', 'high-risk boost alveolar', 'human boost acute respiratory', 'human boost pulmonary capillary', 'human boost angiotensin 2', 'human boost lung injury', 'human boost receptor', 'human boost coronavirus', 'human boost inflammation', 'human boost acute', 'human boost decrease', 'human boost infection', 'human boost child', 'human boost immunity', 'human boost infection', 'human boost child', 'human boost covid-19', 'human boost alveolar']",3948,understanding relationship localization cy5-ova small intestinal permeability may contribute establishing whether oral vaccination newborn capitalize transient permeability gut closure promote immune protection 
1536,390.0,1.0,"['two consider pcv10', 'two consider n197', 'two consider n199', 'pcv-naÃ\x83\x83Ã\x83\x82ve consider pcv10', 'pcv-naÃ\x83\x83Ã\x83\x82ve consider n197', 'pcv-naÃ\x83\x83Ã\x83\x82ve consider n199', 'child consider pcv10', 'child consider n197', 'child consider n199']",3951,information important countries considering catch-up vaccination pcv introduction context vaccination humanitarian crises 
1537,390.0,4.0,['pneumococcus evaluate real-time'],3954,immunogenicity assessed measuring serotype-specific igg opsonophagocytosis opa memory b cells bmem 
1538,390.0,7.0,['bmem induce 24'],3957,sustained 24 months age point pcv10-type carriage 60 lower pcv10 group unvaccinated group 
1539,390.0,9.0,['second follow child'],3959,interpretation demonstrate strong protective immune responses vaccinees following single dose pcv10 18 months age potential impact herd protection substantial reduction vaccine-type carriage 
1540,390.0,10.0,"['influenza consider covid-19', 'influenza consider covid-19']",3960,single dose pcv10 second year life could considered part catch-up campaigns humanitarian crises protect children high-risk pneumococcal disease 
1541,391.0,0.0,"['cohort receive covid-19', 'patient receive covid-19']",3961,background unique influenza season occurring midst pandemic interest assessing role influenza vaccine covid-19 susceptibility severity 
1542,391.0,4.0,"['covid-19 receive vaccine', 'patient receive vaccine']",3965,results total 27201 patients received laboratory testing covid-19 
1543,391.0,6.0,['influenza need covid-19'],3967,vaccinated patients testing positive covid-19 less likely require hospitalization odds ratio 058 95 ci 046-073 p 001 mechanical ventilation odds ratio 045 95 ci 027-078 p 004 shorter hospital length stay risk ratio 076 95 ci 065-089 p 001 
1544,391.0,7.0,"['sars-cov-2 boost vaccine', 'sars-cov-2 decrease vaccine', 'sars-cov-2 improve vaccine']",3968,conclusion influenza vaccination associated decreased positive covid-19 testing improved clinical outcomes promoted reduce burden covid-19 
1545,392.0,0.0,"['mouse mediate sarna', 'mouse mediate vaccine', 'mouse mediate adenoviral', 'mouse mediate vaccine', 'mouse mediate chadox1', 'mouse mediate ncov-19azd1222', 'mouse mediate sars-cov-2']",3969,several vaccines demonstrated efficacy sars-cov-2 mediated disease yet limited data immune response induced heterologous vaccination regimens using alternate vaccine modalities 
1546,392.0,2.0,['prime-boost dose boost'],3971,demonstrate antibody responses higher two-dose heterologous vaccination regimens single-dose regimens 
1547,392.0,3.0,"['cd4 cells evaluate mouse', 'cellular evaluate mouse', 'th1 evaluate mouse']",3972,neutralising titres heterologous prime-boost least comparable higher titres measured homologous prime boost vaccination viral vectors 
1548,393.0,0.0,['covid-19 infect two-dose'],3975,sars-cov-2 infected 122 million persons worldwide 
1549,393.0,2.0,"['vaccine prim two-dose', 'convalescent prim two-dose', 'vaccine prim vaccinee', 'vaccine prim two-dose', 'convalescent prim vaccinee', 'convalescent prim two-dose']",3977,requirement boosting response priming first dose uncertain convalescents already primed natural infection 
1550,393.0,3.0,"['vaccine dose herd', 'vaccine dose immunity', 'convalescent dose herd', 'convalescent dose immunity', 'vaccine develop herd', 'vaccine develop immunity', 'convalescent develop herd', 'convalescent develop immunity']",3978,mounting evidences suggest single vaccine dose convalescents develop antibody total neutralizing levels similar ones measured naÃÂve vaccinees full two-dose course 
1551,393.0,4.0,"['immunity optimize donor', 'immunity optimize plasma', 'sars-cov-2 optimize donor', 'sars-cov-2 optimize plasma', 'quarantine optimize donor', 'quarantine optimize plasma']",3979,concerns remain equivalent duration response optimizing vaccine delivery convalescents seems effective could accelerate achievement herd immunity 
1552,394.0,1.0,['mixed-design induce antibody'],3981,date however utility immunoassays remains unclear 
1553,394.0,2.0,"['patient compare medical staff', 'sars-cov-2 compare medical staff']",3982,mixed-design evaluation study compared diagnostic accuracy serological immunoassays based various sars-cov-2 proteins assessed neutralizing activity antibodies patient sera 
1554,394.0,3.0,"['immunosorbent follow three', 'immunosorbent follow enzyme-linked', 'immunosorbent follow elisa', 'immunosorbent follow nucleoprotein', 'immunosorbent follow lfi', 'sars-cov-2 follow three', 'sars-cov-2 follow enzyme-linked', 'sars-cov-2 follow immunosorbent', 'sars-cov-2 follow elisa', 'sars-cov-2 follow nucleoprotein', 'sars-cov-2 follow lfi', 'immunosorbent include sars-cov-2', 'immunosorbent include three', 'immunosorbent include enzyme-linked', 'immunosorbent include elisa', 'immunosorbent include nucleoprotein', 'immunosorbent include lfi', 'immunosorbent confirm sars-cov-2', 'immunosorbent confirm three', 'immunosorbent confirm enzyme-linked', 'immunosorbent confirm elisa', 'immunosorbent confirm nucleoprotein', 'immunosorbent confirm lfi']",3983,methods consecutive patients admitted confirmed sars-cov-2 infection prospectively followed alongside medical staff biobank samples winter 20182019 
1555,394.0,5.0,"['one thousand perform 112', 'one thousand perform sars-cov-2', 'seventy-seven perform 112', 'seventy-seven perform sars-cov-2']",3985,neutralization assays live sars-cov-2 performed 
1556,394.0,6.0,"['igg establish 893', 'igg establish 729', 'elisa establish 893', 'elisa establish 729', '884 establish 893', '884 establish 729']",3986,results one thousand four hundred seventy-seven individuals included comprising 112 sars-cov-2 positives defined positive real-time pcr result prevalence 76 
1557,394.0,7.0,"['sars-cov-2 receive 963', 'sars-cov-2 receive serum', 'sars-cov-2 receive dilution', 'sars-cov-2 receive sars-cov-2-negative', 'sars-cov-2 receive serum', 'sars-cov-2 show sars-cov-2-negative', 'sars-cov-2 show serum', '963 show sars-cov-2-negative', '963 show serum', 'sars-cov-2 show sars-cov-2-negative', 'sars-cov-2 show serum', 'serum show sars-cov-2-negative', 'dilution show sars-cov-2-negative', 'dilution show serum']",3987,igg seroconversion occurred day 0 day 21 elisas showed sensitivities 884 rbd 893 s1 729 n protein specificity 94 tests 
1558,394.0,8.0,"['elisa show immunity', 'elisa show sars-cov-2', 'sars-cov-2 show immunity']",3988,54 sars-cov-2 positive individuals 963 showed full neutralization live sars-cov-2 serum dilutions 8805 116 none 6 sars-cov-2-negative sera revealed neutralizing activity 
1559,394.0,9.0,"['covid-19-associated promise 12-17 years', 'covid-19-associated promise adolescent', 'adult promise 12-17 years', 'adult promise adolescent', 'covid-19-associated aim 12-17 years', 'covid-19-associated aim adult', 'covid-19-associated aim adolescent']",3989,conclusions elisas targeting rbd s1 protein sars-cov-2 promising immunoassays shall evaluated studies verifying diagnostic accuracy protective immunity sars-cov-2 
1560,395.0,0.0,"['covid-19 need 12-15', 'covid-19 need immunization', 'vaccine need 12-15', 'vaccine need immunization', 'covid-19 receive immunization', 'vaccine receive immunization', 'person receive immunization']",3990,covid-19-associated hospitalizations occur older adults severe disease requires hospitalization occurs age groups including adolescents aged 12-17 years 1 
1561,395.0,3.0,"['coronavirus describe covid-net', 'coronavirus describe covid-19-associated', 'coronavirus describe adolescent', 'coronavirus describe 12-17', 'coronavirus describe year', 'coronavirus describe adolescent', 'coronavirus describe person', 'coronavirus describe adolescent', 'coronavirus describe march', 'coronavirus describe 204', 'coronavirus describe adolescent', 'coronavirus describe covid-19', 'coronavirus describe death', 'coronavirus associate covid-19-associated', 'coronavirus associate adolescent', 'coronavirus associate 12-17', 'coronavirus associate year', 'coronavirus associate adolescent', 'coronavirus associate person', 'coronavirus associate adolescent', 'coronavirus associate march', 'coronavirus associate 204', 'coronavirus associate adolescent', 'coronavirus associate covid-19', 'coronavirus associate death', 'covid-net associate covid-19-associated', 'covid-net associate adolescent', 'covid-net associate 12-17', 'covid-net associate year', 'covid-net associate adolescent', 'covid-net associate person', 'covid-net associate adolescent', 'covid-net associate march', 'covid-net associate 204', 'covid-net associate adolescent', 'covid-net associate covid-19', 'covid-net associate death', 'coronavirus compare 12-17', 'coronavirus compare year', 'coronavirus compare adolescent', 'coronavirus compare person', 'coronavirus compare adolescent', 'coronavirus compare march', 'coronavirus compare 204', 'coronavirus compare adolescent', 'coronavirus compare covid-19', 'coronavirus compare death', 'covid-net compare 12-17', 'covid-net compare year', 'covid-net compare adolescent', 'covid-net compare person', 'covid-net compare adolescent', 'covid-net compare march', 'covid-net compare 204', 'covid-net compare adolescent', 'covid-net compare covid-19', 'covid-net compare death', 'covid-19-associated compare 12-17', 'covid-19-associated compare year', 'covid-19-associated compare adolescent', 'covid-19-associated compare person', 'covid-19-associated compare adolescent', 'covid-19-associated compare march', 'covid-19-associated compare 204', 'covid-19-associated compare adolescent', 'covid-19-associated compare covid-19', 'covid-19-associated compare death', 'coronavirus associate adolescent', 'coronavirus associate person', 'coronavirus associate adolescent', 'coronavirus associate march', 'coronavirus associate 204', 'coronavirus associate adolescent', 'coronavirus associate covid-19', 'coronavirus associate death', 'covid-net associate adolescent', 'covid-net associate person', 'covid-net associate adolescent', 'covid-net associate march', 'covid-net associate 204', 'covid-net associate adolescent', 'covid-net associate covid-19', 'covid-net associate death', 'covid-19-associated associate adolescent', 'covid-19-associated associate person', 'covid-19-associated associate adolescent', 'covid-19-associated associate march', 'covid-19-associated associate 204', 'covid-19-associated associate adolescent', 'covid-19-associated associate covid-19', 'covid-19-associated associate death', 'adolescent associate person', 'adolescent associate march', 'adolescent associate 204', 'adolescent associate covid-19', 'adolescent associate death', '12-17 associate adolescent', '12-17 associate person', '12-17 associate adolescent', '12-17 associate march', '12-17 associate 204', '12-17 associate adolescent', '12-17 associate covid-19', '12-17 associate death', 'year associate adolescent', 'year associate person', 'year associate adolescent', 'year associate march', 'year associate 204', 'year associate adolescent', 'year associate covid-19', 'year associate death', 'coronavirus induce person', 'coronavirus induce adolescent', 'coronavirus induce march', 'coronavirus induce 204', 'coronavirus induce adolescent', 'coronavirus induce covid-19', 'coronavirus induce death', 'covid-net induce person', 'covid-net induce adolescent', 'covid-net induce march', 'covid-net induce 204', 'covid-net induce adolescent', 'covid-net induce covid-19', 'covid-net induce death', 'covid-19-associated induce person', 'covid-19-associated induce adolescent', 'covid-19-associated induce march', 'covid-19-associated induce 204', 'covid-19-associated induce adolescent', 'covid-19-associated induce covid-19', 'covid-19-associated induce death', 'adolescent induce person', 'adolescent induce march', 'adolescent induce 204', 'adolescent induce covid-19', 'adolescent induce death', '12-17 induce person', '12-17 induce adolescent', '12-17 induce march', '12-17 induce 204', '12-17 induce adolescent', '12-17 induce covid-19', '12-17 induce death', 'year induce person', 'year induce adolescent', 'year induce march', 'year induce 204', 'year induce adolescent', 'year induce covid-19', 'year induce death', 'adolescent induce person', 'adolescent induce march', 'adolescent induce 204', 'adolescent induce covid-19', 'adolescent induce death', 'coronavirus expand 204', 'coronavirus expand adolescent', 'coronavirus expand covid-19', 'coronavirus expand death', 'covid-net expand 204', 'covid-net expand adolescent', 'covid-net expand covid-19', 'covid-net expand death', 'covid-19-associated expand 204', 'covid-19-associated expand adolescent', 'covid-19-associated expand covid-19', 'covid-19-associated expand death', 'adolescent expand 204', 'adolescent expand covid-19', 'adolescent expand death', '12-17 expand 204', '12-17 expand adolescent', '12-17 expand covid-19', '12-17 expand death', 'year expand 204', 'year expand adolescent', 'year expand covid-19', 'year expand death', 'adolescent expand 204', 'adolescent expand covid-19', 'adolescent expand death', 'person expand 204', 'person expand adolescent', 'person expand covid-19', 'person expand death', 'adolescent expand 204', 'adolescent expand covid-19', 'adolescent expand death', 'march expand 204', 'march expand adolescent', 'march expand covid-19', 'march expand death', 'coronavirus recommend 204', 'coronavirus recommend adolescent', 'coronavirus recommend covid-19', 'coronavirus recommend death', 'covid-net recommend 204', 'covid-net recommend adolescent', 'covid-net recommend covid-19', 'covid-net recommend death', 'covid-19-associated recommend 204', 'covid-19-associated recommend adolescent', 'covid-19-associated recommend covid-19', 'covid-19-associated recommend death', 'adolescent recommend 204', 'adolescent recommend covid-19', 'adolescent recommend death', '12-17 recommend 204', '12-17 recommend adolescent', '12-17 recommend covid-19', '12-17 recommend death', 'year recommend 204', 'year recommend adolescent', 'year recommend covid-19', 'year recommend death', 'adolescent recommend 204', 'adolescent recommend covid-19', 'adolescent recommend death', 'person recommend 204', 'person recommend adolescent', 'person recommend covid-19', 'person recommend death', 'adolescent recommend 204', 'adolescent recommend covid-19', 'adolescent recommend death', 'march recommend 204', 'march recommend adolescent', 'march recommend covid-19', 'march recommend death', 'coronavirus provide covid-19', 'coronavirus provide death', 'covid-net provide covid-19', 'covid-net provide death', 'covid-19-associated provide covid-19', 'covid-19-associated provide death', 'adolescent provide covid-19', 'adolescent provide death', '12-17 provide covid-19', '12-17 provide death', 'year provide covid-19', 'year provide death', 'adolescent provide covid-19', 'adolescent provide death', 'person provide covid-19', 'person provide death', 'adolescent provide covid-19', 'adolescent provide death', 'march provide covid-19', 'march provide death', '204 provide covid-19', '204 provide death', 'adolescent provide covid-19', 'adolescent provide death', 'coronavirus evaluate death', 'covid-net evaluate death', 'covid-19-associated evaluate death', 'adolescent evaluate death', '12-17 evaluate death', 'year evaluate death', 'adolescent evaluate death', 'person evaluate death', 'adolescent evaluate death', 'march evaluate death', '204 evaluate death', 'adolescent evaluate death', 'covid-19 evaluate death']",3993,understanding describing epidemiology covid-19-associated hospitalizations adolescents comparing adolescent hospitalizations associated vaccine-preventable respiratory viruses influenza offers evidence benefits expanding recommended age range vaccination provides baseline context assess vaccination impact 
1562,395.0,4.0,"['march associate mid-march', 'march test mid-march']",3994,using coronavirus disease 2019-associated hospitalization surveillance network covid-net cdc examined covid-19-associated hospitalizations among adolescents aged 12-17 years including demographic clinical characteristics adolescents admitted january 1-march 31 2021 hospitalization rates hospitalizations per 100000 persons among adolescents march 1 2020-april 24 2021 among 204 adolescents likely hospitalized primarily covid-19 january 1-march 31 2021 314 admitted intensive care unit icu 49 required invasive mechanical ventilation associated deaths 
1563,395.0,5.0,"['covid-19-associated peak influenza', 'covid-19-associated peak influenza', '25-30 peak influenza', '25-30 peak influenza']",3995,march 1 2020-april 24 2021 weekly adolescent hospitalization rates peaked 21 per 100000 early january 2021 declined 06 mid-march rose 13 april 
1564,395.0,6.0,"['covid-19-associated associate 2021', 'covid-19-associated associate adolescent', 'covid-19-associated associate covid-19', 'covid-19-associated associate person']",3996,cumulative covid-19-associated hospitalization rates october 1 2020-april 24 2021 25-30 times higher influenza-associated hospitalization rates three recent influenza seasons 2017-18 2018-19 2019-20 obtained influenza hospitalization surveillance network flusurv-net 
1565,396.0,1.0,"['912 test 166', 'kidney test 166', 'recipient test 166', 'sars-cov-2 test 166', 'igg test 166', 'antibody test 166']",3999,march 16 june 2 2020 132 kidney transplant recipients tested positive sars-cov-2 rt-pcr 
1566,396.0,3.0,"['975 test sars-cov-2', 'patient test sars-cov-2']",4001,fifty-five 152 patients previously tested positive rt-pcr remaining 97 significant symptoms previously tested rt-pcr 
1567,397.0,3.0,"['cellular relate spf', 'cellular relate cat', 'cellular relate f9', 'cellular relate two', 'cellular relate fcv', 'cellular relate cytokine', 'cellular relate mrna', 'cellular relate interferon', 'cellular relate ifn', 'cellular relate peripheral', 'cellular relate blood', 'cellular relate pbmcs', 'cellular relate antibody', 'cellular test cytokine', 'cellular test mrna', 'cellular test interferon', 'cellular test ifn', 'cellular test peripheral', 'cellular test blood', 'cellular test pbmcs', 'cellular test antibody', 'spf test cytokine', 'spf test mrna', 'spf test interferon', 'spf test ifn', 'spf test peripheral', 'spf test blood', 'spf test pbmcs', 'spf test antibody', 'cat test cytokine', 'cat test mrna', 'cat test interferon', 'cat test ifn', 'cat test peripheral', 'cat test blood', 'cat test pbmcs', 'cat test antibody', 'f9 test cytokine', 'f9 test mrna', 'f9 test interferon', 'f9 test ifn', 'f9 test peripheral', 'f9 test blood', 'f9 test pbmcs', 'f9 test antibody', 'two test cytokine', 'two test mrna', 'two test interferon', 'two test ifn', 'two test peripheral', 'two test blood', 'two test pbmcs', 'two test antibody']",4012,protection fcv related humoral cellular immunity latter studied detail 
1568,397.0,7.0,"['infection detect granzyme b', 'infection detect pbmcs', 'infection detect cat', 'infection detect cat', 'mrna detect granzyme b', 'mrna detect pbmcs', 'mrna detect cat', 'mrna detect cat', 'granzyme b vaccinate pbmcs', 'granzyme b vaccinate cat', 'granzyme b vaccinate cat', 'infection vaccinate pbmcs', 'infection vaccinate cat', 'infection vaccinate cat', 'mrna vaccinate pbmcs', 'mrna vaccinate cat', 'mrna vaccinate cat', 'perforin vaccinate pbmcs', 'perforin vaccinate cat', 'perforin vaccinate cat']",4016,remarkably ifn-ÃÂ³-releasing pbmcs detected vaccinated cats upon stimulation vaccine strain first heterologous fcv challenge strain 
1569,397.0,10.0,"['fcv vaccinate lymphocyte', 'fcv vaccinate cytokine', 'fcv vaccinate mrna']",4019,second challenge vaccinated cats higher number ifn-ÃÂ³-releasing pbmcs stimulated second challenge virus control cats 
1570,397.0,11.0,"['fcv detect pbmcs', 'cellular detect pbmcs', 'spf detect pbmcs', 'cat detect pbmcs', 'fcv consider pbmcs', 'cellular consider pbmcs', 'spf consider pbmcs', 'cat consider pbmcs']",4020,second fcv challenge less significant differences detected groups regarding lymphocyte subsets cytokine mrna transcription levels 
1571,397.0,12.0,"['adenovirus modify diarrhea', 'adenovirus modify child', 'adenovirus induce diarrhea', 'adenovirus induce child', 'hadv induce diarrhea', 'hadv induce child']",4021,conclusion modified-live fcv vaccination induced cellular humoral crossimmunity spf cats innate immune mechanisms secretory membranolytic pathways ifn-ÃÂ³-releasing pbmcs seem important host immune defence fcv 
1572,398.0,0.0,"['hadv associate fecal', 'hadv associate child', 'hadv associate diarrhea', 'child associate fecal', 'child associate diarrhea', 'shandong associate fecal', 'shandong associate child', 'shandong associate diarrhea', 'china associate fecal', 'china associate child', 'china associate diarrhea']",4022,background human adenovirus hadv recognized one common enteric viruses associated acute diarrhea children 
1573,398.0,1.0,"['dna induce adenovirus', 'stool induce adenovirus', 'stool induce dna']",4023,present study carried demonstrate molecular epidemiological characterization hadv infections among children shandong province china july 2017 june 2018 methods fecal specimens collected children 5 years old acute diarrhea 
1574,398.0,5.0,"['656 test hadv', '656 test 747', 'fecal test hadv', 'fecal test 747', 'specimen test hadv', 'specimen test 747']",4027,demographic information clinical manifestation data also analyzed 
1575,398.0,8.0,"['diarrhea observe fever', 'diarrhea observe vomiting', 'vomiting observe fever']",4030,seasonal pattern could observed peak december january february 
1576,398.0,10.0,"['hadv-3 1837 detect 408 249', 'hadv-3 1837 detect 249', 'hadv-3 1837 detect hadv-1', 'hadv-3 1837 detect hadv-2', 'hadv-3 1837 detect 204', 'hadv-41 detect 408 249', 'hadv-41 detect 249', 'hadv-41 detect hadv-1', 'hadv-41 detect hadv-2', 'hadv-41 detect 204', '949 detect 408 249', '949 detect 249', '949 detect hadv-1', '949 detect hadv-2', '949 detect 204', 'hadv-31 detect 408 249', 'hadv-31 detect 249', 'hadv-31 detect hadv-1', 'hadv-31 detect hadv-2', 'hadv-31 detect 204', '749 detect 408 249', '749 detect 249', '749 detect hadv-1', '749 detect hadv-2', '749 detect 204', 'hadv-7 detect 408 249', 'hadv-7 detect 249', 'hadv-7 detect hadv-1', 'hadv-7 detect hadv-2', 'hadv-7 detect 204', 'hadv-40 detect 408 249', 'hadv-40 detect 249', 'hadv-40 detect hadv-1', 'hadv-40 detect hadv-2', 'hadv-40 detect 204']",4032,phylogenetic analysis four species b c f detected seven different serotypes identified 
1577,398.0,11.0,"['hadv infection follow shandong', 'diarrhea follow shandong', 'child follow shandong']",4033,hadv-41 4898 2449 common serotype followed hadv-3 1837 949 hadv-31 1429 749 hadv-7 816 449 hadv-40 408 249 hadv-1 408 249 hadv-2 204 149 
1578,399.0,0.0,"['cancer induce tumor', 'cancer induce relapse']",4036,adoptive transfer vitro expanded chimeric antigen receptor car -redirected cd19-specific cells induce dramatic disease regression patients leukemia lymphomas 
1579,399.0,1.0,"['vivo hamper b cell', 'vivo hamper cmv', 'vivo hamper remission', 'vivo hamper cmv-specific', 'vivo emerge b cell', 'vivo emerge cmv', 'vivo emerge remission', 'vivo emerge cmv-specific']",4037,however full potential emerging modality hampered cancer settings significant rate therapeutic failure arising attenuated engraftment persistence car-redirected cells tumor relapse following adoptive transfer 
1580,399.0,4.0,['influenza observe b'],4040,new approach would overcome multiple challenges current car cell technology including short cell persistence limited duration response inability re-stimulate cells relapse persistent disease 
1581,400.0,1.0,"['272 perform influenza', '272 perform influenza', '272 perform 257', '272 perform 201', '272 perform influenza', '272 perform 739']",4042,methods performed retrospective analysis patients university hospital northern germany laboratory-confirmed influenza winter season 2017ÃÂÂ2018 analyzed underlying conditions complications outcome 
1582,400.0,2.0,"['182 diagnose two', '182 diagnose one', '182 diagnose one', '182 diagnose perimyocarditis', 'adult diagnose two', 'adult diagnose one', 'adult diagnose one', 'adult diagnose perimyocarditis', '145 diagnose two', '145 diagnose one', '145 diagnose one', '145 diagnose perimyocarditis', 'pneumonia diagnose two', 'pneumonia diagnose one', 'pneumonia diagnose one', 'pneumonia diagnose perimyocarditis']",4043,results total 272 cases influenza diagnosed 70 influenza 257 201 influenza b 739 1 co-infection 
1583,400.0,3.0,"['eleven hospitalize ten', 'eleven hospitalize pneumonia', '145 hospitalize ten', '145 hospitalize pneumonia', 'patient hospitalize ten', 'patient hospitalize pneumonia']",4044,182 adults 145 hospitalized 73 developed pneumonia 11 developed myocardial infarction two transient ischemic attack one stroke one perimyocarditis 
1584,400.0,7.0,"['ninety correlate respiratory tract', 'ninety correlate febrile seizures', 'ninety correlate child', 'ninety correlate b', 'ninety correlate influenza', 'ninety correlate child', 'ninety correlate child', 'ninety correlate meningeal', 'influenza correlate respiratory tract', 'influenza correlate febrile seizures', 'influenza correlate child', 'influenza correlate b', 'influenza correlate child', 'influenza correlate child', 'influenza correlate meningeal']",4048,underlying cardiac insufficiency correlated higher mortality 751 versus 4126 patients without cardiac insufficiency p 005 
1585,400.0,9.0,"['influenza die patient', 'influenza die pneumonia', 'influenza die 4390', 'influenza die 478', 'influenza die patient', 'influenza die 305']",4050,child died 
1586,400.0,10.0,"['patient know myocardial infarction', 'patient know heart disease', 'patient know cardiac insufficiency', 'patient know pneumonia', 'patient know coronary', 'influenza know myocardial infarction', 'influenza know heart disease', 'influenza know cardiac insufficiency', 'influenza know pneumonia', 'influenza know patient', 'influenza know coronary', 'myocardial infarction receive heart disease', 'myocardial infarction receive cardiac insufficiency', 'myocardial infarction receive coronary', 'patient receive heart disease', 'patient receive cardiac insufficiency', 'patient receive coronary', 'influenza receive heart disease', 'influenza receive cardiac insufficiency', 'influenza receive coronary', 'pneumonia receive heart disease', 'pneumonia receive cardiac insufficiency', 'pneumonia receive coronary']",4051,influenza vaccination status known 149 adult patients pneumonia occurred frequently non-vaccinated individuals 4390 478 vaccinated patients 1859 305 p 005 
1587,400.0,11.0,"['covid-19 monitor immunity', 'covid-19 monitor sars-cov-2', 'covid-19 monitor spanish', 'covid-19 monitor influenza', 'covid-19 monitor diphtheria', 'covid-19 monitor tetanus', 'covid-19 monitor pertussis', 'covid-19 monitor vaccine', 'covid-19 monitor boost', 'covid-19 monitor sars-cov-2', 'covid-19 monitor cohort', 'covid-19 monitor symptom', 'covid-19 monitor sars-cov-2', 'covid-19 monitor sars-cov-2', 'covid-19 monitor woman', 'covid-19 monitor spanish', 'covid-19 monitor 183', 'covid-19 monitor vaccine', 'covid-19 monitor influenza', 'covid-19 monitor 529', 'covid-19 use influenza', 'covid-19 use diphtheria', 'covid-19 use tetanus', 'covid-19 use pertussis', 'covid-19 use vaccine', 'covid-19 use boost', 'covid-19 use sars-cov-2', 'covid-19 use cohort', 'covid-19 use symptom', 'covid-19 use sars-cov-2', 'covid-19 use sars-cov-2', 'covid-19 use woman', 'covid-19 use spanish', 'covid-19 use 183', 'covid-19 use vaccine', 'covid-19 use influenza', 'covid-19 use 529', 'immunity use influenza', 'immunity use diphtheria', 'immunity use tetanus', 'immunity use pertussis', 'immunity use vaccine', 'immunity use boost', 'immunity use sars-cov-2', 'immunity use cohort', 'immunity use symptom', 'immunity use sars-cov-2', 'immunity use sars-cov-2', 'immunity use woman', 'immunity use spanish', 'immunity use 183', 'immunity use vaccine', 'immunity use influenza', 'immunity use 529', 'sars-cov-2 use influenza', 'sars-cov-2 use diphtheria', 'sars-cov-2 use tetanus', 'sars-cov-2 use pertussis', 'sars-cov-2 use vaccine', 'sars-cov-2 use boost', 'sars-cov-2 use cohort', 'sars-cov-2 use symptom', 'sars-cov-2 use woman', 'sars-cov-2 use spanish', 'sars-cov-2 use 183', 'sars-cov-2 use vaccine', 'sars-cov-2 use influenza', 'sars-cov-2 use 529', 'spanish use influenza', 'spanish use diphtheria', 'spanish use tetanus', 'spanish use pertussis', 'spanish use vaccine', 'spanish use boost', 'spanish use sars-cov-2', 'spanish use cohort', 'spanish use symptom', 'spanish use sars-cov-2', 'spanish use sars-cov-2', 'spanish use woman', 'spanish use 183', 'spanish use vaccine', 'spanish use influenza', 'spanish use 529']",4052,conclusion patients influenza monitored secondary pneumonia myocardial infarction vaccination enforced especially patients coronary heart disease cardiac insufficiency 
1588,401.0,0.0,"['cancer elicit antigen-primed', 'cancer elicit dc']",4053,covid-19 pandemic raised questions possible cross immunity resulting common vaccination programs sars-cov-2 infection therefore spanish obstetric emergency group performed multicenter prospective study vaccination status influenza tdap diphtheria tetanus pertussis vaccine boost administered adulthood consecutive cases sars-cov-2 infection pregnancy cohort order assess possible association clinical presentation severity symptoms sars-cov-2 infection well determine factors may affect vaccination adherence total 1150 sars-cov-2 positive pregnant women 78 spanish hospitals analyzed 183 received either vaccine 23 vaccinated influenza 529 tdap 415 received vaccines association observed vaccination status clinical presentation sars-cov-2 infection andor severity symptoms however lower adherence administration vaccines observed latin-american subgroup based results reinforce importance maternal vaccination programs actual pandemic health education campaigns specially targeted groups less likely participate programs well future sars-cov-2 vaccination campaign
1589,402.0,1.0,"['dc observe lymph nodes', 'dc observe lns', 'cell observe lymph nodes', 'cell observe lns', 'tumor observe lymph nodes', 'tumor observe lns']",4055,complexity immune response many factors determine efficacy dc therapy 
1590,402.0,4.0,['tumor enable clinician'],4058,magnetovaccination alternative approach tracks vivo labeled dcs simultaneously capture tumor antigen mr contrast agent situ enabling accurate quantification antigen presentation cells lns 
1591,402.0,5.0,"['venous sinus use chadox1', 'venous sinus use ncov-19', 'venous sinus use ad26cov2s', 'venous sinus use covid-19', 'venous sinus use vaccine', 'cerebral use chadox1', 'cerebral use ncov-19', 'cerebral use ad26cov2s', 'cerebral use covid-19', 'cerebral use vaccine', 'thrombosis use chadox1', 'thrombosis use ncov-19', 'thrombosis use ad26cov2s', 'thrombosis use covid-19', 'thrombosis use vaccine', 'thrombocytopenia use chadox1', 'thrombocytopenia use ncov-19', 'thrombocytopenia use ad26cov2s', 'thrombocytopenia use covid-19', 'thrombocytopenia use vaccine']",4059,ultimate clinical premise mri dc tracking would use changes ln mri signal early imaging biomarker predict efficacy tumor vaccination anti-tumor response long treatment outcome becomes apparent may aid clinicians interim treatment management 
1592,403.0,1.0,"['thrombocytopenia induce cerebral', 'thrombocytopenia induce thrombosis', 'thrombocytopenia induce covid-19', 'heparin-induced induce cerebral', 'heparin-induced induce thrombosis', 'heparin-induced induce covid-19', 'thrombocytopenia induce cerebral', 'thrombocytopenia induce thrombosis', 'thrombocytopenia induce covid-19', 'platelet induce cerebral', 'platelet induce thrombosis', 'platelet induce covid-19', '4heparin induce cerebral', '4heparin induce thrombosis', '4heparin induce covid-19', 'antibody induce cerebral', 'antibody induce thrombosis', 'antibody induce covid-19', 'patient induce cerebral', 'patient induce thrombosis', 'patient induce covid-19', 'thrombocytopenia associate platelet', 'thrombocytopenia associate 4heparin', 'thrombocytopenia associate antibody', 'thrombocytopenia associate patient', 'thrombocytopenia associate cerebral', 'thrombocytopenia associate thrombosis', 'thrombocytopenia associate covid-19']",4061,immune-mediated response associated platelet factor 4heparin antibodies proposed underlying pathomechanism 
1593,403.0,2.0,"['participant observe cerebral venous', 'participant observe cerebral venous', 'participant observe finland netherlands', 'participant observe patient', 'participant observe thrombosis', 'participant observe thrombosis', 'participant observe consortium', 'participant observe switzerland', 'participant observe sweden', 'participant observe mexico', 'participant observe iran', 'participant observe costa', 'participant observe rica', 'cerebral venous induce finland netherlands', 'cerebral venous induce thrombosis', 'cerebral venous induce thrombosis', 'cerebral venous induce consortium', 'cerebral venous induce switzerland', 'cerebral venous induce sweden', 'cerebral venous induce mexico', 'cerebral venous induce iran', 'cerebral venous induce costa', 'cerebral venous induce rica', 'participant induce cerebral venous', 'participant induce finland netherlands', 'participant induce thrombosis', 'participant induce thrombosis', 'participant induce consortium', 'participant induce switzerland', 'participant induce sweden', 'participant induce mexico', 'participant induce iran', 'participant induce costa', 'participant induce rica', 'patient induce cerebral venous', 'patient induce finland netherlands', 'patient induce thrombosis', 'patient induce thrombosis', 'patient induce consortium', 'patient induce switzerland', 'patient induce sweden', 'patient induce mexico', 'patient induce iran', 'patient induce costa', 'patient induce rica', 'cerebral venous diagnose finland netherlands', 'cerebral venous diagnose switzerland', 'cerebral venous diagnose sweden', 'cerebral venous diagnose mexico', 'cerebral venous diagnose iran', 'cerebral venous diagnose costa', 'cerebral venous diagnose rica', 'cerebral venous diagnose finland netherlands', 'cerebral venous diagnose switzerland', 'cerebral venous diagnose sweden', 'cerebral venous diagnose mexico', 'cerebral venous diagnose iran', 'cerebral venous diagnose costa', 'cerebral venous diagnose rica', 'participant diagnose finland netherlands', 'participant diagnose switzerland', 'participant diagnose sweden', 'participant diagnose mexico', 'participant diagnose iran', 'participant diagnose costa', 'participant diagnose rica', 'patient diagnose finland netherlands', 'patient diagnose switzerland', 'patient diagnose sweden', 'patient diagnose mexico', 'patient diagnose iran', 'patient diagnose costa', 'patient diagnose rica', 'thrombosis diagnose finland netherlands', 'thrombosis diagnose switzerland', 'thrombosis diagnose sweden', 'thrombosis diagnose mexico', 'thrombosis diagnose iran', 'thrombosis diagnose costa', 'thrombosis diagnose rica', 'thrombosis diagnose finland netherlands', 'thrombosis diagnose switzerland', 'thrombosis diagnose sweden', 'thrombosis diagnose mexico', 'thrombosis diagnose iran', 'thrombosis diagnose costa', 'thrombosis diagnose rica']",4062,objective determine frequencies admission thrombocytopenia heparin-induced thrombocytopenia presence platelet factor 4heparin antibodies patients diagnosed cerebral venous sinus thrombosis prior covid-19 pandemic 
1594,403.0,4.0,"['patient include platelet', 'patient include 4heparin', 'patient include antibody', 'plasma include platelet', 'plasma include 4heparin', 'plasma include antibody']",4064,952 patients 865 available baseline platelet count included 
1595,403.0,9.0,"['patient diagnose thrombocytopenia', 'patient diagnose 0', 'patient diagnose platelet', 'patient diagnose 4heparin', 'patient diagnose antibody', 'cerebral diagnose thrombocytopenia', 'cerebral diagnose 0', 'cerebral diagnose platelet', 'cerebral diagnose 4heparin', 'cerebral diagnose antibody', 'venous diagnose thrombocytopenia', 'venous diagnose 0', 'venous diagnose platelet', 'venous diagnose 4heparin', 'venous diagnose antibody', 'thrombosis diagnose thrombocytopenia', 'thrombosis diagnose 0', 'thrombosis diagnose platelet', 'thrombosis diagnose 4heparin', 'thrombosis diagnose antibody']",4069,heparin-induced thrombocytopenia platelet factor 4heparin antibodies diagnosed single patient 01 95 ci 01 -07 
1596,403.0,10.0,"['patient include heparin-induced', 'patient include thrombocytopenia', 'patient include platelet', 'patient include 4heparin', 'patient include antibody', 'cerebral include heparin-induced', 'cerebral include thrombocytopenia', 'cerebral include platelet', 'cerebral include 4heparin', 'cerebral include antibody', 'thrombosis include heparin-induced', 'thrombosis include thrombocytopenia', 'thrombosis include platelet', 'thrombosis include 4heparin', 'thrombosis include antibody', 'covid-19 include heparin-induced', 'covid-19 include thrombocytopenia', 'covid-19 include platelet', 'covid-19 include 4heparin', 'covid-19 include antibody', 'thrombocytopenia include heparin-induced', 'thrombocytopenia include platelet', 'thrombocytopenia include 4heparin', 'thrombocytopenia include antibody']",4070,convenience sample 93 patients cerebral venous sinus thrombosis included laboratory analysis 8 9 thrombocytopenia none 95 ci 0 -4 platelet factor 4heparin antibodies 
1597,404.0,2.0,"['erosion develop erythema', 'erosion develop 1b']",4075,injection site 7cm distal evolving patch 
1598,404.0,4.0,"['2014 experience africa', '2014 experience 11000', '2014 experience death', '2014 experience vaccine', 'ebola experience africa', 'ebola experience 11000', 'ebola experience death', 'ebola experience vaccine', '2014 flush death', '2014 flush vaccine', 'ebola flush death', 'ebola flush vaccine', 'west flush death', 'west flush vaccine', 'africa flush death', 'africa flush vaccine']",4077,patient also experienced facial flushing 15 minutes vaccine administered 
1599,405.0,0.0,"['adenovirus induce ebola', 'adenovirus induce ebov', 'adenovirus induce vaccine', 'adenovirus induce hadv-5-makgp', 'adenovirus induce hadv-5', 'adenovirus induce vaccine', 'adenovirus induce cellular', 'adenovirus highlight hadv-5', 'adenovirus highlight vaccine', 'adenovirus highlight cellular', 'ebola highlight hadv-5', 'ebola highlight vaccine', 'ebola highlight cellular', 'ebov highlight hadv-5', 'ebov highlight vaccine', 'ebov highlight cellular', 'vaccine highlight hadv-5', 'vaccine highlight cellular', 'hadv-5-makgp highlight hadv-5', 'hadv-5-makgp highlight vaccine', 'hadv-5-makgp highlight cellular']",4078,2014 ebola outbreak west africa resulted 11000 deaths highlighting need vaccine 
1600,405.0,1.0,"['immunity base ebov', 'immunity base infection', 'vaccine base ebov', 'vaccine base infection', 'cellular base ebov', 'cellular base infection']",4079,phase clinical trial human adenovirus type 5 vector-based ebola virus ebov vaccine hadv-5-makgp showed homologous prime-boost regimen hadv-5 vaccine elicited robust humoral response weak cellular immune response 
1601,405.0,2.0,"['newcastle exist lasota', 'newcastle exist vaccine', 'newcastle exist gp', 'newcastle exist ebov', 'newcastle exist makona', 'newcastle exist rlseb-gp', 'newcastle boost gp', 'newcastle boost ebov', 'newcastle boost makona', 'newcastle boost rlseb-gp', 'lasota boost gp', 'lasota boost ebov', 'lasota boost makona', 'lasota boost rlseb-gp', 'vaccine boost gp', 'vaccine boost ebov', 'vaccine boost makona', 'vaccine boost rlseb-gp']",4080,due pre-existing anti-vector immunity boosting vaccine increase magnitude cellular immune response contributes significantly protection ebov infection 
1602,405.0,3.0,"['cellular generate vaccine', 'cellular generate mouse', 'cellular generate hadv-5-vectored', 'cellular generate ebola', 'cellular generate elisa', 'cellular base hadv-5-vectored', 'cellular base ebola', 'cellular base elisa', 'vaccine base hadv-5-vectored', 'vaccine base ebola', 'vaccine base elisa', 'mouse base hadv-5-vectored', 'mouse base ebola', 'mouse base elisa']",4081, generated recombinant newcastle disease virus ndv based lasota vaccine strain expressing gp protein ebov variant makona rlseb-gp using reverse genetics technology 
1603,405.0,4.0,"['elisa use rlseb-gp', 'elisa use hadv-5ndv', 'elisa use ebov', 'elisa use cellular', 'elisa use vaccine', 'mouse use rlseb-gp', 'mouse use hadv-5ndv', 'mouse use ebov', 'mouse use cellular', 'mouse use vaccine', 'rlseb-gp use hadv-5ndv', 'rlseb-gp use ebov', 'rlseb-gp use cellular', 'rlseb-gp use vaccine']",4082,humoral cellular immune responses vaccine candidate mice immunized using homologous prime-boost regimen heterologous prime-boost regimen hadv-5-vectored ebola vaccine assessed using elisa elispot assays 
1604,405.0,5.0,"['gp-specific antibody show hadv-5-makgp-primed', 'gp-specific antibody show rlseb-gp-boosted', 'gp-specific antibody show hadv-5ndv', 'gp-specific antibody show mouse', 'ebov show hadv-5-makgp-primed', 'ebov show rlseb-gp-boosted', 'ebov show hadv-5ndv', 'ebov show mouse', 'gp-specific antibody prim hadv-5ndv', 'gp-specific antibody prim mouse', 'ebov prim hadv-5ndv', 'ebov prim mouse', 'hadv-5-makgp-primed prim hadv-5ndv', 'hadv-5-makgp-primed prim mouse']",4083,elisa elispot results showed mice primed rlseb-gp boosted hadv-5-makgp ndvhadv-5 reversed primed hadv-5-makgp boosted rlseb-gp hadv-5ndv exhibited more-potent ebov gp-specific antibody cellular immune responses receiving vaccine twice 
1605,405.0,6.0,"['hadv-5 detect human', 'hadv-5 detect vaccine', 'prime-ndv detect human', 'prime-ndv detect vaccine', 'boost detect human', 'boost detect vaccine', 'immunity detect human', 'immunity detect vaccine']",4084,robust ebov gp-specific antibody t-cell responses detected hadv-5-makgp-primed rlseb-gp-boosted hadv-5ndv mice 
1606,405.0,7.0,"['patient induce malignancy', 'patient induce covid-19', 'patient induce blood', 'patient induce 2020', 'patient boost blood', 'patient boost 2020', 'hematologic boost blood', 'hematologic boost 2020', 'malignancy boost blood', 'malignancy boost 2020', 'covid-19 boost blood', 'covid-19 boost 2020']",4085,results suggest hadv-5 prime-ndv boost regimen effective stimulating ebov-specific immunity homologous regimens alone indicating potential boosting ability ndv vector human vaccine use 
1607,406.0,1.0,"['antigen receptor confer -t cell', 'antigen receptor confer car', 'covid-19 confer -t cell', 'covid-19 confer car', 'vaccine confer -t cell', 'vaccine confer car', 'patient confer -t cell', 'patient confer car', 'cd19 confer -t cell', 'cd19 confer car']",4087,likely result combination immunodeficiency conferred disease therapeutics 
1608,406.0,2.0,"['cd19 aim antigen', 'car-t aim antigen', 'b-cell aim antigen', 'aplasia aim antigen']",4088,immunogenicity covid-19 vaccines patients exposure cd19 directed chimeric antigen receptor car -t cell therapy established 
1609,406.0,3.0,"['herein affect cd19', 'herein affect car-t', 'mrna affect cd19', 'mrna affect car-t', 'covid-19 affect cd19', 'covid-19 affect car-t', 'vaccine affect cd19', 'vaccine affect car-t', 'patient affect cd19', 'patient affect car-t', 'herein cause mrna', 'herein cause covid-19', 'herein cause vaccine', 'herein cause patient', 'herein cause lymphoma', 'herein cause cd19', 'herein cause car-t']",4089,cd19 car-t cell therapies cause b-cell aplasia turn affect humoral immune response novel antigens 
1610,406.0,4.0,"['patient induce covid-19', 'patient induce vaccine', 'patient induce hematologic', 'patient induce malignancy', 'patient evaluate vaccine', 'patient evaluate hematologic', 'patient evaluate malignancy']",4090,herein present results prospectively conducted clinical study evaluate immune responses mrna based covid-19 vaccines patients lymphoma received cd19 directed car-t cell therapy 
1611,406.0,5.0,"['plasma enrol b cell', 'plasma enrol car- cells', 'plasma enrol vaccine', 'plasma enrol patient', 'peripheral enrol b cell', 'peripheral enrol car- cells', 'peripheral enrol vaccine', 'peripheral enrol patient', 'blood enrol b cell', 'blood enrol car- cells', 'blood enrol vaccine', 'blood enrol patient', 'b cell evaluate car- cells', 'b cell evaluate patient', 'plasma evaluate car- cells', 'plasma evaluate patient', 'peripheral evaluate car- cells', 'peripheral evaluate patient', 'blood evaluate car- cells', 'blood evaluate patient', 'vaccine evaluate car- cells', 'vaccine evaluate patient']",4091,methods patients healthy controls enrolled prospective clinical study evaluating immune responses commercial covid-19 rna vaccines patients hematologic malignancies 
1612,406.0,8.0,['cpa associate genscript'],4094,plasma samples analyzed enzyme-linked immunosorbent assay elisa using different full-length recombinant sars-cov-2 proteins control proteins 
1613,406.0,14.0,"['ten receive vaccine', 'ten receive vaccine', 'patient receive vaccine', 'patient receive vaccine', 'ten aim vaccine', 'patient aim vaccine']",4100,patients received cd19 directed car-t cell therapy 
1614,406.0,17.0,['vaccine show 1b'],4103,peripheral blood plasma 34 hcs already showed substantial sars-cov-2 neutralizing activity 4 weeks first dose covid-19 mrna vaccine none 5 cd19 car-t patients analyzed evidenced antibody-mediated neutralizing activity blood point time figure 1a 
1615,406.0,18.0,"['car-t show 1b', 'patient show 1b', 'sars-cov-2 show 1b', 'blood show 1b']",4104,around 4 weeks receiving second dose vaccine 4 hcs tested evidenced complete almost complete neutralizing activity figure 1b 
1616,406.0,19.0,"['immunity show patient', 'immunity show anti-flu', 'immunity show 2a', 'covid-19 show patient', 'covid-19 show anti-flu', 'covid-19 show 2a', 'vaccine show patient', 'vaccine show anti-flu', 'vaccine show 2a', 'immunity mediate 2a', 'covid-19 mediate 2a', 'vaccine mediate 2a', 'car-t mediate 2a', 'patient mediate 2a']",4105,marked contrast 1 14 car-t patients analyzed evidenced relevant antibody-mediated sars-cov-2 neutralizing activity blood figure 1b 
1617,406.0,20.0,"['vaccine mediate 2b', 'vaccine mediate car-t', 'vaccine mediate patient']",4106,interestingly asked whether globally insufficient antibody-mediated immunity underlying cause lack response covid-19 vaccine car-t patients found clearly case since anti-flu -tt -ebv responses equivalent ones observed hcs figure 2a 
1618,406.0,21.0,"['car-t observe 2b', 'patient observe 2b', 'igg observe 2b', 'sars-cov-2 observe 2b']",4107,however 4 weeks post second dose vaccine hcs showed marked antibody titers viral spike proteins including ÃÂÂdeltaÃÂÂ variants figure 2b case car-t patients 
1619,406.0,27.0,"['american provide director', 'american provide director', 'american provide kitegilead', 'american provide director']",4113,apr dj contributed equally figure 1 disclosures dahiya kite gilead company consultancy atara biotherapeutics consultancy bms consultancy jazz pharmaceuticals research funding miltenyi biotech research funding 
1620,407.0,0.0,"['bnt162b2 show sars-cov-2', 'bnt162b2 show covid-19-related']",4115,background covid-19 mrna vaccines shown highly efficacious preventing disease randomized controlled trials nonetheless evidence real-world effectiveness vaccine limited 
1621,407.0,1.0,"['cohort evaluate member', 'cohort evaluate israel', 'cohort evaluate one', 'cohort evaluate bnt162b2', 'cohort prevent one', 'cohort prevent bnt162b2', 'member prevent one', 'member prevent bnt162b2', 'israel prevent one', 'israel prevent bnt162b2']",4116,study objective evaluate effectiveness bnt162b2 vaccine preventing sars-cov-2 infection covid-19-related hospitalization mortality 
1622,407.0,2.0,"['sars-cov-2 vaccinate vaccine', 'protection-period vaccinate vaccine', 'sars-cov-2 include protection-period', 'sars-cov-2 include vaccine']",4117,methods historical cohort study included members large health provider israel vaccinated least one dose bnt162b2 
1623,407.0,3.0,"['bnt162b2 confirm 740', '477 confirm 740']",4118,primary outcome incidence rate sars-cov-2 infection confirmed rt-pcr 7 27 days second dose protection-period compared days 1 7 first dose protection vaccine assumed reference-period 
1624,407.0,4.0,"['infection test ci 261-1150', 'infection test 548', '728 test ci 261-1150', '728 test 548', 'infection vaccinate ci 261-1150', 'infection vaccinate 728', 'infection vaccinate 548']",4119,results data 1178597 individuals vaccinated bnt162b2 analyzed mean age 477 years sd181 484 males 872454 740 reached protection period 
1625,407.0,5.0,"['vaccine receive ci79', 'vaccine receive ci88', 'vaccine receive -97', 'vaccine receive covid-19', 'vaccine compare ci88', 'vaccine compare -97', 'vaccine compare covid-19', 'ci79 compare ci88', 'ci79 compare -97', 'ci79 compare covid-19']",4120,overall 4514 infections occurred reference period compared 728 protection period yielding weighted mean daily incidence 548 per 100000 95 ci 261-1150 per 100000 54 per 100000 95 ci 35-84 per 100000 respectively 
1626,407.0,6.0,"['patient prevent ci37', 'vaccine prevent ci37']",4121,vaccine effectiveness preventing infection 90 95 ci79 - 95 94 95 ci88 -97 covid-19 
1627,408.0,2.0,"['pcp test previous', 'pcp establish previous']",4127,analysed results 34 indicators healthcare quality standard eqa comprising different types treatment 4 follow-up 5 control 10 screening 7 vaccinations 4 quaternary prevention 4 
1628,408.0,3.0,"['indicator aim 2020', 'greater aim 2020', 'greater aim indicator']",4128,pcp calculated indicator s percentage change february march april 2020 respective results previous month used t-student test paired data compare percentage change month previous year 
1629,408.0,5.0,"['indicator observe ci -', 'indicator observe ldl', 'indicator observe cholesterol', 'indicator observe 382', 'indicator observe 301', 'indicator observe blood', 'indicator observe ci', 'indicator observe -']",4130,results observed negative effect 85 eqa indicators march 68 april 
1630,408.0,6.0,"['indicator highlight 286', 'indicator highlight 333', 'indicator highlight 455', 'indicator highlight 371', 'diabetic highlight 286', 'diabetic highlight 333', 'diabetic highlight 455', 'diabetic highlight 371', 'foot highlight 286', 'foot highlight 333', 'foot highlight 455', 'foot highlight 371']",4131,90 control indicators negative effect highlighting control ldl cholesterol reduction - 269 95 ci - 317 - 223 march - 341 95 ci - 382 - 301 april control blood pressure reduction - 213 95 ci - 234 - 19 - 259 95 ci - 28 - 237 
1631,408.0,9.0,"['covid-19 observe indicator', 'covid-19 observe patient']",4134,finally among indicators quaternary prevention observed negative effects march april although case lower inadequacy means better clinical outcome 
1632,408.0,11.0,"['hepatitis c strengthen infectious diseases', 'vaccine strengthen infectious diseases', 'immunodeficiency strengthen infectious diseases', 'hiv-1 strengthen infectious diseases', 'hcv strengthen infectious diseases']",4136,hand indicators quaternary prevention strengthened results improved 
1633,409.0,0.0,"['innate induce th1', 'immune induce th1']",4137,effective vaccines human immunodeficiency virus-1 hiv-1 hepatitis c virus hcv remain significant challenge infectious diseases 
1634,409.0,1.0,"['simian observe boost', 'simian observe cohort', 'simian observe volunteer', 'simian observe hcv-hiv-1', 'simian observe vaccine', 'adenovirus observe boost', 'adenovirus observe cohort', 'adenovirus observe volunteer', 'adenovirus observe hcv-hiv-1', 'adenovirus observe vaccine', 'simian develop hcv-hiv-1', 'simian develop vaccine', 'adenovirus develop hcv-hiv-1', 'adenovirus develop vaccine', 'boost develop hcv-hiv-1', 'boost develop vaccine', 'cohort develop hcv-hiv-1', 'cohort develop vaccine', 'volunteer develop hcv-hiv-1', 'volunteer develop vaccine']",4138,given innate immune response key controlling scale nature developing adaptive immune responses targeting natural killer nk cells promote t-helper type 1 th1 -type immune response production interferon-ÃÂ³ ifnÃÂ³ remains untapped strategic target improved vaccination approaches 
1635,409.0,3.0,"['cytomegalovirus provide hcmv', 'cytomegalovirus provide participant', 'hcmv provide participant']",4140,early late timepoints demonstrated metabolic changes contributed sustained proliferation nk cells 
1636,409.0,5.0,"['summary describe hcmv', 'summary describe vaccine', 'summary describe human', 'summary observe hcmv', 'summary observe vaccine', 'summary observe human']",4142,changes restricted molecularly defined adaptive nk cells indeed canonical nk cells produced ifnÃÂ³ response vaccination equally impacted individuals latent hcmv 
1637,410.0,1.0,"['cohort infect sars-cov-2', 'cohort infect 2021']",4145,studies patient trajectories outcomes among hospitalised patients infected b117 essential hospital capacity planning 
1638,410.0,10.0,"['patient boost respiratory syndrome', 'patient boost coronavirus-2', 'patient boost sars-cov-2', 'patient boost chronic', 'patient boost leukaemia', 'patient boost tkis', 'cancer boost respiratory syndrome', 'cancer boost coronavirus-2', 'cancer boost sars-cov-2', 'cancer boost patient', 'cancer boost chronic', 'cancer boost leukaemia', 'cancer boost tkis', 'tyrosine boost respiratory syndrome', 'tyrosine boost coronavirus-2', 'tyrosine boost sars-cov-2', 'tyrosine boost patient', 'tyrosine boost chronic', 'tyrosine boost leukaemia', 'tyrosine boost tkis', 'inhibitor boost respiratory syndrome', 'inhibitor boost coronavirus-2', 'inhibitor boost sars-cov-2', 'inhibitor boost patient', 'inhibitor boost chronic', 'inhibitor boost leukaemia', 'inhibitor boost tkis']",4154,findings along success ongoing vaccination programmes encouraging ongoing capacity planning hospital sector 
1639,411.0,0.0,"['solid classify sars-cov-2', 'solid classify bnt162b2', 'solid classify vaccine', 'malignancy classify sars-cov-2', 'malignancy classify bnt162b2', 'malignancy classify vaccine']",4155,patients receiving targeted cancer treatments tyrosine kinase inhibitors tkis classified clinically extremely vulnerable group develop severe acute respiratory syndrome coronavirus-2 sars-cov-2 including patients chronic myeloid leukaemia cml taking tkis 
1640,411.0,3.0,"['immunoglobulin evaluate id50 501-2000', 'immunoglobulin evaluate cml', 'immunoglobulin evaluate serum', 'immunoglobulin evaluate dilution', 'immunoglobulin evaluate infection', 'immunoglobulin evaluate 200-500', 'immunoglobulin evaluate antibody', 'immunoglobulin evaluate nine', 'immunoglobulin evaluate patient', 'g evaluate id50 501-2000', 'g evaluate cml', 'g evaluate serum', 'g evaluate dilution', 'g evaluate infection', 'g evaluate 200-500', 'g evaluate antibody', 'g evaluate nine', 'g evaluate patient']",4158,seroconversion cellular immune response vaccination assessed 
1641,411.0,4.0,"['t-cell detect patient', 't-cell detect cd4', 't-cell detect nine', 't-cell detect cd8', 't-cell detect nine', 'patient detect cd4', 'patient detect nine', 'patient detect cd8', 'patient detect t-cell', 'patient detect nine']",4159,day 21 vaccination anti-spike immunoglobulin g detected 1416 87ÃÂ5 patients cml developed neutralising antibody response serum dilution inhibits 50 infection id50 50 including medium id50 200-500 high id50 501-2000 neutralising antibodies titres nine 16 56ÃÂ25 patients 
1642,411.0,5.0,"['sars-cov-2 see tumour lymphoid', 'bnt162b2 see tumour lymphoid', 'vaccine see tumour lymphoid', 'patient see tumour lymphoid', 'cml see tumour lymphoid', 'antibody see tumour lymphoid', 't-cell see tumour lymphoid', 'patient see tumour lymphoid']",4160,t-cell response seen 1415 93ÃÂ3 evaluable patients polyfunctional responses seen 1215 80 patients polyfunctional cd4 response nine 15 polyfunctional cd8 t-cell response nine 15 
1643,411.0,6.0,"['cd4 show fh cells', 'cd4 show viral infections', 'cd4 show sars-cov-2', 'cd4 show vaccine', 'cd4 show sars-cov-2', 'cd4 show infection', 'cd4 show pro-inflammatory', 'cd4 show monocyte', 'cd4 show proliferating', 'cd4 show peripheral', 'cd4 show blood', 'cd4 show blood', 'cd4 show lung', 'cd4 show sars-cov-2', 'fh cells neutralize vaccine', 'fh cells neutralize sars-cov-2', 'fh cells neutralize infection', 'fh cells neutralize pro-inflammatory', 'fh cells neutralize monocyte', 'fh cells neutralize proliferating', 'fh cells neutralize peripheral', 'fh cells neutralize blood', 'fh cells neutralize cd4', 'fh cells neutralize blood', 'fh cells neutralize lung', 'fh cells neutralize sars-cov-2', 'viral infections neutralize vaccine', 'viral infections neutralize sars-cov-2', 'viral infections neutralize infection', 'viral infections neutralize pro-inflammatory', 'viral infections neutralize monocyte', 'viral infections neutralize proliferating', 'viral infections neutralize peripheral', 'viral infections neutralize blood', 'viral infections neutralize cd4', 'viral infections neutralize blood', 'viral infections neutralize lung', 'viral infections neutralize sars-cov-2', 'cd4 neutralize vaccine', 'cd4 neutralize sars-cov-2', 'cd4 neutralize infection', 'cd4 neutralize pro-inflammatory', 'cd4 neutralize monocyte', 'cd4 neutralize proliferating', 'cd4 neutralize peripheral', 'cd4 neutralize blood', 'cd4 neutralize blood', 'cd4 neutralize lung', 'cd4 neutralize sars-cov-2', 'sars-cov-2 neutralize vaccine', 'sars-cov-2 neutralize infection', 'sars-cov-2 neutralize pro-inflammatory', 'sars-cov-2 neutralize monocyte', 'sars-cov-2 neutralize proliferating', 'sars-cov-2 neutralize peripheral', 'sars-cov-2 neutralize blood', 'sars-cov-2 neutralize cd4', 'sars-cov-2 neutralize blood', 'sars-cov-2 neutralize lung', 'fh cells see infection', 'fh cells see pro-inflammatory', 'fh cells see monocyte', 'fh cells see proliferating', 'fh cells see peripheral', 'fh cells see blood', 'fh cells see cd4', 'fh cells see blood', 'fh cells see lung', 'fh cells see sars-cov-2', 'viral infections see infection', 'viral infections see pro-inflammatory', 'viral infections see monocyte', 'viral infections see proliferating', 'viral infections see peripheral', 'viral infections see blood', 'viral infections see cd4', 'viral infections see blood', 'viral infections see lung', 'viral infections see sars-cov-2', 'cd4 see infection', 'cd4 see pro-inflammatory', 'cd4 see monocyte', 'cd4 see proliferating', 'cd4 see peripheral', 'cd4 see blood', 'cd4 see blood', 'cd4 see lung', 'cd4 see sars-cov-2', 'sars-cov-2 see infection', 'sars-cov-2 see pro-inflammatory', 'sars-cov-2 see monocyte', 'sars-cov-2 see proliferating', 'sars-cov-2 see peripheral', 'sars-cov-2 see blood', 'sars-cov-2 see cd4', 'sars-cov-2 see blood', 'sars-cov-2 see lung', 'vaccine see infection', 'vaccine see pro-inflammatory', 'vaccine see monocyte', 'vaccine see proliferating', 'vaccine see peripheral', 'vaccine see blood', 'vaccine see cd4', 'vaccine see blood', 'vaccine see lung', 'vaccine see sars-cov-2']",4161,data demonstrate immunogenicity single dose sars-cov-2 bnt162b2 vaccine patients cml neutralising antibodies polyfunctional t-cell responses seen contrast patients solid tumour lymphoid haematological malignancies 
1644,412.0,0.0,"['covid-19 generate sars-cov-2', 'covid-19 generate worker', 'covid-19 generate mrna-based', 'covid-19 generate vaccine', 'vaccine generate sars-cov-2', 'vaccine generate worker', 'vaccine generate covid-19', 'vaccine generate mrna-based', 'vaccine generate covid-19', 'expert generate sars-cov-2', 'expert generate worker', 'expert generate covid-19', 'expert generate mrna-based', 'expert generate covid-19', 'expert generate vaccine', 'person generate sars-cov-2', 'person generate worker', 'person generate covid-19', 'person generate mrna-based', 'person generate covid-19', 'person generate vaccine', 'covid-19 generate sars-cov-2', 'covid-19 generate worker', 'covid-19 generate mrna-based', 'covid-19 generate vaccine', 'immunity generate sars-cov-2', 'immunity generate worker', 'immunity generate covid-19', 'immunity generate mrna-based', 'immunity generate covid-19', 'immunity generate vaccine', 'vaccine generate sars-cov-2', 'vaccine generate worker', 'vaccine generate covid-19', 'vaccine generate mrna-based', 'vaccine generate covid-19', 'covid-19 investigate vaccine', 'vaccine investigate covid-19', 'expert investigate covid-19', 'expert investigate vaccine', 'person investigate covid-19', 'person investigate vaccine', 'covid-19 investigate vaccine', 'immunity investigate covid-19', 'immunity investigate vaccine', 'vaccine investigate covid-19', 'sars-cov-2 investigate covid-19', 'sars-cov-2 investigate vaccine', 'worker investigate covid-19', 'worker investigate vaccine', 'covid-19 investigate vaccine']",4162,cd4 follicular helper fh cells important generation durable specific humoral protection viral infections degree sars-cov-2 infection generates fh cells stimulates germinal center response important question investigate vaccine options current pandemic report sars-cov-2 infection resulted transient accumulation pro-inflammatory monocytes proliferating fh cells h 1 profile peripheral blood cd4 helper cell responses skewed predominantly toward h 1 response blood lung lymph nodes observed generation germinal center fh cells specific sars-cov-2 spike nucleocapsid n proteins corresponding early appearance antiviral serum igg antibodies data suggest vaccine promoting h 1-type fh responses target protein may lead protective immunity
1645,414.0,0.0,"['heart prioritize heart disease', 'heart prioritize patient', 'heart prioritize achd', 'heart prioritize patient', 'heart prioritize vaccine', 'chd prioritize heart disease', 'chd prioritize patient', 'chd prioritize achd', 'chd prioritize patient', 'chd prioritize vaccine']",4164,individuals highest risk adverse outcomes covid-19 prioritized vaccine allocation policies 
1646,414.0,1.0,"['covid-19 emerge delta', 'vaccine emerge delta', 'worker emerge delta']",4165,conducted literature review published studies comprehend congenital heart disease chd covid-19 order present overall evidences exposure clinical risk patients adult congenital heart disease achd propose risk profile schema patients incorporated vaccine distribution decisions 
1647,415.0,2.0,"['hcws consider covid-19', 'hcws consider 114', 'hcws consider infection', 'hcws consider person-days', 'hcws consider infection', 'hcws consider 830084', 'hcws consider person-days', 'hcws consider 823', 'hcws consider 751-874', 'person-days consider hcws', 'person-days consider covid-19', 'person-days consider 114', 'person-days consider infection', 'person-days consider infection', 'person-days consider 830084', 'person-days consider 823', 'person-days consider 751-874']",4168,accounted covariates demographics community background infection incidence well information bias regarding covid-19 diagnosis vaccination status 
1648,415.0,5.0,"['tetanus-reduced receive diphtheria-acellular', 'tetanus-reduced receive pertussis', 'tetanus-reduced receive vaccine', 'tetanus-reduced receive adult', 'tetanus-reduced receive small-scale', 'tetanus-reduced receive pertussis', 'tetanus-reduced receive korea', 'tetanus-reduced receive vaccine', 'tetanus-reduced receive stain', 'tetanus-reduced provide korea', 'tetanus-reduced provide vaccine', 'tetanus-reduced provide stain', 'diphtheria-acellular provide korea', 'diphtheria-acellular provide vaccine', 'diphtheria-acellular provide stain', 'pertussis provide korea', 'pertussis provide vaccine', 'pertussis provide stain', 'vaccine provide korea', 'vaccine provide stain', 'adult provide korea', 'adult provide vaccine', 'adult provide stain', 'small-scale provide korea', 'small-scale provide vaccine', 'small-scale provide stain']",4171,independently found re-infection among prior covid-19 contributing 74557 re-infection-free person-days adding evidence base robustness naturally acquired immunity 
1649,416.0,0.0,"['gc emphasize fha', 'korean emphasize fha', 'tdap emphasize fha', 'vaccine emphasize fha', 'gc3111 emphasize fha', 'vaccine emphasize fha', 'gc3111 emphasize fha', 'gc reduce gc3111', 'gc reduce vaccine', 'gc reduce gc3111', 'gc reduce fha', 'korean reduce gc3111', 'korean reduce vaccine', 'korean reduce gc3111', 'korean reduce fha', 'tdap reduce gc3111', 'tdap reduce vaccine', 'tdap reduce gc3111', 'tdap reduce fha']",4172,background necessity tetanus-reduced dose diphtheria-acellular pertussis tdap vaccine adolescence adults emphasized since resurgence small-scale pertussis korea worldwide due waning effect vaccine variant pathogenic stains late 1990s 
1650,416.0,1.0,"['tdap develop tdap vaccine', 'tdap develop vaccine', 'tdap develop murine', 'vaccine develop tdap vaccine', 'vaccine develop murine', 'two develop tdap vaccine', 'two develop vaccine', 'two develop murine', 'tdap develop tdap vaccine', 'tdap develop vaccine', 'tdap develop murine', 'vaccine develop tdap vaccine', 'vaccine develop murine']",4173,greencross pharma gc pharma korean company developed tdap vaccine gc3111 2010 recently enhanced vaccine gc3111 produced previously 2010 reinforce antibody response filamentous hemagglutinin fha 
1651,416.0,2.0,"['two compare pertussis', 'two compare vaccine', 'two compare booster', 'two compare tdap', 'two compare vaccine', 'two compare tdap', 'two compare vaccine', 'two compare tdap', 'two compare vaccine', 'two compare gc3111', 'two compare gc3111', 'balbc compare pertussis', 'balbc compare vaccine', 'balbc compare booster', 'balbc compare tdap', 'balbc compare vaccine', 'balbc compare tdap', 'balbc compare vaccine', 'balbc compare tdap', 'balbc compare vaccine', 'balbc compare gc3111', 'balbc compare gc3111', 'mouse compare pertussis', 'mouse compare vaccine', 'mouse compare booster', 'mouse compare tdap', 'mouse compare vaccine', 'mouse compare tdap', 'mouse compare vaccine', 'mouse compare tdap', 'mouse compare vaccine', 'mouse compare gc3111', 'mouse compare gc3111', 'two compare pertussis', 'two compare vaccine', 'two compare booster', 'two compare tdap', 'two compare vaccine', 'two compare tdap', 'two compare vaccine', 'two compare tdap', 'two compare vaccine', 'two compare gc3111', 'two compare gc3111', 'two evaluate vaccine', 'two evaluate booster', 'two evaluate tdap', 'two evaluate vaccine', 'two evaluate tdap', 'two evaluate vaccine', 'two evaluate tdap', 'two evaluate vaccine', 'two evaluate gc3111', 'two evaluate gc3111', 'balbc evaluate vaccine', 'balbc evaluate booster', 'balbc evaluate tdap', 'balbc evaluate vaccine', 'balbc evaluate tdap', 'balbc evaluate vaccine', 'balbc evaluate tdap', 'balbc evaluate vaccine', 'balbc evaluate gc3111', 'balbc evaluate gc3111', 'mouse evaluate vaccine', 'mouse evaluate booster', 'mouse evaluate tdap', 'mouse evaluate vaccine', 'mouse evaluate tdap', 'mouse evaluate vaccine', 'mouse evaluate tdap', 'mouse evaluate vaccine', 'mouse evaluate gc3111', 'mouse evaluate gc3111', 'two evaluate vaccine', 'two evaluate booster', 'two evaluate tdap', 'two evaluate vaccine', 'two evaluate tdap', 'two evaluate vaccine', 'two evaluate tdap', 'two evaluate vaccine', 'two evaluate gc3111', 'two evaluate gc3111', 'diphtheria-tetanus-acellular evaluate vaccine', 'diphtheria-tetanus-acellular evaluate booster', 'diphtheria-tetanus-acellular evaluate tdap', 'diphtheria-tetanus-acellular evaluate vaccine', 'diphtheria-tetanus-acellular evaluate tdap', 'diphtheria-tetanus-acellular evaluate vaccine', 'diphtheria-tetanus-acellular evaluate tdap', 'diphtheria-tetanus-acellular evaluate vaccine', 'diphtheria-tetanus-acellular evaluate gc3111', 'diphtheria-tetanus-acellular evaluate gc3111', 'pertussis evaluate vaccine', 'pertussis evaluate booster', 'pertussis evaluate tdap', 'pertussis evaluate vaccine', 'pertussis evaluate tdap', 'pertussis evaluate vaccine', 'pertussis evaluate tdap', 'pertussis evaluate vaccine', 'pertussis evaluate gc3111', 'pertussis evaluate gc3111', 'two induce tdap', 'two induce vaccine', 'two induce tdap', 'two induce vaccine', 'two induce gc3111', 'two induce gc3111', 'balbc induce tdap', 'balbc induce vaccine', 'balbc induce tdap', 'balbc induce vaccine', 'balbc induce gc3111', 'balbc induce gc3111', 'mouse induce tdap', 'mouse induce vaccine', 'mouse induce tdap', 'mouse induce vaccine', 'mouse induce gc3111', 'mouse induce gc3111', 'two induce tdap', 'two induce vaccine', 'two induce tdap', 'two induce vaccine', 'two induce gc3111', 'two induce gc3111', 'diphtheria-tetanus-acellular induce tdap', 'diphtheria-tetanus-acellular induce vaccine', 'diphtheria-tetanus-acellular induce tdap', 'diphtheria-tetanus-acellular induce vaccine', 'diphtheria-tetanus-acellular induce gc3111', 'diphtheria-tetanus-acellular induce gc3111', 'pertussis induce tdap', 'pertussis induce vaccine', 'pertussis induce tdap', 'pertussis induce vaccine', 'pertussis induce gc3111', 'pertussis induce gc3111', 'vaccine induce tdap', 'vaccine induce tdap', 'vaccine induce gc3111', 'vaccine induce gc3111', 'booster induce tdap', 'booster induce vaccine', 'booster induce tdap', 'booster induce vaccine', 'booster induce gc3111', 'booster induce gc3111', 'tdap induce vaccine', 'tdap induce vaccine', 'tdap induce gc3111', 'tdap induce gc3111', 'vaccine induce tdap', 'vaccine induce tdap', 'vaccine induce gc3111', 'vaccine induce gc3111']",4174,study immunogenicity efficacy enhanced tdap vaccine compared evaluated two tdap vaccines gc3111 vaccine produced 2010 previously commercially available tdap vaccine murine model 
1652,416.0,4.0,"['gc3111 evaluate vaccine', 'gc3111 evaluate hemagglutinin']",4176,humoral response assessed 1 week 2 4 weeks tdap booster vaccination 
1653,416.0,5.0,"['interferon enhance hbp antigen', 'interferon enhance ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³', 'interferon enhance th1', 'interferon enhance interleukin', 'interferon enhance il-5', 'interferon enhance th2', 'interferon enhance interleukin', 'interferon enhance il-17', 'interferon enhance th17', 'interferon enhance cytokine', 'interferon enhance booster', 'interferon enhance three', 'interferon enhance bordetella', 'interferon enhance pertussis', 'interferon enhance hbp', 'interferon enhance vaccine', 'interferon enhance hbp', 'interferon generate hbp antigen', 'interferon generate interleukin', 'interferon generate il-5', 'interferon generate th2', 'interferon generate interleukin', 'interferon generate il-17', 'interferon generate th17', 'interferon generate cytokine', 'interferon generate booster', 'interferon generate three', 'interferon generate bordetella', 'interferon generate pertussis', 'interferon generate hbp', 'interferon generate vaccine', 'interferon generate hbp', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ generate hbp antigen', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ generate interleukin', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ generate il-5', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ generate th2', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ generate interleukin', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ generate il-17', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ generate th17', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ generate cytokine', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ generate booster', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ generate three', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ generate bordetella', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ generate pertussis', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ generate hbp', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ generate vaccine', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ generate hbp', 'interferon compare hbp antigen', 'interferon compare interleukin', 'interferon compare il-17', 'interferon compare th17', 'interferon compare cytokine', 'interferon compare booster', 'interferon compare three', 'interferon compare bordetella', 'interferon compare pertussis', 'interferon compare hbp', 'interferon compare vaccine', 'interferon compare hbp', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ compare hbp antigen', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ compare interleukin', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ compare il-17', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ compare th17', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ compare cytokine', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ compare booster', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ compare three', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ compare bordetella', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ compare pertussis', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ compare hbp', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ compare vaccine', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ compare hbp', 'th1 compare hbp antigen', 'th1 compare interleukin', 'th1 compare il-17', 'th1 compare th17', 'th1 compare cytokine', 'th1 compare booster', 'th1 compare three', 'th1 compare bordetella', 'th1 compare pertussis', 'th1 compare hbp', 'th1 compare vaccine', 'th1 compare hbp', 'interleukin compare hbp antigen', 'interleukin compare il-17', 'interleukin compare th17', 'interleukin compare cytokine', 'interleukin compare booster', 'interleukin compare three', 'interleukin compare bordetella', 'interleukin compare pertussis', 'interleukin compare hbp', 'interleukin compare vaccine', 'interleukin compare hbp', 'il-5 compare hbp antigen', 'il-5 compare interleukin', 'il-5 compare il-17', 'il-5 compare th17', 'il-5 compare cytokine', 'il-5 compare booster', 'il-5 compare three', 'il-5 compare bordetella', 'il-5 compare pertussis', 'il-5 compare hbp', 'il-5 compare vaccine', 'il-5 compare hbp']",4177,enhanced gc3111 generated similar humoral response compare commercial vaccine filamentous hemagglutinin fha 
1654,416.0,7.0,"['immunity perform secretion', 'immunity perform three']",4179,bacterial challenge test performed 4 weeks booster vaccination 
1655,417.0,3.0,"['150 1400 develop six', '150 1400 develop antibody', 'patient develop six', 'patient develop antibody', 'dilution develop six', 'dilution develop antibody', '13200 develop six', '13200 develop antibody', 'six develop antibody', 'antigen develop six', 'antigen develop antibody']",4189,multi-sars-cov-2 assay multiparameter serology test developed serological confirmation past-infections used determine reactivity six different sars-cov-2 antigens 
1656,417.0,5.0,"['resultsmedian use two', 'resultsmedian use 120', 'resultsmedian use 127', 'resultsmedian use 187', 'resultsmedian use antibody', '20 use two', '20 use 120', '20 use 127', '20 use 187', '20 use antibody', 'resultsmedian modify two', 'resultsmedian modify 120', 'resultsmedian modify 127', 'resultsmedian modify 187', 'resultsmedian modify antibody', '20 modify two', '20 modify 120', '20 modify 127', '20 modify 187', '20 modify antibody']",4191,nonlinear mixed-effects modelling applied convert intensity readings 3 determined dilutions single quantification value antibody 
1657,417.0,6.0,"['398 infect 420', '398 infect 171', '398 infect 620', '398 infect 225', '398 infect s2', '398 infect vaccine', '398 vaccinate 171', '398 vaccinate 620', '398 vaccinate 225', '398 vaccinate s2', '398 vaccinate vaccine', '420 vaccinate 171', '420 vaccinate 620', '420 vaccinate 225', '420 vaccinate s2', '420 vaccinate vaccine']",4192,resultsmedian half-life 20 naturally infected vs 74 vaccinated subjects two doses respectively 120 vs 50 days rbd 127 vs 53 days s1 187 vs 86 days s2 antibodies 
1658,417.0,9.0,['sars-cov-2 describe immunity'],4195,conversion helps define sustainability specific immune responses relevant viral antigen help defining protection characteristics infection vaccination 
1659,418.0,1.0,"['antibody infect rt-qpcr', 'antibody infect sars-cov2', 'patient infect rt-qpcr', 'patient infect sars-cov2']",4197, assumed patients infected sars-cov-2 develop antibodies case coronaviruses like mers-cov sars-cov 
1660,418.0,2.0,['bgi test roche'],4198,present study analyzed development antibodies 77 patients oncologic diagnosis 26 days positive rt-qpcr testing sars-cov2 
1661,418.0,5.0,"['sars-cov2 induce immunity', 'sars-cov2 induce covid-19', 'sars-cov2 show immunity', 'sars-cov2 show covid-19']",4201,despite multiple testing remaining patients show measurable antibody concentrations subsequent tests 
1662,419.0,2.0,"['participant describe dementia', 'participant describe 225', 'participant describe 845']",4206,settings data drawn uk biobank cohort study total 228 223 participants hospital episodes statistics primary care linkage health records 
1663,419.0,9.0,"['immunisation associate dementia', 'zostavax associate dementia']",4213,conclusion history shingles associated increased risk dementia 
1664,420.0,1.0,"['child protect three', 'child protect vaccine']",4216,pentavalent vaccine protects five major infections including diphtheria tetanus pertussis hepatitis b hepb haemophilus influenzae type b hib added iranian national immunization program november 2014 study aimed determine pentavalent vaccine adverse events immunogenicity iranian children population sari northern iran 
1665,420.0,4.0,"['elisa receive vaccine', 'elisa receive vaccine', 'elisa follow vaccine']",4219,possible local systemic complications vaccine recorded 7 days following vaccination 
1666,420.0,6.0,"['vaccine use hepb', 'vaccine use gmt15354', 'vaccine use euml', 'vaccine use diphtheria', 'vaccine use gmt043', 'vaccine use euml', 'vaccine use pertussis', 'vaccine use gmt1944', 'vaccine use euml', 'tetanus use hepb', 'tetanus use gmt15354', 'tetanus use euml', 'tetanus use diphtheria', 'tetanus use gmt043', 'tetanus use euml', 'tetanus use pertussis', 'tetanus use gmt1944', 'tetanus use euml', '100 use hepb', '100 use gmt15354', '100 use euml', '100 use diphtheria', '100 use gmt043', '100 use euml', '100 use pertussis', '100 use gmt1944', '100 use euml', 'euml use hepb', 'euml use gmt15354', 'euml use diphtheria', 'euml use gmt043', 'euml use pertussis', 'euml use gmt1944', 'gmt244 use hepb', 'gmt244 use gmt15354', 'gmt244 use euml', 'gmt244 use diphtheria', 'gmt244 use gmt043', 'gmt244 use euml', 'gmt244 use pertussis', 'gmt244 use gmt1944', 'gmt244 use euml']",4221,statistical analysis performed spss 200 software chi-square fisher s exact tests used analysis 
1667,420.0,10.0,"['vaccine observe hepatitis b', 'vaccine observe diphtheria', 'vaccine observe tetanus', 'vaccine observe pertussis', 'iran observe hepatitis b', 'iran observe diphtheria', 'iran observe tetanus', 'iran observe pertussis']",4225,serious side effects observed 
1668,420.0,13.0,['vaccine induce iran'],4228,study severe complication leading contraindication subsequent injections reported 
1669,420.0,14.0,"['asthma exacerbations continue upper-respiratory tract', 'asthma exacerbations continue virus diseases', 'asthma exacerbations continue allergic rhinitis', 'asthma exacerbations continue asthma therapies', 'asthma exacerbations continue rhinovirus', 'asthma exacerbations continue influenza', 'asthma exacerbations continue influenza', 'asthma exacerbations continue vaccine', 'asthma exacerbations continue influenza', 'asthma exacerbations continue vaccine', 'asthma exacerbations continue rhinovirus', 'asthma exacerbations continue asthma', 'asthma exacerbations continue viral', 'asthma exacerbations continue asthmatic', 'asthma exacerbations continue covid-19', 'asthma exacerbations continue asthmatic', 'asthma exacerbations continue asthmatic', 'asthma exacerbations continue asthma', 'asthma exacerbations continue covid-19', 'asthma exacerbations continue covid-19-infected', 'asthma exacerbations continue patient', 'asthmatic continue upper-respiratory tract', 'asthmatic continue virus diseases', 'asthmatic continue allergic rhinitis', 'asthmatic continue asthma exacerbations', 'asthmatic continue asthma therapies', 'asthmatic continue rhinovirus', 'asthmatic continue influenza', 'asthmatic continue influenza', 'asthmatic continue vaccine', 'asthmatic continue influenza', 'asthmatic continue vaccine', 'asthmatic continue rhinovirus', 'asthmatic continue asthma', 'asthmatic continue viral', 'asthmatic continue covid-19', 'asthmatic continue asthma', 'asthmatic continue covid-19', 'asthmatic continue covid-19-infected', 'asthmatic continue patient', 'viral continue upper-respiratory tract', 'viral continue virus diseases', 'viral continue allergic rhinitis', 'viral continue asthma exacerbations', 'viral continue asthma therapies', 'viral continue rhinovirus', 'viral continue influenza', 'viral continue influenza', 'viral continue vaccine', 'viral continue influenza', 'viral continue vaccine', 'viral continue rhinovirus', 'viral continue asthma', 'viral continue asthmatic', 'viral continue covid-19', 'viral continue asthmatic', 'viral continue asthmatic', 'viral continue asthma', 'viral continue covid-19', 'viral continue covid-19-infected', 'viral continue patient', 'illness continue upper-respiratory tract', 'illness continue virus diseases', 'illness continue allergic rhinitis', 'illness continue asthma exacerbations', 'illness continue asthma therapies', 'illness continue rhinovirus', 'illness continue influenza', 'illness continue influenza', 'illness continue vaccine', 'illness continue influenza', 'illness continue vaccine', 'illness continue rhinovirus', 'illness continue asthma', 'illness continue viral', 'illness continue asthmatic', 'illness continue covid-19', 'illness continue asthmatic', 'illness continue asthmatic', 'illness continue asthma', 'illness continue covid-19', 'illness continue covid-19-infected', 'illness continue patient', 'asthmatic replace asthma exacerbations', 'asthmatic replace upper-respiratory tract', 'asthmatic replace virus diseases', 'asthmatic replace allergic rhinitis', 'asthmatic replace asthma exacerbations', 'asthmatic replace asthma therapies', 'asthmatic replace rhinovirus', 'asthmatic replace influenza', 'asthmatic replace influenza', 'asthmatic replace vaccine', 'asthmatic replace influenza', 'asthmatic replace vaccine', 'asthmatic replace rhinovirus', 'asthmatic replace asthma', 'asthmatic replace viral', 'asthmatic replace covid-19', 'asthmatic replace asthma', 'asthmatic replace covid-19', 'asthmatic replace covid-19-infected', 'asthmatic replace patient', 'viral replace asthma exacerbations', 'viral replace upper-respiratory tract', 'viral replace virus diseases', 'viral replace allergic rhinitis', 'viral replace asthma exacerbations', 'viral replace asthma therapies', 'viral replace rhinovirus', 'viral replace influenza', 'viral replace influenza', 'viral replace vaccine', 'viral replace influenza', 'viral replace vaccine', 'viral replace rhinovirus', 'viral replace asthma', 'viral replace asthmatic', 'viral replace covid-19', 'viral replace asthmatic', 'viral replace asthmatic', 'viral replace asthma', 'viral replace covid-19', 'viral replace covid-19-infected', 'viral replace patient', 'illness replace asthma exacerbations', 'illness replace upper-respiratory tract', 'illness replace virus diseases', 'illness replace allergic rhinitis', 'illness replace asthma exacerbations', 'illness replace asthma therapies', 'illness replace rhinovirus', 'illness replace influenza', 'illness replace influenza', 'illness replace vaccine', 'illness replace influenza', 'illness replace vaccine', 'illness replace rhinovirus', 'illness replace asthma', 'illness replace viral', 'illness replace asthmatic', 'illness replace covid-19', 'illness replace asthmatic', 'illness replace asthmatic', 'illness replace asthma', 'illness replace covid-19', 'illness replace covid-19-infected', 'illness replace patient']",4229, present policy replacing triple dtp vaccine pentavalent vaccine continued iran 
1670,422.0,1.0,"['patient observe vaccine', 'patient observe igg', 'patient observe diphtheria', 'patient observe tetanus', 'patient observe streptococcus', 'patient observe pneumoniae', 'patient observe vaccine', 'patient observe igg', 'patient observe diphtheria', 'patient observe tetanus', 'patient observe streptococcus', 'patient observe pneumoniae', 'serum observe vaccine', 'serum observe igg', 'serum observe diphtheria', 'serum observe tetanus', 'serum observe streptococcus', 'serum observe pneumoniae', 'igg observe vaccine', 'igg observe diphtheria', 'igg observe tetanus', 'igg observe streptococcus', 'igg observe pneumoniae', '400 observe vaccine', '400 observe igg', '400 observe diphtheria', '400 observe tetanus', '400 observe streptococcus', '400 observe pneumoniae', 'serum observe vaccine', 'serum observe igg', 'serum observe diphtheria', 'serum observe tetanus', 'serum observe streptococcus', 'serum observe pneumoniae', 'igg observe vaccine', 'igg observe diphtheria', 'igg observe tetanus', 'igg observe streptococcus', 'igg observe pneumoniae']",4232,exploratory proof concept study objective determine prevalence humoral immunodeficiency patients cll serum igg ÃÂÂ 400 mgdl evaluate efficacy subcutaneous immunoglobulin scig population 
1671,422.0,3.0,"['fifteen treat 570', 'fifteen treat 827', 'fifteen treat 615', 'fifteen treat 515', 'patient treat 570', 'patient treat 827', 'patient treat 615', 'patient treat 515']",4234,patients evidence humoral dysfunction treated scig hizentra every 7ÃÂ2 days 24 weeks 
1672,422.0,4.0,"['1415 enrol vaccine', '1415 enrol scig', '933 enrol vaccine', '933 enrol scig']",4235,results fifteen patients enrolled median igg 782 mgdl iqr 570 827 615 40 responded vaccination td 515 33 responded vaccination ppv23 
1673,422.0,5.0,"['patient show 565', 'patient show 819', 'scig show 565', 'scig show 819', 'serum show 565', 'serum show 819', 'igg show 565', 'igg show 819', 'patient show 819', 'scig show 819', 'serum show 819', 'igg show 819']",4236,1415 933 demonstrated humoral immunodeficiency evidenced suboptimal vaccine responses treated scig 
1674,422.0,6.0,"['streptococcus treat serotypes', 'pneumoniae treat serotypes']",4237,patients treated scig serum igg increased 670 mgdl iqr 565 819 1054 mgdl iqr 1040 1166 24 weeks 95 ci 271ÃÂÂ540 
1675,422.0,8.0,"['patient decrease 400', 'immunodeficiency decrease 400']",4239,non-neutropenic infections nni decreased 14 5 treatment scig 
1676,422.0,9.0,"['patient show serum', 'patient show igg', 'patient show igg', 'patient show streptococcus', 'patient show pneumoniae', 'patient show reliance', 'patient show antibiotic']",4240,conclusions patients cll demonstrate humoral immunodeficiency despite igg 400 mgdl 
1677,423.0,0.0,"['autoimmune induce respiratory syndrome', 'autoimmune induce coronavirus', 'autoimmune induce sars-cov-2', 'endocrine induce respiratory syndrome', 'endocrine induce coronavirus', 'endocrine induce sars-cov-2', 'asia induce respiratory syndrome', 'asia induce coronavirus', 'asia induce sars-cov-2']",4243,background autoimmuneinflammatory syndrome induced adjuvants asia comprises four entities including postvaccination phenomenon appears exposed adjuvants vaccines increase immune response 
1678,423.0,2.0,"['vaccine receive autoimmune', 'vaccine receive thyroid']",4245,patient s findings two female health care workers received sars-cov-2 vaccine three days later developed clinical manifestations thyroid hyperactivity increased thyroid hormone levels thyroid function tests suppressed thyroid-stimulating hormone elevated antithyroid antibodies 
1679,423.0,3.0,"['patient show asia', 'patient show vaccine', 'patient show thyroid', 'patient show hyperfunction', 'patient show antithyroid', 'patient show antibody', 'patient induce antithyroid', 'patient induce antibody', 'asia induce antithyroid', 'asia induce antibody', 'vaccine induce antithyroid', 'vaccine induce antibody', 'thyroid induce antithyroid', 'thyroid induce antibody']",4246,summary vaccines shown trigger immune response leads broad spectrum autoimmune diseases including autoimmune thyroid disease 
1680,423.0,4.0,['graf meet sars-cov-2'],4247,patients met diagnostic criteria asia exposed adjuvant vaccine developed clinical manifestations thyroid hyperfunction within days appearance antithyroid antibodies despite healthy vaccination 
1681,423.0,5.0,"['covid-19 receive patient', 'covid-19 receive sars-cov-2', 'covid-19 receive hcp', 'cancer receive patient', 'cancer receive sars-cov-2', 'cancer receive hcp']",4248,conclusion graves disease occur sars-cov-2 vaccination 
1682,424.0,0.0,"['fondazione acquire lombardy', 'fondazione acquire cancer', 'fondazione acquire patient', 'fondazione acquire sars-cov-2', 'fondazione acquire hcp', 'milano acquire lombardy', 'milano acquire cancer', 'milano acquire patient', 'milano acquire sars-cov-2', 'milano acquire hcp', 'one acquire lombardy', 'one acquire cancer', 'one acquire patient', 'one acquire sars-cov-2', 'one acquire hcp', 'fondazione protect cancer', 'fondazione protect patient', 'fondazione protect sars-cov-2', 'fondazione protect hcp', 'milano protect cancer', 'milano protect patient', 'milano protect sars-cov-2', 'milano protect hcp', 'one protect cancer', 'one protect patient', 'one protect sars-cov-2', 'one protect hcp', 'three protect cancer', 'three protect patient', 'three protect sars-cov-2', 'three protect hcp', 'lombardy protect cancer', 'lombardy protect patient', 'lombardy protect sars-cov-2', 'lombardy protect hcp']",4249,since beginning covid-19 outbreak cancer centers adopted specific procedures protect patients monitor possible spread sars-cov-2 among healthcare personnel hcp 
1683,424.0,2.0,"['hcp screen cancer', 'hcp screen patient', 'hcp respond cancer', 'hcp respond patient']",4251,one hundred ten hcp answered questionnaire screened nasopharyngeal swabs well igmigg levels seropositive hcps screened every 40-45 days using sars-cov-2-specific serology 
1684,424.0,4.0,['vaccine provide covid-19'],4253,monitoring asymptomatic hcp might provide useful information organize healthcare service cancer center waiting effectiveness active immunization sars-cov-2 vaccines provide protection infection 
1685,425.0,0.0,"['coronavirus need primate', 'sars-cov-2 need primate', 'vaccine need primate', 'upper need primate']",4254,background vaccines prevent coronavirus disease 2019 covid-19 urgently needed 
1686,425.0,3.0,"['bronchoalveolar-lavage evaluate nasal swab', 'bronchoalveolar-lavage evaluate polymerase', 'bronchoalveolar-lavage evaluate lung-tissue']",4257,antibody t-cell responses assessed upper- lower-airway challenge sars-cov-2 
1687,425.0,4.0,"['mrna-1273 evaluate 501', 'mrna-1273 evaluate 100-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'vaccine evaluate 501', 'vaccine evaluate 100-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'serum evaluate 501', 'serum evaluate 100-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'live-virus evaluate 501', 'live-virus evaluate 100-Ã\x83\x83Ã\x83\x82Ã\x82Âµg', 'dilution evaluate 501', 'dilution evaluate 100-Ã\x83\x83Ã\x83\x82Ã\x82Âµg']",4258,active viral replication viral genomes bronchoalveolar-lavage bal fluid nasal swab specimens assessed polymerase chain reaction histopathological analysis viral quantification performed lung-tissue specimens 
1688,425.0,5.0,"['type 1 induce cd4 t-cell', 'type 1 induce cd8 t-cell', 'type 1 induce th2', 'type 1 exceed cd8 t-cell', 'type 1 exceed th2', 'cd4 t-cell exceed cd8 t-cell', 'cd4 t-cell exceed th2', 'th1 exceed cd8 t-cell', 'th1 exceed th2']",4259,results mrna-1273 vaccine candidate induced antibody levels exceeding human convalescent-phase serum live-virus reciprocal 50 inhibitory dilution id50 geometric mean titers 501 10-ÃÂµg dose group 3481 100-ÃÂµg dose group 
1689,425.0,7.0,"['nose vaccinate vaccine', 'eight vaccinate vaccine', 'animal vaccinate vaccine', '100-Ã\x83\x83Ã\x83\x82Ã\x82Âµg vaccinate vaccine', 'inflammation vaccinate vaccine', 'antigen vaccinate vaccine', 'lung vaccinate vaccine']",4261,viral replication detectable bal fluid day 2 challenge seven eight animals vaccinated groups 
1690,426.0,0.0,"['team circulate 8805', 'team circulate 8804', 'nine circulate 8805', 'nine circulate 8804']",4266,background influenza h3n2 h1n1 pdm09 b viruses co-circulated europe 2017-18 predominated influenza b who-recommended trivalent vaccine components lineage-mismatched b i-move hospital network measured 2017-18 seasonal influenza vaccine effectiveness ive influenza h3n2 b among hospitalised patients 8805 65 years europe 
1691,426.0,5.0,"['patient include vaccine', 'patient include ive']",4271,results included 3483 patients 376 influenza h3n2 928 b cases 2028 controls 
1692,426.0,6.0,"['influenza vaccinate 8805', 'h3n2 vaccinate 8805', 'h3n2 vaccinate influenza', 'influenza receive 8805', 'h3n2 receive 8805', 'h3n2 receive influenza', 'influenza mismatch 8805', 'h3n2 mismatch 8805', 'h3n2 mismatch influenza']",4272, 99 vaccinated patients received b lineage-mismatched trivalent vaccine 
1693,426.0,11.0,"['aged match eua', 'aged match 1-3', '8805 match eua', '8805 match 1-3', 'covid-19 match eua', 'covid-19 match 1-3', 'covid-19 match eua', 'covid-19 match 1-3', 'aged protect eua', 'aged protect 1-3', '8805 protect eua', '8805 protect 1-3', 'covid-19 protect eua', 'covid-19 protect 1-3', 'covid-19 protect eua', 'covid-19 protect 1-3', 'vaccine protect eua', 'vaccine protect 1-3', 'aged reinforce covid-19', 'aged reinforce covid-19', 'aged reinforce vaccine', 'aged reinforce eua', 'aged reinforce 1-3']",4277,reinforce importance influenza vaccination older adults even poorly matched vaccine still protects one three four population severe influenza 
1694,427.0,0.0,"['pfizer-biontech receive 8805', 'vaccine receive 8805', 'covid-19-associated receive 8805', 'adult receive 8805']",4278,adults aged 8805 65 years increased risk severe outcomes covid-19 identified priority group receive first covid-19 vaccines approved use emergency use authorization eua united states 1-3 
1695,427.0,2.0,"['vaccine hospitalize adult', 'vaccine hospitalize 8805', 'vaccine hospitalize year', 'vaccine age adult', 'vaccine age 8805', 'vaccine age year', 'covid-19-associated age adult', 'covid-19-associated age 8805', 'covid-19-associated age year']",4280,among 417 hospitalized adults aged 8805 65 years including 187 case-patients 230 controls median age 73 years 48 female 73 non-hispanic white 17 non-hispanic black 6 hispanic 4 lived long-term care facility 
1696,428.0,0.0,"['blood detect cd8 cells', 'blood detect sars-cov-2', 'blood detect antigen-specific', 'blood detect cd4', 'blood detect covid-19', 'blood detect convalescent', 'blood detect 10', 'blood detect donor', 'blood detect sars-cov-2', 'interferon-gamma detect cd8 cells', 'interferon-gamma detect sars-cov-2', 'interferon-gamma detect antigen-specific', 'interferon-gamma detect cd4', 'interferon-gamma detect covid-19', 'interferon-gamma detect convalescent', 'interferon-gamma detect 10', 'interferon-gamma detect blood', 'interferon-gamma detect donor', 'interferon-gamma detect sars-cov-2', 'ifn- gamma need convalescent', 'ifn- gamma need 10', 'ifn- gamma need blood', 'ifn- gamma need donor', 'ifn- gamma need sars-cov-2', 'cd8 cells need convalescent', 'cd8 cells need 10', 'cd8 cells need blood', 'cd8 cells need donor', 'cd8 cells need sars-cov-2', 'blood need convalescent', 'blood need 10', 'blood need donor', 'blood need sars-cov-2', 'interferon-gamma need convalescent', 'interferon-gamma need 10', 'interferon-gamma need blood', 'interferon-gamma need donor', 'interferon-gamma need sars-cov-2', 'sars-cov-2 need convalescent', 'sars-cov-2 need 10', 'sars-cov-2 need blood', 'sars-cov-2 need donor', 'antigen-specific need convalescent', 'antigen-specific need 10', 'antigen-specific need blood', 'antigen-specific need donor', 'antigen-specific need sars-cov-2', 'cd4 need convalescent', 'cd4 need 10', 'cd4 need blood', 'cd4 need donor', 'cd4 need sars-cov-2', 'ifn- gamma mediate cd8 cells', 'ifn- gamma mediate sars-cov-2', 'ifn- gamma mediate antigen-specific', 'ifn- gamma mediate cd4', 'ifn- gamma mediate covid-19', 'ifn- gamma mediate convalescent', 'ifn- gamma mediate 10', 'ifn- gamma mediate blood', 'ifn- gamma mediate donor', 'ifn- gamma mediate sars-cov-2', 'blood mediate cd8 cells', 'blood mediate sars-cov-2', 'blood mediate antigen-specific', 'blood mediate cd4', 'blood mediate covid-19', 'blood mediate convalescent', 'blood mediate 10', 'blood mediate donor', 'blood mediate sars-cov-2', 'interferon-gamma mediate cd8 cells', 'interferon-gamma mediate sars-cov-2', 'interferon-gamma mediate antigen-specific', 'interferon-gamma mediate cd4', 'interferon-gamma mediate covid-19', 'interferon-gamma mediate convalescent', 'interferon-gamma mediate 10', 'interferon-gamma mediate blood', 'interferon-gamma mediate donor', 'interferon-gamma mediate sars-cov-2']",4285,backgroundan immunodiagnostic assay sensitively detects cell-mediated immune response sars-cov-2 needed epidemiological investigation clinical assessment cell-mediated immune response vaccines particularly context emerging variants might escape antibody responses 
1697,428.0,2.0,"['blood use left', 'blood use sars-cov-2', 'blood use peptide', 'blood use mitogen', 'lithium use left', 'lithium use sars-cov-2', 'lithium use peptide', 'lithium use mitogen', 'heparin use left', 'heparin use sars-cov-2', 'heparin use peptide', 'heparin use mitogen']",4287,sars-cov-2 igra applied contacts households index cases 
1698,428.0,3.0,"['845 provide 790-890', '845 provide 866']",4288,freshly collected blood lithium heparin tube left unstimulated stimulated sars-cov-2 peptide pool stimulated mitogen 
1699,428.0,6.0,"['household induce 100', 'household induce 1212', 'household induce 652', 'household induce 500', 'household induce 612', 'household induce 435', 'household induce 1023', 'household induce 254-746', 'household induce 217', 'household induce 923-423']",4291,ifn- gamma response remained relatively robust 10 months post-infection 38 vs 13 iuml respectively 
1700,428.0,7.0,"['igg show 739', 'igg show 1723', '100 show 739', '100 show 1723', '1212 show 739', '1212 show 1723']",4292,14 households igra showed positivity rate 100 1212 652 1523 igg 500 612 435 1023 index cases contacts respectively exhibiting difference 50 95 ci 254-746 217 95 ci 923-423 respectively 
1701,428.0,10.0,"['convalescent receive igg', 'convalescent receive covid-19']",4295,key pointssars-cov-2 immunodiagnostics needed identify infected individuals order understand transmission dynamics emerging variants assess vaccine response 
1702,429.0,0.0,"['vaccine cause worker', 'vaccine cause hcws', 'vaccine cause ltcfs', 'vaccine cause cox', 'vaccine cause sars-cov-2']",4297,covid-19 caused high morbidity mortality long-term care facilities ltcfs worldwide 
1703,429.0,1.0,"['827 814 use covid-19', '753 use covid-19', '- use covid-19', '861 use covid-19', 'ci use covid-19', '745-864 use covid-19', 'vaccine use covid-19']",4298,estimated vaccine effectiveness among residents health care workers hcws ltcfs using cox regressions 
1704,429.0,3.0,"['hemorrhagic fever associate infectious disease', 'hemorrhagic fever associate cchfv', 'cchf associate infectious disease', 'cchf associate hemorrhagic fever', 'cchf associate cchfv']",4300,covid-19 associated death 931 among residents hospitalisations occurred among hcw ÃÂÂ 7 days 2nd dose 
1705,430.0,0.0,"['cchf emerge case-fatality', 'infection emerge case-fatality', 'crimean emerge case-fatality', 'peninsula emerge case-fatality']",4301,crimeanÃÂÂcongo hemorrhagic fever cchf emerging zoonotic infectious disease caused crimeanÃÂÂcongo hemorrhagic fever virus cchfv 
1706,430.0,3.0,"['kelkit06 evaluate mouse', 'kelkit06 evaluate e6', 'kelkit06 evaluate sucrose', 'kelkit06 evaluate formalin-inactivated', 'cchf evaluate mouse', 'cchf evaluate e6', 'cchf evaluate sucrose', 'cchf evaluate formalin-inactivated']",4304,present study evaluated development immunogenicity immune response durations cell-culture-derived inactivated vaccine ccvax formulations comparison mouse-brain-derived vaccine mbvax formulations 
1707,430.0,4.0,"['vaccine treat md', 'vaccine treat 10', 'vaccine treat alum', 'vaccine treat balbc', 'ld treat md', 'ld treat 10', 'ld treat alum', 'ld treat balbc', 'vaccine lactate alum', 'vaccine lactate balbc', 'ld lactate alum', 'ld lactate balbc', 'md lactate alum', 'md lactate balbc', 'vaccine purify balbc', 'ld purify balbc', 'md purify balbc', '10 purify balbc']",4305,study kelkit06 cchf virus strain propagated suckling mice vero e6 cells purified sucrose gradient 
1708,430.0,5.0,"['mouse formulate 3-week', 'vaccine formulate 3-week', 'mouse inactivate vaccine', 'mouse inactivate three', 'mouse inactivate 3-week']",4306,formalin-inactivated vaccine candidates formulated various doses low dose ld 5 ÃÂg medium dose md 10 ÃÂg high dose hd 20 ÃÂg mixed alum adjuvant 
1709,430.0,6.0,"['igg receive mbvax', 'igg receive ccvax']",4307,balbc mice received doses vaccine formulations three times 3-week intervals 
1710,430.0,7.0,"['igg evaluate immunization', 'igg compare immunization']",4308,humoral endpoint igg responses evaluated compared mbvax ccvax treatments 
1711,430.0,8.0,"['igg evaluate mouse', 'ccvax evaluate mouse', 'mbvax evaluate mouse', 'igg evaluate mouse']",4309,duration presence igg neutralizing antibody ab titers evaluated compared 1 year immunization 
1712,430.0,9.0,"['ccvax enhance immunization', '2- enhance immunization']",4310,humoral igg responses indicated ccvax mbvax candidates enhanced igg endpoint titers dose-dependent manner induced strongly ccvax groups mbvax mice 
1713,430.0,10.0,['immunization receive ccvax'],4311,fold changes neutralizing ab levels also found higher ccvax groups 2- 76-fold second week last immunization 
1714,430.0,12.0,"['cell-culture-purified induce immunity', 'cell-culture-purified induce mouse', 'cell-culture-purified induce mouse-brain-derived', 'cell-culture-purified induce vaccine', 'formalin-inactivated induce immunity', 'formalin-inactivated induce mouse', 'formalin-inactivated induce mouse-brain-derived', 'formalin-inactivated induce vaccine', 'cell-culture-purified neutralize immunity', 'cell-culture-purified neutralize mouse', 'cell-culture-purified neutralize mouse-brain-derived', 'cell-culture-purified neutralize vaccine', 'formalin-inactivated neutralize immunity', 'formalin-inactivated neutralize mouse', 'formalin-inactivated neutralize mouse-brain-derived', 'formalin-inactivated neutralize vaccine', 'vaccine neutralize immunity', 'vaccine neutralize mouse', 'vaccine neutralize mouse-brain-derived']",4313,ccvax formulations induced higher igg neutralizing ab titers measured time points 
1715,430.0,13.0,"['antibody show complement', 'antibody show phagocytosis', 'antibody show human', 'antibody show blood', 'antibody show leukocyte', 'antibody show vaccine-naÃ\x83\x83Ã\x83\x82ve', 'antibody show pcv13-vaccinated', 'antibody inactivate vaccine-naÃ\x83\x83Ã\x83\x82ve', 'antibody inactivate pcv13-vaccinated', 'complement inactivate vaccine-naÃ\x83\x83Ã\x83\x82ve', 'complement inactivate pcv13-vaccinated', 'phagocytosis inactivate vaccine-naÃ\x83\x83Ã\x83\x82ve', 'phagocytosis inactivate pcv13-vaccinated', 'human inactivate vaccine-naÃ\x83\x83Ã\x83\x82ve', 'human inactivate pcv13-vaccinated', 'blood inactivate vaccine-naÃ\x83\x83Ã\x83\x82ve', 'blood inactivate pcv13-vaccinated']",4314,study showed cell-culture-purified formalin-inactivated vaccine candidates induced strong robust immunity vaccinated mice dose-dependently mouse-brain-derived vaccines 
1716,431.0,1.0,"['inhibitor base two', 'complement base two']",4316,serotype 4 pneumococci model two different physiologic opsonophagocytosis assays based either hirudin-anticoagulated whole blood washed cells edta-anticoagulated blood reconstituted active serum compared 
1717,431.0,7.0,"['cytomegalovirus increase influenza', 'cytomegalovirus increase adult', 'cmv increase influenza', 'cmv increase adult', 'immunosenescence increase influenza', 'immunosenescence increase adult', 'cytomegalovirus induce immunosenescence', 'cytomegalovirus induce influenza', 'cytomegalovirus induce adult', 'cmv induce immunosenescence', 'cmv induce influenza', 'cmv induce adult']",4322,findings suggest treatment alternative complement pathway inhibitors increase susceptibility invasive pneumococcal infection non-immune subjects impede pneumococcal clearance vaccinated individuals 
1718,432.0,2.0,"['np n improve volunteer', 'adult improve volunteer', 'two improve volunteer', '7406 improve volunteer', 'cet improve volunteer', 'np n investigate cet', 'np n investigate volunteer', 'adult investigate cet', 'adult investigate volunteer', 'two investigate cet', 'two investigate volunteer', 'np n combine cet', 'np n combine volunteer', 'adult combine cet', 'adult combine volunteer', 'two combine cet', 'two combine volunteer', '7406 combine cet', '7406 combine volunteer']",4325,thus aim study investigate whether regular practice combined exercise training improve specific antibody response ivv cmv-seropositive older adults 
1719,432.0,4.0,"['serum collect immunoglobulin', 'serum collect np', 'serum collect p', 'serum collect cet', 'immunoglobulin collect np', 'immunoglobulin collect p', 'immunoglobulin collect cet', 'immunoglobulin collect serum']",4327,volunteer groups submitted ivv blood samples collected pre 30 days post vaccination 
1720,432.0,10.0,"['cd8 cells receive il-10', 'cd8 cells receive p', 'cd8 cells receive summary', 'cet receive il-10', 'cet receive p', 'cet receive summary', 'p receive il-10', 'p receive summary']",4333,addition hemagglutination inhibition hai assay found 322 np group 326 cet group responders ivv displayed reductions cmv serostatus p 005 p 0001 respectively increases naive effector cd8 cells post-vaccination p 001 
1721,432.0,11.0,"['cmv-seropositive show cd8 cells', 'cmv-seropositive show cet', 'adult show cd8 cells', 'adult show cet']",4334,however responders cet group showed significant reductions ratio effector naive cd8 cells p 005 increased il-10 levels post-vaccination p 0001 
1722,432.0,12.0,"['bbv152 show toll-like', 'bbv152 show receptor', 'bbv152 show agonist', 'bbv152 show alum', 'bbv152 show algel', 'sars-cov-2 show toll-like', 'sars-cov-2 show receptor', 'sars-cov-2 show agonist', 'sars-cov-2 show alum', 'sars-cov-2 show algel', 'vaccine show toll-like', 'vaccine show receptor', 'vaccine show agonist', 'vaccine show alum', 'vaccine show algel']",4335,summary study demonstrates improvement response ivv cmv-seropositive older adults related anti-inflammatory status enhancement naive cd8 cells particularly associated regular practice cet 
1723,433.0,0.0,"['three formulate algel', 'three formulate one', 'three formulate algel-only', 'three formulate antigen', 'three formulate algel-imdg', 'three formulate herein', 'algel-imdg formulate algel', 'algel-imdg formulate one', 'algel-imdg formulate algel-only', 'algel-imdg formulate antigen', 'algel-imdg formulate herein', 'three adsorb algel-imdg', 'three adsorb herein', 'algel-imdg adsorb herein', 'algel-imdg adsorb herein', 'algel adsorb algel-imdg', 'algel adsorb herein', 'one adsorb algel-imdg', 'one adsorb herein', 'algel-only adsorb algel-imdg', 'algel-only adsorb herein', 'antigen adsorb algel-imdg', 'antigen adsorb herein']",4336,background bbv152 whole-virion inactivated sars-cov-2 vaccine 3 ÃÂµg 6 ÃÂµg formulated toll-like receptor 78 agonist molecule imdg adsorbed alum algel 
1724,433.0,5.0,['investigator do two'],4341,block randomisation done use interactive web response system 
1725,433.0,6.0,"['vaccine mask four-fold', 'vaccine mask plaque-reduction', 'sars-cov-2 mask four-fold', 'sars-cov-2 mask plaque-reduction', 'vaccine relate sars-cov-2', 'vaccine relate four-fold', 'vaccine relate plaque-reduction']",4342,participants investigators study coordinators study-related personnel sponsor masked treatment group allocation 
1726,433.0,8.0,"['t-helper-1 receive second', 'th1 receive second', 'th2 receive second']",4344,primary outcome assessed participants received doses vaccine 
1727,433.0,9.0,"['participant mediate one', 'participant mediate vaccine']",4345,cell-mediated responses secondary outcome assessed t-helper-1 th1 th2 profiling 2 weeks second dose day 42 
1728,433.0,10.0,"['blood receive participant', 'blood receive 104']",4346,safety assessed participants received least one dose vaccine 
1729,433.0,12.0,"['sept receive 921', 'sept receive participant', 'sept receive 380', 'sept receive algel-imdg', 'sept receive n190', 'sept receive algel-imdg', 'sept receive n190']",4348,trial registered clinicaltrialsgov nct04471519 
1730,433.0,17.0,"['algel-imdg report th1', 'algel-imdg report participant', 'algel-imdg report 190', 'algel-imdg report th1', 'algel-imdg report participant', 'algel-imdg report 190']",4353,seroconversion based mnt50 day 56 reported 162 88ÃÂ0 95 ci 82ÃÂ4-92ÃÂ3 184 participants 3 ÃÂµg algel-imdg group 171 96ÃÂ6 92ÃÂ8-98ÃÂ8 177 participants 6 ÃÂµg algel-imdg group 
1731,433.0,18.0,"['algel-imdg bias algel', 'algel-imdg bias algel', 'algel-imdg elicit algel']",4354,3 ÃÂµg algel-imdg 6 ÃÂµg algel-imdg formulations elicited t-cell responses biased th1 phenotype day 42 significant difference proportion participants solicited local systemic adverse reaction 3 ÃÂµg algel-imdg group 38 20ÃÂ0 95 ci 14ÃÂ7-26ÃÂ5 190 6 ÃÂµg algel-imdg group 40 21ÃÂ1 15ÃÂ5-27ÃÂ5 190 observed days 0-7 days 28-35 serious adverse events reported study 
1732,434.0,1.0,"['typhoid reduce nepali', 'typhoid reduce child', 'conjugate reduce nepali', 'conjugate reduce child', 'vaccine reduce nepali', 'vaccine reduce child']",4362,vaccination help curb disease might reduce transmission 
1733,434.0,4.0,"['2020 mask typhoid fever', 'blood mask typhoid fever']",4365,methods participant-masked observer-masked individually randomised trial lalitpur nepal 20 019 children aged 9 months younger 16 years randomly assigned 11 ratio receive single dose tcv typbar tcv bharat biotech international india capsular group meningococcal conjugate vaccine mena 
1734,434.0,10.0,"['typhoid fever confirm person-years', 'typhoid fever confirm tcv', 'typhoid fever confirm 342', 'typhoid fever confirm 100', 'typhoid fever confirm person-years', '100 confirm person-years', '100 confirm tcv', '100 confirm 342', '100 confirm person-years']",4371,protective efficacy tcv blood culture-confirmed typhoid fever 2 years 79ÃÂ0 95 ci 61ÃÂ9ÃÂÂ88ÃÂ5 p 0ÃÂ0001 
1735,435.0,0.0,"['vaccine vaccinate sars-cov-2', 'vaccine vaccinate rhesus', 'vaccine vaccinate macaque', 'sars-cov-2 vaccinate rhesus', 'sars-cov-2 vaccinate macaque', 'vaccine induce sars-cov-2', 'vaccine induce rhesus', 'vaccine induce macaque', 'sars-cov-2 induce rhesus', 'sars-cov-2 induce macaque']",4378,development portfolio covid-19 vaccines vaccinate global population remains urgent public health imperative1 
1736,435.0,1.0,"['five show squalene-in-water', 'five show emulsion', 'five show 945', 'five show as37', 'five show toll-like', 'five show receptor', 'five show tlr7', 'five show agonist', 'five show alum', 'five show cpg1018-alum', 'five show tlr9', 'five show agonist', 'five show alum', 'five show alum', 'five establish as37', 'five establish toll-like', 'five establish receptor', 'five establish tlr7', 'five establish agonist', 'five establish alum', 'five establish cpg1018-alum', 'five establish tlr9', 'five establish agonist', 'five establish alum', 'five establish alum', 'squalene-in-water establish as37', 'squalene-in-water establish toll-like', 'squalene-in-water establish receptor', 'squalene-in-water establish tlr7', 'squalene-in-water establish agonist', 'squalene-in-water establish alum', 'squalene-in-water establish cpg1018-alum', 'squalene-in-water establish tlr9', 'squalene-in-water establish agonist', 'squalene-in-water establish alum', 'squalene-in-water establish alum', 'emulsion establish as37', 'emulsion establish toll-like', 'emulsion establish receptor', 'emulsion establish tlr7', 'emulsion establish agonist', 'emulsion establish alum', 'emulsion establish cpg1018-alum', 'emulsion establish tlr9', 'emulsion establish agonist', 'emulsion establish alum', 'emulsion establish alum', '945 establish as37', '945 establish toll-like', '945 establish receptor', '945 establish tlr7', '945 establish agonist', '945 establish alum', '945 establish cpg1018-alum', '945 establish tlr9', '945 establish agonist', '945 establish alum', '945 establish alum', 'five bind alum', 'five bind cpg1018-alum', 'five bind tlr9', 'five bind agonist', 'five bind alum', 'five bind alum', 'squalene-in-water bind alum', 'squalene-in-water bind cpg1018-alum', 'squalene-in-water bind tlr9', 'squalene-in-water bind agonist', 'squalene-in-water bind alum', 'squalene-in-water bind alum', 'emulsion bind alum', 'emulsion bind cpg1018-alum', 'emulsion bind tlr9', 'emulsion bind agonist', 'emulsion bind alum', 'emulsion bind alum', '945 bind alum', '945 bind cpg1018-alum', '945 bind tlr9', '945 bind agonist', '945 bind alum', '945 bind alum', 'as37 bind alum', 'as37 bind cpg1018-alum', 'as37 bind tlr9', 'as37 bind agonist', 'as37 bind alum', 'as37 bind alum', 'toll-like bind alum', 'toll-like bind cpg1018-alum', 'toll-like bind tlr9', 'toll-like bind agonist', 'toll-like bind alum', 'toll-like bind alum', 'receptor bind alum', 'receptor bind cpg1018-alum', 'receptor bind tlr9', 'receptor bind agonist', 'receptor bind alum', 'receptor bind alum', 'tlr7 bind alum', 'tlr7 bind cpg1018-alum', 'tlr7 bind tlr9', 'tlr7 bind agonist', 'tlr7 bind alum', 'tlr7 bind alum', 'agonist bind alum', 'agonist bind cpg1018-alum', 'agonist bind tlr9', 'agonist bind alum', 'agonist bind alum', 'five display tlr9', 'five display agonist', 'five display alum', 'five display alum', 'squalene-in-water display tlr9', 'squalene-in-water display agonist', 'squalene-in-water display alum', 'squalene-in-water display alum', 'emulsion display tlr9', 'emulsion display agonist', 'emulsion display alum', 'emulsion display alum', '945 display tlr9', '945 display agonist', '945 display alum', '945 display alum', 'as37 display tlr9', 'as37 display agonist', 'as37 display alum', 'as37 display alum', 'toll-like display tlr9', 'toll-like display agonist', 'toll-like display alum', 'toll-like display alum', 'receptor display tlr9', 'receptor display agonist', 'receptor display alum', 'receptor display alum', 'tlr7 display tlr9', 'tlr7 display agonist', 'tlr7 display alum', 'tlr7 display alum', 'agonist display tlr9', 'agonist display alum', 'agonist display alum', 'alum display tlr9', 'alum display agonist']",4379,demonstrate capacity subunit vaccine comprising sars-cov-2 spike protein receptor-binding domain displayed i53-50 protein nanoparticle scaffold hereafter designated rbd-np stimulate robust durable neutralizing-antibody responses protection sars-cov-2 rhesus macaques 
1737,435.0,2.0,"['immunization evaluate cd4 cell', 'immunization evaluate bronchoalveolar lavage', 'immunization evaluate cpg1018-alum', 'immunization evaluate as37', 'immunization evaluate alum', 'immunization evaluate sars-cov-2', 'immunization evaluate pharynx', 'immunization evaluate naris', 'immunization include cd4 cell', 'immunization include bronchoalveolar lavage', 'immunization include sars-cov-2', 'immunization include pharynx', 'immunization include naris', 'cpg1018-alum include cd4 cell', 'cpg1018-alum include bronchoalveolar lavage', 'cpg1018-alum include sars-cov-2', 'cpg1018-alum include pharynx', 'cpg1018-alum include naris', 'as37 include cd4 cell', 'as37 include bronchoalveolar lavage', 'as37 include sars-cov-2', 'as37 include pharynx', 'as37 include naris']",4380,evaluated five adjuvants including essai ow 1849101 squalene-in-water emulsion as03 945 -tocopherol-containing oil-in-water emulsion as37 toll-like receptor 7 tlr7 agonist adsorbed alum cpg1018-alum tlr9 agonist formulated alum alum 
1738,435.0,4.0,"['immunization observe rbd-np-as03', 'sars-cov-2 observe rbd-np-as03']",4382,neutralizing-antibody response live virus maintained 180 days vaccination rbd-np as03 rbd-np-as03 correlated protection infection 
1739,435.0,5.0,"['45-fold neutralize 16-fold', '45-fold neutralize b1351', '45-fold neutralize neutralizing-antibody', 'b1351 neutralize 16-fold', 'b1351 neutralize neutralizing-antibody', '45-fold show neutralizing-antibody', 'b1351 show neutralizing-antibody', '16-fold show neutralizing-antibody', 'b1351 show neutralizing-antibody']",4383,rbd-np immunization cross-neutralized b117 sars-cov-2 variant efficiently showed reduced response b1351 variant 
1740,435.0,8.0,"['sars-cov-2 induce nursing staff', 'sars-cov-2 induce cancer', 'sars-cov-2 induce patient', 'sars-cov-2 induce vaccine', 'sars-cov-2 induce covid-19', 'sars-cov-2 induce cancer', 'sars-cov-2 induce patient', 'sars-cov-2 induce medical', 'sars-cov-2 induce patient', 'sars-cov-2 induce covid-19', 'sars-cov-2 induce one', 'sars-cov-2 induce cancer', 'sars-cov-2 induce patient', 'sars-cov-2 induce coreo-trial', 'sars-cov-2 induce cohort', 'sars-cov-2 induce covid-19', 'pneumonia induce nursing staff', 'pneumonia induce cancer', 'pneumonia induce patient', 'pneumonia induce vaccine', 'pneumonia induce covid-19', 'pneumonia induce sars-cov-2', 'pneumonia induce cancer', 'pneumonia induce patient', 'pneumonia induce medical', 'pneumonia induce patient', 'pneumonia induce covid-19', 'pneumonia induce one', 'pneumonia induce cancer', 'pneumonia induce patient', 'pneumonia induce coreo-trial', 'pneumonia induce cohort', 'pneumonia induce covid-19', 'death induce nursing staff', 'death induce cancer', 'death induce patient', 'death induce vaccine', 'death induce covid-19', 'death induce sars-cov-2', 'death induce cancer', 'death induce patient', 'death induce medical', 'death induce patient', 'death induce covid-19', 'death induce one', 'death induce cancer', 'death induce patient', 'death induce coreo-trial', 'death induce cohort', 'death induce covid-19', 'sars-cov-2 boost nursing staff', 'sars-cov-2 boost pneumonia', 'sars-cov-2 boost death', 'sars-cov-2 boost cancer', 'sars-cov-2 boost patient', 'sars-cov-2 boost vaccine', 'sars-cov-2 boost covid-19', 'sars-cov-2 boost cancer', 'sars-cov-2 boost patient', 'sars-cov-2 boost medical', 'sars-cov-2 boost patient', 'sars-cov-2 boost covid-19', 'sars-cov-2 boost one', 'sars-cov-2 boost cancer', 'sars-cov-2 boost patient', 'sars-cov-2 boost coreo-trial', 'sars-cov-2 boost cohort', 'sars-cov-2 boost covid-19']",4386,data highlight efficacy adjuvanted rbd-np vaccine promoting protective immunity sars-cov-2 led phase iii clinical trials vaccine nct04742738 nct04750343 
1741,437.0,0.0,"['optimal introduce infant', 'vaccine introduce infant']",4388,background october 2012 maternal pertussis vaccination program introduced england women 28 32 weeks pregnancy 
1742,437.0,2.0,"['pertussis evaluate pre-', 'pertussis evaluate post-policy', 'pertussis induce pre-', 'pertussis induce post-policy']",4390,study assesses impact offering maternal pertussis vaccination earlier pregnancy hospitalized infant pertussis cases 
1743,437.0,6.0,['201 aim 151'],4394,median hospital duration calculated competing risk survival analysis undertaken assess multiple factors 
1744,437.0,10.0,"['preterm see infant', 'infant see preterm', 'preterm age infant', 'infant age preterm', 'pertussis age preterm', 'pertussis age infant']",4398,significantly longer hospital stays seen cases aged 0ÃÂÂ4 weeks median 3 days infants aged 5ÃÂÂ8 weeks premature infants median 4 days term infants cases coinfections median 1 day without coinfection 
1745,438.0,1.0,"['five induce meningococcal', 'five induce conjugate', 'five induce vaccine', 'uk induce meningococcal', 'uk induce conjugate', 'uk induce vaccine', 'chimpanzee induce meningococcal', 'chimpanzee induce conjugate', 'chimpanzee induce vaccine', 'adenovirus-vectored induce meningococcal', 'adenovirus-vectored induce conjugate', 'adenovirus-vectored induce vaccine', 'vaccine induce meningococcal', 'vaccine induce conjugate', 'chadox1 induce meningococcal', 'chadox1 induce conjugate', 'chadox1 induce vaccine', 'ncov-19 induce meningococcal', 'ncov-19 induce conjugate', 'ncov-19 induce vaccine']",4401,assessed safety reactogenicity immunogenicity viral vectored coronavirus vaccine expresses spike protein sars-cov-2 
1746,438.0,2.0,"['adult observe chadox1', 'adult observe ncov-19', 'adult observe particle', 'adult observe injection', 'sars-cov-2 observe chadox1', 'sars-cov-2 observe ncov-19', 'sars-cov-2 observe particle', 'sars-cov-2 observe injection', 'covid-19-like observe chadox1', 'covid-19-like observe ncov-19', 'covid-19-like observe particle', 'covid-19-like observe injection', 'symptom observe chadox1', 'symptom observe ncov-19', 'symptom observe particle', 'symptom observe injection', 'adult do sars-cov-2', 'adult do covid-19-like', 'adult do symptom', 'adult do chadox1', 'adult do ncov-19', 'adult do particle', 'adult do injection']",4402,methods phase 12 single-blind randomised controlled trial five trial sites uk chimpanzee adenovirus-vectored vaccine chadox1 ncov-19 expressing sars-cov-2 spike protein compared meningococcal conjugate vaccine menacwy control 
1747,438.0,3.0,"['two age paracetamol', 'two age ten']",4403,healthy adults aged 18-55 years history laboratory confirmed sars-cov-2 infection covid-19-like symptoms randomly assigned 11 receive chadox1 ncov-19 dose 5ÃÂÃÂÃÂÃÂÃÂÃÂÃÂ1010 viral particles menacwy single intramuscular injection 
1748,438.0,4.0,"['participant include vaccine', 'chadox1 include vaccine', 'ncov-19 include vaccine', 'prime-boost include vaccine']",4404,protocol amendment two five sites allowed prophylactic paracetamol administered vaccination 
1749,438.0,5.0,"['elisa receive sars-cov-2', 'elisa receive plaque', 'elisa receive prnt50', 'elisa receive mna80', 'elisa receive mna90', 'elisa receive marburg', 'elisa receive vn', 'elisa receive pseudovirus', 'elisa receive cellular', 'sars-cov-2 receive plaque', 'sars-cov-2 receive prnt50', 'sars-cov-2 receive mna80', 'sars-cov-2 receive mna90', 'sars-cov-2 receive marburg', 'sars-cov-2 receive vn', 'sars-cov-2 receive pseudovirus', 'sars-cov-2 receive cellular', 'elisa treat mna80', 'elisa treat mna90', 'elisa treat marburg', 'elisa treat vn', 'elisa treat pseudovirus', 'elisa treat cellular', 'sars-cov-2 treat mna80', 'sars-cov-2 treat mna90', 'sars-cov-2 treat marburg', 'sars-cov-2 treat vn', 'sars-cov-2 treat pseudovirus', 'sars-cov-2 treat cellular', 'three treat mna80', 'three treat mna90', 'three treat marburg', 'three treat vn', 'three treat pseudovirus', 'three treat cellular', 'sars-cov-2 treat mna80', 'sars-cov-2 treat mna90', 'sars-cov-2 treat marburg', 'sars-cov-2 treat vn', 'sars-cov-2 treat pseudovirus', 'sars-cov-2 treat cellular', 'plaque treat mna80', 'plaque treat mna90', 'plaque treat marburg', 'plaque treat vn', 'plaque treat pseudovirus', 'plaque treat cellular', 'prnt50 treat mna80', 'prnt50 treat mna90', 'prnt50 treat marburg', 'prnt50 treat vn', 'prnt50 treat pseudovirus', 'prnt50 treat cellular']",4405,ten participants assigned non-randomised unblinded chadox1 ncov-19 prime-boost group received two-dose schedule booster vaccine administered 28 days first dose 
1750,438.0,13.0,"['chadox1 enrol muscle ache', 'chadox1 enrol chill', 'chadox1 enrol headache', 'ncov-19 enrol muscle ache', 'ncov-19 enrol chill', 'ncov-19 enrol headache', 'paracetamol enrol muscle ache', 'paracetamol enrol chill', 'paracetamol enrol headache', 'pain enrol muscle ache', 'pain enrol chill', 'pain enrol headache', 'chadox1 indicate headache', 'ncov-19 indicate headache', 'paracetamol indicate headache', 'pain indicate headache', 'chill indicate headache']",4413,findings april 23 may 21 2020 1077 participants enrolled assigned receive either chadox1 ncov-19 n543 menacwy n534 ten enrolled non-randomised chadox1 ncov-19 prime-boost group 
1751,438.0,15.0,"['ncov-19 relate mononuclear cells', 'ncov-19 relate 856', 'ncov-19 relate peripheral', 'ncov-19 relate blood', 'ncov-19 relate 493-1802', 'ncov-19 relate n43', 't-cell relate mononuclear cells', 't-cell relate 856', 't-cell relate peripheral', 't-cell relate blood', 't-cell relate 493-1802', 't-cell relate n43']",4415,serious adverse events related chadox1 ncov-19 
1752,438.0,16.0,"['igg peak 639', '157 peak 639', 'elisa peak 639', 'eu peak 639', 'n127 peak 639']",4416,chadox1 ncov-19 group spike-specific t-cell responses peaked day 14 median 856 spot-forming cells per million peripheral blood mononuclear cells iqr 493-1802 n43 
1753,438.0,17.0,"['antibody develop participant', 'antibody develop 100', 'antibody develop participant', 'antibody develop booster', 'sars-cov-2 develop participant', 'sars-cov-2 develop 100', 'sars-cov-2 develop participant', 'sars-cov-2 develop booster']",4417,anti-spike igg responses rose day 28 median 157 elisa units eu 96-317 n127 boosted following second dose 639 eu 360-792 n10 
1754,438.0,18.0,"['nine nine detect ten', 'nine nine detect ten', 'nine nine detect marburg', 'participant detect ten', 'participant detect ten', 'participant detect marburg']",4418,neutralising antibody responses sars-cov-2 detected 32 91 35 participants single dose measured mna80 35 100 participants measured prnt50 
1755,438.0,21.0,"['cellular show large-scale', 'cellular show vaccine']",4421,interpretation chadox1 ncov-19 showed acceptable safety profile homologous boosting increased antibody responses 
1756,439.0,0.0,"['antibody neutralize immunity', 'antibody neutralize vaccine', 'antibody play immunity', 'antibody play vaccine', 'antibody protect immunity', 'antibody protect vaccine']",4424,background antibodies play important role neutralizing invading pathogens protecting host re-infection 
1757,439.0,1.0,"['west provide three', 'iranian provide three', 'covid-19 provide three']",4425,thus accurate assessment antibodies pandemic provide important evidence monitoring pathogen exposure understanding role antibodies protective immunity helping vaccine development 
1758,439.0,2.0,"['four- six enrol pso', 'sars-cov-2-specific enrol pso', 'antibody enrol pso', 'three enrol pso', 'four- six receive pso', 'sars-cov-2-specific receive pso', 'antibody receive pso', 'three receive pso']",4426,methods study 96 west iranian recovered covid-19 subjects recruited based clinical symptoms disease severity categorized three different groups mild moderate severe 
1759,439.0,4.0,"['mount test sars-cov-2-specific', 'mount test igg']",4428,also association igg antibody titer clinical symptoms disease severity examined 
1760,439.0,6.0,['igg induce symptom'],4430,furthermore antibody persisted serum recovered covid-19 subjects least six months pso demonstrated little decrease 
1761,439.0,10.0,"['sars-cov-2-specific use covid-19', 'sars-cov-2-specific use covid-19', 'sars-cov-2-specific diagnose covid-19', 'sars-cov-2-specific test covid-19']",4434,also could used diagnosing covid-19 subjects tested later outside optimal period 
1762,440.0,0.0,"['cytokine follow multiple myeloma', 'cytokine follow n70', 'cytokine follow bowel', 'cytokine follow n130', 'cytokine follow four', 'cytokine follow mrna', 'cytokine follow vaccine', 'cytokine follow bnt162b2', 'cytokine follow mrna-1273', 'cytokine follow findingsfour', 'patient follow multiple myeloma', 'patient follow n70', 'patient follow bowel', 'patient follow n130', 'patient follow four', 'patient follow mrna', 'patient follow vaccine', 'patient follow bnt162b2', 'patient follow mrna-1273', 'patient follow findingsfour', 'solid follow multiple myeloma', 'solid follow n70', 'solid follow bowel', 'solid follow n130', 'solid follow four', 'solid follow mrna', 'solid follow vaccine', 'solid follow bnt162b2', 'solid follow mrna-1273', 'solid follow findingsfour', 'tumor follow multiple myeloma', 'tumor follow n70', 'tumor follow bowel', 'tumor follow n130', 'tumor follow four', 'tumor follow mrna', 'tumor follow vaccine', 'tumor follow bnt162b2', 'tumor follow mrna-1273', 'tumor follow findingsfour']",4436,backgroundknowledge humoral cellular immunogenicity kinetics following sars-cov-2 mrna vaccinations immunosuppressed patients limited 
1763,440.0,3.0,"['cellular correlate ifn- gamma', 'cellular correlate patient', 'cellular correlate patient', 'cellular correlate six', 'cellular neutralize patient', 'cellular neutralize six', 'patient neutralize six']",4439,s1-specific igg levels correlated neutralizing antibody titers 
1764,440.0,4.0,"['196 correlate ibd', '196 correlate patient', '196 correlate 963', '196 correlate 100', '196 correlate vaccinee', 'patient correlate ibd', 'patient correlate 963', 'patient correlate 100', 'patient correlate vaccinee']",4440,antibody responses correlated cellular responses controls ibd patients ifn- gamma antibody responses sot mm patients 
1765,440.0,6.0,"['patient receive six', 'patient receive cellular', 'patient induce six', 'patient induce cellular', 'patient vaccinate six', 'patient vaccinate cellular']",4442,vaccinees receiving mrna-1273 presented higher antibody levels vaccinated bnt162b2 
1766,440.0,7.0,['cellular follow vaccine'],4443,interpretationcancer patients may launch inadequate seroresponse immediate time range following vaccination six months correlating vaccine-specific cellular responses 
1767,440.0,8.0,"['patient induce vaccine', 'patient induce tnf-', 'patient induce inhibitor']",4444,findings propose antibody testing immunosuppressed - along cellular testing - provides guidance administration additional vaccine doses may indicate necessity antibody treatment 
1768,440.0,12.0,['sars-cov-2 acknowledge covid-19'],4448,hs acknowledge funding austrian science fund fwf p 34253-b 
1769,441.0,0.0,"['specimen provide infant', 'specimen provide child']",4449,serological testing sars-cov-2 antibodies provides important research diagnostic information relating covid-19 immune response surveillance 
1770,441.0,1.0,"['blood cover antibody', 'spot cover antibody', 'db cover antibody']",4450,major challenge addressing protection post-infection vaccination difficulty specimen collection infants children 
1771,441.0,2.0,"['db collect enzyme', 'db collect eia', 'db collect serum', 'sars-cov-2 collect enzyme', 'sars-cov-2 collect eia', 'sars-cov-2 collect db', 'sars-cov-2 collect serum', 'antibody collect enzyme', 'antibody collect eia', 'antibody collect db', 'antibody collect serum', 'three collect enzyme', 'three collect eia', 'three collect db', 'three collect serum']",4451,dried blood spots dbs collected finger prick heel prick minimally invasive sample collection alternative previously used detect antibodies viruses 
1772,441.0,3.0,['db evaluate serum'],4452,study evaluated dbs detection sars-cov-2 antibodies three commercially available enzyme eia chemiluminescent clia immunoassays analysing paired dbs serum samples collected 54 subjects 
1773,441.0,4.0,"['db correlate covid-19', 'db correlate infant', 'db correlate child', 'blood correlate covid-19', 'blood correlate infant', 'blood correlate child', 'plasma correlate covid-19', 'plasma correlate infant', 'plasma correlate child', 'serum correlate covid-19', 'serum correlate infant', 'serum correlate child', 'eias correlate covid-19', 'eias correlate infant', 'eias correlate child']",4453,demonstrate testing dbs samples highly sensitive specific quantitative results strongly correlated paired serum 
1774,441.0,5.0,"['respiratory infections induce child', 'respiratory infections induce influenza-like', 'respiratory infections induce antiviral', 'respiratory infections induce vaccine', 'respiratory infections induce influenza', 'respiratory infections induce infection', 'respiratory infections induce infant', 'respiratory infections induce child', 'respiratory infections induce adult', 'respiratory infections induce cdisc', 'respiratory infections induce consortium', 'respiratory infections derive child', 'respiratory infections derive influenza-like', 'respiratory infections derive antiviral', 'respiratory infections derive vaccine', 'respiratory infections derive influenza', 'respiratory infections derive infection', 'respiratory infections derive infant', 'respiratory infections derive child', 'respiratory infections derive adult', 'respiratory infections derive cdisc', 'respiratory infections derive consortium']",4454,results suggest dbs derived blood viable alternative plasma serum use eias clias particular utility minimally invasive collection tool covid-19 serological testing infants children 
1775,443.0,1.0,"['cohort design xinyang city', 'cohort design shangcheng', 'cohort design china', 'cohort design anti-sftsv', 'xinyang city use china', 'xinyang city use anti-sftsv', 'cohort use china', 'cohort use anti-sftsv', 'shangcheng use china', 'shangcheng use anti-sftsv']",4457,study designed measure seroprevalence sftsv antibody healthy population residing high endemic region 
1776,443.0,2.0,"['igg perform nab', 'enzyme-linked perform nab', 'immunosorbent perform nab']",4458,methods cohort study performed healthy residents shangcheng county xinyang city april december 2018 highest sfts incidence china reported 
1777,443.0,5.0,"['119 enrol 40587', '119 enrol nab', '119 enrol 134', '119 enrol 47350', '119 enrol 158', '119 enrol 80508', '119 enrol igg']",4461,results totally 886 individuals recruited 
1778,443.0,6.0,"['patient increase p', 'patient increase tea', 'patient increase nab', '2440 increase p', '2440 increase tea', '2440 increase nab', '50 increase p', '50 increase tea', '50 increase nab']",4462,baseline seroprevalence tested epidemic season 119 70587 igg 68 40587 nab increased 134 47350 77 27350 epidemic season 158 80508 98 50508 post epidemic 
1779,443.0,7.0,"['patient relate 2691', 'patient relate cat', 'patient relate 2648', 'patient relate cohort', 'patient age cat', 'patient age 2648', 'patient age cohort', '2691 age cat', '2691 age 2648', '2691 age cohort', 'patient adjust cat', 'patient adjust 2648', 'patient adjust cohort', '2691 adjust cat', '2691 adjust 2648', '2691 adjust cohort']",4463,igg antibody-based seropositivity significantly related patients aged ÃÂÂ 70 years old adjusted odds ratio 2440 95 confidence interval ci 1334ÃÂÂ4461 compared group 50 years old p 0004 recent contact cats adjusted 2195 95 ci 1261ÃÂÂ3818 p 0005 working tea garden adjusted 1698 95 ci 1002ÃÂÂ2880 p 0049 applying multivariate logistic regression model 
1780,443.0,8.0,"['1-year relate igg', '1-year relate nab']",4464,nab based seropositivity similarly related patients aged ÃÂÂ 70 years old adjusted 2691 95 ci 1271ÃÂÂ5695 compared group 50 years old p 0010 recent contact cats 2648 95 ci 1419ÃÂÂ4941 p 0002 
1781,443.0,9.0,"['immunity observe vaccine', 'sftsv observe vaccine']",4465,cohort individuals continually sampled 1-year apart anti-sftsv igg maintained stable level nab level reduced 
1782,444.0,0.0,"['cd4 cells affect cd4 cell', 'cd4 cells affect igg', 'cd4 cells affect antigen-specific', 'cd4 cells affect immunity', 'cd4 cells affect vaccine', 'epitope affect cd4 cell', 'epitope affect igg', 'epitope affect antigen-specific', 'epitope affect immunity', 'epitope affect vaccine', 'cd4 cells vary cd4 cell', 'cd4 cells vary epitope', 'cd4 cells vary igg', 'cd4 cells vary antigen-specific', 'cd4 cells vary immunity', 'cd4 cells vary vaccine']",4469,effectiveness seasonal influenza vaccination varies individuals might affected vaccination history among factors 
1783,444.0,1.0,"['immunization show vaccine', 'immunization show participant', 'immunization show vaccine', 'immunization show vaccine', 'immunization monitor participant', 'immunization monitor vaccine', 'immunization monitor vaccine', 'immunization conserve vaccine', 'participant conserve vaccine']",4470,show monitoring frequencies cd4 cells specific conserved hemagglutinin epitope ha 118-132 titres igg corresponding recombinant hemagglutinin protein antigen-specific cd4 cell antibody responses closely linked pre-existing immunity vaccine history 
1784,444.0,2.0,"['cd4 cells observe antibody', 'follicular observe antibody']",4471,upon immunization strong early reaction observed vaccine naÃÂve participants also vaccine experienced individuals received respective seasonal vaccine previous year 
1785,444.0,6.0,"['patient exist multiple myeloma', 'patient exist covid-19', 'lymphocytic exist multiple myeloma', 'lymphocytic exist covid-19', 'multiple myeloma provide covid-19', 'patient provide covid-19', 'lymphocytic provide covid-19', 'leukemia provide covid-19']",4475,thus pre-existing immunity vaccine history contribute response seasonal influenza vaccines 
1786,445.0,0.0,"['patient induce sars-cov2', 'patient induce antibody', 'patient induce people-and']",4476,recent research suggests patients chronic lymphocytic leukemia multiple myeloma may diminished immune response covid-19 vaccination 
1787,446.0,4.0,"['patient enrol symptom', 'patient enrol participant', '143 enrol symptom', '143 enrol participant']",4482,method materials recruited 619 healthy sardinian controls 182 sars-cov-2 patients 
1788,446.0,7.0,"['patient hospitalize g6pdh', 'patient hospitalize g6pdh', 'autoimmune hospitalize g6pdh']",4485,results male sex older age frequent hospitalized patients none vaccinated previous seasonal flu vaccination campaignes 
1789,446.0,9.0,"['hla-a 0205 induce c 0701', 'hla-a 0205 induce hla-a 3002', 'hla-a 0205 induce b 1402', 'hla-a 0205 induce 182', 'hla-a 0205 induce patient', 'hla-a 0205 induce hla-c', 'hla-a 0205 induce three-loci', 'hla-a 0205 induce patient', 'b 5801 induce c 0701', 'b 5801 induce hla-a 3002', 'b 5801 induce b 1402', 'b 5801 induce 182', 'b 5801 induce patient', 'b 5801 induce hla-c', 'b 5801 induce three-loci', 'b 5801 induce patient']",4487,none patients carried beta-thalassemia trait relatively common finding sardinian population 
1790,446.0,13.0,['influenza induce salivarian'],4491,genetic factors resulted negative influence disease course presence hla-drb1 0801 allele g6pdh deficiency beta-thalassemic trait 
1791,446.0,14.0,"['trypanosomes predispose trypanosoma', 'trypanosomes predispose evansi', 'trypanosomes predispose africa', 'trypanosomes predispose europe', 'extracellular predispose trypanosoma', 'extracellular predispose evansi', 'extracellular predispose africa', 'extracellular predispose europe', 'protozoan predispose trypanosoma', 'protozoan predispose evansi', 'protozoan predispose africa', 'protozoan predispose europe', 'infection predispose trypanosoma', 'infection predispose evansi', 'infection predispose africa', 'infection predispose europe']",4492,absence influenza vaccination could predisposing factor severe disease 
1792,447.0,2.0,"['scrna-seq indicate trypanosome', 'scrna-seq indicate mouse', 'scrna-seq indicate two', 'scrna-seq indicate infection']",4495,success parasite attributed capacity evade disable mammalian defense response 
1793,447.0,3.0,['parasitemia use infection'],4496,unravel latter applied first time scrna-seq analysis splenocytes trypanosome infected mice two time points infection ie 
1794,447.0,5.0,"['follicle combine aicda', 'follicle combine gc-like', 'follicle combine parasitemia', 'follicle combine xbp1', 'follicle combine cd138', 'follicle combine plasma', 'follicle combine tbx21', 'follicle combine cd11c', 'follicle combine memory', 'follicle receive xbp1', 'follicle receive cd138', 'follicle receive plasma', 'follicle receive tbx21', 'follicle receive cd11c', 'follicle receive memory', 'aicda receive xbp1', 'aicda receive cd138', 'aicda receive plasma', 'aicda receive tbx21', 'aicda receive cd11c', 'aicda receive memory', 'gc-like receive xbp1', 'gc-like receive cd138', 'gc-like receive plasma', 'gc-like receive tbx21', 'gc-like receive cd11c', 'gc-like receive memory']",4498,analysis combined flow cytometry elisa revealing t evansi induces prompt activation splenic igm cd1d marginal zone igm int igd follicular b cells coinciding increase plasma igg2c ab levels 
1795,447.0,7.0,"['-- induce infection', 'mouse induce infection', 'mount induce infection', 'igg induce infection']",4500,ablation immature cd93 bone marrow vpreb3 ly6d ighm expressing transitional spleen b cells prevented mature peripheral b cell replenishment 
1796,447.0,10.0,"['igm fold anti-trypanosome', 'igm fold vaccine', 'anti-trypanosome fold vaccine']",4503,hence conclude immune competent mice trypanosomosis associated b cell activation switched igg production rapidly induced t evansi facilitating escape detrimental natural igm killing activity resulting increased host susceptibility 
1797,448.0,0.0,"['cardiometabolic associate covid-19', 'cardiometabolic associate subgroup']",4505,aims risks associated diabetes obesity hypertension severe covid-19 may confounded differ sociodemographic background 
1798,448.0,1.0,"['case-control associate patient', 'case-control associate covid-19', 'case-control associate 10860', 'case-control associate or', 'case-control report 10860', 'case-control report or', '1086 report 10860', '1086 report or', 'patient report 10860', 'patient report or', 'covid-19 report 10860', 'covid-19 report or']",4506,assessed risks associated cardiometabolic factors severe covid-19 accounting socioeconomic factors subgroups age sex region birth 
1799,448.0,7.0,"['diabetes associate covid-19', 'obesity associate covid-19']",4512,risk associated type 2 diabetes higher women p0001 patients region birth outside european union eu p0004 
1800,448.0,9.0,['swedish imply patient'],4514,type 2 diabetes implied greater risk among women non-eu immigrants 
1801,449.0,2.0,['infection use vaccine'],4519,design setting participantswe conducted series observational retrospective analyses using electronic health records ehrs columbia university irving medical centernew york presbyterian cuimcnyp september 21 2021 new york adult residence pcr test records included analysis 
1802,449.0,3.0,"['vaccine use infection', 'vaccine use cohort', 'vaccine use cohort', 'vaccine use pre-vaccinated', 'vaccine use infection', 'vaccine evaluate cohort', 'vaccine evaluate cohort', 'vaccine evaluate pre-vaccinated', 'vaccine evaluate infection', 'infection evaluate cohort', 'infection evaluate cohort', 'infection evaluate pre-vaccinated']",4520,main outcomes measurespoisson regression used assess association breakthrough infection rate vaccinated individuals multiple risk factors - including vaccine brand demographics underlying conditions - adjusting calendar month prior number visits observational days 
1803,449.0,5.0,"['vaccine match cohort', 'vaccine match two', 'vaccine match infection', 'vaccine match cohort', 'vaccine match resultsindividuals', 'covid-19 match cohort', 'covid-19 match two', 'covid-19 match infection', 'covid-19 match cohort', 'covid-19 match resultsindividuals', 'vaccine vaccinate cohort', 'vaccine vaccinate two', 'vaccine vaccinate infection', 'vaccine vaccinate cohort', 'vaccine vaccinate resultsindividuals', 'covid-19 vaccinate cohort', 'covid-19 vaccinate two', 'covid-19 vaccinate infection', 'covid-19 vaccinate cohort', 'covid-19 vaccinate resultsindividuals']",4522,infection incident rate also compared vaccinated individuals longitudinally matched unvaccinated individuals 
1804,449.0,6.0,"['modernamrna-1273 associate 148', 'modernamrna-1273 associate 109', 'modernamrna-1273 associate 200', 'modernamrna-1273 associate infection', '117 associate 148', '117 associate 109', '117 associate 200', '117 associate infection', '235 associate 148', '235 associate 109', '235 associate 200', '235 associate infection', '111 associate 148', '111 associate 109', '111 associate 200', '111 associate infection', 'modernamrna-1273 compare 148', 'modernamrna-1273 compare 109', 'modernamrna-1273 compare 200', 'modernamrna-1273 compare infection', '117 compare 148', '117 compare 109', '117 compare 200', '117 compare infection', '235 compare 148', '235 compare 109', '235 compare 200', '235 compare infection', '111 compare 148', '111 compare 109', '111 compare 200', '111 compare infection', 'modernamrna-1273 match infection', '117 match infection', '235 match infection', '111 match infection', '148 match infection', '109 match infection', '200 match infection']",4523,cox regression used estimate association vaccine covid-19 associated severe outcomes comparing breakthrough cohort two matched unvaccinated infection cohorts 
1805,449.0,9.0,"['covid-19 receive death', 'covid-19 receive adj']",4526,increased incidence rate found vaccines time 
1806,449.0,14.0,['sars-cov-2 experience vaccine'],4531,immunocompromised individuals among highest risk groups experiencing breakthrough infections 
1807,449.0,17.0,"['ehr infect infection', '2021 infect infection']",4534,clinical outcomes differ vaccinated still sars-cov-2 infected individuals non-vaccinated infected individuals 
1808,449.0,18.0,"['pre-vaccinated use sars-cov-2', 'pre-vaccinated use infection', 'pre-vaccinated use subgroup']",4535,findingsthis retrospective study uses cuimcnyp ehr data september 21 2021 individuals vaccinated pfizerbnt162b2 male compromised immune systems significantly higher incidence rate ratios breakthrough infections 
1809,449.0,20.0,"['cancer provide scientist', 'vaccine provide scientist']",4537,meaningleveraging real-world ehr data provides insight may optimally benefit booster covid-19 vaccination 
1810,450.0,2.0,"['hla collect irr', 'hla collect ct']",4540,published results 94 cts 64 therapeutic vaccines collected 
1811,450.0,3.0,"['silico receive mp', 'silico receive hla-genotyped', 'silico receive ct', 'silico receive mp-subjects', 'silico receive epitope', 'silico receive hla', 'silico base ct', 'silico base mp-subjects', 'silico base epitope', 'silico base hla', 'mp base silico', 'mp base ct', 'mp base mp-subjects', 'mp base epitope', 'mp base hla', 'hla-genotyped base silico', 'hla-genotyped base ct', 'hla-genotyped base mp-subjects', 'hla-genotyped base epitope', 'hla-genotyped base hla', 'silico increase hla', 'mp increase hla', 'hla-genotyped increase hla', 'silico increase hla', 'ct increase hla', 'mp-subjects increase hla']",4541,found preselection ct subjects based single matching hla allele increase immune response rates irr compared non-preselected cts median 60 vs 57 p 04490 
1812,450.0,5.0,"['multi-antigen evaluate multi-epitope', 'multi-antigen evaluate hla', 'multi-antigen evaluate hla', 'multi-antigen evaluate epitope', 'vaccine evaluate multi-epitope', 'vaccine evaluate hla', 'vaccine evaluate hla', 'vaccine evaluate epitope', 'multi-antigen correlate multi-epitope', 'multi-antigen correlate hla', 'multi-antigen correlate hla', 'multi-antigen correlate epitope', 'vaccine correlate multi-epitope', 'vaccine correlate hla', 'vaccine correlate hla', 'vaccine correlate epitope', 'multi-antigen predict hla', 'multi-antigen predict hla', 'multi-antigen predict epitope', 'vaccine predict hla', 'vaccine predict hla', 'vaccine predict epitope', 'multi-antigen bind hla', 'multi-antigen bind epitope', 'vaccine bind hla', 'vaccine bind epitope', 'multi-epitope bind hla', 'multi-epitope bind epitope', 'hla bind epitope']",4543,found vitro measured irrs correlated frequency predicted multiple autologous allele-binding epitopes auc 063ÃÂÂ079 
1813,450.0,6.0,"['t-cell aim epitope', 't-cell aim hlas', 't-cell aim patient', 't-cell receive epitope', 't-cell receive hlas', 't-cell receive patient']",4544,subgroup analysis multi-antigen targeting vaccine cts revealed correlation clinical response rates crrs predicted multi-epitope irrs hla threshold ÃÂÂ 3 r 07463 p 00004 single hla allele-binding epitopes r 02865 p 02491 
1814,450.0,7.0,"['autoimmune diseases induce risk', 'autoimmune diseases induce influenza', 'autoimmune diseases induce virus', 'autoimmune diseases aim influenza', 'autoimmune diseases aim virus']",4545,results suggest crr depends induction broad t-cell responses irr crr predicted epitopes binding multiple autologous hlas considered 
1815,451.0,0.0,"['autoimmune diseases develop sle sjogren', 'autoimmune diseases develop rheumatoid', 'autoimmune diseases develop arthritis', 'autoimmune diseases develop ra', 'autoimmune diseases develop bowel', 'influenza develop sle sjogren', 'influenza develop rheumatoid', 'influenza develop arthritis', 'influenza develop ra', 'influenza develop bowel', 'autoimmune diseases compare rheumatoid', 'autoimmune diseases compare arthritis', 'autoimmune diseases compare ra', 'autoimmune diseases compare bowel', 'sle sjogren compare rheumatoid', 'sle sjogren compare arthritis', 'sle sjogren compare ra', 'sle sjogren compare bowel', 'influenza compare rheumatoid', 'influenza compare arthritis', 'influenza compare ra', 'influenza compare bowel']",4546,patients suffering autoimmune diseases appear greater risk developing infections influenza virus compared healthy controls due immunosuppressive treatment suggesting importance vaccination 
1816,451.0,2.0,"['patient induce influenza', 'influenza recommend patient']",4548,overall vaccination generally well tolerated sle patients literature recommends inactivated influenza vaccine sle patients according recommendations schedules general population annually seasonal influenza viruses 
1817,451.0,4.0,"['coronavirus observe autoimmune', 'covid-19 observe autoimmune', 'influenza observe autoimmune']",4550,patients ra ibd vaccination efficacy inactivated influenza vaccine determined case-by-case basis taking patient therapy account 
1818,451.0,6.0,"['ltcf protect covid-19', 'ltcf protect spain', 'ltcf protect covid-19', 'ltcf observe covid-19', 'spain observe covid-19']",4552,public health measures recommended protect individuals vaccinations keeping mind possibility multiple covid-19 vaccines currently available 
1819,454.0,1.0,"['cochrane provide influenza', 'cochrane provide influenza']",4558,meta-analysis aimed provide current supportive evidence breadth validity observed protective effects influenza vaccination cardiovascular respiratory adverse outcomes all-cause mortality older adults general adult population 
1820,454.0,2.0,"['people receive cardiovascular diseases', 'people receive respiratory diseases', 'people receive 075-091', 'people receive cardiovascular diseases', 'people receive respiratory diseases', 'people receive 075-091', 'cardiovascular diseases emerge respiratory diseases', 'cardiovascular diseases emerge 075-091', 'people emerge respiratory diseases', 'people emerge 075-091', 'people emerge respiratory diseases', 'people emerge 075-091', '070-078 emerge respiratory diseases', '070-078 emerge 075-091', 'cardiovascular diseases compare respiratory diseases', 'cardiovascular diseases compare 075-091', 'people compare respiratory diseases', 'people compare 075-091', 'people compare respiratory diseases', 'people compare 075-091', '070-078 compare respiratory diseases', '070-078 compare 075-091']",4559,methods searched pubmed embase web science cochrane library identify published studies comparing influenza vaccination placebo database inception november 11 2018 included studies reporting associations influenza vaccination risk aforementioned adverse outcomes 
1821,454.0,4.0,['influenza perform cardiovascular'],4561,performed subgroup analysis age sex regioncountry found protective effects evident general adult population particularly robust older adults pre-existing specific diseases 
1822,454.0,6.0,"['patient benefit respiratory tract', 'patient benefit covid-19', 'patient benefit coronavirus', 'patient benefit coronavirus', 'patient benefit sars-cov-2', 'patient benefit organ', 'patient benefit peripheral', 'patient benefit lung', 'patient benefit lung', 'patient benefit covid-19', 'patient benefit lung', 'patient benefit lung', 'patient benefit sars-cov-2', 'patient exist respiratory tract', 'patient exist coronavirus', 'patient exist sars-cov-2', 'patient exist organ', 'patient exist peripheral', 'patient exist lung', 'patient exist lung', 'patient exist covid-19', 'patient exist lung', 'patient exist lung', 'patient exist sars-cov-2', 'coronavirus exist respiratory tract', 'coronavirus exist sars-cov-2', 'coronavirus exist organ', 'coronavirus exist peripheral', 'coronavirus exist lung', 'coronavirus exist lung', 'coronavirus exist patient', 'coronavirus exist covid-19', 'coronavirus exist lung', 'coronavirus exist lung', 'coronavirus exist patient', 'coronavirus exist sars-cov-2', 'covid-19 exist respiratory tract', 'covid-19 exist coronavirus', 'covid-19 exist sars-cov-2', 'covid-19 exist organ', 'covid-19 exist peripheral', 'covid-19 exist lung', 'covid-19 exist lung', 'covid-19 exist patient', 'covid-19 exist lung', 'covid-19 exist lung', 'covid-19 exist patient', 'covid-19 exist sars-cov-2', 'coronavirus exist respiratory tract', 'coronavirus exist sars-cov-2', 'coronavirus exist organ', 'coronavirus exist peripheral', 'coronavirus exist lung', 'coronavirus exist lung', 'coronavirus exist patient', 'coronavirus exist covid-19', 'coronavirus exist lung', 'coronavirus exist lung', 'coronavirus exist patient', 'coronavirus exist sars-cov-2']",4563,preventative measure benefit general population well old age pre-existing specific diseases 
1823,455.0,0.0,"['hepatitis b induce liver', 'hepatitis b induce cirrhosis', 'hepatitis b induce liver', 'hepatitis b induce cancer', '250 million induce liver', '250 million induce cirrhosis', '250 million induce liver', '250 million induce cancer']",4564,providing medical care patients suffering coronavirus disease 2019 covid-19 pandemic major challenge government healthcare systems around world new coronavirus called severe acute respiratory syndrome coronavirus 2 sars-cov-2 shows high organ specificity lower respiratory tract since far effective treatment vaccination virus early diagnostic recognition great importance due specific aspects infection mainly begins peripheral lung parenchyma lung ultrasonography suitable diagnostic imaging method identify suspected cases early stages disease serial ultrasound examinations patients confirmed covid-19 promptly detect changes affected lung tissue bedside article summarizes diagnostic potential lung ultrasound respect screening therapeutic decision-making patients suspected confirmed sars-cov-2 pneumonia
1824,456.0,0.0,"['hepatitis b set hbv-infected', 'hepatitis b set hepatocytes', 'hepatitis b set immunity', 'hepatitis b set immunity', 'hepatitis b set hbv', 'hepatitis b set patient', 'hepatitis b set chronic', 'hepatitis b set dysfunctional', 'hepatitis b set immunity', 'hbv set hepatitis b', 'hbv set hepatitis b', 'hbv set hepatitis b', 'hbv set hepatitis b', 'hbv set hepatitis b', 'hbv set hepatitis b', 'hbv set hbv-infected', 'hbv set hepatocytes', 'hbv set immunity', 'hbv set immunity', 'hbv set patient', 'hbv set chronic', 'hbv set dysfunctional', 'hbv set immunity', 'hepatitis b develop immunity', 'hepatitis b develop immunity', 'hepatitis b develop hbv', 'hepatitis b develop patient', 'hepatitis b develop chronic', 'hepatitis b develop dysfunctional', 'hepatitis b develop immunity', 'hbv develop hepatitis b', 'hbv develop hepatitis b', 'hbv develop hepatitis b', 'hbv develop hepatitis b', 'hbv develop hepatitis b', 'hbv develop hepatitis b', 'hbv develop immunity', 'hbv develop immunity', 'hbv develop patient', 'hbv develop chronic', 'hbv develop dysfunctional', 'hbv develop immunity', 'immunity develop hepatitis b', 'immunity develop hepatitis b', 'immunity develop hepatitis b', 'immunity develop hepatitis b', 'immunity develop hepatitis b', 'immunity develop hepatitis b', 'immunity develop hbv', 'immunity develop patient', 'immunity develop chronic', 'immunity develop dysfunctional', 'hbv-infected develop hepatitis b', 'hbv-infected develop hepatitis b', 'hbv-infected develop hepatitis b', 'hbv-infected develop hepatitis b', 'hbv-infected develop hepatitis b', 'hbv-infected develop hepatitis b', 'hbv-infected develop immunity', 'hbv-infected develop immunity', 'hbv-infected develop hbv', 'hbv-infected develop patient', 'hbv-infected develop chronic', 'hbv-infected develop dysfunctional', 'hbv-infected develop immunity']",4565,chronic hepatitis b affects 250 million individuals worldwide putting risk developing liver cirrhosis liver cancer 
1825,456.0,1.0,['myeloid cell characterize hepatitis b'],4566,antiviral immune responses key eliminating hepatitis b virus hbv infections insufficient antiviral immunity characterized failure eliminate hbv-infected hepatocytes associated chronic hepatitis b prophylactic vaccination hepatitis b successfully established protective immunity infection hepatitis b virus instrumental controlling hepatitis b however prophylactic vaccination schemes successful mounting protective immunity eliminate hbv infections patients chronic hepatitis b discuss current knowledge development efficacy therapeutic vaccination strategies chronic hepatitis b particular emphasis pathogenetic understanding dysfunctional anti-viral immunity 
1826,457.0,1.0,"['primate modify rsv f', 'primate modify human', 'primate modify immunization', 'primate modify vaccine', 'primate modify three', 'nhps modify rsv f', 'nhps modify human', 'nhps modify immunization', 'nhps modify vaccine', 'nhps modify three', 'anatomy modify rsv f', 'anatomy modify human', 'anatomy modify immunization', 'anatomy modify vaccine', 'anatomy modify three', 'primate induce rsv f', 'primate induce immunization', 'primate induce vaccine', 'primate induce three', 'nhps induce rsv f', 'nhps induce immunization', 'nhps induce vaccine', 'nhps induce three', 'anatomy induce rsv f', 'anatomy induce immunization', 'anatomy induce vaccine', 'anatomy induce three', 'human induce rsv f', 'human induce immunization', 'human induce vaccine', 'human induce three', 'primate circulate rsv f', 'primate circulate anatomy', 'primate circulate human', 'primate circulate immunization', 'primate circulate vaccine', 'primate circulate three', 'nhps circulate rsv f', 'nhps circulate anatomy', 'nhps circulate human', 'nhps circulate immunization', 'nhps circulate vaccine', 'nhps circulate three']",4569,boosting circulating antibodies transferred foetus would offer immune protection virus ultimately disease 
1827,457.0,3.0,"['monkey infect mother', 'old-world infect mother', 'monkey infect mother', 'monkey know old-world', 'monkey know mother']",4571,three species nhps known ability infected human rsv experimental challenge studies tested rsv-specific antibodies 
1828,457.0,5.0,"['rsv associate new-borns', 'rsv associate new-borns', 'rsv associate mother', 'agms associate rsv', 'agms associate new-borns', 'agms associate new-borns', 'agms associate mother', 'rsv receive new-borns', 'rsv receive new-borns', 'rsv receive mother', 'agms receive new-borns', 'agms receive new-borns', 'agms receive mother', 'rsv receive new-borns', 'rsv receive new-borns', 'rsv receive mother']",4573,higher overall antibody levels associated greater durability found offspring 
1829,457.0,7.0,['vaccine perform immunity'],4575,findings accomplished small treatment group sizes demonstrate model provides efficient resource sparing translatable preclinical vivo system evaluating vaccine candidates maternal immunization 
1830,458.0,0.0,"['primer need vaccine', 'booster need vaccine']",4576,many vaccines multiple injections required confer protective immunity targeted pathogens 
1831,458.0,3.0,"['bovine develop antigen', 'bovine develop poly', 'bovine develop plga', 'bovine develop monomer', 'serum develop antigen', 'serum develop poly', 'serum develop plga', 'serum develop monomer', 'albumin develop antigen', 'albumin develop poly', 'albumin develop plga', 'albumin develop monomer']",4579,study developed parenterally injectable core-shell microspheres delayed pulsatile release profile could serve booster vaccine formulation 
1832,458.0,4.0,['particle observe microfluidic'],4580,microspheres contained bovine serum albumin bsa model antigen poly dl-lactide-co-glycolide plga various dl-lactide glycolide monomer ratios shell material 
1833,458.0,7.0,"['bovine increase polymer', 'bovine increase bulk', 'serum increase polymer', 'serum increase bulk', 'bovine increase polymer', 'bovine increase bulk', 'serum increase polymer', 'serum increase bulk', 'albumin increase polymer', 'albumin increase bulk']",4583,lag time increased increasing lactide content polymer ranged 3 7 weeks 
1834,458.0,10.0,"['adult show antibody', 'adult show hcmv']",4586,altogether findings show injectable core-shell microspheres combined primer promising alternative current multiple-injection vaccines 
1835,459.0,4.0,['infection display vil-10'],4591,one case displayed nk cells characteristic cmv infection hcmv dna became undetectable 
1836,459.0,5.0,"['hcmv block vaccine', 'hcmv block people']",4592,cases infection may persist seroconversion blocked vil-10 
1837,459.0,6.0,['vaccine prevent sars-cov-2'],4593,future research seek mechanisms prevent individual seroconverting despite persistent hcmv infection hcmv vaccines may work well people 
1838,460.0,2.0,"['covid-19 evaluate specimen', 'covid-19 evaluate 246']",4596,toward end evaluated analytical clinical performance abbott sars-cov-2 igg roche anti-sars-cov-2 immunoassays 
1839,460.0,11.0,"['respiratory show sars-cov-2', 'respiratory show vaccine', 'respiratory show sars-cov-2', 'respiratory show vaccine', 'respiratory show coronavirus', 'respiratory show covid-19', 'syndrome show sars-cov-2', 'syndrome show vaccine', 'syndrome show sars-cov-2', 'syndrome show vaccine', 'syndrome show coronavirus', 'syndrome show covid-19']",4605,conclusions study demonstrates similar analytical clinical performance abbott roche sars-cov-2 antibody assays roche assay may slightly sensitive patients tested within 0-6 days first positive rt-pcr sars-cov-2 
1840,461.0,2.0,"['cox vaccinate covid-19', 'cox vaccinate delta', 'cox vaccinate vaccine', 'vaccine vaccinate covid-19', 'vaccine vaccinate delta', 'cox perform vaccine', 'cox perform covid-19', 'cox perform delta', 'cox perform vaccine']",4608,methodswe performed retrospective cohort study vaccine breakthrough infections fully vaccinated persons veterans health administration 
1841,461.0,4.0,"['ad26cov2s vaccinate sars-cov-2', 'ad26cov2s vaccinate ahr', 'ad26cov2s vaccinate ahr', 'ad26cov2s vaccinate ci', 'ad26cov2s vaccinate covid-19', 'ad26cov2s vaccinate ahr', 'bnt162b2 vaccinate sars-cov-2', 'bnt162b2 vaccinate ahr', 'bnt162b2 vaccinate ahr', 'bnt162b2 vaccinate ci', 'bnt162b2 vaccinate covid-19', 'bnt162b2 vaccinate ahr', 'ad26cov2s document ahr', 'ad26cov2s document ahr', 'ad26cov2s document ci', 'ad26cov2s document covid-19', 'ad26cov2s document ahr', 'bnt162b2 document ahr', 'bnt162b2 document ahr', 'bnt162b2 document ci', 'bnt162b2 document covid-19', 'bnt162b2 document ahr', 'mrna-1273 document ahr', 'mrna-1273 document ahr', 'mrna-1273 document ci', 'mrna-1273 document covid-19', 'mrna-1273 document ahr', 'ad26cov2s receive ahr', 'ad26cov2s receive ci', 'ad26cov2s receive covid-19', 'ad26cov2s receive ahr', 'bnt162b2 receive ahr', 'bnt162b2 receive ci', 'bnt162b2 receive covid-19', 'bnt162b2 receive ahr', 'mrna-1273 receive ahr', 'mrna-1273 receive ci', 'mrna-1273 receive covid-19', 'mrna-1273 receive ahr', 'sars-cov-2 receive ahr', 'sars-cov-2 receive ci', 'sars-cov-2 receive covid-19', 'sars-cov-2 receive ahr', 'ahr receive ci', 'ahr receive covid-19', 'ad26cov2s receive ahr', 'bnt162b2 receive ahr', 'mrna-1273 receive ahr', 'sars-cov-2 receive ahr', 'ci receive ahr']",4610,resultsamong 3032561 fully vaccinated persons documented sars-cov-2 infection occurred 11197 037 covid-19 hospitalization occurred 2080 007 
1842,461.0,5.0,"['covid-19 document sars-cov-2', 'hispanic document sars-cov-2']",4611,compared ad26cov2s bnt162b2 mrna-1273 lower occurrence documented sars-cov-2 infection ahr 054 95 confidence interval ci 051-058 ahr 036 95 ci 033-038 respectively covid-19 hospitalization ahr 056 95 ci 047-066 ahr 030 025-035 respectively 
1843,461.0,6.0,['covid-19 associate vaccine'],4612,documented sars-cov-2 infection covid-19 hospitalization associated younger age hispanic latino ethnicity number comorbidities previous sars-cov-2 infection 
1844,461.0,9.0,['covid-19 document vaccine'],4615,mrna-1273 bnt162b2 protective documented sars-cov-2 infection covid-19 hospitalization compared ad26cov2s 
1845,461.0,10.0,"['sars-cov-2 observe antibody', 'sars-cov-2 observe covid-19', 'sars-cov-2 observe vaccine', 'sars-cov-2 bolster antibody', 'sars-cov-2 bolster covid-19', 'sars-cov-2 bolster vaccine']",4616,efforts limit covid-19 transmission bolster vaccine coverage would also curtail vaccine breakthrough 
1846,462.0,0.0,"['vaccine-induced indicate methodsomicron', 'antibody indicate methodsomicron']",4617,backgroundthe sars-cov-2 omicron variant designated variant concern voc world health organization carries numerous spike protein mutations found evade neutralizing antibodies elicited covid-19 vaccines 
1847,462.0,11.0,"['plasma associate single-dose', 'plasma associate influenza', 'plasma associate immunity', 'plasma associate patient', 'cell associate single-dose', 'cell associate influenza', 'cell associate immunity', 'cell associate patient', 'pcds associate single-dose', 'pcds associate influenza', 'pcds associate immunity', 'pcds associate patient', 'plasma induce pcds', 'plasma induce influenza', 'plasma induce single-dose', 'plasma induce influenza', 'plasma induce immunity', 'plasma induce patient', 'cell induce pcds', 'cell induce influenza', 'cell induce single-dose', 'cell induce influenza', 'cell induce immunity', 'cell induce patient']",4628,data suggest omicron variant may associated lower covid-19 vaccine effectiveness 
1848,463.0,1.0,"['tandem need influenza', 'fluzone need influenza', 'high-dose need influenza']",4630,strategies improve immunity influenza patients clearly needed 
1849,463.0,2.0,"['patient compare saline', 'patient compare injection']",4631,performed randomized double-blind placebo-controlled clinical trial comparing tandem fluzone high-dose influenza vaccination standard-of-care influenza vaccination 
1850,463.0,3.0,"['122 base fluzone', '122 base vaccine', 'pcd base fluzone', 'pcd base vaccine', 'patient base fluzone', 'patient base vaccine']",4632,standard-of-care vaccination single-dose age-based vaccination standard dose 65 years high dose 8805 65 years patients arm received saline placebo injection 30 days 
1851,463.0,4.0,"['hemagglutinin enrol h1n1', 'hemagglutinin enrol h3n2', 'hemagglutinin enrol influenza', 'hemagglutinin enrol patient', 'hemagglutinin enrol tandem', 'hemagglutinin enrol 873', 'hemagglutinin enrol 632', 'hemagglutinin enrol p', 'hemagglutinin enrol 600', 'hemagglutinin enrol 316', 'hemagglutinin receive patient', 'hemagglutinin receive tandem', 'hemagglutinin receive 873', 'hemagglutinin receive 632', 'hemagglutinin receive p', 'hemagglutinin receive 600', 'hemagglutinin receive 316', 'h1n1 receive patient', 'h1n1 receive tandem', 'h1n1 receive 873', 'h1n1 receive 632', 'h1n1 receive p', 'h1n1 receive 600', 'h1n1 receive 316', 'h3n2 receive patient', 'h3n2 receive tandem', 'h3n2 receive 873', 'h3n2 receive 632', 'h3n2 receive p', 'h3n2 receive 600', 'h3n2 receive 316', 'influenza receive patient', 'influenza receive tandem', 'influenza receive 873', 'influenza receive 632', 'influenza receive p', 'influenza receive 600', 'influenza receive 316', 'hemagglutinin receive 600', 'hemagglutinin receive 316', 'h1n1 receive 600', 'h1n1 receive 316', 'h3n2 receive 600', 'h3n2 receive 316', 'influenza receive 600', 'influenza receive 316', 'patient receive 600', 'patient receive 316', 'tandem receive 600', 'tandem receive 316', '873 receive 600', '873 receive 316', '632 receive 600', '632 receive 316', 'p receive 600', 'p receive 316']",4633,total 122 pcd patients enrolled 47 received single-dose standard-of-care vaccination 75 received 2 doses fluzone high-dose vaccine 
1852,463.0,6.0,"['vaccine show immunity', 'vaccine show coronavirus', 'vaccine show patient', 'vaccine receive coronavirus', 'vaccine receive patient', 'immunity receive coronavirus', 'immunity receive patient']",4635,data demonstrate tandem high-dose influenza vaccination separated 30 days leads higher serologic hai titer responses durable influenza-specific immunity pcd patients 
1853,464.0,2.0,"['cohort perform patient', 'italian perform patient', 'covid perform patient']",4640,methods retrospective analysis performed italian cohort composed transplanted waitlisted patients january 2002-march 2020 time frame 
1854,464.0,3.0,"['hla evaluate covid', 'hla evaluate sars-cov-2', 'n265 evaluate covid', 'n265 evaluate sars-cov-2', 'covid evaluate sars-cov-2', 'n56 evaluate covid', 'n56 evaluate sars-cov-2']",4641,data cohort merged italian registry covid subjects evaluating infection status transplanted waitlisted patients 
1855,464.0,4.0,"['covid-19 test patient', 'covid-19 test or42', 'covid-19 test 00001', 'covid-19 test hla-drb1', '0112 test patient', '0112 test or42', '0112 test 00001', '0112 test hla-drb1', 'covid-19 compare 00001', 'covid-19 compare hla-drb1', '0112 compare 00001', '0112 compare hla-drb1', 'italian compare 00001', 'italian compare hla-drb1', 'patient compare 00001', 'patient compare hla-drb1', 'or42 compare 00001', 'or42 compare hla-drb1']",4642,total 56304 cases studied aim comparing hla ab0 frequencies according presence n265 covid absence n56 039 covid sars-cov-2 infection 
1856,464.0,8.0,"['blood bind covid', 'blood bind 455', 'blood bind covid', 'blood bind patient', 'blood bind 390', 'blood bind 102-166', 'blood show covid', 'blood show patient', 'blood show 390', 'blood show 102-166', 'covid show patient', 'covid show 390', 'covid show 102-166']",4646,peptide binding prediction analyses showed drb1 08 alleles unable bind viral peptides high affinity 
1857,465.0,0.0,"['vaccine observe covid19', 'recipient observe covid19', 'sars-cov-2 observe covid19']",4649,vaccines proving highly effective controlling hospitalisation deaths associated sars-cov-2 infection emergence viral variants novel antigenic profiles threatens diminish efficacy 
1858,465.0,1.0,"['infection inform africa', 'infection inform sars-cov-2', 'infection inform bnt162b2', 'infection inform chadox1', 'infection inform vaccine', 'india inform africa', 'india inform sars-cov-2', 'india inform bnt162b2', 'india inform chadox1', 'india inform vaccine', 'b1351 inform africa', 'b1351 inform sars-cov-2', 'b1351 inform bnt162b2', 'b1351 inform chadox1', 'b1351 inform vaccine', 'infection minimize bnt162b2', 'infection minimize chadox1', 'infection minimize vaccine', 'india minimize bnt162b2', 'india minimize chadox1', 'india minimize vaccine', 'b1351 minimize bnt162b2', 'b1351 minimize chadox1', 'b1351 minimize vaccine', 'south minimize bnt162b2', 'south minimize chadox1', 'south minimize vaccine', 'africa minimize bnt162b2', 'africa minimize chadox1', 'africa minimize vaccine', 'sars-cov-2 minimize bnt162b2', 'sars-cov-2 minimize chadox1', 'sars-cov-2 minimize vaccine']",4650,assessment ability sera vaccine recipients neutralise sars-cov-2 variants inform success strategies minimising covid19 cases design effective antigenic formulations 
1859,465.0,3.0,"['b16172 vaccinate glycoprotein', 'b16172 vaccinate b1351', 'b16172 vaccinate south', 'b16172 vaccinate african', 'b16172 vaccinate 629-fold', 'b16172 vaccinate vaccine']",4652,across vaccinated individuals spike glycoproteins b16171 b16172 conferred reductions neutralisation 431 511-fold respectively 
1860,465.0,4.0,"['two approach chadox1', 'bnt162b2 approach two', 'bnt162b2 approach chadox1', 'two confer chadox1', 'bnt162b2 confer two', 'bnt162b2 confer chadox1']",4653,reduction seen b16172 lineage approached conferred glycoprotein b1351 south african variant 629-fold reduction known associated reduced vaccine efficacy 
1861,465.0,5.0,"['two elicit b1351', 'two elicit pseudoviruses', 'two elicit b16172', 'two elicit b1351', 'bnt162b2 elicit b1351', 'bnt162b2 elicit pseudoviruses', 'bnt162b2 elicit b16172', 'bnt162b2 elicit b1351', '777 elicit b1351', '777 elicit pseudoviruses', '777 elicit b16172', '777 elicit b1351', '1130 elicit b1351', '1130 elicit pseudoviruses', '1130 elicit b16172', '1130 elicit b1351', '956-fold elicit b1351', '956-fold elicit pseudoviruses', '956-fold elicit b16172', '956-fold elicit b1351', 'b16171 elicit b1351', 'b16171 elicit pseudoviruses', 'b16171 elicit b16172', 'b16171 elicit b1351']",4654,neutralising antibody titres elicited vaccination two doses bnt162b2 significantly higher elicited vaccination two doses chadox1 
1862,465.0,9.0,"['two base vaccine', 'two base bnt162b2', 'two base chadox1-induced', 'two base immunity', 'two update bnt162b2', 'two update chadox1-induced', 'two update immunity', 'vaccine update bnt162b2', 'vaccine update chadox1-induced', 'vaccine update immunity']",4658,accordingly booster vaccines based updated variants likely required time prevent productive infection 
1863,465.0,10.0,"['acute respiratory induce cardiovascular complications', 'acute respiratory induce cardiovascular', 'cardiovascular complications need acute respiratory', 'cardiovascular need acute respiratory']",4659,study also suggests two dose regimes vaccine required maximal bnt162b2 chadox1-induced immunity 
1864,466.0,0.0,"['cardiovascular induce acute cardiovascular', 'cardiovascular induce ehr', 'acute cardiovascular underlie ehr', 'cardiovascular underlie ehr']",4660,background although acute respiratory infections lead cardiovascular complications effect underlying cardiovascular risk incidence acute respiratory infections cardiovascular complications following acute respiratory infection individuals without established cardiovascular disease unknown 
1865,466.0,1.0,"['cohort associate cprd', 'cohort associate aurum', 'ehrs associate cprd', 'ehrs associate aurum', 'cohort investigate ehrs', 'cohort investigate cprd', 'cohort investigate aurum', 'cohort increase cprd', 'cohort increase aurum', 'ehrs increase cprd', 'ehrs increase aurum']",4661,aimed investigate whether cardiovascular risk associated increased risk acute respiratory infection acute cardiovascular events acute respiratory infection using 10 years linked electronic health record ehr data england 
1866,466.0,2.0,"['cardiovascular disease base sept 1', 'cardiovascular disease base influenza', 'cardiovascular disease base cprd', 'cardiovascular disease base patient', 'cardiovascular disease base cardiovascular', 'cardiovascular disease base hypertension', 'cardiovascular disease base cardiovascular', 'cardiovascular disease base qrisk2', 'cardiovascular disease base 10', 'cardiovascular disease use sept 1', 'cardiovascular disease use influenza', 'cardiovascular disease use cprd', 'cardiovascular disease use patient', 'cardiovascular disease use cardiovascular', 'cardiovascular disease use hypertension', 'cardiovascular disease use cardiovascular', 'cardiovascular disease use qrisk2', 'cardiovascular disease use 10', 'cardiovascular disease receive sept 1', 'cardiovascular disease receive cprd', 'cardiovascular disease receive patient', 'cardiovascular disease receive cardiovascular', 'cardiovascular disease receive hypertension', 'cardiovascular disease receive cardiovascular', 'cardiovascular disease receive qrisk2', 'cardiovascular disease receive 10', 'influenza receive sept 1', 'influenza receive cprd', 'influenza receive patient', 'influenza receive cardiovascular', 'influenza receive hypertension', 'influenza receive cardiovascular', 'influenza receive qrisk2', 'influenza receive 10']",4662,methods retrospective population-based cohort study used ehrs primary care providers registered clinical practice research datalink cprd gold aurum databases england 
1867,466.0,4.0,"['acute aim infection', 'cox aim infection']",4664,using multivariable poisson regression models calculated incidence rate ratios irrs systemic acute respiratory infection 
1868,466.0,5.0,"['075 use sept 1', '075 use 526 480', '075 use patient', '075 use 212', '075 use 930', '075 use hypertension', '075 use 607', '075 use qrisk2', '075 use acute', '321 use sept 1', '321 use 526 480', '321 use patient', '321 use 212', '321 use 930', '321 use hypertension', '321 use 607', '321 use qrisk2', '321 use acute', 'cprd use sept 1', 'cprd use 526 480', 'cprd use patient', 'cprd use 212', 'cprd use 930', 'cprd use hypertension', 'cprd use 607', 'cprd use qrisk2', 'cprd use acute', '075 aim sept 1', '075 aim 526 480', '075 aim patient', '075 aim 212', '075 aim 930', '075 aim hypertension', '075 aim 607', '075 aim qrisk2', '075 aim acute', '321 aim sept 1', '321 aim 526 480', '321 aim patient', '321 aim 212', '321 aim 930', '321 aim hypertension', '321 aim 607', '321 aim qrisk2', '321 aim acute', 'cprd aim sept 1', 'cprd aim 526 480', 'cprd aim patient', 'cprd aim 212', 'cprd aim 930', 'cprd aim hypertension', 'cprd aim 607', 'cprd aim qrisk2', 'cprd aim acute']",4665,among individuals acute respiratory infection used multivariable cox regression calculate hazard ratios hrs risk acute cardiovascular events within 1 year infection 
1869,466.0,6.0,"['alcohol associate qrisk2', 'alcohol associate infection', 'alcohol associate hypertension', 'alcohol associate qrisk2', 'alcohol associate qrisk2', 'alcohol associate 442', 'smoking associate qrisk2', 'smoking associate infection', 'smoking associate hypertension', 'smoking associate qrisk2', 'smoking associate qrisk2', 'smoking associate 442', 'hypertension associate qrisk2', 'hypertension associate infection', 'hypertension associate qrisk2', 'hypertension associate qrisk2', 'hypertension associate 442', 'alcohol associate qrisk2', 'alcohol associate infection', 'alcohol associate hypertension', 'alcohol associate qrisk2', 'alcohol associate qrisk2', 'alcohol associate 442', 'alcohol include infection', 'alcohol include hypertension', 'alcohol include qrisk2', 'alcohol include qrisk2', 'alcohol include 442', 'smoking include infection', 'smoking include hypertension', 'smoking include qrisk2', 'smoking include qrisk2', 'smoking include 442', 'hypertension include infection', 'hypertension include qrisk2', 'hypertension include qrisk2', 'hypertension include 442', 'alcohol include infection', 'alcohol include hypertension', 'alcohol include qrisk2', 'alcohol include qrisk2', 'alcohol include 442', 'qrisk2 include infection', 'qrisk2 include hypertension', 'qrisk2 include 442']",4666,findings identified 6 075 321 individuals aged 40ÃÂÂ64 years data cprd linked data hospital episode statistics admitted patient care database sept 1 2008 aug 31 2018 individuals 4 212 930 including 526 480 12ÃÂ5 hypertension 607 087 14ÃÂ4 qrisk2 score ÃÂÂ10 included assessment incidence acute respiratory infection 
1870,466.0,7.0,"['408 adjust respiratory infection', '408 adjust acute cardiovascular', '408 adjust acute', '408 adjust 4196']",4667,adjusting confounders age sex ethnicity socioeconomic status body-mass index alcohol consumption smoking status consultation frequency hypertension analysis alcohol consumption consultation frequency qrisk2 analysis incidence acute respiratory infection higher individuals hypertension without irr 1ÃÂ04 95 ci 1ÃÂ03ÃÂÂ1ÃÂ05 higher qrisk2 score 10 higher qrisk2 score less 10 1ÃÂ39 1ÃÂ37ÃÂÂ1ÃÂ40 
1871,467.0,2.0,"['balbc receive ifn', 'c57bl6 receive ifn']",4674,better understand yf17d vaccination identify suitable mouse model evaluated immunogenicity protective efficacy yf17d five complementary mouse models ie 
1872,467.0,4.0,"['cd4 t-cells induce c57bl6', 'immunity induce c57bl6', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x82Â³ induce c57bl6']",4676,alike ifnar -- mice yf17d induced either wt mice strong humoral immune responses dominated igg2ac isotype th1 type antibodies yet ifnar blocked 
1873,467.0,6.0,"['intracranial induce c57bl6 mice', 'intracranial induce yf17d', 'intracranial induce balbc']",4678,surprisingly vaccine-induced protection largely mouse model dependent 
1874,467.0,7.0,"['infection confer antibody', 'yfv-specific confer antibody', 'igg confer antibody']",4679,full protection lethal intracranial challenge massive reduction virus loads conferred already minimal dose 2 pfu yf17d balbc ifnar -- mice c57bl6 mice 
1875,467.0,8.0,"['c57bl6 serve immunity', 'c57bl6 serve yf17d-derived', 'c57bl6 serve vaccine', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x83\x83Ã\x83\x82Ã\x82Â² serve immunity', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x83\x83Ã\x83\x82Ã\x82Â² serve yf17d-derived', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x83\x83Ã\x83\x82Ã\x82Â² serve vaccine', 'receptor serve immunity', 'receptor serve yf17d-derived', 'receptor serve vaccine', 'mouse serve immunity', 'mouse serve yf17d-derived', 'mouse serve vaccine', 'c57bl6 indicate mouse', 'c57bl6 indicate yf17d-induced', 'c57bl6 indicate immunity', 'c57bl6 indicate yf17d-derived', 'c57bl6 indicate vaccine', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x83\x83Ã\x83\x82Ã\x82Â² indicate mouse', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x83\x83Ã\x83\x82Ã\x82Â² indicate yf17d-induced', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x83\x83Ã\x83\x82Ã\x82Â² indicate immunity', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x83\x83Ã\x83\x82Ã\x82Â² indicate yf17d-derived', 'ifn-Ã\x83\x83Ã\x83\x82Ã\x83\x83Ã\x83\x82Ã\x82Â² indicate vaccine', 'receptor indicate mouse', 'receptor indicate yf17d-induced', 'receptor indicate immunity', 'receptor indicate yf17d-derived', 'receptor indicate vaccine']",4680,correlation analysis infection outcome pre-challenge immunological markers indicates yfv-specific igg might suffice protection even absence detectable levels neutralizing antibodies 
1876,467.0,9.0,['covid-19 induce vaccine'],4681,finally propose addition ifnar -- mice c57bl6 mice temporally blocked ifn-ÃÂÃÂ² receptors represent promising immunocompetent mouse model study yf17d-induced immunity evaluation yf17d-derived vaccines 
1877,468.0,2.0,"['fibrillation consider covid-19', 'fibrillation consider vaccine', 'one consider covid-19', 'one consider vaccine']",4684,however research regarding use vaccine still ongoing 
1878,468.0,8.0,"['blood show sars-cov2', 'blood show hstn-i', 'blood show patient']",4690,ecg showed af rapid ventricular response 
1879,468.0,9.0,"['atrial show amiodarone', 'atrial show aspirin', 'atrial show atorvastatin', 'atrial show ecg', 'atrial show post-therapy', 'atrial show ecg', 'fibrillation show amiodarone', 'fibrillation show aspirin', 'fibrillation show atorvastatin', 'fibrillation show ecg', 'fibrillation show post-therapy', 'fibrillation show ecg']",4691,routine blood test showed abnormality rapid antigen sars-cov2 negative hs troponin hstn-i 25 ngl 
1880,468.0,11.0,"['sars-cov-2 modify fibrillation', 'sars-cov-2 modify noaf']",4693,ecg post therapy converted sinus rhythm 26 hours 
1881,468.0,13.0,['patient receive noaf'],4695,receiving covid-19 vaccine immune system mimic primary infection 
1882,468.0,14.0,"['hs-tni develop troponin', 'sub-febrile develop troponin']",4696,unclear patients developed noaf 
1883,468.0,15.0,"['critically ill receive patient', 'critically ill receive myocardial', 'critically ill receive patient']",4697,however found observational zone hs-tni value sub-febrile temperature 
1884,469.0,0.0,"['cellular mutate two', 'cellular mutate bnt162b2', 'cellular mutate ad26cov2s', 'cellular mutate n41', 'cellular mutate bnt162b2', 'cellular mutate n24', 'cellular elicit ad26cov2s', 'cellular elicit n41', 'cellular elicit bnt162b2', 'cellular elicit n24', 'two elicit ad26cov2s', 'two elicit n41', 'two elicit bnt162b2', 'two elicit n24', 'bnt162b2 elicit ad26cov2s', 'bnt162b2 elicit n41', 'bnt162b2 elicit n24']",4700,rapid spread highly mutated sars-cov-2 omicron variant raised substantial concerns protective efficacy currently available vaccines 
1885,469.0,1.0,"['41c8baorghighwiredtldtlvardef vaccinate post-kala-azar', 'ac4522orghighwiredtldtlvardef vaccinate post-kala-azar', '1eed52b_hps_format_figexp vaccinate post-kala-azar']",4701,assessed omicron-specific humoral cellular immune responses 65 individuals vaccinated two immunizations bnt162b2 boosted least 6 months either ad26cov2s johnson johnson n41 bnt162b2 pfizer n24 table s1 
1886,470.0,0.0,"['chad63-kh observe pkdl', 'chad63-kh observe leish2a', 'vaccine observe pkdl', 'vaccine observe leish2a', 'sudanese observe pkdl', 'sudanese observe leish2a', 'patient observe pkdl', 'patient observe leish2a']",4703,post-kala-azar dermal leishmaniasis pkdl chronic stigmatizing skin condition occurring frequently apparent clinical cure visceral leishmaniasis 
1887,470.0,1.0,"['three-phase induce adolescent', 'three-phase induce patient', 'three-phase induce patient', 'sixteen induce adolescent', 'sixteen induce patient', 'sixteen induce patient']",4704,given urgent need new treatments conducted phase iia safety immunogenicity trial chad63-kh vaccine sudanese patients persistent pkdl 
1888,470.0,6.0,"['vaccine provide patient', 'vaccine provide 723', 'vaccine induce 723', 'patient induce 723']",4709,ambisome provided patients significant remaining disease last visit 
1889,470.0,7.0,"['patient show 523', 'patient show 217', '304 show 523', '304 show 217']",4710,chad63-kh vaccine showed minimal adverse reactions pkdl patients induced potent innate cell-mediated immune responses measured whole-blood transcriptomics elispot 
1890,470.0,8.0,"['blood monitor patient', 'blood test patient']",4711,723 patients 304 monitored study completion showed 90 clinical improvement 523 217 showed partial improvement 
1891,470.0,9.0,"['chad63-kh vaccine receive five', 'vaccine-related receive five']",4712,logistic regression model applied blood transcriptomic data identified immune modules predictive patients 90 clinical improvement 
1892,470.0,10.0,"['axillary observe covid-19', 'axillary observe metastasis', 'axillary observe patient', 'axillary observe metastasis', 'axillary observe patient', 'lymphadenopathy observe metastasis', 'lymphadenopathy observe patient']",4713,randomized controlled trial determine whether clinical responses vaccine-related whether chad63-kh vaccine clinical utility underway 
1893,471.0,1.0,"['patient elicit covid-19', 'patient elicit two']",4715,initial radiologic diagnosis raised concerns metastasis 
1894,471.0,2.0,"['lymph receive lymphadenopathy', 'biopsy receive lymphadenopathy', 'lymph receive lymphadenopathy', 'biopsy receive lymphadenopathy']",4716,however investigation revealed patients received covid-19 vaccinations ipsilateral arm prior imaging 
1895,471.0,3.0,"['axillary confirm vaccine', 'swelling confirm vaccine', 'lymphadenopathy confirm vaccine', 'symptom confirm vaccine']",4717,two cases lymph node biopsy results confirmed vaccination-related reactive lymphadenopathy 
1896,472.0,1.0,"['patient elicit covid-19', 'patient elicit two']",4722,initial radiologic diagnosis raised concerns metastasis 
1897,472.0,2.0,"['lymph receive lymphadenopathy', 'node receive lymphadenopathy', 'biopsy receive lymphadenopathy', 'lymph receive lymphadenopathy', 'node receive lymphadenopathy', 'biopsy receive lymphadenopathy']",4723,however investigation revealed patients received covid-19 vaccinations ipsilateral arm prior imaging 
1898,472.0,3.0,"['axillary confirm covid-19', 'axillary confirm vaccine', 'swelling confirm covid-19', 'swelling confirm vaccine', 'lymphadenopathy confirm covid-19', 'lymphadenopathy confirm vaccine', 'symptom confirm covid-19', 'symptom confirm vaccine']",4724,two cases lymph node biopsy confirmed vaccination related reactive lymphadenopathy 
1899,473.0,2.0,"['participant vaccinate cohort', 'participant vaccinate cohort', 'corona-infectious-virus vaccinate cohort', 'corona-infectious-virus vaccinate cohort']",4729,objective estimate risk breakthrough infections among fully vaccinated people pwh without pwoh hiv us 
1900,473.0,5.0,"['ahr aim jansen', 'ahr aim cohort', 'covid-19 aim jansen', 'covid-19 aim cohort', 'vaccine aim jansen', 'vaccine aim cohort', 'bnt162b2 aim jansen', 'bnt162b2 aim cohort', 'mrna-1273 aim jansen', 'mrna-1273 aim cohort']",4732,incidence rates per 1000 person-years cumulative incidence breakthrough infections 95 confidence intervals estimated hiv status 
1901,473.0,7.0,"['infection investigate sars-cov-2', 'infection investigate covid-19', 'covid-19 investigate sars-cov-2']",4734,risk factors breakthroughs among pwh also investigated 
1902,473.0,8.0,"['31840 describe pwh versus', '31840 describe pwoh', '31840 describe person-years', '77759 describe pwh versus', '77759 describe pwoh', '77759 describe person-years', 'infection describe pwh versus', 'infection describe pwoh', 'infection describe person-years']",4735,exposure hiv infection outcome covid-19 breakthrough infections defined laboratory evidence sars-cov-2 infection covid-19 diagnosis individual fully vaccinated 
1903,473.0,10.0,"['infection vaccinate 128', 'pwh vaccinate 128', 'pwoh vaccinate 128']",4737,cumulative incidence 210 days date fully vaccinated low albeit higher pwh versus pwoh overall 28 versus 21 log-rank p 0001 risk difference07 04 10 within vaccine type 
1904,473.0,15.0,"['people expand death', 'people expand coronavirus', 'people expand covid-19', 'people expand pre-covid-19', 'diabetes expand death', 'diabetes expand coronavirus', 'diabetes expand covid-19', 'diabetes expand pre-covid-19', 'mellitus expand death', 'mellitus expand coronavirus', 'mellitus expand covid-19', 'mellitus expand pre-covid-19']",4742,recommendations additional vaccine doses expanded pwh 
1905,474.0,0.0,"['leumit increase diabetes', 'leumit increase pre-covid-19', 'leumit increase hba1c', 'lh increase diabetes', 'lh increase pre-covid-19', 'lh increase hba1c', '183 increase diabetes', '183 increase pre-covid-19', '183 increase hba1c', 'leumit develop hba1c', 'lh develop hba1c', '183 develop hba1c', 'patient develop hba1c', 'diabetes develop hba1c', 'pre-covid-19 develop hba1c']",4743,introduction people diabetes mellitus increased risk developing severe disease death contracting coronavirus disease 2019 covid-19 effect pre-covid-19 infection glycemic control disease outcomes still unclear 
1906,474.0,1.0,"['patient emerge lh', 'patient emerge hba1c']",4744,previous study published leumit health services lhs including 183 patients diabetes pre-covid-19 infection hba1c 9 associated need hospitalization disease 
1907,474.0,2.0,"['patient die diabetes', 'patient die pre-diabetes', 'lh die diabetes', 'lh die pre-diabetes', 'covid-19 die diabetes', 'covid-19 die pre-diabetes']",4745,current study present clinical characteristics patients died covid-19 lhs demonstrate significant link pre-infection hba1c 
1908,474.0,3.0,"['covid-19 consider patient', 'covid-19 consider survivor', 'covid-19 observe survivor']",4746,methods collected demographic clinical laboratory information regarding patients insured lhs contracted covid-19 1st february 31st may 2020 diabetes pre-diabetes 
1909,474.0,5.0,"['hba1c die dementia cerebrovascular', 'hba1c die heart failure', 'hba1c die patient', 'hba1c die obesity', 'hba1c die sglt-2', 'hba1c die inhibitor', 'creatinine die dementia cerebrovascular', 'creatinine die heart failure', 'creatinine die patient', 'creatinine die obesity', 'creatinine die sglt-2', 'creatinine die inhibitor', 'hemoglobin die dementia cerebrovascular', 'hemoglobin die heart failure', 'hemoglobin die patient', 'hemoglobin die obesity', 'hemoglobin die sglt-2', 'hemoglobin die inhibitor', 'iron die dementia cerebrovascular', 'iron die heart failure', 'iron die patient', 'iron die obesity', 'iron die sglt-2', 'iron die inhibitor', 'vitamin die dementia cerebrovascular', 'vitamin die heart failure', 'vitamin die patient', 'vitamin die obesity', 'vitamin die sglt-2', 'vitamin die inhibitor']",4748,results identified 888 patients 24 27 died covid-19 
1910,474.0,8.0,['covid-19 associate at-risk'],4751,conclusions pre- covid-19 hba1c levels prior cerebrovascular disease associated increased risk mortality 
1911,474.0,10.0,"['vaccine need large-scale', 'cancer need large-scale', 'vaccine receive large-scale', 'cancer receive large-scale']",4753,study needed understand potential mechanism causality poor glycemic control covid-19 death 
1912,475.0,0.0,['mrna improve patient'],4754,mrna vaccines cancer advantages safety improved therapeutic efficacy large-scale production 
1913,475.0,1.0,"['rna-seq receive tcga', '494 receive tcga']",4755,therefore purpose identify immune biomarkers analyze immune status developing mrna vaccines selecting appropriate patients vaccination 
1914,475.0,10.0,"['myrf classify trim29', 'myrf classify uba6', 'plxnb2 classify trim29', 'plxnb2 classify uba6']",4764,luad patients classified four signatures c apobec mutation age tobacco 
1915,475.0,16.0,"['luad receive immune cells', 'luad receive patient', 'luad receive gprin1']",4770,besides identified immune subtypes cold immunity patients is2 is4 ideal mrna vaccination recipients 
1916,475.0,17.0,"['myrf receive patient', 'plxnb2 receive patient', 'slc9a4 receive patient', 'trim29 receive patient', 'uba6 receive patient', 'myrf provide patient', 'plxnb2 provide patient', 'slc9a4 provide patient', 'trim29 provide patient', 'uba6 provide patient']",4771,finally luad immune landscape revealed immune cells prognostic conditions provides important information select patients vaccination 
1917,476.0,1.0,"['escherichia show etec', 'escherichia show enterotoxin', 'escherichia show child', 'escherichia show 5', 'escherichia show diarrhea', 'escherichia show antibiotic']",4775,licensed vaccines etec 
1918,476.0,2.0,"['225 aim child', '225 characterize child']",4776,study aimed characterizing escherichia coli etec enterotoxins colonization factors children 5 years acute diarrhea taken antibiotics prior seeking medical attention hospital 
1919,476.0,5.0,"['225 screen 102', '225 screen etec']",4779,positives screened 11 colonization factors pcr 
1920,476.0,7.0,"['isolates detect stp', 'isolates detect 688', 'isolates detect 312', 'human detect stp', 'human detect 688', 'human detect 312', 'sth detect stp', 'sth detect 688', 'sth detect 312', 'heat-stable detect stp', 'heat-stable detect 688', 'heat-stable detect 312', 'toxin detect stp', 'toxin detect 688', 'toxin detect 312']",4781,heat-stable toxin st gene detected 16 696 
1921,476.0,10.0,"['609 detect cs6', '609 detect 429', '609 detect cfai', '609 detect cs21', '609 detect 214', 'etec detect cs6', 'etec detect 429', 'etec detect cfai', 'etec detect cs21', 'etec detect 214']",4784,st lt toxin genes detected 2 87 etec isolates 
1922,476.0,11.0,"['cs7 detect cs5', 'cs7 detect etec', 'cs7 detect isolate', 'cs7 detect cfai']",4785,cf genes detected 14 609 etec strains majority cs6 6 429 gene followed combination cfai cs21 gene detected 3 214 
1923,477.0,2.0,"['infection test lateral', 'sars-cov-2 test lateral', 'sars-cov-2 test infection']",4795,methods prospective observational study examined proportion probability self-reported systemic local side-effects within 8 days vaccination individuals using covid symptom study app received one two doses bnt162b2 vaccine one dose chadox1 ncov-19 vaccine 
1924,477.0,3.0,"['health-care test obesity', 'health-care test 30', 'health-care test 8805', 'health-care test 30']",4796,also compared infection rates subset vaccinated individuals subsequently tested sars-cov-2 pcr lateral flow tests infection rates unvaccinated controls 
1925,477.0,4.0,"['dec adjust 627', 'dec adjust 383', 'dec adjust 655', 'dec adjust 282', 'dec adjust 103', 'dec adjust one', 'dec adjust bnt162b2', 'dec adjust 207', 'dec adjust 280', 'dec adjust one', 'dec adjust chadox1', 'dec adjust ncov-19']",4797,analyses adjusted age 8804 55 years vs 55 years sex health-care worker status binary variable obesity bmi 30 kgm2vs 8805 30 kgm2 comorbidities binary variable without comorbidities 
1926,477.0,5.0,"['155 vaccinate 473 345', '155 vaccinate bnt162b2', '155 vaccinate 280', '155 vaccinate chadox1', '155 vaccinate ncov-19', '282 vaccinate 473 345', '282 vaccinate bnt162b2', '282 vaccinate 280', '282 vaccinate chadox1', '282 vaccinate ncov-19', '103 vaccinate 473 345', '103 vaccinate bnt162b2', '103 vaccinate 280', '103 vaccinate chadox1', '103 vaccinate ncov-19', 'bnt162b2 vaccinate 473 345', 'bnt162b2 vaccinate 280', 'bnt162b2 vaccinate chadox1', 'bnt162b2 vaccinate ncov-19', '207 vaccinate 473 345', '207 vaccinate bnt162b2', '207 vaccinate 280', '207 vaccinate chadox1', '207 vaccinate ncov-19', '473 345 receive ncov-19', '155 receive ncov-19', '282 receive ncov-19', '103 receive ncov-19', 'bnt162b2 receive ncov-19', '207 receive ncov-19', 'bnt162b2 receive ncov-19', '280 receive ncov-19']",4798,findings dec 8 march 10 2021 627 383 individuals reported vaccinated 655 590 doses 282 103 received one dose bnt162b2 28 207 received second dose 345 280 received one dose chadox1 ncov-19 
1927,477.0,6.0,"['150 report bnt162b2 68Ã\x83\x83Ã\x83\x825', '150 report 208', '150 report 767', '150 report 179', '150 report bnt162b2', '150 report 104', '150 report 282', '150 report 177', '150 report 655', '150 report chadox1', '150 report ncov-19']",4799,systemic side-effects reported 13ÃÂ5 38 155 282 103 individuals first dose bnt162b2 22ÃÂ0 6216 28 207 second dose bnt162b2 33ÃÂ7 116 473 345 280 first dose chadox1 ncov-19 
1928,477.0,7.0,"['side-effects report dose', 'side-effects report chadox1', 'side-effects report ncov-19', 'side-effects report bnt162b2', 'side-effects report sars-cov-2', 'side-effects report infection']",4800,local side-effects reported 71ÃÂ9 150 023 208 767 individuals first dose bnt162b2 68ÃÂ5 9025 13 179 second dose bnt162b2 58ÃÂ7 104 282 177 655 first dose chadox1 ncov-19 
1929,477.0,9.0,"['103 infect sars-cov-2', '622 infect sars-cov-2', '340 infect sars-cov-2', '464 infect sars-cov-2']",4802,local effects similarly higher individuals previously infected without known past infection 1ÃÂ4 times first dose chadox1 ncov-19 1ÃÂ2 times first dose bnt162b2 
1930,477.0,10.0,"['infection vaccinate ncov-19 69', 'infection vaccinate chadox1', 'infection vaccinate bnt162b2', 'infection vaccinate bnt162b2', 'infection vaccinate 45-59', 'infection test ncov-19 69', 'infection test bnt162b2', 'infection test bnt162b2', 'infection test 45-59']",4803,3106 103 622 vaccinated individuals 50 340 464 356 unvaccinated controls tested positive sars-cov-2 infection 
1931,477.0,11.0,"['side-effects start vaccine', 'bnt162b2 start vaccine', 'chadox1 start vaccine']",4804,significant reductions infection risk seen starting 12 days first dose reaching 60 95 ci 49-68 chadox1 ncov-19 69 66-72 bnt162b2 21-44 days 72 63-79 bnt162b2 45-59 days 
1932,478.0,2.0,"['175 establish cd4 cd8', '175 establish plasma', '175 establish specimen', '175 establish sars-cov-2-s', '175 establish antibody', '175 establish sars-cov-2-s-reactive', '175 establish ifn-']",4810,methodsthe sample comprised 46 residents 34 females age 60-100 years 10 covid-19 prior vaccination 
1933,479.0,1.0,"['adult induce pneumonia', 'adult use pneumonia', 'adult claim pneumonia']",4821,methods conducted retrospective cohort study using representative healthcare claims database approx 
1934,479.0,4.0,['8805 perform adult'],4824,sensitivity analyses using broader restrictive case definitions also performed 
1935,479.0,6.0,"['8805 age 2032', '8805 age 1061', '8805 age 1053', '8805 age pneumonia']",4826,adults aged 16 59 years ir overall cap hospitalized cap outpatient cap 551 96 466 hospitalization rate 17 
1936,479.0,8.0,"['adult consider 608', 'adult consider 108', '8805 consider 608', '8805 consider adult', '8805 consider 108', 'at-risk consider 608', 'at-risk consider adult', 'at-risk consider 108', 'high-risk consider 608', 'high-risk consider adult', 'high-risk consider 108', 'adult hospitalize 108', '8805 hospitalize adult', '8805 hospitalize 108', 'at-risk hospitalize adult', 'at-risk hospitalize 108', 'high-risk hospitalize adult', 'high-risk hospitalize 108', '608 hospitalize adult', '608 hospitalize 108', 'adult increase 108', '8805 increase 108', 'at-risk increase 108', 'high-risk increase 108', '608 increase 108', 'adult increase 108', 'adult fold 108', '8805 fold 108', 'at-risk fold 108', 'high-risk fold 108', '608 fold 108', 'adult fold 108']",4828,pneumonia coded primary secondary diagnosis position considered hospitalized patients ir increased 15-fold 1560 elderly 8805 60 years 
1937,479.0,10.0,['adult hospitalize patient'],4830,high mortality hospitalized cap adults 8805 18 observed in-hospital 185 30 days 229 one-year 445 cap onset 
1938,480.0,1.0,"['monocyte receive hla-dr', 'monocyte receive patient', 'monocyte receive sars-cov-2-specific', 'monocyte receive t-cell', 'monocyte receive nucleoprotein', 'monocyte receive sars-cov-2', 'monocyte receive peptide', 'monocyte receive non-specific']",4835,data 15 consecutive patients sequentially recorded intensive care unit admission 
1939,480.0,6.0,"['sars-cov-2-specific increase virus-specific', 'sars-cov-2-specific increase cd8', 'sars-cov-2-specific increase t-cells', 'cd4 increase virus-specific', 'cd4 increase cd8', 'cd4 increase t-cells', 't-cells increase virus-specific', 't-cells increase cd8']",4840,intermediate cd14cd16 monocytes increased early reduction classic cd14cd16- monocytes 
1940,481.0,0.0,"['antibody induce igg', 'antibody induce sars-cov-2', 'antibody induce mrna', 'antibody induce vaccine', 'nabs induce igg', 'nabs induce sars-cov-2', 'nabs induce mrna', 'nabs induce vaccine']",4847,sustainability coronavirus 19 covid-19 vaccine-induced immunity severe acute respiratory syndrome coronavirus 2 sars-cov-2 critical determined inform public health decisions vaccination programs prevention measures covid-19 
1941,481.0,2.0,"['sars-cov-2 follow three hundred', 'sars-cov-2 follow piscataway', 'sars-cov-2 follow mannheim', 'sars-cov-2 follow germany']",4849,assessments performed following time points second vaccination 2 weeks 1 month 3 months 6 months 9 months 
1942,481.0,9.0,"['thrombosis reflect chadox1', 'thrombosis reflect ncov-19', 'thrombosis reflect vaccine', 'thrombosis decline vaccine', 'thrombocytopenia decline vaccine', 'chadox1 decline vaccine']",4856,finding may reflect declining degree immune protection covid-19 advocates administration booster vaccine shots especially areas emerging outbreaks 
1943,482.0,1.0,"['vipit coin platelet', 'vipit coin chadox1', 'vipit coin ncov-19', 'vipit coin vaccine', 'vipit coin antibody', 'patient coin platelet', 'patient coin chadox1', 'patient coin ncov-19', 'patient coin vaccine', 'patient coin antibody', 'immunoglobulin coin platelet', 'immunoglobulin coin chadox1', 'immunoglobulin coin ncov-19', 'immunoglobulin coin vaccine', 'immunoglobulin coin antibody', 'ivig coin platelet', 'ivig coin chadox1', 'ivig coin ncov-19', 'ivig coin vaccine', 'ivig coin antibody', 'vipit induce immunoglobulin', 'vipit induce ivig', 'vipit induce platelet', 'vipit induce chadox1', 'vipit induce ncov-19', 'vipit induce vaccine', 'vipit induce antibody', 'patient induce immunoglobulin', 'patient induce ivig', 'patient induce platelet', 'patient induce chadox1', 'patient induce ncov-19', 'patient induce vaccine', 'patient induce antibody', 'vipit reflect chadox1', 'vipit reflect ncov-19', 'vipit reflect vaccine', 'vipit reflect antibody', 'patient reflect chadox1', 'patient reflect ncov-19', 'patient reflect vaccine', 'patient reflect antibody', 'immunoglobulin reflect chadox1', 'immunoglobulin reflect ncov-19', 'immunoglobulin reflect vaccine', 'immunoglobulin reflect antibody', 'ivig reflect chadox1', 'ivig reflect ncov-19', 'ivig reflect vaccine', 'ivig reflect antibody', 'platelet reflect chadox1', 'platelet reflect ncov-19', 'platelet reflect vaccine', 'platelet reflect antibody']",4858,term vaccine-induced prothrombotic immune thrombocytopenia vipit coined reflect new phenomenon 
1944,484.0,1.0,"['child provide 4895', 'adolescent provide 4895', 'adolescent provide child', 'adolescent investigate child']",4868,systematic review summarise studies investigated immunogenicity safety routine vaccines children adolescents jard immunosuppressive treatment 
1945,484.0,9.0,['child attenuate infection'],4876,safety concerns live attenuated vaccines however studies reported results 
1946,484.0,11.0,"['vaccine emphasize booster', 'one-third emphasize booster', 'child emphasize booster']",4878,importance completion vaccination schedules stressed 
1947,484.0,13.0,"['mid-december observe coronavirus', 'mid-december observe covid-19', 'israel observe coronavirus', 'israel observe covid-19']",4880,supplementary information online version contains supplementary material available 101007s00431-021-04283-w 
1948,485.0,2.0,"['covid-19 boost patient', 'covid-19 boost immunity', 'vaccine boost patient', 'vaccine boost immunity', 'covid-19 receive immunity', 'vaccine receive immunity', 'patient receive immunity']",4883, patients primary secondary immunodeficiencies encouraged receive vaccine 
1949,485.0,3.0,"['cellular base vaccine', 'cellular base cohort', 'cellular base patient', 'immune base vaccine', 'immune base cohort', 'immune base patient']",4884,although efficacy rna-based covid-19 vaccines demonstrated general population little known efficacy safety patients inborn errors immunity iei 
1950,485.0,4.0,"['patient evaluate blood', 'patient evaluate mononuclear', 'patient evaluate covid-19', 'patient evaluate vaccine', 'plasma evaluate blood', 'plasma evaluate mononuclear', 'plasma evaluate covid-19', 'plasma evaluate vaccine']",4885,objective aim evaluate humoral cellular immune response covid-19 vaccine cohort patients iei 
1951,485.0,5.0,"['antinucleocapsid antibody enrol enzyme', 'antinucleocapsid antibody enrol cellular', 'antinucleocapsid antibody collect cellular', 'enzyme collect cellular']",4886,methods total 26 adult patients enrolled plasma peripheral blood mononuclear cells collected 2 weeks following second dose pfizer-biontech covid-19 vaccine 
1952,485.0,7.0,"['cohort evaluate immunodeficiency', 'cohort evaluate twenty-two', 'cohort use immunodeficiency', 'cohort use twenty-two', 'patient use immunodeficiency', 'patient use twenty-two', 'cohort aim twenty-two', 'patient aim twenty-two']",4888,cellular immune response evaluated using elispot estimating il-2 ifn-ÃÂÃÂ³ secretion response pooled sars-cov-2 s- m-peptides 
1953,485.0,9.0,['patient receive s-peptide-specific'],4890,twenty-two receiving immunoglobulin replacement therapy 
1954,485.0,11.0,"['patient report s-protein-specific', 'patient report cellular']",4892,none patients reported significant adverse events 
1955,485.0,12.0,"['coronavirus vaccinate respiratory syndrome', 'coronavirus vaccinate nucleic acid', 'coronavirus vaccinate covid-19', 'coronavirus vaccinate sars-cov-2', 'coronavirus vaccinate globe', 'coronavirus vaccinate death', 'coronavirus vaccinate member', 'coronavirus vaccinate covid-19', 'coronavirus vaccinate infection', 'coronavirus vaccinate child', 'coronavirus vaccinate child', 'coronavirus vaccinate adult', 'coronavirus vaccinate sars-cov-2', 'coronavirus vaccinate child', 'coronavirus vaccinate symptom', 'coronavirus vaccinate infant', 'coronavirus vaccinate covid-19', 'coronavirus vaccinate adult', 'coronavirus vaccinate specimen', 'coronavirus vaccinate transcriptase', 'coronavirus vaccinate polymerase', 'coronavirus vaccinate patient', 'respiratory syndrome develop nucleic acid', 'respiratory syndrome develop globe', 'respiratory syndrome develop death', 'respiratory syndrome develop member', 'respiratory syndrome develop covid-19', 'respiratory syndrome develop infection', 'respiratory syndrome develop child', 'respiratory syndrome develop child', 'respiratory syndrome develop adult', 'respiratory syndrome develop sars-cov-2', 'respiratory syndrome develop child', 'respiratory syndrome develop symptom', 'respiratory syndrome develop infant', 'respiratory syndrome develop covid-19', 'respiratory syndrome develop adult', 'respiratory syndrome develop specimen', 'respiratory syndrome develop transcriptase', 'respiratory syndrome develop polymerase', 'respiratory syndrome develop patient', 'coronavirus develop nucleic acid', 'coronavirus develop globe', 'coronavirus develop death', 'coronavirus develop member', 'coronavirus develop covid-19', 'coronavirus develop infection', 'coronavirus develop child', 'coronavirus develop child', 'coronavirus develop adult', 'coronavirus develop sars-cov-2', 'coronavirus develop child', 'coronavirus develop symptom', 'coronavirus develop infant', 'coronavirus develop covid-19', 'coronavirus develop adult', 'coronavirus develop specimen', 'coronavirus develop transcriptase', 'coronavirus develop polymerase', 'coronavirus develop patient', 'covid-19 develop nucleic acid', 'covid-19 develop globe', 'covid-19 develop death', 'covid-19 develop member', 'covid-19 develop infection', 'covid-19 develop child', 'covid-19 develop child', 'covid-19 develop adult', 'covid-19 develop sars-cov-2', 'covid-19 develop child', 'covid-19 develop symptom', 'covid-19 develop infant', 'covid-19 develop adult', 'covid-19 develop specimen', 'covid-19 develop transcriptase', 'covid-19 develop polymerase', 'covid-19 develop patient', 'coronavirus develop nucleic acid', 'coronavirus develop globe', 'coronavirus develop death', 'coronavirus develop member', 'coronavirus develop covid-19', 'coronavirus develop infection', 'coronavirus develop child', 'coronavirus develop child', 'coronavirus develop adult', 'coronavirus develop sars-cov-2', 'coronavirus develop child', 'coronavirus develop symptom', 'coronavirus develop infant', 'coronavirus develop covid-19', 'coronavirus develop adult', 'coronavirus develop specimen', 'coronavirus develop transcriptase', 'coronavirus develop polymerase', 'coronavirus develop patient', 'sars-cov-2 develop nucleic acid', 'sars-cov-2 develop globe', 'sars-cov-2 develop death', 'sars-cov-2 develop member', 'sars-cov-2 develop covid-19', 'sars-cov-2 develop infection', 'sars-cov-2 develop child', 'sars-cov-2 develop child', 'sars-cov-2 develop adult', 'sars-cov-2 develop child', 'sars-cov-2 develop symptom', 'sars-cov-2 develop infant', 'sars-cov-2 develop covid-19', 'sars-cov-2 develop adult', 'sars-cov-2 develop specimen', 'sars-cov-2 develop transcriptase', 'sars-cov-2 develop polymerase', 'sars-cov-2 develop patient']",4893,conclusion vaccinating patients iei safe patients able develop vaccine-specific antibody response s-protein-specific cellular response 
1956,487.0,1.0,"['participant observe twelve', 'hypertension observe twelve']",4896,conducted placebo-controlled dose escalation study investigate safety tolerability immunological responses angiotensin ii vaccine agmg0201 
1957,487.0,2.0,"['patient treat low-dose', 'patient treat high-dose']",4897,agmg0201 administered participants mild moderate hypertension 18 79 years age 
1958,487.0,5.0,"['antibody show agmg0201', 'antibody show patient', 'antibody show high-dose']",4900,results showed treatment-related adverse events classified mild moderate severity including pain erythema injection site 
1959,487.0,7.0,"['respiratory syndrome induce sars-cov-2', 'coronavirus induce sars-cov-2']",4902,overall agmg0201 well tolerated 
1960,488.0,1.0,"['antibody evaluate sars-cov-2', 'antibody evaluate elisa', 'antibody evaluate sars-cov-2', 'antibody evaluate sars-cov-2', 'antibody evaluate diasorin', 'sars-cov-2 evaluate elisa', 'sars-cov-2 evaluate diasorin']",4904,serological assays used check immunization assess herd immunity 
1961,488.0,2.0,['100 evaluate serum'],4905,evaluated commercially available assays designed quantify antibodies directed sars-cov-2 spike antigen either total wantaÃÂ sars-cov-2 ab elisa igg sars-cov-2 igg ii quant alinity abbott liaison sars-cov-2 trimerics igg diasorin 
1962,488.0,12.0,"['three compare diasorin', 'antigen compare diasorin', 'antibody compare diasorin', 'three design diasorin', 'antigen design diasorin', 'antibody design diasorin', 'two design diasorin']",4915,importance standardization correlation virus neutralization assays critical points compare performance serological assays designed quantify anti-sars-cov-2 antibodies order identify optimal use 
1963,489.0,2.0,"['u perform 18-20', 'u perform 2-week']",4921,methods analysis performed part prospective covid-19 health action response marines study charm 
1964,489.0,3.0,"['quarantine include 2-week', 'quarantine include participant', 'quarantine include sars-cov-2', 'quarantine include dilution', 'quarantine include elisa', 'quarantine include participant', 'quarantine follow sars-cov-2', 'quarantine follow dilution', 'quarantine follow elisa', 'quarantine follow participant', '2-week follow sars-cov-2', '2-week follow dilution', '2-week follow elisa', '2-week follow participant', 'quarantine follow sars-cov-2', 'quarantine follow dilution', 'quarantine follow elisa', 'quarantine follow participant', 'participant follow sars-cov-2', 'participant follow dilution', 'participant follow elisa']",4922,charm included predominantly male us marine recruits aged 18-20 years following 2-week unsupervised quarantine home 
1965,489.0,4.0,['covid-19-related treat sars-cov-2'],4923,home quarantine period upon arrival marine-supervised 2-week quarantine facility college campus hotel participants enrolled assessed baseline sars-cov-2 igg seropositivity defined dilution 1150 receptor-binding domain full-length spike protein elisa 
1966,489.0,5.0,"['infection complete quarantine', 'infection complete participant', 'infection complete covid-19-related', 'infection complete symptom', 'infection complete participant', 'infection establish quarantine', 'infection establish participant', 'infection establish covid-19-related', 'infection establish symptom', 'infection establish participant', 'infection relate participant', 'quarantine relate participant', 'covid-19-related relate participant', 'symptom relate participant']",4924,participants also completed questionnaire consisting demographic information risk factors reporting 14 specific covid-19-related symptoms unspecified symptom brief medical history 
1967,489.0,7.0,"['three exclude swab', 'three exclude quarantine', 'three exclude serum', 'three exclude quarantine', 'three exclude sars-cov-2', 'three exclude marine', 'three exclude depot-parris']",4926,participants excluded stage positive pcr test quarantine 
1968,490.0,1.0,"['cross-sectional observe 100', 'cross-sectional observe community', 'cross-sectional observe wuhan', 'cross-sectional observe household']",4942,aimed determine seroprevalence kinetics anti-sars-cov-2 antibodies population level wuhan inform development vaccination strategies 
1969,490.0,3.0,"['wuhan invite symptom', 'wuhan invite covid-19', 'wuhan invite covid-19', 'wuhan invite venous', 'wuhan enrol symptom', 'wuhan enrol covid-19', 'wuhan enrol covid-19', 'wuhan enrol venous', 'participant enrol symptom', 'participant enrol covid-19', 'participant enrol covid-19', 'participant enrol venous']",4944,households systematically selected community family members invited community health-care centres participate 
1970,490.0,4.0,"['blood induce pan-immunoglobulins', 'blood induce iga', 'blood induce igg', 'blood induce antibody', 'blood induce sars-cov-2', 'blood induce nucleocapsid', 'blood induce antibody', 'blood induce two']",4945,eligible individuals lived wuhan least 14 days since dec 1 2019 eligible participants consented participate completed standardised electronic questionnaire demographic clinical questions self-reported symptoms associated covid-19 previous diagnosis covid-19 
1971,490.0,5.0,"['june 11 induce oct', 'june 11 induce dec', 'june 11 induce 2020', 'june 11 induce blood']",4946,venous blood sample taken immunological testing april 14-15 2020 blood samples tested presence pan-immunoglobulins igm iga igg antibodies sars-cov-2 nucleocapsid protein neutralising antibodies assessed 
1972,490.0,6.0,"['4600 do 3599', '4600 do family', '4600 do 9702', '4600 do 9542']",4947,two successive follow-ups june 11 june 13 oct 9 dec 5 2020 blood samples taken 
1973,490.0,7.0,"['3556 select 532', 'family select 532']",4948,findings 4600 households randomly selected 3599 families 78ÃÂ2 9702 individuals attended baseline visit 
1974,490.0,14.0,"['igg neutralize 437 100', 'igg neutralize antibody', 'igg neutralize 100', 'igg neutralize second', 'igg neutralize second', 'igg neutralize 437', 'igg neutralize 329', 'igg neutralize 362', 'igg confirm 437 100', 'igg confirm second', 'igg confirm second', 'igg confirm 437', 'igg confirm 329', 'igg confirm 362', 'antibody confirm 437 100', 'antibody confirm second', 'antibody confirm second', 'antibody confirm 437', 'antibody confirm 329', 'antibody confirm 362', '100 confirm 437 100', '100 confirm second', '100 confirm second', '100 confirm 437', '100 confirm 329', '100 confirm 362']",4955,however neutralising antibody titres lower asymptomatic individuals confirmed cases symptomatic individuals 
1975,490.0,15.0,"['cross-sectional decrease antibody', 'cross-sectional decrease sars-cov-2', 'cross-sectional decrease antibody']",4956,although titres igg decreased time proportion individuals igg antibodies decrease substantially 30 100 30 baseline 26 89ÃÂ7 29 second follow-up among confirmed cases 65 100 65 baseline 58 92ÃÂ1 63 second follow-up among symptomatic individuals 437 100 437 baseline 329 90ÃÂ9 362 second follow-up among asymptomatic individuals 
1976,490.0,17.0,"['peking union need chinese', 'peking union indicate chinese']",4958,durability data humoral responses indicate mass vaccination needed effect herd protection prevent resurgence epidemic 
1977,490.0,19.0,"['patient see respiratory syndrome', 'patient see coronavirus', 'patient see sars-cov-2']",4960,translation chinese translation abstract see supplementary materials section 
1978,491.0,4.0,"['187 use sars-cov-2', '187 use sars-cov-2', '501 use sars-cov-2', '501 use sars-cov-2', 'patient use sars-cov-2', 'patient use sars-cov-2']",4965,evaluated risk factors infection death using multivariable logistic regression analyses 
1979,491.0,6.0,"['254 include 159-405', '254 include 767', '254 include 530-1111', '254 include toronto', '254 include 195-477', '254 include indian', '254 include 102-281', '254 include 203', '254 include 138-297']",4967,sars-cov-2 infection 117 626 admitted hospital case fatality rate 283 
1980,491.0,7.0,"['patient include sars-cov-2', 'patient include infection', 'patient include death', 'patient include coronavirus']",4968,significant predictors infection included in-centre hemodialysis versus home dialysis odds ratio 254 95 confidence interval ci 159-405 living long-term care residence 767 95 ci 530-1111 living greater toronto area 327 95 ci 221-480 black ethnicity 305 95 ci 195-477 indian subcontinent ethnicity 170 95 ci 102-281 non-white ethnicities 203 95 ci 138-297 lower income quintiles 182 95 ci 115-289 
1981,491.0,8.0,"['mexico undergo hypertension', 'mexico undergo influenza', 'mexico undergo cardiovascular', 'patient undergo hypertension', 'patient undergo influenza', 'patient undergo cardiovascular', 'mexico increase cardiovascular', 'patient increase cardiovascular', 'arterial increase cardiovascular', 'hypertension increase cardiovascular', 'influenza increase cardiovascular']",4969,interpretation patients undergoing long-term dialysis increased risk sars-cov-2 infection death coronavirus disease 2019 special attention paid addressing risk factors infection patients prioritized vaccination 
1982,492.0,3.0,"['663 induce influenza-like illness', '663 induce people', '663 induce influenza', '663 induce death']",4973,setting data obtained influenza epidemiological surveillance system mexico database 
1983,492.0,4.0,"['influenza age death', 'influenza age diabetes', 'influenza age obesity', 'influenza age smoking', 'death age influenza', 'death age diabetes', 'death age obesity', 'death age smoking', 'influenza confirm diabetes', 'influenza confirm obesity', 'influenza confirm smoking', 'death confirm diabetes', 'death confirm obesity', 'death confirm smoking', 'death confirm diabetes', 'death confirm obesity', 'death confirm smoking', 'influenza confirm diabetes', 'influenza confirm obesity', 'influenza confirm smoking']",4974,participants 32 663 cases influenza people aged ÃÂÂ20 years confirmed case influenza-like illness severe respiratory infection andor influenza death investigated 
1984,492.0,6.0,"['460 increase one', '460 increase 192', '460 increase 663', '460 increase obesity', '460 increase 187', '663 increase one', '663 increase 192', '663 increase obesity', '663 increase 187']",4976,results hospitalisation frequency increased age 
1985,492.0,9.0,"['fatality see p', 'fatality see 178', 'fatality see p', 'influenza see p', 'influenza see 178', 'influenza see p', 'influenza see p', 'influenza see 178', 'influenza see p', 'p see 178']",4979,3496 deaths due influenza mortality rate 069ÃÂ1 00 000 inhabitants highest rates seen aged ÃÂÂ80 years 80ÃÂÂ89 years 20 ÃÂÂ90 years 36 
1986,492.0,11.0,"['multisystem include covid-19', 'adult include covid-19', 'coronavirus include covid-19']",4981,conclusions findings support need include sah public policies influenza vaccination secondary prevention measure avoid fatal outcomes 
1987,493.0,1.0,"['patient include cdc', 'patient include covid-19', 'patient include vaccine']",4983,mis-a included list adverse events monitored part emergency use authorizations issued covid-19 vaccines 
1988,493.0,4.0,['patient review cdc'],4986,vaccine adverse events reporting system vaers also reviewed possible cases mis-a 
1989,493.0,7.0,"['patient introduce seven', 'respiratory introduce seven', 'syndrome introduce seven', 'coronavirus introduce seven', 'sars-cov-2 introduce seven']",4989,overall 16 80 patients preceding covid-19-like illness median 26 days range 11ÃÂÂ78 days mis-a onset 
1990,493.0,11.0,"['covid-19 report sars-cov-2', 'covid-19 report infection', 'vaccine report sars-cov-2', 'vaccine report infection', 'covid-19 receive sars-cov-2', 'covid-19 receive infection', 'vaccine receive sars-cov-2', 'vaccine receive infection']",4993,conclusions although 7 patients reported received covid-19 vaccine evidence prior sars-cov-2 infection 
1991,494.0,0.0,"['antibody describe sars-cov-2', 'convalescent describe sars-cov-2']",4995,recently severe acute respiratory syndrome coronavirus 2 sars-cov-2 variant b11529 omicron described 
1992,494.0,1.0,['serum test b11529'],4996, analyze titers neutralizing antibodies sera convalescent vaccinated individuals new b11529 variant compared titers variants concern b117 b1351 b16172 using replication competent sars-cov-2 variants 
1993,494.0,2.0,"['b11529 neutralize sars-cov-2', 'immune neutralize sars-cov-2']",4997,found sera vaccinated individuals neutralized b11529 variant much lesser extent variant analyzed 
1994,494.0,3.0,['vaccine infect sars-cov-23'],4998,neutralization capacity b11529 maintained best sera super immune individuals infected vaccinated vaccinated infected 
1995,495.0,0.0,"['live-virus develop plasma', 'live-virus develop adult', 'live-virus develop covid-19', 'live-virus develop two', 'live-virus develop south', 'live-virus develop africa', 'live-virus develop infection', '501yv2 develop plasma', '501yv2 develop adult', '501yv2 develop covid-19', '501yv2 develop two', '501yv2 develop south', '501yv2 develop africa', '501yv2 develop infection', 'live-virus reduce covid-19', 'live-virus reduce two', 'live-virus reduce south', 'live-virus reduce africa', 'live-virus reduce infection', '501yv2 reduce covid-19', '501yv2 reduce two', '501yv2 reduce south', '501yv2 reduce africa', '501yv2 reduce infection', 'plasma reduce covid-19', 'plasma reduce two', 'plasma reduce south', 'plasma reduce africa', 'plasma reduce infection', 'adult reduce covid-19', 'adult reduce two', 'adult reduce south', 'adult reduce africa', 'adult reduce infection']",4999,sars-cov-2 variants concern voc arisen independently multiple locations12 may reduce efficacy current vaccines target spike glycoprotein sars-cov-23 
